Genes,DisGeNET_Term,DisGeNET_Pvalue_Adjusted,GeDiPNet_Term,GeDiPNet_Pvalue_Adjusted,Orphanet_Term,Orphanet_Pvalue_Adjusted,Virus_Host_Term,Virus_Host_Pvalue_Adjusted,Host organism(s)_Intact,Confidence value(s)_Intact,Taxid interactor A_Intact,Taxid interactor B_Intact
AATK,Acute myelomonocytic leukemia; Ovarian Mucinous Adenocarcinoma; Metastatic melanoma; Psoriasis; Adenocarcinoma of lung (disorder),0.7880542567584415; 0.7880542567584415; 0.7940665326856218; 0.8019075543217649; 0.8098851543361193,Ovarian Adenocarcinoma; Anxiety Disorder; Lung Adenocarcinoma,0.7765582368651238; 0.8507213163251659; 0.9350723667380212,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; 1p36 deletion syndrome ORPHA:1606; Usher syndrome type 1 ORPHA:231169; Beckwith-Wiedemann syndrome due to CDKN1C mutation ORPHA:231120; Infant acute respiratory distress syndrome ORPHA:70587; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome ORPHA:436144; Spinocerebellar ataxia type 13 ORPHA:98768; Familial short QT syndrome ORPHA:51083; Adult hypophosphatasia ORPHA:247676; Childhood-onset hypophosphatasia ORPHA:247667; Infantile hypophosphatasia ORPHA:247651; Odontohypophosphatasia ORPHA:247685; Perinatal lethal hypophosphatasia ORPHA:247623; Prenatal benign hypophosphatasia ORPHA:247638,0.0155394890951578; 0.0184072076199886; 0.2661730864557679; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
ABCA7,"Neurofibrillary degeneration (morphologic abnormality); Disease Exacerbation; Muscle Hypertonia; Familial lichen amyloidosis; Spasmodic movement; Involuntary jerking movements; Eosinophil count procedure; Eosinophil count result; Agitation; Abnormal social behavior; Abnormal social interactions; Deposits immunoreactive to beta-amyloid protein; Presenile dementia; Myoclonus; Alzheimer's Disease; Autoimmune Diseases; Sjogren's Syndrome; Language Disorders; Plaque, Amyloid; Primary Sj??gren's syndrome; Cerebral atrophy; Multiple Sclerosis; Neutrophil count (procedure); Senile Plaques; Hallucinations; Social disinhibition; Blood basophil count (lab test); Impaired cognition; Alzheimer's Disease, Focal Onset; Acute Confusional Senile Dementia; Alzheimer Disease, Late Onset; Mild cognitive disorder; Confusion; Memory impairment; Parkinsonian Disorders; Hallucinations, Sensory; Alzheimer Disease, Early Onset; Amyloidosis; Forgetful; Memory Loss; Parkinson Disease; Familial Alzheimer Disease (FAD); Age related macular degeneration; Seizures; Epilepsy",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8101097852323003; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8486035047899471; 0.8648405521677974; 0.8648405521677974; 0.8672189956534445; 0.8690346447728063; 0.8769418330148872; 0.8772392350816924; 0.8786853464107758; 0.8980854850210683; 0.9478210444156088; 0.963331724428282,Oculovestibuloauditory Syndrome; Oculomotor Apraxia; Semantic Dementia; Senile Plaques; Parkinson Disease; Hallucinations; Mental Retardation; Alzheimer Disease; Cerebral Cortical Atrophy; Dysgraphia; Senile Dementia; Language Disorders; Aphasia; Mental Depression,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8182883735985873; 0.8337953215113012; 0.8337953215113012; 0.8457525389282121; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.8903630091389316,Autosomal dominant centronuclear myopathy ORPHA:169189; Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Idiopathic CD4 lymphocytopenia ORPHA:228000; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Adult-onset dystonia-parkinsonism ORPHA:199351; Barth syndrome ORPHA:111; Infantile neuroaxonal dystrophy ORPHA:35069; Megaconial congenital muscular dystrophy ORPHA:280671; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Intermediate osteopetrosis ORPHA:210110; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; Coats plus syndrome ORPHA:313838; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; Charcot-Marie-Tooth disease type 2B2 ORPHA:101101; Ataxia-oculomotor apraxia type 4 ORPHA:459033; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; Gray platelet syndrome ORPHA:721; Osteogenesis imperfecta type 5 ORPHA:216828; Glycogen storage disease due to liver phosphorylase kinase deficiency ORPHA:264580; Familial focal epilepsy with variable foci ORPHA:98820; Combined immunodeficiency due to STIM1 deficiency ORPHA:317430; Autosomal dominant Charcot-Marie-Tooth disease type 2M ORPHA:228179; Autosomal dominant intermediate Charcot-Marie-Tooth disease type B ORPHA:100044; Fetal akinesia-cerebral and retinal hemorrhage syndrome ORPHA:363409; Porphyria variegata ORPHA:79473; Nephrogenic diabetes insipidus ORPHA:223; Pseudo-von Willebrand disease ORPHA:52530; NON RARE IN EUROPE: Alzheimer disease ORPHA:238616,0.0036432528126817; 0.0081550609410495; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2386105733903937; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Human adenovirus 11+34 encapsidation protein IVa2 (gene: IVa2); Human adenovirus 34 maturation protein IVa2 (gene: IVa2); Human adenovirus 35 IVa2; Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Human adenovirus 14 IVa2 protein (gene: IVa2); Human adenovirus 55 pIVa2 50.9 kDa protein; Human adenovirus 66 maturation protein IVA2 (gene: IVa2); Human mastadenovirus E encapsidation protein IVa2 (gene: IVa2); Human adenovirus E4 protein IVa2; Human adenovirus 23 IVa2 (gene: IVa2); Human adenovirus 3+7 maturation protein IVA2 (gene: IVa2); Human adenovirus 54 pIVa2; Human adenovirus 67 pIVa2; Human adenovirus 11a IVa2; Human adenovirus 63 IVa2 protein (gene: IVa2); Human adenovirus 22 IVa2 (gene: IVa2); Human adenovirus 64 IVa2 protein; Human adenovirus D37 pIVa2 (gene: pIVa2); Human adenovirus 65 pIVa2; Human adenovirus Chiba_E086/2012 pIVa2 (gene: pIVa2); Human adenovirus D8 pIVa2 protein (gene: pIVa2); Human mastadenovirus A encapsidation protein IVa2 (gene: IVa2); Human adenovirus 12 maturation protein (protein IVA2); Human mastadenovirus C encapsidation protein IVa2 (gene: IVa2); Human adenovirus 2 IVa2; Human adenovirus 16 maturation protein IVA2 (gene: IVa2); Human adenovirus 6 maturation protein pIVa2 (gene: pIVa2); Human mastadenovirus A IVa2; Titi monkey adenovirus ECC-2011 IVa2; Human adenovirus 49 pIVa2; Human adenovirus 19 pIVa2 (gene: IVa2); Human adenovirus 71 maturation protein (gene: IVa2); Human adenovirus 56 IVa2 protein (gene: IVa2); Human mastadenovirus D encapsidation protein IVa2 (gene: IVa2); Human adenovirus D10 pIVa2 (gene: pIVa2); Papiine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Human adenovirus 36 IVa2; Human adenovirus 58 IVa2 (gene: pIVa2); Human adenovirus 43 encapsidation protein IVa2 (gene: IVa2); Human adenovirus 52 IVa2 (gene: IVa2); Human adenovirus 68 maturation protein IVA2 (gene: IVa2); Human adenovirus 1 IVa2; Human adenovirus 46 IVa2; Human adenovirus 5 IVa2; Human adenovirus 7 IVa2; Human adenovirus 18 IVa2 protein (gene: IVa2); Human adenovirus 41 IVa2; Human adenovirus 61 pIVa2; Human adenovirus B3 protein IVa2 (gene: IVa2); Human adenovirus 7d2 maturation protein IVA2 (gene: IVa2); Human adenovirus 21 maturation protein IVa2 (gene: IVa2); Human adenovirus 50 maturation protein IVa2 (gene: IVa2); Human mastadenovirus F encapsidation protein IVa2 (gene: IVa2),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764,,,,
ABCG1,"Malignant neoplasm of breast; Breast Carcinoma; Colorectal Carcinoma; Non-Small Cell Lung Carcinoma; Hypercholesterolemia; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Vascular Diseases; Malignant neoplasm of prostate; Colorectal Cancer; Prostate carcinoma; Mesothelioma; Serum total cholesterol measurement; Eclampsia; As If Personality; Hypertriglyceridemic Waist; Pulmonary Alveolar Proteinosis; Lipoidosis; Gout; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Cardiovascular Diseases; Diabetes; Diabetes Mellitus; Chronic myeloproliferative disorder; Liver Cirrhosis, Experimental; MAJOR AFFECTIVE DISORDER 8; MAJOR AFFECTIVE DISORDER 9; MAJOR AFFECTIVE DISORDER 7; Myocardial Infarction; AMYOTROPHIC LATERAL SCLEROSIS 6 (disorder); Kidney Failure, Chronic; Lung diseases; Narcolepsy; Extramedullary Hematopoiesis (disorder); Eating Disorders; MAJOR AFFECTIVE DISORDER 4; MAJOR AFFECTIVE DISORDER 6; Myeloproliferative disease; AMYOTROPHIC LATERAL SCLEROSIS 1, AUTOSOMAL RECESSIVE; MAJOR AFFECTIVE DISORDER 1; Diabetes Mellitus, Non-Insulin-Dependent; Triglycerides measurement; Amyotrophic Lateral Sclerosis, Sporadic; AMYOTROPHIC LATERAL SCLEROSIS 1; PITUITARY ADENOMA PREDISPOSITION (disorder); MAJOR AFFECTIVE DISORDER 2; Peripheral Neuropathy; Hyperlipoproteinemia Type IIa; Endothelial dysfunction; Down Syndrome; Smell Perception; Weight Gain; Metabolic Syndrome X; Myocardial Ischemia; Amyloidosis; Coronary Artery Disease; Pulmonary Fibrosis; Age related macular degeneration; Obesity; Bipolar Disorder; Trisomy; Mood Disorders; Coronary heart disease",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7945683314244791; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8101097852323003; 0.8101097852323003; 0.8101097852323003; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8190761496232595; 0.8232134984476662; 0.8270909867833504; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8420665668584452; 0.843190898187174; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8672189956534445; 0.887595340546704; 0.8911256045597441; 0.8980854850210683; 0.8989612563669234; 0.900167961295542; 0.9029289778792944; 0.9093740881835894; 0.9119978323790848,Gout; Gouty Arthritis; Eating Disorders; Lateral Sclerosis; Bipolar Disorder; Colorectal Neoplasms; Kidney Failure; Colorectal Cancer,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8444537302152433; 0.943322675973118; 0.9510372690456612; 0.9658957825498884; 0.9832345076528324,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency ORPHA:477857; Estrogen resistance syndrome ORPHA:785,0.7929682744768703; 0.8922466888454011,Human adenovirus 11+34 encapsidation protein IVa2 (gene: IVa2); Human adenovirus 34 maturation protein IVa2 (gene: IVa2); Human adenovirus 35 IVa2; Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Human adenovirus 14 IVa2 protein (gene: IVa2); Human adenovirus 55 pIVa2 50.9 kDa protein; Human adenovirus 23 IVa2 (gene: IVa2); Human adenovirus 67 pIVa2; Human adenovirus 11a IVa2; Human adenovirus 63 IVa2 protein (gene: IVa2); Human adenovirus 22 IVa2 (gene: IVa2); Human adenovirus 64 IVa2 protein; Human adenovirus D37 pIVa2 (gene: pIVa2); Human adenovirus 65 pIVa2; Human adenovirus Chiba_E086/2012 pIVa2 (gene: pIVa2); Human mastadenovirus A encapsidation protein IVa2 (gene: IVa2); Human adenovirus 12 maturation protein (protein IVA2); Human mastadenovirus C encapsidation protein IVa2 (gene: IVa2); Human adenovirus 2 IVa2; Human adenovirus 6 maturation protein pIVa2 (gene: pIVa2); Human mastadenovirus A IVa2; Titi monkey adenovirus ECC-2011 IVa2,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
ACAP3,,,,,"Otospondylomegaepiphyseal dysplasia ORPHA:1427; Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Familial lipase maturation factor 1 deficiency ORPHA:535453; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Spinocerebellar ataxia type 21 ORPHA:98773; 1p36 deletion syndrome ORPHA:1606; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Adult-onset dystonia-parkinsonism ORPHA:199351; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Infantile neuroaxonal dystrophy ORPHA:35069; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Lymphangioleiomyomatosis ORPHA:538; Oculocutaneous albinism type 2 ORPHA:79432; Tuberous sclerosis complex ORPHA:805; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Albers Schonberg osteopetrosis ORPHA:53; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; BAP1-related tumor predisposition syndrome ORPHA:289539; Cerebellar-facial-dental syndrome ORPHA:444072; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Kufor-Rakeb syndrome ORPHA:306674; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Steinert myotonic dystrophy ORPHA:273; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; D-2-hydroxyglutaric aciduria ORPHA:79315; Smith-Magenis syndrome ORPHA:819; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome ORPHA:412069; Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome ORPHA:95433; Brachyolmia-amelogenesis imperfecta syndrome ORPHA:2899; CLN4B disease ORPHA:228343; Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome ORPHA:500144; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; Hereditary hypophosphatemic rickets with hypercalciuria ORPHA:157215; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; POMT1-related  limb-girdle muscular dystrophy R11 ORPHA:86812; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361; Scheie syndrome ORPHA:93474; TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome ORPHA:562569; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; Lethal congenital contracture syndrome type 3 ORPHA:137783; 17p11.2 microduplication syndrome ORPHA:1713; Distal 16p11.2 microdeletion syndrome ORPHA:261222; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression ORPHA:391316; Intellectual disability-epilepsy-extrapyramidal syndrome ORPHA:468620; PMP22-RAI1 contiguous gene duplication syndrome ORPHA:477817; Proximal 16p11.2 microdeletion syndrome ORPHA:261197; Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency ORPHA:329249; Congenital muscular dystrophy with intellectual disability ORPHA:370968; Uveal melanoma ORPHA:39044; Wolf-Hirschhorn syndrome ORPHA:280; Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome ORPHA:459061; Peutz-Jeghers syndrome ORPHA:2869; Isolated focal cortical dysplasia type IIa ORPHA:269001; AKT2-related familial partial lipodystrophy ORPHA:79085; Familial LCAT deficiency ORPHA:79293; Fish-eye disease ORPHA:79292; Hypoinsulinemic hypoglycemia and body hemihypertrophy ORPHA:293964; Primary lateral sclerosis ORPHA:35689; Spastic paraplegia type 7 ORPHA:99013; Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies ORPHA:221145; MORM syndrome ORPHA:75858",0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1117946631214258; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.3977968344535308; 0.4100904865085126; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Human adenovirus 1 fiber; Human adenovirus 5 fiber; Hendra henipavirus phosphoprotein P (gene: P/V/C); Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Horsepox virus HSPV011a; Nipah henipavirus P phosphoprotein; Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Cowpox virus CPXV027 protein (gene: CPXV027 CDS); Titi monkey adenovirus ECC-2011 fiber; Vaccinia virus hypothetical protein; Ectromelia virus ERPV ankyrin and nfkb inhibitor; Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Horsepox virus HSPV022 (ankyrin-like protein; Provisional); Human mastadenovirus E fiber (gene: L5); Human adenovirus E4 fiber protein; Monkeypox virus ankyrin-like protein; Horsepox virus HSPV033c (ankyrin repeats); Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Vaccinia virus ankyrin-like protein (gene: C9L); Horsepox virus HSPV201a (ankyrin repeats); Yaba-like disease virus 147R protein (gene: 147R); Cowpox virus CPXV041 protein (gene: CPXV041 CDS); Horsepox virus HSPV035 (ankyrin repeats); Horsepox virus HSPV004 (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: C1L); Yaba monkey tumor virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: K1L); Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Variola virus hypothetical protein (gene: B19R); Vaccinia virus Ankara CP77 Host range protein f1; Vaccinia virus Ankara Host range protein; Cowpox virus CPXV039 (gene: CPXV039 CDS); Variola virus hypothetical protein (gene: B21R); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Vaccinia virus ankyrin-like protein (gene: B18R); Variola virus hypothetical protein (gene: D7L); Horsepox virus HSPV033b (Ankyrin repeats); Variola virus hypothetical protein (gene: G3R); Orf virus ORF126 ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Horsepox virus HSPV020b (ankyrin repeats); Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Horsepox virus HSPV005c (Ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara CP77 host range protein f4; Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Horsepox virus HSPV014b (ankyrin repeats); Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyin-like protein (gene: M1L); Yaba-like disease virus 146R protein (gene: 146R); Vaccinia virus Ankara CP77 host range protein f2; Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Variola virus hypothetical protein (gene: B6R); Vaccinia virus ankyrin-like protein; Orf virus ORF129 ankyrin repeat protein; Cowpox virus CPXV017 protein (gene: CPXV017 CDS); Variola virus ankyin-like protein (gene: O1L); Horsepox virus HSPV194 (ankyrin repeats); Cowpox virus CPXV006 protein (gene: CPXV006 CDS); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Yaba-like disease virus 148R protein (gene: 148R); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D1L); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9018002218631122; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9058994261255549; 0.9071659214187592; 0.9115856929326512; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9364561700418303; 0.9366403811337995; 0.9383505321091749; 0.9383505321091749; 0.9386073090182748; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9563208507960556,,,,
ACOT7,"Malignant neoplasm of ovary; Ovarian Carcinoma; Liver carcinoma; Epithelial ovarian cancer; Glioblastoma; Neoplasms; Childhood Glioblastoma; Adult Glioblastoma; Whooping cough due to unspecified organism; Pertussis; Epilepsy, Temporal Lobe",0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.98328107300087,,,"PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Distal hereditary motor neuropathy type 5 ORPHA:139536; Familial congenital mirror movements ORPHA:238722; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; Ichthyosis-prematurity syndrome ORPHA:88621; Neu-Laxova syndrome ORPHA:2671; Myoclonus-dystonia syndrome ORPHA:36899; Anterior segment developmental anomaly ORPHA:88632; Congenital primary aphakia ORPHA:83461; Essential fructosuria ORPHA:2056; Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome ORPHA:171848; MEDNIK syndrome ORPHA:171851; Multiple benign circumferential skin creases on limbs ORPHA:2505; Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency ORPHA:331176; Distal 17p13.3 microdeletion syndrome ORPHA:261257; Hemolytic anemia due to glucophosphate isomerase deficiency ORPHA:712; Phosphoserine aminotransferase deficiency, infantile/juvenile form ORPHA:284417; Smith-Lemli-Opitz syndrome ORPHA:818",0.0155394890951578; 0.1068643725150898; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ADA,"Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; B-Cell Lymphomas; leukemia; Reticulosarcoma; Sideroblastic anemia; MYELODYSPLASTIC SYNDROME; HIV Encephalopathy; Pancreatic Ductal Adenocarcinoma; HIV encephalitis; Middle East Respiratory Syndrome; Malignant neoplasm of lung; Malignant neoplasm of prostate; Lymphopenia; Chronic heart failure; T-Cell Lymphoma; Glioblastoma; Prostate carcinoma; Pulmonary Edema; Peptic Ulcer; Primary immune deficiency disorder; Hydatidiform Mole; Immunologic Deficiency Syndromes; Malignant Neoplasms; melanoma; Lung Neoplasms; Retinal Diseases; Lymphadenopathy; Body fluid retention; Chronic lung disease; Diffusely thickened skin; Severe B lymphocytopenia; Absence of B cells; Congenital hypoplastic anemia; Diarrhea; Recurrent upper respiratory tract infection; Thick skin; Histiocytic sarcoma; Vesicular Stomatitis; Skin Carcinogenesis; Recurrent opportunistic infections; Pulmonary Valve Insufficiency; Pulmonary Alveolar Proteinosis; Lymphocytosis; Severe Combined Immunodeficiency; Anterior rib cupping; Macrocytosis; Low Vision; pricking of skin; Dementia; Somatic mosaicism; Other specified peritonitis; Lupus Erythematosus, Systemic; Childhood Glioblastoma; Acquired Immunodeficiency Syndrome; Adult Glioblastoma; Recurrent pulmonary infections; Multiple pulmonary infections; Trypanosomiasis; Bone marrow myeloid dysplasia; Acute leukemia; Presenile dementia; Recurrent pneumonia; Acute lymphocytic leukemia; Pancytopenia; GALACTOSIALIDOSIS; Increased IgE level; Autoimmune Diseases; Ketosis; Rheumatoid Arthritis; Post MI; Diabetes; Anemia, Hemolytic, Congenital; Venous Engorgement; Active Hyperemia; B lymphocytopenia; Desquamation of skin soon after birth; IgM deficiency; Reactive Hyperemia; Diabetes Mellitus; Abnormality of the skeletal system; Uveitis; Leptospirosis; Hyperglycemia; Huntington Disease; Symmetrical dyschromatosis of extremities; Adenosine deaminase deficiency; Dermatofibrosarcoma; Diffuse mesangial sclerosis (disorder); Edema; Vasculitis; Recurrent fungal infections; Myeloid Leukemia, Chronic; Post-kala-azar dermal leishmaniasis; T-Lymphocytopenia; Recurrent viral infection; Peyronie Disease; Liver Cirrhosis, Experimental; Xerosis; Pre-Eclampsia; Hairy Cell Leukemia; Pneumonitis; Kidney Failure, Chronic; Autistic Disorder; Dry skin; Lung diseases; Severe combined immunodeficiency due to adenosine deaminase deficiency; Infectious disease of lung; Degenerative polyarthritis; Wiskott-Aldrich Syndrome; Tuberculosis, Meningeal; Chromosome 8, trisomy; Idiopathic thrombocytopenia; Cockayne Syndrome; Dyslipidemias; Hyperemia; Reactive airway disease; Diabetes Mellitus, Insulin-Dependent; XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; Autoimmune thrombocytopenia; Platyspondyly; Fever; Recurrent otitis media; Precursor Cell Lymphoblastic Leukemia Lymphoma; Impaired cognition; Chronic granulomatous disease; Diabetes Mellitus, Non-Insulin-Dependent; Dermatofibrosarcoma Protuberans; Giant Cell Fibroblastoma; Omenn Syndrome; Inflammation; X-Linked Combined Immunodeficiency Diseases; Pleural Tuberculosis; Polyarteritis Nodosa; Nephrotic Syndrome; Immune thrombocytopenic purpura; Hypersensitivity; Cognition Disorders; Malignant Peripheral Nerve Sheath Tumor; Combined immunodeficiency; Hemorrhage; Pneumonia; Wheezing; Splenomegaly; Spinal Cord Diseases; Amyotrophic Lateral Sclerosis; Immune System Diseases; Chronic diarrhea; Autoimmune hemolytic anemia; Paranasal Sinus Diseases; Granulomatous Disease, Chronic, X-Linked; Skin Diseases, Genetic; Sparse or absent eyebrows; Sparse/absent eyebrows; Absence of eyebrow; Aplasia/Hypoplasia of the eyebrow; Exfoliative dermatitis; Hypertensive disease; Lymphoproliferative Disorders; Alopecia; Inflammatory dermatosis; Metabolic Syndrome X; Abnormality of pelvic girdle bone morphology; Immunoglobulin A deficiency (disorder); Recurrent bacterial infection; Increased susceptibility to bacterial infections; Prone to bacterial infection; Sinusitis; Choriocarcinoma; Eosinophilia; Dermatitis; Undifferentiated leukemia; Leishmaniasis; hiv-infection/aids; Hepatomegaly; Coronary Artery Disease; Anemia, Diamond-Blackfan; Pruritus; Pediatric Obesity; Malignant Pleural Mesothelioma; Measles; Congestive heart failure; Obesity; Acute Undifferentiated Leukemia; Pleural Effusion, Malignant; Maturity onset diabetes mellitus in young; Anoxia; Anemia, Sickle Cell; Bronchopulmonary Dysplasia; Intellectual Disability; Anemia, Hemolytic; Essential Hypertension; Autism Spectrum Disorders; Asthma; Impaired glucose tolerance; Hashimoto Disease; Undergrowth; Failure to gain weight; Pediatric failure to thrive",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8101097852323003; 0.8138488881521341; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8508164886128737; 0.8523465762428218; 0.8554819098734854; 0.8610447277138289; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.8815127642200768; 0.8851456306720444; 0.8851456306720444; 0.8867509400747969; 0.887595340546704; 0.887595340546704; 0.887595340546704; 0.8911256045597441; 0.8911256045597441; 0.8935933996254593; 0.8938510789776706; 0.8976039441125321; 0.8989612563669234; 0.900167961295542; 0.9039108388826153; 0.9119978323790848; 0.9184153253162451; 0.9252532782268056; 0.9446671211493156; 0.9478210444156088; 0.951016614400691; 0.9557184806547836; 0.9639249377588224; 0.9672478180546946; 0.9734506818882446; 0.9855010111136676; 0.9884235744717738; 0.9896536639644284; 0.9896536639644284,Omenn Syndrome; Spinal Cord Diseases; Severe Combined Immunodeficiency Disease; Eosinophilia; Mesangial Sclerosis; Lymphoma; Hyperemia; Otitis Media; Autoimmune Hemolytic Anemia; Immune Thrombocytopenic Purpura; B-Cell Lymphoma; Exfoliative Dermatitis; Dermatitis; Thyroiditis; Pancreatic Adenocarcinoma; Lung Cancer; Hypothyroidism; Sinusitis; Lung Neoplasms; Autism; Alopecia; Anemia; Asthma; Nephrotic Syndrome,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8165359516083085; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8706864397989688; 0.8706864397989688; 0.8879896755141929; 0.8897718769742773; 0.8903301324869451; 0.911896615143974; 0.9367173114041438; 0.9369188149054885; 0.9832345076528324; 0.9832345076528324,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Severe combined immunodeficiency due to adenosine deaminase deficiency ORPHA:277; Omenn syndrome ORPHA:39041; Hydranencephaly ORPHA:2177; NDE1-related microhydranencephaly ORPHA:443162,0.3832844616405875; 0.7929682744768703; 0.8447648476081987; 0.8922466888454011; 0.8922466888454011,,,,,,
ADAM8,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasm; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Colorectal Cancer; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Triple Negative Breast Neoplasms; Lung Neoplasms; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Squamous cell carcinoma; Rheumatoid Arthritis; Airway Obstruction; Allergic disposition; Pneumonitis; Myocardial Infarction; Synovitis; Liver diseases; CNS disorder; Superficial ulcer; bone destruction; Pneumonia; Drug-Induced Liver Disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced; Chronic Obstructive Airway Disease; Brain Tumor, Primary; Asthma",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8140222479282434; 0.8168901801930506; 0.8168901801930506; 0.8232134984476662; 0.834094492023826; 0.8523465762428218; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8578473133580928; 0.8648405521677974; 0.9189398569397552; 0.9672478180546946,,,"Idiopathic CD4 lymphocytopenia ORPHA:228000; Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Megaconial congenital muscular dystrophy ORPHA:280671; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Intermediate osteopetrosis ORPHA:210110; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Aicardi-Goutieres syndrome ORPHA:51; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Autosomal dominant dopa-responsive dystonia ORPHA:98808; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; GTP cyclohydrolase I deficiency ORPHA:2102; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; NIK deficiency ORPHA:447731; Waldenstrom macroglobulinemia ORPHA:33226; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204; Dehydrated hereditary stomatocytosis ORPHA:3202; Takayasu arteritis ORPHA:3287; Autosomal recessive malignant osteopetrosis ORPHA:667; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; Gray platelet syndrome ORPHA:721; Multiple intestinal atresia ORPHA:2300; Osteogenesis imperfecta type 5 ORPHA:216828; Palmoplantar keratoderma-esophageal carcinoma syndrome ORPHA:2198; Revesz syndrome ORPHA:3088; Metaphyseal anadysplasia ORPHA:1040; Dysosteosclerosis ORPHA:1782; Autosomal dominant severe congenital neutropenia ORPHA:486; Epidermodysplasia verruciformis ORPHA:302; Charcot-Marie-Tooth disease type 1C ORPHA:101083; Congenital isolated ACTH deficiency ORPHA:199296; Neutrophil immunodeficiency syndrome ORPHA:183707; Mitochondrial neurogastrointestinal encephalomyopathy ORPHA:298; Familial hemophagocytic lymphohistiocytosis ORPHA:540; BENTA disease ORPHA:464336; Cherubism ORPHA:184; Odonto-onycho-dermal dysplasia ORPHA:2721; Persistent polyclonal B-cell lymphocytosis ORPHA:300324; Schopf-Schulz-Passarge syndrome ORPHA:50944; Severe combined immunodeficiency due to CARD11 deficiency ORPHA:357237; Recurrent infection due to specific granule deficiency ORPHA:169142; Common variable immunodeficiency ORPHA:1572; Blau syndrome ORPHA:90340; Nasopharyngeal carcinoma ORPHA:150; Autosomal recessive hypohidrotic ectodermal dysplasia ORPHA:248",0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1054066549396977; 0.1294848460749822; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2047219337649946; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8564946241562607; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ADARB1,"Non-Small Cell Lung Carcinoma; Malignant neoplasm of lung; Ki-1+ Anaplastic Large Cell Lymphoma; Liver carcinoma; Hepatocarcinogenesis; Glioblastoma; Astrocytoma; Primary malignant neoplasm of lung; Hepatitis D Infection; Carcinoma of lung; Malignant neoplasm of liver; Sclerocystic Ovaries; Mental disorders; Abnormal behavior; Hodgkin Disease; Brain Neoplasms; Sarcoma; Lupus Erythematosus, Systemic; Alzheimer's Disease; Liver neoplasms; Schizophrenia; Liver Cirrhosis; Glioblastoma Multiforme; Amyotrophic Lateral Sclerosis; Other specified transient cerebral ischemias; Migraine Disorders; Transient Ischemic Attack; Bipolar I disorder; Body mass index; Finding of body mass index; Hyperactive behavior; Obesity; Bipolar Disorder; Mood Disorders; Polycystic Ovary Syndrome; Psychotic Disorders; Behcet Syndrome; Unipolar Depression; Major Depressive Disorder",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8232134984476662; 0.8342163953428735; 0.8402911822757345; 0.8402911822757345; 0.8648405521677974; 0.8816060628973529; 0.882453254162044; 0.8867509400747969; 0.8867509400747969; 0.8878860377518915; 0.8989612563669234; 0.900167961295542; 0.9093740881835894; 0.9174808175273056; 0.939985154445373; 0.9446671211493156; 0.9455834988784428; 0.9658628445524134,Sclerocystic Ovaries; Psychosis; Polycystic Ovary Syndrome; Schizophrenia; Diabetes Mellitus; Bipolar Disorder,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.919442421650838; 0.943322675973118,,,,,,,,
AGPAT2,"Malignant neoplasm of ovary; Growth hormone excess; Ovarian Carcinoma; Malignant neoplasm of pancreas; Tall stature; Pancreatic carcinoma; Nephrolithiasis; Advanced bone age; Russell-Silver syndrome; Triangular face; Endometrial Carcinoma; Long foot; Osteosarcoma; Osteosarcoma of bone; Adenocarcinoma of pancreas; Spastic paraplegia 17; Congenital Generalized Lipodystrophy Type 2; Sclerocystic Ovaries; Hyperplasia of supraorbital margins; Hyperplasia of supraorbital ridge; Hypertrophy of supraorbital margins; Hypertrophy of supraorbital ridge; Prominent supraorbital ridges; Large hand; Large auricle; Large pinnae; Macrotia; Hypertrophy of lower jaw; mandibular excess (physical finding); Mandibular hyperplasia; Increased appetite (finding); Abnormal pigmentation; Hyperphagia; Increased size of the mandible; Decreased serum leptin; Class III malocclusion; Acromegaly; Fanconi-Bickel Syndrome; Lipoatrophic Diabetes Mellitus; Serum triglycerides raised; Diabetes; Diabetes Mellitus; Bone Cysts; Myeloid Leukemia, Chronic; Skeletal muscle hypertrophy; Hyperinsulinism; Familial generalized lipodystrophy; Decreased fertility in females; Precocious Puberty; ovarian neoplasm; Broad foot; Liver Cirrhosis; Acanthosis Nigricans; Hereditary Motor and Sensory-Neuropathy Type II; Splenomegaly; Mental deficiency; Steatohepatitis; Peripheral motor neuropathy; Liver Dysfunction; Lipoatrophy; Acute pancreatitis; Generalized hirsutism; Metabolic Syndrome X; Fatty Liver; Hypertrophy of clitoris; Subclinical abnormal liver function tests; Transaminases increased; Elevated liver enzymes; Increased liver function tests; Liver enzymes abnormal; Liver function tests abnormal finding; Elevated hepatic transaminases; Dull intelligence; Low intelligence; Mental impairment; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Hirsutism; Hepatomegaly; Poor school performance; Obesity; Insulin Resistance; Polycystic Ovary Syndrome; Mental Retardation; Sweating; Hyperhidrosis disorder; Increased sweating; Umbilical hernia; Hypertrophic Cardiomyopathy; Lipodystrophy; Intellectual Disability; Trichohepatoenteric Syndrome; Liver Failure",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8168901801930506; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8584283190330553; 0.8610447277138289; 0.8628363180844141; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.8757755363384367; 0.876210765330195; 0.8769418330148872; 0.8771562273432176; 0.8774809019744603; 0.887595340546704; 0.8913141512402477; 0.8989612563669234; 0.9098977259629772; 0.9174808175273056; 0.922229272318747; 0.9307095582633488; 0.9307095582633488; 0.9307095582633488; 0.9457739154209; 0.9459312971127588; 0.946564927793026; 0.9478210444156088; 0.94939825643792; 0.9816840072553962,Nephrolithiasis; Congenital Lipodystrophy; Immunologic Deficiency Syndromes; Somatotropin Deficiency; Lipoatrophy; Renal Glomerular Disease; Polycystic Ovary Syndrome; Precocious Puberty; Isolated Somatotropin Deficiency; Secondary Physiologic Amenorrhea; Osteopenia; Pancreatitis; Macrotia; Hypertrophy Of Clitoris; Malocclusion; Lipodystrophy; Atrial Fibrillation; Kidney Disease; Talipes Transversoplanus; Fatty Liver; Mental Retardation; Acanthosis Nigricans; Myocardial Infarction; Hyperinsulinism; Ventricular Hypertrophy; Osteoporosis; Pulmonary Arterial Hypertension; Diabetes Mellitus; Scoliosis; Atherosclerosis; Nervous System Diseases; Congestive Heart Failure; Liver Failure; Hypertrophic Cardiomyopathy; Renal Insufficiency; Congenital Exomphalos; Cirrhosis; Myopathy,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.829560580336605; 0.8321692755697452; 0.8337953215113012; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.8903630091389316; 0.919442421650838; 0.924275664330454; 0.941216656523771; 0.9492120794677584; 0.9543024119762946; 0.9543024119762946; 0.9726837163662044; 0.9726837163662044; 0.980894832851993; 0.9832345076528324; 0.986561188259959,"Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Multiple endocrine neoplasia type 1 ORPHA:652; CLN11 disease ORPHA:314629; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; Marinesco-Sjogren syndrome ORPHA:559; Adrenomyeloneuropathy ORPHA:139399; CLN10 disease ORPHA:228337; Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; X-linked cerebral adrenoleukodystrophy ORPHA:139396; CADDS ORPHA:369942; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Galactokinase deficiency ORPHA:79237; Dysosteosclerosis ORPHA:1782; Rare isolated myopia ORPHA:98619; 5-oxoprolinase deficiency ORPHA:33572; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; Congenital bile acid synthesis defect type 1 ORPHA:79301; Congenital factor XII deficiency ORPHA:330; F12-related hereditary angioedema with normal C1Inh ORPHA:100054; Hyperammonemia due to N-acetylglutamate synthase deficiency ORPHA:927; Mucopolysaccharidosis type 7 ORPHA:584; Sanfilippo syndrome type B ORPHA:79270; Embryonal rhabdomyosarcoma ORPHA:99757; Ethylmalonic encephalopathy ORPHA:51188; Fucosidosis ORPHA:349; Glycogen storage disease due to acid maltase deficiency, infantile onset ORPHA:308552; Glycogen storage disease due to acid maltase deficiency, late-onset ORPHA:420429; Leukocyte adhesion deficiency type II ORPHA:99843; NON RARE IN EUROPE: Paget disease of bone ORPHA:280110; Congenital generalized lipodystrophy ORPHA:528; Argininosuccinic aciduria ORPHA:23; Autosomal recessive spastic paraplegia type 76 ORPHA:488594",0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011,,,,,,
AHNAK2,ANOPHTHALMIA AND PULMONARY HYPOPLASIA,0.7880542567584415,Lupus Erythematosus,0.9145387439550552,"Bilateral perisylvian polymicrogyria ORPHA:98889; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Frank-Ter Haar syndrome ORPHA:137834; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; 19p13.3 microduplication syndrome ORPHA:447980; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Non-immune hydrops fetalis ORPHA:363999; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; Isolated biliary atresia ORPHA:30391; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Aplasia cutis congenita ORPHA:1114; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Atelosteogenesis type I ORPHA:1190; Atelosteogenesis type III ORPHA:56305; Boomerang dysplasia ORPHA:1263; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Familial Alzheimer-like prion disease ORPHA:280397; Fatal familial insomnia ORPHA:466; Gerstmann-Straussler-Scheinker syndrome ORPHA:356; Huntington disease-like 1 ORPHA:157941; Inherited Creutzfeldt-Jakob disease ORPHA:282166; Kuru ORPHA:454745; Larsen syndrome ORPHA:503; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Nance-Horan syndrome ORPHA:627; PrP systemic amyloidosis ORPHA:397606; RIN2 syndrome ORPHA:217335; Scalp-ear-nipple syndrome ORPHA:2036; Sporadic fatal insomnia ORPHA:586130; Familial primary localized cutaneous amyloidosis ORPHA:353220; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Papillary renal cell carcinoma ORPHA:319298; Erythrokeratodermia variabilis ORPHA:317; Severe generalized junctional epidermolysis bullosa ORPHA:79404; Bamforth-Lazarus syndrome ORPHA:1226; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Chondrodysplasia-disorder of sex development syndrome ORPHA:1422; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Isolated hyperchlorhidrosis ORPHA:542657; Laryngo-onycho-cutaneous syndrome ORPHA:2407; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; Neurofibromatosis type 2 ORPHA:637; Palmoplantar keratoderma, Nagashima type ORPHA:140966; Griscelli syndrome type 3 ORPHA:79478; Neonatal inflammatory skin and bowel disease ORPHA:294023; Trichorhinophalangeal syndrome type 2 ORPHA:502; Unverricht-Lundborg disease ORPHA:308; Athyreosis ORPHA:95713; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea ORPHA:238763",0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.44,Homo sapiens,rubvd;rubvm;rubvn;rubvo;rubvr;rubvt;rubvv
AKAP8,Malignant neoplasm of breast; Autistic Disorder; Unipolar Depression; Major Depressive Disorder,0.4084380369379369; 0.8019075543217649; 0.9455834988784428; 0.9658628445524134,Mental Depression; Breast Cancer,0.8903630091389316; 0.8903630091389316,CAMOS syndrome ORPHA:83472; QRICH1-related intellectual disability-chondrodysplasia syndrome ORPHA:580940,0.1991445465001551; 0.3832844616405875,,,,,,
AKR1C4,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Leukemia, Myelocytic, Acute; Malignant neoplasm of prostate; Prostate carcinoma; Dementia; Mild dementia; Paranoid ideation; Presenile dementia; Alzheimer's Disease; Polycythemia Vera; Manic Disorder; Manic; Virus Diseases; Bacterial Infections; Thrombocythemia, Essential; 46, XY Disorders of Sex Development; Alcoholic Intoxication, Chronic; Depression, Bipolar; Primary Sj??gren's syndrome; Chronic Lymphocytic Leukemia; Senile Plaques; Impaired cognition; Paranoia; Triglycerides measurement; Cognition Disorders; Congenital Abnormality; Anemia; Kartagener Syndrome; Cerebrovascular accident; Cerebellar degeneration; Persistent infection; Bipolar Disorder",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8270909867833504; 0.8402911822757345; 0.8584283190330553; 0.8608860081595284; 0.8648405521677974; 0.8838621755797691; 0.8851456306720444; 0.900167961295542,"46, XY Disorder Of Sex Development; 46, XY Sex Reversal; Manic Disorder; Paranoia; Ambiguous Genitalia; Male Pseudohermaphroditism; Cryptorchidism; Bipolar Disorder",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.943322675973118,"Alkaptonuria ORPHA:56; 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency ORPHA:752; Rotor syndrome ORPHA:3111; Dubin-Johnson syndrome ORPHA:234; Congenital factor XIII deficiency ORPHA:331; Atypical hemolytic uremic syndrome with anti-factor H antibodies ORPHA:93581; C3 glomerulopathy ORPHA:329918; Familial afibrinogenemia ORPHA:98880; Familial dysfibrinogenemia ORPHA:98881; Familial hypodysfibrinogenemia ORPHA:248408; Familial hypofibrinogenemia ORPHA:101041; 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency ORPHA:753; AApoAII amyloidosis ORPHA:238269; AFib amyloidosis ORPHA:93562; Caroli disease ORPHA:53035; Congenital analbuminemia ORPHA:86816; Congenital bile acid synthesis defect type 2 ORPHA:79303; Congenital factor II deficiency ORPHA:325; Congenital factor XI deficiency ORPHA:329; Congenital high-molecular-weight kininogen deficiency ORPHA:483; Corticosteroid-binding globulin deficiency ORPHA:199247; Dihydropyrimidinuria ORPHA:38874; Familial apolipoprotein A5 deficiency ORPHA:530849; Fanconi-Bickel syndrome ORPHA:2088; Hawkinsinuria ORPHA:2118; Hemochromatosis type 3 ORPHA:225123; Hereditary fructose intolerance ORPHA:469; Hereditary thrombophilia due to congenital antithrombin deficiency ORPHA:82; Hyperlipidemia due to hepatic triacylglycerol lipase deficiency ORPHA:140905; Hypertryptophanemia ORPHA:2224; IRIDA syndrome ORPHA:209981; NON RARE IN EUROPE: Congenital isolated thyroxine-binding globulin deficiency ORPHA:209893; NON RARE IN EUROPE: Familial dysalbuminemic hyperthyroxinemia ORPHA:276271; Severe hereditary thrombophilia due to congenital protein C deficiency ORPHA:745; Tyrosinemia type 2 ORPHA:28378; Tyrosinemia type 3 ORPHA:69723; Urocanic aciduria ORPHA:210128; 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency ORPHA:443087; Cerebral sinovenous thrombosis ORPHA:329217; Cholesterol-ester transfer protein deficiency ORPHA:79506; NON RARE IN EUROPE: Hyperlipoproteinemia type 4 ORPHA:413; Immunodeficiency due to a late component of complement deficiency ORPHA:169150; Intrahepatic cholestasis of pregnancy ORPHA:69665; Primary Fanconi renotubular syndrome ORPHA:3337; NON RARE IN EUROPE: Non rare thrombophilia ORPHA:64738; C3 glomerulonephritis ORPHA:329931; Sitosterolemia ORPHA:2882; Ataxia with vitamin E deficiency ORPHA:96; Benign recurrent intrahepatic cholestasis type 2 ORPHA:99961; Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome ORPHA:2848; Congenital prekallikrein deficiency ORPHA:749; Crigler-Najjar syndrome type 1 ORPHA:79234; Crigler-Najjar syndrome type 2 ORPHA:79235; Cystinuria type B ORPHA:93613; Enzalutamide toxicity ORPHA:529828; Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia ORPHA:79258; Glycogen storage disease due to hepatic glycogen synthase deficiency ORPHA:2089; Hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency ORPHA:217467; Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency ORPHA:209902; Hypoplasminogenemia ORPHA:722; Idiopathic hypercalciuria ORPHA:2197; Letrozole toxicity ORPHA:529831; Mild hemophilia B ORPHA:169799; Moderately severe hemophilia B ORPHA:169796; NON RARE IN EUROPE: Gilbert syndrome ORPHA:357; NON RARE IN EUROPE: Trimethylaminuria ORPHA:35056; Ornithine transcarbamylase deficiency ORPHA:664; PLG-related hereditary angioedema with normal C1Inh ORPHA:537072; Primary hyperoxaluria type 1 ORPHA:93598; Progressive familial intrahepatic cholestasis type 2 ORPHA:79304; Severe hemophilia B ORPHA:169793; Severe primary trimethylaminuria ORPHA:468726; Symptomatic form of hemophilia B in female carriers ORPHA:177929; Transient familial neonatal hyperbilirubinemia ORPHA:2312; Dense deposit disease ORPHA:93571",0.1991445465001551; 0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ANGEL2,,,,,Myhre syndrome ORPHA:2588; ALG13-CDG ORPHA:324422; Ataxia-telangiectasia ORPHA:100; Ataxia-telangiectasia variant ORPHA:370109; Pierpont syndrome ORPHA:487825,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ANP32B,"Malignant neoplasm of breast; Reticulocyte count (procedure); Breast Carcinoma; Carcinogenesis; B-Cell Lymphomas; leukemia; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Colorectal Carcinoma; Leukemogenesis; Adenoma; Glioma; IMMUNE SUPPRESSION; Colorectal Cancer; Glioblastoma; Neoplasm Metastasis; Monoclonal Gammopathy of Undetermined Significance; Red Blood Cell Count measurement; Hematologic Neoplasms; Multiple Myeloma; Malignant neoplasm of stomach; Hodgkin Disease; Tumor Progression; Lupus Erythematosus, Systemic; Coronary Arteriosclerosis; Granulomatosis with polyangiitis; Periodontitis; Stomach Carcinoma; Autoimmune Diseases; Squamous cell carcinoma; Solid Neoplasm; Rheumatoid Arthritis; Rhinosinusitis; Rheumatism; Malignant Glioma; Multiple Sclerosis; Waldenstrom Macroglobulinemia; Psoriasis; Myocardial Infarction; Seborrheic dermatitis; Adenocarcinoma of large intestine; Chronic Lymphocytic Leukemia; Degenerative polyarthritis; Autoimmune thrombocytopenia; Osteopenia; Immune thrombocytopenic purpura; Common Variable Immunodeficiency; Thrombocytopenia due to platelet alloimmunization; Dermatitis, Atopic; Coronary Artery Disease; Eczema; Coronary heart disease; Acquired Hypogammaglobulinemia; Asthma; Colitis; Lupus Nephritis",0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8168901801930506; 0.8212681436603975; 0.8232134984476662; 0.8402911822757345; 0.8610447277138289; 0.8867509400747969; 0.887595340546704; 0.909484944705772; 0.9119978323790848; 0.9154499654632742; 0.9672478180546946; 0.9738491767258852; 0.9896536639644284,,,Hermansky-Pudlak syndrome type 7 ORPHA:231531; AICA-ribosiduria ORPHA:250977; DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome ORPHA:494444; Oculopharyngeal muscular dystrophy ORPHA:270; Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome ORPHA:477814; Ribose-5-P isomerase deficiency ORPHA:440706; Myxoid/round cell liposarcoma ORPHA:99967; Leber plus disease ORPHA:99718; Autosomal dominant Charcot-Marie-Tooth disease type 2B ORPHA:99936; Histiocytoid cardiomyopathy ORPHA:137675; MT-ATP6-related mitochondrial spastic paraplegia ORPHA:320360; NARP syndrome ORPHA:644; Poikiloderma with neutropenia ORPHA:221046; Periodic paralysis with later-onset distal motor neuropathy ORPHA:397750; Isolated ATP synthase deficiency ORPHA:254913; MERRF ORPHA:551; Leber hereditary optic neuropathy ORPHA:104; Mitochondrial DNA-associated Leigh syndrome ORPHA:255210; MELAS ORPHA:550,0.3832844616405875; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8939858547904395; 0.896422440954666; 0.8977183736895791; 0.8977183736895791; 0.9025296114347576,,,,,,
AOC3,"Adenocarcinoma; Colorectal Carcinoma; Vascular Diseases; Colorectal Cancer; Lymphocytic infiltration; Nodular glomerulosclerosis; melanoma; Chronic lung disease; AURAL ATRESIA, CONGENITAL; Arteriosclerosis; Atherosclerosis; Invasive Carcinoma; Alzheimer's Disease; Aortic Aneurysm, Ruptured; Cerebral Amyloid Angiopathy; MYOPATHY, MYOFIBRILLAR, DESMIN-RELATED; Diabetes; Diabetes Mellitus; Uveitis; Cytomegalovirus Infections; Aortic Aneurysm; Pneumonitis; Psoriasis; Kidney Diseases; Sclerosis; Paratuberculosis; Proliferative diabetic retinopathy; Diabetes Mellitus, Insulin-Dependent; Chronic Kidney Insufficiency; Diabetes Mellitus, Non-Insulin-Dependent; Lymphoproliferative Disorder of the Skin; Inflammatory abnormality of the eye; Adult type dermatomyositis; Pneumonia; Hypertensive disease; Reperfusion Injury; Diabetes Mellitus, Experimental; Streptozotocin Diabetes; Alloxan Diabetes; Dermatomyositis; Intracranial Aneurysm; Cerebrovascular accident; Amyloidosis; Uremia; Diabetic Angiopathies; Age related macular degeneration; Obesity; Neuropathy; Diabetic Nephropathy; Chronic Kidney Diseases; Arthritis; Myopathy; Metabolic Diseases; Myositis",0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8474481237156937; 0.8584283190330553; 0.8642802827048847; 0.8642802827048847; 0.8642802827048847; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8672189956534445; 0.882453254162044; 0.8867509400747969; 0.8980854850210683; 0.8989612563669234; 0.914995991166204; 0.9390727893210336; 0.9393256300017014; 0.9431511078237256; 0.9557184806547836; 0.9564633032157428; 0.9658628445524134,Diabetic Nephropathy; Paratuberculosis; Hypertension; Glomerulosclerosis; Kidney Disease; Diabetes Mellitus; Renal Insufficiency,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8210988731657684; 0.919442421650838; 0.9726837163662044,Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; Diencephalic-mesencephalic junction dysplasia ORPHA:319192; Acetazolamide-responsive myotonia ORPHA:99736; CIDEC-related familial partial lipodystrophy ORPHA:435651; Hyperkalemic periodic paralysis ORPHA:682; Myotonia fluctuans ORPHA:99734; Myotonia permanens ORPHA:99735; Paramyotonia congenita of Von Eulenburg ORPHA:684; Adult hypophosphatasia ORPHA:247676; Childhood-onset hypophosphatasia ORPHA:247667; Infantile hypophosphatasia ORPHA:247651; Odontohypophosphatasia ORPHA:247685; PLIN1-related familial partial lipodystrophy ORPHA:280356; Perinatal lethal hypophosphatasia ORPHA:247623; Prenatal benign hypophosphatasia ORPHA:247638; Classical-like Ehlers-Danlos syndrome type 1 ORPHA:230839; Pancreatic insufficiency-anemia-hyperostosis syndrome ORPHA:199337; Transient infantile hypertriglyceridemia and hepatosteatosis ORPHA:300293,0.1054066549396977; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
APC2,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Relative macrocephaly; Tall stature; Colorectal Carcinoma; Colon Carcinoma; Advanced bone age; Malignant tumor of colon; Atrial Premature Complexes; Colorectal Neoplasms; Adenoma; Mammary Neoplasms; Hyperplasia of nose; Hypertrophy of nose; Large nose; Colorectal Cancer; Frontal bossing; Large auricle; Large pinnae; Macrotia; Aplasia/Hypoplasia of the corpus callosum; Hypertrophy of lower jaw; mandibular excess (physical finding); Mandibular hyperplasia; Conductive hearing loss; Increased size of the mandible; Bulging forehead; Prominent forehead; Tumor Progression; Premature tooth eruption; Class III malocclusion; Feeding difficulties in infancy; Alzheimer's Disease; Anteverted nostril; Cognitive delay; Sotos' syndrome; Increased head circumference; Huntington Disease; Pineal Gland Neoplasm; Global developmental delay; Mental and motor retardation; Teratocarcinoma; Long face; Abnormality of immune system physiology; Precocious Puberty; Adenocarcinoma of lung (disorder); Big calvaria; Increased size of skull; Difficulty speaking; Problems speaking; Poor speech; Downward slant of palpebral fissure; Hypoglycemia; Turridolichocephaly; Narrow cranium shape; Narrow head shape; Narrow skull shape; Long narrow head; Alzheimer Disease, Late Onset; Dilated ventricles (finding); Mental deficiency; Dull intelligence; Low intelligence; Inflammatory Bowel Diseases; Mammary Neoplasms, Human; Orbital separation excessive; High forehead; Hyperactive behavior; Poor school performance; Obesity; Depressed nasal ridge; Byzanthine arch palate; Muscle hypotonia; Mental Retardation; Intellectual Disability; Colitis",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8138488881521341; 0.8168901801930506; 0.8168901801930506; 0.8232134984476662; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8757755363384367; 0.8757755363384367; 0.8815127642200768; 0.8815127642200768; 0.8851456306720444; 0.8867509400747969; 0.8878860377518915; 0.8913141512402477; 0.8989612563669234; 0.9083161862856644; 0.9119978323790848; 0.9124568647908072; 0.922229272318747; 0.9478210444156088; 0.9738491767258852,Sacrococcygeal Teratoma; Hypoglycemia; Developmental Delay; Macrocephaly; Precocious Puberty; Urogenital Abnormalities; Nervous System Neoplasms; Frontal Bossing; Macrotia; Accessory Kidney; Malocclusion; Hearing Loss; Craniosynostosis; Mammary Neoplasms; Mental Retardation; Developmental Dysplasia Of The Hip; Marfan Syndrome; Vesicoureteral Reflux; Multiple Renal Cysts; Cryptorchidism; Inflammatory Bowel Disease; Cardiovascular Abnormalities; Heart Septal Defects; Breast Cancer; Strabismus; Scoliosis; Micrognathism; Breast Carcinoma; Dolichocephaly; Colorectal Neoplasms; High Palate; Hypospadias; Obesity; Colorectal Cancer; Patent Ductus Arteriosus,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8337953215113012; 0.8356859041719433; 0.8477374749042494; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8662301945830305; 0.8903301324869451; 0.8903630091389316; 0.8908485337686392; 0.924275664330454; 0.9398381935810408; 0.9398381935810408; 0.9398381935810408; 0.9510372690456612; 0.9578111936867284; 0.974502015052702; 0.9832345076528324; 0.9832345076528324; 0.9946608061329084,"Otospondylomegaepiphyseal dysplasia ORPHA:1427; PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Spinocerebellar ataxia type 21 ORPHA:98773; 1p36 deletion syndrome ORPHA:1606; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Familial infantile myoclonic epilepsy ORPHA:352582; Spastic paraplegia-optic atrophy-neuropathy syndrome ORPHA:320406; Intellectual disability-epilepsy-extrapyramidal syndrome ORPHA:468620; DOORS syndrome ORPHA:79500; Focal epilepsy-intellectual disability-cerebro-cerebellar malformation ORPHA:352587; Primary dystonia, DYT4 type ORPHA:98805; Progressive myoclonic epilepsy with dystonia ORPHA:352596; Right sided atrial isomerism ORPHA:97548; Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome ORPHA:163727; Gorlin syndrome ORPHA:377; Idiopathic central precocious puberty ORPHA:169615; Early infantile epileptic encephalopathy ORPHA:1934; Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome ORPHA:1171; Rapid-onset dystonia-parkinsonism ORPHA:71517; Congenitally uncorrected transposition of the great arteries ORPHA:860; Sotos syndrome ORPHA:821; Ventriculomegaly-cystic kidney disease ORPHA:443988; Horizontal gaze palsy with progressive scoliosis ORPHA:2744; Myoclonic-astatic epilepsy ORPHA:1942; NKX6-2-related autosomal recessive hypomyelinating leukodystrophy ORPHA:527497",0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7593059616185558; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Influenza A virus (A/New York/599/1996(H3N2)) matrix protein 1 (gene: M1); Influenza A virus (A/New York/602/1996(H3N2)) matrix protein 1 (gene: M1); Influenza A virus (A/Northern Territory/60/1968(H3N2)) matrix protein 1 (gene: M1); Influenza A virus (A/Korea/426/1968(H2N2)) membrane protein M1 (gene: M1); Influenza A virus (A/Shanghai/02/2013(H7N9)) matrix protein 1 (gene: M1),0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096,,,,
ARHGAP11B,,,,,Acute myeloid leukemia with t(6;9)(p23;q34) ORPHA:402014; Autosomal recessive chorioretinopathy-microcephaly syndrome ORPHA:2518; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; NON RARE IN EUROPE: Primary ovarian failure ORPHA:619; ANE syndrome ORPHA:157954; Chuvash erythrocytosis ORPHA:238557; Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Von Hippel-Lindau disease ORPHA:892; Cone dystrophy with supernormal rod response ORPHA:209932; Congenital lactase deficiency ORPHA:53690; Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome ORPHA:457351; Posterior column ataxia-retinitis pigmentosa syndrome ORPHA:88628; Male infertility with azoospermia or oligozoospermia due to single gene mutation ORPHA:399805,0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9039465713743752,,,,,,
ARHGAP29,"Malignant neoplasm of breast; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Cleft palate with cleft lip; Lymphoma, Lymphocytic, Intermediate",0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415,"Malnutrition; Cleft Palate And Bilateral Cleft Lip; Velopharyngeal Insufficiency; Cleft Lip With Or Without Cleft Palate; Oropharyngeal Dysphagia; Hypoplasia Of The Maxilla; Lymphoma, Lymphocytic, Intermediate; Otitis Media; Malignant Lymphoma, Lymphocytic, Intermediate Differentiation; Hearing Loss; Breast Cancer",0.6734982286750932; 0.7311975666200533; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8903630091389316,"Cleft lip/palate ORPHA:199306; Non-immune hydrops fetalis ORPHA:363999; 1p31p32 microdeletion syndrome ORPHA:401986; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Atrial septal defect, ostium primum type ORPHA:99106; Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency ORPHA:91135; Chondrosarcoma ORPHA:55880; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Craniolenticulosutural dysplasia ORPHA:50814; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency ORPHA:300179; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa ORPHA:436274; Familial primary localized cutaneous amyloidosis ORPHA:353220; Papillary renal cell carcinoma ORPHA:319298; Pulmonary venoocclusive disease ORPHA:31837; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; Hereditary papillary renal cell carcinoma ORPHA:47044; Hypopigmentation-punctate palmoplantar keratoderma syndrome ORPHA:324561; NON RARE IN EUROPE: Autosomal dominant ichthyosis vulgaris ORPHA:462; Osteofibrous dysplasia ORPHA:488265; Congenital diaphragmatic hernia ORPHA:2140; Griscelli syndrome type 3 ORPHA:79478; Neonatal inflammatory skin and bowel disease ORPHA:294023; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Trichorhinophalangeal syndrome type 2 ORPHA:502; Auriculocondylar syndrome ORPHA:137888; Goldmann-Favre syndrome ORPHA:53540; Juvenile cataract-microcornea-renal glucosuria syndrome ORPHA:247794; Autosomal recessive polycystic kidney disease ORPHA:731; Myelodysplastic syndrome ORPHA:52688",0.2567797333165013; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human respirovirus 3 phosphoprotein,0.8999095837312036,,,,
ARID3B,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Mammary Neoplasms; Invasive carcinoma of breast; Malignant Head and Neck Neoplasm; Neoplasm Metastasis; Neuroblastoma; Central neuroblastoma; Tumor Initiation; Retinoblastoma; ovarian neoplasm,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076,Goldenhar Syndrome; Endometriosis,0.7765582368651238; 0.9726139569926774,Congenital non-communicating hydrocephalus ORPHA:269510; Spinocerebellar ataxia type 40 ORPHA:423275; Huntington disease ORPHA:399; NUT midline carcinoma ORPHA:443167; Familial medullary thyroid carcinoma ORPHA:99361; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia ORPHA:363972; Partial hydatidiform mole ORPHA:254693; Familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement ORPHA:2196; Tatton-Brown-Rahman syndrome ORPHA:404443,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ARID5A,,,Leukemia,0.7765582368651238,"Autosomal dominant centronuclear myopathy ORPHA:169189; Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Familial isolated pituitary adenoma ORPHA:314777; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Camurati-Engelmann disease ORPHA:1328; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; Infantile inflammatory bowel disease with neurological involvement ORPHA:565788; NIK deficiency ORPHA:447731; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204; Autosomal recessive malignant osteopetrosis ORPHA:667; Hermansky-Pudlak syndrome type 7 ORPHA:231531; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; Palmoplantar keratoderma-esophageal carcinoma syndrome ORPHA:2198; Revesz syndrome ORPHA:3088; Ependymoma ORPHA:251636; RELA fusion-positive ependymoma ORPHA:530792; Pediatric systemic lupus erythematosus ORPHA:93552; Combined immunodeficiency due to ORAI1 deficiency ORPHA:317428; Combined immunodeficiency due to STIM1 deficiency ORPHA:317430; Hereditary pediatric Behcet-like disease ORPHA:476102; Obesity due to pro-opiomelanocortin deficiency ORPHA:71526; Mitochondrial neurogastrointestinal encephalomyopathy ORPHA:298; Birdshot chorioretinopathy ORPHA:179; Combined immunodeficiency due to OX40 deficiency ORPHA:431149; Severe combined immunodeficiency due to adenosine deaminase deficiency ORPHA:277; Tubular aggregate myopathy ORPHA:2593; Charcot-Marie-Tooth disease type 1D ORPHA:101084; Charcot-Marie-Tooth disease type 4E ORPHA:99951; High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement ORPHA:480541",0.0036432528126817; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ARL4C,"Carcinogenesis; Adenocarcinoma; Colorectal Carcinoma; Lymphoma; Malignant neoplasm of lung; Colorectal Cancer; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Immunologic Deficiency Syndromes; Bile duct carcinoma; Myeloid Leukemia, Chronic; leiomyosarcoma; HIV Infections; Mental Depression; Disseminated Malignant Neoplasm; Depressive disorder",0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8026798872257774; 0.8145035474981049; 0.8769418330148872; 0.8867509400747969; 0.9103315000053974,,,"Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085; Brachydactyly type B2 ORPHA:140908; Stapes ankylosis with broad thumbs and toes ORPHA:140917; Tarsal-carpal coalition syndrome ORPHA:1412; Early-onset Lafora body disease ORPHA:324290; Fuhrmann syndrome ORPHA:2854; Phocomelia, Schinzel type ORPHA:2879",0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,,,,,,
ARMC6,High density lipoprotein measurement,0.7880542567584415,,,Galactokinase deficiency ORPHA:79237; Ichthyosis-prematurity syndrome ORPHA:88621; TELO2-related intellectual disability-neurodevelopmental disorder ORPHA:488642; Testicular regression syndrome ORPHA:983; Acute intermittent porphyria ORPHA:79276; Autosomal recessive ataxia due to PEX10 deficiency ORPHA:247815; Combined oxidative phosphorylation defect type 23 ORPHA:444013; Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome ORPHA:363694; Ocular anomalies-axonal neuropathy-developmental delay syndrome ORPHA:496790; RFVT2-related riboflavin transporter deficiency ORPHA:572543; THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome ORPHA:363444; Transketolase deficiency ORPHA:488618; Familial melanoma ORPHA:618; 8q24.3 microdeletion syndrome ORPHA:508488; Auditory neuropathy-optic atrophy syndrome ORPHA:542585; Bjornstad syndrome ORPHA:123; DDX41-related hematologic malignancy predisposition syndrome ORPHA:488647; Disseminated superficial actinic porokeratosis ORPHA:79152; Essential fructosuria ORPHA:2056; GMPPB-related  limb-girdle muscular dystrophy R19 ORPHA:363623; GRACILE syndrome ORPHA:53693; Glutaryl-CoA dehydrogenase deficiency ORPHA:25; Hyperimmunoglobulinemia D with periodic fever ORPHA:343; Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome ORPHA:508498; Macrocephaly-developmental delay syndrome ORPHA:397612; Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome ORPHA:363649; Methylmalonic aciduria due to transcobalamin receptor defect ORPHA:280183; Mevalonic aciduria ORPHA:29; NTHL1-related attenuated familial adenomatous polyposis ORPHA:454840; Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome ORPHA:543470; PYCR2-related microcephaly-progressive leukoencephalopathy ORPHA:481152; Renal tubulopathy-encephalopathy-liver failure syndrome ORPHA:254902; Short stature-brachydactyly-obesity-global developmental delay syndrome ORPHA:464288; Schwannomatosis ORPHA:93921; ALG1-CDG ORPHA:79327; Autosomal recessive cerebelloparenchymal disorder type 3 ORPHA:1170; CODAS syndrome ORPHA:1458; Combined oxidative phosphorylation defect type 17 ORPHA:369913; Isolated sedoheptulokinase deficiency ORPHA:440713; Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome ORPHA:457284; 3-methylglutaconic aciduria type 7 ORPHA:445038; CLN4A disease ORPHA:228340; CLN6 disease ORPHA:228363,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6873535151929783; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ASMTL,"Leukemia, Myelocytic, Acute; Acute Myeloid Leukemia, M1; Acute Myeloid Leukemia (AML-M2); Carney Complex; Intellectual Disability",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8168901801930506; 0.9478210444156088,Leukemia; Myeloid Leukemia,0.7765582368651238; 0.8356859041719433,,,,,,,,
ATG16L2,Crohn Disease,0.7880542567584415,Crohn Disease,0.8903630091389316,Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Adult-onset dystonia-parkinsonism ORPHA:199351; Barth syndrome ORPHA:111; Infantile neuroaxonal dystrophy ORPHA:35069; Megaconial congenital muscular dystrophy ORPHA:280671; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Intermediate osteopetrosis ORPHA:210110; Autosomal dominant spastic ataxia type 1 ORPHA:251282; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; 2q37 microdeletion syndrome ORPHA:1001; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome ORPHA:500144; NIK deficiency ORPHA:447731; Coats plus syndrome ORPHA:313838; Dehydrated hereditary stomatocytosis ORPHA:3202; CLN3 disease ORPHA:228346; Classic galactosemia ORPHA:79239; Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome ORPHA:352662; Craniosynostosis-dental anomalies ORPHA:284149; Grange syndrome ORPHA:79094; Gray platelet syndrome ORPHA:721; Nephrogenic syndrome of inappropriate antidiuresis ORPHA:93606; Osteogenesis imperfecta type 5 ORPHA:216828; Glycogen storage disease due to liver phosphorylase kinase deficiency ORPHA:264580; Hermansky-Pudlak syndrome with pulmonary fibrosis ORPHA:231500; Familial focal epilepsy with variable foci ORPHA:98820; Laron syndrome with immunodeficiency ORPHA:220465; Pityriasis rubra pilaris ORPHA:2897; Nodular fasciitis ORPHA:477742; Autosomal dominant multiple pterygium syndrome ORPHA:65743; Cherubism ORPHA:184; Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome ORPHA:538574; Primary sclerosing cholangitis ORPHA:171; Calpain-3-related  limb-girdle muscular dystrophy R1 ORPHA:267; Combined malonic and methylmalonic acidemia ORPHA:289504; Histidinemia ORPHA:2157; Native American myopathy ORPHA:168572; Predisposition to invasive fungal disease due to CARD9 deficiency ORPHA:457088; Pseudo-von Willebrand disease ORPHA:52530; Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia ORPHA:313808; Congenital vertebral-cardiac-renal anomalies syndrome ORPHA:521438; Hereditary clear cell renal cell carcinoma ORPHA:422526; Autoimmune polyendocrinopathy type 1 ORPHA:3453; Severe combined immunodeficiency due to IKK2 deficiency ORPHA:397787,0.0081550609410495; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ATG4A,Malignant neoplasm of breast; Breast Carcinoma; Malignant neoplasm of ovary; Ovarian Carcinoma; Crohn Disease,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415,,,"CEDNIK syndrome ORPHA:66631; Carnitine-acylcarnitine translocase deficiency ORPHA:159; Hemolytic anemia due to diphosphoglycerate mutase deficiency ORPHA:714; Neutral lipid storage disease with ichthyosis ORPHA:98907; Aspartylglucosaminuria ORPHA:93; Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome ORPHA:486815; Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency ORPHA:308425; Autosomal erythropoietic protoporphyria ORPHA:79278; X-linked intellectual disability, Nascimento type ORPHA:163956; Leukoencephalopathy-dystonia-motor neuropathy syndrome ORPHA:163684; Mitochondrial pyruvate carrier deficiency ORPHA:447784",0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ATP2C2,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Specific language impairment; Surfactant protein D measurement; Dyslexia; Language Disorders; Chronic Obstructive Airway Disease; Attention deficit hyperactivity disorder,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8648405521677974; 0.9770263358372888,Leukemia; Chronic Obstructive Pulmonary Disease; Attention Deficit Hyperactivity Disorder,0.7765582368651238; 0.966063509695942; 0.980894832851993,"Bilateral frontoparietal polymicrogyria ORPHA:101070; Van der Woude syndrome ORPHA:888; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Autosomal recessive cerebral atrophy ORPHA:363969; Congenital intrauterine infection-like syndrome ORPHA:1229; Congenital tufting enteropathy ORPHA:92050; EEM syndrome ORPHA:1897; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Lethal congenital contracture syndrome type 2 ORPHA:137776; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; Liddle syndrome ORPHA:526; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Gelatinous drop-like corneal dystrophy ORPHA:98957; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Syndromic congenital sodium diarrhea ORPHA:563708; Blepharo-cheilo-odontic syndrome ORPHA:1997; Idiopathic pulmonary fibrosis ORPHA:2032; Localized junctional epidermolysis bullosa ORPHA:251393; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Idiopathic bronchiectasis ORPHA:60033; Mullerian aplasia and hyperandrogenism ORPHA:247768; Neuropathy with hearing impairment ORPHA:139512; SERKAL syndrome ORPHA:139466; Systemic primary carnitine deficiency ORPHA:158; Microvillus inclusion disease ORPHA:2290; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; Hypocalcified amelogenesis imperfecta ORPHA:100032; Autosomal recessive distal renal tubular acidosis ORPHA:402041; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Autosomal recessive spastic paraplegia type 35 ORPHA:171629; Ectodermal dysplasia-syndactyly syndrome ORPHA:247820; Epithelial recurrent erosion dystrophy ORPHA:293381; Fatty acid hydroxylase-associated neurodegeneration ORPHA:329308; Ichthyosis-hypotrichosis syndrome ORPHA:91132; Late-onset junctional epidermolysis bullosa ORPHA:79406; MUC1-related autosomal dominant tubulointerstitial kidney disease ORPHA:88949; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Uncombable hair syndrome ORPHA:1410; Congenital sodium diarrhea ORPHA:103908; Diffuse panbronchiolitis ORPHA:171700; Cystic fibrosis ORPHA:586; Posterior polymorphous corneal dystrophy ORPHA:98973",0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5047266821728011; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ATP6V0D1,Lyme Disease; Schizophrenia,0.7880542567584415; 0.8067197998685076,,,"VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; CLN11 disease ORPHA:314629; Marinesco-Sjogren syndrome ORPHA:559; Beta-propeller protein-associated neurodegeneration ORPHA:329284; CCDC115-CDG ORPHA:468684; CLN10 disease ORPHA:228337; Mucolipidosis type IV ORPHA:578; Metachromatic leukodystrophy, adult form ORPHA:309271; Metachromatic leukodystrophy, juvenile form ORPHA:309263; Metachromatic leukodystrophy, late infantile form ORPHA:309256; ACys amyloidosis ORPHA:100008; Clear cell renal carcinoma ORPHA:319276; Mucolipidosis type III gamma ORPHA:423470; Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome ORPHA:480864; Atypical Gaucher disease due to saposin C deficiency ORPHA:309252; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Encephalopathy due to prosaposin deficiency ORPHA:139406; Galactosialidosis ORPHA:351; Genetic hyperferritinemia without iron overload ORPHA:254704; Hereditary hyperferritinemia-cataract syndrome ORPHA:163; L-ferritin deficiency ORPHA:440731; Neuroferritinopathy ORPHA:157846; Infantile Krabbe disease ORPHA:206436; Yunis-Varon syndrome ORPHA:3472; Infantile nephropathic cystinosis ORPHA:411629; Juvenile nephropathic cystinosis ORPHA:411634; Ocular cystinosis ORPHA:411641; Transaldolase deficiency ORPHA:101028; Autosomal dominant deafness-onychodystrophy syndrome ORPHA:79499; Fetal Gaucher disease ORPHA:85212; Gaucher disease type 2 ORPHA:77260; Gaucher disease type 3 ORPHA:77261; Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome ORPHA:2072; NON RARE IN EUROPE: Parkinson disease ORPHA:319705; Niemann-Pick disease type A ORPHA:77292; Niemann-Pick disease type B ORPHA:77293; Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency ORPHA:263297; Polyglucosan body myopathy type 2 ORPHA:456369; Proximal myopathy with extrapyramidal signs ORPHA:401768; NON RARE IN EUROPE: Hidradenitis suppurativa ORPHA:387; Behavioral variant of frontotemporal dementia ORPHA:275864",0.0155394890951578; 0.1040670578681756; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8953775799945711,,,,,,
ATP8A1,Non-Small Cell Lung Carcinoma; Cytokine Measurement,0.7765852775619541; 0.8690346447728063,,,Distal monosomy 1q ORPHA:36367; Succinic semialdehyde dehydrogenase deficiency ORPHA:22; Early-onset parkinsonism-intellectual disability syndrome ORPHA:2379; SHORT syndrome ORPHA:3163; Pseudohypoaldosteronism type 2D ORPHA:300525; Complex lethal osteochondrodysplasia ORPHA:457378; Renal pseudohypoaldosteronism type 1 ORPHA:171871,0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,,,,
B3GALT4,Ehlers-Danlos Syndrome,0.8497448945325101,,,Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; CCDC115-CDG ORPHA:468684; Revesz syndrome ORPHA:3088,0.0155394890951578; 0.0155394890951578; 0.1991445465001551; 0.3832844616405875,,,,,,
BAG2,Carcinogenesis,0.7333611688795861,,,"Adult polyglucosan body disease ORPHA:206583; Glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form ORPHA:308712; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form ORPHA:308684; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form ORPHA:308698; Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form ORPHA:308670; Glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form ORPHA:308655; Glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form ORPHA:308638; Glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form ORPHA:308621",0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,Salivirus NG-J1 3D; Nipah henipavirus P phosphoprotein,0.8999095837312036; 0.8999095837312036,,,,
BAIAP2,Carcinogenesis; Uric acid measurement (procedure); Mental disorders; Abnormal behavior; Memory performance; Gout; Impaired cognition; Cognition Disorders; Seizures; Autism Spectrum Disorders; Attention deficit hyperactivity disorder,0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8190761496232595; 0.8270909867833504; 0.9478210444156088; 0.9639249377588224; 0.9770263358372888,Gout; Gouty Arthritis; Anxiety Disorder; Mental Depression; Mood Disorder,0.7765582368651238; 0.7765582368651238; 0.8507213163251659; 0.8903630091389316; 0.9726139569926774,"Antley-Bixler syndrome ORPHA:83; Bilateral frontoparietal polymicrogyria ORPHA:101070; Bilateral perisylvian polymicrogyria ORPHA:98889; Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933",0.0414176838632111; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087,"Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human immunodeficiency virus nef protein (gene: nef); Tai Forest ebolavirus spike glycoprotein (gene: GP); Influenza B virus nonstructural protein 1 (gene: NS1); Reston ebolavirus spike glycoprotein (gene: GP); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) hemagglutinin (gene: HA); Macacine alphaherpesvirus 1 large tegument protein (gene: UL36); Bundibugyo ebolavirus spike glycoprotein (gene: GP); Dengue virus 1 membrane glycoprotein M (gene: flavivirus polyprotein); Dengue virus 2 membrane glycoprotein M (gene: flavivirus polyprotein); Vaccinia virus cowpox A-type inclusion protein; Variola virus hypothetical protein (gene: A49L); Dengue virus 3 membrane glycoprotein M (gene: flavivirus polyprotein); Dengue virus 4 membrane glycoprotein M (gene: flavivirus polyprotein); Ebola virus - Mayinga, Zaire, 1976 virion spike glycoprotein precursor (gene: GP); Zaire ebolavirus spike glycoprotein (gene: GP); Dengue virus 1 membrane glycoprotein precursor M (gene: flavivirus polyprotein); Dengue virus 4 membrane glycoprotein precursor M (gene: flavivirus polyprotein); Dengue virus 2 membrane glycoprotein precursor M (gene: flavivirus polyprotein); Dengue virus 3 membrane glycoprotein precursor M (gene: flavivirus polyprotein); Lake Victoria marburgvirus - DRC1999 glycoprotein (gene: GP); Yaba monkey tumor virus sulfhydryl oxidase; Monkeypox virus cowpox A-type inclusion protein; Ravn virus - Ravn, Kenya, 1987 glycoprotein (gene: GP); Influenza A virus (A/California/04/2009(H1N1)) polymerase PB1 (gene: PB1); Influenza A virus (A/California/07/2009(H1N1)) polymerase PB1 (gene: PB1); Influenza A virus (A/Korea/426/1968(H2N2)) PB1 polymerase subunit (gene: PB1); Influenza A virus (A/New York/392/2004(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/New York/599/1996(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/New York/602/1996(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/Northern Territory/60/1968(H3N2)) polymerase PB1 (gene: PB1); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) polymerase PB1 (gene: PB1); Influenza A virus (A/Shanghai/02/2013(H7N9)) polymerase PB1 (gene: PB1); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) polymerase (gene: PB1); Marburg marburgvirus glycoprotein (gene: GP); Lake Victoria marburgvirus - Leiden glycoprotein (gene: GP); Marburg virus - Musoke, Kenya, 1980 glycoprotein (gene: GP); Lake Victoria marburgvirus - Angola2005 glycoprotein (gene: GP); Mumps virus phoshoprotein (gene: V/P); Mumps virus genotype G phosphoprotein (gene: P)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9287050575620676; 0.9597398910543528; 0.9626366082099888,Escherichia coli;In vitro,0.44;0.72;0.74,Homo sapiens;chemical synthesis;eco57,Homo sapiens
BAIAP3,Carcinogenesis; Anxiety Disorders; Anxiety,0.7333611688795861; 0.946564927793026; 0.9708740267329932,,,Bilateral frontoparietal polymicrogyria ORPHA:101070; Amelocerebrohypohidrotic syndrome ORPHA:1946,0.1040670578681756; 0.8922466888454011,,,,,,
BCL2L10,"Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; B-Cell Lymphomas; leukemia; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Leukemogenesis; Malignant neoplasm of lung; Malignant neoplasm of prostate; de novo myelodysplastic syndromes; Liver carcinoma; Colorectal Cancer; Adult Myelodysplastic Syndrome; Prostate carcinoma; Neoplasm Metastasis; Epithelioma; Multiple Myeloma; Malignant neoplasm of stomach; Lymphoma, Follicular; Acute leukemia; Stomach Carcinoma; Small cell carcinoma of lung; Metastatic Neoplasm; Affective Disorders, Psychotic; Childhood Myelodysplastic Syndrome; Toxic Epidermal Necrolysis",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649,,,,,,,,,,
BCL2L11,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Non-Functioning Pituitary Gland Neoplasm; leukemia; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Atrial Premature Complexes; Lymphoma; Leukemogenesis; Non-Small Cell Lung Carcinoma; Colorectal Neoplasms; Adenoma; Mammary Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Lymphoma, Non-Hodgkin; Liver carcinoma; Malignant Head and Neck Neoplasm; Osteosarcoma; Colorectal Cancer; T-Cell Lymphoma; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Epithelioma; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Neuroblastoma; Central neuroblastoma; Monocyte count procedure; Monocyte count result; Immunologic Deficiency Syndromes; melanoma; Multiple Myeloma; Lung Neoplasms; Extraskeletal Myxoid Chondrosarcoma; Glucocorticoid Receptor Deficiency; Eosinophil count procedure; Eosinophil count result; Prolactinoma; Refractory Hodgkin Lymphoma; Burkitt Lymphoma; Hodgkin Disease; Sarcoma; Lupus Erythematosus, Systemic; Renal Cell Carcinoma; Lymphoma, Follicular; Alzheimer's Disease; Acute lymphocytic leukemia; Hepatitis C; Solid Neoplasm; Rheumatoid Arthritis; Carcinoid Tumor; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Small cell carcinoma of lung; Huntington Disease; Childhood Acute Lymphoblastic Leukemia; Adult Lymphoma; Childhood Lymphoma; Gonadal Dysgenesis, 45,X; Myeloid Leukemia, Chronic; Myeloid Leukemia; B-CELL MALIGNANCY, LOW-GRADE; Ovarian Diseases; Chronic Lymphocytic Leukemia; Adenocarcinoma of lung (disorder); Precursor B-cell lymphoblastic leukemia; Precursor Cell Lymphoblastic Leukemia Lymphoma; Blood basophil count (lab test); Autoimmune Lymphoproliferative Syndrome; Diabetes Mellitus, Non-Insulin-Dependent; Primary sclerosing cholangitis; Infection; Cholangitis, Sclerosing; Tuberculosis; Pituitary Neoplasms; Traditional Serrated Adenoma; Growth Hormone-Secreting Pituitary Adenoma; Dysautonomia, Familial; Severe Sepsis; Lymphoproliferative Disorders; Female Breast Carcinoma; Malignant neoplasm of female breast; Progressive cGVHD; Renal carcinoma; Leukemia, B-Cell; Neuroendocrine Tumors; Addictive Behavior; Trisomy; Progressive Neoplastic Disease; Carcinoid tumor no ICD-O subtype",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8272008757995397; 0.8337767145465158; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8508164886128737; 0.8523465762428218; 0.8578473133580928; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.887595340546704; 0.9015731019095328; 0.9029289778792944; 0.9265708351135048; 0.9393256300017014,"Sclerosing Cholangitis; Prostate Cancer; Lymphocytic Leukemia; Prostate Cancer, Hereditary; Cholangitis; Diabetes Mellitus; Breast Carcinoma",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8885757656973042; 0.919442421650838; 0.9398381935810408,,,Human gammaherpesvirus 4 hypothetical protein (gene: BHRF1); Human herpesvirus 4 type 2 BHRF1; Vaccinia virus Hypothetical protein (gene: F1L); Vaccinia virus Ankara apoptosis inhibitor; Human herpesvirus 4 type 2 BALF1,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
BCL7B,Adenocarcinoma; Uric acid measurement (procedure); C-reactive protein measurement; Lung Neoplasms; High density lipoprotein measurement; Williams Syndrome; Metabolic Syndrome X; Calcification of coronary artery,0.750391252594775; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8610447277138289; 0.9377696084218796,Gout; Gouty Arthritis,0.7765582368651238; 0.7765582368651238,Hermansky-Pudlak syndrome type 7 ORPHA:231531; CEDNIK syndrome ORPHA:66631; Williams syndrome ORPHA:904,0.3832844616405875; 0.5867963421058087; 0.8922466888454011,,,,,,
BCLAF1,"Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Carcinogenesis; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Lymphoma, Non-Hodgkin; Small cell carcinoma of lung; Cytomegalovirus Infections; Muscular Dystrophy, Emery-Dreifuss",0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8212681436603975,Lung Carcinoma,0.8139950454942313,"Vocal cord and pharyngeal distal myopathy ORPHA:600; Non-specific syndromic intellectual disability ORPHA:528084; 1q44 microdeletion syndrome ORPHA:238769; Alazami syndrome ORPHA:319671; DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect ORPHA:330050; X-linked intellectual disability-short stature-overweight syndrome ORPHA:457240; Angiocentric glioma ORPHA:251671; Neuroendocrine tumor of stomach ORPHA:100075; Acute myeloblastic leukemia with maturation ORPHA:98834; Joubert syndrome with ocular defect ORPHA:220493; Differentiated thyroid carcinoma ORPHA:146; Joubert syndrome with Jeune asphyxiating thoracic dystrophy ORPHA:397715; 12q15q21.1 microdeletion syndrome ORPHA:289513; 16p13.2 microdeletion syndrome ORPHA:500055; Autosomal recessive spastic paraplegia type 71 ORPHA:401840; B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome ORPHA:567502; Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome ORPHA:504476; Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome ORPHA:508542; Ferro-cerebro-cutaneous syndrome ORPHA:397922; Multiple congenital anomalies-hypotonia-seizures syndrome type 2 ORPHA:300496; Paroxysmal nocturnal hemoglobinuria ORPHA:447; Severe myopia-generalized joint laxity-short stature syndrome ORPHA:527450; Xq25 microduplication syndrome ORPHA:521258; Autosomal thrombocytopenia with normal platelets ORPHA:168629; Extraskeletal Ewing sarcoma ORPHA:370334; Systemic mastocytosis with associated hematologic neoplasm ORPHA:98849; Autosomal dominant optic atrophy, classic form ORPHA:98673; 5p13 microduplication syndrome ORPHA:329802; Absence of fingerprints-congenital milia syndrome ORPHA:1658; Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome ORPHA:444463; Autosomal dominant spastic paraplegia type 4 ORPHA:100985; Autosomal recessive spastic paraplegia type 60 ORPHA:401800; Autosomal recessive spastic paraplegia type 69 ORPHA:401830; Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome ORPHA:500150; Buschke-Ollendorff syndrome ORPHA:1306; Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion ORPHA:284169; Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation ORPHA:466950; Fragile X syndrome ORPHA:908; Fragile X-associated tremor/ataxia syndrome ORPHA:93256; HNRNPDL-related  limb-girdle muscular dystrophy D3 ORPHA:55596; Huriez syndrome ORPHA:384; Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome ORPHA:529965; Isolated congenital adermatoglyphia ORPHA:289465; Isolated osteopoikilosis ORPHA:166119; Melorheostosis with osteopoikilosis ORPHA:1879; Pseudohypoaldosteronism type 2E ORPHA:300530; STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome ORPHA:502434; Symptomatic form of fragile X syndrome in female carrier ORPHA:449291; Toriello-Carey syndrome ORPHA:3338; Toriello-Lacassie-Droste syndrome ORPHA:3339; Werner syndrome ORPHA:902; Woodhouse-Sakati syndrome ORPHA:3464; X-linked intellectual disability-hypotonia-movement disorder syndrome ORPHA:457260; Xq27.3q28 duplication syndrome ORPHA:261483; 17q24.2 microdeletion syndrome ORPHA:529962; NON RARE IN EUROPE: Melanoma ORPHA:411533; Melanoma of soft tissue ORPHA:97338; Proximal spinal muscular atrophy type 1 ORPHA:83330; Proximal spinal muscular atrophy type 2 ORPHA:83418; Proximal spinal muscular atrophy type 3 ORPHA:83419; Cornelia de Lange syndrome ORPHA:199; Infantile nephronophthisis ORPHA:93591; Senior-Loken syndrome ORPHA:3156; 15q11q13 microduplication syndrome ORPHA:238446; Angelman syndrome due to a point mutation ORPHA:411511; Angelman syndrome due to paternal uniparental disomy of chromosome 15 ORPHA:98795; Autosomal dominant optic atrophy plus syndrome ORPHA:1215; Cardiospondylocarpofacial syndrome ORPHA:3238; Familial acute necrotizing encephalopathy ORPHA:88619; Fatty acyl-CoA reductase 1 deficiency ORPHA:438178; Klippel-Trenaunay syndrome ORPHA:90308; Microcephaly-thin corpus callosum-intellectual disability syndrome ORPHA:397951; NON RARE IN EUROPE: Specific language impairment ORPHA:458713; 12q14 microdeletion syndrome ORPHA:94063",0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.795266832401002; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
BRSK2,Malignant neoplasm of pancreas; Pancreatic carcinoma; Alzheimer's Disease; Limbic Encephalitis; Small cell carcinoma of lung,0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,Non-Syndromic Intellectual Disability; Neurodevelopmental Disorders; Developmental Delay; Mental Retardation; Apraxia; Cryptorchidism; Autism; Attention Deficit Hyperactivity Disorder,0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.8337953215113012; 0.8457525389282121; 0.861756360478846; 0.911896615143974; 0.980894832851993,"Paroxysmal exertion-induced dyskinesia ORPHA:98811; Oculocutaneous albinism type 2 ORPHA:79432; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Bilateral generalized polymicrogyria ORPHA:208447; Benign hereditary chorea ORPHA:1429; Familial infantile myoclonic epilepsy ORPHA:352582; Spastic paraplegia-optic atrophy-neuropathy syndrome ORPHA:320406; Usher syndrome type 1 ORPHA:231169; Interstitial lung disease due to ABCA3 deficiency ORPHA:440402; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; Autosomal dominant hyperinsulinism due to Kir6.2 deficiency ORPHA:276580; Autosomal recessive hyperinsulinism due to Kir6.2 deficiency ORPHA:79644; DOORS syndrome ORPHA:79500; Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency ORPHA:276603; Familial gastric type 1 neuroendocrine tumor ORPHA:464756; Focal epilepsy-intellectual disability-cerebro-cerebellar malformation ORPHA:352587; Intermediate DEND syndrome ORPHA:99989; Leukoencephalopathy with mild cerebellar ataxia and white matter edema ORPHA:363540; Primary dystonia, DYT4 type ORPHA:98805; Progressive myoclonic epilepsy type 8 ORPHA:424027; Progressive myoclonic epilepsy with dystonia ORPHA:352596; Right sided atrial isomerism ORPHA:97548; Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome ORPHA:163727; Autosomal dominant otospondylomegaepiphyseal dysplasia ORPHA:166100; Congenital fibrosis of extraocular muscles ORPHA:45358; Idiopathic central precocious puberty ORPHA:169615; Permanent neonatal diabetes mellitus ORPHA:99885; Early infantile epileptic encephalopathy ORPHA:1934; Autosomal dominant non-syndromic intellectual disability ORPHA:178469; DEND syndrome ORPHA:79134; Autosomal dominant Charcot-Marie-Tooth disease type 2K ORPHA:99944; Autosomal dominant keratitis ORPHA:2334; Autosomal recessive Charcot-Marie-Tooth disease with hoarseness ORPHA:101097; Autosomal recessive intermediate Charcot-Marie-Tooth disease type A ORPHA:217055; Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome ORPHA:1171; Charcot-Marie-Tooth disease type 2H ORPHA:101102; Charcot-Marie-Tooth disease type 4A ORPHA:99948; Foveal hypoplasia-presenile cataract syndrome ORPHA:2253; Isolated optic nerve hypoplasia/aplasia ORPHA:137902; Monosomy 9q22.3 ORPHA:77301; Morning glory disc anomaly ORPHA:35737; Polymicrogyria due to TUBB2B mutation ORPHA:300573; Rapid-onset dystonia-parkinsonism ORPHA:71517; Schilbach-Rott syndrome ORPHA:2353; Spinocerebellar ataxia type 14 ORPHA:98763; Congenitally uncorrected transposition of the great arteries ORPHA:860; Autosomal dominant hyperinsulinism due to SUR1 deficiency ORPHA:276575; Autosomal recessive hyperinsulinism due to SUR1 deficiency ORPHA:79643; Autosomal spastic paraplegia type 72 ORPHA:401849; Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency ORPHA:276598; Distal arthrogryposis type 5D ORPHA:329457; Oculoauricular syndrome, Schorderet type ORPHA:157962; Renal coloboma syndrome ORPHA:1475; Infantile convulsions and choreoathetosis ORPHA:31709; Usher syndrome type 2 ORPHA:231178; Presynaptic congenital myasthenic syndromes ORPHA:98914; Normosmic congenital hypogonadotropic hypogonadism ORPHA:432; Autosomal dominant Charcot-Marie-Tooth disease type 2E ORPHA:99939; Autosomal spastic paraplegia type 30 ORPHA:101010; Charcot-Marie-Tooth disease type 1F ORPHA:101085; Charcot-Marie-Tooth disease type 2B5 ORPHA:228374; Classic progressive supranuclear palsy syndrome ORPHA:240071; Huntington disease-like 2 ORPHA:98934; KCNQ2-related epileptic encephalopathy ORPHA:439218; Primary dystonia, DYT2 type ORPHA:99657; Progressive myoclonic epilepsy type 7 ORPHA:435438; Progressive supranuclear palsy-corticobasal syndrome ORPHA:240103; Progressive supranuclear palsy-parkinsonism syndrome ORPHA:240085; Progressive supranuclear palsy-progressive non-fluent aphasia syndrome ORPHA:240112; Progressive supranuclear palsy-pure akinesia with gait freezing syndrome ORPHA:240094; Spinocerebellar ataxia type 42 ORPHA:458803; Occipital pachygyria and polymicrogyria ORPHA:280640; PEHO syndrome ORPHA:2836; NON RARE IN EUROPE: Hereditary essential tremor ORPHA:862; Dysequilibrium syndrome ORPHA:1766; Childhood absence epilepsy ORPHA:64280; Malignant migrating focal seizures of infancy ORPHA:293181",0.0155394890951578; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2661730864557679; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7593059616185558; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8953775799945711,Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
BTN2A2,Encephalomyelitis; Schizophrenia; Cockayne Syndrome; Intelligence; Coronary heart disease; Xeroderma Pigmentosum; Autism Spectrum Disorders,0.8019075543217649; 0.8067197998685076; 0.8101097852323003; 0.9093740881835894; 0.9119978323790848; 0.9377481698983606; 0.9639249377588224,Schizophrenia; Coronary Heart Disease; Development Disorder,0.7860378120955526; 0.861756360478846; 0.9726139569926774,,,"Human betaherpesvirus 6B glycoprotein (gene: U85); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Human mastadenovirus A E3 CR1-beta1; Human adenovirus 41 E3 31.6K; Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.915880438522078; 0.9197295331382644; 0.9237501457186692,,,,
BTRC,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of pancreas; Hepatoblastoma; Colorectal Carcinoma; Pancreatic carcinoma; Leukemia, Myelocytic, Acute; Lymphoma; Malignant neoplasm of lung; Liver carcinoma; Colorectal Cancer; Glioblastoma; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma, Endometrioid; Prostatic Neoplasms; Carcinoma of lung; Triple Negative Breast Neoplasms; Central neuroblastoma; melanoma; Ectrodactyly; Multiple Myeloma; Lung Neoplasms; Malignant neoplasm of stomach; Nasopharyngeal carcinoma; Syndactyly of fingers; Oligodactyly; Neuroectodermal Tumor, Primitive; Stomach Carcinoma; Huntington Disease; Stomach Neoplasms; Colonic Neoplasms; Multiple tumors; Patent ductus arteriosus; Medulloblastoma; Papillary thyroid carcinoma",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8044379824544406; 0.8212681436603975; 0.8272008757995397; 0.8402911822757345; 0.8548862007194026; 0.8757755363384367,Ectrodactyly; Isolated Split Hand-Split Foot Malformation; Aniridia; Oligodactyly; Hearing Loss; Syndactyly Of Fingers,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8903630091389316,Atypical juvenile parkinsonism ORPHA:391411; Isolated split hand-split foot malformation ORPHA:2440,0.5867963421058087; 0.606625035400596,Human respirovirus 3 phosphoprotein; Human betaherpesvirus 6B glycoprotein (gene: U85); Yaba-like disease virus 141R protein (gene: 141R); Human immunodeficiency virus 2 vpx protein; Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Ectromelia virus ERPV hemagglutinin; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Vaccinia virus Ankara double-stranded RNA binding protein; Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9237501457186692,,,,
C11ORF52,,,,,"Antley-Bixler syndrome ORPHA:83; Van der Woude syndrome ORPHA:888; Apparent mineralocorticoid excess ORPHA:320; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Congenital intrauterine infection-like syndrome ORPHA:1229; Congenital tufting enteropathy ORPHA:92050; Isolated neonatal sclerosing cholangitis ORPHA:480556; Lethal congenital contracture syndrome type 2 ORPHA:137776; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Familial hypercholanemia ORPHA:238475; Cleft lip/palate ORPHA:199306; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Familial hyperprolactinemia ORPHA:397685; Gelatinous drop-like corneal dystrophy ORPHA:98957; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Bifid uvula ORPHA:99771; Blepharo-cheilo-odontic syndrome ORPHA:1997; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Submucosal cleft palate ORPHA:155878; Alopecia-intellectual disability syndrome ORPHA:2850; NON RARE IN EUROPE: Hypodontia ORPHA:2227; Lethal acantholytic erosive disorder ORPHA:158687; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Bartsocas-Papas syndrome ORPHA:1234; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; CHAND syndrome ORPHA:1401; Carvajal syndrome ORPHA:65282; Cholangiocarcinoma ORPHA:70567; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Low isolated anorectal malformation ORPHA:171215; Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome ORPHA:397744; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; X-linked recessive ocular albinism ORPHA:54; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; Hereditary diffuse gastric cancer ORPHA:26106; Ollier disease ORPHA:296; Autosomal recessive distal renal tubular acidosis ORPHA:402041; Autosomal dominant Charcot-Marie-Tooth disease type 2C ORPHA:99937; Autosomal dominant brachyolmia ORPHA:93304; Autosomal dominant congenital benign spinal muscular atrophy ORPHA:1216; Autosomal recessive extra-oral halitosis ORPHA:562538; Congenital bile acid synthesis defect type 4 ORPHA:79095; Familial digital arthropathy-brachydactyly ORPHA:85169; Metatropic dysplasia ORPHA:2635; Naxos disease ORPHA:34217; Neurodegenerative syndrome due to cerebral folate transport deficiency ORPHA:217382; Parastremmatic dwarfism ORPHA:2646; Scapuloperoneal spinal muscular atrophy ORPHA:431255; Spondyloepiphyseal dysplasia, Maroteaux type ORPHA:263482; Spondylometaphyseal dysplasia, Kozlowski type ORPHA:93314; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; 3-hydroxy-3-methylglutaryl-CoA synthase deficiency ORPHA:35701; AA amyloidosis ORPHA:85445; Adenylosuccinate synthetase-like 1-related distal myopathy ORPHA:482601; Brain demyelination due to methionine adenosyltransferase deficiency ORPHA:168598; Isolated sulfite oxidase deficiency ORPHA:99731; Monoamine oxidase A deficiency ORPHA:3057; OBSOLETE: Alpha-1-antichymotrypsin deficiency ORPHA:93594; REN-related autosomal dominant tubulointerstitial kidney disease ORPHA:217330; Maffucci syndrome ORPHA:163634; Pachydermoperiostosis ORPHA:2796; Bifunctional enzyme deficiency ORPHA:300; Kaposiform hemangioendothelioma ORPHA:2122; Tufted angioma ORPHA:1063; Hereditary methemoglobinemia ORPHA:621",0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2567797333165013; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.4621817429362311; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
C17ORF99,,,,,Hemochromatosis type 3 ORPHA:225123; Rh deficiency syndrome ORPHA:71275; Classic congenital lipoid adrenal hyperplasia due to STAR deficency ORPHA:325524; Hyper-IgM syndrome type 2 ORPHA:101089; Non-classic congenital lipoid adrenal hyperplasia due to STAR deficency ORPHA:325529,0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
C2CD2L,,,,,Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; COG1-CDG ORPHA:263508; External auditory canal aplasia/hypoplasia ORPHA:141074; Pityriasis rubra pilaris ORPHA:2897; Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997,0.0081550609410495; 0.0155394890951578; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,,,,,,
CAMK2N2,,,,,PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Spinocerebellar ataxia type 21 ORPHA:98773; Paroxysmal exertion-induced dyskinesia ORPHA:98811; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Distal hereditary motor neuropathy type 5 ORPHA:139536; Bilateral generalized polymicrogyria ORPHA:208447; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Familial infantile myoclonic epilepsy ORPHA:352582; Spastic paraplegia-optic atrophy-neuropathy syndrome ORPHA:320406; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; Autosomal recessive dopa-responsive dystonia ORPHA:101150; Autosomal recessive spastic paraplegia type 26 ORPHA:101006; Mazabraud syndrome ORPHA:57782; McCune-Albright syndrome ORPHA:562; Monostotic fibrous dysplasia ORPHA:93277; Polyostotic fibrous dysplasia ORPHA:93276; Progressive myoclonic epilepsy type 8 ORPHA:424027; Progressive osseous heteroplasia ORPHA:2762; Pseudohypoparathyroidism type 1A ORPHA:79443; Pseudohypoparathyroidism type 1C ORPHA:79444; Pseudopseudohypoparathyroidism ORPHA:79445; Right sided atrial isomerism ORPHA:97548; Congenital fibrosis of extraocular muscles ORPHA:45358; Myoclonus-dystonia syndrome ORPHA:36899; Anterior segment developmental anomaly ORPHA:88632; Autosomal dominant Charcot-Marie-Tooth disease type 2K ORPHA:99944; Autosomal recessive Charcot-Marie-Tooth disease with hoarseness ORPHA:101097; Autosomal recessive intermediate Charcot-Marie-Tooth disease type A ORPHA:217055; Charcot-Marie-Tooth disease type 2H ORPHA:101102; Charcot-Marie-Tooth disease type 4A ORPHA:99948; Congenital primary aphakia ORPHA:83461; Mulibrey nanism ORPHA:2576; Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome ORPHA:231720,0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,,,,,,
CBL,"Malignant neoplasm of breast; Reticulocyte count (procedure); Breast Carcinoma; Carcinogenesis; B-Cell Lymphomas; leukemia; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Lymphoma; Non-Small Cell Lung Carcinoma; Refractory anemia, without ringed sideroblasts, without excess blasts; Myelomonocytic leukemia; Triangular face; Vascular Diseases; Glioma; Malignant neoplasm of lung; Myelodysplastic-Myeloproliferative Diseases; Refractory anemias; Mastocytosis, Systemic; Glioblastoma; Frontal bossing; Neoplasm Metastasis; Bloom Syndrome; Prostatic Neoplasms; Squamous cell carcinoma of the head and neck; Platelet Count measurement; Turner Syndrome, Male; Hematologic Neoplasms; Juvenile Myelomonocytic Leukemia; Ewings sarcoma; Malignant neoplasm of stomach; Joint laxity; Large auricle; Large pinnae; Macrotia; Lymphocytosis; Refractory anaemia with excess blasts; Neuroepithelioma, Peripheral; Fine hair; Lupus Erythematosus, Systemic; Monosomy; secondary acute myeloid leukemia; Abdominal Cryptorchidism; Inguinal Cryptorchidism; Acute leukemia; Congenital chromosomal disease; Platelet hematocrit measurement; Acute lymphocytic leukemia; Stomach Carcinoma; Cognitive delay; Polycythemia Vera; Unilateral Cryptorchidism; Core binding factor acute myeloid leukemia; Jacobsen Distal 11q Deletion Syndrome; Hyperglycemia; Preleukemia; Global developmental delay; Thrombocytosis; Vasculitis; Myeloid Leukemia, Chronic; Mental and motor retardation; Chronic myeloproliferative disorder; Thrombocythemia, Essential; Noonan Syndrome; Bilateral Cryptorchidism; Acquired cubitus valgus; Wide spaced nipples; Child Development Disorders, Specific; Child Development Deviations; Chronic Lymphocytic Leukemia; Encephalomyelitis; Posteriorly rotated ear; Lupus Erythematosus; Lymphoma, T-Cell, Cutaneous; Lupus Erythematosus, Discoid; Blast Phase; Myeloproliferative disease; Depressed philtrum; Gastrointestinal Neoplasms; Diabetes Mellitus, Insulin-Dependent; Deep philtrum; Delayed speech and language development; Overlap syndrome; Downward slant of palpebral fissure; Lupus Vulgaris; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Growth Disorders; Human immunodeficiency virus, type 2 [HIV-2] infection in conditions classified elsewhere and of unspecified site; Systemic Scleroderma; Speech impairment; Mitral regurgitation, mild; Ewings sarcoma-primitive neuroectodermal tumor (PNET); Isochromosomes; Sparse hair; Thin, sparse hair; Cryptorchidism; Birthmark; Language Delay; Abetalipoproteinemia; Cafe-au-Lait Spots; Other specified transient cerebral ischemias; Moyamoya disease 1; Generalized hypotonia; Male sterility; Mitral Valve Insufficiency; Speech Delay; Lymphoproliferative Disorders; Neck webbing; Moyamoya Disease; Leukemia, Myelomonocytic, Chronic; Bicuspid aortic valve; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Range of joint movement increased; Thick vermilion border; Cardiac defects; Low set ears; Subfertility, Male; Primary Myelofibrosis; Transient Ischemic Attack; Orbital separation excessive; Congenital Epicanthus; Pectus excavatum; Cytopenia; Congenital anemia; Epileptic encephalopathy; Developmental Disabilities; Hydrops Fetalis; Long philtrum; Intellectual Disability; Short neck; Aortic Valve Stenosis; Blepharoptosis; Genetic Diseases, Inborn; Male infertility",0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7945683314244791; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026798872257774; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8114747041691183; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8232134984476662; 0.8270909867833504; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.843190898187174; 0.843190898187174; 0.8474481237156937; 0.8508164886128737; 0.8523465762428218; 0.8554819098734854; 0.8576420926340393; 0.8578473133580928; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8700543109506378; 0.8745234584149799; 0.876210765330195; 0.8816060628973529; 0.8851456306720444; 0.8867509400747969; 0.8980854850210683; 0.9001392794088324; 0.9015731019095328; 0.917543617287358; 0.929814249105729; 0.9390727893210336; 0.9459312971127588; 0.9478210444156088; 0.954882372756482; 0.957487573707278; 0.9770263358372888; 0.9926099929361648; 0.9960101498067662,Hematologic Neoplasms; Myelomonocytic Leukemia; Systemic Mastocytosis; Cubitus Valgus; Myelodysplastic Syndrome; Developmental Delay; Leukemia; Frontal Bossing; Macrotia; Vasculitis; Noonan Syndrome; Movement Disorders; Neck Webbing; Mental Retardation; Cryptorchidism; Aortic Valve Sclerosis; Posteriorly Rotated Ear; Bicuspid Aortic Valve; Development Disorder; Dysmorphic Features; Congenital Epicanthus; Ptosis; Congenital Pectus Excavatum,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.829560580336605; 0.8337953215113012; 0.8337953215113012; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.9166047043368432; 0.9726139569926774; 0.9726139569926774; 0.974502015052702; 0.9832345076528324; 0.9832345076528324,Acromelic frontonasal dysplasia ORPHA:1827; Distal 22q11.2 microdeletion syndrome ORPHA:261330; Dyschromatosis symmetrica hereditaria ORPHA:41; Huntington disease ORPHA:399; 15q24 microdeletion syndrome ORPHA:94065; BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy ORPHA:363454; SIN3A-related intellectual disability syndrome due to a point mutation ORPHA:500166; Angiocentric glioma ORPHA:251671; Juvenile myelomonocytic leukemia ORPHA:86834; Rubinstein-Taybi syndrome due to EP300 haploinsufficiency ORPHA:353284; Temtamy preaxial brachydactyly syndrome ORPHA:363417; Cardiofaciocutaneous syndrome ORPHA:1340; Aggressive systemic mastocytosis ORPHA:98850; Acute myeloid leukemia with t(8;16)(p11;p13) translocation ORPHA:370026; Chuvash erythrocytosis ORPHA:238557; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia ORPHA:363972; Rubinstein-Taybi syndrome due to 16p13.3 microdeletion ORPHA:353281; Rubinstein-Taybi syndrome due to CREBBP mutations ORPHA:353277; Von Hippel-Lindau disease ORPHA:892; Severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome ORPHA:363686; Noonan syndrome ORPHA:648,0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6196505963261838; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8029813443753846; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9025296114347576,Human T-lymphotropic virus 3 envelope (gene: env); Human T-cell lymphotropic virus type 2b env; Human T-lymphotropic virus 4 envelope glycoprotein (gene: env); Human adenovirus 11+34 encapsidation protein IVa2 (gene: IVa2); Human adenovirus 34 maturation protein IVa2 (gene: IVa2); Human adenovirus 35 IVa2; Human T-lymphotropic virus 2 p21E envelope protein; Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Human T-cell leukemia virus type I gp46 SU (gene: env); Human T-lymphotropic virus 2 hypothetical protein (env propeptide); Rio Bravo virus anchored core protein C; Human adenovirus 66 maturation protein IVA2 (gene: IVa2); Yaba monkey tumor virus ankyrin repeat protein; Human mastadenovirus E encapsidation protein IVa2 (gene: IVa2); Human adenovirus E4 protein IVa2; Rio Bravo virus core protein C; Modoc virus capsid protein; Tai Forest ebolavirus spike glycoprotein (gene: GP); Human adenovirus 3+7 maturation protein IVA2 (gene: IVa2); Orf virus ORF057 putative protein-tyrosine phosphatase; Reston ebolavirus spike glycoprotein (gene: GP); Human respirovirus 3 phosphoprotein; Human adenovirus 54 pIVa2; Human rhinovirus A20 2C; Cercopithecine betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Human adenovirus D8 pIVa2 protein (gene: pIVa2); Human parainfluenza virus 1 strain Washington/1964 phosphoprotein (gene: P); Human respirovirus 1 phosphoprotein (gene: P); Louping ill virus putative enchored capsid (core) protein; Modoc virus anchored capsid protein; Yellow fever virus core protein C; Powassan virus anchored core protein C; Orf virus ORF008 ankyrin repeat protein; Human betaherpesvirus 5 chemokine vCXCL1 (gene: UL146); Langat virus capsid protein; Human T-cell leukemia virus type I p21 TM (gene: env); Sudan ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus - Nakisamata structural glycoprotein (gene: GP); Alkhumra hemorrhagic fever virus core protein C; Alkhumra hemorrhagic fever virus anchored core protein C; Powassan virus core protein C; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF026 putative IMV redox protein; Human immunodeficiency virus envelope glycoprotein (gene: env); Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Monkeypox virus ankyrin-like protein; Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV011c (ankyrin repeats); Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Human adenovirus 64 E3 48.9 kDa protein; Yaba monkey tumor virus ankyrin-like protein; Norovirus GI/Hu/JP/2007/GI.P3_GI.3/Shimizu/KK2866 full_polyprotein 1..1799; Ectromelia virus ERPV ankyrin; Human adenovirus D37 48.9 kDa (gene: E3); Horsepox virus HSPV033b (Ankyrin repeats); Variola virus hypothetical protein (gene: G3R); Orf virus ORF129 ankyrin repeat protein; Cowpox virus CPXV006 protein (gene: CPXV006 CDS),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9383505321091749; 0.9397923093369096,In vitro,0.44,Homo sapiens,chemical synthesis
CBS,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Cerebellar malformation; leukemia; Ovarian Carcinoma; Reduced tensile strength of hair; Fractured hair; Fragile hair; Brittle hair; Reticulosarcoma; Tall stature; Colorectal Carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Arterial thrombosis; Leukemogenesis; Amblyopia; Vascular Diseases; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Low Grade Lymphoma (neoplasm); Lymphoma, Non-Hodgkin; Liver carcinoma; Mycoses; Aneurysm, Dissecting; Thromboembolism; Colorectal Cancer; Epithelial ovarian cancer; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Hyperhomocysteinemia; Immunologic Deficiency Syndromes; melanoma; Multiple Myeloma; Lung Neoplasms; Neoplasms; Selenium measurement; Malignant neoplasm of stomach; Sparse scalp hair; Folic Acid Deficiency; Increase in blood pressure; Sinus Thrombosis, Intracranial; Abnormality of amino acid metabolism; Embolism and Thrombosis; Varying degree of multiple fractures; Frequent fractures; Increased fracture rate; Fractures, Multiple; Vitamin B 6 Deficiency; Generalized osteoporosis with pathologic fractures; Coronary Arteriosclerosis; Infant, Premature; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Acute lymphocytic leukemia; Pulmonary Embolism; Stomach Carcinoma; High Grade Lymphoma (neoplasm); Leishmaniasis, New World; Cardiovascular Diseases; Neural Tube Defects; Glaucoma; Hypermethioninemia; Demyelinating Diseases; Diabetes; Biconcave vertebral bodies; Cancer Relapse; Drug-induced depressive state; Homocysteinemia; Diabetes Mellitus; Malignant hyperpyrexia due to anesthesia; Huntington Disease; Childhood Acute Lymphoblastic Leukemia; Cystathionine beta-Synthase Deficiency Disease; Disproportionate tall stature; Lymphoma, Diffuse; Malignant neoplasm of colon stage IV; Homocysteine measurement; Renal Artery Stenosis; Lymphoma, Mixed-Cell; Myocardial Infarction; Diffuse Mixed-Cell Lymphoma; Meningomyelocele; Hepatic methionine adenosyltransferase deficiency; Limitation of joint mobility; Autistic Disorder; Arachnodactyly; Lymphoma, Undifferentiated; Lens dislocation; Arteriopathic disease; Liver neoplasms; Lymphoma, Intermediate-Grade; Knee joint valgus deformity; ovarian neoplasm; Schizophrenia; Ectopia Lentis; Homocystinuria; Personality Disorders; Hypopigmentation disorder; Inborn Errors of Metabolism; Lymphoma, Small Noncleaved-Cell; Oral candidiasis; Pancreatitis; Congenital pectus carinatum; Impaired cognition; Diabetes Mellitus, Non-Insulin-Dependent; Connective Tissue Diseases; Thrombophilia; Cognition Disorders; Neurodegenerative Disorders; Spina Bifida; Meningioma, benign, no ICD-O subtype; Venous Thrombosis; Subarachnoid Hemorrhage; Arterial Occlusive Diseases; Curvature of spine; Cardiac Arrest; Adrenoleukodystrophy; Peroxisomal Disorders; Mental deficiency; Steatohepatitis; Aortic Aneurysm, Thoracic; Acquired scoliosis; Endothelial dysfunction; Down Syndrome; Hypertensive disease; Cutis marmorata; Ehlers-Danlos Syndrome; Central nervous system demyelination; Premature coronary artery disease; Deep Vein Thrombosis; Fatty Liver; Intracranial Aneurysm; Cerebrovascular accident; Joint stiffness; Chronic Obstructive Airway Disease; Tooth Crowding; Tooth mass arch size discrepancy; Tooth size discrepancy; Congenital aneurysm of ascending aorta; Inadequate arch length for tooth size; Factor V Leiden mutation; Acute Megakaryocytic Leukemias; Dull intelligence; Low intelligence; Cataract; Hernia, Inguinal; Mental Depression; Mitral Valve Prolapse Syndrome; Inflammatory Bowel Diseases; Congenital arteriovenous malformation; Coronary Artery Disease; Hyperactive behavior; Poor school performance; Meningioma; Brain Ischemia; Pectus excavatum; Obesity; Heart Diseases; Bipolar Disorder; Frontotemporal dementia; Cerebral Ischemia; Congenital Heart Defects; Depressive disorder; Byzanthine arch palate; Coronary heart disease; Kyphoscoliosis deformity of spine; Hyperkyphosis; Septicemia; Malnutrition; Sepsis; Mental Retardation; Anemia, Sickle Cell; Kyphosis deformity of spine; Renal Insufficiency; Intellectual Disability; Seizures; Myopia; Congenital heart disease; Pheochromocytoma; Cerebral Infarction; Epilepsy; Osteoporosis",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.8363138748299018; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8420665668584452; 0.8474481237156937; 0.8486035047899471; 0.8497448945325101; 0.8523465762428218; 0.8578473133580928; 0.8584283190330553; 0.8628363180844141; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8745234584149799; 0.8745234584149799; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8774809019744603; 0.8815127642200768; 0.8815127642200768; 0.887595340546704; 0.8878860377518915; 0.8913141512402477; 0.8973454964837912; 0.8980854850210683; 0.8980854850210683; 0.8989612563669234; 0.8989612563669234; 0.900167961295542; 0.9024758035783405; 0.9083161862856644; 0.9098977259629772; 0.9103315000053974; 0.9119978323790848; 0.9119978323790848; 0.9146732238562176; 0.9154499654632742; 0.917543617287358; 0.9184153253162451; 0.9189398569397552; 0.922229272318747; 0.9252532782268056; 0.9288355565549664; 0.946564927793026; 0.9478210444156088; 0.9478210444156088; 0.9506863447189738; 0.9540608878641196; 0.9557184806547836; 0.9564633032157428; 0.963331724428282; 0.9639249377588224,Malnutrition; Hyperhomocysteinemia; Stroke; Melanoma; Lens Subluxation; Hypopigmentation Disorder; Homocystinuria; Psychosis; Hypertension; Retinal Detachment; Developmental Delay; Lymphoma; Subcutaneous Hemorrhage; Diffuse Lymphoma; Personality Disorders; Schizophrenia; Anorexia; Pancreatitis; Optic Atrophy; High Grade Lymphoma; Intermediate Grade Lymphoma; Low Grade Lymphoma; Reticulosarcoma; Hemiplegia/hemiparesis; Esophageal Varix; Ectopia Lentis; Cutis Marmorata; Fatty Liver; Mental Retardation; Marfan Syndrome; Non-Hodgkin Lymphoma; Myocardial Infarction; Congenital Arteriovenous Malformation; Arachnodactyly; Osteoporosis; Urticaria; Thoracic Aortic Aneurysm And Aortic Dissection; Glaucoma; Mental Depression; Congenital Pectus Carinatum; Acquired Kyphoscoliosis; Congenital Kyphoscoliosis; Diabetes Mellitus; Scoliosis; Cardiovascular Diseases; Mitral Valve Prolapse; Bipolar Disorder; High Palate; Cataract; Myopia; Congenital Pectus Excavatum,0.6734982286750932; 0.7311975666200533; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8091514409416879; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.831108575640545; 0.8321692755697452; 0.8337953215113012; 0.8477374749042494; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.8903301324869451; 0.8903630091389316; 0.8903630091389316; 0.8903630091389316; 0.9024492468099392; 0.9145387439550552; 0.9147194468246628; 0.919442421650838; 0.924275664330454; 0.924275664330454; 0.9318760199717074; 0.943322675973118; 0.9578111936867284; 0.974502015052702; 0.9832345076528324; 0.9832345076528324,"Dyschromatosis universalis hereditaria ORPHA:241; Familial pseudohyperkalemia ORPHA:90044; Neu-Laxova syndrome ORPHA:2671; 3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form ORPHA:79351; Blepharophimosis-ptosis-epicanthus inversus syndrome plus ORPHA:572333; Blepharophimosis-ptosis-epicanthus inversus syndrome type 1 ORPHA:572354; Blepharophimosis-ptosis-epicanthus inversus syndrome type 2 ORPHA:572361; Atypical glycine encephalopathy ORPHA:289863; Infantile glycine encephalopathy ORPHA:289860; Classic homocystinuria ORPHA:394; Neonatal glycine encephalopathy ORPHA:289857",0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.795266832401002; 0.8922466888454011; 0.8922466888454011,,,,,,
CCDC102A,,,,,Brachydactyly type B2 ORPHA:140908; Spondylo-ocular syndrome ORPHA:85194; Stapes ankylosis with broad thumbs and toes ORPHA:140917; Tarsal-carpal coalition syndrome ORPHA:1412; Aneurysm-osteoarthritis syndrome ORPHA:284984; Caudal regression sequence ORPHA:3027,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.8922466888454011,,,,,,
CCK,"Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; androgen independent prostate cancer; Malignant tumor of colon; Esophageal carcinoma; Lymphoma; Non-Small Cell Lung Carcinoma; Hypercholesterolemia; Pancreatic Neoplasm; Cholera Infantum; Pancreatic intraepithelial neoplasia; Adenoma; Intestinal Cancer; Esophageal Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Lymphoma, Non-Hodgkin; Biliary Tract Neoplasm; Liver carcinoma; Pancreatitis, Alcoholic; Malignant neoplasm of esophagus; Osteosarcoma; Thyroid carcinoma; Cholelithiasis; Colorectal Cancer; Rhabdomyosarcoma; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; insulinoma; Neoplasm Metastasis; Functional Gastrointestinal Disorders; Neuroepithelioma; Neuroblastoma; Lymphocytic infiltration; Central neuroblastoma; Malignant Neoplasms; Ewings sarcoma; Adenocarcinoma of pancreas; Lung Neoplasms; Gastrointestinal Diseases; Neoplasms; Gall Bladder Diseases; Unconscious State; Malignant neoplasm of stomach; Mental disorders; Myxoid cyst; Abnormal behavior; Brain Neoplasms; Pancreatitis, Chronic; Nasopharyngeal carcinoma; Sarcoma; Primary Effusion Lymphoma; Neuroectodermal Tumor, Primitive; Alzheimer's Disease; Stomach Carcinoma; Anorexia; Round cell tumor; Nicotine withdrawal; Cholecystolithiasis; Chronic constipation; Diabetes Mellitus; Biliary Tract Cancer; Small cell carcinoma of lung; Dyskinesia, Medication-Induced; Waxy flexibility; Manic; Dyskinesia, Drug-Induced; Alcohol Withdrawal Delirium; AICARDI-GOUTIERES SYNDROME 1; Panic Attacks; Alcoholic Intoxication, Chronic; Teratocarcinoma; Alcohol abuse; Malignant neoplasm of gallbladder; Physical Activity Measurement; Catalepsy; leiomyosarcoma; Schizophrenia; Carcinoma, Small Cell; Adenocarcinoma of lung (disorder); Convulsions; Herpes Simplex Infections; Encephalopathy, Toxic; Toxic Encephalitis; Hallucinations; Liver diseases; Other cataract; Absence Seizures; Pancreatitis; Fever; PANIC DISORDER 1; Generalized seizures; Diabetes Mellitus, Non-Insulin-Dependent; Decrease in appetite; Neurotoxicity Syndromes; Seizures, Focal; Inflammation; Hyperkinesia, Generalized; Gastric Adenocarcinoma; Gallbladder Carcinoma; Meningioma, benign, no ICD-O subtype; Neurobehavioral Manifestations; Recurrent tumor; Gastroesophageal reflux disease; Panic Disorder; Alcohol withdrawal syndrome; Celiac Disease; Liver Dysfunction; Single Seizure; Seizures, Auditory; Seizures, Clonic; Seizures, Sensory; Seizures, Somatosensory; Vertiginous seizure; Atonic Absence Seizures; Generalized Absence Seizures; Gustatory seizure; Jacksonian Seizure; Non-epileptic convulsion; Nonepileptic Seizures; Olfactory seizure; Epileptic Seizures; Tonic Seizures; Convulsive Seizures; Epileptic drop attack; Tonic - clonic seizures; Complex partial seizures; Medullary carcinoma of thyroid; gliosarcoma; Parkinson Disease; Body mass index; Finding of body mass index; Heart failure; Neuroendocrine Tumors; Hyperactive behavior; Meningioma; Congestive heart failure; Obesity; Visual seizure; Bipolar Disorder; Myoclonic Seizures; Polycystic Ovary Syndrome; Irritable Bowel Syndrome; Gastric ulcer; Anxiety Disorders; Seizures; Tumor Angiogenesis; Anxiety",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026798872257774; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8101097852323003; 0.8140222479282434; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8578473133580928; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.8769418330148872; 0.8772392350816924; 0.8867509400747969; 0.8867509400747969; 0.8867509400747969; 0.887595340546704; 0.8878860377518915; 0.8973454964837912; 0.8976039441125321; 0.8989612563669234; 0.900167961295542; 0.900167961295542; 0.914995991166204; 0.9174808175273056; 0.9265708351135048; 0.929235785949896; 0.946564927793026; 0.9478210444156088; 0.9656926709728724; 0.9708740267329932,Functional Gastrointestinal Disorders; Gastrointestinal Diseases; Dyskinesia; Manic Disorder; Catalepsy; Schizophrenia; Anorexia; Pancreatitis; Gastric Ulcer; Hypotonic Seizures; Seizure; Jacksonian Seizure; Clonic Seizures,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.7860378120955526; 0.8091514409416879; 0.8115918568696846; 0.8115918568696846; 0.8601151608808731; 0.861756360478846; 0.861756360478846; 0.8903301324869451,Autosomal recessive spastic paraplegia type 75 ORPHA:459056; Craniosynostosis-microretrognathia-severe intellectual disability syndrome ORPHA:565858; Gollop-Wolfgang complex ORPHA:1986; Menstrual cycle-dependent periodic fever ORPHA:498251; Mesoaxial synostotic syndactyly with phalangeal reduction ORPHA:157801; Tibial aplasia-ectrodactyly syndrome ORPHA:3329,0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CCNA2,"Malignant neoplasm of breast; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; androgen independent prostate cancer; Malignant tumor of colon; Esophageal carcinoma; Non-Small Cell Lung Carcinoma; Colorectal Neoplasms; Endometrial Carcinoma; Esophageal Neoplasms; Mammary Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Invasive carcinoma of breast; Malignant neoplasm of esophagus; Osteosarcoma; Acute Promyelocytic Leukemia; Colorectal Cancer; Vulval intraepithelial neoplasia; Liver and Intrahepatic Biliary Tract Carcinoma; Multiple malignancy; Hepatocarcinogenesis; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Neoplasm Metastasis; Malignant neoplasm of liver; Multiple Myeloma; Retinal Diseases; Primary Malignant Liver Neoplasm; Malignant neoplasm of stomach; Ganglioglioma; Malformations of Cortical Development; Adenocarcinoma of colon; Renal Cell Carcinoma; Coronary Arteriosclerosis; Acute leukemia; Arteriosclerosis; Atherosclerosis; Chondrosarcoma; Stomach Carcinoma; Early Hepatocellular Carcinoma; Rheumatoid Arthritis; Metaphyseal chondrodysplasia; Sjogren's Syndrome; Chronic inflammatory disorder; PACHYONYCHIA CONGENITA 3; Conventional (Clear Cell) Renal Cell Carcinoma; Dejerine-Sottas Disease (disorder); Hepatic necrosis; Mental Retardation, Psychosocial; Ulcer; Experimental Organism Basal Cell Carcinoma; Liver Cirrhosis, Experimental; Profound Mental Retardation; Psoriasis; Myocardial Infarction; Embryonal Carcinoma; Liver neoplasms; Stomach Neoplasms; ovarian neoplasm; Schizophrenia; Herpes Simplex Infections; Fibrosis; Proliferative diabetic retinopathy; Precursor Cell Lymphoblastic Leukemia Lymphoma; Myocarditis; Plexiform Neurofibroma; DOSAGE-SENSITIVE SEX REVERSAL; Fibrosis, Liver; Chronic leukemia (category); Carcinoma, Transitional Cell; Systemic Scleroderma; Mental deficiency; Thymoma; Hepatitis B; Restenosis; Giant Cell Tumors; Exanthema; Myocardial Ischemia; Retinopathy of Prematurity; Neurofibromatosis 2; Hyperactive behavior; Barrett Esophagus; Heart Diseases; Septicemia; Sepsis; Idiopathic Pulmonary Fibrosis; Mixed Salivary Gland Tumor; Intellectual Disability; Ischemic cardiomyopathy; Cardiomyopathies; Endometriosis; Neurofibromatosis 1",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8508164886128737; 0.8554819098734854; 0.8619324281003841; 0.8648405521677974; 0.8774809019744603; 0.887595340546704; 0.8878860377518915; 0.8980854850210683; 0.8989612563669234; 0.917543617287358; 0.9189398569397552; 0.9393256300017014; 0.9401670107659288; 0.9478210444156088; 0.94939825643792; 0.9557184806547836; 0.960644037248553; 0.9896536639644284,Carcinoma Of The Head And Neck; Schizophrenia; Mental Retardation,0.4532988396145482; 0.7860378120955526; 0.8337953215113012,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Filippi syndrome ORPHA:3255; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Citrullinemia type II ORPHA:247585; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Hydrolethalus ORPHA:2189; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Hereditary coproporphyria ORPHA:79273; Jawad syndrome ORPHA:313795; Meacham syndrome ORPHA:3097; Linear nevus sebaceus syndrome ORPHA:2612; Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome ORPHA:477993; Inclusion body myopathy with Paget disease of bone and frontotemporal dementia ORPHA:52430; Nephroblastoma ORPHA:654; Acute myeloid leukemia with NPM1 somatic mutations ORPHA:402026; Autosomal dominant spastic paraplegia type 13 ORPHA:100994; Chudley-McCullough syndrome ORPHA:314597; Pelizaeus-Merzbacher-like disease due to HSPD1 mutation ORPHA:280288; Primary peritoneal carcinoma ORPHA:168829; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Muir-Torre syndrome ORPHA:587; Osteosarcoma ORPHA:668; Familial pancreatic carcinoma ORPHA:1333; Fanconi anemia ORPHA:84; Combined immunodeficiency with granulomatosis ORPHA:157949; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; Bloom syndrome ORPHA:125; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Exercise-induced hyperinsulinism ORPHA:165991; Ketoacidosis due to monocarboxylate transporter-1 deficiency ORPHA:438075; Metabolic myopathy due to lactate transporter defect ORPHA:171690; VACTERL with hydrocephalus ORPHA:3412; ICF syndrome ORPHA:2268; Seckel syndrome ORPHA:808; Autosomal recessive primary microcephaly ORPHA:2512; Roberts syndrome ORPHA:3103; Constitutional mismatch repair deficiency syndrome ORPHA:252202",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1068643725150898; 0.1068643725150898; 0.1419890644363008; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7593059616185558; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8211968342881582; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Yaba-like disease virus 142R protein (gene: 142R); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Human papillomavirus type 53 early protein (gene: E7); Banna virus strain JKT-6423 Vp7; Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Variola virus hypothetical protein (gene: B1R); Vaccinia virus Ankara serine/threonine-protein kinase-like; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Monkeypox virus ser/thr protein kinase-like protein; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Yaba monkey tumor virus 142R; Monkeypox virus Zaire-96-I-16 B11R (gene: B11R); Human papillomavirus type 34 early protein (gene: E7); Horsepox virus HSPV189 (Serine/threonine protein kinase); Vaccinia virus ser/thr protein kinase-like protein (gene: B12R)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
CCNB1,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; leukemia; Ovarian Carcinoma; Colorectal Carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Esophageal carcinoma; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Colorectal Neoplasms; Endometrial Carcinoma; Esophageal Neoplasms; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Promyelocytic leukemia; Liver carcinoma; Malignant neoplasm tonsil; Malignant neoplasm of esophagus; Malignant Head and Neck Neoplasm; Osteosarcoma; Acute Promyelocytic Leukemia; Ataxia Telangiectasia; Colorectal Cancer; Epithelial ovarian cancer; Tonsillar Carcinoma; Vulval intraepithelial neoplasia; Liver and Intrahepatic Biliary Tract Carcinoma; Leukemia, T-Cell; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Embryonal Neoplasm; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Epithelioma; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of liver; Neuroblastoma; Central neuroblastoma; melanoma; Multiple Myeloma; Adrenal Cortical Adenoma; Malignant neoplasm of stomach; Sclerocystic Ovaries; Ganglioglioma; Congenital contractural arachnodactyly; Benign Prostatic Hyperplasia; Malformations of Cortical Development; Brain Neoplasms; Nasopharyngeal carcinoma; Esophageal Diseases; Renal Cell Carcinoma; Lymphoma, Follicular; Retinoblastoma; Stomach Carcinoma; CARCINOMA OF VULVA; Fanconi Anemia; Squamous cell carcinoma; Rheumatoid Arthritis; Tonsillitis; Dejerine-Sottas Disease (disorder); Squamous cell carcinoma of vulva; HER2-positive carcinoma of breast; Disruptive, Impulse Control, and Conduct Disorders; Luminal A Breast Carcinoma; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Degenerative polyarthritis; Type II Mucolipidosis; HIV Infections; Luminal B Breast Carcinoma; Colonic Neoplasms; Gastric Adenocarcinoma; Malignant neoplasm of vulva; DOSAGE-SENSITIVE SEX REVERSAL; Glioblastoma Multiforme; Cholangiocarcinoma; Disease due to Parvoviridae; Restenosis; Medulloblastoma; Squamous cell carcinoma of esophagus; Choriocarcinoma; Shigella Infections; Aplasia Cutis Congenita; Secondary malignant neoplasm of lymph node; Visual seizure; Polycystic Ovary Syndrome; Pituitary Diseases; Endometriosis",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8145035474981049; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8342163953428735; 0.8402911822757345; 0.8402911822757345; 0.8508164886128737; 0.8548862007194026; 0.8610447277138289; 0.8769418330148872; 0.8815127642200768; 0.8911256045597441; 0.900167961295542; 0.900167961295542; 0.9174808175273056; 0.93156380601526; 0.960644037248553,Carcinoma Of The Head And Neck; Sclerocystic Ovaries; Liver Carcinoma; Polycystic Ovary Syndrome,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Currarino syndrome ORPHA:1552; Filippi syndrome ORPHA:3255; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Citrullinemia type II ORPHA:247585; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Hydrolethalus ORPHA:2189; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Autosomal recessive cutis laxa type 2B ORPHA:357064; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Jawad syndrome ORPHA:313795; PYCR1-related De Barsy syndrome ORPHA:293633; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; Linear nevus sebaceus syndrome ORPHA:2612; Familial congenital mirror movements ORPHA:238722; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome ORPHA:477993; Inclusion body myopathy with Paget disease of bone and frontotemporal dementia ORPHA:52430; Neu-Laxova syndrome ORPHA:2671; Acquired partial lipodystrophy ORPHA:79087; Acute myeloid leukemia with NPM1 somatic mutations ORPHA:402026; Autosomal dominant spastic paraplegia type 13 ORPHA:100994; Charcot-Marie-Tooth disease type 4B1 ORPHA:99955; Pelizaeus-Merzbacher-like disease due to HSPD1 mutation ORPHA:280288; Progressive myoclonic epilepsy type 9 ORPHA:457265; Muir-Torre syndrome ORPHA:587; 3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form ORPHA:79351; ALDH18A1-related De Barsy syndrome ORPHA:35664; ALG8-CDG ORPHA:79325; Autosomal dominant spastic paraplegia type 9A ORPHA:447753; Autosomal dominant spastic paraplegia type 9B ORPHA:447757; Autosomal recessive spastic paraplegia type 9B ORPHA:447760; Exercise-induced hyperinsulinism ORPHA:165991; Familial clubfoot due to 5q31 microdeletion ORPHA:293144; Familial clubfoot due to PITX1 point mutation ORPHA:293150; Ketoacidosis due to monocarboxylate transporter-1 deficiency ORPHA:438075; Metabolic myopathy due to lactate transporter defect ORPHA:171690; Mirror-image polydactyly ORPHA:498494; S-adenosylhomocysteine hydrolase deficiency ORPHA:88618; STT3A-CDG ORPHA:370921; Brachydactyly-elbow wrist dysplasia syndrome ORPHA:1275; Familial isolated congenital asplenia ORPHA:101351; Geroderma osteodysplastica ORPHA:2078; Autosomal recessive Kenny-Caffey syndrome ORPHA:93324; Brain calcification, Rajab type ORPHA:178506; Combined immunodeficiency due to TFRC deficiency ORPHA:476113; Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome ORPHA:496756; Phosphoserine aminotransferase deficiency, infantile/juvenile form ORPHA:284417; Sanjad-Sakati syndrome ORPHA:2323; Autosomal dominant Charcot-Marie-Tooth disease type 2D ORPHA:99938; Cardiomyopathy-hypotonia-lactic acidosis syndrome ORPHA:91130; RARS-related autosomal recessive hypomyelinating leukodystrophy ORPHA:438114; Triose phosphate-isomerase deficiency ORPHA:868",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1068643725150898; 0.1068643725150898; 0.1419890644363008; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human papillomavirus 122 transforming protein E7 (gene: E7); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human papillomavirus 111 E7 protein (gene: E7); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Yaba-like disease virus 142R protein (gene: 142R); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Human papillomavirus 159 E7 protein (gene: E7); Human papillomavirus type 81 E7 protein (gene: E7); Monkeypox virus ser/thr kinase; Human papillomavirus type 62 putative transforming protein E7 (gene: E7); Variola virus Ser/Thr kinase (gene: C14L); Human papillomavirus type 53 early protein (gene: E7); Banna virus strain JKT-6423 Vp7; Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Human papillomavirus 113 E7 protein (gene: E7); Variola virus hypothetical protein (gene: B1R); Vaccinia virus Ankara serine/threonine-protein kinase-like; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Human papillomavirus 9 early protein (gene: E7); Human papillomavirus type 97 E7 protein; Monkeypox virus ser/thr protein kinase-like protein; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Alphapapillomavirus 7 E7 protein (gene: E7); Human papillomavirus type 18 E7 protein (gene: E7); Human papillomavirus type 59 ORF putative E7; Human papillomavirus type 39 E7 (gene: E7); Human papillomavirus type 54 transforming protein (gene: E7); Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Yaba monkey tumor virus 142R; Monkeypox virus Zaire-96-I-16 B11R (gene: B11R); Human papillomavirus 110 E7 protein (gene: E7); Human papillomavirus type 34 early protein (gene: E7); Human papillomavirus type 45 early protein (gene: E7); Human papillomavirus type 68 E7 (gene: E7); Human papillomavirus type 26 early protein (gene: E7); Human papillomavirus type 82 E7; Human papillomavirus 104 E7 protein (gene: E7); Human papillomavirus type 49 E7 protein (gene: E7); Mupapillomavirus 1 E7 protein (gene: E7); Human papillomavirus type 67 E7; Human papillomavirus 15 early protein (gene: E7); Horsepox virus HSPV189 (Serine/threonine protein kinase); Human papillomavirus type 68b E7 protein (gene: E7); Human papillomavirus 17 early protein (gene: E7); Human papillomavirus type 32 early protein (gene: E7); Human papillomavirus type 69 E7; Human papillomavirus type 68a E7 protein; Human papillomavirus type 30 early protein (gene: E7); Human papillomavirus FA75/KI88-03 E7 protein (gene: E7); Human papillomavirus type 16 transforming protein (gene: E7); Orf virus ORF130 putative serine/threonine protein kinase; Human papillomavirus 107 E7 protein (gene: E7); Vaccinia virus ser/thr protein kinase-like protein (gene: B12R); Human papillomavirus type 52 early protein (gene: E7); Human gammaherpesvirus 8 vIRF-4 (gene: vIRF-4)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
CCNB2,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Laryngeal Squamous Cell Carcinoma; Non-Small Cell Lung Carcinoma; Adenoma; Glioma; Malignant neoplasm of lung; Ataxia Telangiectasia; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Lung Neoplasms; Squamous cell carcinoma; invasive cancer; Liver Cirrhosis, Experimental; Adenocarcinoma of lung (disorder); Pituitary Adenoma; Pituitary Neoplasms",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8098851543361193; 0.834094492023826; 0.8368219249856942,Liver Carcinoma,0.7765582368651238,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Currarino syndrome ORPHA:1552; Filippi syndrome ORPHA:3255; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Citrullinemia type II ORPHA:247585; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Hyper-IgM syndrome type 5 ORPHA:101092; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Hydrolethalus ORPHA:2189; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XY complete gonadal dysgenesis ORPHA:242; Autosomal recessive cutis laxa type 2B ORPHA:357064; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Jawad syndrome ORPHA:313795; Meacham syndrome ORPHA:3097; PYCR1-related De Barsy syndrome ORPHA:293633; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; Familial prostate cancer ORPHA:1331; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome ORPHA:477993; Li-Fraumeni syndrome ORPHA:524; Nephroblastoma ORPHA:654; Chudley-McCullough syndrome ORPHA:314597; Hemolytic anemia due to glutathione reductase deficiency ORPHA:90030; Osteosarcoma ORPHA:668; Fanconi anemia ORPHA:84; Adrenocortical carcinoma ORPHA:1501; Choroid plexus carcinoma ORPHA:251899; Papilloma of choroid plexus ORPHA:2807",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1068643725150898; 0.1068643725150898; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7593059616185558; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Vaccinia virus Ser/Thr kinase (gene: F10L); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
CCND3,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Reticulocyte count (procedure); Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; B-Cell Lymphomas; leukemia; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Laryngeal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Lymphoma; Endometrial Neoplasms; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Adenoma; Thyroid Neoplasm; Endometrial Carcinoma; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Refractory anemias; Lymphoma, Non-Hodgkin; Liver carcinoma; Osteosarcoma; Thyroid carcinoma; Colorectal Cancer; T-Cell Lymphoma; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Primary malignant neoplasm of lung; insulinoma; Acute myelomonocytic leukemia; Prostatic Neoplasms; Monoclonal Gammopathy of Undetermined Significance; Carcinoma of lung; Red Blood Cell Count measurement; Monocyte count procedure; Monocyte count result; Malignant Neoplasms; melanoma; Ewings sarcoma; Multiple Myeloma; Gastric lymphoma; High density lipoprotein measurement; Burkitt Lymphoma; Childhood T Acute Lymphoblastic Leukemia; Mean corpuscular hemoglobin concentration determination; Tumor Progression; Sarcoma; Lymphoma, Follicular; Retinoblastoma; Mean Corpuscular Volume (result); Squamous cell carcinoma; Rheumatoid Arthritis; Familial Partial Lipodystrophy, Type 2; Crohn Disease; Myeloid Leukemia, Chronic; Smoldering myeloma; Malignant Glioma; Hemoglobin measurement; Secondary malignant neoplasm of liver; Adult Non-Hodgkin Lymphoma; Red cell distribution width determination; Waldenstrom Macroglobulinemia; RDW - Red blood cell distribution width result; Childhood Non-Hodgkin Lymphoma; Malignant lymphoma - lymphoplasmacytic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Endometrial Hyperplasia; Salivary duct carcinoma; Paresis; Inflammatory Bowel Diseases; Muscle Weakness",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8642802827048847; 0.8815127642200768; 0.9512505437112568,Lymphoblastic Leukemia; Malignant Neoplasm; Inflammatory Bowel Disease; Crohn Disease,0.7765582368651238; 0.8115918568696846; 0.861756360478846; 0.8903630091389316,Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Incontinentia pigmenti ORPHA:464; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Camurati-Engelmann disease ORPHA:1328; Infantile inflammatory bowel disease with neurological involvement ORPHA:565788; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204; Dehydrated hereditary stomatocytosis ORPHA:3202; Brachydactyly type B2 ORPHA:140908; Hermansky-Pudlak syndrome type 8 ORPHA:231537; Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome ORPHA:480864; Stapes ankylosis with broad thumbs and toes ORPHA:140917; Tarsal-carpal coalition syndrome ORPHA:1412; Combined immunodeficiency due to ORAI1 deficiency ORPHA:317428; Becker nevus syndrome ORPHA:64755; Developmental malformations-deafness-dystonia syndrome ORPHA:79107; Congenital erythropoietic porphyria ORPHA:79277; Bleeding diathesis due to thromboxane synthesis deficiency ORPHA:220443; Primary familial polycythemia ORPHA:90042,0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Banna virus strain JKT-6423 Vp7; Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Cowpox virus CPXV206 protein (gene: CPXV206 CDS)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
CCNE1,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; leukemia; Ovarian Carcinoma; Adenocarcinoma; Colorectal Carcinoma; Leukemogenesis; Non-Small Cell Lung Carcinoma; Pancreatic Neoplasm; Carcinoma breast stage IV; Adenoma; Thyroid Neoplasm; Endometrial Carcinoma; Mammary Neoplasms; Glioma; Liver carcinoma; Osteosarcoma; Colorectal Cancer; Epithelial ovarian cancer; Glioblastoma; Osteosarcoma of bone; Disease Exacerbation; Neoplasm Metastasis; Carcinoma, Endometrioid; Neuroblastoma; Central neuroblastoma; Malignant Neoplasms; Multiple Myeloma; Lung Neoplasms; Malignant neoplasm of stomach; Adult Hepatocellular Carcinoma; Tumor Progression; Sarcoma; Retinoblastoma; Congenital chromosomal disease; Stomach Carcinoma; Fanconi Anemia; Squamous cell carcinoma; Classical Hodgkin's Lymphoma; Carcinoid Tumor; Fallopian Tube Carcinoma; ovarian neoplasm; Fibrosis; Neoplasm of uncertain or unknown behavior of ovary; Fibrosis, Liver; Carcinoma, Transitional Cell; Medullomyoblastoma; Melanotic medulloblastoma; Hypertensive disease; Medulloblastoma; Desmoplastic Medulloblastoma; Squamous cell carcinoma of esophagus; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Adult Medulloblastoma; Inflammatory Bowel Diseases; Mammary Neoplasms, Human; Neuroendocrine Tumors; Secondary malignant neoplasm of lymph node; Cystadenocarcinoma, Serous; Childhood Medulloblastoma; Urothelial Carcinoma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8067197998685076; 0.8145035474981049; 0.8232134984476662; 0.8272008757995397; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8548862007194026; 0.8584283190330553; 0.8610447277138289; 0.8769418330148872; 0.8771562273432176; 0.8774809019744603; 0.8815127642200768; 0.8815127642200768; 0.887595340546704; 0.900167961295542; 0.9154499654632742; 0.9262273158806068; 0.9441119274323576,Carcinoma Of The Head And Neck; Ovarian Neoplasm; Liver Carcinoma; Ovarian Carcinoma; Ovarian Cancer; Bladder Neoplasm; Urinary Bladder Cancer; Malignant Neoplasm; Mammary Neoplasms; Marfan Syndrome; Medullomyoblastoma; Breast Cancer; Medulloblastoma; Breast Carcinoma,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8477374749042494; 0.861756360478846; 0.8903630091389316; 0.9024492468099392; 0.9398381935810408,Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Large congenital melanocytic nevus ORPHA:626; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Hereditary coproporphyria ORPHA:79273; Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Bosley-Salih-Alorainy syndrome ORPHA:69737; Male infertility due to large-headed multiflagellar polyploid spermatozoa ORPHA:137893,0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Banna virus strain JKT-6423 Vp7; Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Variola virus hypothetical protein (gene: B1R); Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Yaba monkey tumor virus 142R",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
CCP110,Malignant neoplasm of lung; Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement; Primary malignant neoplasm of lung; Carcinoma of lung; Chronic myeloproliferative disorder; Myeloproliferative disease; Multiple Chronic Conditions,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7945683314244791; 0.8138488881521341; 0.882453254162044,,,"Vocal cord and pharyngeal distal myopathy ORPHA:600; Non-specific syndromic intellectual disability ORPHA:528084; Angiocentric glioma ORPHA:251671; Joubert syndrome with ocular defect ORPHA:220493; Joubert syndrome with Jeune asphyxiating thoracic dystrophy ORPHA:397715; Autosomal recessive spastic paraplegia type 54 ORPHA:320380; Aniridia-cerebellar ataxia-intellectual disability syndrome ORPHA:1065; Short rib-polydactyly syndrome, Majewski type ORPHA:93269; Jeune syndrome ORPHA:474; Joubert syndrome ORPHA:475; Short rib-polydactyly syndrome, Beemer-Langer type ORPHA:93268; Senior-Loken syndrome ORPHA:3156; Retinitis pigmentosa ORPHA:791; Orofaciodigital syndrome type 2 ORPHA:2751; Spastic paraplegia-severe developmental delay-epilepsy syndrome ORPHA:464282",0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CD14,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Thromboangiitis Obliterans; B-Cell Lymphomas; leukemia; Malignant neoplasm of pancreas; Asymptomatic human immunodeficiency virus infection; Colorectal Carcinoma; Pancreatic carcinoma; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Lymphoma; Non-Small Cell Lung Carcinoma; Hypercholesterolemia; Colorectal Neoplasms; Acute asthma; Adenoma; Vascular Diseases; Lymphoma, Extranodal NK-T-Cell; Mammary Neoplasms; Monocytic leukemia; Malignant neoplasm of gastrointestinal tract; Chronic Fatigue Syndrome; Malignant neoplasm of prostate; stage, non-small cell lung cancer; Lymphoma, Non-Hodgkin; IMMUNE SUPPRESSION; Liver carcinoma; Pancreatitis, Alcoholic; Osteosarcoma; Acute Promyelocytic Leukemia; Colorectal Cancer; Chronic heart failure; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Nephroblastoma; Sudden infant death syndrome; Neoplasm Metastasis; Prion Diseases; Acute myelomonocytic leukemia; Peptic Ulcer; Prostatic Neoplasms; Acute Myeloid Leukemia, M1; Mesothelioma; Neuroblastoma; Choroideremia; Multiple Myeloma; Mycoplasma Infections; Dysgerminoma; Refractory cytopenia with multilineage dysplasia; Campylobacter jejuni infection; Malignant neoplasm of stomach; Diarrhea; Recurrent upper respiratory tract infection; Histiocytic sarcoma; Congenital contractural arachnodactyly; Giant Cell Tumor of Bone; Invasive Ductal Breast Carcinoma; Traveler's diarrhea; Very Low Birth Weight; Pancreatitis, Chronic; M5b Acute differentiated monocytic leukemia; pricking of skin; Infection caused by Helicobacter pylori; Status Asthmaticus; Childhood nephrotic syndrome; Corneal infection; Food Allergy; Gram-Negative Bacterial Infections; Lupus Erythematosus, Systemic; Gout; Renal Cell Carcinoma; secondary acute myeloid leukemia; Acquired Immunodeficiency Syndrome; heavy drinking; Gangrene; Invasive meningococcal disease; Coronary Arteriosclerosis; Acute leukemia; Infant, Premature; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Periodontitis; TNF receptor-associated periodic fever syndrome (TRAPS); Acute lymphocytic leukemia; Burning Mouth Syndrome; Choledochal Cyst; Leukemic Infiltration; Stomach Carcinoma; Immediate hypersensitivity; Autoimmune Diseases; Juvenile psoriatic arthritis; Hepatitis C; Acute myocardial infarction; Cardiovascular Diseases; Age-related cataract; Immune Reconstitution Inflammatory Syndrome; Acute periodontitis; Rheumatoid Arthritis; Juvenile-Onset Still Disease; Coronary Occlusion; Genital ulcers; Coinfection; Airway Obstruction; Ankylosing spondylitis; Uveitis; Septicaemia due to gram-negative organism, unspecified; Bacterial sepsis; Malignant histiocytosis; Patent ductus arteriosus - persisting type; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Sjogren's Syndrome; Periodontitis, Juvenile; Severe periodontitis; Crohn Disease; Myelodysplasia; Multiple Organ Failure; Nasal allergies; Non-ST Elevated Myocardial Infarction; Cholestasis; Cytomegalovirus Infections; Virus Diseases; Myeloid Leukemia, Chronic; Myeloid Leukemia; Osteoporosis, Postmenopausal; Bacterial Infections; Peri-Implantitis; Juvenile arthritis; Hemangioma; Jaundice, Obstructive; Eczema Herpeticum; Pouchitis; IGA Glomerulonephritis; Hyperinsulinism; Chronic Periodontitis; Allergic disposition; Primary Sj??gren's syndrome; Alcohol abuse; Cerebral atrophy; Multiple Sclerosis; Pneumonitis; Psoriasis; Myocardial Infarction; Superficial spreading malignant melanoma of skin; Tumor Necrosis Factor Receptor 1-Associated Periodic Syndrome; Decreased Concentration; Systemic Inflammatory Response Syndrome; Paroxysmal nocturnal hemoglobinuria; Signs and Symptoms, Respiratory; Chronic Lymphocytic Leukemia; Synovitis; Infectious disease of lung; Degenerative polyarthritis; Gingival Diseases; Acute Coronary Syndrome; Histiocytosis, Langerhans-Cell; Lupus Erythematosus; Nonalcoholic Steatohepatitis; Melioidosis; Angina, Unstable; Respiratory Tract Infections; Brain Injuries, Focal; Chromosome 8, trisomy; Injuries, Acute Brain; Brain Injuries; Brain Lacerations; Schizophrenia; Lupus Erythematosus, Discoid; Chronic Infantile Neurological, Cutaneous, and Articular Syndrome; Appendicitis; West Nile viral infection; Acute GVH disease; Hereditary hemochromatosis; Liver diseases; Fibrosis; HIV Infections; Diabetes Mellitus, Insulin-Dependent; Upper Respiratory Infections; Pancreatitis; Precursor B-cell lymphoblastic leukemia; Stable angina; Ulcerative Colitis; Precursor Cell Lymphoblastic Leukemia Lymphoma; Multiple Sclerosis, Relapsing-Remitting; Bronchial Hyperreactivity; Gastrointestinal Carcinoid Tumor; Mucosa-Associated Lymphoid Tissue Lymphoma; Impaired cognition; Chronic granulomatous disease; Graft-vs-Host Disease; Peritonitis; Diabetes Mellitus, Non-Insulin-Dependent; Chromosome 5, trisomy 5q; Periapical Periodontitis; Juvenile rheumatoid arthritis; Liver Cirrhosis; Monocytosis; Myelodysplastic Syndrome with Isolated del(5q); Lupus Vulgaris; Hypersensitivity; MIXED LINEAGE LEUKEMIA; Hirschsprung Disease; Amyotrophic Lateral Sclerosis, Sporadic; Periodontal Diseases; 5q-syndrome; Infection; Fibrosis, Liver; Meningitis, Bacterial; Pneumonia; Wheezing; Pituitary Adenoma; Subfertility; Tuberculosis; Cholestasis in newborn; Cholangiocarcinoma; Amyotrophic Lateral Sclerosis; Patent ductus arteriosus; Systemic Scleroderma; Oligoarticular Juvenile Idiopathic Arthritis; Optic Neuritis; Adrenoleukodystrophy; Steatohepatitis; Common Variable Immunodeficiency; Pneumococcal Infections; Hyperlipoproteinemia Type IIa; Celiac Disease; Icterus; Rhinitis; Infectious Otitis Media; Otitis Media; Sarcoidosis, Pulmonary; Obstructive nephropathy; Hepatitis B; Severe Sepsis; Acute pancreatitis; Carotid Atherosclerosis; Restenosis; Cirrhosis; X-linked agammaglobulinemia; Allergic sensitization; Metabolic Syndrome X; Squamous cell carcinoma of esophagus; Tuberculosis, Pulmonary; Cerebrovascular accident; Myocardial Ischemia; Carotid Stenosis; Chronic Obstructive Airway Disease; Respiratory Tract Diseases; Severe Dengue; Amyloidosis; Hepatitis B, Chronic; Cataract; Encephalitis, St. Louis; Arthropathy; Lichen Planus, Oral; Necrotizing Enterocolitis; Parkinson Disease; Childhood asthma; Inflammatory Bowel Diseases; Bronchiolitis; Dermatitis, Atopic; Pain; Middle Cerebral Artery Occlusion; Allergic asthma; Coronary Artery Disease; Aplasia Cutis Congenita; Guillain-Barre Syndrome; Congestive heart failure; Obesity; Malignant Fibrous Histiocytoma; Mitral Valve Stenosis; Leprosy; Respiration Disorders; Fatigue; Peripheral Vascular Diseases; Cerebral Ischemia; Eczema; Coronary heart disease; Lymphoma, Large-Cell, Follicular; Alcoholic Liver Diseases; Mucocutaneous Lymph Node Syndrome; Septicemia; Sepsis; Malaria, Falciparum; Gaucher Disease; Allergic rhinitis (disorder); Liver Cirrhosis, Alcoholic; Sarcoidosis; Complete atrioventricular block; Overweight; Cerebrovascular Disorders; Chronic Kidney Diseases; Biliary Atresia; Hepatitis C, Chronic; Graves Disease; Malaria; Liver Failure, Acute; Peripheral Arterial Diseases; Cerebral Infarction; Aortic Aneurysm, Abdominal; Asthma; Agenesis of corpus callosum; Hypercholesterolemia, Familial; Impaired glucose tolerance; Weight decreased; Cystic Fibrosis; Non-alcoholic Fatty Liver Disease",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8009048756462318; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026798872257774; 0.8037546774788534; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8101097852323003; 0.8101097852323003; 0.8138488881521341; 0.8140222479282434; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8270909867833504; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.834094492023826; 0.834094492023826; 0.834094492023826; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.843190898187174; 0.8474481237156937; 0.8497448945325101; 0.8508164886128737; 0.8554819098734854; 0.8584283190330553; 0.8584283190330553; 0.8610447277138289; 0.8610447277138289; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8672189956534445; 0.8745234584149799; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8772392350816924; 0.8774809019744603; 0.8815127642200768; 0.8815127642200768; 0.8867509400747969; 0.887595340546704; 0.887595340546704; 0.887595340546704; 0.887595340546704; 0.8911256045597441; 0.8959157818691486; 0.8976039441125321; 0.8989612563669234; 0.8989612563669234; 0.8989612563669234; 0.9001392794088324; 0.900167961295542; 0.9029289778792944; 0.9039108388826153; 0.9083161862856644; 0.909484944705772; 0.9119978323790848; 0.9119978323790848; 0.914995991166204; 0.914995991166204; 0.917543617287358; 0.9189398569397552; 0.9193385822373632; 0.9214835359141188; 0.922577745415874; 0.9262273158806068; 0.929235785949896; 0.929814249105729; 0.929814249105729; 0.9387505562433404; 0.9393256300017014; 0.9401670107659288; 0.9432051631882106; 0.94939825643792; 0.9512505437112568; 0.9527677537004838; 0.9557184806547836; 0.9564633032157428; 0.9578035687879456; 0.9672478180546946; 0.9701053690483854; 0.9707275133033936; 0.9734506818882446; 0.9740616963450036; 0.9874278479946328; 0.9924277189223056,"Gout; Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Liver Cirrhosis; Seronegative Polyarthritis; Still Disease; Liver Fibrosis; Arthritis; Non-Alcoholic Fatty Liver Disease; Eczema; Asthma",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8903301324869451; 0.9046917974656596; 0.951883341147811; 0.9658957825498884; 0.9832345076528324,"Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Heme oxygenase-1 deficiency ORPHA:562509; Thrombomodulin-related bleeding disorder ORPHA:436169; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; ACys amyloidosis ORPHA:100008; Charcot-Marie-Tooth disease type 4D ORPHA:99950; Clear cell renal carcinoma ORPHA:319276; Duane retraction syndrome with congenital deafness ORPHA:529574; Fructose-1,6-bisphosphatase deficiency ORPHA:348; Hemochromatosis type 4 ORPHA:139491; Mucolipidosis type III gamma ORPHA:423470; Multicentric carpo-tarsal osteolysis with or without nephropathy ORPHA:2774; Metaphyseal anadysplasia ORPHA:1040; Pediatric systemic lupus erythematosus ORPHA:93552; ABri amyloidosis ORPHA:97345; ADan amyloidosis ORPHA:97346; Atypical Gaucher disease due to saposin C deficiency ORPHA:309252; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319581; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319569; Ayme-Gripp syndrome ORPHA:1272; Encephalopathy due to prosaposin deficiency ORPHA:139406; Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease ORPHA:439854; Genetic hyperferritinemia without iron overload ORPHA:254704; Hereditary hyperferritinemia-cataract syndrome ORPHA:163; L-ferritin deficiency ORPHA:440731; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency ORPHA:99898; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; NON RARE IN EUROPE: Wolff-Parkinson-White syndrome ORPHA:907; Neuroferritinopathy ORPHA:157846; Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies ORPHA:397758; Tangier disease ORPHA:31150; Infantile Krabbe disease ORPHA:206436; Chronic mucocutaneous candidiasis ORPHA:1334; Acute myeloid leukemia with CEBPA somatic mutations ORPHA:319480; Alpha-1-antitrypsin deficiency ORPHA:60; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency ORPHA:319589; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency ORPHA:319574; Cerebrotendinous xanthomatosis ORPHA:909; Farber disease ORPHA:333; Fowler vasculopaty ORPHA:221126; Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation ORPHA:178396; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency ORPHA:319547; RNF13-related severe early-onset epileptic encephalopathy ORPHA:544503; Recurrent Neisseria infections due to factor D deficiency ORPHA:169467; Spinal muscular atrophy-progressive myoclonic epilepsy syndrome ORPHA:2590; Sterile multifocal osteomyelitis with periostitis and pustulosis ORPHA:210115; Congenital factor XIII deficiency ORPHA:331; ALys amyloidosis ORPHA:93561; C1 inhibitor deficiency ORPHA:459353; Cholesteryl ester storage disease ORPHA:75234; Congenital factor V deficiency ORPHA:326; Congenital myopathy, Paradas type ORPHA:199329; Diaphragmatic hernia-short bowel-asplenia syndrome ORPHA:527468; Distal myopathy with anterior tibial onset ORPHA:178400; Dysferlin-related  limb-girdle muscular dystrophy R2 ORPHA:268; East Texas bleeding disorder ORPHA:391320; Enamel-renal syndrome ORPHA:1031; Hereditary angioedema type 1 ORPHA:100050; Hereditary angioedema type 2 ORPHA:100051; Keratolytic winter erythema ORPHA:50943; Lysinuric protein intolerance ORPHA:470; Miyoshi myopathy ORPHA:45448; Osteopetrosis with renal tubular acidosis ORPHA:2785; Susceptibility to localized juvenile periodontitis ORPHA:447740; Wolman disease ORPHA:75233; Hereditary renal hypouricemia ORPHA:94088; Intermittent hydrarthrosis ORPHA:329967; NON RARE IN EUROPE: Alzheimer disease ORPHA:238616; Hemoglobin M disease ORPHA:330041; Hyperandrogenism due to cortisone reductase deficiency ORPHA:168588; Immunodeficiency due to a classical component pathway complement deficiency ORPHA:169147; Autosomal dominant hyper-IgE syndrome ORPHA:2314; Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity ORPHA:437552; Beta-thalassemia intermedia ORPHA:231222; Beta-thalassemia major ORPHA:231214; Chronic lymphoproliferative disorder of natural killer cells ORPHA:512017; Dominant beta-thalassemia ORPHA:231226; Early-onset calcifying leukoencephalopathy-skeletal dysplasia ORPHA:556985; Hemoglobin C disease ORPHA:2132; Hemoglobin C-beta-thalassemia syndrome ORPHA:231242; Hemoglobin D disease ORPHA:90039; Hemoglobin E disease ORPHA:2133; Hemoglobin E-beta-thalassemia syndrome ORPHA:231249; STAT3-related early-onset multisystem autoimmune disease ORPHA:438159; Sickle cell anemia ORPHA:232; Sickle cell-beta-thalassemia disease syndrome ORPHA:251359; Sickle cell-hemoglobin C disease syndrome ORPHA:251365; Sickle cell-hemoglobin D disease syndrome ORPHA:251370; Sickle cell-hemoglobin E disease syndrome ORPHA:251375; T-cell large granular lymphocyte leukemia ORPHA:86872; Nasu-Hakola disease ORPHA:2770; Autosomal systemic lupus erythematosus ORPHA:300345",0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.44,Homo sapiens,chemical synthesis
CD52,"leukemia; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Lymphoma; Adult T-Cell Lymphoma/Leukemia; Ki-1+ Anaplastic Large Cell Lymphoma; Promyelocytic leukemia; Mastocytosis, Systemic; Acute Promyelocytic Leukemia; Leukemia, T-Cell; Hematologic Neoplasms; Multiple Myeloma; Acute lymphocytic leukemia; Autoimmune Diseases; Diabetes; Diabetes Mellitus; Chronic lymphocytic leukaemia refractory; Leukemia, T-Cell, Chronic; Waldenstrom Macroglobulinemia; Chronic Lymphocytic Leukemia; Encephalomyelitis; Acute GVH disease; Diabetes Mellitus, Insulin-Dependent; T-Cell Prolymphocytic Leukemia; Graft-vs-Host Disease; Hypereosinophilia; Idiopathic Hypereosinophilic Syndrome; Tuberculosis; Prolymphocytic Leukemia; Polyarthritis; Peripheral T-Cell Lymphoma",0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8101097852323003; 0.8145035474981049; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8368219249856942; 0.8402911822757345; 0.8523465762428218; 0.876210765330195,,,Familial isolated pituitary adenoma ORPHA:314777; Aicardi-Goutieres syndrome ORPHA:51; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; Autosomal dominant dopa-responsive dystonia ORPHA:98808; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; GTP cyclohydrolase I deficiency ORPHA:2102; Waldenstrom macroglobulinemia ORPHA:33226; Takayasu arteritis ORPHA:3287; Autosomal recessive malignant osteopetrosis ORPHA:667; Bleeding disorder due to CalDAG-GEFI deficiency ORPHA:420566; Congenital non-communicating hydrocephalus ORPHA:269510; Revesz syndrome ORPHA:3088; Severe combined immunodeficiency due to CORO1A deficiency ORPHA:228003; Spinocerebellar ataxia type 40 ORPHA:423275; Variant ABeta2M amyloidosis ORPHA:314652; Epidermodysplasia verruciformis ORPHA:302; Galactose mutarotase deficiency ORPHA:570422; Laron syndrome with immunodeficiency ORPHA:220465; Neutrophil immunodeficiency syndrome ORPHA:183707; Obesity due to pro-opiomelanocortin deficiency ORPHA:71526; WHIM syndrome ORPHA:51636; Cystic leukoencephalopathy without megalencephaly ORPHA:85136; Familial hemophagocytic lymphohistiocytosis ORPHA:540; Aland Islands eye disease ORPHA:178333; BENTA disease ORPHA:464336; Combined immunodeficiency due to OX40 deficiency ORPHA:431149; Griscelli syndrome type 2 ORPHA:79477; Hyperinsulinism due to UCP2 deficiency ORPHA:276556; Persistent polyclonal B-cell lymphocytosis ORPHA:300324; Severe combined immunodeficiency due to CARD11 deficiency ORPHA:357237; T-B+ severe combined immunodeficiency due to JAK3 deficiency ORPHA:35078; X-linked severe congenital neutropenia ORPHA:86788; X-linked thrombocytopenia with normal platelets ORPHA:852; Acute basophilic leukemia ORPHA:86849; Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome ORPHA:538574; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia ORPHA:632; Complete hydatidiform mole ORPHA:254688; Autosomal agammaglobulinemia ORPHA:33110; Omenn syndrome ORPHA:39041; Common variable immunodeficiency ORPHA:1572; Brain dopamine-serotonin vesicular transport disease ORPHA:352649; Charcot-Marie-Tooth disease type 1D ORPHA:101084; Charcot-Marie-Tooth disease type 4E ORPHA:99951; Combined immunodeficiency due to CD27 deficiency ORPHA:238505; Combined immunodeficiency due to DOCK8 deficiency ORPHA:217390; Combined immunodeficiency due to IL21R deficiency ORPHA:357329; Combined immunodeficiency due to ZAP70 deficiency ORPHA:911; DOCK2 deficiency ORPHA:447737; Hereditary central diabetes insipidus ORPHA:30925; Hyper-IgM syndrome type 3 ORPHA:101090; Hyperzincemia and hypercalprotectinemia ORPHA:251523; Leukocyte adhesion deficiency type I ORPHA:99842; Leukocyte adhesion deficiency type III ORPHA:99844; NON RARE IN EUROPE: Psoriatic arthritis ORPHA:40050; Pancytopenia due to IKZF1 mutations ORPHA:317473; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome ORPHA:69126; Renin-angiotensin-aldosterone system-blocker-induced angioedema ORPHA:100057; Severe combined immunodeficiency due to LCK deficiency ORPHA:280142; Short stature due to growth hormone qualitative anomaly ORPHA:629; Spondyloenchondrodysplasia ORPHA:1855; T-B+ severe combined immunodeficiency due to gamma chain deficiency ORPHA:276; Isolated growth hormone deficiency type II ORPHA:231679; Stevens-Johnson syndrome ORPHA:36426; Wiskott-Aldrich syndrome ORPHA:906; Adult-onset myasthenia gravis ORPHA:391490; Giant cell arteritis ORPHA:397; Narcolepsy type 2 ORPHA:83465; Diffuse cutaneous systemic sclerosis ORPHA:220393; NON RARE IN EUROPE: Ulcerative colitis ORPHA:771; NON RARE IN EUROPE: Multiple sclerosis ORPHA:802; Narcolepsy type 1 ORPHA:2073; Primary biliary cholangitis ORPHA:186; Systemic lupus erythematosus ORPHA:536; Recurrent infections associated with rare immunoglobulin isotypes deficiency ORPHA:183675; T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta ORPHA:169160; Autosomal dominant thrombocytopenia with platelet secretion defect ORPHA:466806; C syndrome ORPHA:1308; Chronic beryllium disease ORPHA:133; Fatal post-viral neurodegenerative disorder ORPHA:391343; Graham Little-Piccardi-Lassueur syndrome ORPHA:505; Immunodeficiency due to CD25 deficiency ORPHA:169100; Isolated delta-storage pool disease ORPHA:248340; Jacobsen syndrome ORPHA:2308; Limited systemic sclerosis ORPHA:220407; Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency ORPHA:319552; Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency ORPHA:319600; NON RARE IN EUROPE: Rheumatoid arthritis ORPHA:284130; Paris-Trousseau thrombocytopenia ORPHA:851; Peripheral primitive neuroectodermal tumor ORPHA:370348; Severe combined immunodeficiency due to LAT deficiency ORPHA:504523; Subcutaneous panniculitis-like T-cell lymphoma ORPHA:86884; T-B+ severe combined immunodeficiency due to CD45 deficiency ORPHA:169157; T-cell immunodeficiency with epidermodysplasia verruciformis ORPHA:324294; TCR-alpha-beta-positive T-cell deficiency ORPHA:397959; X-linked agammaglobulinemia ORPHA:47; X-linked lymphoproliferative disease due to SH2D1A deficiency ORPHA:538931; Bullous pemphigoid ORPHA:703; Classic mycosis fungoides ORPHA:2584; Limbic encephalitis with LGI1 antibodies ORPHA:163908; Pediatric multiple sclerosis ORPHA:477738; Sezary syndrome ORPHA:3162; Sarcoidosis ORPHA:797; Spinocerebellar ataxia with axonal neuropathy type 2 ORPHA:64753; Chronic granulomatous disease ORPHA:379; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome ORPHA:238569; NON RARE IN EUROPE: Celiac disease ORPHA:555; NON RARE IN EUROPE: Diabetes mellitus type 1 ORPHA:243377; Autoimmune lymphoproliferative syndrome ORPHA:3261; Granulomatosis with polyangiitis ORPHA:900; Idiopathic aplastic anemia ORPHA:88; Oligoarticular juvenile idiopathic arthritis ORPHA:85410; Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis ORPHA:85408; NON RARE IN EUROPE: Crohn disease ORPHA:206; B-cell chronic lymphocytic leukemia ORPHA:67038; Behcet disease ORPHA:117,0.0414176838632111; 0.1294848460749822; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8029813443753846; 0.8447648476081987; 0.8564946241562607; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8939858547904395; 0.896422440954666; 0.9025296114347576,,,,,,
CDA,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; leukemia; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Lymphoma; Non-Small Cell Lung Carcinoma; Mammary Neoplasms; Monocytic leukemia; Liver carcinoma; Colorectal Cancer; Spondylarthritis; Neuroblastoma; Central neuroblastoma; Osteoarthritis, Spine; Malignant neoplasm of stomach; Diarrhea; Hemolytic-Uremic Syndrome; Malignant mesothelioma; M5b Acute differentiated monocytic leukemia; Infection caused by Helicobacter pylori; Stromal Neoplasm; Lupus Erythematosus, Systemic; Hyalinosis, Systemic; Acute leukemia; Mean Corpuscular Volume (result); Alzheimer's Disease; Stomach Carcinoma; Sickle Cell Dactylitis; Palmar-plantar erythrodysesthesia syndrome; Solid Neoplasm; Congenital dyserythropoietic anemia, type II; Myelodysplasia; Congenital dyserythropoietic anemia; Plaque, Amyloid; Leukopenia; Thrombocytopenia; Degenerative polyarthritis; Senile Plaques; HIV Infections; Avellino corneal dystrophy; Retroviridae Infections; Intervertebral Disc Degeneration; Hepatitis B; Down Syndrome; Anemia; Progressive cGVHD; Xeroderma Pigmentosum, Complementation Group D; Acute Megakaryocytic Leukemias; Mammary Neoplasms, Human; Malnutrition; Progressive Neoplastic Disease; Neutropenia",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8145035474981049; 0.8270909867833504; 0.8272008757995397; 0.841396342333011; 0.841396342333011; 0.8420665668584452; 0.8584283190330553; 0.8610447277138289; 0.8642802827048847; 0.8745234584149799; 0.8815127642200768; 0.9184153253162451; 0.9265708351135048; 0.9387505562433404,Mammary Neoplasms; Marfan Syndrome; Breast Cancer; Breast Carcinoma,0.8165359516083085; 0.8477374749042494; 0.8903630091389316; 0.9398381935810408,"Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Heme oxygenase-1 deficiency ORPHA:562509; Thrombomodulin-related bleeding disorder ORPHA:436169; Hemochromatosis type 5 ORPHA:447792; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Cryptogenic multifocal ulcerous stenosing enteritis ORPHA:468635; Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder ORPHA:477787; Galactosialidosis ORPHA:351; Neutral lipid storage disease with ichthyosis ORPHA:98907; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency ORPHA:319589; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency ORPHA:319574; Epithelial basement membrane dystrophy ORPHA:98956; FTH1-related iron overload ORPHA:247790; Glycogen storage disease due to liver glycogen phosphorylase deficiency ORPHA:369; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency ORPHA:319547; Reis-Bucklers corneal dystrophy ORPHA:98961; Thiel-Behnke corneal dystrophy ORPHA:98960; Congenital myopathy, Paradas type ORPHA:199329; Distal myopathy with anterior tibial onset ORPHA:178400; Dysferlin-related  limb-girdle muscular dystrophy R2 ORPHA:268; Miyoshi myopathy ORPHA:45448",0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CDC25C,"Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Malignant neoplasm of pancreas; Hepatoblastoma; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Malignant tumor of colon; Lymphoma; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Endometrial Carcinoma; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Ataxia Telangiectasia; Liver and Intrahepatic Biliary Tract Carcinoma; Prostate carcinoma; Primary malignant neoplasm of lung; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of liver; Turner Syndrome, Male; melanoma; Multiple Myeloma; Hodgkin Disease; Nasopharyngeal carcinoma; Retinoblastoma; Stomach Carcinoma; Squamous cell carcinoma; Solid Neoplasm; Polycystic liver disease; Indolent Non-Hodgkin Lymphoma; Liver neoplasms; Stomach Neoplasms; Schizophrenia; Polycystic Kidney Diseases; Gastrointestinal Carcinoid Tumor; Pituitary Adenoma; Ataxia; Cerebellar Ataxia",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8067197998685076; 0.8168901801930506; 0.8190761496232595; 0.834094492023826; 0.8402911822757345; 0.906476206143938,Liver Carcinoma; Schizophrenia,0.7765582368651238; 0.7860378120955526,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Currarino syndrome ORPHA:1552; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Citrullinemia type II ORPHA:247585; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Small cell lung cancer ORPHA:70573; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Hydrolethalus ORPHA:2189; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Jawad syndrome ORPHA:313795; Meacham syndrome ORPHA:3097; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; Familial prostate cancer ORPHA:1331; Li-Fraumeni syndrome ORPHA:524; Primary peritoneal carcinoma ORPHA:168829; 46,XY partial gonadal dysgenesis ORPHA:251510; Atrial septal defect-atrioventricular conduction defects syndrome ORPHA:1479; Hypothyroidism due to deficient transcription factors involved in pituitary development or function ORPHA:226307",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1068643725150898; 0.1068643725150898; 0.1419890644363008; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2844858212863536; 0.3891940933600213; 0.5867963421058087; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011,,,,,,
CDC34,"Esophageal carcinoma; Esophageal Neoplasms; Liver carcinoma; Malignant neoplasm of esophagus; intracranial glioma; Primary malignant neoplasm of lung; Carcinoma of lung; Pemphigus and fogo selvagem; Papillary Renal Cell Carcinoma; Papillary renal cell carcinoma, sporadic; Herpes Simplex Infections",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8098851543361193,,,Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Early-onset posterior subcapsular cataract ORPHA:441447; Autosomal recessive cerebellar ataxia due to STUB1 deficiency ORPHA:412057; Peutz-Jeghers syndrome ORPHA:2869; Adult-onset autosomal recessive sideroblastic anemia ORPHA:255132; Childhood-onset spasticity with hyperglycinemia ORPHA:401866,0.0144185025972157; 0.220389120533256; 0.5867963421058087; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011,Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61),0.8999095837312036; 0.8999095837312036,In vitro,0.68,Homo sapiens,Homo sapiens
CDC42BPB,Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Myotonic Dystrophy; Infiltrating duct carcinoma of female breast; Large cell carcinoma of lung; Adenocarcinoma of large intestine; Adult Diffuse Large B-Cell Lymphoma; Childhood Diffuse Large B-Cell Lymphoma; Neurodevelopmental Disorders,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7967714690735718; 0.8019075543217649; 0.8402911822757345; 0.8402911822757345; 0.9015731019095328,Infiltrating Duct Carcinoma Of Female Breast; Neurodevelopmental Disorders; Diffuse Lymphoma; Mental Depression; Colorectal Cancer,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8903630091389316; 0.9832345076528324,"NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Monosomy 22q13.3 ORPHA:48652; Bilateral perisylvian polymicrogyria ORPHA:98889; Saldino-Mainzer syndrome ORPHA:140969; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Frank-Ter Haar syndrome ORPHA:137834; Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Progressive myoclonic epilepsy type 5 ORPHA:402082; Synaptic congenital myasthenic syndromes ORPHA:98915; Familial hypercholanemia ORPHA:238475; Autosomal dominant intermediate Charcot-Marie-Tooth disease type E ORPHA:93114; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Hereditary folate malabsorption ORPHA:90045; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Dermatofibrosarcoma protuberans ORPHA:31112; Shprintzen-Goldberg syndrome ORPHA:2462; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Idiopathic pulmonary fibrosis ORPHA:2032; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Autosomal dominant adult-onset proximal spinal muscular atrophy ORPHA:209335; CLCN4-related X-linked intellectual disability syndrome ORPHA:485350; Dentatorubral pallidoluysian atrophy ORPHA:101; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Multiple myeloma ORPHA:29073; Pierson syndrome ORPHA:2670; Severe congenital hypochromic anemia with ringed sideroblasts ORPHA:300298; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; Wolfram-like syndrome ORPHA:411590; X-linked creatine transporter deficiency ORPHA:52503; Carpenter syndrome ORPHA:65759; Spondyloepimetaphyseal dysplasia with joint laxity ORPHA:93359; Hereditary diffuse gastric cancer ORPHA:26106; Aplasia cutis congenita ORPHA:1114; Juvenile nephronophthisis ORPHA:93592; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Acrokeratosis verruciformis of Hopf ORPHA:79151; Alpha-dystroglycan-related  limb-girdle muscular dystrophy R16 ORPHA:280333; Atelosteogenesis type I ORPHA:1190; Atelosteogenesis type III ORPHA:56305; Atrophoderma vermiculata ORPHA:79100; Autosomal spastic paraplegia type 58 ORPHA:397946; Boomerang dysplasia ORPHA:1263; Darier disease ORPHA:218; Dent disease type 2 ORPHA:93623; Familial hypocalciuric hypercalcemia type 2 ORPHA:101049; Keipert syndrome ORPHA:2662; LAMA5-related multisystemic syndrome ORPHA:521450; Larsen syndrome ORPHA:503; Legius syndrome ORPHA:137605; Lethal osteosclerotic bone dysplasia ORPHA:1832; Muscle-eye-brain disease with bilateral multicystic leucodystrophy ORPHA:370997; Nance-Horan syndrome ORPHA:627; Oculocerebrorenal syndrome of Lowe ORPHA:534; Phakomatosis cesiomarmorata ORPHA:79484; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Autosomal dominant hypocalcemia ORPHA:428; Pulmonary venoocclusive disease ORPHA:31837; Total early-onset cataract ORPHA:98994; Autosomal dominant Charcot-Marie-Tooth disease type 2O ORPHA:284232; Autosomal dominant neovascular inflammatory vitreoretinopathy ORPHA:329211; DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy ORPHA:209341; Familial generalized lentiginosis ORPHA:231040; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Growth delay due to insulin-like growth factor I resistance ORPHA:73273; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; Phakomatosis cesioflammea ORPHA:79483; Unverricht-Lundborg disease ORPHA:308; Epithelioid hemangioendothelioma ORPHA:157791; Cystic fibrosis ORPHA:586; Periventricular nodular heterotopia ORPHA:98892; Action myoclonus-renal failure syndrome ORPHA:163696; Drug- or toxin-induced pulmonary arterial hypertension ORPHA:275786; Keratosis follicularis spinulosa decalvans ORPHA:2340",0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5047266821728011; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6335420546867965; 0.6873535151929783; 0.6873535151929783; 0.7007232363756918; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Yaba-like disease virus 11L protein (gene: 11L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
CDH1,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Reticulocyte count (procedure); Adenomatous Polyposis Coli; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; leukemia; Ovarian Carcinoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; Leukemia, Myelocytic, Acute; Nephrolithiasis; Metaplasia; MYELODYSPLASTIC SYNDROME; Malignant tumor of colon; Atrial Premature Complexes; Esophageal carcinoma; Lymphoma; Leukemogenesis; Endometrial Neoplasms; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Prostatic Intraepithelial Neoplasias; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Gastrinoma; Pancreatic Neoplasm; Carcinoma breast stage IV; Adenoma; Thyroid Neoplasm; Endometrial Carcinoma; Esophageal Neoplasms; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Rotting teeth; Liver carcinoma; Invasive carcinoma of breast; Malignant neoplasm tonsil; Malignant neoplasm of esophagus; Thyroid carcinoma; intracranial glioma; Dental caries; Colorectal Cancer; Epithelial ovarian cancer; Tonsillar Carcinoma; Liver and Intrahepatic Biliary Tract Carcinoma; Hepatocarcinogenesis; Prostate carcinoma; Astrocytoma; Nephroblastoma; Disease Exacerbation; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Abnormality of vision; Epithelioma; Carcinoma, Endometrioid; Prostatic Neoplasms; Monoclonal Gammopathy of Undetermined Significance; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Triple Negative Breast Neoplasms; Mesothelioma; Malignant neoplasm of liver; Familial lichen amyloidosis; Ductal Carcinoma; Malignant Neoplasms; Hematologic Neoplasms; Malignant neoplasm of nasopharynx; melanoma; Multiple Myeloma; Lung Neoplasms; Gastric lymphoma; Lobular carcinoma in situ of breast; Metastatic malignant neoplasm to brain; Prolactinoma; Mycoplasma Infections; Metastatic Prostate Carcinoma; Dysgerminoma; Ovarian papillary adenocarcinoma; Malignant neoplasm of stomach; Transitional cell carcinoma of bladder; Optic Atrophy, Autosomal Dominant; Noninfiltrating Intraductal Carcinoma; Cancer of Nasopharynx; Sebaceous Adenocarcinoma; Adult Hepatocellular Carcinoma; OTOFACIOCERVICAL SYNDROME 1; Papillary cystic tumor; Congenital contractural arachnodactyly; Malignant mesothelioma; Well Differentiated Oligodendroglioma; Cleft palate with cleft lip; Invasive Ductal Breast Carcinoma; Brain Neoplasms; Secondary malignant neoplasm of ovary; Apocrine Carcinoma; Chronic cholecystitis; Cleft palate and bilateral cleft lip; Distichiasis; Intestinal adenocarcinoma; Krukenberg Tumor; Malignant neoplasm of large intestine; Nasopharyngeal carcinoma; Conductive hearing loss; Hepatitis B Virus-Related Hepatocellular Carcinoma; Mucoepidermoid Carcinoma; oligodendroglioma; Infection caused by Helicobacter pylori; Glaucoma, Open-Angle; Tumor Progression; Adenocarcinoma of colon; ACTH-Secreting Pituitary Adenoma; Renal Cell Carcinoma; Rectal Neoplasms; ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1; Syndactyly of fingers; Congenital euryblepharon; Kabuki syndrome eyelids; Tumor Initiation; Mean Corpuscular Volume (result); Atherosclerosis; Invasive Carcinoma; Congenital chromosomal disease; Alzheimer's Disease; Neoplastic Syndromes, Hereditary; Stomach Carcinoma; Carcinoma of urinary bladder, superficial; High Grade Lymphoma (neoplasm); Pancreatic Intraductal Papillary Mucinous Neoplasm, Gastric-Type; OROFACIAL CLEFT 1; Fanconi Anemia; gallbladder neoplasm; Squamous cell carcinoma; Uterine Cervical Neoplasm; Solid Neoplasm; Carcinoma in situ of uterine cervix; Gastritis, Atrophic; Cleft upper lip; Papillary Renal Cell Carcinoma; Biliary Tract Cancer; Adenoma of large intestine; Salivary gland carcinoma; Helicobacter Infections; Peg-shaped teeth; Pointed tooth; Nasopharyngeal Neoplasms; Carcinoma; Li-Fraumeni Syndrome; Small cell carcinoma of lung; Crohn Disease; Conventional (Clear Cell) Renal Cell Carcinoma; Invasive Lobular Breast Carcinoma; Intrahepatic Cholangiocarcinoma; Prostate cancer, familial; Cytomegalovirus Infections; Virus Diseases; Myeloid Leukemia, Chronic; Benign neoplasm of stomach; Carcinoma in situ of stomach; Neoplasm of uncertain or unknown behavior of stomach; Ulcer; Metastasis from malignant tumor of prostate; Primary malignant neoplasm; Lobular Neoplasia; Carcinoma, Spindle-Cell; Nerve Degeneration; Undifferentiated carcinoma; Neoplasms, Neuroepithelial; Fibrolamellar Hepatocellular Carcinoma; Pseudomyxoma Peritonei; Hereditary Malignant Neoplasm; Pemphigus Vulgaris; Vitiligo; Breast cancer, lobular; Cervical Squamous Cell Carcinoma; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Adenocarcinoma of large intestine; Malignant neoplasm of gallbladder; Chronic Lymphocytic Leukemia; Cervical Adenocarcinoma; Hereditary Diffuse Gastric Cancer; Non-infiltrating lobular carcinoma; Precancerous Conditions; leiomyosarcoma; Stomach Neoplasms; Malignant neoplasm of salivary gland; Ovarian adenocarcinoma; ovarian neoplasm; Adenocarcinoma of lung (disorder); Blast Phase; Breast adenocarcinoma; Hereditary non-polyposis colorectal cancer syndrome; Gastrointestinal Neoplasms; Paget Disease Extramammary; Carcinoma, Signet Ring Cell; Ulcerative Colitis; Carcinomatosis; Mucosa-Associated Lymphoid Tissue Lymphoma; Lip and Oral Cavity Carcinoma; Verrucous carcinoma; Extrahepatic Cholangiocarcinoma; Luminal B Breast Carcinoma; Colonic Neoplasms; Inflammation; precancerous lesions; Liver Cirrhosis; Sarcoma, Spindle Cell; Cleft Lip with or without Cleft Palate; Neoplasm Invasiveness; Epstein-Barr Virus Infections; polyps; Endometriosis of ovary; Infection; Meningioma, benign, no ICD-O subtype; Pituitary Adenoma; Pituitary Neoplasms; Lymphatic Metastasis; Carcinoma, Transitional Cell; Hereditary Nonpolyposis Colorectal Neoplasms; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Cholangiocarcinoma; Laryngeal neoplasm; Micronychia (disorder); Anaplastic carcinoma; Thymoma; Colorectal cancer metastatic; Hepatitis B; Sporadic Breast Carcinoma; Familial multiple trichoepitheliomata; Medulloblastoma; Cirrhosis; Squamous cell carcinoma of esophagus; Renal carcinoma; Anaplasia; Condition, Preneoplastic; Liver Neoplasms, Experimental; Experimental Hepatoma; Familial (FPAH); Hepatoma, Novikoff; Carcinoma, Lobular; Oncocytic Neoplasm; Hepatoma, Morris; Hepatitis B, Chronic; Papillary thyroid carcinoma; Hyperplasia; Hepatitis, Chronic; Adenocarcinoma Of Esophagus; Low grade glioma; Malignant neoplasm of endometrium; Kidney Calculi; Uterine Corpus Cancer; Childhood asthma; Cytogenetically normal acute myeloid leukemia; Kidney Neoplasm; Hereditary Nonpolyposis Colorectal Cancer; Mammary Ductal Carcinoma; Mammary Neoplasms, Human; Malignant neoplasm of kidney; Oxyphilic Adenoma; Orbital separation excessive; Carcinoma, Papillary; Hereditary pancreatitis; Hyperactive behavior; Pulmonary Fibrosis; Familial primary gastric lymphoma; Malignant neoplasm of mouth; Meningioma; Marginal Zone B-Cell Lymphoma; Secondary malignant neoplasm of lymph node; Eczema; Neoplasms, Experimental; Salivary Gland Neoplasms; synovial sarcoma; Squamous cell carcinoma of tongue; Abnormality of metabolism/homeostasis; Hurthle Cell Tumor; Curvature of digit; Congenital clinodactyly; VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding); Irritable Bowel Syndrome; Cyst; Gastritis; Secondary malignant neoplasm of bone; Hypodontia; Nodule; Neoplastic Cell Transformation; Endometriosis; Cutaneous Melanoma; Asthma; Breast Cancer, Familial; Mammary Neoplasms, Experimental; Adenoid Cystic Carcinoma; Cardiomyopathy, Familial Idiopathic",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7950434752274518; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8026798872257774; 0.8044379824544406; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8114747041691183; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8474481237156937; 0.8523465762428218; 0.8548862007194026; 0.8554819098734854; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8711129600224142; 0.8745234584149799; 0.8757755363384367; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8771562273432176; 0.8774809019744603; 0.8774809019744603; 0.8774809019744603; 0.8790903385143003; 0.8806784681730055; 0.8815127642200768; 0.8818220091065441; 0.882453254162044; 0.8851456306720444; 0.887080330932516; 0.887595340546704; 0.8878860377518915; 0.8911256045597441; 0.8942113186235617; 0.8946938397586319; 0.8973454964837912; 0.8980854850210683; 0.900167961295542; 0.909484944705772; 0.9098977259629772; 0.9117936912777788; 0.9119978323790848; 0.9119978323790848; 0.914995991166204; 0.914995991166204; 0.9154499654632742; 0.9193385822373632; 0.9262273158806068; 0.9265708351135048; 0.929235785949896; 0.9399783595775548; 0.946564927793026; 0.9534337109847604; 0.9561991866282916; 0.9578035687879456; 0.960644037248553; 0.9639249377588224; 0.9672478180546946; 0.9707275133033936; 0.9738491767258852; 0.9896536639644284; 0.999617369136378,"Malnutrition; Cleft Palate And Bilateral Cleft Lip; Ovarian Neoplasm; Velopharyngeal Insufficiency; Prostate Cancer; Melanoma; Prostatic Neoplasms; Oropharyngeal Dysphagia; Prostate Cancer, Hereditary; Ovarian Papillary Adenocarcinoma; Dysgerminoma; Hereditary Cancer Syndrome; Congenital Euryblepharon; Hereditary Breast Cancer; Hypoplasia Of The Maxilla; Ductal Carcinoma; Ovarian Carcinoma; Stomach Neoplasms; Invasive Duct And Lobular Carcinoma; Ovarian Cancer; Endometrial Neoplasms; Benign Neoplasm Of Stomach; Peg-Shaped Teeth; Otitis Media; Bladder Neoplasm; Gastritis; Urinary Bladder Cancer; Nasopharyngeal Carcinoma; Hearing Loss; Endometrial Carcinoma; Anaplastic Carcinoma; Mammary Neoplasms; Colonic Neoplasms; Malignant Melanoma Of Skin; Neural Tube Defect; Marfan Syndrome; Thyroid Carcinoma; Pancreatic Neoplasm; Hereditary Nonpolyposis Colorectal Cancer; Gastric Cancer; Stomach Carcinoma; Mesothelioma; Ovarian Epithelial Carcinoma; Malignant Neoplasm Of Salivary Gland; Ulcerative Colitis; Salivary Gland Neoplasm; Pancreatic Cancer; Syndactyly Of Fingers; Breast Cancer; Carcinoma; Adenocarcinoma; Breast Carcinoma; Colorectal Neoplasms; Imperforate Anus; Colorectal Cancer; Clinodactyly; Hypodontia",0.6734982286750932; 0.7311975666200533; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8210988731657684; 0.8356859041719433; 0.8457525389282121; 0.8477374749042494; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8827958376161968; 0.8903301324869451; 0.8903630091389316; 0.8903630091389316; 0.9069867032339078; 0.9350723667380212; 0.9398381935810408; 0.9510372690456612; 0.974502015052702; 0.9832345076528324; 0.9832345076528324; 0.986561188259959,"Antley-Bixler syndrome ORPHA:83; Van der Woude syndrome ORPHA:888; Apparent mineralocorticoid excess ORPHA:320; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Autosomal recessive cerebral atrophy ORPHA:363969; Congenital intrauterine infection-like syndrome ORPHA:1229; Congenital tufting enteropathy ORPHA:92050; EEM syndrome ORPHA:1897; Familial expansile osteolysis ORPHA:85195; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Isolated neonatal sclerosing cholangitis ORPHA:480556; Lethal congenital contracture syndrome type 2 ORPHA:137776; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Cleft lip/palate ORPHA:199306; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; Liddle syndrome ORPHA:526; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Familial hyperprolactinemia ORPHA:397685; Gelatinous drop-like corneal dystrophy ORPHA:98957; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Syndromic congenital sodium diarrhea ORPHA:563708; Bifid uvula ORPHA:99771; Blepharo-cheilo-odontic syndrome ORPHA:1997; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Submucosal cleft palate ORPHA:155878; Cleft lip and alveolus ORPHA:141291; Isolated cleft lip ORPHA:199302; Lethal acantholytic erosive disorder ORPHA:158687; Bartsocas-Papas syndrome ORPHA:1234; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; CHAND syndrome ORPHA:1401; Carvajal syndrome ORPHA:65282; Cholangiocarcinoma ORPHA:70567; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Idiopathic bronchiectasis ORPHA:60033; Low isolated anorectal malformation ORPHA:171215; Mullerian aplasia and hyperandrogenism ORPHA:247768; Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome ORPHA:397744; SERKAL syndrome ORPHA:139466; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Systemic primary carnitine deficiency ORPHA:158; X-linked recessive ocular albinism ORPHA:54; Congenital bilateral absence of vas deferens ORPHA:48; Microvillus inclusion disease ORPHA:2290; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; Hereditary diffuse gastric cancer ORPHA:26106; Hypocalcified amelogenesis imperfecta ORPHA:100032; Apert syndrome ORPHA:87; Autosomal recessive spastic paraplegia type 35 ORPHA:171629; Cranio-osteoarthropathy ORPHA:1525; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome ORPHA:1555; Ectodermal dysplasia-syndactyly syndrome ORPHA:247820; Epidermolysis bullosa simplex due to exophilin 5 deficiency ORPHA:412189; FGFR2-related bent bone dysplasia ORPHA:313855; Familial scaphocephaly syndrome, McGillivray type ORPHA:168624; Familial steroid-resistant nephrotic syndrome with adrenal insufficiency ORPHA:506334; Fatty acid hydroxylase-associated neurodegeneration ORPHA:329308; Glucose-galactose malabsorption ORPHA:35710; Harlequin ichthyosis ORPHA:457; Ichthyosis-hypotrichosis syndrome ORPHA:91132; Isolated congenital digital clubbing ORPHA:217059; Jackson-Weiss syndrome ORPHA:1540; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Pfeiffer syndrome type 2 ORPHA:93259; Pfeiffer syndrome type 3 ORPHA:93260; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Serrated polyposis syndrome ORPHA:157798; Xanthinuria type I ORPHA:93601; Neonatal severe primary hyperparathyroidism ORPHA:417; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; Hereditary breast cancer ORPHA:227535; Pulmonary alveolar microlithiasis ORPHA:60025; Diffuse panbronchiolitis ORPHA:171700; NON RARE IN EUROPE: Idiopathic infantile nystagmus ORPHA:651; Pachydermoperiostosis ORPHA:2796; Posterior polymorphous corneal dystrophy ORPHA:98973; Hypotrichosis simplex ORPHA:55654; Aquagenic palmoplantar keratoderma ORPHA:498359; Glutamate-cysteine ligase deficiency ORPHA:33574; Seborrhea-like dermatitis with psoriasiform elements ORPHA:168606",0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2567797333165013; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8329982337461243; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Macacine alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Dengue virus 3 envelope protein E (gene: flavivirus polyprotein); Cowpox virus CPXV209 protein (gene: CPXV209 CDS); Rio Bravo virus envelope protein; Human adenovirus 56 CR1 beta protein (gene: E3); Vaccinia virus IL-beta-binding protein (gene: VACWR-B15R); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Vaccinia virus Ankara Interleukin-1 beta receptor; Molluscum contagiosum virus subtype 1 MC033L (gene: MC033L); Yaba-like disease virus 123R protein (gene: 123R); Yaba monkey tumor virus IEV and EEV membrane glycoprotein; Molluscum contagiosum virus subtype 1 MC143R (gene: MC143R)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9103786566415374; 0.9397923093369096; 0.9450424991150602,In vitro,0.88,Homo sapiens,Homo sapiens
CDH15,"Mastocytosis, Systemic; Colorectal Cancer; Rhabdomyosarcoma; Sudden infant death syndrome; Familial lichen amyloidosis; Sclerocystic Ovaries; Medium-chain acyl-coenzyme A dehydrogenase deficiency; Renal Cell Carcinoma; Indolent Systemic Mastocytosis; Alcoholic Intoxication, Chronic; Hypoglycemia; Vomiting; Anaphylaxis (non medication); Mental deficiency; Exanthema; Dull intelligence; Low intelligence; Heart failure; Poor school performance; Polycystic Ovary Syndrome; Severe mental retardation (I.Q. 20-34); Mental Retardation; Intellectual Disability; Endometriosis",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8232134984476662; 0.8270909867833504; 0.8402911822757345; 0.8402911822757345; 0.8619324281003841; 0.8757755363384367; 0.8757755363384367; 0.8867509400747969; 0.8913141512402477; 0.9174808175273056; 0.917543617287358; 0.922229272318747; 0.9478210444156088; 0.960644037248553,Non-Syndromic Intellectual Disability; Sclerocystic Ovaries; Polycystic Ovary Syndrome; Mental Retardation,0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.8337953215113012,Autosomal dominant non-syndromic intellectual disability ORPHA:178469; Fetal akinesia deformation sequence ORPHA:994; Postsynaptic congenital myasthenic syndromes ORPHA:98913; Carney complex-trismus-pseudocamptodactyly syndrome ORPHA:319340; Cataract-glaucoma syndrome ORPHA:162; Congenital myopathy with reduced type 2 muscle fibers ORPHA:544602; Lethal multiple pterygium syndrome ORPHA:33108; Trismus-pseudocamptodactyly syndrome ORPHA:3377,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CDH3,"Malignant neoplasm of breast; Breast Carcinoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Reduced tensile strength of hair; Fractured hair; Fragile hair; Brittle hair; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Adenoma; Tooth problem; Mammary Neoplasms; Abnormality of the dentition; Malignant neoplasm of prostate; Rotting teeth; Dental caries; Colorectal Cancer; Epithelial ovarian cancer; Prostate carcinoma; Neoplasm Metastasis; Sparse body hair; Abnormality of vision; Prostatic Neoplasms; Familial lichen amyloidosis; Cone-Rod Dystrophies; melanoma; Ectrodactyly; Retinal Diseases; Sparse scalp hair; Selective tooth agenesis; Absence of a tooth; Malignant mesothelioma; Severe Combined Immunodeficiency; Fine hair; Mucoepidermoid Carcinoma; Renal Cell Carcinoma; Syndactyly of fingers; Pili Torti; Squamous cell carcinoma; invasive cancer; Cone dystrophy; Sparse eyelashes; Adenoma of large intestine; Crohn Disease; Sparse and thin eyebrow; Hypotrichosis; Absent eyebrow; Agenesis of eyebrows; Aplasia of eyebrows; Madarosis of eyebrow; Multiple Sclerosis; Red cell distribution width determination; Reduced visual acuity; RDW - Red blood cell distribution width result; Abnormality of macular pigmentation; Macular pigmentary changes; Blindness, Legal; Hereditary macular dystrophy; Blindness; Decreased width of tooth; Ulcerative Colitis; Microdontia (disorder); Decreased size of teeth; Split-Hand/Foot Malformation; Nail abnormality; Corpus Luteum Cyst; Macular dystrophy; Contracture of joint of hand; Nail Diseases; Split hand foot deformity 1; Widely spaced teeth; Claw hand; Ectodermal Dysplasia; Macular degeneration; Congenital Camptodactyly; Short stature; Age related macular degeneration; Ovarian Cysts; Syndactyly; Intellectual Disability; Endometriosis",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7967714690735718; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8769418330148872; 0.8774809019744603; 0.8815127642200768; 0.8980854850210683; 0.8989612563669234; 0.914995991166204; 0.9478210444156088; 0.960644037248553,Ectrodactyly; Melanocytic Nevus; Nystagmus; Disorder Of Eye; Retinal Diseases; Absent Eyebrow; Hypotrichosis; Colorectal Adenoma; Congenital Camptodactyly; Macular Dystrophy; Skeletal Dysplasia; Osteochondrodysplasia; Colonic Neoplasms; Corpus Luteum Cyst; Ectodermal Dysplasia; Ulcerative Colitis; Ovarian Cysts; Microdontia; Syndactyly Of Fingers; Strabismus; Hyperkeratosis; Colorectal Neoplasms; Dwarfism; Syndactyly; Multiple Sclerosis; Colorectal Cancer,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8182883735985873; 0.8210988731657684; 0.8210988731657684; 0.8476516371290275; 0.8566038214826551; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.8908485337686392; 0.9436990979382386; 0.9510372690456612; 0.9510372690456612; 0.9543024119762946; 0.980894832851993; 0.9832345076528324,"Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Van der Woude syndrome ORPHA:888; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Congenital tufting enteropathy ORPHA:92050; EEM syndrome ORPHA:1897; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Cleft lip/palate ORPHA:199306; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; Liddle syndrome ORPHA:526; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Gelatinous drop-like corneal dystrophy ORPHA:98957; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Syndromic congenital sodium diarrhea ORPHA:563708; Bifid uvula ORPHA:99771; Blepharo-cheilo-odontic syndrome ORPHA:1997; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Submucosal cleft palate ORPHA:155878; Cleft lip and alveolus ORPHA:141291; Isolated cleft lip ORPHA:199302; NON RARE IN EUROPE: Hypodontia ORPHA:2227; Localized junctional epidermolysis bullosa ORPHA:251393; Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism ORPHA:100034; Mullerian aplasia and hyperandrogenism ORPHA:247768; Neuropathy with hearing impairment ORPHA:139512; SERKAL syndrome ORPHA:139466; Sebocystomatosis ORPHA:841; Tricho-dento-osseous syndrome ORPHA:3352; X-linked recessive ocular albinism ORPHA:54; Hypocalcified amelogenesis imperfecta ORPHA:100032; Autosomal recessive distal renal tubular acidosis ORPHA:402041; Pachyonychia congenita ORPHA:2309; Apert syndrome ORPHA:87; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome ORPHA:1555; Ectodermal dysplasia-syndactyly syndrome ORPHA:247820; FGFR2-related bent bone dysplasia ORPHA:313855; Familial scaphocephaly syndrome, McGillivray type ORPHA:168624; Familial steroid-resistant nephrotic syndrome with adrenal insufficiency ORPHA:506334; Harlequin ichthyosis ORPHA:457; Hereditary hypotrichosis with recurrent skin vesicles ORPHA:217407; Jackson-Weiss syndrome ORPHA:1540; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Netherton syndrome ORPHA:634; Pfeiffer syndrome type 2 ORPHA:93259; Pfeiffer syndrome type 3 ORPHA:93260; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Bladder exstrophy ORPHA:93930; Oligodontia ORPHA:99798; Ectodermal dysplasia-skin fragility syndrome ORPHA:158668; Fraser syndrome ORPHA:2052; NON RARE IN EUROPE: Idiopathic infantile nystagmus ORPHA:651; Congenital hereditary facial paralysis-variable hearing loss syndrome ORPHA:306530; Nail-patella syndrome ORPHA:2614; Nail-patella-like renal disease ORPHA:2613",0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2567797333165013; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.4621817429362311; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8778481542696168; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CDKN1A,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Growth hormone excess; Superinfection; Non-Functioning Pituitary Gland Neoplasm; leukemia; Ovarian Carcinoma; Parathyroid hyperplasia; Adenocarcinoma; Malignant neoplasm of pancreas; Hepatoblastoma; Mitochondrial Respiratory Chain Deficiencies; Colorectal Carcinoma; Pancreatic carcinoma; Pituitary growth hormone cell adenoma; Laryngeal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; Leukemia, Myelocytic, Acute; Right Ventricular Hypertrophy; Subcutaneous lipoma; Fasting hyperinsulinemia; androgen independent prostate cancer; TARSAL-CARPAL COALITION SYNDROME; Hyperinsulinemic hypoglycemia; MYELODYSPLASTIC SYNDROME; Malignant tumor of colon; Malignant neoplasm of body of stomach; Malignant tumor of greater curve of stomach; Malignant tumor of lesser curve of stomach; Esophageal carcinoma; Lymphoma; Leukemogenesis; Endometrial Neoplasms; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Myelomonocytic leukemia; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic intraepithelial neoplasia; Adenoma; Intestinal Cancer; Thyroid Neoplasm; Rhabdoid Tumor of the Kidney; Cholangitis; Nevus; Endometrial Carcinoma; Esophageal Neoplasms; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Monocytic leukemia; Malignant neoplasm of lung; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Juvenile polyp; Hyperparathyroidism, Secondary; Refractory anemias; Lymphoma, Non-Hodgkin; Zollinger-Ellison syndrome; Promyelocytic leukemia; Liver carcinoma; Invasive carcinoma of breast; Elevated circulating parathyroid hormone level; Malignant neoplasm of esophagus; Malignant Head and Neck Neoplasm; Osteosarcoma; Rhabdoid Tumor; Thyroid carcinoma; intracranial glioma; Acute Promyelocytic Leukemia; Ataxia Telangiectasia; Colorectal Cancer; Epithelial ovarian cancer; Rhabdomyosarcoma; Leukemia, T-Cell; Multiple malignancy; Hepatocarcinogenesis; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; Parathyroid Adenoma; Primary malignant neoplasm of lung; insulinoma; cervical cancer; Neoplasm Metastasis; Bloom Syndrome; Malignant neoplasm of testis; Peptic Ulcer; Prostatic Neoplasms; Carcinoma of lung; Cockayne Syndrome, Type I; Malignant neoplasm of thyroid; Squamous cell carcinoma of the head and neck; Mesothelioma; Neuroblastoma; Hyperhomocysteinemia; Central neuroblastoma; Serum total cholesterol measurement; Interstitial Cystitis; Nodular glomerulosclerosis; Biliary cirrhosis; Malignant Neoplasms; Hematologic Neoplasms; melanoma; Intestinal Neoplasms; Adenocarcinoma of pancreas; Multiple Myeloma; Lung Neoplasms; Episodic abdominal pain; Intermittent abdominal pain; Adenoviral infections; Prolactinoma; Metastatic Prostate Carcinoma; Adrenal Cortical Adenoma; Melanocytic nevus; Angiofibroma; Malignant neoplasm of stomach; Burkitt Lymphoma; Optic Atrophy, Autosomal Dominant; Noninfiltrating Intraductal Carcinoma; Diarrhea; Sebaceous Adenocarcinoma; Adult Hepatocellular Carcinoma; Viral hepatitis; Hypopharyngeal Neoplasms; Lupus-like syndrome; Hypercalcemia; Papillary serous cystadenocarcinoma; Malignant mesothelioma; Hodgkin Disease; Esophagitis; Invasive Ductal Breast Carcinoma; Brain Neoplasms; Adenomyoma; Common wart; Nasopharyngeal carcinoma; M5b Acute differentiated monocytic leukemia; Malignant Testicular Germ Cell Tumor; Dementia; Glaucoma, Open-Angle; Tumor Progression; Adenocarcinoma of colon; Atypical polypoid adenomyoma; Sarcoma; Lupus Erythematosus, Systemic; Fuchs Endothelial Dystrophy; Monosomy; Renal Cell Carcinoma; Benign melanocytic nevus; ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1; Lymphoma, Follicular; Anal intraepithelial neoplasia; Bile Duct Neoplasms; Corneal fibrosis; Presenile dementia; Retinoblastoma; Primary Effusion Lymphoma; Arteriosclerosis; Atherosclerosis; Acromegaly; Alzheimer's Disease; Acute lymphocytic leukemia; Systemic Anaplastic Large Cell Lymphoma; Hyperoxia; Chondrosarcoma; Stomach Carcinoma; Carcinoma of urinary bladder, superficial; Autoimmune Diseases; Hepatitis C; Fanconi Anemia; Glaucoma; Liver and Intrahepatic Bile Duct Epithelial Neoplasm; Liver and Intrahepatic Bile Duct Neoplasm; Olfactory Neuroblastoma; Squamous cell carcinoma; Single tumor; Uterine Cervical Neoplasm; Solid Neoplasm; Classical Hodgkin's Lymphoma; invasive cancer; Rheumatoid Arthritis; Hyperparathyroidism; Diabetes; Diabetes Mellitus; Carcinoid Tumor; Lyme Disease; Li-Fraumeni Syndrome; Hyperglycemia; Small cell carcinoma of lung; Huntington Disease; Childhood Acute Lymphoblastic Leukemia; PACHYONYCHIA CONGENITA 3; Anaplastic thyroid carcinoma; Condyloma; Conventional (Clear Cell) Renal Cell Carcinoma; Intrahepatic Cholangiocarcinoma; Follicular adenoma; Metastatic Neoplasm; Hypertrophy of kidney; Mature B-Cell Non-Hodgkin Lymphoma; Virus Diseases; Myeloid Leukemia, Chronic; Myeloid Leukemia; Primary central nervous system lymphoma; Disease due to Papilloma virus; Papillomatosis; Primary Cutaneous Anaplastic Large Cell Lymphoma; Malignant Glioma; Ulcer; Laryngeal Diseases; Central Serous Chorioretinopathy; Metastasis from malignant tumor of prostate; Papilloma, Squamous Cell; Differentiating Neuroblastoma; Hypertrophy; Liver Cirrhosis, Experimental; Undifferentiated carcinoma; Oropharynx (excludes nasopharynx); Nijmegen Breakage Syndrome; Teratocarcinoma; Pancreatic carcinoma, familial; Psoriasis; Myocardial Infarction; Cholesteatoma; Granuloma; Melanocytic nevus of skin; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Adenocarcinoma of large intestine; Multiple Endocrine Neoplasia Type 1; Lung diseases; Fibrosarcoma; Chronic Lymphocytic Leukemia; Skin Erosion; Muscular Dystrophy, Facioscapulohumeral; Degenerative polyarthritis; Hereditary Diffuse Gastric Cancer; Liver neoplasms; Human papilloma virus infection; Kidney Diseases; Cervix Diseases; Perianal Squamous Intraepithelial Neoplasia; Precancerous Conditions; Stomach Neoplasms; Histiocytosis, Langerhans-Cell; Malignant neoplasm of salivary gland; Lupus Erythematosus; Nonalcoholic Steatohepatitis; ovarian neoplasm; Adenocarcinoma of lung (disorder); Lupus Erythematosus, Discoid; Herpes Simplex Infections; Fluid overload; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Dysplastic Nevus; Breast adenocarcinoma; GASTRIC CANCER, INTESTINAL; Liver diseases; Fibrosis; Hamartoma; HIV Infections; Renal hypertension; Polycystic Kidney Diseases; Ulcerative Colitis; Precursor Cell Lymphoblastic Leukemia Lymphoma; Lip and Oral Cavity Carcinoma; Diabetes Mellitus, Non-Insulin-Dependent; Bowen's Disease; Endometrial adenocarcinoma; Primary biliary cirrhosis; Colonic Neoplasms; Inflammation; Mouth Neoplasms; precancerous lesions; Liver Cirrhosis; Carcinoma, Neuroendocrine; Gastric Adenocarcinoma; Lupus Vulgaris; Thyroid Gland Follicular Adenoma; polyps; Triglycerides measurement; Astrocytoma, low grade; Ocular Hypertension; Actinic keratosis; Adrenal Gland Neoplasms; Fibrosis, Liver; Lipoid nephrosis; Glioblastoma Multiforme; Pituitary Neoplasms; Carcinoma, Transitional Cell; Adenocarcinoma of rectum; Premature aging syndrome; Chronic viral hepatitis; Cardiac Arrest; Pulmonary Cystic Fibrosis; Papilloma; Steatohepatitis; Cervical Intraepithelial Neoplasia; Bronchogenic Carcinoma; Chondrodysplasia; Hepatitis B; Down Syndrome; HIV Coinfection; Hypertensive disease; keratoacanthoma; Cirrhosis; Bone Diseases; Anemia; Rectal Carcinoma; Reperfusion Injury; Squamous cell carcinoma of esophagus; Testicular Germ Cell Tumor; Renal carcinoma; Leukemia, B-Cell; Papillary thyroid carcinoma; Cholestasis, Extrahepatic; Adenocarcinoma Of Esophagus; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Parkinson Disease; Kidney Neoplasm; Inflammatory Bowel Diseases; Malignant neoplasm of kidney; Dermatitis, Atopic; Heart failure; Malignant neoplasm of mouth; Meningioma; Congestive heart failure; Acoustic Neuroma; Obesity; Squamous cell carcinoma of skin; Secondary malignant neoplasm of lymph node; Pulmonary Hypertension; synovial sarcoma; Soft Tissue Neoplasms; Cicatrix, Hypertrophic; Polycystic Ovary Syndrome; Hamman-Rich syndrome; Sarcoidosis; Werner Syndrome; Fibroid Tumor; Carcinoma of larynx; Diabetic Nephropathy; Idiopathic Pulmonary Fibrosis; Arthritis; Kaposi Sarcoma; Urothelial Carcinoma; Hepatitis A; Uterine Fibroids; Squamous cell carcinoma of lung; Acute Erythroblastic Leukemia; Tumor Angiogenesis; Asthma; Cystic Fibrosis",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8044379824544406; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8138488881521341; 0.8138488881521341; 0.8138488881521341; 0.8140222479282434; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8342163953428735; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8420665668584452; 0.843190898187174; 0.8474481237156937; 0.8486035047899471; 0.8554819098734854; 0.8578473133580928; 0.8584283190330553; 0.8584283190330553; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.8771562273432176; 0.8772392350816924; 0.8774809019744603; 0.8815127642200768; 0.8818220091065441; 0.8867509400747969; 0.8867509400747969; 0.8946938397586319; 0.8973454964837912; 0.8976039441125321; 0.8980854850210683; 0.8989612563669234; 0.8989612563669234; 0.900167961295542; 0.9103315000053974; 0.9119978323790848; 0.9146732238562176; 0.914995991166204; 0.9174808175273056; 0.9262273158806068; 0.929235785949896; 0.929814249105729; 0.9373358316580888; 0.9377696084218796; 0.9390727893210336; 0.9393256300017014; 0.9431511078237256; 0.9435654233359168; 0.9441119274323576; 0.9459312971127588; 0.9557184806547836; 0.9564633032157428; 0.9639249377588224; 0.9656926709728724; 0.9672478180546946; 0.9874278479946328,Adrenocortical Adenoma; Insulinoma; Adrenocortical Carcinoma; Multiple Endocrine Neoplasia; Parathyroid Hyperplasia; Glucagonoma; Angiofibroma; Zollinger-Ellison Syndrome; Subcutaneous Lipoma; Thymoma; Prolactinoma; Parathyroid Adenoma; Peptic Ulcer; Diabetic Nephropathy; Esophagitis; Prostate Cancer; Hyperinsulinemic Hypoglycemia; Hyperparathyroidism; Prostatic Neoplasms; Hypercalcemia; Pituitary Adenoma; Ischemic Stroke; Intestinal Cancer; Papillomatosis; Stomach Neoplasms; Glomerulosclerosis; Facioscapulohumeral Muscular Dystrophy; Thyroid Gland Follicular Adenoma; Cholestasis; Bladder Neoplasm; Intestinal Neoplasms; Urinary Bladder Cancer; Atrial Fibrillation; Malignant Neoplasm; Paroxysmal Atrial Fibrillation; Colonic Neoplasms; Kidney Disease; Papilloma; Gastric Cancer; Lung Cancer; Malignant Mesothelioma; Lung Neoplasms; Breast Carcinoma; Esophagus Neoplasm,0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4904280964420943; 0.5957016454669307; 0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.8210988731657684; 0.829560580336605; 0.861756360478846; 0.8706864397989688; 0.8877197959767673; 0.8903301324869451; 0.9398381935810408; 0.9832345076528324,"Multiple endocrine neoplasia type 1 ORPHA:652; Heme oxygenase-1 deficiency ORPHA:562509; Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972",0.0473879273649914; 0.1040670578681756; 0.1991445465001551; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,,,In vitro,0.44,Homo sapiens,Homo sapiens;chemical synthesis
CDKN1C,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Hydatidiform Mole, Partial; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Cerebellar malformation; leukemia; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Hepatoblastoma; Relative macrocephaly; Beckwith-Wiedemann Syndrome; Adrenocortical cytomegaly; Overgrowth of external genitalia; Pancreatic hyperplasia; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Nephrolithiasis; HEMIHYPERPLASIA, ISOLATED; MENTAL RETARDATION, X-LINKED, SNYDER-ROBINSON TYPE; Advanced bone age; TARSAL-CARPAL COALITION SYNDROME; Hyperinsulinemic hypoglycemia; MYELODYSPLASTIC SYNDROME; Malignant tumor of colon; Asymmetric overgrowth; Posterior helix pit; Esophageal carcinoma; Neonatal hypoglycemia; Endometrial Neoplasms; Non-Small Cell Lung Carcinoma; Small adrenal gland; Adrenal hypoplasia; Congenital exomphalos; Adult T-Cell Lymphoma/Leukemia; Russell-Silver syndrome; Complete hydatidiform mole; Pancreatic Neoplasm; Adenoma; Thyroid Neoplasm; Nevus; Endometrial Carcinoma; Renal cortical cysts; Transient neonatal diabetes mellitus; Congenital hemihypertrophy; Esophageal Neoplasms; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Low Grade Lymphoma (neoplasm); Congenital omphalocele; Liver carcinoma; Overgrowth Syndrome; Malignant neoplasm of esophagus; Rhabdoid Tumor; Triploidy syndrome; Colorectal Cancer; Epithelial ovarian cancer; Rhabdomyosarcoma; HYDATIDIFORM MOLE, RECURRENT, 1; Leukemia, T-Cell; Diastasis recti; Glioblastoma; Prostate carcinoma; Nephroblastoma; Frontal bossing; Primary malignant neoplasm of lung; insulinoma; Neoplasm Metastasis; Enlarged kidney; Carcinoma of lung; Fetal overgrowth; Generalized overgrowth; Overgrowth; Squamous cell carcinoma of the head and neck; Mesothelioma; Neuroblastoma; Hydatidiform Mole; Central neuroblastoma; Port-Wine Stain; Malignant Neoplasms; melanoma; Eclampsia; Lung Neoplasms; Glucocorticoid Receptor Deficiency; Neoplasms; Renal glomerular disease; Adrenal Cortical Adenoma; Melanocytic nevus; Cleft palate, isolated; Gonadoblastoma; Large, late-closing fontanelle; Wide bregma sutures; Large bregma sutures; Large fontanelle; SPLIT-HAND/FOOT MALFORMATION 4; Hypercalcemia; Prominent metopic ridge; Simple Endometrial Hyperplasia; Complex Endometrial Hyperplasia; Malignant neoplasm of large intestine; Nasopharyngeal carcinoma; Bulging forehead; Prominent forehead; Williams Syndrome; Infection caused by Helicobacter pylori; Tumor Progression; Sarcoma; Lupus Erythematosus, Systemic; X-linked Adrenal Hypoplasia; Increased calcium level in kidney; Benign melanocytic nevus; Rectal Neoplasms; Prominent back of the head; Prominent occiput; Lymphoma, Follicular; Cleft Palate; Retinoblastoma; Arteriosclerosis; Atherosclerosis; Congenital chromosomal disease; Gestational Trophoblastic Neoplasms; Acute lymphocytic leukemia; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Placental dysfunction; Diabetes Mellitus, Transient Neonatal, 1; Squamous cell carcinoma; Diabetes; Diabetes Mellitus; Childhood Acute Lymphoblastic Leukemia; Tumors of Adrenal Cortex; Pyle metaphyseal dysplasia; Atypical Endometrial Hyperplasia; Prominent eyes; Protruding eyes; Prominent globes; Malignant Glioma; Exophthalmos; Primary malignant neoplasm; Nephrocalcinosis; IGA Glomerulonephritis; Hyperinsulinism; Disorders of Sex Development; Abnormal development of end part of bone; Epiphyseal dysplasia; SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; Multiple Sclerosis; Thrombocytopenia; Myocardial Infarction; Glomerulosclerosis (disorder); Liver neoplasms; Kidney Diseases; Pseudohypoparathyroidism; ovarian neoplasm; Schizophrenia; Lymphoma, T-Cell, Cutaneous; Isolated somatotropin deficiency; Blast Phase; Adult Acute Lymphocytic Leukemia; Endometrial Hyperplasia; Adenocarcinoma, Tubular; Precursor Cell Lymphoblastic Leukemia Lymphoma; Mucosa-Associated Lymphoid Tissue Lymphoma; Lip and Oral Cavity Carcinoma; Diabetes Mellitus, Non-Insulin-Dependent; Dandy-Walker Syndrome; Gestational trophoblastic disease; Congenital hypoplasia of penis; Adrenocortical carcinoma; Postnatal growth retardation; Adrenal gland hypofunction; Adrenal Gland Neoplasms; Micromelia; Embryonal Rhabdomyosarcoma; Congenital Abnormality; Adrenal cortical hypofunction; Macroglossia; Agenesis; Osteogenesis Imperfecta; Cryptorchidism; Hypogonadism; HELLP Syndrome; Oral Cavity Carcinoma; Down Syndrome; Hypercalciuria; Vesico-Ureteral Reflux; Neoplasm, Residual; Concave bridge of nose; Depressed nasal root/bridge; Rectal Carcinoma; Small testicle; Depressed nasal bridge; Carcinoma, Cribriform; Carcinoma, Granular Cell; Adenocarcinoma, Basal Cell; Chronic Obstructive Airway Disease; Prader-Willi Syndrome; Conn Syndrome; Low set ears; Adenocarcinoma, Oxyphilic; Delayed bone age; Choriocarcinoma; Muscular Dystrophy, Duchenne; Short stature; Hydrocephalus; Hepatomegaly; Secondary malignant neoplasm of lymph node; Infant, Small for Gestational Age; Congenital ear anomaly NOS (disorder); Dwarfism; Thickened facial skin with coarse facial features; Intrauterine retardation; Coarse facial features; Muscle hypotonia; Cardiomegaly; Fetal Growth Retardation; Small nose; Short nose; Penile hypospadias; Hydronephrosis; Intellectual Disability; Hypospadias; Uranostaphyloschisis; Cardiomyopathies; Asthma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8101097852323003; 0.8114747041691183; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8270909867833504; 0.8272008757995397; 0.8363138748299018; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8420665668584452; 0.8554819098734854; 0.8576420926340393; 0.8578473133580928; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8584283190330553; 0.8584283190330553; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8690346447728063; 0.8700543109506378; 0.8745234584149799; 0.8769418330148872; 0.8769418330148872; 0.8815127642200768; 0.8815127642200768; 0.8851456306720444; 0.887595340546704; 0.900167961295542; 0.9083161862856644; 0.9098977259629772; 0.9098977259629772; 0.9103315000053974; 0.9111864999692114; 0.9117936912777788; 0.9124568647908072; 0.9184153253162451; 0.9307095582633488; 0.937361082398064; 0.9390727893210336; 0.9393256300017014; 0.9457739154209; 0.9478210444156088; 0.94939825643792; 0.9534337109847604; 0.9557184806547836; 0.9672478180546946,Adrenocortical Carcinoma; Beckwith-Wiedemann Syndrome; Gonadoblastoma; Nephrolithiasis; Congenital Hemihypertrophy; Hepatoblastoma; Melanoma; Silver-Russell Syndrome; Endometrial Hyperplasia; Hypercalcemia; Nephroblastoma; Phakomatosis Pigmentovascularis; Hypoglycemia; Somatotropin Deficiency; Russell-Silver Syndrome; Renal Glomerular Disease; Isolated Somatotropin Deficiency; Endometrial Neoplasms; Schizophrenia; Pyle Metaphyseal Dysplasia; Frontal Bossing; Congenital Omphalocele; Proptosis; Nephrocalcinosis; Penis Agenesis; Epiphyseal Dysplasia; Endometrial Carcinoma; Vesicoureteral Reflux; Cryptorchidism; Micromelia; Lung Cancer; Macroglossia; Lung Neoplasms; Carcinoma; Cardiomyopathy; Hypogonadism; Adenocarcinoma; Dwarfism; Hypospadias; Hydronephrosis,0.4532988396145482; 0.4904280964420943; 0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.7860378120955526; 0.7860378120955526; 0.8082616889285628; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.8706864397989688; 0.8879896755141929; 0.8903301324869451; 0.9069867032339078; 0.9145387439550552; 0.9259420053407031; 0.9350723667380212; 0.9510372690456612; 0.974502015052702; 0.9870402800551054,"Classic Hodgkin lymphoma, nodular sclerosis type ORPHA:98843; Beckwith-Wiedemann syndrome due to CDKN1C mutation ORPHA:231120; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome ORPHA:436144; Silver-Russell syndrome due to a point mutation ORPHA:397590; IMAGe syndrome ORPHA:85173; Familial short QT syndrome ORPHA:51083",0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.795266832401002,,,,,,
CDKN2B,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Growth hormone excess; Non-Functioning Pituitary Gland Neoplasm; leukemia; Ovarian Carcinoma; Parathyroid hyperplasia; Adenocarcinoma; Malignant neoplasm of pancreas; Hepatoblastoma; Colorectal Carcinoma; Pancreatic carcinoma; Pituitary growth hormone cell adenoma; Laryngeal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Leukemia, Myelocytic, Acute; Subcutaneous lipoma; Fasting hyperinsulinemia; Melanoma astrocytoma syndrome; TARSAL-CARPAL COALITION SYNDROME; Hyperinsulinemic hypoglycemia; MYELODYSPLASTIC SYNDROME; Malignant tumor of colon; Esophageal carcinoma; Lymphoma; Leukemogenesis; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Refractory anemia, without ringed sideroblasts, without excess blasts; Colorectal Neoplasms; Gastrinoma; Pancreatic Neoplasm; Adenoma; Thyroid Neoplasm; Rhabdoid Tumor of the Kidney; Nevus; Endometrial Carcinoma; Esophageal Neoplasms; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Abnormality of the lymphatic system; Refractory anemias; stage, non-small cell lung cancer; Lymphoma, Non-Hodgkin; Zollinger-Ellison syndrome; de novo myelodysplastic syndromes; Liver carcinoma; Invasive carcinoma of breast; Malignant Meningioma; Elevated circulating parathyroid hormone level; Malignant neoplasm of esophagus; Osteosarcoma; Rhabdoid Tumor; Thyroid carcinoma; Acute Promyelocytic Leukemia; Aneurysm, Dissecting; Colorectal Cancer; Epithelial ovarian cancer; Rhabdomyosarcoma; Leukemia, Plasma Cell; T-Cell Lymphoma; Leukemia, T-Cell; Hepatocarcinogenesis; Mycosis fungoides/Sezary syndrome NOS; Glioblastoma; Prostate carcinoma; Astrocytoma; Parathyroid Adenoma; Primary malignant neoplasm of lung; insulinoma; Neoplasm Metastasis; Epithelioma; Peptic Ulcer; Monoclonal Gammopathy of Undetermined Significance; Carcinoma of lung; Malignant neoplasm of thyroid; Squamous cell carcinoma of the head and neck; Mesothelioma; Neuroblastoma; Central neuroblastoma; Malignant Neoplasms; Hematologic Neoplasms; melanoma; Familial Atypical Mole Melanoma Syndrome; Juvenile Myelomonocytic Leukemia; Ewings sarcoma; Adenocarcinoma of pancreas; Multiple Myeloma; Lung Neoplasms; Episodic abdominal pain; Intermittent abdominal pain; Prolactinoma; Neoplasms; Adrenal Cortical Adenoma; Melanocytic nevus; Angiofibroma; Opisthorchis Viverrini-Related Cholangiocarcinoma; Malignant neoplasm of stomach; Burkitt Lymphoma; Diarrhea; Myxoid cyst; Skin Carcinogenesis; Mature T ALL; Hypercalcemia; Malignant mesothelioma; Hodgkin Disease; Esophagitis; Refractory anaemia with excess blasts; Childhood T Acute Lymphoblastic Leukemia; Well Differentiated Oligodendroglioma; Brain Neoplasms; Supratentorial Neoplasms; Malignant neoplasm of border of tongue; Malignant neoplasm of dorsal surface of tongue; Malignant neoplasm of ventral surface of tongue; Malignant tumor of base of tongue; Malignant tumor of junctional zone of tongue; malignant tumor of lingual tonsil; Myxoid chondrosarcoma; Malignant neoplasm of large intestine; Nasopharyngeal carcinoma; oligodendroglioma; Glaucoma, Open-Angle; Tumor Progression; Sarcoma; Abnormality of the hair; Abnormality of the hair shaft; Hematological Disease; Monosomy; Renal Cell Carcinoma; secondary acute myeloid leukemia; Keratosis; Lymphoma, Follicular; Lymphatic Diseases; Coronary Arteriosclerosis; Acute leukemia; Retinoblastoma; Arteriosclerosis; Atherosclerosis; Acromegaly; Congenital chromosomal disease; Periodontitis; Freckles; Acute lymphocytic leukemia; Chondrosarcoma; Stomach Carcinoma; CARCINOMA OF VULVA; Hepatitis C; Hyperlipidemia, Familial Combined; Cardiovascular Diseases; Glaucoma; Squamous cell carcinoma; Acute periodontitis; Solid Neoplasm; Hyperparathyroidism; Diabetes; Diabetes Mellitus; Biliary Tract Cancer; Nervous System Neoplasms; Atypical meningioma; Periodontitis, Juvenile; Small cell carcinoma of lung; Childhood Acute Lymphoblastic Leukemia; Pleomorphic Xanthoastrocytoma; Conventional (Clear Cell) Renal Cell Carcinoma; Follicular adenoma; Myelodysplasia; Blastic plasmacytoid dendritic cell neoplasm; Oral infection; Poisoning; Myeloid Leukemia, Chronic; Myeloid Leukemia; Aortic Aneurysm; Refractory anemia with excess blasts in transformation (clinical); Aneurysmal disease; Primary cutaneous B-cell lymphoma; Malignant Glioma; Ulcer; Laryngeal Diseases; Metastatic melanoma; Nerve Sheath Tumors; Experimental Organism Basal Cell Carcinoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Chronic Periodontitis; Xerosis; Allergic disposition; Hereditary Malignant Neoplasm; Hairy Cell Leukemia; Thrombocytopenia; Myocardial Infarction; Dry skin; Multiple Endocrine Neoplasia Type 1; Chronic Lymphocytic Leukemia; Arteriopathic disease; neurofibroma; Human papilloma virus infection; Aortic Diseases; Stomach Neoplasms; Recurrent Childhood Acute Lymphoblastic Leukemia; ovarian neoplasm; Adenocarcinoma of lung (disorder); Neurofibromatoses; Lymphoma, T-Cell, Cutaneous; Hereditary Leiomyomatosis and Renal Cell Cancer; Blast Phase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Myeloproliferative disease; Plasma cell dyscrasia; Liver diseases; Adult Acute Lymphocytic Leukemia; Diabetes Mellitus, Insulin-Dependent; Precursor B-cell lymphoblastic leukemia; Childhood Rhabdomyosarcoma; Precursor Cell Lymphoblastic Leukemia Lymphoma; Hyperkeratosis; Mammary Tumorigenesis; Diabetes Mellitus, Non-Insulin-Dependent; African Trypanosomiasis; Malignant neoplasm of tongue; Mouth Neoplasms; Liver Cirrhosis; Infant Acute Lymphoblastic Leukemia; Immune thrombocytopenic purpura; Thyroid Gland Follicular Adenoma; polyps; Therapy-related myelodysplastic syndrome; Hereditary Melanoma; Low Tension Glaucoma; Malignant Peripheral Nerve Sheath Tumor; Actinic keratosis; Hematopoetic Myelodysplasia; Meningioma, benign, no ICD-O subtype; Pituitary Adenoma; Glioblastoma Multiforme; Carcinoma, Transitional Cell; Cholangiocarcinoma; Glaucoma, Primary Open Angle; Acute respiratory failure; Papilloma; Aneurysm; Sezary Syndrome; Liposarcoma, Dedifferentiated; Adult Acute Myeloblastic Leukemia; Hepatitis B; Hypertensive disease; Familial multiple trichoepitheliomata; Medulloblastoma; Cirrhosis; Leukemia, Myelomonocytic, Chronic; Neoplasm, Residual; Follicular thyroid carcinoma; Kartagener Syndrome; Plasmacytoma; Squamous cell carcinoma of esophagus; Cerebrovascular accident; Parathyroid Neoplasms; Anaplastic Oligodendroglioma; Medullary carcinoma of thyroid; Primary Myelofibrosis; Hyperplasia; Hepatitis, Chronic; Precursor cell lymphoblastic lymphoma; Rheumatic Fever; Carcinoma, Papillary; Coronary Artery Disease; Leukoplakia, Oral; Malignant Pleural Mesothelioma; nervous system disorder; Hepatitis, Alcoholic; mixed gliomas; Meningioma; Mycosis Fungoides; Lymphoid leukemia; Coronary heart disease; Chordoma; Anaplastic astrocytoma; Uveal melanoma; Pituitary Diseases; Kidney Failure, Acute; Skin Neoplasms; Ependymoma; Endometriosis; Cutaneous Melanoma; Ischemic stroke",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7940665326856218; 0.7967714690735718; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8114747041691183; 0.8138488881521341; 0.8138488881521341; 0.8138488881521341; 0.8140222479282434; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8342163953428735; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.841396342333011; 0.8474481237156937; 0.8523465762428218; 0.8548862007194026; 0.8554819098734854; 0.8576420926340393; 0.8578473133580928; 0.8584283190330553; 0.8608860081595284; 0.8608860081595284; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8690346447728063; 0.8757755363384367; 0.876210765330195; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.887080330932516; 0.887595340546704; 0.887595340546704; 0.8935933996254593; 0.8959157818691486; 0.8959157818691486; 0.8959157818691486; 0.8973454964837912; 0.8989612563669234; 0.9083161862856644; 0.9119978323790848; 0.9189398569397552; 0.9262273158806068; 0.929235785949896; 0.93156380601526; 0.9373358316580888; 0.9434459508692176; 0.9564633032157428; 0.960644037248553; 0.9639249377588224; 0.9896536639644284,Adrenocortical Adenoma; Insulinoma; Adrenocortical Carcinoma; Multiple Endocrine Neoplasia; Parathyroid Hyperplasia; Glucagonoma; Angiofibroma; Zollinger-Ellison Syndrome; Subcutaneous Lipoma; Thymoma; Prolactinoma; Parathyroid Adenoma; Peptic Ulcer; Esophagitis; Melanoma; Hyperinsulinemic Hypoglycemia; Hyperparathyroidism; Hypercalcemia; Myelodysplastic Syndrome; Pituitary Adenoma; Atypical Mole Melanoma Syndrome; Stomach Neoplasms; Lymphoma; Lymphoblastic Leukemia; Coronary Arteriosclerosis; Thyroid Gland Follicular Adenoma; Retinal Diseases; Cholestasis; Malignant Neoplasm; Nasopharyngeal Neoplasms; Mammary Neoplasms; Nevus; Pancreatic Neoplasm; Coronary Artery Disease; Glaucoma; Diabetes Mellitus; Lung Adenocarcinoma; Glioma,0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4532988396145482; 0.4904280964420943; 0.5957016454669307; 0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8457525389282121; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.919442421650838; 0.9350723667380212; 0.9748811500794422,Multiple endocrine neoplasia type 1 ORPHA:652; Familial atypical multiple mole melanoma syndrome ORPHA:404560; Melanoma and neural system tumor syndrome ORPHA:252206; Familial melanoma ORPHA:618; Diaphyseal medullary stenosis-bone malignancy syndrome ORPHA:85182; KLHL9-related early-onset distal myopathy ORPHA:399081,0.0473879273649914; 0.5867963421058087; 0.5867963421058087; 0.6873535151929783; 0.8922466888454011; 0.8922466888454011,Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Human adenovirus 1 fiber; Human adenovirus 5 fiber; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Horsepox virus HSPV011a; Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Cowpox virus CPXV027 protein (gene: CPXV027 CDS); Vaccinia virus hypothetical protein; Ectromelia virus ERPV ankyrin and nfkb inhibitor; Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Horsepox virus HSPV022 (ankyrin-like protein; Provisional); Monkeypox virus ankyrin-like protein; Horsepox virus HSPV033c (ankyrin repeats); Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Vaccinia virus ankyrin-like protein (gene: C9L); Horsepox virus HSPV201a (ankyrin repeats); Yaba-like disease virus 147R protein (gene: 147R); Cowpox virus CPXV041 protein (gene: CPXV041 CDS); Horsepox virus HSPV035 (ankyrin repeats); Horsepox virus HSPV004 (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: C1L); Yaba monkey tumor virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: K1L); Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Variola virus hypothetical protein (gene: B19R); Vaccinia virus Ankara CP77 Host range protein f1; Vaccinia virus Ankara Host range protein; Cowpox virus CPXV039 (gene: CPXV039 CDS); Variola virus hypothetical protein (gene: B21R); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Vaccinia virus ankyrin-like protein (gene: B18R); Variola virus hypothetical protein (gene: D7L); Horsepox virus HSPV033b (Ankyrin repeats); Variola virus hypothetical protein (gene: G3R); Orf virus ORF126 ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Horsepox virus HSPV020b (ankyrin repeats); Vaccinia virus Ankara CP77 host range protein f3; Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Horsepox virus HSPV005c (Ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara CP77 host range protein f4; Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Horsepox virus HSPV011b (ankyrin repeats); Horsepox virus HSPV014b (ankyrin repeats); Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyin-like protein (gene: M1L); Yaba-like disease virus 146R protein (gene: 146R); Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Variola virus hypothetical protein (gene: B6R); Vaccinia virus ankyrin-like protein; Orf virus ORF129 ankyrin repeat protein; Cowpox virus CPXV017 protein (gene: CPXV017 CDS); Variola virus ankyin-like protein (gene: O1L); Horsepox virus HSPV194 (ankyrin repeats); Cowpox virus CPXV006 protein (gene: CPXV006 CDS); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Yaba-like disease virus 148R protein (gene: 148R); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D1L); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9018002218631122; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9058994261255549; 0.9071659214187592; 0.9115856929326512; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.928070054828895; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9364561700418303; 0.9366403811337995; 0.9383505321091749; 0.9383505321091749; 0.9386073090182748; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9563208507960556,,,,
CDKN2D,"Malignant neoplasm of breast; Carcinoma of bladder; Breast Carcinoma; Malignant neoplasm of ovary; Ovarian Carcinoma; Melanoma astrocytoma syndrome; MYELODYSPLASTIC SYNDROME; Atrial Premature Complexes; Leukemogenesis; Adult T-Cell Lymphoma/Leukemia; Gastrinoma; Pancreatic Neoplasm; Nevus; Glioma; Malignant neoplasm of lung; Abnormality of the lymphatic system; Refractory anemias; Promyelocytic leukemia; Osteosarcoma; Acute Promyelocytic Leukemia; Epithelial ovarian cancer; Leukemia, T-Cell; Parathyroid Adenoma; Primary malignant neoplasm of lung; insulinoma; Carcinoma of lung; Neuroblastoma; Central neuroblastoma; melanoma; Familial Atypical Mole Melanoma Syndrome; Melanocytic nevus; Malignant neoplasm of stomach; Ganglioglioma; Infection caused by Helicobacter pylori; Sarcoma; Abnormality of the hair; Abnormality of the hair shaft; Lymphatic Diseases; Retinoblastoma; Freckles; Rat Adrenal Gland Pheochromocytoma; Autoimmune Diseases; Rheumatoid Arthritis; Carcinoid Tumor; Sjogren's Syndrome; Xerosis; Congenital deafness; Multiple Sclerosis; Dry skin; Embryonal Carcinoma; Degenerative polyarthritis; Hereditary Diffuse Gastric Cancer; Encephalomyelitis; Human T-cell lymphotrophic virus, type I [HTLV-I]; Stomach Neoplasms; stage, neuroblastoma; Precursor B-cell lymphoblastic leukemia; gastritis h pylori; Gallbladder Carcinoma; Psoriasis vulgaris; Amyotrophic Lateral Sclerosis; Thymoma; Celiac Disease; Medulloblastoma; Parkinson Disease; Secondary malignant neoplasm of lymph node; Dwarfism; Cutaneous Melanoma",0.4084380369379369; 0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8098851543361193; 0.8168901801930506; 0.8168901801930506; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8548862007194026; 0.8772392350816924; 0.900167961295542; 0.9098977259629772; 0.9639249377588224,Stomach Neoplasms; Gastric Cancer,0.7765582368651238; 0.861756360478846,CCDC115-CDG ORPHA:468684; 8p11.2 deletion syndrome ORPHA:251066; Brachydactyly type B2 ORPHA:140908; Hermansky-Pudlak syndrome type 7 ORPHA:231531; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; Stapes ankylosis with broad thumbs and toes ORPHA:140917; Tarsal-carpal coalition syndrome ORPHA:1412; Early-onset Lafora body disease ORPHA:324290; Obesity due to CEP19 deficiency ORPHA:397615,0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703,"Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Human adenovirus 1 fiber; Human adenovirus 5 fiber; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Horsepox virus HSPV011a; Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Cowpox virus CPXV027 protein (gene: CPXV027 CDS); Titi monkey adenovirus ECC-2011 fiber; Vaccinia virus hypothetical protein; Ectromelia virus ERPV ankyrin and nfkb inhibitor; Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Horsepox virus HSPV022 (ankyrin-like protein; Provisional); Human mastadenovirus E fiber (gene: L5); Human adenovirus E4 fiber protein; Monkeypox virus ankyrin-like protein; Horsepox virus HSPV033c (ankyrin repeats); Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Horsepox virus HSPV201a (ankyrin repeats); Yaba-like disease virus 147R protein (gene: 147R); Cowpox virus CPXV041 protein (gene: CPXV041 CDS); Horsepox virus HSPV035 (ankyrin repeats); Horsepox virus HSPV004 (ankyrin repeats); Yaba monkey tumor virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: K1L); Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Variola virus hypothetical protein (gene: B19R); Vaccinia virus Ankara CP77 Host range protein f1; Vaccinia virus Ankara Host range protein; Cowpox virus CPXV039 (gene: CPXV039 CDS); Variola virus hypothetical protein (gene: B21R); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Vaccinia virus ankyrin-like protein (gene: B18R); Variola virus hypothetical protein (gene: D7L); Variola virus hypothetical protein (gene: G3R); Orf virus ORF126 ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Horsepox virus HSPV020b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Horsepox virus HSPV005c (Ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara CP77 host range protein f4; Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Horsepox virus HSPV011b (ankyrin repeats); Horsepox virus HSPV014b (ankyrin repeats); Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyin-like protein (gene: M1L); Yaba-like disease virus 146R protein (gene: 146R); Vaccinia virus Ankara CP77 host range protein f2; Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Variola virus hypothetical protein (gene: B6R); Vaccinia virus ankyrin-like protein; Orf virus ORF129 ankyrin repeat protein; Cowpox virus CPXV017 protein (gene: CPXV017 CDS); Variola virus ankyin-like protein (gene: O1L); Horsepox virus HSPV194 (ankyrin repeats); Cowpox virus CPXV006 protein (gene: CPXV006 CDS); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Yaba-like disease virus 148R protein (gene: 148R); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D1L); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9018002218631122; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9058994261255549; 0.9071659214187592; 0.9115856929326512; 0.915880438522078; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.928070054828895; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9364561700418303; 0.9366403811337995; 0.9383505321091749; 0.9383505321091749; 0.9386073090182748; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9563208507960556,,,,
CDX2,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Metaplasia; Malignant tumor of colon; Esophageal carcinoma; Leukemogenesis; Endometrial Neoplasms; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Pancreatic intraepithelial neoplasia; Adenoma; Intestinal Cancer; Endometrial Carcinoma; Esophageal Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Juvenile polyp; Liver carcinoma; Malignant neoplasm of esophagus; Cholelithiasis; Colorectal Cancer; Epithelial ovarian cancer; Intestinal Polyposis; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Ductal Carcinoma; Monocyte count procedure; Monocyte count result; Malignant Neoplasms; melanoma; Intestinal Neoplasms; Adenocarcinoma of pancreas; Lung Neoplasms; Adenoviral infections; Peutz-Jeghers Syndrome; Neoplasms; Bile Reflux; Malignant neoplasm of stomach; Mucinous Adenocarcinoma; Congenital contractural arachnodactyly; Esophagitis; Benign Prostatic Hyperplasia; Invasive Ductal Breast Carcinoma; Esophageal dysplasia; Intramucosal Adenocarcinoma; Pancreatitis, Chronic; Malignant neoplasm of large intestine; Large cell neuroendocrine carcinoma; Infection caused by Helicobacter pylori; Tumor Progression; Adenocarcinoma of colon; Rectal Neoplasms; Bladder Adenocarcinoma; Acute leukemia; Congenital chromosomal disease; Intestinal Polyps; Acute lymphocytic leukemia; Stomach Carcinoma; Intestinal metaplasia of gastric mucosa; Adenocarcinoma, intestinal type; Hamartomatous polyp; Squamous cell carcinoma; invasive cancer; Gastritis, Atrophic; Barrett Epithelium; Carcinoma; Periodontitis, Juvenile; Small cell carcinoma of lung; Huntington Disease; Childhood Acute Lymphoblastic Leukemia; Cystadenocarcinoma, Mucinous; Gastrointestinal carcinoma; Crohn Disease; Metastatic Neoplasm; Pancreatic Diseases; Myeloid Leukemia, Chronic; Adenosquamous carcinoma; Metastatic melanoma; Experimental Organism Basal Cell Carcinoma; ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, NONDELETION TYPE, X-LINKED; Gastrointestinal inflammation; Multiple Sclerosis; Psoriasis; Stage III Colon Cancer AJCC v7; Adenocarcinoma of large intestine; Malignant neoplasm of gallbladder; Stage III Colon Cancer; Cognitive changes; Liver neoplasms; Enterocolitis; Precancerous Conditions; Stomach Neoplasms; Adenomatous Polyps; Carcinoma, Small Cell; Adenocarcinoma of lung (disorder); Herpes Simplex Infections; Mucinous neoplasm; Premenopausal breast cancer; Hamartoma; HIV Infections; Precursor B-cell lymphoblastic leukemia; Stage II Colon Cancer AJCC v7; Poorly differentiated carcinoma; Adenocarcinoma, Tubular; Ulcerative Colitis; Precursor Cell Lymphoblastic Leukemia Lymphoma; Stage II Colon Cancer; Diabetes Mellitus, Non-Insulin-Dependent; Gastro-esophageal reflux disease with esophagitis; Juvenile polyposis syndrome; Osteopenia; Colonic Neoplasms; Secondary malignant neoplasm of lung; Gastric Adenocarcinoma; Secondary malignant neoplasm of pancreas; Anastomosis; Gallbladder Carcinoma; polyps; Hirschsprung Disease; Hereditary pyropoikilocytosis; Tuberculosis; Gastroesophageal reflux disease; Cholangiocarcinoma; Colorectal cancer metastatic; Peptic Esophagitis; Colonic Polyps; Medullary carcinoma; Turcot syndrome (disorder); Neoplasm, Residual; Rectal Carcinoma; Hyperplastic Polyp; Tuberculosis, Pulmonary; HER2 gene amplification; Chronic Obstructive Airway Disease; Papillary thyroid carcinoma; Adenocarcinoma Of Esophagus; Multiple polyps; Hereditary Nonpolyposis Colorectal Cancer; Inflammatory Bowel Diseases; Pain; Neuroendocrine Tumors; Hyperactive behavior; Barrett Esophagus; Obesity; Secondary malignant neoplasm of lymph node; Osteoarthritis, Knee; Ductal Breast Carcinoma; Malignant neoplasm of skin; Gastritis; Osteoporosis",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7940665326856218; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8044379824544406; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8523465762428218; 0.8554819098734854; 0.8578473133580928; 0.8584283190330553; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.8769418330148872; 0.8769418330148872; 0.8790903385143003; 0.8815127642200768; 0.887595340546704; 0.887595340546704; 0.8878860377518915; 0.8980854850210683; 0.8989612563669234; 0.900167961295542; 0.9262273158806068; 0.9307095582633488; 0.93413028051677; 0.9399783595775548; 0.9639249377588224,Colonic Neoplasms,0.8210988731657684,"Familial expansile osteolysis ORPHA:85195; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Acrocapitofemoral dysplasia ORPHA:63446; Guttmacher syndrome ORPHA:2957; Hand-foot-genital syndrome ORPHA:2438; 17q12 microdeletion syndrome ORPHA:261265; Partial pancreatic agenesis ORPHA:2805; Bilateral microtia-deafness-cleft palate syndrome ORPHA:140963; Brachydactyly-syndactyly, Zhao type ORPHA:93409; Congenital chloride diarrhea ORPHA:53689; Congenital sucrase-isomaltase deficiency ORPHA:35122; Microtia ORPHA:83463; NON RARE IN EUROPE: Brachydactyly type D ORPHA:93385; Syndactyly type 5 ORPHA:93406; Synpolydactyly type 1 ORPHA:295195; VACTERL/VATER association ORPHA:887; Zygodactyly type 3 ORPHA:295191; MODY ORPHA:552; Enteric anendocrinosis ORPHA:83620; Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome ORPHA:293864",0.1991445465001551; 0.1991445465001551; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5),0.8999095837312036,,,,
CEBPB,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; B-Cell Lymphomas; leukemia; Parathyroid hyperplasia; Malignant neoplasm of pancreas; Hepatoblastoma; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Esophageal carcinoma; Lymphoma; Carcinoma breast stage IV; Adenoma; Thyroid Neoplasm; Esophageal Neoplasms; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Hyperparathyroidism, Secondary; Refractory anemias; Promyelocytic leukemia; Liver carcinoma; Malignant neoplasm of esophagus; Acute Promyelocytic Leukemia; Colorectal Cancer; Liver and Intrahepatic Biliary Tract Carcinoma; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Prostatic Neoplasms; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Malignant neoplasm of liver; Serum total cholesterol measurement; melanoma; Ewings sarcoma; Lung Neoplasms; Adenovirus Infections; Neoplasms; Malignant neoplasm of stomach; High density lipoprotein measurement; Bile duct carcinoma; Giant Cell Tumor of Bone; Adult Fibrosarcoma; Malignant neoplasm of large intestine; Dementia; Lupus Erythematosus, Systemic; Paget Disease; Renal Cell Carcinoma; Presenile dementia; Alzheimer's Disease; Stomach Carcinoma; Osteitis Deformans; Hepatitis C; Cardiovascular Diseases; Congenital neutropenia; Glaucoma; Adult Anaplastic Large Cell Lymphoma; Squamous cell carcinoma; Rheumatoid Arthritis; Severe congenital neutropenia; Diabetes; Diabetes Mellitus; Conventional (Clear Cell) Renal Cell Carcinoma; Metastatic Neoplasm; Virus Diseases; Myeloid Leukemia; Cleidocranial Dysplasia; Anaplastic Large Cell Lymphoma, ALK-Positive; Allergic disposition; Leukoencephalopathy, Progressive Multifocal; Anaplastic large B-cell lymphoma; Fibrosarcoma; Chronic Lymphocytic Leukemia; Embryonal Carcinoma; Degenerative polyarthritis; Liver neoplasms; Kidney Diseases; Brain Injuries, Focal; Injuries, Acute Brain; Brain Injuries; Brain Lacerations; Adenocarcinoma of lung (disorder); HIV Infections; Sterility, Postpartum; Subfertility, Female; Female sterility; Delirium, Dementia, Amnestic, Cognitive Disorders; Gastrointestinal Carcinoid Tumor; Dengue Fever; Diabetes Mellitus, Non-Insulin-Dependent; Connective Tissue Diseases; Female infertility; Epstein-Barr Virus Infections; Infection; Vitamin D Deficiency; Tuberculosis; Steatohepatitis; Neurocognitive Disorders; Erythroblastosis; Squamous cell carcinoma of esophagus; Fatty Liver; Low density lipoprotein cholesterol measurement; Papillary thyroid carcinoma; Parkinson Disease; Pulmonary Fibrosis; nervous system disorder; Brain Ischemia; Obesity; Cerebral Ischemia; Hamman-Rich syndrome; Fibroid Tumor; Arthritis; Hepatitis C, Chronic; Kaposi Sarcoma; Uterine Fibroids",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8554819098734854; 0.8610447277138289; 0.8628363180844141; 0.8648405521677974; 0.8757755363384367; 0.8772392350816924; 0.8911256045597441; 0.8959157818691486; 0.8980854850210683; 0.8989612563669234; 0.9083161862856644; 0.9262273158806068; 0.9373358316580888; 0.9431511078237256; 0.9432051631882106; 0.9435654233359168; 0.9557184806547836,Liver Carcinoma; Fatty Liver; Subfertility; Cerebral Ischemia; Alveolitis; Pulmonary Fibrosis,0.7765582368651238; 0.8321692755697452; 0.8356859041719433; 0.9069867032339078; 0.9398381935810408; 0.9832345076528324,"Atrial septal defect, sinus venosus type ORPHA:99105; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Heme oxygenase-1 deficiency ORPHA:562509; Thrombomodulin-related bleeding disorder ORPHA:436169; CLN10 disease ORPHA:228337; Clear cell renal carcinoma ORPHA:319276; Pediatric systemic lupus erythematosus ORPHA:93552; Acute myeloid leukemia with CEBPA somatic mutations ORPHA:319480; FTH1-related iron overload ORPHA:247790; Glycogen storage disease due to liver glycogen phosphorylase deficiency ORPHA:369; Recurrent Neisseria infections due to factor D deficiency ORPHA:169467",0.0155394890951578; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,Monkeypox virus ankyrin-like protein,0.8999095837312036,In vitro,0.44,Homo sapiens,Homo sapiens
CENPA,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Colorectal Carcinoma; Colorectal Neoplasms; Liver carcinoma; Colorectal Cancer; Epithelial ovarian cancer; Triple Negative Breast Neoplasms; Adenocarcinoma of lung (disorder); aggressive cancer; Scleroderma; Systemic Scleroderma,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8098851543361193; 0.8168901801930506; 0.8212681436603975; 0.8402911822757345,Liver Carcinoma,0.7765582368651238,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Currarino syndrome ORPHA:1552; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Hydrolethalus ORPHA:2189; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Autosomal recessive cutis laxa type 2B ORPHA:357064; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Hereditary coproporphyria ORPHA:79273; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Meacham syndrome ORPHA:3097; PYCR1-related De Barsy syndrome ORPHA:293633; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; Li-Fraumeni syndrome ORPHA:524; Acquired partial lipodystrophy ORPHA:79087; Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Baller-Gerold syndrome ORPHA:1225; Bosley-Salih-Alorainy syndrome ORPHA:69737; Progressive myoclonic epilepsy type 9 ORPHA:457265; RAPADILINO syndrome ORPHA:3021; Rothmund-Thomson syndrome type 2 ORPHA:221016; Amish nemaline myopathy ORPHA:98902; Spondyloepimetaphyseal dysplasia with multiple dislocations ORPHA:93360; Familial isolated congenital asplenia ORPHA:101351; SPONASTRIME dysplasia ORPHA:93357",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1068643725150898; 0.1068643725150898; 0.1419890644363008; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,Influenza B virus (B/Memphis/12/97) HA protein; Cowpox virus Ati or CPXV158 protein (gene: ati); Human adenovirus 41 E2A DBP; Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); Vaccinia virus cowpox A-type inclusion protein; Variola virus hypothetical protein (gene: A28L); Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; BK polyomavirus large T antigen; Influenza A virus (A/Korea/426/1968(H2N2)) nonstructural protein 1 (gene: NS1); Human papillomavirus 138 replication protein (gene: E1); JC polyomavirus hypothetical protein; Human papillomavirus 17 early protein (gene: E1),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764,,,,
CEP41,Biparietal narrowing; Decreased width of the skull; Ewings sarcoma; Joubert syndrome with ocular defect; Feeding difficulties in infancy; Nystagmus; Cognitive delay; Defective or absent horizontal voluntary eye movements; Global developmental delay; Mental and motor retardation; Oculomotor apraxia; Gait abnormality; Long face; Episodic tachypnea; Molar tooth sign on MRI; Apnea; Retinal Dystrophies; Congenital hypoplasia of penis; Feeding difficulties; Mental deficiency; Generalized hypotonia; Cerebellar vermis hypoplasia; Dull intelligence; Low intelligence; Familial aplasia of the vermis; Poor school performance; Cystic Kidney Diseases; Cerebellar Ataxia; Muscle hypotonia; Mental Retardation; Congenital ocular coloboma (disorder); Intellectual Disability; Autism Spectrum Disorders; Polydactyly; Ciliopathies,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8145035474981049; 0.8190761496232595; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.843190898187174; 0.8610447277138289; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8913141512402477; 0.8959157818691486; 0.906476206143938; 0.9124568647908072; 0.922229272318747; 0.9432051631882106; 0.9478210444156088; 0.9639249377588224; 0.9685329573219852; 0.98328107300087,Retinal Dystrophy; Oculovestibuloauditory Syndrome; Oculomotor Apraxia; Joubert Syndrome With Ocular Defect; Nystagmus; Developmental Delay; Polymicrogyria; Disorder Of Eye; Schizophrenia; Fundus Coloboma; Retinal Coloboma; Oral Cleft; Dextrocardia; Penis Agenesis; Joubert Syndrome; Mental Retardation; Cerebellar Vermis Agenesis; Autism Spectrum Disorder; Polydactyly Of Toes; Strabismus; Congenital Cerebral Hernia; Scoliosis; Congenital Coloboma Of Iris; Hydrocephalus; Polydactyly; Situs Inversus; Ciliopathies; Agenesis Of Corpus Callosum; Ptosis; Hirschsprung Disease,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8201196687803188; 0.8337953215113012; 0.861756360478846; 0.8662301945830305; 0.8903630091389316; 0.8908485337686392; 0.924275664330454; 0.924275664330454; 0.9318760199717074; 0.9574431947800732; 0.9578111936867284; 0.9658957825498884; 0.9658957825498884; 0.980894832851993; 0.9832345076528324; 0.9832345076528324,Joubert syndrome with ocular defect ORPHA:220493; Joubert syndrome ORPHA:475; Meckel syndrome ORPHA:564,0.606625035400596; 0.8922466888454011; 0.8977183736895791,,,,,,
CERS5,Malignant neoplasm of breast; Breast Carcinoma; Colon Carcinoma; Malignant tumor of colon; Systolic Pressure,0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.8098851543361193,Hypertension,0.7765582368651238,Navajo neurohepatopathy ORPHA:255229,0.7929682744768703,Human immunodeficiency virus envelope glycoprotein (gene: env); Yaba monkey tumor virus ankyrin-like protein; Yaba monkey tumor virus 72L; Junin mammarenavirus L protein; Lassa mammarenavirus L protein; Guanarito mammarenavirus L protein,0.8999095837312036; 0.9057542447893764; 0.9359472799230178; 0.9397923093369096; 0.9397923093369096; 0.9450424991150602,,,,
CETN3,"Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Glioma; Astrocytoma; Neoplasms; Meningioma, benign, no ICD-O subtype; Pituitary Neoplasms; Meningioma",0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8272008757995397; 0.8368219249856942; 0.8973454964837912,,,Alazami syndrome ORPHA:319671; Brachydactyly-short stature-retinitis pigmentosa syndrome ORPHA:166035; Hypomyelination with brain stem and spinal cord involvement and leg spasticity ORPHA:363412; Medium chain acyl-CoA dehydrogenase deficiency ORPHA:42; Oral-facial-digital syndrome with short stature and brachymesophalangy ORPHA:508501; Parkinson-dementia complex of Guam ORPHA:90020; Cerebrofaciothoracic dysplasia ORPHA:1394,0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CHKA,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Leukemogenesis; Non-Small Cell Lung Carcinoma; Prostatic Intraepithelial Neoplasias; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Refractory anemias; stage, non-small cell lung cancer; Liver carcinoma; Colorectal Cancer; Epithelial ovarian cancer; T-Cell Lymphoma; Liver and Intrahepatic Biliary Tract Carcinoma; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of liver; Neuroblastoma; Central neuroblastoma; Hematologic Neoplasms; Adenovirus Infections; Tumor Progression; Status Dysraphicus; Rheumatoid Arthritis; Aortic Valve Insufficiency; Rachischisis; Congenital muscular dystrophy (disorder); Colonic Neoplasms; Spina Bifida; Other specified transient cerebral ischemias; Hepatitis B; Transient Ischemic Attack",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8212681436603975; 0.8272008757995397; 0.8402911822757345; 0.841396342333011; 0.8816060628973529,Status Dysraphicus; Rachischisis; Spina Bifida,0.7765582368651238; 0.7765582368651238; 0.8974842552599366,,,,,,,,
CHM,"Breast Carcinoma; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Progressive visual loss; Decreased visual acuity, progressive; Hermanski-Pudlak Syndrome; Neuroblastoma; Central neuroblastoma; Malignant Neoplasms; Choroideremia; Retinal Diseases; Difficulties with night vision; Central blindness; Chorioretinal degeneration; Night Blindness; Choroidal and/or chorioretinal disorder; Low Vision; Dementia; Presenile dementia; Alzheimer's Disease; Canine Osteosarcoma; Visual Impairment; Solid Neoplasm; Chorioretinal atrophy; Electroretinogram abnormal; Primary malignant neoplasm; Alcoholic Intoxication, Chronic; Essential Tremor; Graft-vs-Host Disease; Alcohol Use Disorder; Degenerative disorder; Retinitis Pigmentosa; Parkinsonian Disorders; Opiate Addiction; Visual field constriction; Parkinson Disease; Autosomal dominant retinitis pigmentosa; Restless Legs Syndrome; Myopia; Mental Retardation, X-Linked; Disorder of eye",0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8098851543361193; 0.8190761496232595; 0.8272008757995397; 0.8363138748299018; 0.8402911822757345; 0.8486035047899471; 0.8554819098734854; 0.8610447277138289; 0.8772392350816924; 0.8774809019744603; 0.8851456306720444; 0.9506863447189738; 0.951016614400691; 0.9578035687879456,Retinal Dystrophy; Choroideremia; Nyctalopia; Chorioretinal Atrophy; Disorder Of Eye; Retinitis Pigmentosa; Myopia,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.861756360478846; 0.9832345076528324,"X-linked intellectual disability, Cabezas type ORPHA:85293; Autosomal recessive spastic paraplegia type 71 ORPHA:401840; COG6-CGD ORPHA:464443; Christianson syndrome ORPHA:85278; Craniolenticulosutural dysplasia ORPHA:50814; Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome ORPHA:363523; Hypomyelination-congenital cataract syndrome ORPHA:85163; MEGDEL syndrome ORPHA:352328; Autosomal recessive spastic paraplegia type 69 ORPHA:401830; Carney complex ORPHA:1359; Choroideremia ORPHA:180; Familial atrial myxoma ORPHA:615; Hyperparathyroidism-jaw tumor syndrome ORPHA:99880; Parathyroid carcinoma ORPHA:143; Reticulate acropigmentation of Kitamura ORPHA:178307; Cataract-intellectual disability-hypogonadism syndrome ORPHA:1387; Autosomal recessive spastic paraplegia type 53 ORPHA:319199; Neonatal epileptic encephalopathy due to glutaminase deficiency ORPHA:557064; Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome ORPHA:457395; Pyruvate dehydrogenase phosphatase deficiency ORPHA:79246; Spastic ataxia-dysarthria due to glutaminase deficiency ORPHA:557056; Micro syndrome ORPHA:2510; Hereditary sensory and autonomic neuropathy type 1 ORPHA:36386",0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CHN2,"Mammary Neoplasms; Malignant neoplasm of liver; Neuroblastoma; Central neuroblastoma; melanoma; Hepatosplenic T-cell lymphoma; Nonproliferative diabetic retinopathy; Liver neoplasms; Precancerous Conditions; Acquired CJD; Diabetes Mellitus, Non-Insulin-Dependent; Diabetic Retinopathy; Condition, Preneoplastic; Psychotic Disorders",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8026504676141903; 0.8145035474981049; 0.8190761496232595; 0.8402911822757345; 0.8648405521677974; 0.939985154445373,Diabetic Nephropathy; Reactive Psychosis; Psychosis; Leukemia; Alzheimer Disease; Liver Cancer; Liver Neoplasms,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8457525389282121; 0.924275664330454; 0.9543024119762946,Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Gamma-aminobutyric acid transaminase deficiency ORPHA:2066; L-Arginine:glycine amidinotransferase deficiency ORPHA:35704,0.1040670578681756; 0.7929682744768703; 0.8922466888454011,,,,,,
CHST4,Adenocarcinoma; Mucinous Adenocarcinoma; Transitional cell carcinoma of bladder; Multiple Endocrine Neoplasia Type 1,0.750391252594775; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649,,,,,,,,,,
CIB2,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Hydatidiform Mole, Partial; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Ovarian Carcinoma; Hepatoblastoma; Beckwith-Wiedemann Syndrome; TARSAL-CARPAL COALITION SYNDROME; MYELODYSPLASTIC SYNDROME; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Complete hydatidiform mole; Adenoma; Nevus; Malignant neoplasm of lung; Malignant neoplasm of prostate; Low Grade Lymphoma (neoplasm); Liver carcinoma; Epithelial ovarian cancer; Rhabdomyosarcoma; HYDATIDIFORM MOLE, RECURRENT, 1; Leukemia, T-Cell; Prostate carcinoma; Nephroblastoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Hydatidiform Mole; Glucocorticoid Receptor Deficiency; Difficulties with night vision; Renal glomerular disease; Melanocytic nevus; Pigmentary iris degeneration; Profound sensorineural hearing impairment; Night Blindness; Aplasia/Hypoplasia of the cerebellum; Nasopharyngeal carcinoma; Infection caused by Helicobacter pylori; Tumor Progression; Sarcoma; Benign melanocytic nevus; Lymphoma, Follicular; Acute lymphocytic leukemia; Abnormal vision; Abnormality of cochlea; Cognitive delay; Usher syndrome, type 1A; Vestibular dysfunction; Vestibular hypofunction; Squamous cell carcinoma; Diabetes; Diabetes Mellitus; Global developmental delay; Mental and motor retardation; Usher Syndrome, Type I; Electroretinogram abnormal; IGA Glomerulonephritis; Hyperinsulinism; Retinal blind spot; Scotoma; Glomerulosclerosis (disorder); Schizophrenia; Mucosa-Associated Lymphoid Tissue Lymphoma; Lip and Oral Cavity Carcinoma; No development of motor milestones; Usher Syndrome; Motor delay; Hemianopsia; High-grade hypermetropia; Embryonal Rhabdomyosarcoma; Nonsyndromic Deafness; Retinitis Pigmentosa; Mental deficiency; Oral Cavity Carcinoma; Familial (FPAH); Chronic Obstructive Airway Disease; Dull intelligence; Low intelligence; Cataract; Choriocarcinoma; Poor school performance; Malignant neoplasm of mouth; Cerebellar Ataxia; Lens Opacities; Mental Retardation; Intellectual Disability; Sensorineural Hearing Loss (disorder); Asthma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8769418330148872; 0.8913141512402477; 0.8946938397586319; 0.906476206143938; 0.9117936912777788; 0.922229272318747; 0.9478210444156088; 0.9520060723130308; 0.9672478180546946,Nyctalopia; Developmental Delay; Disorder Of Eye; Schizophrenia; Subcortical Cerebral Atrophy; Non-Syndromic Sensorineural Deafness; Hearing Loss; Motor Delay; Usher Syndrome; Hallucinations; Mental Retardation; Deafness; Hemianopsia; Anxiety Disorder; Cerebral Cortical Atrophy; Rod-cone Dystrophy; Mental Depression; Nonsyndromic Deafness; Cataract,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.8337953215113012; 0.8337953215113012; 0.8337953215113012; 0.8457525389282121; 0.8476516371290275; 0.8507213163251659; 0.861756360478846; 0.8903301324869451; 0.8903630091389316; 0.9398381935810408; 0.974502015052702,Usher syndrome type 1 ORPHA:231169; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; Classic Bartter syndrome ORPHA:93605; Intellectual disability-developmental delay-contractures syndrome ORPHA:3454; Male infertility due to large-headed multiflagellar polyploid spermatozoa ORPHA:137893; X-linked Emery-Dreifuss muscular dystrophy ORPHA:98863,0.2661730864557679; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703,,,,,,
CKB,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Adenocarcinoma; Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Cervix carcinoma; Malignant tumor of cervix; Colorectal Cancer; Epithelial ovarian cancer; cervical cancer; Neoplasm Metastasis; Malignant neoplasm of stomach; Tumor Progression; Hematological Disease; Alzheimer's Disease; Stomach Carcinoma; Hepatitis C; Uveitis; Small cell carcinoma of lung; Huntington Disease; Secondary malignant neoplasm of liver; Regurgitation; Pick Disease of the Brain; Myocardial Infarction; Hereditary Diffuse Gastric Cancer; Precancerous Conditions; Acute Coronary Syndrome; Stomach Neoplasms; Schizophrenia; Adenocarcinoma, Tubular; Colonic Neoplasms; Hypoglycemia; polyps; Left Ventricular Hypertrophy; Carcinoma, Cribriform; Carcinoma, Granular Cell; Adenocarcinoma, Basal Cell; Adenocarcinoma, Oxyphilic; Cardiomyopathy, Dilated",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8037546774788534; 0.8044379824544406; 0.8067197998685076; 0.8168901801930506; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8745234584149799; 0.9564633032157428,Stomach Neoplasms; Schizophrenia; Left Ventricular Hypertrophy; Lung Carcinoma; Myocardial Infarction; Gastric Cancer; Coronary Syndrome; Carcinoma; Adenocarcinoma,0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8139950454942313; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.9069867032339078; 0.9350723667380212,"Paroxysmal exertion-induced dyskinesia ORPHA:98811; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Distal hereditary motor neuropathy type 5 ORPHA:139536; Benign hereditary chorea ORPHA:1429; Coloboma of choroid and retina ORPHA:98942; Coloboma of iris ORPHA:98944; Achondroplasia ORPHA:15; Autosomal dominant spastic paraplegia type 31 ORPHA:101011; Beckwith-Wiedemann syndrome due to CDKN1C mutation ORPHA:231120; Camptodactyly-tall stature-scoliosis-hearing loss syndrome ORPHA:85164; Classic Bartter syndrome ORPHA:93605; Crouzon syndrome-acanthosis nigricans syndrome ORPHA:93262; Hypochondroplasia ORPHA:429; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome ORPHA:436144; Muenke syndrome ORPHA:53271; Progressive myoclonic epilepsy type 8 ORPHA:424027; Right sided atrial isomerism ORPHA:97548; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome ORPHA:85165; Thanatophoric dysplasia type 1 ORPHA:1860; Thanatophoric dysplasia type 2 ORPHA:93274; X-linked creatine transporter deficiency ORPHA:52503; Paroxysmal non-kinesigenic dyskinesia ORPHA:98810; Brain-lung-thyroid syndrome ORPHA:209905; Distal arthrogryposis type 5D ORPHA:329457; Oculoauricular syndrome, Schorderet type ORPHA:157962; Coloboma of eye lens ORPHA:98943; Coloboma of eyelid ORPHA:98946; Coloboma of macula ORPHA:98945; Coloboma of optic disc ORPHA:98947",0.0155394890951578; 0.0473879273649914; 0.1068643725150898; 0.1991445465001551; 0.3977968344535308; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CLDN2,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Hepatoblastoma; Colorectal Carcinoma; Colon Carcinoma; Metaplasia; Malignant tumor of colon; Non-Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma breast stage IV; Adenoma; Mammary Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Pancreatitis, Alcoholic; Cholelithiasis; Colorectal Cancer; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma, Endometrioid; Carcinoma of lung; Malignant Neoplasms; Malignant neoplasm of stomach; Diarrhea; Pancreatitis, Chronic; Tumor Progression; Salmonella infections; Cholecystolithiasis; Secondary malignant neoplasm of skin; Squamous cell carcinoma; Carcinoid Tumor; Crohn Disease; Bacterial Infections; Secondary malignant neoplasm of liver; Primary malignant neoplasm; Cholecystitis; Adenocarcinoma of lung (disorder); Cholesterol gallstones; Pancreatitis; Ulcerative Colitis; Secondary malignant neoplasm of lung; Inflammatory Bowel Diseases; Necrotizing enterocolitis in fetus OR newborn; Secondary malignant neoplasm of lymph node; Colitis",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8098851543361193; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8232134984476662; 0.8815127642200768; 0.8980854850210683; 0.900167961295542; 0.9738491767258852,Pancreatitis; Obstructive Azoospermia,0.8115918568696846; 0.8115918568696846,"Isolated neonatal sclerosing cholangitis ORPHA:480556; HNF1B-related autosomal dominant tubulointerstitial kidney disease ORPHA:93111; Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome ORPHA:476119; Chromophobe renal cell carcinoma ORPHA:319303; Hyperinsulinism due to HNF1A deficiency ORPHA:324575; Hyperinsulinism due to HNF4A deficiency ORPHA:263455; Autosomal dominant primary hypomagnesemia with hypocalciuria ORPHA:34528; Bilateral multicystic dysplastic kidney ORPHA:97364; Medullary sponge kidney ORPHA:1309; Renal dysplasia, bilateral ORPHA:93173; Renal dysplasia, unilateral ORPHA:93172; Unilateral multicystic dysplastic kidney ORPHA:97363; Rotor syndrome ORPHA:3111; Acrocapitofemoral dysplasia ORPHA:63446; Aromatic L-amino acid decarboxylase deficiency ORPHA:35708; CIDEC-related familial partial lipodystrophy ORPHA:435651; Dubin-Johnson syndrome ORPHA:234; Progressive familial intrahepatic cholestasis type 5 ORPHA:480476; X-linked Charcot-Marie-Tooth disease type 1 ORPHA:101075; X-linked progressive cerebellar ataxia ORPHA:1175; 17q12 microdeletion syndrome ORPHA:261265; Brachytelephalangic chondrodysplasia punctata ORPHA:79345; Hereditary fructose intolerance ORPHA:469; Hereditary hypercarotenemia and vitamin A deficiency ORPHA:199285; Autosomal recessive infantile hypercalcemia ORPHA:300547",0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CLDN9,Malignant neoplasm of prostate; Prostatic Neoplasms,0.7880542567584415; 0.7880542567584415,Prostate Cancer; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238,Dominant hypophosphatemia with nephrolithiasis or osteoporosis ORPHA:244305,0.7929682744768703,,,,,,
CLGN,Multiple malignancy; Seminoma,0.7880542567584415; 0.7880542567584415,,,"Hyperphenylalaninemia due to DNAJC12 deficiency ORPHA:508523; 46,XY partial gonadal dysgenesis ORPHA:251510; WAGR syndrome ORPHA:893; Combined pituitary hormone deficiencies, genetic forms ORPHA:95494",0.7929682744768703; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011,,,,,,
CLIC3,Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Malignant neoplasm of ovary; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Neoplasm Metastasis; Eclampsia; Mucoepidermoid Carcinoma; Tumor Progression; Secondary malignant neoplasm of lymph node,0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.900167961295542,,,Idiopathic juvenile osteoporosis ORPHA:85193; Annular epidermolytic ichthyosis ORPHA:281139; Autosomal dominant epidermolytic ichthyosis ORPHA:312; Congenital reticular ichthyosiform erythroderma ORPHA:281190; Hypoparathyroidism-sensorineural deafness-renal disease syndrome ORPHA:2237,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CLK3,Carcinoma of bladder; Cleft upper lip,0.4084380369379369; 0.7880542567584415,Bladder Carcinoma,0.9231137872214272,Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Birt-Hogg-Dube syndrome ORPHA:122; Familial spontaneous pneumothorax ORPHA:2903; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; CAMOS syndrome ORPHA:83472; Coats plus syndrome ORPHA:313838; CLN3 disease ORPHA:228346; Grange syndrome ORPHA:79094; Glycogen storage disease due to liver phosphorylase kinase deficiency ORPHA:264580; Hermansky-Pudlak syndrome with pulmonary fibrosis ORPHA:231500; Familial focal epilepsy with variable foci ORPHA:98820; Pityriasis rubra pilaris ORPHA:2897; Combined malonic and methylmalonic acidemia ORPHA:289504; Renal-hepatic-pancreatic dysplasia ORPHA:294415,0.0081550609410495; 0.0155394890951578; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Horsepox virus HSPV181 (ankyrin repeats)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
CLSTN3,Colorectal Cancer; Amyloidosis,0.7880542567584415; 0.8672189956534445,Schizophrenia; Colorectal Cancer,0.7860378120955526; 0.9832345076528324,"Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; 1p36 deletion syndrome ORPHA:1606; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; Gorlin syndrome ORPHA:377; SYNGAP1-related developmental and epileptic encephalopathy ORPHA:544254; Dopamine beta-hydroxylase deficiency ORPHA:230",0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.1040670578681756; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,,,,
CLU,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Dementia, familial Danish; Colon Carcinoma; androgen independent prostate cancer; Malignant tumor of colon; Lymphoma; Endometrial Neoplasms; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Hypercholesterolemia; HIV Encephalopathy; Prostatic Intraepithelial Neoplasias; Colorectal Neoplasms; HIV encephalitis; Adenoma; Thyroid Neoplasm; Endometrial Carcinoma; Vascular Diseases; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Mastocytosis, Systemic; Liver carcinoma; Malignant Meningioma; Osteosarcoma; Thyroid carcinoma; Colorectal Cancer; Epithelial ovarian cancer; Multiple malignancy; Hepatocarcinogenesis; Glioblastoma; Osteosarcoma of bone; Hemangioblastoma; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Prion Diseases; Epithelioma; Exfoliation Syndrome; Malignant neoplasm of testis; Hepatitis D Infection; Carcinoma, Endometrioid; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of thyroid; Squamous cell carcinoma of the head and neck; Triple Negative Breast Neoplasms; Neuroblastoma; Central neuroblastoma; Immunologic Deficiency Syndromes; Malignant Neoplasms; melanoma; Lung Neoplasms; Metastatic Prostate Carcinoma; Neoplasms; Libman-Sacks Disease; PERIODONTITIS, LOCALIZED AGGRESSIVE; Malignant neoplasm of stomach; AURAL ATRESIA, CONGENITAL; Noninfiltrating Intraductal Carcinoma; Membranous glomerulonephritis; Myxoid cyst; Hemolytic-Uremic Syndrome; Skin Carcinogenesis; Papillary serous cystadenocarcinoma; Hodgkin Disease; Benign Prostatic Hyperplasia; Brain Neoplasms; Sensory denervation disorder; Pancreatitis, Chronic; Nasopharyngeal carcinoma; Asthenozoospermia; Malignant Testicular Germ Cell Tumor; Dementia; Tumor Progression; Endometrial Diseases; Sarcoma; Lupus Erythematosus, Systemic; Fuchs Endothelial Dystrophy; Renal Cell Carcinoma; Seminoma; Presenile dementia; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Periodontitis; Stomach Carcinoma; Juvenile psoriatic arthritis; Hepatitis C; Glaucoma; Cystadenoma, Mucinous; Squamous cell carcinoma; Infiltrating Cervical Carcinoma; Rheumatoid Arthritis; Juvenile-Onset Still Disease; Diabetes; Desmoplastic melanoma; Diabetes Mellitus; Carcinoid Tumor; Aortic Valve Insufficiency; Adenoma of large intestine; Diffuse Intrinsic Pontine Glioma; Retinal Degeneration; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; PACHYONYCHIA CONGENITA 3; Thinking and speaking disturbances; Hormone refractory prostate cancer; Acute malaria; Fish-Eye Disease; Pathologic Neovascularization; Cholestasis; Pancreatic Diseases; Polyneuropathy; Secondary malignant neoplasm of liver; Primary malignant neoplasm; CADASIL Syndrome; Metastatic melanoma; Juvenile arthritis; Hemangioma; Plaque, Amyloid; Endometrial Endometrioid Adenocarcinoma; Chronic Periodontitis; Adult-Onset Still Disease; Pre-Eclampsia; Cerebral atrophy; Multiple Sclerosis; Oligospermia; Fleck corneal dystrophy; Kidney Failure, Chronic; Fibrosarcoma; Synovitis; Degenerative polyarthritis; Encephalomyelitis; Senile Plaques; Liver neoplasms; Kidney Diseases; Gingival Diseases; Acute Coronary Syndrome; ovarian neoplasm; Schizophrenia; Adenocarcinoma of lung (disorder); Convulsions; Liver diseases; Absence Seizures; Prostatic Hypertrophy; Ulcerative Colitis; Generalized seizures; Impaired cognition; Diabetes Mellitus, Non-Insulin-Dependent; Seizures, Focal; Colonic Neoplasms; Inflammation; Trigeminal Neuralgia; Nephrotic Syndrome; Secondary malignant neoplasm of lung; Liver Cirrhosis; Testicular Neoplasms; Angle Closure Glaucoma; Metastatic Carcinoma; Alzheimer's Disease, Focal Onset; Acute Confusional Senile Dementia; Prostatic Hyperplasia; Amyotrophic Lateral Sclerosis, Sporadic; Periodontal Diseases; Neurodegenerative Disorders; Fibrosis, Liver; Osteoarthrosis Deformans; Anti-Basement Membrane Glomerulonephritis; Glioblastoma Multiforme; Recurrent tumor; Traditional Serrated Adenoma; AMYOTROPHIC LATERAL SCLEROSIS 1; Glaucoma, Primary Open Angle; Alzheimer Disease, Late Onset; Mixed cryoglobulinemia; Retinitis Pigmentosa; Mild cognitive disorder; Primary Carcinoma; Papilloma; Single Seizure; Seizures, Auditory; Seizures, Clonic; Seizures, Sensory; Seizures, Somatosensory; Vertiginous seizure; Atonic Absence Seizures; Generalized Absence Seizures; Gustatory seizure; Jacksonian Seizure; Non-epileptic convulsion; Nonepileptic Seizures; Olfactory seizure; Down Syndrome; Epileptic Seizures; Tonic Seizures; Hypertensive disease; Drug-Induced Liver Disease; Chronic graft-versus-host disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Cirrhosis; Convulsive Seizures; Cystadenoma; Hepatitis, Drug-Induced; Squamous cell carcinoma of esophagus; NEUROTICISM; Epileptic drop attack; Tonic - clonic seizures; Alzheimer Disease, Early Onset; Complex partial seizures; Atrophic; Von Hippel-Lindau Syndrome; Amyloidosis; Mental Depression; Proteinuria; Parkinson Disease; Familial Alzheimer Disease (FAD); Thyroid Nodule; Hepatolenticular Degeneration; Carcinoma, Papillary; nervous system disorder; Brain Ischemia; Secondary malignant neoplasm of lymph node; Visual seizure; Depressive disorder; Pulmonary Hypertension; Coronary heart disease; Adverse reaction to drug; Drug toxicity; Lesion of brain; Myoclonic Seizures; Acute Kidney Insufficiency; Acute kidney injury; Pituitary Diseases; Ischemia of kidney; Kidney Failure, Acute; Refractory cancer; Skin Neoplasms; Seizures; Malaria; Epilepsy; Ureteral obstruction; Renal fibrosis",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7940665326856218; 0.8009048756462318; 0.8009048756462318; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026798872257774; 0.8037546774788534; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8140222479282434; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.834094492023826; 0.8342163953428735; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8420665668584452; 0.843190898187174; 0.8474481237156937; 0.8474481237156937; 0.8523465762428218; 0.8523465762428218; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8554819098734854; 0.8578473133580928; 0.8578473133580928; 0.8578473133580928; 0.8610447277138289; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8672189956534445; 0.8769418330148872; 0.8769418330148872; 0.8772392350816924; 0.8786853464107758; 0.8815127642200768; 0.8867509400747969; 0.887080330932516; 0.8959157818691486; 0.8980854850210683; 0.900167961295542; 0.900167961295542; 0.9103315000053974; 0.9103315000053974; 0.9119978323790848; 0.9119978323790848; 0.9119978323790848; 0.914995991166204; 0.914995991166204; 0.9193385822373632; 0.9258401930327972; 0.93156380601526; 0.9349647051157376; 0.9373358316580888; 0.9377696084218796; 0.9434459508692176; 0.9478210444156088; 0.9512505437112568; 0.963331724428282; 0.963331724428282; 0.98964300672626,"Prostate Cancer; Melanoma; Nonbacterial Verrucal Endocardiosis; Prostatic Neoplasms; Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Seronegative Polyarthritis; Still Disease; Schizophrenia; Kidney Disease; Lateral Sclerosis; Alzheimer Disease; Hypotonic Seizures; Seizure; Osteoarthrosis Deformans; Senile Dementia; Jacksonian Seizure; Cognitive Disorder; Clonic Seizures; Arthritis; Lupus Erythematosus; Impaired Cognition; Acute Kidney Insufficiency; Kidney Failure",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8210988731657684; 0.8444537302152433; 0.8457525389282121; 0.8601151608808731; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.9046917974656596; 0.9145387439550552; 0.9231137872214272; 0.9578111936867284; 0.9658957825498884,"Bilateral frontoparietal polymicrogyria ORPHA:101070; 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency ORPHA:752; CLCN4-related X-linked intellectual disability syndrome ORPHA:485350; Microphthalmia with limb anomalies ORPHA:1106; Autosomal recessive extra-oral halitosis ORPHA:562538; Autosomal dominant spastic paraplegia type 17 ORPHA:100998; Severe neurodegenerative syndrome with lipodystrophy ORPHA:363400",0.1040670578681756; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
COQ10A,"Liver Cirrhosis, Experimental",0.8014900279306119,,,Isobutyryl-CoA dehydrogenase deficiency ORPHA:79159; Telethonin-related  limb-girdle muscular dystrophy R7 ORPHA:34514; Familial steroid-resistant nephrotic syndrome with sensorineural deafness ORPHA:280406; Glycogen storage disease due to muscle beta-enolase deficiency ORPHA:99849,0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,,,,
COQ7,"Low Vision; Serum creatinine raised; Cognitive delay; Visual Impairment; COENZYME Q10 DEFICIENCY; Global developmental delay; Polyneuropathy; Mental and motor retardation; Congenital deafness; Peripheral demyelination; Steroid resistant nephrotic syndrome of childhood; Steroid-resistant nephrotic syndrome; Hearing Loss, Partial; Deafness; No development of motor milestones; Motor delay; Postnatal growth retardation; Feeding difficulties; Neurodegenerative Disorders; hearing impairment; Small for gestational age (disorder); Low Birth Weights; Peripheral Neuropathy; RENAL ADYSPLASIA; Generalized hypotonia; Renal dysplasia; Maternal oligohydramnios; Oligohydramnios; Pain; Mitochondrial Diseases; Infant, Small for Gestational Age; Intrauterine retardation; Muscle hypotonia; Fetal Growth Retardation; Respiratory distress; Muscle Weakness; Congenital hypoplasia of lung; Flexion contractures of joints; Flexion contracture; Contracture of joint; Contracture; Dyspnea",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8554819098734854; 0.8648405521677974; 0.8774809019744603; 0.887595340546704; 0.8989612563669234; 0.9083161862856644; 0.9111864999692114; 0.9124568647908072; 0.9307095582633488; 0.9393256300017014; 0.9512505437112568; 0.9557184806547836; 0.9614320311453906; 0.9621920228183704; 0.9639249377588224; 0.9769594699984444; 0.9858417751377604,Coenzyme Q10 Deficiency; Hypertension; Developmental Delay; Left Ventricular Hypertrophy; Motor Delay; Renal Dysplasia; Polyneuropathy; Pulmonary Hypoplasia,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8210988731657684; 0.8903630091389316; 0.9436990979382386; 0.9658957825498884,,,Human T-lymphotropic virus 3 envelope (gene: env); Human T-cell lymphotropic virus type 2b env; Human T-lymphotropic virus 4 envelope glycoprotein (gene: env); Human T-lymphotropic virus 2 p21E envelope protein; Japanese encephalitis virus hypothetical protein; Human T-cell leukemia virus type I gp46 SU (gene: env); Human T-lymphotropic virus 2 hypothetical protein (env propeptide); Ntaya virus full_polyprotein 1..3427; Cowpox virus Ati or CPXV158 protein (gene: ati); Ilheus virus full_polyprotein 1..3424; West Nile virus SA381/00 non-structural protein 5; West Nile virus lineage 1 RNA-dependent RNA polymerase NS5 (gene: flavivirus polyprotein); West Nile virus lineage 2 RNA-dependent RNA polymerase NS5 (gene: flavivirus polyprotein); Murray Valley encephalitis virus NS5; West Nile virus H442 non-structural protein 5; West Nile virus SPU116/89 non-structural protein 5; West Nile virus SA93/01 non-structural protein 5; Zika virus RNA-dependent RNA polymerase NS5 (gene: flavivirus polyprotein); Yellow fever virus RNA-dependent RNA polymerase; Langat virus nonstructural protein NS5; Dengue virus 3 RNA-dependent RNA polymerase NS5 (gene: flavivirus polyprotein); Dengue virus 1 RNA-dependent RNA polymerase NS5 (gene: flavivirus polyprotein); Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); Dengue virus 2 RNA-dependent RNA polymerase NS5 (gene: flavivirus polyprotein); Kyasanur Forest disease virus NS5; Powassan virus RNA-dependent RNA polymerase; Wesselsbron virus full_polyprotein 1..3405; Louping ill virus RNA-dependent RNA polymerase; Vaccinia virus cowpox A-type inclusion protein; Variola virus hypothetical protein (gene: A28L); Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; Influenza A virus (A/California/04/2009(H1N1)) matrix protein 2 (gene: M2); Yaba monkey tumor virus anti-apoptotic membrane protein; Karshi virus (Royal Farm virus) full_polyprotein 1..3416; Omsk hemorrhagic fever virus full_polyprotein 1..3414; Monkeypox virus cowpox A-type inclusion protein; Hendra henipavirus phosphoprotein P (gene: P/V/C); Nipah henipavirus P phosphoprotein; Variola virus double-strand RNA-binding protein (gene: E3L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
CORO1A,"Malignant neoplasm of breast; Breast Carcinoma; Hydatidiform Mole, Partial; Carcinogenesis; Malignant neoplasm of ovary; Cerebellar malformation; leukemia; Ovarian Carcinoma; Epidermodysplasia Verruciformis; Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Complete hydatidiform mole; Mammary Neoplasms; Liver carcinoma; Triploidy syndrome; Colorectal Cancer; Lymphopenia; HYDATIDIFORM MOLE, RECURRENT, 1; Nephroblastoma; insulinoma; Neoplasm Metastasis; Primary immune deficiency disorder; Hydatidiform Mole; Immunologic Deficiency Syndromes; Malignant Neoplasms; Neoplasms; Severe Combined Immunodeficiency; Malignant neoplasm of large intestine; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Gestational Trophoblastic Neoplasms; Cognitive delay; Squamous cell carcinoma; Carcinoma; Childhood Acute Lymphoblastic Leukemia; Global developmental delay; Virus Diseases; Mental and motor retardation; Primary malignant neoplasm; Carcinoma, Spindle-Cell; Undifferentiated carcinoma; Lupus Erythematosus; ovarian neoplasm; Lupus Erythematosus, Discoid; Adult Acute Lymphocytic Leukemia; Carcinomatosis; Lupus Vulgaris; Tuberculosis; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Anaplastic carcinoma; Muscular Dystrophy, Duchenne; Hydrocephalus; Hyperactive behavior; Recurrent respiratory infections; Attention deficit hyperactivity disorder",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7950434752274518; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8190761496232595; 0.8232134984476662; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8815127642200768; 0.8851456306720444; 0.8878860377518915; 0.9083161862856644; 0.9770263358372888,Omenn Syndrome; Immunologic Deficiency Syndromes; Severe Combined Immunodeficiency Disease; Lymphopenia; Developmental Delay; Immunodeficiency; Anaplastic Carcinoma; Carcinoma,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.9069867032339078,Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Familial isolated pituitary adenoma ORPHA:314777; Autosomal dominant spastic ataxia type 1 ORPHA:251282; LIPE-related familial partial lipodystrophy ORPHA:435660; Aicardi-Goutieres syndrome ORPHA:51; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; Coats plus syndrome ORPHA:313838; Autosomal recessive malignant osteopetrosis ORPHA:667; Bleeding disorder due to CalDAG-GEFI deficiency ORPHA:420566; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; Congenital non-communicating hydrocephalus ORPHA:269510; Grange syndrome ORPHA:79094; Hermansky-Pudlak syndrome type 7 ORPHA:231531; Multiple intestinal atresia ORPHA:2300; Nephrogenic syndrome of inappropriate antidiuresis ORPHA:93606; Severe combined immunodeficiency due to CARMIL2 deficiency ORPHA:542301; Severe combined immunodeficiency due to CORO1A deficiency ORPHA:228003; Spinocerebellar ataxia type 40 ORPHA:423275; Familial focal epilepsy with variable foci ORPHA:98820; Autosomal dominant severe congenital neutropenia ORPHA:486; Epidermodysplasia verruciformis ORPHA:302; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; Neutrophil immunodeficiency syndrome ORPHA:183707; WHIM syndrome ORPHA:51636; Cystic leukoencephalopathy without megalencephaly ORPHA:85136; Familial hemophagocytic lymphohistiocytosis ORPHA:540; Autosomal dominant Charcot-Marie-Tooth disease type 2I ORPHA:99942; Autosomal dominant Charcot-Marie-Tooth disease type 2J ORPHA:99943; Autosomal dominant intermediate Charcot-Marie-Tooth disease type D ORPHA:100046; Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain ORPHA:324585; BENTA disease ORPHA:464336; Charcot-Marie-Tooth disease type 1B ORPHA:101082; Combined immunodeficiency due to OX40 deficiency ORPHA:431149; Hyperinsulinism due to UCP2 deficiency ORPHA:276556; Persistent polyclonal B-cell lymphocytosis ORPHA:300324; Severe combined immunodeficiency due to CARD11 deficiency ORPHA:357237; T-B+ severe combined immunodeficiency due to JAK3 deficiency ORPHA:35078; X-linked severe congenital neutropenia ORPHA:86788; X-linked thrombocytopenia with normal platelets ORPHA:852; Acute basophilic leukemia ORPHA:86849; Recurrent infection due to specific granule deficiency ORPHA:169142; Complete hydatidiform mole ORPHA:254688; Autosomal agammaglobulinemia ORPHA:33110; Common variable immunodeficiency ORPHA:1572; Combined immunodeficiency due to CD27 deficiency ORPHA:238505; Combined immunodeficiency due to IL21R deficiency ORPHA:357329; Combined immunodeficiency due to ZAP70 deficiency ORPHA:911; DOCK2 deficiency ORPHA:447737; Hyperzincemia and hypercalprotectinemia ORPHA:251523; Leukocyte adhesion deficiency type I ORPHA:99842; Leukocyte adhesion deficiency type III ORPHA:99844; NON RARE IN EUROPE: Psoriatic arthritis ORPHA:40050; Pancytopenia due to IKZF1 mutations ORPHA:317473; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome ORPHA:69126; Severe combined immunodeficiency due to LCK deficiency ORPHA:280142; T-B+ severe combined immunodeficiency due to gamma chain deficiency ORPHA:276; Stevens-Johnson syndrome ORPHA:36426; Wiskott-Aldrich syndrome ORPHA:906; Immunodeficiency by defective expression of MHC class II ORPHA:572; Narcolepsy type 2 ORPHA:83465; Narcolepsy type 1 ORPHA:2073; Primary biliary cholangitis ORPHA:186; Precursor B-cell acute lymphoblastic leukemia ORPHA:99860,0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1294848460749822; 0.1991445465001551; 0.1991445465001551; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8029813443753846; 0.8564946241562607; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
COX19,Cytochrome-c Oxidase Deficiency,0.8486035047899471,,,TMEM199-CDG ORPHA:466703; Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome ORPHA:467176,0.3832844616405875; 0.8922466888454011,,,,,,
CRADD,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Osteosarcoma; Osteosarcoma of bone; Agyria; Lissencephaly; Renal Cell Carcinoma; Alzheimer's Disease; Macrocephaly; Papillary Renal Cell Carcinoma; Increased head circumference; Conventional (Clear Cell) Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Delayed speech and language development; Sarcomatoid Renal Cell Carcinoma; Collecting Duct Carcinoma of the Kidney; Hip circumference; Speech impairment; Mental deficiency; Language Delay; Speech Delay; Dull intelligence; Low intelligence; Body mass index; Finding of body mass index; Poor school performance; Septicemia; Sepsis; Mental Retardation; Body Height; Intellectual Disability",0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8168901801930506; 0.8190761496232595; 0.8272008757995397; 0.8363138748299018; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8757755363384367; 0.8757755363384367; 0.8867509400747969; 0.8867509400747969; 0.8913141512402477; 0.917543617287358; 0.9189398569397552; 0.922229272318747; 0.9390727893210336; 0.9478210444156088,Non-Syndromic Intellectual Disability; Stereotyped Behavior; Dyskinetic Syndrome; Lissencephaly; Salaam Seizures; Cortical Dysplasia; Developmental Delay; Macrocephaly; Polymicrogyria; Hypoplasia Of Corpus Callosum; Central Visual Impairment; Dyssomnia; Pachygyria; Motor Delay; Mental Retardation; Cerebral Atrophy; Chromophobe Carcinoma; Alzheimer Disease; Absence Of Septum Pellucidum; Papillary Renal Carcinoma; Sleep Disorders; Seizure; Knee Osteoarthritis; Renal Carcinoma; Microcephaly; Mental Depression; Osteoarthritis Of Hip; Arthritis; Autism,0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7949861636679444; 0.8115918568696846; 0.8201196687803188; 0.8210988731657684; 0.8210988731657684; 0.8337953215113012; 0.8339308890552987; 0.8356859041719433; 0.8457525389282121; 0.8476516371290275; 0.8476516371290275; 0.8601151608808731; 0.861756360478846; 0.861756360478846; 0.8727045307126416; 0.8903630091389316; 0.8903630091389316; 0.8903630091389316; 0.9046917974656596; 0.911896615143974,Carnitine-acylcarnitine translocase deficiency ORPHA:159; Biotinidase deficiency ORPHA:79241; Autosomal recessive non-syndromic intellectual disability ORPHA:88616,0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,,,,
CTCF,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Superinfection; leukemia; Ovarian Carcinoma; Beckwith-Wiedemann Syndrome; Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Leukemogenesis; Adult T-Cell Lymphoma/Leukemia; Russell-Silver syndrome; Tooth problem; Endometrial Carcinoma; Mammary Neoplasms; Glioma; Abnormality of the dentition; Malignant neoplasm of lung; Malignant neoplasm of prostate; Myotonic Dystrophy; Liver carcinoma; Invasive carcinoma of breast; Malignant Head and Neck Neoplasm; Osteosarcoma; Acute Promyelocytic Leukemia; Colorectal Cancer; Epithelial ovarian cancer; Liver and Intrahepatic Biliary Tract Carcinoma; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Nephroblastoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Malignant neoplasm of testis; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of liver; Ductal Carcinoma; Lung Neoplasms; Lobular carcinoma in situ of breast; Metastatic Prostate Carcinoma; Neoplasms; Noninfiltrating Intraductal Carcinoma; MYELOPROLIFERATIVE SYNDROME, TRANSIENT; Mental disorders; Myxoid cyst; Abnormal behavior; Benign Prostatic Hyperplasia; Invasive Ductal Breast Carcinoma; Asthenozoospermia; Williams Syndrome; Infection caused by Helicobacter pylori; Tumor Progression; ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1; Leukemia, Megakaryoblastic, of Down Syndrome; MYOTONIC DYSTROPHY 1; Retinoblastoma; Acute lymphocytic leukemia; Cognitive delay; Strawberry nevus of skin; Squamous cell carcinoma; Childhood Acute Lymphoblastic Leukemia; Global developmental delay; Metastatic Neoplasm; Myeloid Leukemia; Mental and motor retardation; Metastasis from malignant tumor of prostate; Teratozoospermia; Oligospermia; Opitz GBBB Syndrome, X-Linked; Granulomatous Slack Skin; Muscular Dystrophy, Facioscapulohumeral; Thin lips; ovarian neoplasm; Schizophrenia; Lymphoma, T-Cell, Cutaneous; Herpes Simplex Infections; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Cornelia De Lange Syndrome; Early infantile epileptic encephalopathy with suppression bursts; Gastrointestinal Carcinoid Tumor; Microcephaly; Infection; Feeding difficulties; Congenital Abnormality; Strabismus; Fragile X Syndrome; Mental deficiency; Cryptorchidism; Sleeplessness; Generalized hypotonia; Sporadic Breast Carcinoma; Friedreich Ataxia; Metabolic Syndrome X; Dull intelligence; Low intelligence; Malignant neoplasm of endometrium; Uterine Corpus Cancer; FRIEDREICH ATAXIA 1; Short stature; Poor school performance; Spinocerebellar Ataxia Type 7; Dwarfism; Hyperopia; Influenza; Mental Retardation; Kaposi Sarcoma; Intellectual Disability; Germ cell tumor; Small head",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8584283190330553; 0.8610447277138289; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8771562273432176; 0.8806784681730055; 0.8815127642200768; 0.8913141512402477; 0.8942113186235617; 0.9098977259629772; 0.914995991166204; 0.9193385822373632; 0.922229272318747; 0.9435654233359168; 0.9478210444156088; 0.9564633032157428; 0.9822381479823692,"Prostatic Neoplasms; Neurodevelopmental Disorders; Nephroblastoma; Leukemia, Megakaryoblastic, Of Down Syndrome; Developmental Delay; Lymphoma; Lymphoblastic Leukemia; Schizophrenia; Granulomatous Slack Skin; Mammary Neoplasms; Movement Disorders; Mental Retardation; Cryptorchidism; Microcephaly; Strabismus; Autism; Dwarfism; Multiple Congenital Anomalies; Dysmorphic Features; Hyperopia",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8165359516083085; 0.829560580336605; 0.8337953215113012; 0.861756360478846; 0.8903630091389316; 0.8908485337686392; 0.911896615143974; 0.9510372690456612; 0.963385108667098; 0.9726139569926774; 0.9801375145248504,Precursor T-cell acute lymphoblastic leukemia ORPHA:99861; Oculofaciocardiodental syndrome ORPHA:2712; 15q24 microdeletion syndrome ORPHA:94065; SIN3A-related intellectual disability syndrome due to a point mutation ORPHA:500166; Acute myeloid leukemia with t(6;9)(p23;q34) ORPHA:402014; Neuroendocrine tumor of stomach ORPHA:100075; Coffin-Siris syndrome ORPHA:1465; 16p13.2 microdeletion syndrome ORPHA:500055; PRUNE1-related neurological syndrome ORPHA:544469; Cardiofaciocutaneous syndrome ORPHA:1340; CTCF-related neurodevelopmental disorder ORPHA:363611; Gabriele-de Vries syndrome ORPHA:506358,0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6467006456772204; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011,Human papillomavirus type 6 E5B (gene: E5B),0.8999095837312036,In vitro,0.44,chick,Homo sapiens
CTIF,Malignant neoplasm of breast; Red Blood Cell Count measurement; Rheumatoid Arthritis; Schizophrenia; Parkinson Disease; Calcification of coronary artery,0.4084380369379369; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8772392350816924; 0.9377696084218796,Schizophrenia; Breast Cancer; Rheumatoid Arthritis,0.7860378120955526; 0.8903630091389316; 0.9251646147729308,"Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Spinocerebellar ataxia type 21 ORPHA:98773; NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; Monosomy 22q13.3 ORPHA:48652; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Bilateral perisylvian polymicrogyria ORPHA:98889; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome ORPHA:412069; Classic Hodgkin lymphoma, nodular sclerosis type ORPHA:98843; Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; Lethal congenital contracture syndrome type 3 ORPHA:137783; Synaptic congenital myasthenic syndromes ORPHA:98915; 19p13.3 microduplication syndrome ORPHA:447980; Congenital insensitivity to pain with severe intellectual disability ORPHA:453510; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Perry syndrome ORPHA:178509; Shprintzen-Goldberg syndrome ORPHA:2462; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Primary pigmented nodular adrenocortical disease ORPHA:189439; CLCN4-related X-linked intellectual disability syndrome ORPHA:485350; Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; Atrophoderma vermiculata ORPHA:79100; Congenital muscular dystrophy with integrin alpha-7 deficiency ORPHA:34520; Lethal osteosclerotic bone dysplasia ORPHA:1832; Distal hereditary motor neuropathy type 7 ORPHA:139589; Miller-Dieker syndrome ORPHA:531; Potocki-Shaffer syndrome ORPHA:52022",0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CYP2U1,"Lower limb hyperreflexia; Hypoplasia of corpus callosum; Toe-walking gait; Cognitive delay; Global developmental delay; Mental and motor retardation; Nerve Degeneration; Spastic Paraplegia; No development of motor milestones; Motor delay; Neurodegenerative Disorders; Spastic gait; Disorder of macula of retina; Gait, Unsteady; Ataxias, Hereditary; Henoch-Schoenlein Purpura; Intellectual Disability; Leukodystrophy; Spastic Paraplegia, Hereditary; Babinski Reflex",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8067197998685076; 0.8212681436603975; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8584283190330553; 0.9265708351135048; 0.9325666311629114; 0.9478210444156088; 0.954882372756482; 0.9561991866282916; 0.9672478180546946,Developmental Delay; Hypoplasia Of Corpus Callosum; Spastic Paraplegia; Motor Delay; Mental Retardation; Impaired Cognition; Peripheral Axonal Neuropathy,0.7765582368651238; 0.7949861636679444; 0.8182883735985873; 0.8210988731657684; 0.8337953215113012; 0.9231137872214272; 0.9259420053407031,Chondrodysplasia-disorder of sex development syndrome ORPHA:1422; Lafora disease ORPHA:501; Autosomal recessive spastic paraplegia type 56 ORPHA:320411,0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
CYTH3,Pregnancy Complications,0.8402911822757345,Heart Failure,0.9024492468099392,Cold-induced sweating syndrome ORPHA:157820; 19p13.3 microduplication syndrome ORPHA:447980; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Potocki-Shaffer syndrome ORPHA:52022,0.1068643725150898; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.8922466888454011,,,In vitro,0.59,Homo sapiens,chemical synthesis
DAZAP2,Multiple Myeloma,0.7880542567584415,,,Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Beta-propeller protein-associated neurodegeneration ORPHA:329284; CCDC115-CDG ORPHA:468684; Hermansky-Pudlak syndrome type 8 ORPHA:231537; TOR1AIP1-related limb-girdle muscular dystrophy ORPHA:424261; Variant ABeta2M amyloidosis ORPHA:314652; ABri amyloidosis ORPHA:97345; ADan amyloidosis ORPHA:97346; CEDNIK syndrome ORPHA:66631; Charcot-Marie-Tooth disease type 1C ORPHA:101083; Hereditary myopathy with lactic acidosis due to ISCU deficiency ORPHA:43115; Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency ORPHA:70592; Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies ORPHA:397758; Acatalasemia ORPHA:926; CLN2 disease ORPHA:228349; Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia ORPHA:284324; RNF13-related severe early-onset epileptic encephalopathy ORPHA:544503; X-linked centronuclear myopathy ORPHA:596; Methylmalonic acidemia with homocystinuria type cblF ORPHA:79284,0.0155394890951578; 0.0155394890951578; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
DDX17,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Colon Carcinoma; Malignant tumor of colon; Non-Small Cell Lung Carcinoma; Mammary Neoplasms; Monosomy; Colonic Neoplasms,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8212681436603975,,,Lymphangioleiomyomatosis ORPHA:538; Tuberous sclerosis complex ORPHA:805; Distal monosomy 1q ORPHA:36367; Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons ORPHA:401964; Dyschromatosis symmetrica hereditaria ORPHA:41; Deafness-enamel hypoplasia-nail defects syndrome ORPHA:3220; Huntington disease ORPHA:399; Isolated focal cortical dysplasia type IIb ORPHA:269008; Uveal melanoma ORPHA:39044; Adult hepatocellular carcinoma ORPHA:210159; Juvenile Huntington disease ORPHA:248111; NEK9-related lethal skeletal dysplasia ORPHA:464366; Nevus comedonicus syndrome ORPHA:64754; Gorlin syndrome ORPHA:377; B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome ORPHA:567502; Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome ORPHA:508542; Multiple endocrine neoplasia type 4 ORPHA:276152; Myhre syndrome ORPHA:2588; Rubinstein-Taybi syndrome due to EP300 haploinsufficiency ORPHA:353284; Sotos syndrome ORPHA:821; Systemic mastocytosis with associated hematologic neoplasm ORPHA:98849; 5q35 microduplication syndrome ORPHA:228415; Beckwith-Wiedemann syndrome due to NSD1 mutation ORPHA:238613; DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion ORPHA:268261; Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome ORPHA:404476; Gynandroblastoma ORPHA:99914; Intellectual disability syndrome due to a DYRK1A point mutation ORPHA:464311; Malignant Sertoli-Leydig cell tumor of the ovary ORPHA:99916; Pleuropulmonary blastoma familial tumor susceptibility syndrome ORPHA:284343; Short stature-pituitary and cerebellar defects-small sella turcica syndrome ORPHA:85442; Kabuki syndrome ORPHA:2322; Immunodeficiency due to MASP-2 deficiency ORPHA:331187; White-Sutton syndrome ORPHA:468678,0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Yaba-like disease virus 88L protein (gene: 88L); Monkeypox virus bifunctional ATPase/nucleoside triphosphate phosphohydrolase-I; Monkeypox virus Zaire-96-I-16 E11L (gene: E11L); Variola virus hypothetical protein (gene: N1L); Orf virus ORF069 early transcription factor VETFs; Cercopithecine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Variola virus RNA helicase NPH-II (gene: K8R); Yaba monkey tumor virus RNA helicase NPH-II; Vaccinia virus RNA helicase NPH-II (gene: I8R); Yaba monkey tumor virus 110R; Orf virus ORF095 DNA helicase; Cowpox virus CPXV087 protein (gene: CPXV087 CDS); Molluscum contagiosum virus subtype 1 MC050R; Molluscum contagiosum virus subtype 1 MC100R (gene: MC100L); Yaba-like disease virus 49R protein (gene: 49R); Vaccinia virus Ankara NTP-dependent RNA helicase, NPH-II; Orf virus ORF036 RNA helicase NPH-II",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,In vitro,0.44,Homo sapiens,Homo sapiens
DEAF1,"Adenocarcinoma; Colorectal Carcinoma; Serum cholesterol raised; Hypercholesterolemia; Colorectal Cancer; Nonverbal; Frontal bossing; Dyskinetic syndrome; Absent speech; Hoarseness; Corticospinal tract hypoplasia; Mental disorders; Abnormal behavior; Agitation; Aplasia/Hypoplasia of the corpus callosum; Hypertrophy of lower jaw; mandibular excess (physical finding); Mandibular hyperplasia; Conductive hearing loss; Increased size of the mandible; Recurrent infections; Horizontal eyebrow; Class III malocclusion; Tented mouth; Tented upper lip; Tented upper lip vermilion; Decreased corneal diameter; Feeding difficulties in infancy; Microcornea; Large face; Anteverted nostril; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Depression and Suicide; Cognitive delay; Delayed eruption of primary teeth; Serum triglycerides raised; Diabetes; Diabetes Mellitus; Hyperacusis; Hyperglycemia; Global developmental delay; Mental Retardation, Psychosocial; Mental and motor retardation; Sunken eyes; Acquired flat foot; Enophthalmos; Gait abnormality; Profound Mental Retardation; Self-harm; Self-Injurious Behavior; Flatfoot; Extrapyramidal sign; Taurodontism; Involuntary Movements; Large elongated pulp chamber; Autistic Disorder; Curvature of little finger; Poor eye contact; Clinodactyly of the 5th finger; Diabetes Mellitus, Insulin-Dependent; Smith-Magenis syndrome; Delayed speech and language development; Upward slant of palpebral fissure; PANIC DISORDER 1; Impaired pain sensation; Reduced fetal movement; Broad flat nasal bridge; Nasal bridge wide; Gastroesophageal reflux disease; Decreased tendon reflex; Speech Disorders; Panic Disorder; Strabismus; Speech impairment; Curvature of spine; Dilated ventricles (finding); Mental deficiency; Abnormal form of the vertebral bodies; Language Delay; Acquired scoliosis; Sleep disturbances; Generalized hypotonia; Failure to thrive in infancy; Speech Delay; Memory impairment; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Dull intelligence; Low intelligence; Mental Depression; Chronic ear infection; Synophrys; Syndactyly of the toes; Open mouth (finding); Short stature; Abnormality of cardiovascular system morphology; Orbital separation excessive; Chronic otitis media; Poor school performance; Acid reflux; Obesity; Neurodevelopmental Disorders; Stereotyped Behavior; Thick lower lip vermilion; Full lower lip; Mood Disorders; Congenital Heart Defects; Depressive disorder; Muscle hypotonia; Short philtrum; Status Epilepticus; Anxiety disease; Heartburn; Mental Retardation; Stereotypic Movement Disorder; Broad forehead; Mood swings; Small nose; Short nose; Physical aggression; Aggressive reaction; Unipolar Depression; Aggressive behavior; Anxiety Disorders; Intellectual Disability; Myopia; Wide skull shape; Broad cranium shape; Brachycephaly; Epilepsy; Electroencephalogram abnormal; Major Depressive Disorder; Anxiety; Attention deficit hyperactivity disorder; Dyschezia; Brachydactyly; Constipation; Genetic Diseases, Inborn",0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8212681436603975; 0.8213459222602666; 0.8232134984476662; 0.8368219249856942; 0.8391186563955684; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.843190898187174; 0.8474481237156937; 0.8474481237156937; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8769418330148872; 0.8774809019744603; 0.8806784681730055; 0.8806784681730055; 0.8815127642200768; 0.882453254162044; 0.8851456306720444; 0.8867509400747969; 0.8913141512402477; 0.8962930275917275; 0.8989612563669234; 0.9015731019095328; 0.9039108388826153; 0.9039108388826153; 0.9039108388826153; 0.9093740881835894; 0.9098977259629772; 0.9103315000053974; 0.9124568647908072; 0.9146732238562176; 0.914995991166204; 0.9154499654632742; 0.9214835359141188; 0.922229272318747; 0.9258401930327972; 0.929814249105729; 0.9366917377729386; 0.937361082398064; 0.9390727893210336; 0.9432051631882106; 0.9446671211493156; 0.9455834988784428; 0.9459312971127588; 0.946564927793026; 0.9478210444156088; 0.9506863447189738; 0.9534337109847604; 0.9534337109847604; 0.957487573707278; 0.963331724428282; 0.9646935500290964; 0.9658628445524134; 0.9708740267329932; 0.9770263358372888; 0.9822381479823692; 0.9896536639644284; 0.9896536639644284; 0.9926099929361648,Non-Syndromic Intellectual Disability; Stereotyped Behavior; Dyskinetic Syndrome; Smith-Magenis Syndrome; Pica; Repetitive Compulsive Behavior; Retinal Detachment; Developmental Delay; Macrocephaly; Microcornea; Precocious Puberty; Hypercholesterolemia; Otitis Media; Frontal Bossing; Malocclusion; Hearing Loss; Dyssomnia; Mental Retardation; Developmental Dysplasia Of The Hip; Taurodontism; Anxiety Disorder; Sleep Disorders; Autism Spectrum Disorder; Hypothyroidism; Microcephaly; Mental Depression; Strabismus; Speech Disorders; Mood Swings; Autism; Scoliosis; Micrognathism; Camptodactyly Of Fingers; Dwarfism; Status Epilepticus; Developmental Regression; Synophrys; Dysmorphic Features; Attention Deficit Hyperactivity Disorder; Myopia; Obesity; Brachycephaly; Gastroesophageal Reflux Disease; Syndactyly Of The Toes; Brachydactyly,0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8201196687803188; 0.8337953215113012; 0.8356859041719433; 0.8457525389282121; 0.8507213163251659; 0.8601151608808731; 0.8662301945830305; 0.8879896755141929; 0.8903630091389316; 0.8903630091389316; 0.8908485337686392; 0.9069867032339078; 0.9069867032339078; 0.911896615143974; 0.924275664330454; 0.9398381935810408; 0.943322675973118; 0.9510372690456612; 0.9543024119762946; 0.9658957825498884; 0.9658957825498884; 0.9726139569926774; 0.980894832851993; 0.9832345076528324; 0.9832345076528324; 0.986561188259959; 0.9870402800551054; 0.9870402800551054; 0.9887104428514284,PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Smith-Magenis syndrome ORPHA:819; Intellectual disability-epilepsy-extrapyramidal syndrome ORPHA:468620; Autosomal dominant non-syndromic intellectual disability ORPHA:178469; MPI-CDG ORPHA:79319,0.0155394890951578; 0.1117946631214258; 0.3832844616405875; 0.7929682744768703; 0.8922466888454011,,,,,,
DEGS1,Osteopetrosis; Esophageal carcinoma; Malignant neoplasm of prostate; Neoplasm Metastasis; Prostatic Neoplasms; Diabetes; Diabetes Mellitus; Polyneuropathy; Obesity,0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8989612563669234,Spastic Quadriplegia; Prostate Cancer; Prostatic Neoplasms; Nystagmus; Developmental Delay; Leukodystrophy; Brainstem Atrophy; Cerebellar Atrophy; Scoliosis; Dysarthria,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.924275664330454; 0.988987376043163,,,,,,,,
DEPDC7,"Liver Cirrhosis, Experimental; Mental Depression; Parkinson Disease; Depressive Symptoms; Depressive disorder",0.8014900279306119; 0.8769418330148872; 0.8772392350816924; 0.905201167721829; 0.9103315000053974,,,GNE myopathy ORPHA:602; Sialuria ORPHA:3166; Glutaric acidemia type 3 ORPHA:35706,0.3832844616405875; 0.3832844616405875; 0.8922466888454011,,,,,,
DGAT1,"Serum cholesterol raised; Hypercholesterolemia; Malignant neoplasm of prostate; Prostate carcinoma; Diarrhea; Arteriosclerosis; Atherosclerosis; Hepatitis C; Diarrheal disorder; Sore to touch; Kidney Failure, Chronic; Decreased albumin; Diabetes Mellitus, Non-Insulin-Dependent; Nephrotic Syndrome; Vomiting; Steatohepatitis; Hypoalbuminemia; Alopecia; Fatty Liver; Heart failure; Congestive heart failure; Obesity; Metabolic Diseases; Hyperlipidemia",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8098851543361193; 0.8190761496232595; 0.8232134984476662; 0.8270909867833504; 0.8402911822757345; 0.8402911822757345; 0.8523465762428218; 0.8628363180844141; 0.8867509400747969; 0.8976039441125321; 0.8989612563669234; 0.9564633032157428; 0.9676817033456722,Protein-losing Enteropathy; Hypercholesterolemia; Hyperlipidemia; Hypoalbuminemia,0.7765582368651238; 0.8115918568696846; 0.861756360478846; 0.8903630091389316,Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; D-2-hydroxyglutaric aciduria ORPHA:79315; Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; D-glyceric aciduria ORPHA:941; 5-oxoprolinase deficiency ORPHA:33572; Embryonal rhabdomyosarcoma ORPHA:99757; Familial renal glucosuria ORPHA:69076,0.1040670578681756; 0.1054066549396977; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,In vitro,0.63,Homo sapiens,Homo sapiens
DHRS3,"Thyroid Neoplasm; Neoplasm Metastasis; Neuroblastoma; Central neuroblastoma; ADULT SYNDROME; Rudiger syndrome 1; Liver Cirrhosis, Experimental; Craniosynostosis; Papillary thyroid carcinoma; Obesity",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8486035047899471; 0.8757755363384367; 0.8989612563669234,,,"46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency ORPHA:752; HELLP syndrome ORPHA:244242; Atypical hemolytic uremic syndrome with complement gene abnormality ORPHA:544472",0.3832844616405875; 0.8922466888454011; 0.8922466888454011,Ectromelia virus ERPV hydroxysteroid dehydrogenase; Cowpox virus CPXV182 protein (gene: CPXV182 CDS); Vaccinia virus hydroxysteroid dehydrogenase (gene: A44L); Horsepox virus HSPV166 (Rossmann-fold NAD(P)(+)-binding proteins); Vaccinia virus Ankara 3 beta-hydroxysteroid dehydrogenase; Molluscum contagiosum virus subtype 1 MC152R (gene: MC152R); Yaba-like disease virus 133L protein (gene: 133L); Monkeypox virus bifunctional hydroxysteroid dehydrogenase/deletion attenuates intradermal lesion in VAC-mouse model; Monkeypox virus Zaire-96-I-16 A45L (gene: A45L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
DHRS9,"Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; androgen independent prostate cancer; Malignant neoplasm of prostate; Prostate carcinoma; Prostatic Diseases; Glaucoma; Alcoholic Intoxication, Chronic; Infection; Epilepsy",0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8272008757995397; 0.963331724428282,,,"Thrombomodulin-related bleeding disorder ORPHA:436169; Metaphyseal anadysplasia ORPHA:1040; Exfoliative ichthyosis ORPHA:289586; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319581; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319569; Cryptogenic multifocal ulcerous stenosing enteritis ORPHA:468635; Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder ORPHA:477787; Haim-Munk syndrome ORPHA:2342; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency ORPHA:99898; Papillon-Lefevre ORPHA:678; Sterile multifocal osteomyelitis with periostitis and pustulosis ORPHA:210115; GM2 gangliosidosis, AB variant ORPHA:309246; Osteopetrosis with renal tubular acidosis ORPHA:2785; Acral peeling skin syndrome ORPHA:263534",0.1040670578681756; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Ectromelia virus ERPV hydroxysteroid dehydrogenase; Cowpox virus CPXV182 protein (gene: CPXV182 CDS); Vaccinia virus hydroxysteroid dehydrogenase (gene: A44L); Horsepox virus HSPV166 (Rossmann-fold NAD(P)(+)-binding proteins); Vaccinia virus Ankara 3 beta-hydroxysteroid dehydrogenase; Molluscum contagiosum virus subtype 1 MC152R (gene: MC152R); Yaba-like disease virus 133L protein (gene: 133L); Monkeypox virus bifunctional hydroxysteroid dehydrogenase/deletion attenuates intradermal lesion in VAC-mouse model; Monkeypox virus Zaire-96-I-16 A45L (gene: A45L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
DIDO1,Colorectal Carcinoma; MYELODYSPLASTIC SYNDROME; Myelodysplastic-Myeloproliferative Diseases; Colorectal Cancer; melanoma; Adenoma of large intestine; Myocardial Infarction,0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649,Myocardial Infarction; Esophagus Neoplasm,0.861756360478846; 0.9832345076528324,"X-linked intellectual disability, Siderius type ORPHA:85287; CAMOS syndrome ORPHA:83472; Precursor T-cell acute lymphoblastic leukemia ORPHA:99861; Dyschromatosis symmetrica hereditaria ORPHA:41; Oculofaciocardiodental syndrome ORPHA:2712; QRICH1-related intellectual disability-chondrodysplasia syndrome ORPHA:580940; Chronic myelomonocytic leukemia ORPHA:98823; Adult hepatocellular carcinoma ORPHA:210159; 15q24 microdeletion syndrome ORPHA:94065; Autosomal dominant Charcot-Marie-Tooth disease type 2Z ORPHA:466768; Floating-Harbor syndrome ORPHA:2044; Pancreatic agenesis-holoprosencephaly syndrome ORPHA:556955; SIN3A-related intellectual disability syndrome due to a point mutation ORPHA:500166; Spondylocarpotarsal synostosis ORPHA:3275; Juvenile amyotrophic lateral sclerosis ORPHA:300605; Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder ORPHA:500180; Kleefstra syndrome due to 9q34 microdeletion ORPHA:96147; Microcephalic osteodysplastic primordial dwarfism type II ORPHA:2637; Perlman syndrome ORPHA:2849; Systemic mastocytosis with associated hematologic neoplasm ORPHA:98849; ADNP syndrome ORPHA:404448; Blepharophimosis-intellectual disability syndrome, MKB type ORPHA:293707; FG syndrome type 1 ORPHA:93932; Short stature-pituitary and cerebellar defects-small sella turcica syndrome ORPHA:85442; Kabuki syndrome ORPHA:2322",0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human papillomavirus 122 transforming protein E7 (gene: E7); Human papillomavirus 111 E7 protein (gene: E7); Human papillomavirus 94 E2 protein (gene: E2); Human papillomavirus 113 E7 protein (gene: E7); Vaccinia virus Ankara soluble TNF receptor II precursor f1; Human gammaherpesvirus 8 K4.1 (gene: K4.1); Human mastadenovirus D membrane glycoprotein E3 gp19K (gene: E3); Human adenovirus 56 19K protein (gene: E3); Orf virus ORF020 dsRNA-binding PKR inhibitor; Human papillomavirus type 27 early protein (gene: E2); Variola virus semaphorin-like protein (gene: A44R); Variola virus hypothetical protein (gene: J7R); Human papillomavirus type XS2 E2 (gene: E2); Banna virus strain JKT-6423 vp12; Human papillomavirus type 72b E2 protein (gene: E2); Monkeypox virus secreted epidermal growth factor-like protein; Monkeypox virus Zaire-96-I-16 epidermal growth factor-like protein (EGF-like protein) (gene: D3R); Human papillomavirus type 78 regulatory protein E2 (gene: E2); Vaccinia virus Ankara vaccinia virus growth factor (VGF); Human betaherpesvirus 5 chemokine vCXCL1 (gene: UL146); Human papillomavirus 3 envelope protein (gene: E2); Kyasanur Forest disease virus NS2B; Human betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Variola virus epidermal growth factor-like protein (EGF-like protein) (gene: D1L); Hepatitis C virus genotype 3 E1 protein; Human papillomavirus type 62 putative regulatory protein E2 (gene: E2); Hepatitis C virus genotype 4 E1 protein; Vaccinia virus epidermal growth factor-like protein (EGF-like protein) (gene: C11R); Monkeypox virus bifunctional DNA-dependent RNA polymerase subunit rpo30/intermediate-gene transcription factor VITF1; Monkeypox virus Zaire-96-I-16 RNA polymerase subunit (gene: F4L); Horsepox virus HSPV016 (Epidermal growth factor-like protein; Provisional); Vaccinia virus semaphorin-like protein; Vaccinia virus Ankara Semaphorin-like protein f2; Human papillomavirus type 68a E2 protein; Human papillomavirus type 34 early protein (gene: E2); Adult diarrheal rotavirus strain J19 NSP1; Norovirus Hu/GII/BG1C0282/2011/BGD protein p48 (gene: POL); Human papillomavirus 117 E2; Human group 1 coronavirus associated with pneumonia ORF 1a; Human betaherpesvirus 5 deoxyuridine triphosphatase (gene: UL72); Norovirus Hu/Norwalk/10313/2010/VNM protein p48 (gene: POL); Norovirus Hu/Norwalk/10378/2010/VNM protein p48 (gene: POL); Norovirus Hu/GII/20469/2010/VNM protein p48 (gene: POL); Human papillomavirus type 53 early protein (gene: E2); Norovirus Hu/GII.4/NIHIC17.9/2013/USA protein p48 (gene: POL); Norovirus Hu/Norwalk/10328/2010/VNM protein p48 (gene: POL); Human papillomavirus type 68b E2 protein (gene: E2); Yaba monkey tumor virus RNA polymerase subunit; Enterovirus B genome polyportein; Enterovirus B73 full_polyprotein 1..2188; Cercopithecine betaherpesvirus 5 chemokine vCXCL7 (gene: UL146D); Human papillomavirus type 87 putative E2 protein (gene: e2); Enterovirus B106 full_polyprotein 1..2192; Human papillomavirus type 102 E2 protein; Human betacoronavirus 2c Jordan-N3/2012 ORF4a protein (gene: ORF4a); Human papillomavirus type 30 early protein (gene: E2); Echovirus E5 full_polyprotein 1..2196; Human papillomavirus type 68 E2 (gene: E2); Echovirus E9 full_polyprotein 1..2203; Human betacoronavirus 2c England-Qatar/2012 ORF4a; Betacoronavirus England 1 NS3B protein (gene: ns3b); Human papillomavirus type 84 putative regulatory protein E2 (gene: E2); Human papillomavirus type 10 envelope protein (gene: E2); Human papillomavirus type 114 E2 protein (gene: E2); Human papillomavirus 15 early protein (gene: E2); Human betacoronavirus 2c EMC/2012 ORF4a (gene: orf4a); Middle East respiratory syndrome-related coronavirus NS4A protein (gene: orf4a); Monkeypox virus double-stranded RNA binding protein; Monkeypox virus Zaire-96-I-16 double-strand RNA-binding protein (gene: F3L); Coxsackievirus A20 full_polyprotein 1..2208; Human poliovirus 3 polyprotein; Human poliovirus 1 enterovirus precursor polypeptide; Coxsackievirus B4 full_polyprotein 1..2183; Coxsackievirus B2 full_polyprotein 1..2187,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9018002218631122; 0.903486026792944; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9359472799230178; 0.9366403811337995,In vitro,0.44,chemical synthesis,Homo sapiens
DIS3L,Medulloblastoma,0.8548862007194026,,,Succinic semialdehyde dehydrogenase deficiency ORPHA:22; Classic maple syrup urine disease ORPHA:268145; Intermittent maple syrup urine disease ORPHA:268173; Thiamine-responsive maple syrup urine disease ORPHA:268184; Intermediate maple syrup urine disease ORPHA:268162,0.1991445465001551; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
DISP2,"Lung Diseases, Interstitial",0.969655257819091,Lung Diseases,0.8903630091389316,"Benign paroxysmal torticollis of infancy ORPHA:71518; Cerebellar ataxia, Cayman type ORPHA:94122; Familial paroxysmal ataxia ORPHA:97; GNB5-related intellectual disability-cardiac arrhythmia syndrome ORPHA:542306; NON RARE IN EUROPE: Non rare obesity ORPHA:521399; Spinocerebellar ataxia type 6 ORPHA:98758; Autosomal dominant nocturnal frontal lobe epilepsy ORPHA:98784",0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
DIXDC1,"Carcinogenesis; Colon Carcinoma; Malignant tumor of colon; Malignant neoplasm of lung; Liver carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Abnormal behavior; Manic Disorder; Manic; Depression, Bipolar; Autistic Disorder; Adenocarcinoma of large intestine; Schizophrenia; Anxiety States, Neurotic; Depression, Neurotic; Melancholia; Depressive Syndrome; Sporadic Breast Carcinoma; Endogenous depression; Anxiety neurosis (finding); Mental Depression; Bipolar Disorder; Depressive disorder; Unipolar Depression; Anxiety Disorders",0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8523465762428218; 0.8610447277138289; 0.8769418330148872; 0.900167961295542; 0.9103315000053974; 0.9455834988784428; 0.946564927793026,Manic Disorder; Schizophrenia; Anxiety Disorder; Melancholia; Mental Depression; Autism; Bipolar Disorder,0.7765582368651238; 0.7860378120955526; 0.8507213163251659; 0.861756360478846; 0.8903630091389316; 0.911896615143974; 0.943322675973118,"Persistent hyperplastic primary vitreous ORPHA:91495; Primary pigmented nodular adrenocortical disease ORPHA:189439; 1p31p32 microdeletion syndrome ORPHA:401986; Autosomal dominant Charcot-Marie-Tooth disease type 2A1 ORPHA:99946; Autosomal recessive spastic paraplegia type 67 ORPHA:401820; Atrial septal defect, ostium primum type ORPHA:99106; Autosomal dominant striatal neurodegeneration ORPHA:228169; Infantile-onset ascending hereditary spastic paralysis ORPHA:293168; Cenani-Lenz syndrome ORPHA:3258; Short rib-polydactyly syndrome, Majewski type ORPHA:93269; Inherited congenital spastic tetraplegia ORPHA:210141; Male infertility due to globozoospermia ORPHA:171709; Bilateral striopallidodentate calcinosis ORPHA:1980; Jeune syndrome ORPHA:474; 15q14 microdeletion syndrome ORPHA:261190; Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Anterior maxillary protrusion-strabismus-intellectual disability syndrome ORPHA:562559; Distal monosomy 12p ORPHA:280325; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; Short rib-polydactyly syndrome, Saldino-Noonan type ORPHA:93270; Congenital ptosis ORPHA:91411; Isolated brachycephaly ORPHA:35099; Isolated plagiocephaly ORPHA:35098; Short rib-polydactyly syndrome, Verma-Naumoff type ORPHA:93271; Hereditary hyperekplexia ORPHA:3197; Joubert syndrome with oculorenal defect ORPHA:2318; Bardet-Biedl syndrome ORPHA:110; Joubert syndrome with renal defect ORPHA:220497; Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome ORPHA:1154; BVES-related limb-girdle muscular dystrophy ORPHA:476084; Becker muscular dystrophy ORPHA:98895; Gordon syndrome ORPHA:376; Lissencephaly syndrome, Norman-Roberts type ORPHA:89844; Marden-Walker syndrome ORPHA:2461; Spinocerebellar ataxia type 27 ORPHA:98764; Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome ORPHA:93358; Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers ORPHA:206546; Hereditary mixed polyposis syndrome ORPHA:157794; Juvenile primary lateral sclerosis ORPHA:247604; Severe early-childhood-onset retinal dystrophy ORPHA:364055; Stargardt disease ORPHA:827",0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8105918570729571; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
DOCK4,"Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Osteosarcoma; Osteosarcoma of bone; Neoplasm Metastasis; C-reactive protein measurement; Neuroblastoma; Central neuroblastoma; response to fenofibrate; Pancytopenia; Dyslexia; Autistic Disorder; Schizophrenia; Adenocarcinoma of lung (disorder)",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193,Schizophrenia; Mental Depression; Autism; Diabetes Mellitus; Bipolar Disorder,0.7860378120955526; 0.8903630091389316; 0.911896615143974; 0.919442421650838; 0.943322675973118,Acromelic frontonasal dysplasia ORPHA:1827; Primary pigmented nodular adrenocortical disease ORPHA:189439; Autosomal dominant Charcot-Marie-Tooth disease type 2A1 ORPHA:99946; Charcot-Marie-Tooth disease type 4H ORPHA:99954; Polyendocrine-polyneuropathy syndrome ORPHA:453533; Tangier disease ORPHA:31150; Autosomal dominant intermediate Charcot-Marie-Tooth disease type F ORPHA:352670; Young-onset Parkinson disease ORPHA:2828; Charcot-Marie-Tooth disease type 4B2 ORPHA:99956; Episodic ataxia type 6 ORPHA:209967; Familial lipoprotein lipase deficiency ORPHA:309015,0.1040670578681756; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus nef protein (gene: nef); Human immunodeficiency virus 1 Nef (gene: nef); Human alphaherpesvirus 2 envelope glycoprotein E (gene: US8),0.8999095837312036; 0.8999095837312036; 0.9450424991150602,,,,
DRAP1,melanoma,0.7880542567584415,Melanoma,0.7765582368651238,"Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Focal dermal hypoplasia ORPHA:2092; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; CADDS ORPHA:369942; Autosomal recessive cerebellar ataxia due to STUB1 deficiency ORPHA:412057; Class I glucose-6-phosphate dehydrogenase deficiency ORPHA:466026; Familial hypocalciuric hypercalcemia type 3 ORPHA:101050; Hyperbiliverdinemia ORPHA:276405; NON RARE IN EUROPE: Glucose-6-phosphate-dehydrogenase deficiency ORPHA:362; Spondylometaphyseal dysplasia, Sedaghatian type ORPHA:93317; Acromegaly ORPHA:963; X-linked Emery-Dreifuss muscular dystrophy ORPHA:98863",0.0144185025972157; 0.0144185025972157; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,,,,,,
DUSP14,Monocyte count procedure; Monocyte count result; melanoma; Encephalomyelitis; Tuberculosis,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8368219249856942,,,Cold-induced sweating syndrome ORPHA:157820; Microcephaly-congenital cataract-psoriasiform dermatitis syndrome ORPHA:488168; Hutchinson-Gilford progeria syndrome ORPHA:740; Restrictive dermopathy ORPHA:1662,0.1068643725150898; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Orf virus ORF057 putative protein-tyrosine phosphatase; Molluscum contagiosum virus subtype 1 MC082L (gene: MC082L),0.8999095837312036; 0.8999095837312036,,,,
DYRK1B,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Colon Carcinoma; Malignant tumor of colon; Serum cholesterol raised; Non-Small Cell Lung Carcinoma; Hypercholesterolemia; Pancreatic Ductal Adenocarcinoma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Osteosarcoma; Rhabdomyosarcoma; Osteosarcoma of bone; Prostate carcinoma; Primary malignant neoplasm of lung; Carcinoma of lung; Adenocarcinoma of pancreas; Increase in blood pressure; Solid Neoplasm; Metastatic melanoma; ovarian neoplasm; Hereditary hemochromatosis; Obesity, Abdominal; Hypertensive disease; Metabolic Syndrome X",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7940665326856218; 0.8067197998685076; 0.8138488881521341; 0.8368219249856942; 0.8474481237156937; 0.8610447277138289,Ovarian Neoplasm; Coronary Stenosis; Hypertension; Ovarian Cancer; Hypercholesterolemia; Myocardial Infarction; Metastatic Melanoma,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.8115918568696846; 0.861756360478846; 0.8903301324869451,Autosomal dominant centronuclear myopathy ORPHA:169189; Familial lipase maturation factor 1 deficiency ORPHA:535453; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; Arnold-Chiari malformation type II ORPHA:1136; Telethonin-related  limb-girdle muscular dystrophy R7 ORPHA:34514,0.0036432528126817; 0.0155394890951578; 0.0155394890951578; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Vaccinia virus Ser/Thr kinase (gene: F10L); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Yaba monkey tumor virus ankyrin repeat protein; Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Yaba-like disease virus 11L protein (gene: 11L); Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Orf virus ORF020 dsRNA-binding PKR inhibitor; Banna virus strain JKT-6423 vp12; Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Yaba monkey tumor virus 142R; Adult diarrheal rotavirus strain J19 NSP1; Human immunodeficiency virus 1 integrase (gene: gag-pol); Monkeypox virus ankyrin-like protein; Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Yaba monkey tumor virus ankyrin-like protein; Yaba monkey tumor virus double-strand RNA-binding protein",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764,,,,
EBAG9,Malignant neoplasm of breast; Bladder Neoplasm; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Endometrial Neoplasms; Pancreatic Neoplasm; Cholangitis; Endometrial Carcinoma; Mammary Neoplasms; Glioma; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Liver carcinoma; Invasive carcinoma of breast; Epithelial ovarian cancer; Tumor Promotion; Prostate carcinoma; Neoplasm Metastasis; Prostatic Neoplasms; Carcinoma of lung; Mesothelioma; Ductal Carcinoma; Eclampsia; Gall Bladder Diseases; Malignant neoplasm of stomach; Hodgkin Disease; Tumor Progression; Renal Cell Carcinoma; Stomach Carcinoma; Squamous cell carcinoma; Rheumatoid Arthritis; Diabetes Mellitus; Intrahepatic Cholangiocarcinoma; Pre-Eclampsia; ovarian neoplasm; Graft-vs-Host Disease; Extrahepatic Cholangiocarcinoma; Endometrial adenocarcinoma; Primary biliary cirrhosis; Gastric Adenocarcinoma; Epstein-Barr Virus Infections; Cholangiocarcinoma; Anemia; Anaplasia; Endometriosis,0.4084380369379369; 0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8584283190330553; 0.8648405521677974; 0.960644037248553,,,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency ORPHA:308425; 3-methylglutaconic aciduria type 1 ORPHA:67046; Dilated cardiomyopathy with ataxia ORPHA:66634,0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.44,chemical synthesis,Homo sapiens
ECI2,"leukemia; MYELODYSPLASTIC SYNDROME; Myeloid Leukemia; Paroxysmal nocturnal hemoglobinuria; Diabetes, Autoimmune; Acquired aplastic anemia; Aplastic Anemia",0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8402911822757345; 0.9710463782716944,,,Beta-ketothiolase deficiency ORPHA:134; Guanidinoacetate methyltransferase deficiency ORPHA:382,0.8922466888454011; 0.8922466888454011,,,,,,
EHD1,"melanoma; Multiple Sclerosis; Autistic Disorder; Schizophrenia; Diabetes Mellitus, Non-Insulin-Dependent; Obesity; Cardiomyopathies",0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8989612563669234; 0.9557184806547836,,,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Incontinentia pigmenti ORPHA:464; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Intermediate osteopetrosis ORPHA:210110; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Camurati-Engelmann disease ORPHA:1328; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; Infantile inflammatory bowel disease with neurological involvement ORPHA:565788; MYH9-related disease ORPHA:182050; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204; Ependymoma ORPHA:251636; RELA fusion-positive ependymoma ORPHA:530792; Autosomal recessive spastic paraplegia type 48 ORPHA:306511; Combined immunodeficiency due to ORAI1 deficiency ORPHA:317428; Becker nevus syndrome ORPHA:64755; Developmental malformations-deafness-dystonia syndrome ORPHA:79107,0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703,,,,,,
EIF1AY,Immune System Diseases; Azoospermia,0.8402911822757345; 0.8648405521677974,,,"45,X/46,XY mixed gonadal dysgenesis ORPHA:1772; Partial chromosome Y deletion ORPHA:1646",0.8922466888454011; 0.8922466888454011,,,,,,
EIF4A3,"Reticulocyte count (procedure); Cervix carcinoma; Pancreatic Neoplasm; Liver carcinoma; Hyperplasia of nose; Hypertrophy of nose; Large nose; Malignant neoplasm of stomach; Congenital hypoplasia; Protruding ear; Stomach Carcinoma; Prominent ear; Cognitive delay; Limb Deformities, Congenital; Global developmental delay; Mental and motor retardation; Abnormality of the voice; Microretrognathia; Proximal placement of thumb; Curvature of little finger; Clinodactyly of the 5th finger; Stomach Neoplasms; Radial ray hypoplasia; Congenital hypoplasia of radius; Pierre Robin Syndrome; Limb defects; Feeding difficulties; Congenital Abnormality; Hypoplasia of thumb; Short phalanx of finger; Cleft uvula; Microstomia; Low set ears; Short metacarpal; Short stature; Byzanthine arch palate; Intellectual Disability; Congenital clubfoot",0.5071083164302358; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8554819098734854; 0.8700543109506378; 0.8774809019744603; 0.8815127642200768; 0.9119978323790848; 0.9478210444156088; 0.951016614400691,Congenital Hypoplasia Of Radius; Developmental Delay; Pierre-Robin Syndrome; Mesomelia; Mental Retardation; Hypoplasia Of Thumb; Microtia; Camptodactyly Of Fingers; Dwarfism; Microstomia; High Palate; Congenital Clubfoot,0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.861756360478846; 0.8974842552599366; 0.943322675973118; 0.9510372690456612; 0.9543024119762946; 0.9578111936867284; 0.9832345076528324,"Amish lethal microcephaly ORPHA:99742; Pontocerebellar hypoplasia type 10 ORPHA:411493; Progressive polyneuropathy with bilateral striatal necrosis ORPHA:217396; Purine nucleoside phosphorylase deficiency ORPHA:760; Richieri Costa-Pereira syndrome ORPHA:3102; Pontocerebellar hypoplasia type 2 ORPHA:2524; Dyskeratosis congenita ORPHA:1775; Cerebrocostomandibular syndrome ORPHA:1393; Fabry disease ORPHA:324; Mandibulofacial dysostosis-microcephaly syndrome ORPHA:79113; Congenital dyserythropoietic anemia type II ORPHA:98873; Glycogen storage disease due to phosphoglycerate kinase 1 deficiency ORPHA:713; Spondyloepimetaphyseal dysplasia, Genevieve type ORPHA:168454; Treacher-Collins syndrome ORPHA:861",0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Yaba-like disease virus 142R protein (gene: 142R); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Cowpox virus CPXV123 protein (gene: CPXV123 CDS); Yaba-like disease virus 88L protein (gene: 88L); Monkeypox virus early gene transcription factor VETF 70 kDa small subunit; Monkeypox virus Zaire-96-I-16 E6R (gene: E6R); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Dengue virus 3 nonstructural protein NS3 (gene: flavivirus polyprotein); Monkeypox virus bifunctional ATPase/nucleoside triphosphate phosphohydrolase-I; Monkeypox virus Zaire-96-I-16 E11L (gene: E11L); Variola virus hypothetical protein (gene: B1R); Vaccinia virus Ankara serine/threonine-protein kinase-like; Variola virus hypothetical protein (gene: N1L); Orf virus ORF069 early transcription factor VETFs; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Human betaherpesvirus 7 DNA replication origin-binding helicase (gene: U73); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Human adenovirus 21a 100 kDa hexon-assembly associated protein (gene: L4); Macacine alphaherpesvirus 1 DNA replication origin-binding helicase (gene: UL9); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Monkeypox virus ser/thr protein kinase-like protein; Human adenovirus 68 100 kDa hexon assembly-associated protein (gene: L4); Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Human mastadenovirus B hexon assembly protein 100K (gene: L4); Human adenovirus B3 L4 100-kDa protein (gene: L4); GB virus C (Pegivirus C, HPgV) NS3 proteinase/ATPase/helicase; Yaba monkey tumor virus 142R; Monkeypox virus Zaire-96-I-16 B11R (gene: B11R); Cercopithecine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Variola virus RNA helicase NPH-II (gene: K8R); Yaba monkey tumor virus RNA helicase NPH-II; Vaccinia virus RNA helicase NPH-II (gene: I8R); Yaba monkey tumor virus 110R; Orf virus ORF095 DNA helicase; Horsepox virus HSPV112 (DEAD-like helicases superfamily); Cowpox virus CPXV087 protein (gene: CPXV087 CDS); Human adenovirus 7 100K; Variola virus hypothetical protein (gene: A18R); Molluscum contagiosum virus subtype 1 MC050R; Molluscum contagiosum virus subtype 1 MC100R (gene: MC100L); Yaba-like disease virus 49R protein (gene: 49R); Human betaherpesvirus 6 U73, origin binding protein (gene: U73); Human betaherpesvirus 6A DNA replication origin-binding helicase (gene: U73); Dengue virus 1 nonstructural protein NS3 (gene: flavivirus polyprotein); Monkeypox virus Zaire-96-I-16 A19R (gene: A19R); Variola virus hypothetical protein (gene: F6R); Horsepox virus HSPV189 (Serine/threonine protein kinase); Human alphaherpesvirus 3 DNA replication origin-binding helicase (gene: ORF51); Vaccinia virus Ankara NTP-dependent RNA helicase, NPH-II; Vaccinia virus Ankara transcription termination factor; Vaccinia virus 70kDa small subunit of early gene transcription factor VETF (gene: D6R); Orf virus ORF072 transcription termination factor NPH-I; Yaba monkey tumor virus 88L; Ectromelia virus ERPV viral early transcription factor small subunit; Papiine alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Vaccinia virus Ankara Early transcription factor 70 kDa subunit; Vaccinia virus DNA helicase (gene: A18R); Vaccinia virus Ankara early gene termination factor/Nucleoside triphosphatase I; Horsepox virus HSPV117; Monkeypox virus DNA helicase; Yaba monkey tumor virus 84R; Ectromelia virus ERPV DNA helicase; Orf virus ORF130 putative serine/threonine protein kinase; Orf virus ORF036 RNA helicase NPH-II; Cowpox virus CPXV128 protein (gene: CPXV128 CDS); Vaccinia virus ATPase, nucleoside triphosphate phosphohydrolase-I, NPH-I (gene: D11L); Molluscum contagiosum virus subtype 1 MC095R (gene: MC095R); Vaccinia virus ser/thr protein kinase-like protein (gene: B12R); Human betaherpesvirus 6B origin binding protein (gene: U73); Yaba-like disease virus 110R protein (gene: 110R); Molluscum contagiosum virus subtype 1 MC123R (gene: MC123R); Cowpox virus CPXV151 protein (gene: CPXV151 CDS); Human alphaherpesvirus 1 DNA replication origin-binding helicase (gene: UL9); Ectromelia virus ERPV helicase NPH-I; Horsepox virus HSPV139 (DEAD-like helicases superfamily); Human alphaherpesvirus 2 DNA replication origin-binding helicase (gene: UL9); Human herpesvirus 3 strain Dumas helicase; Hepatitis C virus subtype 2k/1b full_polyprotein 1..3010; Monkeypox virus bifunctional DNA/RNA-helicase/DExH-NPH-II; Monkeypox virus Zaire-96-I-16 RNA helicase NPH-II (gene: I8R); Horsepox virus HSPV078 (RNA helicase NPH-II); Ectromelia virus ERPV RNA helicase",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764,,,,
EMG1,Fatty acid measurement; Hyperplasia of nose; Hypertrophy of nose; Large nose; Nephroblastoma; Sloping forehead; Ewings sarcoma; Abnormal joint morphology; Feeding difficulties in infancy; Neural Tube Defects; Curvature of little finger; Severe postnatal growth retardation; Clinodactyly of the 5th finger; HIV Infections; Scleroderma; Small for gestational age (disorder); Low Birth Weights; Systemic Scleroderma; Vertical Talus; Cryptorchidism; HIV Coinfection; Flexion contracture of proximal interphalangeal joint; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Joint stiffness; Micrognathism; Severe global developmental delay; Amyloidosis; Arthropathy; Short stature; Severe psychomotor retardation; Death in infancy; Death in early childhood; Small head,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8145035474981049; 0.8212681436603975; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8578473133580928; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8672189956534445; 0.8769418330148872; 0.8815127642200768; 0.8815127642200768; 0.9390727893210336; 0.9393256300017014; 0.9822381479823692,Oral Cleft; Vertical Talus; Cryptorchidism; Microcephaly; Micrognathism; Camptodactyly Of Fingers; Dwarfism,0.8115918568696846; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.9398381935810408; 0.943322675973118; 0.9510372690456612,TMEM199-CDG ORPHA:466703; Schnyder corneal dystrophy ORPHA:98967; Bowen-Conradi syndrome ORPHA:1270; Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect ORPHA:466784; RFT1-CDG ORPHA:244310; Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency ORPHA:397593,0.3832844616405875; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ENOX2,Malignant neoplasm of breast; Cervix carcinoma; Malignant tumor of cervix; Rhabdomyosarcoma; cervical cancer; Malignant Neoplasms; Neoplasms; Malignant neoplasm of stomach; Malignant mesothelioma; Stomach Carcinoma; Benign Neoplasm; Intellectual Disability,0.4084380369379369; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.887595340546704; 0.9478210444156088,Malignant Neoplasm; Malignant Mesothelioma; Benign Neoplasm; Neoplasms,0.8115918568696846; 0.8877197959767673; 0.9087218501169084; 0.980894832851993,,,,,,,,
ENTPD2,"Malignant neoplasm of pancreas; Pancreatic carcinoma; Liver carcinoma; Biliary cirrhosis; melanoma; Biliary Cirrhosis, Secondary; Pancreatitis, Chronic; Tumor Progression; Cytomegalovirus Infections; Liver neoplasms; Primary biliary cirrhosis; Hypertensive disease",0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8212681436603975; 0.8474481237156937,Biliary Cholangitis; Biliary Cirrhosis,0.7765582368651238; 0.7765582368651238,Antley-Bixler syndrome ORPHA:83; Bilateral frontoparietal polymicrogyria ORPHA:101070; Apparent mineralocorticoid excess ORPHA:320; NON RARE IN EUROPE: Hypodontia ORPHA:2227; Systemic primary carnitine deficiency ORPHA:158; Autosomal recessive spastic paraplegia type 35 ORPHA:171629; Fatty acid hydroxylase-associated neurodegeneration ORPHA:329308; Naxos disease ORPHA:34217; Marie Unna hereditary hypotrichosis ORPHA:444,0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.4621817429362311; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
ERI1,Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Platelet distribution width measurement; Platelet distribution width result; Narcolepsy,0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076,Developmental Delay; Narcolepsy; Renal Aplasia,0.7765582368651238; 0.8260230451542778; 0.8827958376161968,Hypomyelination-congenital cataract syndrome ORPHA:85163; Temtamy preaxial brachydactyly syndrome ORPHA:363417; Cutis marmorata telangiectatica congenita ORPHA:1556; Greenberg dysplasia ORPHA:1426; Hermansky-Pudlak syndrome with neutropenia ORPHA:183678; Regressive spondylometaphyseal dysplasia ORPHA:448267; Reynolds syndrome ORPHA:779; Xeroderma pigmentosum variant ORPHA:90342; Fetal encasement syndrome ORPHA:465824; Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome ORPHA:86818; Hermansky-Pudlak syndrome without pulmonary fibrosis ORPHA:231512,0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human alphaherpesvirus 1 DNA polymerase catalytic subunit (gene: UL30),0.8999095837312036,,,,
ESAM,Neoplasm Metastasis; Pneumonitis; Schizophrenia; Pneumonia; Chronic Obstructive Airway Disease; Disseminated Malignant Neoplasm,0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.834094492023826; 0.8648405521677974; 0.8867509400747969,Schizophrenia,0.7860378120955526,Hemochromatosis type 5 ORPHA:447792; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; Diencephalic-mesencephalic junction dysplasia ORPHA:319192; Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome ORPHA:69735; Von Willebrand disease type 1 ORPHA:166078; Von Willebrand disease type 2A ORPHA:166084; Von Willebrand disease type 2B ORPHA:166087; Von Willebrand disease type 2M ORPHA:166090; Von Willebrand disease type 2N ORPHA:166093; Von Willebrand disease type 3 ORPHA:166096,0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 6B glycoprotein (gene: U85); Variola virus hypothetical protein (gene: B20R); Ectromelia virus ERPV IFN alpha/beta receptor; Human adenovirus 52 E3 CR1-beta1 (gene: E3); Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Cowpox virus CPXV209 protein (gene: CPXV209 CDS); Human herpesvirus 4 type 2 BARF1; Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Human adenovirus 56 CR1 beta protein (gene: E3); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Vaccinia virus Ankara soluble and cell surface interferon-alpha/beta receptor; Ectromelia virus ERPV IL-1 beta receptor; Human gammaherpesvirus 8 K14; Monkeypox virus IFN-alpha/beta-receptor-like secreted glycoprotein; Monkeypox virus Zaire-96-I-16 B16R (gene: B16R); Vaccinia virus IFN-alpha/beta-receptor-like secreted glycoprotein (gene: B19R); Horsepox virus HSPV195 (immunoglobulin like protein); Human betaherpesvirus 5 membrane protein UL6 (gene: UL6); Human betaherpesvirus 5 envelope glycoprotein UL4 (gene: UL4); Cowpox virus CPXV212 protein (gene: CPXV212 CDS); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Variola virus hypothetical protein (gene: J9R); Human mastadenovirus A E3 CR1-beta1; Horsepox virus HSPV192 (IL-beta-binding protein; Provisional); Human adenovirus 64 E3 48.9 kDa protein; Horsepox virus HSPV177 (Immunoglobulin like); Human adenovirus 23 CR1 b protein (gene: E3); Human adenovirus D37 48.9 kDa (gene: E3); Human adenovirus 61 E3 CR1 beta; Molluscum contagiosum virus subtype 1 MC162R (gene: MC162R); Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Vaccinia virus hemagglutinin (gene: A56R); Cercopithecine betaherpesvirus 5 membrane protein RL11M (gene: RL11M); Human adenovirus 41 E3 31.6K; Human adenovirus 71 E3 CR1-beta (gene: E3); Human adenovirus 43 CR1-beta protein (gene: E3); Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human adenovirus D8 45.5kDa protein (gene: E3); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Human adenovirus 65 E3 CR1-b; Yaba monkey tumor virus Ig domain OX-2-like protein; Cercopithecine betaherpesvirus 5 membrane protein RL11Q (gene: RL11Q); Monkeypox virus bifunctional IL-1-beta-inhibitor; Human mastadenovirus A E3 CR1-alpha1; Human adenovirus 19 CR1-beta (gene: E3); Human adenovirus 63 CR1 beta protein (gene: E3); Human adenovirus 67 E3 CR1-b; Human adenovirus 58 CR1-beta (gene: E3); Human mastadenovirus D membrane glycoprotein E3 CR1-beta (gene: E3); Human adenovirus D10 CR1-beta protein (gene: E3)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.915880438522078; 0.915880438522078; 0.9176018655958595; 0.9187390604217726; 0.9197295331382644; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9287050575620676; 0.9359472799230178; 0.9364561700418303; 0.9397923093369096; 0.9397923093369096; 0.9626366082099888; 0.9687349764960514; 0.9738234079697116; 0.9738234079697116,,,,
EVI5L,Age at menarche,0.9214835359141188,,,Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Otospondylomegaepiphyseal dysplasia ORPHA:1427; Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Spinocerebellar ataxia type 21 ORPHA:98773; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; BAP1-related tumor predisposition syndrome ORPHA:289539; Cerebellar-facial-dental syndrome ORPHA:444072; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Kufor-Rakeb syndrome ORPHA:306674; LIPE-related familial partial lipodystrophy ORPHA:435660; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Steinert myotonic dystrophy ORPHA:273; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Smith-Magenis syndrome ORPHA:819; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome ORPHA:412069; CLN4B disease ORPHA:228343; Charcot-Marie-Tooth disease type 4F ORPHA:99952; Lethal congenital contracture syndrome type 3 ORPHA:137783; Spastic paraplegia-optic atrophy-neuropathy syndrome ORPHA:320406; Intellectual disability-epilepsy-extrapyramidal syndrome ORPHA:468620; Perry syndrome ORPHA:178509; Mazabraud syndrome ORPHA:57782; McCune-Albright syndrome ORPHA:562; Monostotic fibrous dysplasia ORPHA:93277; Polyostotic fibrous dysplasia ORPHA:93276; Progressive osseous heteroplasia ORPHA:2762; Pseudohypoparathyroidism type 1A ORPHA:79443; Pseudohypoparathyroidism type 1C ORPHA:79444; Pseudopseudohypoparathyroidism ORPHA:79445; Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome ORPHA:488613; Hemolytic anemia due to adenylate kinase deficiency ORPHA:86817; Neurofibromatosis-Noonan syndrome ORPHA:638,0.0144185025972157; 0.0144185025972157; 0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1117946631214258; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,,,,,,
EXOC3L4,Platelet Count measurement; Biliary cirrhosis; Serum gamma-glutamyl transferase measurement; Platelet mean volume determination (procedure); Platelet hematocrit measurement; Primary biliary cirrhosis,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8212681436603975,,,HNF1B-related autosomal dominant tubulointerstitial kidney disease ORPHA:93111; Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome ORPHA:476119; Chromophobe renal cell carcinoma ORPHA:319303; Hyperinsulinism due to HNF1A deficiency ORPHA:324575; Hyperinsulinism due to HNF4A deficiency ORPHA:263455; Phosphoenolpyruvate carboxykinase deficiency ORPHA:2880; NON RARE IN EUROPE: Heterozygous familial hypercholesterolemia ORPHA:406; Hyaluronidase deficiency ORPHA:67041,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011,,,,,,
FAM83F,Malignant neoplasm of breast; Squamous cell carcinoma of esophagus,0.4084380369379369; 0.8610447277138289,Prostate Cancer; Breast Cancer,0.7765582368651238; 0.8903630091389316,Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Autosomal recessive cerebral atrophy ORPHA:363969; Congenital intrauterine infection-like syndrome ORPHA:1229; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; Liddle syndrome ORPHA:526; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Syndromic congenital sodium diarrhea ORPHA:563708; Idiopathic bronchiectasis ORPHA:60033; Mullerian aplasia and hyperandrogenism ORPHA:247768; SERKAL syndrome ORPHA:139466; Congenital bilateral absence of vas deferens ORPHA:48; NON RARE IN EUROPE: Recurrent acute pancreatitis ORPHA:64740; Familial thyroid dyshormonogenesis ORPHA:95716; Epidermolysis bullosa simplex due to exophilin 5 deficiency ORPHA:412189; Glucose-galactose malabsorption ORPHA:35710; Neonatal severe primary hyperparathyroidism ORPHA:417; Genetic transient congenital hypothyroidism ORPHA:226316; Pulmonary alveolar microlithiasis ORPHA:60025; Maternal riboflavin deficiency ORPHA:411712; Osteosclerotic metaphyseal dysplasia ORPHA:500548,0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Monkeypox virus Zaire-96-I-16 phospholipase-D-like protein (gene: C4L); Monkeypox virus phospholipase-D-like protein; Horsepox virus HSPV038 (phospholipase-D-like protein; Provisional); Vaccinia virus Ankara DNA nicking-joining enzyme; Cowpox virus CPXV044 (gene: CPXV044 CDS); Ectromelia virus ERPV nicking/joining enzyme; Vaccinia virus phospholipase-D-like protein (gene: K4L); Orf virus ORF011 putative EEV envelope phospholipase; Variola virus palmytilated EEV membrane glycoprotein (gene: C17L); Vaccinia virus palmytilated EEV membrane glycoprotein (gene: F13L); Monkeypox virus Zaire-96-I-16 palmytilated EEV membrane glycoprotein (gene: C19L); Cowpox virus CPXV061 protein (gene: CPXV061 CDS); Horsepox virus HSPV053 (palmytilated EEV membrane glycoprotein); Ectromelia virus ERPV EEV phospholipase; Yaba monkey tumor virus palmytilated EEV membrane glycoprotein,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
FANK1,,,,,X-linked hypophosphatemia ORPHA:89936,0.8922466888454011,"Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Vaccinia virus Ser/Thr kinase (gene: F10L); Yaba monkey tumor virus ankyrin repeat protein; Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Yaba-like disease virus 11L protein (gene: 11L); Human rhinovirus A20 2C; Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Human rhinovirus A88 2C (P2-C); Human adenovirus 1 fiber; Human adenovirus 5 fiber; Human rhinovirus QCE 2C; Monkeypox virus cowpox A-type inclusion protein; Human adenovirus 28 fiber; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Horsepox virus HSPV011a; Human adenovirus 22 fiber protein (gene: L5); Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Cowpox virus CPXV027 protein (gene: CPXV027 CDS); Echovirus E19 2C; Titi monkey adenovirus ECC-2011 fiber; Vaccinia virus hypothetical protein; Ectromelia virus ERPV ankyrin and nfkb inhibitor; Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Human rhinovirus A89 2C; Horsepox virus HSPV022 (ankyrin-like protein; Provisional); Human mastadenovirus E fiber (gene: L5); Human adenovirus E4 fiber protein; Monkeypox virus ankyrin-like protein; Enterovirus C109 2C; Human adenovirus Chiba_E086/2012 fiber (gene: L5); Horsepox virus HSPV033c (ankyrin repeats); Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Vaccinia virus ankyrin-like protein (gene: C9L); Horsepox virus HSPV201a (ankyrin repeats); Yaba-like disease virus 147R protein (gene: 147R); Cowpox virus CPXV041 protein (gene: CPXV041 CDS); Horsepox virus HSPV035 (ankyrin repeats); Horsepox virus HSPV004 (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: C1L); Rhinovirus A P2-C polypeptide; Yaba monkey tumor virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: K1L); Vaccinia virus Ankara putative monoglyceride lipase f2; Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Variola virus hypothetical protein (gene: B19R); Coxsackievirus A18 2C protein; Vaccinia virus Ankara CP77 Host range protein f1; Vaccinia virus Ankara Host range protein; Human rhinovirus A7 2C; Cowpox virus CPXV039 (gene: CPXV039 CDS); Variola virus hypothetical protein (gene: B21R); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Human adenovirus 71 fiber (gene: L5); Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Vaccinia virus ankyrin-like protein (gene: B18R); Human adenovirus 19 fiber (gene: L5); Human adenovirus 58 fiber (gene: L5); Human adenovirus D10 fiber (gene: L5); Human adenovirus 65 L5 fiber; Human mastadenovirus D fiber (gene: L5); Human adenovirus 56 fiber protein (gene: L5); Human adenovirus 64 L5 fiber protein; Human adenovirus D37 fiber (gene: L5); Horsepox virus HSPV033b (Ankyrin repeats); Human adenovirus D8 fiber (gene: L5); Human adenovirus 54 fiber; Variola virus hypothetical protein (gene: G3R); Orf virus ORF126 ankyrin repeat protein; Human mastadenovirus D fiber; Human adenovirus 17 fiber; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Human adenovirus 63 fiber protein (gene: L5); Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Horsepox virus HSPV020b (ankyrin repeats); Human adenovirus 49 fiber; Vaccinia virus Ankara CP77 host range protein f3; Human adenovirus 23 fibre protein (gene: L5); Human adenovirus 67 L5 fiber; Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Horsepox virus HSPV005c (Ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Human adenovirus 46 fiber; Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara CP77 host range protein f4; Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Horsepox virus HSPV011b (ankyrin repeats); Horsepox virus HSPV014b (ankyrin repeats); Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyin-like protein (gene: M1L); Yaba-like disease virus 146R protein (gene: 146R); Vaccinia virus Ankara CP77 host range protein f2; Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Variola virus hypothetical protein (gene: B6R); Vaccinia virus ankyrin-like protein; Orf virus ORF129 ankyrin repeat protein; Cowpox virus CPXV017 protein (gene: CPXV017 CDS); Variola virus ankyin-like protein (gene: O1L); Horsepox virus HSPV194 (ankyrin repeats); Cowpox virus CPXV006 protein (gene: CPXV006 CDS); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Yaba-like disease virus 148R protein (gene: 148R); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D1L); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9018002218631122; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9058994261255549; 0.9058994261255549; 0.9058994261255549; 0.9065231464138438; 0.9071659214187592; 0.9115856929326512; 0.9118403763180049; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9176642913406818; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.928070054828895; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9364561700418303; 0.9366403811337995; 0.9383505321091749; 0.9383505321091749; 0.9386073090182748; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9563208507960556,,,,
FARP2,Esophageal carcinoma; Esophageal Neoplasms; Liver carcinoma; Malignant neoplasm of esophagus; Prostate carcinoma; Squamous cell carcinoma of the head and neck; Seasonal Affective Disorder; Chromosome 2q37 deletion syndrome; Hepatitis E; Fibrinogen assay; Nasopharyngeal Neoplasms; Vitiligo; Autistic Disorder; Chronic Lymphocytic Leukemia; Phenylketonurias; Leigh Disease; Diphtheria,0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8145035474981049; 0.8402911822757345; 0.8867509400747969,Prostate Cancer; Lymphocytic Leukemia; Vitiligo; Nasopharyngeal Carcinoma; Autism,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.911896615143974,GNE myopathy ORPHA:602; Sialuria ORPHA:3166; Dent disease type 1 ORPHA:93622,0.3832844616405875; 0.3832844616405875; 0.5867963421058087,Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Dugbe virus L protein; Human papillomavirus 94 E2 protein (gene: E2); Human papillomavirus 117 E2; Human papillomavirus type 90 putative regulatory protein E2 (gene: E2),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
FBXO44,Malignant neoplasm of prostate; Prostatic Neoplasms; Sclerocystic Ovaries; Polycystic Ovary Syndrome,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.9174808175273056,Prostate Cancer; Prostatic Neoplasms; Sclerocystic Ovaries; Polycystic Ovary Syndrome,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238,Amelocerebrohypohidrotic syndrome ORPHA:1946,0.8922466888454011,,,,,,
FCHSD1,,,,,Nodular fasciitis ORPHA:477742; COFS syndrome ORPHA:1466,0.5867963421058087; 0.8922466888454011,"Human T-lymphotropic virus 3 envelope (gene: env); Human T-cell lymphotropic virus type 2b env; Human T-lymphotropic virus 4 envelope glycoprotein (gene: env); Human immunodeficiency virus nef protein (gene: nef); Human T-lymphotropic virus 2 hypothetical protein (env propeptide); Vaccinia virus cowpox A-type inclusion protein; Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; Lake Victoria marburgvirus - DRC1999 glycoprotein (gene: GP); Ravn virus - Ravn, Kenya, 1987 glycoprotein (gene: GP); Marburg marburgvirus glycoprotein (gene: GP)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
FGD3,Malignant neoplasm of breast; Breast Carcinoma; Thyroid carcinoma; Skeletal dysplasia; Osteochondrodysplasias,0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.8815127642200768; 0.9117936912777788,,,"Familial isolated pituitary adenoma ORPHA:314777; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; Coats plus syndrome ORPHA:313838; Bleeding disorder due to CalDAG-GEFI deficiency ORPHA:420566; Congenital non-communicating hydrocephalus ORPHA:269510; Fructose-1,6-bisphosphatase deficiency ORPHA:348; Grange syndrome ORPHA:79094; Gray platelet syndrome ORPHA:721; Nephrogenic syndrome of inappropriate antidiuresis ORPHA:93606; Osteogenesis imperfecta type 5 ORPHA:216828; Severe combined immunodeficiency due to CORO1A deficiency ORPHA:228003; Spinocerebellar ataxia type 40 ORPHA:423275; Epidermodysplasia verruciformis ORPHA:302; WHIM syndrome ORPHA:51636; Familial hemophagocytic lymphohistiocytosis ORPHA:540; Aland Islands eye disease ORPHA:178333; Hyperinsulinism due to UCP2 deficiency ORPHA:276556; Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944; Serrated polyposis syndrome ORPHA:157798; X-linked severe congenital neutropenia ORPHA:86788; X-linked thrombocytopenia with normal platelets ORPHA:852; Acute basophilic leukemia ORPHA:86849; Dominant hypophosphatemia with nephrolithiasis or osteoporosis ORPHA:244305; Nephrogenic diabetes insipidus ORPHA:223; Blau syndrome ORPHA:90340; Combined immunodeficiency due to DOCK8 deficiency ORPHA:217390; X-linked Charcot-Marie-Tooth disease type 6 ORPHA:352675; NON RARE IN EUROPE: Ulcerative colitis ORPHA:771; NON RARE IN EUROPE: Multiple sclerosis ORPHA:802; Female infertility due to oocyte meiotic arrest ORPHA:488191",0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
FGFBP1,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Colorectal Carcinoma; Pancreatic intraepithelial neoplasia; Invasive carcinoma of breast; Colorectal Cancer; Adenocarcinoma of pancreas; Invasive Carcinoma; Squamous cell carcinoma; Adenomatous polyp of colon; Kidney Diseases; Precancerous Conditions; Hypertensive disease,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8474481237156937,,,"Van der Woude syndrome ORPHA:888; EEM syndrome ORPHA:1897; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Gelatinous drop-like corneal dystrophy ORPHA:98957; Bifid uvula ORPHA:99771; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Submucosal cleft palate ORPHA:155878; Cleft lip and alveolus ORPHA:141291; Isolated cleft lip ORPHA:199302; Localized junctional epidermolysis bullosa ORPHA:251393; Bartsocas-Papas syndrome ORPHA:1234; CHAND syndrome ORPHA:1401; Neuropathy with hearing impairment ORPHA:139512; Sebocystomatosis ORPHA:841; Hypocalcified amelogenesis imperfecta ORPHA:100032; Intermediate generalized junctional epidermolysis bullosa ORPHA:79402; Pachyonychia congenita ORPHA:2309; Self-improving collodion baby ORPHA:281122; Acral self-healing collodion baby ORPHA:281127; Bathing suit ichthyosis ORPHA:100976; Epithelial recurrent erosion dystrophy ORPHA:293381; Harlequin ichthyosis ORPHA:457; Hereditary hypotrichosis with recurrent skin vesicles ORPHA:217407; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Late-onset junctional epidermolysis bullosa ORPHA:79406; Metaphyseal chondrodysplasia, Spahr type ORPHA:2501; Netherton syndrome ORPHA:634; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Spondyloepimetaphyseal dysplasia, Missouri type ORPHA:93356; Xanthinuria type I ORPHA:93601; Bladder exstrophy ORPHA:93930; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Uncombable hair syndrome ORPHA:1410; Erythrokeratodermia variabilis ORPHA:317; Idiopathic juvenile osteoporosis ORPHA:85193; Hypoplastic amelogenesis imperfecta ORPHA:100031; Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form ORPHA:79399; Autosomal dominant generalized epidermolysis bullosa simplex, severe form ORPHA:79396; Epidermolysis bullosa simplex with mottled pigmentation ORPHA:79397; KID syndrome ORPHA:477; Localized epidermolysis bullosa simplex ORPHA:79400; Severe generalized junctional epidermolysis bullosa ORPHA:79404; AA amyloidosis ORPHA:85445; Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering ORPHA:402003; Autosomal recessive generalized epidermolysis bullosa simplex ORPHA:89838; Bamforth-Lazarus syndrome ORPHA:1226; Dermatopathia pigmentosa reticularis ORPHA:86920; Ectodermal dysplasia-skin fragility syndrome ORPHA:158668; Epidermolysis bullosa simplex with circinate migratory erythema ORPHA:158681; Epidermolytic palmoplantar keratoderma ORPHA:2199; Familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement ORPHA:31043; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Monilethrix ORPHA:573; Naegeli-Franceschetti-Jadassohn syndrome ORPHA:69087; Palmoplantar keratoderma, Nagashima type ORPHA:140966; Peeling skin syndrome type B ORPHA:263553; Acrodermatitis continua of Hallopeau ORPHA:163931; Autosomal recessive infantile hypercalcemia ORPHA:300547; Generalized pustular psoriasis ORPHA:247353; Hypotrichosis simplex of the scalp ORPHA:90368; Isolated focal non-epidermolytic palmoplantar keratoderma ORPHA:448264; Meesmann corneal dystrophy ORPHA:98954; Pure hair and nail ectodermal dysplasia ORPHA:69084; Pustulosis palmaris et plantaris ORPHA:163927; Athyreosis ORPHA:95713; Congenital non-bullous ichthyosiform erythroderma ORPHA:79394; White sponge nevus ORPHA:171723; ADULT syndrome ORPHA:978; Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome ORPHA:1071; EEC syndrome ORPHA:1896; Kindler epidermolysis bullosa ORPHA:2908; Limb-mammary syndrome ORPHA:69085; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Severe combined immunodeficiency due to FOXN1 deficiency ORPHA:169095",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
FRY,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Ovarian Carcinoma; Colorectal Cancer; Epithelial ovarian cancer; Prostate carcinoma; Carcinoma of lung; Mental Retardation, Psychosocial; Liver Cirrhosis, Experimental; Profound Mental Retardation; Narcolepsy; Adenocarcinoma of lung (disorder); Systolic Pressure; Diabetes Mellitus, Non-Insulin-Dependent; Endometrioid carcinoma ovary; Ovarian Serous Adenocarcinoma; Mental deficiency; Calcification of coronary artery; Intellectual Disability; Squamous cell carcinoma of lung",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8190761496232595; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.9377696084218796; 0.9478210444156088; 0.9564633032157428,Ovarian Neoplasm; Ovarian Endometrioid Carcinoma; Prostate Cancer; Ovarian Serous Adenocarcinoma; Lung Carcinoma; Colonic Neoplasms; Narcolepsy; Mental Retardation; Lung Cancer; Diabetes Mellitus; Lung Adenocarcinoma; Breast Carcinoma; Colorectal Neoplasms; Colorectal Cancer,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8139950454942313; 0.8210988731657684; 0.8260230451542778; 0.8337953215113012; 0.8706864397989688; 0.919442421650838; 0.9350723667380212; 0.9398381935810408; 0.9510372690456612; 0.9832345076528324,"Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Distal monosomy 1q ORPHA:36367; 2q37 microdeletion syndrome ORPHA:1001; SHORT syndrome ORPHA:3163; Autosomal recessive ataxia, Beauce type ORPHA:88644; Autosomal recessive myogenic arthrogryposis multiplex congenita ORPHA:319332; Charcot-Marie-Tooth disease type 4H ORPHA:99954; Diencephalic-mesencephalic junction dysplasia ORPHA:319192; Pseudohypoaldosteronism type 2D ORPHA:300525; Tangier disease ORPHA:31150; Spinocerebellar ataxia type 1 ORPHA:98755; Angelman syndrome due to imprinting defect in 15q11-q13 ORPHA:411515; Antenatal Bartter syndrome ORPHA:93604; Familial short QT syndrome ORPHA:51083; Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome ORPHA:496689; Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome ORPHA:496686; Malonic aciduria ORPHA:943; Multifocal pattern dystrophy simulating fundus flavimaculatus ORPHA:99003; Adult-onset foveomacular vitelliform dystrophy ORPHA:99000; Fundus albipunctatus ORPHA:227796; Acute myeloid leukemia with t(8;21)(q22;q22) translocation ORPHA:102724",0.0155394890951578; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
FSTL3,Malignant neoplasm of breast; Breast Carcinoma; Mammary Neoplasms; Invasive carcinoma of breast; Eclampsia; Rheumatism; Diminished ovarian reserve; Liver neoplasms; Steatohepatitis; Fatty Liver; Heart failure; Congestive heart failure; Obesity; Cardiac fibrosis; Renal Insufficiency,0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8402911822757345; 0.8628363180844141; 0.8867509400747969; 0.8976039441125321; 0.8989612563669234; 0.929814249105729; 0.946564927793026,,,"Crisponi syndrome ORPHA:1545; Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Cold-induced sweating syndrome ORPHA:157820; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Familial cortical myoclonus ORPHA:319189; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Early-onset posterior polar cataract ORPHA:98993; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Atypical Werner syndrome ORPHA:79474; Autosomal recessive Emery-Dreifuss muscular dystrophy ORPHA:98855; Autosomal semi-dominant severe lipodystrophic laminopathy ORPHA:280365; Charcot-Marie-Tooth disease type 2B1 ORPHA:98856; Congenital insensitivity to pain with severe intellectual disability ORPHA:453510; Congenital muscular dystrophy due to LMNA mutation ORPHA:157973; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome ORPHA:2229; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation ORPHA:300751; Familial partial lipodystrophy, Dunnigan type ORPHA:2348; Familial partial lipodystrophy, Kobberling type ORPHA:79084; Heart-hand syndrome, Slovenian type ORPHA:168796; LMNA-related cardiocutaneous progeria syndrome ORPHA:363618; Mandibuloacral dysplasia with type A lipodystrophy ORPHA:90153; Cap myopathy ORPHA:171881; Congenital short bowel syndrome ORPHA:2301; Thyroid ectopia ORPHA:95712; Autosomal dominant omodysplasia ORPHA:93328; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Hereditary combined deficiency of vitamin K-dependent clotting factors ORPHA:98434; Congenital generalized lipodystrophy ORPHA:528",0.0155394890951578; 0.0414176838632111; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2475924359068358; 0.2844858212863536; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.8105918570729571,,,,,,
FXR2,Autistic Disorder; Fragile X Syndrome,0.8019075543217649; 0.8402911822757345,,,Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; Early-onset posterior polar cataract ORPHA:98993; Perry syndrome ORPHA:178509; POMGNT1-related  limb-girdle muscular dystrophy R15 ORPHA:206564; Congenital muscular dystrophy without intellectual disability ORPHA:370980; Autosomal dominant Charcot-Marie-Tooth disease type 2A2 ORPHA:99947; Hereditary motor and sensory neuropathy type 5 ORPHA:64751; Multiple symmetric lipomatosis ORPHA:2398; Severe early-onset axonal neuropathy due to MFN2 deficiency ORPHA:90118; Congenital muscular dystrophy with cerebellar involvement ORPHA:370959,0.0144185025972157; 0.0144185025972157; 0.0144185025972157; 0.1040670578681756; 0.1991445465001551; 0.2475924359068358; 0.3832844616405875; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human papillomavirus 94 E2 protein (gene: E2); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) hemagglutinin (gene: HA); Human papillomavirus type 27 early protein (gene: E2); Human papillomavirus type 6 E5B (gene: E5B); Human papillomavirus type 163 E7 (gene: E7); Human papillomavirus type 69 E2,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,In vitro,0.69,Homo sapiens,Homo sapiens
GALNT6,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Colorectal Carcinoma; Mammary Neoplasms; Epithelial ovarian cancer,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415,,,,,,,,,,
GAS2L1,"Leukemia, Myelocytic, Acute; Acute Myeloid Leukemia, M1; Acute Myeloid Leukemia (AML-M2); Schizophrenia",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076,Leukemia; Myeloid Leukemia,0.7765582368651238; 0.8356859041719433,"Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; CLN10 disease ORPHA:228337; Classic Hodgkin lymphoma, nodular sclerosis type ORPHA:98843; Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; 19p13.3 microduplication syndrome ORPHA:447980; ACys amyloidosis ORPHA:100008; Autosomal dominant intermediate Charcot-Marie-Tooth disease type E ORPHA:93114; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; 5-oxoprolinase deficiency ORPHA:33572; Microduplication Xp11.22p11.23 syndrome ORPHA:217377; Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome ORPHA:397933; Paroxysmal non-kinesigenic dyskinesia ORPHA:98810; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Hemolytic anemia due to adenylate kinase deficiency ORPHA:86817; Lethal osteosclerotic bone dysplasia ORPHA:1832; Deafness-lymphedema-leukemia syndrome ORPHA:3226; Monocytopenia with susceptibility to infections ORPHA:228423; Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom ORPHA:500159",0.0144185025972157; 0.0144185025972157; 0.0144185025972157; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
GCNT3,Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Malignant tumor of colon; Colorectal Neoplasms; Liver carcinoma; Colorectal Cancer; Neoplasm Metastasis; Colonic Neoplasms,0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8212681436603975,,,"Autosomal recessive cerebral atrophy ORPHA:363969; Familial expansile osteolysis ORPHA:85195; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; HNF1B-related autosomal dominant tubulointerstitial kidney disease ORPHA:93111; Chromophobe renal cell carcinoma ORPHA:319303; Hyperinsulinism due to HNF1A deficiency ORPHA:324575; Hyperinsulinism due to HNF4A deficiency ORPHA:263455; Autosomal dominant primary hypomagnesemia with hypocalciuria ORPHA:34528; Bilateral multicystic dysplastic kidney ORPHA:97364; Medullary sponge kidney ORPHA:1309; Renal dysplasia, bilateral ORPHA:93173; Renal dysplasia, unilateral ORPHA:93172; Unilateral multicystic dysplastic kidney ORPHA:97363; Congenital bilateral absence of vas deferens ORPHA:48; NON RARE IN EUROPE: Recurrent acute pancreatitis ORPHA:64740; Familial thyroid dyshormonogenesis ORPHA:95716; Hypoplastic amelogenesis imperfecta ORPHA:100031; Autism spectrum disorder-epilepsy-arthrogryposis syndrome ORPHA:370943; Genetic transient congenital hypothyroidism ORPHA:226316; Cystinuria type A ORPHA:93612; Hereditary chronic pancreatitis ORPHA:676; Tropical pancreatitis ORPHA:103918; Iminoglycinuria ORPHA:42062",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
GDF11,Colorectal Carcinoma; Congenital exomphalos; Colorectal Neoplasms; Congenital omphalocele; Colorectal Cancer; Triple Negative Breast Neoplasms; Neoplasms; Alzheimer's Disease; Currarino triad; Agenesis; Secondary malignant neoplasm of lymph node,0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8402911822757345; 0.900167961295542,,,DOORS syndrome ORPHA:79500; Focal epilepsy-intellectual disability-cerebro-cerebellar malformation ORPHA:352587; Progressive myoclonic epilepsy with dystonia ORPHA:352596; Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome ORPHA:163727,0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,,,,,,
GDF15,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Malignant neoplasm of pancreas; Mitochondrial Respiratory Chain Deficiencies; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Sideroblastic anemia; Metaplasia; Malignant tumor of colon; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Refractory anemia, without ringed sideroblasts, without excess blasts; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Adenoma; Intestinal Cancer; Thyroid Neoplasm; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Refractory anemias; Biliary Tract Neoplasm; Pulmonary Thromboembolisms; Liver carcinoma; Malignant Head and Neck Neoplasm; Mycoses; Thyroid carcinoma; Ataxia Telangiectasia; Colorectal Cancer; Liver and Intrahepatic Biliary Tract Carcinoma; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of thyroid; Squamous cell carcinoma of the head and neck; Malignant neoplasm of liver; Van der Woude syndrome; melanoma; Intestinal Neoplasms; Multiple Myeloma; Lung Neoplasms; Pregnancy in Diabetics; Metastatic Prostate Carcinoma; Malignant neoplasm of stomach; Viral hepatitis; Skin Pigmentation Disorder; Benign Prostatic Hyperplasia; Well Differentiated Oligodendroglioma; Brain Neoplasms; oligodendroglioma; Dementia; Stromal Neoplasm; Tumor Progression; Low Grade Prostatic Intraepithelial Neoplasia; Prostatic Diseases; Prostatic Adenoma; Coronary Arteriosclerosis; Presenile dementia; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Intestinal Polyps; Pulmonary Embolism; Stomach Carcinoma; Anorexia; Hepatitis C; Acute myocardial infarction; Cardiovascular Diseases; Squamous cell carcinoma; Polycythemia Vera; Mitochondrial Myopathies; Rheumatoid Arthritis; Diabetes; Diabetes Mellitus; Huntington Disease; Anaplastic thyroid carcinoma; Hormone refractory prostate cancer; Follicular adenoma; Metastatic Neoplasm; Central nervous system lesion; Mouth Diseases; Virus Diseases; Malignant Glioma; Metastasis from malignant tumor of prostate; Refractory anemia with ringed sideroblasts; Metastatic melanoma; Chronic myeloproliferative disorder; Thrombocythemia, Essential; Bile duct proliferation; Vitiligo; Pneumonitis; Myocardial Infarction; Degenerative polyarthritis; Liver neoplasms; Precancerous Conditions; Acute Coronary Syndrome; Stomach Neoplasms; Adenomatous Polyps; ovarian neoplasm; Adenocarcinoma of lung (disorder); Gastrointestinal Neoplasms; Superficial ulcer; Impaired cognition; Diabetes Mellitus, Non-Insulin-Dependent; Liver Cirrhosis; Hemochromatosis; Iron Overload; Pneumonia; Recurrent tumor; Pregnancy Complications; Systemic Scleroderma; Idiopathic pulmonary hypertension; Mild cognitive disorder; Left Ventricular Hypertrophy; Cachexia; Endothelial dysfunction; Parkinsonian Disorders; Cirrhosis; Anemia; Weight Gain; Follicular thyroid carcinoma; Cerebrovascular accident; Myocardial Ischemia; Atrial Fibrillation; Chronic Obstructive Airway Disease; Premature Birth; Adenocarcinoma Of Esophagus; Parkinson Disease; Adult Liver Carcinoma; Lewy Body Disease; Heart failure; Coronary Artery Disease; Pulmonary Fibrosis; Congestive heart failure; Barrett Esophagus; Obesity; Mitochondrial Diseases; High-Grade Prostatic Intraepithelial Neoplasia; Thalassemia; Anemia, Sickle Cell; Idiopathic pulmonary arterial hypertension; VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding); Neoplasms, Intracranial; Heart Decompensation; Diabetic Nephropathy; Heart Failure, Right-Sided; Hepatitis C, Chronic; Myocardial Failure; Secondary malignant neoplasm of bone; Essential Hypertension; Left-Sided Heart Failure; beta^+^ Thalassemia; early pregnancy; beta Thalassemia; Ischemic stroke",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7940665326856218; 0.7945683314244791; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8037546774788534; 0.8044379824544406; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8486035047899471; 0.8554819098734854; 0.8584283190330553; 0.8584283190330553; 0.8584283190330553; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8769418330148872; 0.8772392350816924; 0.8806784681730055; 0.8851456306720444; 0.8867509400747969; 0.887595340546704; 0.8911256045597441; 0.8976039441125321; 0.8980854850210683; 0.8989612563669234; 0.8989612563669234; 0.9024758035783405; 0.9117936912777788; 0.9252532782268056; 0.9262273158806068; 0.9262273158806068; 0.9307095582633488; 0.9387505562433404; 0.9390727893210336; 0.942246125102556; 0.9432051631882106; 0.9432051631882106; 0.946564927793026; 0.9557184806547836; 0.9561991866282916; 0.9564633032157428; 0.9571401094099016; 0.9598257094806012; 0.9896536639644284,Sideroblastic Anemia; Prostate Cancer; Melanoma; Prostatic Neoplasms; Gastrointestinal Neoplasms; Liver Carcinoma; Mouth Diseases; Coronary Arteriosclerosis; Left Ventricular Hypertrophy; Myocardial Infarction; Coronary Artery Disease; Heart Failure; Congestive Heart Failure; Myocardial Ischemia,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.8115918568696846; 0.861756360478846; 0.861756360478846; 0.9024492468099392; 0.9543024119762946; 0.9578111936867284,Congenital bile acid synthesis defect type 1 ORPHA:79301; Hemolytic anemia due to glutathione reductase deficiency ORPHA:90030; Pseudohypoaldosteronism type 2B ORPHA:88939; Severe congenital hypochromic anemia with ringed sideroblasts ORPHA:300298; Xanthinuria type II ORPHA:93602; Aromatase deficiency ORPHA:91; Aromatase excess syndrome ORPHA:178345; Erythrocyte galactose epimerase deficiency ORPHA:308473; Generalized galactose epimerase deficiency ORPHA:308487; Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria ORPHA:99646; REN-related autosomal dominant tubulointerstitial kidney disease ORPHA:217330; Congenital sialidosis type 2 ORPHA:93400; Juvenile sialidosis type 2 ORPHA:93399; Sialidosis type 1 ORPHA:812,0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.44,Homo sapiens,Homo sapiens
GGTLC1,"Carcinogenesis; Cholestatic liver disease; Amyloidosis, Familial; Liver carcinoma; Cholelithiasis; Prostate carcinoma; Neoplasm Metastasis; Ewings sarcoma; Neoplasms; Infection by Wuchereria bancrofti; Malignant neoplasm of stomach; Arthrogryposis renal dysfunction cholestasis syndrome; Elephantiasis; Viral hepatitis, type G; Lupus Erythematosus, Systemic; heavy drinking; Benign recurrent intrahepatic cholestasis; Stomach Carcinoma; Hepatitis C; Eosinophilia, Tropical; Diabetes; Diabetes Mellitus; Pulmonary Pathology; Cholestasis; Plaque, Amyloid; Filarial Elephantiases; Viremia; Leukopenia; Nonalcoholic Steatohepatitis; Liver diseases; Progressive intrahepatic cholestasis (disorder); Fibrosis, Liver; Cholestasis in newborn; Steatohepatitis; Cholestasis of pregnancy; Hypertensive disease; Keratoconus; Hypophosphatemia; Fatty Liver; Pruritus; Hypertension, Portal; Melanoma, B16; Asthma",0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8140222479282434; 0.8190761496232595; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8584283190330553; 0.8610447277138289; 0.8628363180844141; 0.8911256045597441; 0.9377481698983606; 0.9621920228183704; 0.9672478180546946,,,Infant acute respiratory distress syndrome ORPHA:70587; Brain-lung-thyroid syndrome ORPHA:209905; Chronic respiratory distress with surfactant metabolism deficiency ORPHA:217566; Interstitial lung disease due to SP-C deficiency ORPHA:440392; Neonatal acute respiratory distress due to SP-B deficiency ORPHA:217563,0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
GNG8,"T-Cell Lymphoma; Lymphoma, T-Cell, Cutaneous; Liver diseases; Liver Dysfunction; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mycosis Fungoides",0.7880542567584415; 0.8098851543361193; 0.8140222479282434; 0.8402911822757345; 0.8648405521677974; 0.8989612563669234,,,Hereditary sensory and autonomic neuropathy type 4 ORPHA:642,0.5867963421058087,,,,,,
GPRIN1,,,,,PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Oculocutaneous albinism type 2 ORPHA:79432; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Spastic paraplegia-optic atrophy-neuropathy syndrome ORPHA:320406; Familial congenital mirror movements ORPHA:238722; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; Ichthyosis-prematurity syndrome ORPHA:88621; Coloboma of choroid and retina ORPHA:98942; Coloboma of iris ORPHA:98944; Aarskog-Scott syndrome ORPHA:915; Autosomal recessive spastic paraplegia type 26 ORPHA:101006; Myoclonus-dystonia syndrome ORPHA:36899; Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome ORPHA:488613; Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome ORPHA:231720,0.0155394890951578; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703,,,,,,
GTF3C6,,,,,Autosomal recessive spastic paraplegia type 77 ORPHA:466722; C11ORF73-related autosomal recessive hypomyelinating leukodystrophy ORPHA:495844; Combined oxidative phosphorylation defect type 14 ORPHA:319519; Keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome ORPHA:281201; McKusick-Kaufman syndrome ORPHA:2473; Multiple mitochondrial dysfunctions syndrome type 1 ORPHA:401869; TMEM70-related mitochondrial encephalo-cardio-myopathy ORPHA:1194,0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
HENMT1,Neuroblastoma; Central neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,0.7880542567584415; 0.7880542567584415; 0.8138488881521341,,,,,,,,,,
HERC1,Reticulocyte count (procedure); Tall stature; Triangular face; Long foot; Frontal bossing; Joint laxity; Large hand; Large auricle; Large pinnae; Macrotia; Hypertrophy of lower jaw; mandibular excess (physical finding); Mandibular hyperplasia; Increased size of the mandible; Bulging forehead; Prominent forehead; Class III malocclusion; Macrocephaly; Cognitive delay; Sparse eyebrow; Increased head circumference; Macroencephaly; Global developmental delay; Prominent eyes; Protruding eyes; Mental and motor retardation; Prominent globes; Exophthalmos; Angelman Syndrome; Acquired flat foot; Flatfoot; Long face; Arachnodactyly; Posteriorly rotated ear; Big calvaria; Increased size of skull; Upward slant of palpebral fissure; Downward slant of palpebral fissure; Convex nasal bridge; Prominent nasal bridge; Curvature of spine; Dilated ventricles (finding); Mental deficiency; Acquired scoliosis; Generalized hypotonia; Hypotrophic malar bone; Malar flattening; Low set ears; Dull intelligence; Low intelligence; Cerebellar atrophy; Orbital separation excessive; Poor school performance; Age related macular degeneration; Lordosis; Byzanthine arch palate; Gait Ataxia; Hyperkyphosis; Severe mental retardation (I.Q. 20-34); Mental Retardation; Kyphosis deformity of spine; Calcification of coronary artery; Intellectual Disability,0.5071083164302358; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026798872257774; 0.8098851543361193; 0.8098851543361193; 0.8168901801930506; 0.8168901801930506; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8490659121857849; 0.8490659121857849; 0.8700543109506378; 0.8757755363384367; 0.8757755363384367; 0.8815127642200768; 0.8851456306720444; 0.8913141512402477; 0.8980854850210683; 0.9083161862856644; 0.9119978323790848; 0.9119978323790848; 0.9154499654632742; 0.917543617287358; 0.922229272318747; 0.9288355565549664; 0.9377696084218796; 0.9478210444156088,Developmental Delay; Macrocephaly; Frontal Bossing; Macrotia; Malocclusion; Proptosis; Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Mental Retardation; Arachnodactyly; Posteriorly Rotated Ear; Scoliosis; High Palate; Chronic Obstructive Pulmonary Disease,0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.861756360478846; 0.8903301324869451; 0.924275664330454; 0.9578111936867284; 0.966063509695942,"Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; 2q37 microdeletion syndrome ORPHA:1001; SHORT syndrome ORPHA:3163; Deafness-enamel hypoplasia-nail defects syndrome ORPHA:3220; Huntington disease ORPHA:399; Autosomal recessive ataxia, Beauce type ORPHA:88644; Autosomal recessive myogenic arthrogryposis multiplex congenita ORPHA:319332; Juvenile Huntington disease ORPHA:248111; Polyendocrine-polyneuropathy syndrome ORPHA:453533; Pseudohypoaldosteronism type 2D ORPHA:300525; Acute promyelocytic leukemia ORPHA:520; APC-related attenuated familial adenomatous polyposis ORPHA:247806; Autosomal recessive spastic paraplegia type 15 ORPHA:100996; Autosomal recessive spastic paraplegia type 54 ORPHA:320380; Familial adenomatous polyposis due to 5q22.2 microdeletion ORPHA:261584; Gardner syndrome ORPHA:79665; Gastric adenocarcinoma and proximal polyposis of the stomach ORPHA:314022; Griscelli syndrome type 1 ORPHA:79476; Microcephalic osteodysplastic primordial dwarfism type II ORPHA:2637; Microcephalic primordial dwarfism, Dauber type ORPHA:319675; Myhre syndrome ORPHA:2588; Neuroectodermal melanolysosomal disease ORPHA:33445; Nicolaides-Baraitser syndrome ORPHA:3051; Perlman syndrome ORPHA:2849; Rubinstein-Taybi syndrome due to EP300 haploinsufficiency ORPHA:353284; Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome ORPHA:521390; Turcot syndrome with polyposis ORPHA:99818; Aniridia-cerebellar ataxia-intellectual disability syndrome ORPHA:1065; Angelman syndrome due to imprinting defect in 15q11-q13 ORPHA:411515; Sotos syndrome ORPHA:821; Acute myeloid leukemia with t(8;16)(p11;p13) translocation ORPHA:370026; 5q35 microduplication syndrome ORPHA:228415; Acute myeloid leukaemia with myelodysplasia-related features ORPHA:86845; Amyotrophic lateral sclerosis type 4 ORPHA:357043; Ataxia-telangiectasia ORPHA:100; Ataxia-telangiectasia variant ORPHA:370109; Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome ORPHA:457193; Autosomal recessive Charcot-Marie-Tooth disease type 2X ORPHA:466775; Autosomal recessive spastic paraplegia type 11 ORPHA:2822; Beckwith-Wiedemann syndrome due to NSD1 mutation ORPHA:238613; Cohen syndrome ORPHA:193; DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion ORPHA:268261; Developmental delay-facial dysmorphism syndrome due to MED13L deficiency ORPHA:369891; Dyggve-Melchior-Clausen disease ORPHA:239; Fleck corneal dystrophy ORPHA:98970; Germinoma of the central nervous system ORPHA:91352; Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome ORPHA:404476; Gynandroblastoma ORPHA:99914; Intellectual disability syndrome due to a DYRK1A point mutation ORPHA:464311; Intellectual disability-hyperkinetic movement-truncal ataxia syndrome ORPHA:369847; Isolated generalized anhidrosis with normal sweat glands ORPHA:468666; Malignant Sertoli-Leydig cell tumor of the ovary ORPHA:99916; Mucolipidosis type II ORPHA:576; Mucolipidosis type III alpha/beta ORPHA:423461; Pleuropulmonary blastoma familial tumor susceptibility syndrome ORPHA:284343; Refractory anemia ORPHA:98826; Refractory anemia with excess blasts ORPHA:86839; Spinocerebellar ataxia type 15/16 ORPHA:98769; Spinocerebellar ataxia type 29 ORPHA:208513; TRAPPC11-related  limb-girdle muscular dystrophy R18 ORPHA:369840; X-linked dystonia-parkinsonism ORPHA:53351; X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome ORPHA:480907; Acquired idiopathic sideroblastic anemia ORPHA:75564; Autosomal recessive spastic paraplegia type 23 ORPHA:101003; Moebius syndrome ORPHA:570; Progressive cerebello-cerebral atrophy ORPHA:247198; Tessier number 7 facial cleft ORPHA:141276; 17q21.31 microdeletion syndrome ORPHA:363958; 2q23.1 microdeletion syndrome ORPHA:228402; 6q25 microdeletion syndrome ORPHA:251056; Acute myeloid leukemia with 11q23 abnormalities ORPHA:98831; Acute undifferentiated leukemia ORPHA:98835; Autosomal recessive spastic paraplegia type 28 ORPHA:101008; Blepharophimosis-intellectual disability syndrome, SBBYS type ORPHA:3047; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome ORPHA:466921; Classic hairy cell leukemia ORPHA:58017; Classic multiminicore myopathy ORPHA:324604; Developmental delay with autism spectrum disorder and gait instability ORPHA:329195; Distal nebulin myopathy ORPHA:399103; Early-onset myopathy with fatal cardiomyopathy ORPHA:289377; Genitopatellar syndrome ORPHA:85201; Hereditary myopathy with early respiratory failure ORPHA:178464; Intermediate epidermolysis bullosa simplex with cardiomyopathy ORPHA:508529; Johanson-Blizzard syndrome ORPHA:2315; Koolen-De Vries syndrome due to a point mutation ORPHA:363965; Langerhans cell histiocytosis ORPHA:389; Megalencephaly-severe kyphoscoliosis-overgrowth syndrome ORPHA:457359; Methylcobalamin deficiency type cblG ORPHA:2170; Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome ORPHA:572013; Pseudohypoaldosteronism type 2C ORPHA:88940; Short stature-delayed bone age due to thyroid hormone metabolism deficiency ORPHA:171706; Short stature-optic atrophy-Pelger-Huet anomaly syndrome ORPHA:391677; Spinocerebellar ataxia type 11 ORPHA:98767; Syringocystadenoma papilliferum ORPHA:840; TBCK-related intellectual disability syndrome ORPHA:488632; Tibial muscular dystrophy ORPHA:609; Titin-related  limb-girdle muscular dystrophy R10 ORPHA:140922; Trichorhinophalangeal syndrome type 1 and 3 ORPHA:77258; Vici syndrome ORPHA:1493; Wiedemann-Steiner syndrome ORPHA:319182; Acute myeloid leukemia with t(9;11)(p22;q23) ORPHA:402017; Cushing disease ORPHA:96253; Hemimegalencephaly ORPHA:99802; Kleefstra syndrome due to a point mutation ORPHA:261652; Mixed phenotype acute leukemia ORPHA:530995; Ochoa syndrome ORPHA:2704; Autosomal dominant epilepsy with auditory features ORPHA:101046; Noonan syndrome with multiple lentigines ORPHA:500; Postaxial polydactyly type A ORPHA:93334",0.0155394890951578; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7150309491065155; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
HERPUD1,"Carcinoma of bladder; Bladder Neoplasm; Carcinogenesis; leukemia; TARSAL-CARPAL COALITION SYNDROME; Adult T-Cell Lymphoma/Leukemia; Glioma; Malignant neoplasm of prostate; Ataxia Telangiectasia; Leukemia, T-Cell; Prostate carcinoma; Neoplasm Metastasis; Prostatic Neoplasms; Hyperhomocysteinemia; Burkitt Lymphoma; Hodgkin Disease; Congenital chromosomal disease; Acute lymphocytic leukemia; Classical Hodgkin's Lymphoma; Myeloid Leukemia, Chronic; Alcoholic Intoxication, Chronic; Reactive systemic amyloidosis; HIV Infections; Precursor Cell Lymphoblastic Leukemia Lymphoma; Triglycerides measurement; Carcinoma, Transitional Cell; Philadelphia chromosome-positive acute lymphoblastic leukemia",0.4084380369379369; 0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8098851543361193; 0.8145035474981049; 0.8190761496232595; 0.8232134984476662; 0.8368219249856942; 0.887595340546704,Prostate Cancer; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome ORPHA:445062,0.5867963421058087; 0.8922466888454011,"Human betaherpesvirus 6 U31, large tegument protein (gene: U31); Human betaherpesvirus 6A large tegument protein (gene: U31); Human betaherpesvirus 6B large tegument protein (gene: U31); Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Dugbe virus L protein; Human betaherpesvirus 7 large tegument protein (gene: U31); Human betaherpesvirus 5 large tegument protein (gene: UL48); Influenza B virus nonstructural protein 1 (gene: NS1); Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); SARS coronavirus Tor2 replicase 1AB; SARS coronavirus P2 full_polyprotein 1..7073; SARS coronavirus nsp3-pp1a/pp1ab (gene: orf1ab); Influenza B virus (B/Memphis/12/97) NS protein; Human immunodeficiency virus envelope glycoprotein (gene: env); SARS coronavirus excised_polyprotein 1..4369 (gene: orf1ab); SARS coronavirus P2 full_polyprotein 1..4382",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764,,,,
HEXIM1,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; leukemia; Leukemia, Myelocytic, Acute; Right Ventricular Hypertrophy; Leukemogenesis; Malignant neoplasm of prostate; Liver carcinoma; Prostate carcinoma; Neuroblastoma; Central neuroblastoma; melanoma; Tumor Progression; Adenocarcinoma of prostate; Myeloid Leukemia; Secondary malignant neoplasm of liver; Liver Cirrhosis, Experimental; Left Ventricular Hypertrophy; Aneurysm; Hypertensive disease; Idiopathic pulmonary arterial hypertension; Muscle degeneration; Myopathy; Acute Erythroblastic Leukemia; Drug Dependence",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8014900279306119; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.9262273158806068; 0.9450328871666054; 0.9557184806547836; 0.9639249377588224; 0.9816840072553962,,,,,Salivirus NG-J1 3D; Influenza B virus (B/Memphis/12/97) HA protein; Vaccinia virus cowpox A-type inclusion protein; Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; Hendra henipavirus phosphoprotein P (gene: P/V/C),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,Escherichia coli,0.59,Homo sapiens,Homo sapiens
HIP1R,Diffuse Large B-Cell Lymphoma; MAJOR AFFECTIVE DISORDER 8; MAJOR AFFECTIVE DISORDER 9; MAJOR AFFECTIVE DISORDER 7; Chronic Lymphocytic Leukemia; Essential Tremor; MAJOR AFFECTIVE DISORDER 4; MAJOR AFFECTIVE DISORDER 6; MAJOR AFFECTIVE DISORDER 1; MAJOR AFFECTIVE DISORDER 2; Parkinson Disease; Bipolar Disorder; Trisomy; Protein Deficiency,0.7333611688795861; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8101097852323003; 0.8101097852323003; 0.8145035474981049; 0.8402911822757345; 0.8772392350816924; 0.900167961295542; 0.9029289778792944; 0.9119978323790848,Schizophrenia; Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Bipolar Disorder,0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.943322675973118,Bilateral frontoparietal polymicrogyria ORPHA:101070,0.1040670578681756,Cowpox virus Ati or CPXV158 protein (gene: ati); Sagiyama virus full_polyprotein 1..1253 (gene: C-E3-E2-6K-E1); Vaccinia virus cowpox A-type inclusion protein; Nipah henipavirus P phosphoprotein,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,Escherichia coli;In vitro,0.56,Homo sapiens,Homo sapiens
HOTAIR,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Laryngeal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; Leukemia, Myelocytic, Acute; TARSAL-CARPAL COALITION SYNDROME; Malignant tumor of colon; Esophageal carcinoma; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasm; Carcinoma breast stage IV; Endometrial Carcinoma; Esophageal Neoplasms; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Malignant neoplasm of esophagus; Osteosarcoma; Colorectal Cancer; Epithelial ovarian cancer; Liver and Intrahepatic Biliary Tract Carcinoma; Hepatocarcinogenesis; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Triple Negative Breast Neoplasms; Malignant neoplasm of liver; Cancer of Digestive System; Ductal Carcinoma; Immunologic Deficiency Syndromes; Malignant Neoplasms; melanoma; Gastrointestinal Diseases; Malignant neoplasm of stomach; Transitional cell carcinoma of bladder; Noninfiltrating Intraductal Carcinoma; Benign Prostatic Hyperplasia; Malignant neoplasm of large intestine; Nasopharyngeal carcinoma; Tumor Progression; Lupus Erythematosus, Systemic; Childhood Glioblastoma; Renal Cell Carcinoma; Adult Glioblastoma; Tumor Initiation; Digestive System Disorders; Stomach Carcinoma; Stage IV Colorectal Cancer; Stage IV Colorectal Cancer AJCC v7; Squamous cell carcinoma; Rheumatoid Arthritis; Carcinoma; Small cell carcinoma of lung; Hormone refractory prostate cancer; Metastatic Neoplasm; Myeloid Leukemia, Chronic; Secondary malignant neoplasm of liver; Primary malignant neoplasm; Leukocyte adhesion deficiency type 1; Gastrointestinal Stromal Sarcoma; Primary Sj??gren's syndrome; Malignant neoplasm of gallbladder; Hereditary Diffuse Gastric Cancer; Childhood Osteosarcoma; Stomach Neoplasms; Adenocarcinoma of lung (disorder); Aortic valve calcification; Gastric Cardia Adenocarcinoma; Gastric Adenocarcinoma; Gallbladder Carcinoma; Multiple tumors; Glioblastoma Multiforme; Recurrent tumor; Lymphatic Metastasis; Carcinoma, Transitional Cell; Neoplasm Recurrence, Local; Malignant Squamous Cell Neoplasm; Aortic Aneurysm, Thoracic; Inflammatory Breast Carcinoma; Hepatitis B; Squamous cell carcinoma of esophagus; Renal carcinoma; Giant Cell Arteritis; Parkinson Disease; Heart Diseases; Secondary malignant neoplasm of lymph node; Malignancy; Urothelial Carcinoma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8098851543361193; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8342163953428735; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.841396342333011; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8772392350816924; 0.8989612563669234; 0.900167961295542; 0.906476206143938; 0.9441119274323576,Liver Carcinoma; Stomach Neoplasms; Cervical Cancer; Gastric Cancer; Uterine Cervix Neoplasm,0.7765582368651238; 0.7765582368651238; 0.861756360478846; 0.861756360478846; 0.861756360478846,,,,,,,,
HOXB13,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Adenocarcinoma; Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Endometrial Neoplasms; Prostatic Intraepithelial Neoplasias; Colorectal Neoplasms; Endometrial Carcinoma; Mammary Neoplasms; Malignant neoplasm of prostate; Colorectal Cancer; Prostate carcinoma; Prostatic Neoplasms; melanoma; Renal Cell Carcinoma; Neoplastic Syndromes, Hereditary; Myxopapillary ependymoma; Solid Neoplasm; Aortic Valve Insufficiency; Prostate cancer, familial; Phyllodes Tumor; ovarian neoplasm; Breast cancer recurrent; Early-Stage Breast Carcinoma; Neoplasm Invasiveness; Recurrent tumor; Squamous cell carcinoma of esophagus; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Mammary Neoplasms, Human; Secondary malignant neoplasm of lymph node",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8145035474981049; 0.8168901801930506; 0.8232134984476662; 0.8368219249856942; 0.8610447277138289; 0.8769418330148872; 0.8771562273432176; 0.8815127642200768; 0.900167961295542,"Prostate Cancer; Melanoma; Prostatic Neoplasms; Prostate Cancer, Hereditary; Hereditary Cancer Syndrome; Ovarian Cancer; Mammary Neoplasms; Colonic Neoplasms; Marfan Syndrome; Breast Cancer; Breast Carcinoma",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.8165359516083085; 0.8210988731657684; 0.8477374749042494; 0.8903630091389316; 0.9398381935810408,"Familial prostate cancer ORPHA:1331; Guttmacher syndrome ORPHA:2957; Hand-foot-genital syndrome ORPHA:2438; Brachydactyly-syndactyly, Zhao type ORPHA:93409; Frontonasal dysplasia-alopecia-genital anomalies syndrome ORPHA:228390; NON RARE IN EUROPE: Brachydactyly type D ORPHA:93385; Syndactyly type 5 ORPHA:93406; Synpolydactyly type 1 ORPHA:295195; VACTERL/VATER association ORPHA:887; Zygodactyly type 3 ORPHA:295191",0.2844858212863536; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
HS6ST1,"Sparse body hair; Cartilage-hair hypoplasia; Reduced bone mineral density; Diabetes; Diabetes Mellitus; Abnormality of the voice; Abnormality of body height; Increased female libido; Generalized osteopenia; Eunuchoid habitus; Hypothalamic gonadotropin-releasing hormone deficiency; Absence of pubertal development; Wide spaced nipples; Erectile abnormalities; Female hypogonadism syndrome; Kallmann Syndrome; Absence of secondary sex characteristics; Anterior hypopituitarism; Osteopenia; Congenital hypoplasia of penis; Decreased testosterone in males; Testicular hypogonadism; Congenital hypoplasia of breast; Infantile uterus; Sense of smell impaired; Anosmia; Secondary physiologic amenorrhea; Cryptorchidism; Congenital hypoplasia of ovary; Hypoplastic ovary; Decreased fertility; Small testicle; Delayed bone age; Hypogonadotropic hypogonadism; Idiopathic hypogonadotropic hypogonadism; Depressive disorder; Primary physiologic amenorrhea; Anxiety disease; Gynecomastia; Non-obstructive azoospermia; Cyst; Idiopathic Pulmonary Fibrosis; Hypogonadism, Isolated Hypogonadotropic; Erectile dysfunction; Delayed Puberty; Osteoporosis; Anxiety",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8138488881521341; 0.8145035474981049; 0.8212681436603975; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8272008757995397; 0.8272008757995397; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8584283190330553; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.9103315000053974; 0.914995991166204; 0.9154499654632742; 0.917543617287358; 0.9193385822373632; 0.929235785949896; 0.9393256300017014; 0.9505280654948344; 0.951016614400691; 0.957487573707278; 0.9639249377588224; 0.9708740267329932,Nystagmus; Schizophrenia; Secondary Physiologic Amenorrhea; Osteopenia; Normosmic Congenital Hypogonadotropic Hypogonadism; Hypogonadotropic Hypogonadism With Or Without Anosmia; Hearing Loss; Diabetes; Congenital Camptodactyly; Penis Agenesis; Female Hypogonadism Syndrome; Skeletal Dysplasia; Osteochondrodysplasia; Kallmann Syndrome; Mirror Movements; Testicular Hypogonadism; Anxiety Disorder; Breast Hypoplasia; Paraplegia; Cryptorchidism; Hypoplasia Of The Ovary; Congenital Sensorineural Hearing Loss; Osteoporosis; Hypopituitarism; Mental Depression; Erectile Dysfunction; Diabetes Mellitus; Non-obstructive Azoospermia; Gynecomastia; Renal Agenesis; Physiologic Amenorrhea; Hypogonadotropic Hypogonadism; Ptosis; Ichthyosis; Obesity; Dysarthria,0.7765582368651238; 0.7860378120955526; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8182883735985873; 0.8210988731657684; 0.8210988731657684; 0.8356859041719433; 0.8457525389282121; 0.8507213163251659; 0.8611702959552964; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.8706864397989688; 0.8903301324869451; 0.8903630091389316; 0.8903630091389316; 0.9046917974656596; 0.919442421650838; 0.919442421650838; 0.951883341147811; 0.9574431947800732; 0.9726837163662044; 0.980894832851993; 0.9832345076528324; 0.9832345076528324; 0.9832345076528324; 0.988987376043163,Antley-Bixler syndrome ORPHA:83; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; NAD(P)HX dehydratase deficiency ORPHA:555402; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; Crouzon disease ORPHA:207; Familial multinodular goiter ORPHA:276399; Hyperprolinemia type 2 ORPHA:79101; Normosmic congenital hypogonadotropic hypogonadism ORPHA:432; Kallmann syndrome ORPHA:478,0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011,,,,,,
HTR7P1,,,,,"Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223",0.1991445465001551; 0.1991445465001551,,,,,,
IER3,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; leukemia; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; MYELODYSPLASTIC SYNDROME; Cervix carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasm; Malignant tumor of cervix; Glioma; Osteosarcoma; Acute Promyelocytic Leukemia; Colorectal Cancer; Liver and Intrahepatic Biliary Tract Carcinoma; Osteosarcoma of bone; cervical cancer; Malignant neoplasm of liver; Malignant neoplasm of stomach; Mental disorders; Abnormal behavior; Severe Combined Immunodeficiency; Lupus Erythematosus, Systemic; Stomach Carcinoma; Autoimmune Diseases; Squamous cell carcinoma; Huntington Disease; Virus Diseases; Dermatitis, Irritant; Lupus Erythematosus; Lupus Erythematosus, Discoid; Pancreatitis; Arteriovenous fistula; Gastric Adenocarcinoma; Lupus Vulgaris; Infection; Sezary Syndrome; Hypertensive disease; Leishmaniasis, Cutaneous; Arsenic Poisoning, Inorganic; Nervous System, Organic Arsenic Poisoning; Arsenic Encephalopathy; Arsenic Induced Polyneuropathy; Arsenic Poisoning; Pseudohyperkalemia Cardiff; Colitis; Dermatologic disorders",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8168901801930506; 0.8168901801930506; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8474481237156937; 0.8554819098734854; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.9578035687879456; 0.9738491767258852; 0.9912501168001682,Hypertension; Dermatitis; Arsenic Encephalopathy; Dermatologic Disorders,0.7765582368651238; 0.861756360478846; 0.8932724875174971; 0.9259420053407031,"Crisponi syndrome ORPHA:1545; Quebec platelet disorder ORPHA:220436; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Thyroid ectopia ORPHA:95712; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; B4GALT1-CDG ORPHA:79332; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972; FTH1-related iron overload ORPHA:247790; Hypoplastic amelogenesis imperfecta ORPHA:100031",0.0155394890951578; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8105918570729571,,,,,,
IFI30,"Malignant neoplasm of breast; Breast Carcinoma; Leukemia, Myelocytic, Acute; Carcinoma breast stage IV; Acute Myeloid Leukemia, M1; melanoma; Hemophilia B; Acute Myeloid Leukemia (AML-M2); Cardiovascular Diseases; Diabetes; Diabetes Mellitus; Hyperglycemia; Tumor Immunity; Experimental Organism Basal Cell Carcinoma; Multiple Sclerosis; Neuromyelitis Optica; Metabolic Syndrome X; Obesity; Dermatitis, Allergic Contact",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8402911822757345; 0.8610447277138289; 0.8989612563669234; 0.9431511078237256,Leukemia; Myeloid Leukemia; Dermatitis; Multiple Sclerosis,0.7765582368651238; 0.8356859041719433; 0.861756360478846; 0.980894832851993,"CLN11 disease ORPHA:314629; Heme oxygenase-1 deficiency ORPHA:562509; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Aicardi-Goutieres syndrome ORPHA:51; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Autosomal dominant dopa-responsive dystonia ORPHA:98808; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; GTP cyclohydrolase I deficiency ORPHA:2102; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; Waldenstrom macroglobulinemia ORPHA:33226; Dehydrated hereditary stomatocytosis ORPHA:3202; Takayasu arteritis ORPHA:3287; Autosomal recessive malignant osteopetrosis ORPHA:667; CLN3 disease ORPHA:228346; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Fructose-1,6-bisphosphatase deficiency ORPHA:348; Multiple intestinal atresia ORPHA:2300; Palmoplantar keratoderma-esophageal carcinoma syndrome ORPHA:2198; Metaphyseal anadysplasia ORPHA:1040; Dysosteosclerosis ORPHA:1782; Pediatric systemic lupus erythematosus ORPHA:93552; Autosomal dominant severe congenital neutropenia ORPHA:486; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; Herpes simplex virus encephalitis ORPHA:1930; Exfoliative ichthyosis ORPHA:289586; Immunodeficiency by defective expression of MHC class I ORPHA:34592; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Charcot-Marie-Tooth disease type 1C ORPHA:101083; Galactose mutarotase deficiency ORPHA:570422; Galactosialidosis ORPHA:351; Genetic hyperferritinemia without iron overload ORPHA:254704; Haim-Munk syndrome ORPHA:2342; Hereditary hyperferritinemia-cataract syndrome ORPHA:163; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia ORPHA:572428; L-ferritin deficiency ORPHA:440731; Mucopolysaccharidosis type 7 ORPHA:584; Neuroferritinopathy ORPHA:157846; Papillon-Lefevre ORPHA:678; Cystic leukoencephalopathy without megalencephaly ORPHA:85136; Mitochondrial neurogastrointestinal encephalomyopathy ORPHA:298; Chronic mucocutaneous candidiasis ORPHA:1334; Acatalasemia ORPHA:926; Alpha-1-antitrypsin deficiency ORPHA:60; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency ORPHA:319589; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency ORPHA:319574; Fowler vasculopaty ORPHA:221126; Fucosidosis ORPHA:349; Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation ORPHA:178396; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency ORPHA:319547; Overgrowth-macrocephaly-facial dysmorphism syndrome ORPHA:137634; Recurrent Neisseria infections due to factor D deficiency ORPHA:169467; Sterile multifocal osteomyelitis with periostitis and pustulosis ORPHA:210115; Transaldolase deficiency ORPHA:101028; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia ORPHA:632; Alpha-N-acetylgalactosaminidase deficiency type 1 ORPHA:79279; Alpha-N-acetylgalactosaminidase deficiency type 2 ORPHA:79280; Alpha-N-acetylgalactosaminidase deficiency type 3 ORPHA:79281; Cholesteryl ester storage disease ORPHA:75234; GM2 gangliosidosis, AB variant ORPHA:309246; Hyper-IgM syndrome type 3 ORPHA:101090; SLC39A8-CDG ORPHA:468699; Spondyloenchondrodysplasia ORPHA:1855; Wolman disease ORPHA:75233; Diffuse cutaneous systemic sclerosis ORPHA:220393; CLN1 disease ORPHA:228329",0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1294848460749822; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2047219337649946; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
IFI44,"androgen independent prostate cancer; Nonspecific interstitial pneumonia; Malignant neoplasm of prostate; Prostate carcinoma; Benign Prostatic Hyperplasia; Lupus Erythematosus, Systemic; Seminoma; Hepatitis C; Rheumatoid Arthritis; Human anaplasmosis due to Anaplasma phagocytophilum; Testicular Neoplasms; Prostatic Hyperplasia; Spinal Muscular Atrophy; liposarcoma; Influenza; Abortion, Tubal; Spontaneous abortion",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8806784681730055; 0.9193385822373632; 0.9446671211493156; 0.963331724428282,Miscarriage,0.9658957825498884,Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Variant ABeta2M amyloidosis ORPHA:314652; Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome ORPHA:391487; Autosomal dominant Kenny-Caffey syndrome ORPHA:93325; Familial normophosphatemic tumoral calcinosis ORPHA:306658; Generalized glucocorticoid resistance syndrome ORPHA:786; Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia ORPHA:572428; MIRAGE syndrome ORPHA:494433; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency ORPHA:319595; Osteocraniostenosis ORPHA:2763; Proteasome-associated autoinflammatory syndrome ORPHA:324977; Susceptibility to viral and mycobacterial infections due to STAT1 deficiency ORPHA:391311; USP18 deficiency ORPHA:481665; Familial Chilblain lupus ORPHA:481662; Singleton-Merten dysplasia ORPHA:85191; 1p21.3 microdeletion syndrome ORPHA:293948; Dihydropyrimidine dehydrogenase deficiency ORPHA:1675; STING-associated vasculopathy with onset in infancy ORPHA:425120; Ataxia-pancytopenia syndrome ORPHA:2585,0.0155394890951578; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
IGSF8,Glioma; Malignant neoplasm of prostate; Glioblastoma; Prostate carcinoma; Neoplasm Metastasis; Prostatic Neoplasms; melanoma; Hepatitis C; Metastatic melanoma; Secondary malignant neoplasm of lung,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7940665326856218; 0.8232134984476662,,,Familial lipase maturation factor 1 deficiency ORPHA:535453; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Focal dermal hypoplasia ORPHA:2092; Kufor-Rakeb syndrome ORPHA:306674; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Leukonychia totalis ORPHA:2387; NAD(P)HX dehydratase deficiency ORPHA:555402; Early myoclonic encephalopathy ORPHA:1935; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome ORPHA:171848; CLN13 disease ORPHA:352709; Infantile cerebellar-retinal degeneration ORPHA:313850,0.0155394890951578; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2386105733903937; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,"Human T-lymphotropic virus 3 envelope (gene: env); Human T-cell lymphotropic virus type 2b env; Human T-lymphotropic virus 4 envelope glycoprotein (gene: env); Human T-lymphotropic virus 2 p21E envelope protein; Japanese encephalitis virus hypothetical protein; Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Human T-cell leukemia virus type I gp46 SU (gene: env); Molluscum contagiosum virus subtype 1 MC069R (gene: MC069R); Influenza B virus (B/Memphis/12/97) HA protein; Ntaya virus full_polyprotein 1..3427; Ilheus virus full_polyprotein 1..3424; Tai Forest ebolavirus spike glycoprotein (gene: GP); Adeno-associated virus 3B capsid protein VP1; Vaccinia virus IMV membrane protein (gene: L1R); Vaccinia virus Ankara myristylated IMV virion protein; Variola virus hypothetical protein (gene: M1R); Cowpox virus CPXV099 protein (gene: CPXV099 CDS); Monkeypox virus myristylprotein; Monkeypox virus Zaire-96-I-16 M1R (gene: M1R); Ectromelia virus ERPV IMV myristylated membrane protein; Horsepox virus HSPV089 (Lipid membrane protein); Cowpox virus CPXV123 protein (gene: CPXV123 CDS); Yaba monkey tumor virus 60R; Yaba-like disease virus 60R protein (gene: 60R); Monkeypox virus early gene transcription factor VETF 70 kDa small subunit; Monkeypox virus Zaire-96-I-16 E6R (gene: E6R); Reston ebolavirus spike glycoprotein (gene: GP); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) hemagglutinin (gene: HA); Human orthopneumovirus fusion protein (gene: F); Dengue virus 2 envelope protein E (gene: flavivirus polyprotein); Human betaherpesvirus 6B glycoprotein (gene: U85); Human immunodeficiency virus 1 Gag-Pol (gene: gag-pol); Influenza A virus (A/California/04/2009(H1N1)) HA1 (gene: HA); Cercopithecine betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Hepatitis B virus pre-capsid protein (gene: C); Bundibugyo ebolavirus spike glycoprotein (gene: GP); Human immunodeficiency virus 1 Pr55(Gag) (gene: gag); Influenza A virus (A/Northern Territory/60/1968(H3N2)) HA2 (gene: HA); HBV genotype D HBeAg (gene: PreC/C); Human gammaherpesvirus 8 K4.1 (gene: K4.1); Influenza A virus (A/Korea/426/1968(H2N2)) HA1 (gene: HA); Influenza A virus (A/New York/392/2004(H3N2)) HA1 (gene: HA); HBV genotype H PC/C protein (gene: PC/C); HBV genotype B preC/C protein (gene: preC/C); HBV genotype C core protein (gene: C); HBV genotype C HBeAg (gene: PreC/C); Variola virus S-S bond formation pathway protein (gene: C13L); Human immunodeficiency virus gag protein (gene: gag); HBV recombinant C/G HBeAg (gene: preC/C); Hepatitis B virus capsid protein (gene: C); HBV recombinant B/C HBc protein (gene: C); Wesselsbron virus full_polyprotein 1..3405; HBV genotype C preC/C protein (gene: preC/C); Macacine alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Dengue virus 3 envelope protein E (gene: flavivirus polyprotein); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Influenza A virus (A/New York/599/1996(H3N2)) HA1 (gene: HA); Adeno-associated virus - 4 capsid; Norovirus GII/Hu/JP/2011/GII/Yuzawa/Gira2HS VP1 (gene: VP1); HBV genotype C HBc protein (gene: C); Yaba-like disease virus 141R protein (gene: 141R); Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Molluscum contagiosum virus subtype 1 MC161R (gene: MC161R); Human immunodeficiency virus 1 Envelope surface glycoprotein gp160, precursor (gene: env); Vaccinia virus cowpox A-type inclusion protein; Influenza A virus (A/Korea/426/1968(H2N2)) hemagglutinin (gene: HA); Influenza A virus (A/Hong Kong/1073/99(H9N2)) Hemagglutinin (gene: ha); Human immunodeficiency virus 2 full_polyprotein 1..521 (gene: gag-pol); Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); HBV genotype B C protein (gene: C); Influenza A virus (A/Northern Territory/60/1968(H3N2)) HA1 (gene: HA); West Nile virus SA93/01 envelope protein; West Nile virus SPU116/89 envelope protein; Human alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Influenza A virus (A/New York/599/1996(H3N2)) hemagglutinin (gene: HA); Human betaherpesvirus 6B G-protein coupled receptor (gene: U12); West Nile virus lineage 1 envelope protein E (gene: flavivirus polyprotein); HBV genotype C C protein (gene: C); Influenza A virus (A/New York/392/2004(H3N2)) hemagglutinin (gene: HA); West Nile virus SA381/00 envelope protein; Norovirus GII.17 VP1 (gene: VP1); Human herpesvirus 4 type 2 BARF1; Influenza A virus (A/New York/602/1996(H3N2)) hemagglutinin (gene: HA); Murray Valley encephalitis virus envelope protein E; Rio Bravo virus envelope protein; West Nile virus H442 envelope protein; Ebola virus - Mayinga, Zaire, 1976 virion spike glycoprotein precursor (gene: GP); Zaire ebolavirus spike glycoprotein (gene: GP); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) haemagglutinin (gene: HA); Norovirus Hu/GII.3/HK71/1978/CHN capsid protein VP1 (gene: VP1); Human T-lymphotropic virus 2 Gag-Pro-Pol; Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Human adenovirus 56 CR1 beta protein (gene: E3); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) HA2 (gene: HA); Norovirus GII/Hu/JP/2000/GII.P12_GII.12/Saitama/KU16 VP1 (gene: VP1); Influenza A virus (A/Northern Territory/60/1968(H3N2)) hemagglutinin (gene: HA); Norovirus GII/Hu/JP/2001/GII.P12_GII.12/Saitama/T15 VP1 (gene: VP1); Norovirus GII/Hu/JP/2001/GII.P12_GII.12/Saitama/T18 VP1 (gene: VP1); Norovirus GII/Hu/JP/2002/GII.P16_GII.17/Saitama/T87 VP1 (gene: VP1); Human betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Human T-cell leukemia virus type I p21 TM (gene: env); Vaccinia virus IL-beta-binding protein (gene: VACWR-B15R); Norovirus Hu/GII/10002/2009/VNM capsid protein VP1 (gene: VP1); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Norovirus Hu/GII.12/CGMH39/2010/TW VP1; Norovirus Hu/GII.12/CGMH40/2010/TW VP1; Norovirus Hu/GII.12/CGMH41/2010/TW VP1; Norovirus Hu/GII.12/CGMH42/2010/TW VP1; Norovirus Hu/GII.12/HS210/2010/USA capsid protein VP1; Norovirus Hu/GII.g-GII.12/Gunnedah/NSW895P/2010/AU VP1; Norovirus Hu/GII.g-GII.12/Wahroonga/NSW004P/2009/AU VP1; Norovirus GII/Hu/JP/2007/GII.P7_GII.14/Fukuoka/KK282 VP1 (gene: VP1); Norovirus Hu/GII.12/HS206/2010/USA VP1; Norovirus Hu/GII.4/CHDC4871/1977/US VP1; Norovirus Hu/GII.4/CHDC5191/1974/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII/10003/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII/10012/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10034/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10054/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10062/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10075/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10078/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10079/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10110/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10114/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10129/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10136/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10145/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10158/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10160/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10163/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10169/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10177/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10179/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10182/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10194/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10203/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10204/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10222/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10238/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10255/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10296/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20010/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20014/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20019/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20067/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20069/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20092/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20093/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20118/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20122/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20128/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20135/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20139/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20140/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20142/2009/VNM capsid protein VP1 (gene: VP1); Macacine alphaherpesvirus 1 envelope glycoprotein D (gene: US6); Sudan ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus - Nakisamata structural glycoprotein (gene: GP); Influenza A virus (A/Korea/426/1968(H2N2)) HA2 (gene: HA); Norovirus Hu/GII.12/CGMH38/2010/TW VP1; Norovirus Hu/GII.14/8610/Saga/2008/JPN capsid protein; Norovirus Hu/GII.4/HS191/2004/USA VP1; Norovirus Hu/GII.4/HS66/2001/USA capsid protein VP1 (gene: VP1); Japanese encephalitis virus prodexcised_polyprotein 1..794; Dengue virus full_polyprotein 1..3387; Ectromelia virus ERPV IL-1 beta receptor; Human immunodeficiency virus 1 Envelope surface glycoprotein gp120 (gene: env); Norovirus Hu/GII.4/CHDC2094/1974/US VP1; Norovirus Hu/GII.4/MD-2004/2004/US VP1; Human immunodeficiency virus pol protein (gene: pol); Human calicivirus NLV/GII/Langen1061/2002/DE major structural protein; Norovirus GII/Hu/JP/2007/GII.P7_GII.14/Sendai/YG99 VP1 (gene: VP1); Norovirus Hu/GII.4/Ohio/7I/2012/USA major capsid protein; Norovirus Hu/Norwalk/10328/2010/VNM capsid protein VP1 (gene: VP1); Human gammaherpesvirus 8 K14; West Nile virus lineage 1 excised_polyprotein 1..787 (gene: flavivirus polyprotein); Papiine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Saint Louis encephalitis virus full_polyprotein 1..3430; Influenza A virus (A/California/07/2009(H1N1)) HA1 (gene: HA); Norovirus Hu/GII-4/CGMH19/2009/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Randwick/NSW882J/2011/AU VP1; Norovirus Hu/GII/Seoul1367/KOR/2010 major capsid protein; Dengue virus 4 envelope protein E (gene: flavivirus polyprotein); Influenza A virus (A/Shanghai/02/2013(H7N9)) HA2 (gene: HA); Norovirus Hu/GII.4/Jannali/NSW774M/2011/AU VP1; Norovirus Hu/GII.4/Ohio/7G/2012/USA major capsid protein; Norovirus Hu/GII.4/Seoul/1071/2010/KOR major capsid protein; Norovirus Hu/GII/Seoul1055/KOR/2010 major capsid protein; Cercopithecine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Human adenovirus 28 fiber; Norovirus Hu/GII-4/CGMH01/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/JB-15/KOR/2008 capsid protein; Human metapneumovirus fusion glycoprotein precursor (gene: F); Norovirus Hu/GII.4/NIHIC1.13/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC1.16/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII/Seoul1072/KOR/2010 major capsid protein; Human betaherpesvirus 5 membrane protein UL6 (gene: UL6); Influenza A virus (A/Puerto Rico/8/1934(H1N1)) HA1 (gene: HA); Norovirus Hu/GII/BG1C0004/2010/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10235/2009/VNM capsid protein VP1 (gene: VP1); Human adenovirus 22 fiber protein (gene: L5); Human immunodeficiency virus envelope glycoprotein (gene: env); Norovirus Hu/GII/10037/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII/BG1C0066/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/GII/BG1C0282/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10199/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20008/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20066/2009/VNM capsid protein VP1 (gene: VP1); Ectromelia virus ERPV hemagglutinin; Norovirus Hu/GII-4/CGMH20/2009/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII/20477/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10176/2009/VNM capsid protein VP1 (gene: VP1); Human adenovirus 31 fiber protein (gene: FIber); Norovirus Hu/GII/BG1C0204/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/GII/BG1C0270/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/GII/BG1C0317/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20094/2009/VNM capsid protein VP1 (gene: VP1); Murray Valley encephalitis virus prodexcised_polyprotein 1..793; Norovirus Hu/Norwalk/10137/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10223/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20044/2009/VNM capsid protein VP1 (gene: VP1); Human betaherpesvirus 5 envelope glycoprotein UL4 (gene: UL4); Human alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Norovirus Hu/Norwalk/10074/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10162/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10173/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20016/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20035/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/20047/2009/VNM capsid protein VP1 (gene: VP1); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Human immunodeficiency virus 1 Pol (gene: gag-pol); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Norovirus GII/Hu/JP/2001/GII.P22_GII.5/Saitama/T49 VP1 (gene: VP1); Norovirus GII/Hu/JP/2010/GII.P4_GII.4/Shimada/ASC96 VP1 (gene: VP1); Norovirus Hu/GII-4/CBNU2/2007/KR capsid protein; Norovirus Hu/GII.4/Berowra/NSW767L/2012/AU VP1; Norovirus Hu/GII.4/NIHIC11.3/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10247/2009/VNM capsid protein VP1 (gene: VP1); Influenza A virus (A/Shanghai/02/2013(H7N9)) hemagglutinin (gene: HA); Norovirus Hu/GII-4/CGMH13/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/CHDC4108/1987/US VP1; Norovirus Hu/Norwalk/10051/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10116/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10183/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10236/2009/VNM capsid protein VP1 (gene: VP1); Human calicivirus Hu/NLV/GII/MD145-12/1987/US capsid protein; Human mastadenovirus A fiber; Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/108 VP1 (gene: VP1); Norovirus GII/Hu/TW/2012/GII.Pe_GII.4_Sydney2012/Taipei/109 VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH23/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH26/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/CHDC3967/1988/US VP1; Norovirus Hu/GII.4/GZ2010-L87/Guangzhou/CHN/2011 major viral capsid protein (gene: VP1); Human adenovirus 12 fiber protein; Norovirus Hu/Norwalk/10368/2010/VNM capsid protein VP1 (gene: VP1); Human mastadenovirus E fiber (gene: L5); Human adenovirus E4 fiber protein; Norovirus Hu/GII-4/CGMH21/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH24/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH25/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH27/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Caringbah/NSW409G/2011/AU VP1; Norovirus Hu/GII.4/HS292/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC13/2011/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC18.1/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC27.1/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC28.4/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/New Orleans/2010/USA VP1; Norovirus Hu/GII.4/SGU-110421/KOR/2011 VP1; Norovirus Hu/GII/20469/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII/BG1C0241-33/2011/BGD capsid protein VP1 (gene: VP1); Norovirus Hu/GII/Seoul1282/KOR/2010 major capsid protein; Norovirus Hu/GII/Seoul1488/KOR/2011 major capsid protein; Norovirus Hu/Norwalk/10325/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10386/2010/VNM capsid protein VP1 (gene: VP1); Human adenovirus Chiba_E086/2012 fiber (gene: L5); Norovirus GII/Hu/JP/2002/GII.P5_GII.5/Saitama/T52 VP1 (gene: VP1); Norovirus Hu/GII-4/CGMH05/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH08/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH16/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Doonside/NSW536I/2011/AU VP1; Norovirus Hu/GII.4/GZ2010-L26/Guangzhou/CHN/2010 major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Jiangsu1/2011/CHN major capsid protein; Norovirus Hu/GII.4/NIHIC2.2/2010/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC2.3/2010/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC27.2/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII/Shanghai/SH2/2008/CHN VP1; Norovirus Hu/Norwalk/10285/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10313/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Norwalk/10378/2010/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/Shanghai/SH5/2009/CHN VP1; Variola virus hypothetical protein (gene: J9R); Norovirus Hu/GII-4/CGMH11/2006/TW major viral capsid protein; Norovirus Hu/GII-4/CGMH14/2007/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH15/2007/TW major viral capsid protein; Norovirus Hu/GII.4/20199/2009/VNM capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/HS288/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.1/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.5/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.6/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.8/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC17.9/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC28.5/2012/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/NIHIC35/2013/USA capsid protein VP1 (gene: VP1); Norovirus Hu/GII.4/Ohio/684/USA VP1; Norovirus Hu/GII.4/Rockdale/NSW006D/2009/AU VP1; Norovirus Hu/Norwalk/20123/2009/VNM capsid protein VP1 (gene: VP1); Human mastadenovirus A E3 CR1-beta1; Horsepox virus HSPV192 (IL-beta-binding protein; Provisional); Modoc virus envelope protein; Norovirus Hu/GII-4/CGMH10/2006/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH22/2010/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII.4/Miranda/NSW850K/2011/AU VP1; Norovirus Hu/Norwalk/20033/2009/VNM capsid protein VP1 (gene: VP1); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) HA2 (gene: HA); Norovirus Hu/GII-4/CGMH18/2008/TW major viral capsid protein (gene: VP1); Norovirus Hu/GII-4/CGMH28/2010/TW major viral capsid protein (gene: VP1); Human adenovirus 43 fiber protein (pIV) (gene: L5); Influenza A virus (A/California/04/2009(H1N1)) hemagglutinin (gene: HA); Influenza A virus (A/California/07/2009(H1N1)) hemagglutinin (gene: HA); Norovirus Hu/GII.4/Guangzhou/GZ2010-L88/CHN/2011 major viral capsid protein; Norovirus Hu/GII.4/Guangzhou/GZ2010-L91/CHN/2011 major viral capsid protein; Human gammaherpesvirus 8 K6 (gene: K6); Human T-lymphotropic virus 2 full_polyprotein 1..982; West Nile virus lineage 2 excised_polyprotein 1..2273 (gene: flavivirus polyprotein); Reston ebolavirus - Reston virion spike glycoprotein precursor (gene: GP); Molluscum contagiosum virus subtype 1 MC013L (gene: MC013L); Vaccinia virus Ankara CD47-like protein; West Nile virus lineage 2 envelope protein E (gene: flavivirus polyprotein); Horsepox virus HSPV177 (Immunoglobulin like); Orf virus ORF132 vascular endothelial growth factor-like protein; Human adenovirus 36 fiber; SARS coronavirus P2 spike glycoprotein precursor; SARS coronavirus E2 glycoprotein precursor (gene: S); SARS coronavirus Tor2 spike glycoprotein; Molluscum contagiosum virus subtype 1 MC148R (gene: MC148R); Human papillomavirus 173 E1; Human adenovirus D37 48.9 kDa (gene: E3); Human adenovirus 71 fiber (gene: L5); Influenza A virus (A/New York/599/1996(H3N2)) HA2 (gene: HA); Influenza A virus (A/New York/602/1996(H3N2)) HA2 (gene: HA); Human adenovirus 19 fiber (gene: L5); Human adenovirus 58 fiber (gene: L5); Human adenovirus D10 fiber (gene: L5); Human adenovirus 61 E3 CR1 beta; Molluscum contagiosum virus subtype 1 MC162R (gene: MC162R); Human adenovirus 65 L5 fiber; Human mastadenovirus D fiber (gene: L5); Human adenovirus 56 fiber protein (gene: L5); Human adenovirus 64 L5 fiber protein; Human adenovirus D37 fiber (gene: L5); Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Influenza A virus (A/New York/392/2004(H3N2)) HA2 (gene: HA); Human adenovirus D8 fiber (gene: L5); Human adenovirus 54 fiber; Human mastadenovirus D fiber; Human adenovirus 17 fiber; Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 63 fiber protein (gene: L5); Human adenovirus 49 fiber; Cercopithecine betaherpesvirus 5 membrane protein RL11M (gene: RL11M); Human adenovirus 23 fibre protein (gene: L5); Human adenovirus 67 L5 fiber; Human adenovirus 41 E3 31.6K; Human adenovirus 46 fiber; Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human adenovirus D8 45.5kDa protein (gene: E3); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Human betaherpesvirus 5 membrane glycoprotein UL11 (gene: UL11); Yaba monkey tumor virus Ig domain OX-2-like protein; Vaccinia virus Ankara Haemagglutinin; Human gammaherpesvirus 4 probable membrane glycoprotein (gene: BILF2); Human herpesvirus 4 type 2 BILF2; Cercopithecine betaherpesvirus 5 membrane protein RL11Q (gene: RL11Q); West Nile virus lineage 2 excised_polyprotein 1..791 (gene: flavivirus polyprotein); Influenza A virus (A/California/04/2009(H1N1)) HA2 (gene: HA); Influenza A virus (A/California/07/2009(H1N1)) HA2 (gene: HA); Human mastadenovirus A E3 CR1-alpha1; Human betaherpesvirus 5 membrane glycoprotein UL7 (gene: UL7); Cercopithecine betaherpesvirus 5 membrane protein US27B (gene: US27B)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9028576823827708; 0.9056300531913352; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9058994261255549; 0.9058994261255549; 0.9065231464138438; 0.9118403763180049; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.915880438522078; 0.9176642913406818; 0.9197295331382644; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9318782091866168; 0.9318782091866168; 0.9364561700418303; 0.9366403811337995; 0.978882862740732,,,,
IPO8,Endometrial Carcinoma; Malignant neoplasm of lung; Primary malignant neoplasm of lung; Carcinoma of lung; Degenerative polyarthritis; Schizophrenia; Inflammatory Bowel Diseases; Bipolar Disorder; Schizoaffective Disorder,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8815127642200768; 0.900167961295542; 0.9441119274323576,Schizophrenia; Schizoaffective Disorder; Bipolar Disorder,0.7860378120955526; 0.9015263516356564; 0.943322675973118,"NEK9-related lethal skeletal dysplasia ORPHA:464366; Nevus comedonicus syndrome ORPHA:64754; Pancreatic agenesis-holoprosencephaly syndrome ORPHA:556955; X-linked intellectual disability, Cabezas type ORPHA:85293; Juvenile amyotrophic lateral sclerosis ORPHA:300605; Juvenile myelomonocytic leukemia ORPHA:86834; Endometrial stromal sarcoma ORPHA:213711; Hereditary late-onset Parkinson disease ORPHA:411602; Endocrine-cerebro-osteodysplasia syndrome ORPHA:199332; Rhizomelic chondrodysplasia punctata type 3 ORPHA:309803; Primary mediastinal large B-cell lymphoma ORPHA:98838; Syndromic diarrhea ORPHA:84064",0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6196505963261838; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
IQCJ-SCHIP1,Adenomatous Polyposis Coli; Total iron binding capacity function; Iron binding capacity total measurement; Conventional (Clear Cell) Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Triglycerides measurement; Waist Circumference; Smoking Behaviors,0.5196624042573144; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8232134984476662; 0.9241582777301016; 0.9564633032157428,Oral Ulcer; Asthma,0.7765582368651238; 0.9832345076528324,,,,,,,,
IQSEC1,Malignant neoplasm of breast; Breast Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Mammary Neoplasms; Malignant neoplasm of lung; Liver carcinoma; Malignant Head and Neck Neoplasm; Neoplasm Metastasis; Ductal Carcinoma; Lung Neoplasms; Secondary malignant neoplasm of liver; Liver neoplasms; Adenocarcinoma of lung (disorder); Brain Aneurysm; Head and Neck Carcinoma,0.4084380369379369; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8098851543361193; 0.8145035474981049; 0.8648405521677974,Non-Syndromic Intellectual Disability; Developmental Delay; Mental Retardation; Lung Cancer; Intracranial Aneurysm; Lung Neoplasms; Dwarfism,0.6734982286750932; 0.7765582368651238; 0.8337953215113012; 0.8706864397989688; 0.8759421888249375; 0.8903301324869451; 0.9510372690456612,"Autosomal dominant centronuclear myopathy ORPHA:169189; Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; 1p36 deletion syndrome ORPHA:1606; Distal monosomy 1q ORPHA:36367; 2q37 microdeletion syndrome ORPHA:1001; Birt-Hogg-Dube syndrome ORPHA:122; Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome ORPHA:500144; Familial spontaneous pneumothorax ORPHA:2903; Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085; Progressive myoclonic epilepsy type 3 ORPHA:263516; Huntington disease ORPHA:399; COG1-CDG ORPHA:263508; External auditory canal aplasia/hypoplasia ORPHA:141074; Primary intraosseous venous malformation ORPHA:140436; Ramon syndrome ORPHA:3019; Spinocerebellar ataxia type 13 ORPHA:98768; Familial advanced sleep-phase syndrome ORPHA:164736; Autosomal recessive non-syndromic intellectual disability ORPHA:88616; Intellectual disability-craniofacial dysmorphism-cryptorchidism syndrome ORPHA:329224; RERE-related neurodevelopmental syndrome ORPHA:494344; Rett syndrome ORPHA:778; Rubinstein-Taybi syndrome due to 16p13.3 microdeletion ORPHA:353281; Rubinstein-Taybi syndrome due to CREBBP mutations ORPHA:353277; Severe neonatal-onset encephalopathy with microcephaly ORPHA:209370; Trisomy Xq28 ORPHA:1762; X-linked intellectual disability-psychosis-macroorchidism syndrome ORPHA:3077; Porphyria due to ALA dehydratase deficiency ORPHA:100924",0.0036432528126817; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ISG15,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of pancreas; Pancreatic carcinoma; Esophageal carcinoma; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Esophageal Neoplasms; Mammary Neoplasms; Refractory anemias; Promyelocytic leukemia; Liver carcinoma; Malignant neoplasm of esophagus; Acute Promyelocytic Leukemia; Ataxia Telangiectasia; Neoplasm Metastasis; Triple Negative Breast Neoplasms; Immunologic Deficiency Syndromes; melanoma; Lung Neoplasms; Hemorrhagic Fever, Crimean; Malignant neoplasm of stomach; Vesicular Stomatitis; Recurrent mycobacterial infections; Nasopharyngeal carcinoma; Hepatitis E; Sindbis virus infection; Lupus Erythematosus, Systemic; Fungal keratitis; Stomach Carcinoma; Inflammatory cardiomyopathy; Autoimmune Diseases; Hepatitis C; Usher Syndrome, Type III; Rheumatoid Arthritis; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Tumor Immunity; Virus Diseases; Infection by Candida albicans; Bacterial Infections; Psoriasis; Listeriosis; Liver neoplasms; ovarian neoplasm; Hepatitis C Virus Infection; Myocarditis; Lip and Oral Cavity Carcinoma; Malignant neoplasm of tongue; Adult type dermatomyositis; Tuberculosis; Congenital Abnormality; Mycobacterium Infections; Hepatitis B; Dermatomyositis; Respiratory Syncytial Virus Infections; Cystitis; Heart failure; Malignant neoplasm of mouth; Congestive heart failure; Influenza; Hepatitis C, Chronic; Malignant neoplasm of larynx",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8138488881521341; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8272008757995397; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8867509400747969; 0.8946938397586319; 0.8976039441125321; 0.9193385822373632; 0.9432051631882106; 0.9571401094099016,Immunologic Deficiency Syndromes; Liver Carcinoma; Psychosis; Involutional Depression; Involutional Paraphrenia; Mental Depression,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8903630091389316,Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome ORPHA:391487; Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect ORPHA:521411; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency ORPHA:319595; Susceptibility to viral and mycobacterial infections due to STAT1 deficiency ORPHA:391311; USP18 deficiency ORPHA:481665,0.0155394890951578; 0.0155394890951578; 0.1040670578681756; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,"Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human adenovirus 11+34 encapsidation protein IVa2 (gene: IVa2); Human adenovirus 34 maturation protein IVa2 (gene: IVa2); Human adenovirus 35 IVa2; Human betaherpesvirus 6 U31, large tegument protein (gene: U31); Human betaherpesvirus 6A large tegument protein (gene: U31); Human betaherpesvirus 6B large tegument protein (gene: U31); Human mastadenovirus B encapsidation protein IVa2 (gene: IVa2); Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Dugbe virus L protein; Human betaherpesvirus 7 large tegument protein (gene: U31); SARS coronavirus endoRNAse (gene: orf1ab); Middle East respiratory syndrome-related coronavirus nsp1 protein (gene: orf1ab); Human betaherpesvirus 5 large tegument protein (gene: UL48); Human adenovirus 14 IVa2 protein (gene: IVa2); Human adenovirus 55 pIVa2 50.9 kDa protein; Human adenovirus 66 maturation protein IVA2 (gene: IVa2); Yaba monkey tumor virus ankyrin repeat protein; Human mastadenovirus E encapsidation protein IVa2 (gene: IVa2); Human adenovirus E4 protein IVa2; Tai Forest ebolavirus spike glycoprotein (gene: GP); SARS coronavirus RNA-dependent RNA polymerase (gene: orf1ab); Horsepox virus HSPV197 (Hypothetical protein); Influenza B virus nonstructural protein 1 (gene: NS1); Human adenovirus 3+7 maturation protein IVA2 (gene: IVa2); Yaba-like disease virus 11L protein (gene: 11L); Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61); SARS coronavirus 2-O-ribose methyltransferase (2-o-MT) (gene: orf1ab); Vaccinia virus Ankara viral core cysteine proteinase; Reston ebolavirus spike glycoprotein (gene: GP); Yaba-like disease virus 140R protein (gene: 140R); Macacine alphaherpesvirus 1 large tegument protein (gene: UL36); SARS coronavirus nsp9-pp1a/pp1ab (gene: orf1ab); Human adenovirus 11a IVa2; Human betaherpesvirus 6B glycoprotein (gene: U85); Variola virus hypothetical protein (gene: K7L); Monkeypox virus viral core cysteine proteinase; Monkeypox virus Zaire-96-I-16 I7L (gene: I7L); SARS coronavirus nsp13-pp1ab (ZD, NTPase/HEL; RNA (gene: orf1ab); Yaba monkey tumor virus 48L; Middle East respiratory syndrome-related coronavirus nsp12 protein (gene: orf1ab); Bundibugyo ebolavirus spike glycoprotein (gene: GP); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Vaccinia virus viral core cysteine proteinase (gene: I7L); Middle East respiratory syndrome-related coronavirus nsp5 protein (gene: orf1ab); Middle East respiratory syndrome-related coronavirus nsp16 protein (gene: orf1ab); SARS coronavirus nsp4-pp1a/pp1ab (gene: orf1ab); Rotavirus A NSP4; Horsepox virus HSPV077 (Vaccinia virus I7 processing peptidase); Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Middle East respiratory syndrome-related coronavirus nsp4 protein (gene: orf1ab); Middle East respiratory syndrome-related coronavirus nsp10 protein (gene: orf1ab); SARS coronavirus formerly known as growth-factor-like protein (gene: orf1ab); Human gammaherpesvirus 8 K4.1 (gene: K4.1); Cowpox virus CPXV050 (gene: CPXV050 CDS); Middle East respiratory syndrome-related coronavirus nsp9 protein (gene: orf1ab); SARS coronavirus 3C-like proteinase (gene: orf1ab); Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Yaba-like disease virus 19L protein (gene: 19L); SARS coronavirus leader protein (gene: orf1ab); Human parainfluenza virus 1 strain Washington/1964 phosphoprotein (gene: P); Human respirovirus 1 phosphoprotein (gene: P); Macacine alphaherpesvirus 1 DNA replication origin-binding helicase (gene: UL9); Human adenovirus 16 maturation protein IVA2 (gene: IVa2); Reston ebolavirus polymerase complex protein (gene: VP35); Human alphaherpesvirus 2 multifunctional expression regulator (gene: UL54); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Ectromelia virus ERPV kelch-like protein; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Vaccinia virus kelch-like protein (gene: A55R); SARS coronavirus Tor2 replicase 1AB; Cercopithecine alphaherpesvirus 2 tegument protein VP22 (gene: UL49); SARS coronavirus P2 full_polyprotein 1..7073; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Yaba-like disease virus 141R protein (gene: 141R); Middle East respiratory syndrome-related coronavirus nsp13 protein (gene: orf1ab); Yaba monkey tumor virus kelch-like protein; Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Variola virus hypothetical protein (gene: A28L); Horsepox virus HSPV043 (Kelch-like protein; Provisional); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); SARS coronavirus nsp3-pp1a/pp1ab (gene: orf1ab); Human betaherpesvirus 6B G-protein coupled receptor (gene: U12); Macacine alphaherpesvirus 1 tegument protein VP22 (gene: UL49); Papiine alphaherpesvirus 2 large tegument protein (gene: UL36); Horsepox virus HSPV029 (kelch-like protein; Provisional); Middle East respiratory syndrome-related coronavirus nsp8 protein (gene: orf1ab); Human parechovirus 6 capsid protein VP0; Influenza B virus (B/Memphis/12/97) NS protein; Variola virus hypothetical protein (gene: B22R); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Orf virus ORF008 ankyrin repeat protein; Ebola virus - Mayinga, Zaire, 1976 virion spike glycoprotein precursor (gene: GP); Zaire ebolavirus spike glycoprotein (gene: GP); Vaccinia virus kelch-like protein (gene: C2L); Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Reston ebolavirus - Reston VP35 (gene: VP35); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Middle East respiratory syndrome-related coronavirus nsp15 protein (gene: orf1ab); SARS coronavirus nsp7-pp1a/pp1ab (gene: orf1ab); Human immunodeficiency virus pol protein (gene: pol); Human gammaherpesvirus 8 K14; Human rhinovirus QCE 3C; Orf virus ORF035 virion core protease; Monkeypox virus cowpox A-type inclusion protein; Middle East respiratory syndrome-related coronavirus nsp3 protein (gene: orf1ab); Orf virus ORF123 ankyrin repeat protein; Human gammaherpesvirus 4 large tegument protein (gene: BPLF1); Human herpesvirus 4 type 2 BPLF1; Human herpesvirus 3 strain Dumas Tegument protein VP22 (gene: ORF9); Human alphaherpesvirus 3 tegument protein VP22 (gene: ORF9); Variola virus hypothetical protein (gene: A35L); Middle East respiratory syndrome-related coronavirus nsp7 protein (gene: orf1ab); Human immunodeficiency virus envelope glycoprotein (gene: env); SARS coronavirus nsp8-pp1a/pp1ab (gene: orf1ab); Ectromelia virus ERPV hemagglutinin; Aichi virus 1 3D; Cercopithecine alphaherpesvirus 2 large tegument protein (gene: UL36); Cowpox virus CPXV086 protein (gene: CPXV086 CDS); Human betacoronavirus 2c EMC/2012 ORF1ab (gene: orf1ab); Yaba-like disease virus 48L protein (gene: 48L); Human group 1 coronavirus associated with pneumonia ORF 1a; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Human alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Variola virus hypothetical protein (gene: J9R); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Human mastadenovirus A E3 CR1-beta1; Human alphaherpesvirus 1 tegument protein VP22 (gene: UL49); Human gammaherpesvirus 8 ORF64 (gene: ORF64); Molluscum contagiosum virus subtype 1 MC049L (gene: MC049L); Molluscum contagiosum virus subtype 1 MC013L (gene: MC013L); SARS coronavirus excised_polyprotein 1..4369 (gene: orf1ab); Horsepox virus HSPV177 (Immunoglobulin like); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); SARS coronavirus P2 full_polyprotein 1..4382; Orf virus ORF128 ankyrin repeat protein; Human adenovirus 61 E3 CR1 beta; Human herpesvirus 3 strain Dumas Large tegument protein deneddylase (gene: ORF22); Human alphaherpesvirus 3 large tegument protein (gene: ORF22); Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Human betacoronavirus 2c Jordan-N3/2012 ORF1ab protein (gene: ORF1ab); Orf virus ORF071 NPH-PPH downregulator; Betacoronavirus England 1 ORF1b protein (gene: orf1ab); Human betacoronavirus 2c England-Qatar/2012 ORF1ab; Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 41 E3 31.6K; Human betacoronavirus 2c Jordan-N3/2012 ORF1a protein (gene: ORF1ab); Molluscum contagiosum virus subtype 1 MC099R (gene: MC099R); Human betacoronavirus 2c EMC/2012 ORF1a (gene: orf1ab); Human adenovirus 18 CR1-beta protein (gene: E3); Human betacoronavirus 2c England-Qatar/2012 ORF1a; Betacoronavirus England 1 ORF1a protein (gene: orf1ab); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Human alphaherpesvirus 1 large tegument protein (gene: UL36); Papiine alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Human group 1 coronavirus associated with pneumonia ORF 1ab; Vaccinia virus Ankara Haemagglutinin; Human coronavirus 229E full_polyprotein 1..4085; Human alphaherpesvirus 2 large tegument protein (gene: UL36); Human coronavirus 229E full_polyprotein 1..6758; Human coronavirus NL63 full_polyprotein 1..6729",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9028576823827708; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9187390604217726; 0.9197295331382644; 0.9224878266317492; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.928070054828895; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9287050575620676; 0.9325850920715436; 0.945571760415642,In vitro,0.44;0.72,Homo sapiens;Human SARS coronavirus,Homo sapiens;Human SARS coronavirus;cvemc
ITM2B,"Malignant neoplasm of breast; Breast Carcinoma; B-Cell Lymphomas; Dementia, familial Danish; Lymphoma; Mammary Neoplasms; Amyloidosis, Familial; Neurofibrillary degeneration (morphologic abnormality); T-Cell Lymphoma; Prion Diseases; Prostatic Neoplasms; Neuroblastoma; Muscle Hypertonia; Central neuroblastoma; Retinal Diseases; Posterior polar cataract; AURAL ATRESIA, CONGENITAL; Myxoid cyst; Pallor of optic disc; Dementia, familial British; Dementia; Photophobia; Presenile dementia; Alzheimer's Disease; Cerebral Amyloid Angiopathy; Cerebral Amyloid Angiopathy, Hereditary; Coinfection; Familial Dementia; Photodysphoria; Amyloid angiopathy; Plaque, Amyloid; Congenital deafness; Progressive neurologic deterioration; Senile Plaques; Hearing Loss, Partial; Deafness; Terminal tremor; Impaired cognition; Tremor; Retinal Dystrophies; Fibrillation; Neurodegenerative Disorders; Lipoma; hearing impairment; Ataxia; Hypertensive disease; Memory impairment; Action Tremor; Muscle Rigidity; Amyloidosis; Memory Loss; Cerebellar Ataxia; Psychotic Disorders; Muscle Spasticity",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8402911822757345; 0.8474481237156937; 0.8474481237156937; 0.8642802827048847; 0.8648405521677974; 0.8672189956534445; 0.8769418330148872; 0.906476206143938; 0.939985154445373; 0.9564633032157428,Stroke; Retinal Dystrophy; Cerebral Amyloid Angiopathy; Ischemic Stroke; Psychosis; Hypertension; Dementia; Spastic Tetraparesis,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.861756360478846; 0.861756360478846,"Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085; 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency ORPHA:752; Duane retraction syndrome with congenital deafness ORPHA:529574; Hemochromatosis type 4 ORPHA:139491; Multicentric carpo-tarsal osteolysis with or without nephropathy ORPHA:2774; ABri amyloidosis ORPHA:97345; ADan amyloidosis ORPHA:97346; Atypical Gaucher disease due to saposin C deficiency ORPHA:309252; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319581; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319569; Ayme-Gripp syndrome ORPHA:1272; Encephalopathy due to prosaposin deficiency ORPHA:139406; Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease ORPHA:439854; Hereditary myopathy with lactic acidosis due to ISCU deficiency ORPHA:43115; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency ORPHA:99898; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; NON RARE IN EUROPE: Wolff-Parkinson-White syndrome ORPHA:907; Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies ORPHA:397758; Infantile Krabbe disease ORPHA:206436; Adult Krabbe disease ORPHA:206448; Cerebrotendinous xanthomatosis ORPHA:909; Farber disease ORPHA:333; Late-infantile/juvenile Krabbe disease ORPHA:206443; RNF13-related severe early-onset epileptic encephalopathy ORPHA:544503; Spinal muscular atrophy-progressive myoclonic epilepsy syndrome ORPHA:2590; Antenatal Bartter syndrome ORPHA:93604; AGel amyloidosis ORPHA:85448; Familial multiple nevi flammei ORPHA:624; Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome ORPHA:528105; Marfan syndrome type 2 ORPHA:284973; Methylmalonic acidemia with homocystinuria type cblF ORPHA:79284; Sanfilippo syndrome type C ORPHA:79271; Sturge-Weber syndrome ORPHA:3205; X-linked myotubular myopathy-abnormal genitalia syndrome ORPHA:456328; Semantic dementia ORPHA:100069; Glycogen storage disease due to LAMP-2 deficiency ORPHA:34587; X-linked intellectual disability, Hedera type ORPHA:93952; X-linked parkinsonism-spasticity syndrome ORPHA:363654",0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ITPRIP,,,,,"Atrial septal defect, sinus venosus type ORPHA:99105; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Camurati-Engelmann disease ORPHA:1328; Infantile inflammatory bowel disease with neurological involvement ORPHA:565788; Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223; Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Polydactyly of a biphalangeal thumb ORPHA:93339; Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy ORPHA:363454; Growth retardation-mild developmental delay-chronic hepatitis syndrome ORPHA:391366; Temtamy preaxial brachydactyly syndrome ORPHA:363417; Loeys-Dietz syndrome ORPHA:60030; Combined immunodeficiency due to Moesin deficiency ORPHA:504530; Paternal uniparental disomy of chromosome 6 ORPHA:96191",0.0155394890951578; 0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
KAT5,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; leukemia; Ovarian Carcinoma; Allergic bronchitis; Colorectal Carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Lymphoma; Leukemogenesis; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Uric acid measurement (procedure); Carcinoma breast stage IV; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Promyelocytic leukemia; Liver carcinoma; Thyroid carcinoma; Colorectal Cancer; Epithelial ovarian cancer; Tumor Promotion; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Malignant neoplasm of thyroid; melanoma; Neoplasms; Benign Prostatic Hyperplasia; Tumor Progression; Salmonella infections; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Autoimmune Diseases; Fanconi Anemia; invasive cancer; Rheumatoid Arthritis; Other specified iron deficiency anemias; Crohn Disease; Bacterial Infections; Metastatic melanoma; Leukoencephalopathy, Progressive Multifocal; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Liver neoplasms; Adult T Acute Lymphoblastic Leukemia; Schizophrenia; Acute GVH disease; Dysplastic Nevus; Bronchial Hyperreactivity; Graft-vs-Host Disease; Neurodegenerative Disorders; Celiac Disease; Sleep disturbances; Hepatitis B; Memory impairment; Sleep Disorders; Papillary thyroid carcinoma; Allergic asthma; Pulmonary Fibrosis; Arthritis, Psoriatic; nervous system disorder; Obesity; Bipolar Disorder; Spinocerebellar Ataxia Type 1; Cerebral Ischemia; Septicemia; Epileptic encephalopathy; Sepsis; Bacteremia; Intellectual Disability; Cerebral Infarction; Metabolic Diseases; Asthma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7940665326856218; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8101097852323003; 0.8138488881521341; 0.8190761496232595; 0.8190761496232595; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8474481237156937; 0.8486035047899471; 0.8757755363384367; 0.887595340546704; 0.8911256045597441; 0.8946938397586319; 0.8959157818691486; 0.8989612563669234; 0.900167961295542; 0.906476206143938; 0.9083161862856644; 0.917543617287358; 0.917543617287358; 0.9189398569397552; 0.9214835359141188; 0.9478210444156088; 0.9564633032157428; 0.9564633032157428; 0.9672478180546946,Gout; Gouty Arthritis,0.7765582368651238; 0.7765582368651238,Yunis-Varon syndrome ORPHA:3472,0.5867963421058087,Human gammaherpesvirus 4 EBNA-2 nuclear protein (gene: BYRF1); Human herpesvirus 4 type 2 EBNA-2,0.9057542447893764; 0.9057542447893764,In vitro,0.56,Homo sapiens,chemical synthesis
KAT7,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Mammary Neoplasms; Mean Corpuscular Volume (result); Aortic Valve Insufficiency; Central Serous Chorioretinopathy; Androgen-Insensitivity Syndrome; Kidney Failure, Acute",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.9039108388826153; 0.9373358316580888,,,RIDDLE syndrome ORPHA:420741; Familial primary hypomagnesemia with normocalciuria and normocalcemia ORPHA:34527,0.8922466888454011; 0.8922466888454011,,,,,,
KATNB1,Cortical gyral simplification; Ataxia Telangiectasia; Agyria; Sloping forehead; Lissencephaly; Malformations of Cortical Development; Microlissencephaly; Invasive Ductal Breast Carcinoma; Hypoplasia of corpus callosum; Cognitive delay; Partial or complete agenesis of corpus callosum; Anaplastic thyroid carcinoma; Partial agenesis of corpus callosum; Global developmental delay; Mental and motor retardation; Oligospermia; Impaired cognition; Microcephaly; Congenital Abnormality; Pachygyria; Dilated ventricles (finding); Polymicrogyria; Holoprosencephaly; Mental impairment; Small head,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8190761496232595; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8584283190330553; 0.8648405521677974; 0.876210765330195; 0.9822381479823692,Microlissencephaly; Partial Agenesis Of Corpus Callosum; Developmental Delay; Polymicrogyria; Hypoplasia Of Corpus Callosum; Pachygyria; Microcephaly; Neuronal Heterotopia; Impaired Cognition,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7949861636679444; 0.8210988731657684; 0.8903630091389316; 0.8932724875174971; 0.9231137872214272,Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; BAP1-related tumor predisposition syndrome ORPHA:289539; Kufor-Rakeb syndrome ORPHA:306674; Pontocerebellar hypoplasia type 9 ORPHA:369920; Intellectual disability-epilepsy-extrapyramidal syndrome ORPHA:468620; Arnold-Chiari malformation type II ORPHA:1136; Microlissencephaly ORPHA:1083; Hereditary isolated aplastic anemia ORPHA:397692,0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703,,,,,,
KCNE3,"Serum total cholesterol measurement; ST segment elevation (finding); Episodic flaccid weakness; Episodic hypokalemia; Hyperkalemic periodic paralysis; Neuroleptic Malignant Syndrome; Periodic hypokalemic paresis; Exercise-induced muscle fatigue; Hypokalemic periodic paralysis type 1; Alzheimer's Disease; Thyrotoxic periodic paralysis; Hypokalemic periodic paralysis; Lone atrial fibrillation; Paramyotonia Congenita (disorder); Familial Periodic Paralysis; periodic paralysis (finding); Brugada Syndrome (disorder); Channelopathies; Increased intramyocellular lipid droplets; Mildly elevated creatine phosphokinase; Long QT Syndrome; Hyperglycemia, Postprandial; Electromyogram abnormal; Triglycerides measurement; Ventricular Fibrillation; Neurodegenerative Disorders; Syncope; Cardiac Arrest; Low density lipoprotein cholesterol measurement; Atrial Fibrillation; Familial M??ni??re disease",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8098851543361193; 0.8138488881521341; 0.8138488881521341; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8769418330148872,Adrenocortical Adenoma; Long QT Syndrome; Hypokalemic Periodic Paralysis; Periodic Hypokalemic Paresis; Trifascicular Block; Paroxysmal Ventricular Tachycardia; Sick Sinus Syndrome; Supraventricular Tachycardia; Brugada Syndrome; Bundle Branch Block; Ventricular Fibrillation; Atrioventricular Block,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8165359516083085; 0.8201196687803188; 0.861756360478846; 0.8662301945830305; 0.8903301324869451,"Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Fructose-1,6-bisphosphatase deficiency ORPHA:348; Hemochromatosis type 4 ORPHA:139491; Galactose mutarotase deficiency ORPHA:570422; Haim-Munk syndrome ORPHA:2342; Papillon-Lefevre ORPHA:678; Adult Krabbe disease ORPHA:206448; Chronic infantile diarrhea due to guanylate cyclase 2C overactivity ORPHA:314373; Farber disease ORPHA:333; Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency ORPHA:314376; Late-infantile/juvenile Krabbe disease ORPHA:206443; Spinal muscular atrophy-progressive myoclonic epilepsy syndrome ORPHA:2590; ALys amyloidosis ORPHA:93561; Brain dopamine-serotonin vesicular transport disease ORPHA:352649; Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome ORPHA:528105; Lysinuric protein intolerance ORPHA:470; Jervell and Lange-Nielsen syndrome ORPHA:90647; Primary hypomagnesemia with secondary hypocalcemia ORPHA:30924; Hypokalemic periodic paralysis ORPHA:681; Brugada syndrome ORPHA:130",0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9157590847454716,,,,,,
KCNK7,,,,,Nephrogenic diabetes insipidus ORPHA:223; Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome ORPHA:538574; Annular epidermolytic ichthyosis ORPHA:281139; Autosomal dominant epidermolytic ichthyosis ORPHA:312; Congenital reticular ichthyosiform erythroderma ORPHA:281190,0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Monkeypox virus cowpox A-type inclusion protein,0.8999095837312036,,,,
KCNQ1OT1,"Carcinogenesis; Malignant neoplasm of pancreas; Hepatoblastoma; Beckwith-Wiedemann Syndrome; Adrenocortical cytomegaly; Overgrowth of external genitalia; Pancreatic hyperplasia; Colorectal Carcinoma; Nephrolithiasis; HEMIHYPERPLASIA, ISOLATED; MENTAL RETARDATION, X-LINKED, SNYDER-ROBINSON TYPE; Advanced bone age; TARSAL-CARPAL COALITION SYNDROME; Asymmetric overgrowth; Posterior helix pit; Esophageal carcinoma; Neonatal hypoglycemia; Russell-Silver syndrome; Colorectal Neoplasms; Tooth problem; Renal cortical cysts; Transient neonatal diabetes mellitus; Congenital hemihypertrophy; Esophageal Neoplasms; Abnormality of the dentition; Congenital omphalocele; Liver carcinoma; Overgrowth Syndrome; Malignant neoplasm of esophagus; Colorectal Cancer; Hepatocarcinogenesis; Diastasis recti; Nephroblastoma; Embryonal Neoplasm; ANOPHTHALMIA AND PULMONARY HYPOPLASIA; Neoplasm Metastasis; Enlarged kidney; Fetal overgrowth; Generalized overgrowth; Overgrowth; Neuroblastoma; Central neuroblastoma; Port-Wine Stain; Pelizaeus-Merzbacher Disease; Malignant neoplasm of stomach; Gonadoblastoma; Noninfiltrating Intraductal Carcinoma; Large, late-closing fontanelle; Wide bregma sutures; Large bregma sutures; Large fontanelle; Asymmetry of the thorax; Prominent metopic ridge; Klippel-Trenaunay-Weber Syndrome; Increased calcium level in kidney; Prominent back of the head; Prominent occiput; Coronary Arteriosclerosis; Congenital chromosomal disease; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Acute myocardial infarction; Neural Tube Defects; Diabetes; Diabetes Mellitus; Tumors of Adrenal Cortex; Prominent eyes; Protruding eyes; Prominent globes; Exophthalmos; Nephrocalcinosis; Angelman Syndrome; Myocardial Infarction; Liver neoplasms; Kidney Diseases; Adenocarcinoma of lung (disorder); Dandy-Walker Syndrome; Adrenocortical carcinoma; Congenital Abnormality; Macroglossia; Curvature of spine; Cryptorchidism; Acquired scoliosis; Facial asymmetry; Inflammatory Breast Carcinoma; Vesico-Ureteral Reflux; Myocardial Ischemia; Congenital defects; Hepatomegaly; Thickened facial skin with coarse facial features; Coarse facial features; Cardiomegaly; Trichohepatoenteric Syndrome; Cardiomyopathies; Mild Mental Retardation",0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8190761496232595; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8576420926340393; 0.8648405521677974; 0.8648405521677974; 0.887595340546704; 0.9103315000053974; 0.9117936912777788; 0.9184153253162451; 0.94939825643792; 0.9557184806547836; 0.9685329573219852,Adrenocortical Carcinoma; Beckwith-Wiedemann Syndrome; Gonadoblastoma; Nephrolithiasis; Congenital Hemihypertrophy; Hepatoblastoma; Long QT Syndrome; Congenital Long QT Syndrome; Nephroblastoma; Phakomatosis Pigmentovascularis; Hypoglycemia; Congenital Omphalocele; Proptosis; Nephrocalcinosis; Meningomyelocele; Mental Retardation; Vesicoureteral Reflux; Cryptorchidism; Macroglossia; Cardiomyopathy; Diabetes Mellitus; Scoliosis,0.4532988396145482; 0.4904280964420943; 0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.8611702959552964; 0.861756360478846; 0.8879896755141929; 0.9145387439550552; 0.919442421650838; 0.924275664330454,Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Isolated hemihyperplasia ORPHA:2128,0.7929682744768703; 0.7929682744768703,,,,,,
KCTD12,Carcinogenesis; Gastrointestinal Stromal Tumors; Schizophrenia; Bipolar Disorder; Mood Disorders,0.7333611688795861; 0.7765852775619541; 0.8067197998685076; 0.900167961295542; 0.9093740881835894,Schizophrenia; Bipolar Disorder; Mood Disorder,0.7860378120955526; 0.943322675973118; 0.9726139569926774,Acromelic frontonasal dysplasia ORPHA:1827; Distal monosomy 1q ORPHA:36367; Thrombomodulin-related bleeding disorder ORPHA:436169; Duane retraction syndrome with congenital deafness ORPHA:529574; Hemochromatosis type 5 ORPHA:447792; Multicentric carpo-tarsal osteolysis with or without nephropathy ORPHA:2774; Uveal melanoma ORPHA:39044; Cryptogenic multifocal ulcerous stenosing enteritis ORPHA:468635; Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder ORPHA:477787; Autosomal dominant intermediate Charcot-Marie-Tooth disease type F ORPHA:352670; Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205; Wagner disease ORPHA:898; Paternal uniparental disomy of chromosome 6 ORPHA:96191,0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Horsepox virus HSPV197 (Hypothetical protein); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV008; Ectromelia virus ERPV kelch-like protein; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Horsepox virus HSPV043 (Kelch-like protein; Provisional),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,In vitro,0.52,Homo sapiens,Homo sapiens
KEAP1,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Hepatoblastoma; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Right Ventricular Hypertrophy; Malignant tumor of colon; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Cholera Infantum; Vascular Diseases; Malignant tumor of cervix; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Invasive carcinoma of breast; Malignant Head and Neck Neoplasm; Colorectal Cancer; Epithelial ovarian cancer; Tumor Promotion; Disease Exacerbation; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Functional Gastrointestinal Disorders; Prostatic Neoplasms; Carcinoma of lung; Triple Negative Breast Neoplasms; Van der Woude syndrome; Immunologic Deficiency Syndromes; melanoma; Lung Neoplasms; Gastrointestinal Diseases; Keratoma; Keratosis Blennorrhagica; Malignant neoplasm of stomach; Euthyroid Goiter; Malignant neoplasm of large intestine; Tumor Progression; Renal Cell Carcinoma; Seminoma; Keratosis; Chemical Carcinogenesis; Alzheimer's Disease; Stomach Carcinoma; Osteitis Deformans; Cardiovascular Diseases; Age-related cataract; gallbladder neoplasm; Squamous cell carcinoma; Diabetes Mellitus; Papillary Renal Cell Carcinoma; Biliary Tract Cancer; Ankylosing spondylitis; Huntington Disease; Pleuropulmonary blastoma; Crohn Disease; Conventional (Clear Cell) Renal Cell Carcinoma; Malignant Glioma; Vascular inflammations; Chromophobe Renal Cell Carcinoma; Cervical Squamous Cell Carcinoma; Psoriasis; Kidney Failure, Chronic; Malignant neoplasm of gallbladder; Lung diseases; Kidney Diseases; Nonalcoholic Steatohepatitis; ovarian neoplasm; Adenocarcinoma of lung (disorder); Basal cell nevus; Tongue Neoplasms; Ulcerative Colitis; Hyperkeratosis; Sarcomatoid Renal Cell Carcinoma; Liver Cirrhosis; Gallbladder Carcinoma; Multinodular goiter; Neurodegenerative Disorders; Collecting Duct Carcinoma of the Kidney; Cholangitis, Sclerosing; Motor neuron atrophy; Diabetic Retinopathy; Amyotrophic Lateral Sclerosis; Other ureteric obstruction; Cervical Intraepithelial Neoplasia; Squamous cell carcinoma of esophagus; Exanthema; Cataract; Respiratory Distress Syndrome, Adult; Polyp of large intestine; Addictive Behavior; Septicemia; Sepsis; Chronic Kidney Diseases; Hepatitis; Basal cell carcinoma; Squamous cell carcinoma of lung; Drug abuse; Chronic kidney disease stage 5; Pulmonary Emphysema",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.8337767145465158; 0.8363138748299018; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8610447277138289; 0.8619324281003841; 0.8769418330148872; 0.8769418330148872; 0.8774809019744603; 0.9015731019095328; 0.917543617287358; 0.9189398569397552; 0.9393256300017014; 0.939985154445373; 0.9431511078237256; 0.9564633032157428; 0.9658628445524134; 0.9694882155560866; 0.9920086799398428,Functional Gastrointestinal Disorders; Gastrointestinal Diseases; Biliary Cholangitis; Ovarian Neoplasm; Prostate Cancer; Keratoma; Keratosis; Keratosis Blennorrhagica; Prostatic Neoplasms; Alveolar Rhabdomyosarcoma; Pilomatrixoma; Biliary Cirrhosis; Seminoma; Medulloepithelioma; Gallbladder Cancer; Cholestasis; Neoplasm Of Gallbladder; Polyp Of Large Intestine; Lung Carcinoma; Chromophobe Carcinoma; Papillary Renal Carcinoma; Thyroid Carcinoma; Ulcerative Colitis; Renal Carcinoma; Hypothyroidism; Cholangitis; Ankylosing Spondylitis; Crohn Disease; Breast Cancer; Carcinoma; Lung Adenocarcinoma; Psoriasis,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8139950454942313; 0.8356859041719433; 0.8476516371290275; 0.8611702959552964; 0.861756360478846; 0.8727045307126416; 0.8879896755141929; 0.8885757656973042; 0.8903301324869451; 0.8903630091389316; 0.8903630091389316; 0.9069867032339078; 0.9350723667380212; 0.974502015052702,Familial multinodular goiter ORPHA:276399,0.3832844616405875,"Horsepox virus HSPV197 (Hypothetical protein); Yaba-like disease virus 140R protein (gene: 140R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV008; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Yaba-like disease virus 19L protein (gene: 19L); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Ectromelia virus ERPV kelch-like protein; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Vaccinia virus kelch-like protein (gene: A55R); Variola virus hypothetical protein (gene: J7R); Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Monkeypox virus Zaire-96-I-16 B1R (gene: B1R); Yaba monkey tumor virus kelch-like protein; Horsepox virus HSPV043 (Kelch-like protein; Provisional); Horsepox virus HSPV029 (kelch-like protein; Provisional); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Variola virus hypothetical protein (gene: B24R); Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus kelch-like protein (gene: C2L); Monkeypox virus Zaire-96-I-16 D17L (gene: D17L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Variola virus hypothetical protein (gene: J8R); Variola virus hypothetical protein (gene: D13L); Vaccinia virus Ankara 18.9k Kelch-like protein; Horsepox virus HSPV187 (kelch-like protein; Provisional); Monkeypox virus Zaire-96-I-16 D16L (gene: D16L); Cowpox virus CPXV204 protein (gene: CPXV204 CDS); Variola virus hypothetical protein (gene: C7L); Vaccinia virus hypothetical protein; Monkeypox virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f2; Monkeypox virus Zaire-96-I-16 D15L (gene: D15L)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764,,,,
KIAA0513,Schizophrenia; Amyotrophic Lateral Sclerosis,0.8067197998685076; 0.8402911822757345,Leukemia; Amyotrophic Lateral Sclerosis,0.7765582368651238; 0.9543024119762946,"Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Birt-Hogg-Dube syndrome ORPHA:122; Familial spontaneous pneumothorax ORPHA:2903; Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085; 8p11.2 deletion syndrome ORPHA:251066; Infantile Krabbe disease ORPHA:206436; Gamma-aminobutyric acid transaminase deficiency ORPHA:2066; Spinocerebellar ataxia type 1 ORPHA:98755; Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome ORPHA:496689; Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome ORPHA:496686; Rett syndrome ORPHA:778; Severe neonatal-onset encephalopathy with microcephaly ORPHA:209370; Trisomy Xq28 ORPHA:1762; X-linked intellectual disability-psychosis-macroorchidism syndrome ORPHA:3077",0.0081550609410495; 0.0155394890951578; 0.0155394890951578; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
KIF20A,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of pancreas; Pancreatic carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasm; melanoma; Melanocytic nevus; Other restrictive cardiomyopathy; Malignant neoplasm of stomach; Histiocytoid Cardiomyopathy; Stomach Carcinoma; Restrictive cardiomyopathy; Stomach Neoplasms,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8044379824544406,Liver Carcinoma; Restrictive Cardiomyopathy; Cardiomyopathy,0.7765582368651238; 0.8115918568696846; 0.9145387439550552,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Currarino syndrome ORPHA:1552; Filippi syndrome ORPHA:3255; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Ear-patella-short stature syndrome ORPHA:2554; Citrullinemia type II ORPHA:247585; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Hydrolethalus ORPHA:2189; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Autosomal recessive cutis laxa type 2B ORPHA:357064; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Jawad syndrome ORPHA:313795; Meacham syndrome ORPHA:3097; PYCR1-related De Barsy syndrome ORPHA:293633; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; Familial congenital mirror movements ORPHA:238722; Familial prostate cancer ORPHA:1331; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome ORPHA:477993; Li-Fraumeni syndrome ORPHA:524; Nephroblastoma ORPHA:654; Neu-Laxova syndrome ORPHA:2671; Acquired partial lipodystrophy ORPHA:79087; Autosomal dominant spastic paraplegia type 13 ORPHA:100994; Baller-Gerold syndrome ORPHA:1225; Chudley-McCullough syndrome ORPHA:314597; Pelizaeus-Merzbacher-like disease due to HSPD1 mutation ORPHA:280288; Progressive myoclonic epilepsy type 9 ORPHA:457265; RAPADILINO syndrome ORPHA:3021; Rothmund-Thomson syndrome type 2 ORPHA:221016; Combined immunodeficiency with granulomatosis ORPHA:157949; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; 3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form ORPHA:79351; ALDH18A1-related De Barsy syndrome ORPHA:35664; Adrenocortical carcinoma ORPHA:1501; Autosomal dominant spastic paraplegia type 9A ORPHA:447753; Autosomal dominant spastic paraplegia type 9B ORPHA:447757; Autosomal recessive spastic paraplegia type 9B ORPHA:447760; Choroid plexus carcinoma ORPHA:251899; Familial clubfoot due to 5q31 microdeletion ORPHA:293144; Familial clubfoot due to PITX1 point mutation ORPHA:293150; Guttmacher syndrome ORPHA:2957; Hand-foot-genital syndrome ORPHA:2438; Macrocephaly-intellectual disability-left ventricular non compaction syndrome ORPHA:466791; Mirror-image polydactyly ORPHA:498494; Papilloma of choroid plexus ORPHA:2807; STT3A-CDG ORPHA:370921; Brachydactyly-elbow wrist dysplasia syndrome ORPHA:1275; Geroderma osteodysplastica ORPHA:2078; Familial isolated restrictive cardiomyopathy ORPHA:75249; 46,XY partial gonadal dysgenesis ORPHA:251510; Atrial septal defect-atrioventricular conduction defects syndrome ORPHA:1479; Branchio-oculo-facial syndrome ORPHA:1297; CAD-CDG ORPHA:448010; Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome ORPHA:306542; Genetic steroid-resistant nephrotic syndrome ORPHA:656",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1068643725150898; 0.1068643725150898; 0.1419890644363008; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2120485863056726; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9267491058512334,,,,,,
KIFC2,,,,,Otospondylomegaepiphyseal dysplasia ORPHA:1427; Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Adult-onset dystonia-parkinsonism ORPHA:199351; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Infantile neuroaxonal dystrophy ORPHA:35069; Lymphangioleiomyomatosis ORPHA:538; Oculocutaneous albinism type 2 ORPHA:79432; Tuberous sclerosis complex ORPHA:805; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Albers Schonberg osteopetrosis ORPHA:53; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; Cerebellar-facial-dental syndrome ORPHA:444072; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Kufor-Rakeb syndrome ORPHA:306674; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Smith-Magenis syndrome ORPHA:819; Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome ORPHA:95433; CLN4B disease ORPHA:228343; Congenital myopathy with internal nuclei and atypical cores ORPHA:319160; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; Hereditary hypophosphatemic rickets with hypercalciuria ORPHA:157215; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; POMT1-related  limb-girdle muscular dystrophy R11 ORPHA:86812; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361; Scheie syndrome ORPHA:93474; TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome ORPHA:562569; Early myoclonic encephalopathy ORPHA:1935; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; 17p11.2 microduplication syndrome ORPHA:1713; Distal 16p11.2 microdeletion syndrome ORPHA:261222; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression ORPHA:391316; PMP22-RAI1 contiguous gene duplication syndrome ORPHA:477817; Proximal 16p11.2 microdeletion syndrome ORPHA:261197; Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency ORPHA:329249; Wolf-Hirschhorn syndrome ORPHA:280; Spinocerebellar ataxia type 13 ORPHA:98768,0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1117946631214258; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2386105733903937; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.4100904865085126; 0.5867963421058087,,,,,,
KLF4,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; leukemia; Ovarian Carcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Right Ventricular Hypertrophy; Malignant tumor of colon; Atrial Premature Complexes; Esophageal carcinoma; Lymphoma; Leukemogenesis; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Pancreatic intraepithelial neoplasia; Adenoma; Vascular Diseases; Esophageal Neoplasms; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of prostate; Liver carcinoma; Malignant Meningioma; Malignant neoplasm of esophagus; Osteosarcoma; Colorectal Cancer; Leukemia, T-Cell; Tumor Promotion; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; Pulmonary Edema; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Triple Negative Breast Neoplasms; Neuroblastoma; Central neuroblastoma; Familial lichen amyloidosis; Cancer of Digestive System; Ductal Carcinoma; Hematologic Neoplasms; melanoma; Intestinal Neoplasms; Multiple Myeloma; Lung Neoplasms; Metastatic malignant neoplasm to brain; Metastatic Prostate Carcinoma; Neoplasms; Squamous cell carcinoma of mouth; Malignant neoplasm of stomach; Burkitt Lymphoma; Skin Carcinogenesis; Intratubular malignant germ cells; Hodgkin Disease; Benign Prostatic Hyperplasia; Severe Combined Immunodeficiency; Cleft palate with cleft lip; Malignant neoplasm of large intestine; Nasopharyngeal carcinoma; Tumor Progression; Adenocarcinoma of colon; Maladaptive behavior associated with physical illness; Sarcoma; Renal Cell Carcinoma; Seminoma; Tumor Initiation; Arteriosclerosis; Atherosclerosis; Congenital chromosomal disease; Acute lymphocytic leukemia; Stomach Carcinoma; Juvenile psoriatic arthritis; Acute myocardial infarction; Cells in urine; Squamous cell carcinoma; Polycythemia Vera; Thrombus; Carcinoma, Pancreatic Ductal; Carcinoma in situ of uterine cervix; Juvenile-Onset Still Disease; Germinoma; Barrett Epithelium; Adenoma of large intestine; Cervix Intraepithelial Neoplasia Grade 3 AJCC v7; Childhood Acute Lymphoblastic Leukemia; Anaplastic thyroid carcinoma; Secretory meningioma; Conventional (Clear Cell) Renal Cell Carcinoma; Metastatic Neoplasm; Myeloid Leukemia, Chronic; Myeloid Leukemia; Aortic Aneurysm; Central Serous Chorioretinopathy; Vascular inflammations; Metastasis from malignant tumor of prostate; Juvenile arthritis; Experimental Organism Basal Cell Carcinoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Cavernous Hemangioma of Brain; SMITH-MCCORT DYSPLASIA 1; Pneumonitis; Cervical Squamous Cell Carcinoma; Myocardial Infarction; Hepatic methionine adenosyltransferase deficiency; Childhood Osteosarcoma; Stomach Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Breast adenocarcinoma; Keratoconjunctivitis Sicca; Precursor B-cell lymphoblastic leukemia; Multiple Sclerosis, Relapsing-Remitting; Mammary Tumorigenesis; Lip and Oral Cavity Carcinoma; Colonic Neoplasms; Stickler syndrome, type 1; Thrombotic Microangiopathies; Gastric Adenocarcinoma; Neurodegenerative Disorders; Pneumonia; Congenital Abnormality; Subarachnoid Hemorrhage; Immune System Diseases; Patent ductus arteriosus; Aortic aneurysm without mention of rupture NOS; Thrombosis; Aneurysm; Hypertensive disease; Medulloblastoma; Rectal Carcinoma; Hyperplastic Polyp; Squamous cell carcinoma of esophagus; Renal carcinoma; Anaplasia; Myocardial Ischemia; Malignant neoplasm of kidney; Malignant neoplasm of mouth; Meningioma; Barrett Esophagus; Obesity; Squamous cell carcinoma of skin; Secondary malignant neoplasm of lymph node; Congenital Heart Defects; Idiopathic pulmonary arterial hypertension; Malignant neoplasm of skin; Secondary malignant neoplasm of bone; Teratoma; Aortic Aneurysm, Abdominal",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8548862007194026; 0.8584283190330553; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8818220091065441; 0.8946938397586319; 0.8973454964837912; 0.8980854850210683; 0.8989612563669234; 0.8989612563669234; 0.900167961295542; 0.9098977259629772; 0.9262273158806068; 0.93413028051677; 0.946564927793026; 0.9505280654948344; 0.9578035687879456,"Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Seronegative Polyarthritis; Still Disease; Meningioma; Arthritis; Myocardial Ischemia; Congenital Heart Defects",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8611702959552964; 0.9046917974656596; 0.9578111936867284; 0.963385108667098,"Atrial septal defect, sinus venosus type ORPHA:99105; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Heme oxygenase-1 deficiency ORPHA:562509; Thrombomodulin-related bleeding disorder ORPHA:436169; ACys amyloidosis ORPHA:100008; Charcot-Marie-Tooth disease type 4D ORPHA:99950; Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Duane retraction syndrome with congenital deafness ORPHA:529574; Multicentric carpo-tarsal osteolysis with or without nephropathy ORPHA:2774; Cryptogenic multifocal ulcerous stenosing enteritis ORPHA:468635; Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder ORPHA:477787; Epithelial basement membrane dystrophy ORPHA:98956; Glycogen storage disease due to liver glycogen phosphorylase deficiency ORPHA:369; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome ORPHA:444138; RIN2 syndrome ORPHA:217335; Reis-Bucklers corneal dystrophy ORPHA:98961; Thiel-Behnke corneal dystrophy ORPHA:98960; Congenital generalized lipodystrophy ORPHA:528; AGel amyloidosis ORPHA:85448; Carnitine palmitoyl transferase 1A deficiency ORPHA:156; Inherited acute myeloid leukemia ORPHA:319465",0.0155394890951578; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human papillomavirus type 6 E5B (gene: E5B),0.8999095837312036,In vitro,0.54,Homo sapiens,Homo sapiens
KLHL29,Red Blood Cell Count measurement; Platelet hematocrit measurement; Hemoglobin measurement; Hematocrit procedure; Hypertensive disease; Coronary heart disease,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8402911822757345; 0.8474481237156937; 0.9119978323790848,Hypertension; Epilepsy; Coronary Heart Disease; Mental Depression; Mood Disorder,0.7765582368651238; 0.8611702959552964; 0.861756360478846; 0.8903630091389316; 0.9726139569926774,Juvenile nephronophthisis ORPHA:93592,0.6335420546867965,"Horsepox virus HSPV197 (Hypothetical protein); Yaba-like disease virus 140R protein (gene: 140R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV008; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Yaba-like disease virus 19L protein (gene: 19L); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Ectromelia virus ERPV kelch-like protein; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Vaccinia virus kelch-like protein (gene: A55R); Variola virus hypothetical protein (gene: J7R); Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Monkeypox virus Zaire-96-I-16 B1R (gene: B1R); Yaba monkey tumor virus kelch-like protein; Horsepox virus HSPV043 (Kelch-like protein; Provisional); Horsepox virus HSPV029 (kelch-like protein; Provisional); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Variola virus hypothetical protein (gene: B24R); Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus kelch-like protein (gene: C2L); Monkeypox virus Zaire-96-I-16 D17L (gene: D17L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Variola virus hypothetical protein (gene: J8R); Variola virus hypothetical protein (gene: D13L); Vaccinia virus Ankara 18.9k Kelch-like protein; Horsepox virus HSPV187 (kelch-like protein; Provisional); Monkeypox virus Zaire-96-I-16 D16L (gene: D16L); Cowpox virus CPXV204 protein (gene: CPXV204 CDS); Variola virus hypothetical protein (gene: C7L); Vaccinia virus hypothetical protein; Monkeypox virus kelch-like protein; Vaccinia virus Ankara 64.7k Kelch-like protein f2",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
KLK8,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Colorectal Carcinoma; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Endometrial Carcinoma; Malignant tumor of cervix; Malignant neoplasm of lung; Colorectal Cancer; Epithelial ovarian cancer; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Lung Neoplasms; Mental disorders; Abnormal behavior; Malignant neoplasm of large intestine; Viral Encephalitis; Psoriasis; Luminal A Breast Carcinoma; Encephalomyelitis; ovarian neoplasm; Schizophrenia; Hyperkeratosis; Inflammatory dermatosis; Mental Depression; Dermatitis; Bipolar Disorder; Depressive disorder,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8190761496232595; 0.8554819098734854; 0.8769418330148872; 0.8815127642200768; 0.900167961295542; 0.9103315000053974,Bipolar Disorder,0.943322675973118,"Van der Woude syndrome ORPHA:888; EEM syndrome ORPHA:1897; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Bifid uvula ORPHA:99771; Cleft hard palate ORPHA:101023; Cleft velum ORPHA:99772; Submucosal cleft palate ORPHA:155878; Cleft lip and alveolus ORPHA:141291; Isolated cleft lip ORPHA:199302; Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism ORPHA:100034; Neuropathy with hearing impairment ORPHA:139512; Sebocystomatosis ORPHA:841; Tricho-dento-osseous syndrome ORPHA:3352; Pachyonychia congenita ORPHA:2309; Self-improving collodion baby ORPHA:281122; Acral self-healing collodion baby ORPHA:281127; Bathing suit ichthyosis ORPHA:100976; Epithelial recurrent erosion dystrophy ORPHA:293381; Hereditary hypotrichosis with recurrent skin vesicles ORPHA:217407; Keratoderma hereditarium mutilans ORPHA:494; Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome ORPHA:2698; Late-onset junctional epidermolysis bullosa ORPHA:79406; Netherton syndrome ORPHA:634; Porokeratotic eccrine ostial and dermal duct nevus ORPHA:166286; Bladder exstrophy ORPHA:93930; Palmoplantar keratoderma-deafness syndrome ORPHA:2202; Severe dermatitis-multiple allergies-metabolic wasting syndrome ORPHA:369992; Uncombable hair syndrome ORPHA:1410; Erythrokeratodermia variabilis ORPHA:317; Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form ORPHA:79399; Autosomal dominant generalized epidermolysis bullosa simplex, severe form ORPHA:79396; Epidermolysis bullosa simplex with mottled pigmentation ORPHA:79397; KID syndrome ORPHA:477; Localized epidermolysis bullosa simplex ORPHA:79400; Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering ORPHA:402003; Autosomal recessive generalized epidermolysis bullosa simplex ORPHA:89838; Dermatopathia pigmentosa reticularis ORPHA:86920; Epidermolysis bullosa simplex with circinate migratory erythema ORPHA:158681; Epidermolytic palmoplantar keratoderma ORPHA:2199; Naegeli-Franceschetti-Jadassohn syndrome ORPHA:69087; Peeling skin syndrome type B ORPHA:263553; Acrodermatitis continua of Hallopeau ORPHA:163931; Generalized pustular psoriasis ORPHA:247353; Hypotrichosis simplex of the scalp ORPHA:90368; Isolated focal non-epidermolytic palmoplantar keratoderma ORPHA:448264; Meesmann corneal dystrophy ORPHA:98954; Pure hair and nail ectodermal dysplasia ORPHA:69084; Pustulosis palmaris et plantaris ORPHA:163927; Congenital non-bullous ichthyosiform erythroderma ORPHA:79394; DITRA ORPHA:404546; Diffuse palmoplantar keratoderma with painful fissures ORPHA:369999; Focal palmoplantar keratoderma with joint keratoses ORPHA:370002; Hereditary palmoplantar keratoderma, Gamborg-Nielsen type ORPHA:86923; Mal de Meleda ORPHA:87503; Postural orthostatic tachycardia syndrome due to NET deficiency ORPHA:443236; Ichthyosis-short stature-brachydactyly-microspherophakia syndrome ORPHA:363992; Striate palmoplantar keratoderma ORPHA:50942; Lamellar ichthyosis ORPHA:313",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,HMO Astrovirus A non-structural protein,0.915880438522078,,,,
LCMT2,,,,,Autosomal dominant hypophosphatemic rickets ORPHA:89937,0.8922466888454011,Horsepox virus HSPV197 (Hypothetical protein); Yaba-like disease virus 140R protein (gene: 140R); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Ectromelia virus ERPV kelch-like protein,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
LIPG,"Malignant neoplasm of breast; Breast Carcinoma; Hypercholesterolemia; Vascular Diseases; Serum total cholesterol measurement; High density lipoprotein measurement; Hemolytic-Uremic Syndrome; Coronary Arteriosclerosis; Retinoblastoma; Arteriosclerosis; Atherosclerosis; Acute myocardial infarction; Cardiovascular Diseases; Diabetes Mellitus; Cholesteryl Ester Transfer Protein Deficiency; Myocardial Infarction; Autistic Disorder; Dyslipidemias; Diabetes Mellitus, Non-Insulin-Dependent; Diabetic Retinopathy; Proliferative retinopathy; Phospholipid measurement; Hypertensive disease; Deep Vein Thrombosis; Metabolic Syndrome X; Allergic asthma; Coronary Artery Disease; Obesity; Depressive Symptoms; Coronary heart disease; Uveal melanoma; Overweight; Germ cell tumor",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8138488881521341; 0.8190761496232595; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8584283190330553; 0.8610447277138289; 0.887595340546704; 0.887595340546704; 0.8989612563669234; 0.905201167721829; 0.9119978323790848; 0.929235785949896; 0.929814249105729; 0.9564633032157428,Alzheimer Disease; Autism,0.8457525389282121; 0.911896615143974,,,,,,,,
LMF2,Malignant neoplasm of breast; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Mean corpuscular hemoglobin concentration determination; Alzheimer's Disease,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415,Breast Cancer,0.8903630091389316,"Atrial septal defect, sinus venosus type ORPHA:99105; Familial lipase maturation factor 1 deficiency ORPHA:535453; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Crisponi syndrome ORPHA:1545; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Barth syndrome ORPHA:111; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Incontinentia pigmenti ORPHA:464; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Intermediate osteopetrosis ORPHA:210110; Multiple endocrine neoplasia type 1 ORPHA:652; Albers Schonberg osteopetrosis ORPHA:53; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; BAP1-related tumor predisposition syndrome ORPHA:289539; CLN11 disease ORPHA:314629; Focal dermal hypoplasia ORPHA:2092; Pontocerebellar hypoplasia type 9 ORPHA:369920; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; D-2-hydroxyglutaric aciduria ORPHA:79315; Adrenomyeloneuropathy ORPHA:139399; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome ORPHA:95433; CLN10 disease ORPHA:228337; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; Leukonychia totalis ORPHA:2387; MYH9-related disease ORPHA:182050; Mucolipidosis type IV ORPHA:578; NAD(P)HX dehydratase deficiency ORPHA:555402; Neutral lipid storage myopathy ORPHA:98908; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361; Scheie syndrome ORPHA:93474; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; X-linked cerebral adrenoleukodystrophy ORPHA:139396; CADDS ORPHA:369942; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Early myoclonic encephalopathy ORPHA:1935; Charcot-Marie-Tooth disease type 2B2 ORPHA:101101; Metachromatic leukodystrophy, adult form ORPHA:309271; Metachromatic leukodystrophy, juvenile form ORPHA:309263; Metachromatic leukodystrophy, late infantile form ORPHA:309256; Ataxia-oculomotor apraxia type 4 ORPHA:459033; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; D-glyceric aciduria ORPHA:941; Intellectual disability-strabismus syndrome ORPHA:363528; MOGS-CDG ORPHA:79330; Mucopolysaccharidosis type 4A ORPHA:309297; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; Spondylo-ocular syndrome ORPHA:85194; TELO2-related intellectual disability-neurodevelopmental disorder ORPHA:488642; Van den Ende-Gupta syndrome ORPHA:2460; 3C syndrome ORPHA:7; Desbuquois syndrome ORPHA:1425; Ependymoma ORPHA:251636; RELA fusion-positive ependymoma ORPHA:530792; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Prolactinoma ORPHA:2965; Rare isolated myopia ORPHA:98619; Chronic myelomonocytic leukemia ORPHA:98823; Alpers-Huttenlocher syndrome ORPHA:726; Ataxia-hypogonadism-choroidal dystrophy syndrome ORPHA:1180; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect ORPHA:521411; Autosomal recessive spastic paraplegia type 39 ORPHA:139480; Autosomal recessive spastic paraplegia type 48 ORPHA:306511; Laurence-Moon syndrome ORPHA:2377; Lethal brain and heart developmental defects ORPHA:580933; Lethal neonatal spasticity-epileptic encephalopathy syndrome ORPHA:435845; MAN1B1-CDG ORPHA:397941; Neuralgic amyotrophy ORPHA:2901; Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome ORPHA:529665; Polyglucosan body myopathy type 1 ORPHA:397937; Recessive mitochondrial ataxia syndrome ORPHA:94125; Sanfilippo syndrome type B ORPHA:79270; Spinocerebellar ataxia with epilepsy ORPHA:254881; Trichomegaly-retina pigmentary degeneration-dwarfism syndrome ORPHA:3363; Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis ORPHA:329173; Autosomal recessive progressive external ophthalmoplegia ORPHA:254886; Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome ORPHA:70595; Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome ORPHA:466794; B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:75496; FLNA-related X-linked myxomatous valvular dysplasia ORPHA:555877; Familial LCAT deficiency ORPHA:79293; Fish-eye disease ORPHA:79292; GMPPB-related  limb-girdle muscular dystrophy R19 ORPHA:363623; Glycogen storage disease due to acid maltase deficiency, infantile onset ORPHA:308552; Glycogen storage disease due to acid maltase deficiency, late-onset ORPHA:420429; Larsen-like syndrome, B3GAT3 type ORPHA:284139; Leukocyte adhesion deficiency type II ORPHA:99843; Melnick-Needles syndrome ORPHA:2484; Neuronal intestinal pseudoobstruction ORPHA:99811; Otopalatodigital syndrome type 1 ORPHA:90650; Otopalatodigital syndrome type 2 ORPHA:90652; Pontocerebellar hypoplasia type 8 ORPHA:324569; Sanfilippo syndrome type A ORPHA:79269; Terminal osseous dysplasia-pigmentary defects syndrome ORPHA:88630; X-linked Ehlers-Danlos syndrome ORPHA:75497; X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome ORPHA:482606; Alveolar soft tissue sarcoma ORPHA:163699; Fibrolamellar hepatocellular carcinoma ORPHA:401920; ALG12-CDG ORPHA:79324; Argininosuccinic aciduria ORPHA:23; Autosomal recessive spastic paraplegia type 76 ORPHA:488594; Childhood-onset basal ganglia degeneration syndrome ORPHA:497906; Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies ORPHA:221145; Fetal Gaucher disease ORPHA:85212; Gaucher disease type 2 ORPHA:77260; Gaucher disease type 3 ORPHA:77261; Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome ORPHA:2072; Glycogen storage disease due to muscle and heart glycogen synthase deficiency ORPHA:137625; Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome ORPHA:369837; NON RARE IN EUROPE: Parkinson disease ORPHA:319705; Niemann-Pick disease type A ORPHA:77292; Niemann-Pick disease type B ORPHA:77293; SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:157965; Null pituitary adenoma ORPHA:314790; Pituitary gigantism ORPHA:99725; Silent pituitary adenoma ORPHA:314786",0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
LMTK3,Malignant neoplasm of breast; Breast Carcinoma; Colorectal Carcinoma; Thyroid Neoplasm; Malignant neoplasm of prostate; Thyroid carcinoma; Colorectal Cancer; Prostate carcinoma; Malignant neoplasm of thyroid; Malignant neoplasm of stomach; Tumor Progression; Stomach Carcinoma,0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,"PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Paroxysmal exertion-induced dyskinesia ORPHA:98811; 1p36 deletion syndrome ORPHA:1606; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Bilateral generalized polymicrogyria ORPHA:208447; Usher syndrome type 1 ORPHA:231169; Crouzon disease ORPHA:207; Fuhrmann syndrome ORPHA:2854; Phocomelia, Schinzel type ORPHA:2879; Spinocerebellar ataxia type 13 ORPHA:98768; Isolated split hand-split foot malformation ORPHA:2440; SYNGAP1-related developmental and epileptic encephalopathy ORPHA:544254; Spinocerebellar ataxia type 14 ORPHA:98763",0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.1040670578681756; 0.1991445465001551; 0.2661730864557679; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Yaba-like disease virus 142R protein (gene: 142R); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Yaba monkey tumor virus ankyrin repeat protein; Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Yaba-like disease virus 11L protein (gene: 11L); Orf virus ORF020 dsRNA-binding PKR inhibitor; Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Yaba monkey tumor virus 142R; Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Orf virus ORF008 ankyrin repeat protein; Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Human immunodeficiency virus pol protein (gene: pol); Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Orf virus ORF130 putative serine/threonine protein kinase; Human immunodeficiency virus 1 integrase (gene: gag-pol); Human immunodeficiency virus 1 Pol (gene: gag-pol); Monkeypox virus ankyrin-like protein; Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Vaccinia virus ankyrin-like protein (gene: B4R); Human alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Ectromelia virus ERPV profilin-like protein; Macaque simian foamy virus Pol (gene: pol); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); African green monkey simian foamy virus Pol precursor (gene: pol); Ectromelia virus ERPV ankyrin; Variola virus hypothetical protein (gene: A47R); Monkeypox virus profilin-like protein; Monkeypox virus Zaire-96-I-16 A42R (gene: A42R); Horsepox virus HSPV164 (Profilin); Vaccinia virus profilin-like protein (gene: A42R); Vaccinia virus Ankara Profilin-1-like; Cowpox virus CPXV179 protein (gene: CPXV179 CDS); Variola virus hypothetical protein (gene: G3R); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Variola virus hypothetical protein (gene: B6R); Simian foamy virus full_polyprotein 1..1146 (gene: pol); Human betaherpesvirus 5 membrane glycoprotein UL18 (gene: UL18)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9237501457186692; 0.9237501457186692; 0.9364561700418303; 0.9496696866493144; 0.9687349764960514,,,,
LPAR6,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Reduced tensile strength of hair; Fractured hair; Fragile hair; Brittle hair; Liver carcinoma; Hypopigmentation of hair; Sparse body hair; Metastatic malignant neoplasm to brain; Woolly hair, congenital; Total Hypotrichosis, Mari type; Fine hair; Hypotrichosis of the scalp; Fair hair; Rough hair texture; Coarse hair; Blonde hair; Sparse eyelashes; Hair Diseases; Crohn Disease; HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; Wooly hair; Afro-textured hair; Kinky hair texture; Nappy hair texture; Sparse and thin eyebrow; Hypotrichosis; Hypotrichosis simplex; Lung diseases; Ulcerative Colitis; Slow-growing hair; Alopecia",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7967714690735718; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8190761496232595; 0.8523465762428218,Woolly Hair; Hypotrichosis Simplex; Hypotrichosis; Strabismus; Alopecia; Cataract,0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8908485337686392; 0.9367173114041438; 0.974502015052702,SHORT syndrome ORPHA:3163; ABri amyloidosis ORPHA:97345; ADan amyloidosis ORPHA:97346; Ayme-Gripp syndrome ORPHA:1272; Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies ORPHA:397758; Adult Krabbe disease ORPHA:206448; Late-infantile/juvenile Krabbe disease ORPHA:206443; Angelman syndrome due to imprinting defect in 15q11-q13 ORPHA:411515; Squamous cell carcinoma of the esophagus ORPHA:99977; Bietti crystalline dystrophy ORPHA:41751; Enamel-renal syndrome ORPHA:1031; Vitamin B12-responsive methylmalonic acidemia type cblA ORPHA:79310; Moyamoya disease ORPHA:2573; Hypotrichosis simplex ORPHA:55654; Woolly hair ORPHA:170,0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
LPCAT3,Fatty acid measurement; Liver carcinoma; Arteriosclerosis; Atherosclerosis; Hyperglycemia; Red cell distribution width determination; RDW - Red blood cell distribution width result; Essential Hypertension,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.9557184806547836,,,"Mucopolysaccharidosis type 7 ORPHA:584; Biotinidase deficiency ORPHA:79241; Fucosidosis ORPHA:349; Carnitine palmitoyl transferase II deficiency, myopathic form ORPHA:228302; Carnitine palmitoyl transferase II deficiency, neonatal form ORPHA:228308; Carnitine palmitoyl transferase II deficiency, severe infantile form ORPHA:228305",0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
LYST,"Paresthesia; Lymphoma; Amblyopia; Hemophagocytic Syndrome; Hypopigmentation of hair; Chediak-Higashi Syndrome; Exfoliation Syndrome; Hermanski-Pudlak Syndrome; Decreased nerve conduction velocity; Immunologic Deficiency Syndromes; Lymphadenopathy; Body fluid retention; Pigmentary iris degeneration; Recurrent cutaneous abscess formation; aspirin sensitivity; Cohen syndrome; Hypothalamic Dysfunction Syndromes; White hair; Low Vision; Recurrent infections; Lupus Erythematosus, Systemic; Photophobia; Periodontitis; Recurrent bacterial skin infections; Nystagmus; Infantile nystagmus; Cognitive delay; Foot-drop; Visual Impairment; Foot dorsiflexor weakness; Lymphohistiocytosis, Hemophagocytic; Epistaxis; Frequent nosebleeds; Global developmental delay; Edema; Cranial nerve palsies; Photodysphoria; Mental and motor retardation; Gingivitis; Onychomycosis; Nerve Degeneration; Piebaldism; Allergic disposition; Generalized hypopigmentation; Gait abnormality; Gingival Hemorrhage; Platelet Storage Pool Deficiency; Neuro-degenerative disease; Decreased platelet count; Reduced visual acuity; Leukopenia; Thrombocytopenia; Gingival Diseases; Spastic Paraplegia; Neutrophil count decreased; Hypopigmentation disorder; Fever; Albinism, Ocular; Tremor; Albinism, Oculocutaneous; Skin Ulcer; Periodontal Diseases; Neurodegenerative Disorders; Abnormality of coagulation; Decreased tendon reflex; Splenomegaly; Strabismus; Peripheral Neuropathy; Mental deficiency; Icterus; Albinism; Anemia; Atrial Fibrillation; Hemoglobin low; Hemorrhagic Disorders; Dull intelligence; Low intelligence; Eosinophilia; Parkinson Disease; Absent tendon reflex; Hepatomegaly; Reflex, Deep Tendon, Absent; Absent reflex; Poor school performance; Recurrent respiratory infections; Increased tendency to bruise; Neuropathy; Eosinophilic disorder; Mental Retardation; Blood Coagulation Disorders; Chronic Kidney Diseases; Intellectual Disability; Seizures; Trichohepatoenteric Syndrome; Nasal Polyps; Epilepsy",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026798872257774; 0.8067197998685076; 0.8101097852323003; 0.8138488881521341; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8368219249856942; 0.8391186563955684; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8578473133580928; 0.8584283190330553; 0.8648405521677974; 0.8648405521677974; 0.8690346447728063; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8772392350816924; 0.8867509400747969; 0.887595340546704; 0.8911256045597441; 0.8911256045597441; 0.8913141512402477; 0.9083161862856644; 0.914995991166204; 0.914995991166204; 0.9193385822373632; 0.922229272318747; 0.9307095582633488; 0.9393256300017014; 0.9478210444156088; 0.9478210444156088; 0.94939825643792; 0.9614320311453906; 0.963331724428282,Gingivitis; Melanocytic Nevus; Hypopigmentation Disorder; Immunologic Deficiency Syndromes; Nystagmus; Cranial Nerve Paralysis; Developmental Delay; Lymphoma; Periodontitis; Leukopenia; Albinism; Ocular Albinism; Spastic Paraplegia; Parkinson Disease; Movement Disorders; Cerebellar Atrophy; Mental Retardation; Neutropenia; Strabismus; Lupus Erythematosus; Anemia; Nervous System Diseases; Developmental Regression; Atrial Septal Defect,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8091514409416879; 0.8115918568696846; 0.8115918568696846; 0.8182883735985873; 0.8182883735985873; 0.829560580336605; 0.8337953215113012; 0.8337953215113012; 0.8476516371290275; 0.8908485337686392; 0.9145387439550552; 0.9369188149054885; 0.9492120794677584; 0.9658957825498884; 0.9832345076528324,"2q37 microdeletion syndrome ORPHA:1001; Cleidocranial dysplasia ORPHA:1452; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504; SHORT syndrome ORPHA:3163; TOR1AIP1-related limb-girdle muscular dystrophy ORPHA:424261; Autosomal recessive ataxia, Beauce type ORPHA:88644; Autosomal recessive myogenic arthrogryposis multiplex congenita ORPHA:319332; Early-onset Lafora body disease ORPHA:324290; External auditory canal aplasia/hypoplasia ORPHA:141074; Generalized glucocorticoid resistance syndrome ORPHA:786; Familial platelet disorder with associated myeloid malignancy ORPHA:71290; Acute promyelocytic leukemia ORPHA:520; 1p21.3 microdeletion syndrome ORPHA:293948; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency ORPHA:574957; Coffin-Lowry syndrome ORPHA:192; Complex lethal osteochondrodysplasia ORPHA:457378; Dihydropyrimidine dehydrogenase deficiency ORPHA:1675; GM3 synthase deficiency ORPHA:370933; Microcephalic primordial dwarfism, Dauber type ORPHA:319675; Nicolaides-Baraitser syndrome ORPHA:3051; Spinocerebellar ataxia type 1 ORPHA:98755; Symptomatic form of Coffin-Lowry syndrome in female carriers ORPHA:276630; Squamous cell carcinoma of the esophagus ORPHA:99977; Acute myeloid leukaemia with myelodysplasia-related features ORPHA:86845; Attenuated Chediak-Higashi syndrome ORPHA:352723; Autosomal dominant vitreoretinochoroidopathy ORPHA:3086; Autosomal recessive bestrophinopathy ORPHA:139455; Bannayan-Riley-Ruvalcaba syndrome ORPHA:109; Best vitelliform macular dystrophy ORPHA:1243; Bietti crystalline dystrophy ORPHA:41751; Calpain-3-related  limb-girdle muscular dystrophy R1 ORPHA:267; Chediak-Higashi syndrome ORPHA:167; Corpus callosum agenesis-neuronopathy syndrome ORPHA:1496; Familial cylindromatosis ORPHA:211; Familial multiple trichoepithelioma ORPHA:867; Lhermitte-Duclos disease ORPHA:65285; MRCS syndrome ORPHA:263347; PDE4D haploinsufficiency syndrome ORPHA:439822; Polycythemia vera ORPHA:729; Proteus-like syndrome ORPHA:2969; Refractory anemia ORPHA:98826; Refractory anemia with excess blasts ORPHA:86839; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome ORPHA:137608; Spinocerebellar ataxia type 15/16 ORPHA:98769; Spinocerebellar ataxia type 29 ORPHA:208513; Spinocerebellar ataxia type 7 ORPHA:94147; Acrodysostosis ORPHA:950; Acrodysostosis with multiple hormone resistance ORPHA:280651; Activated PI3K-delta syndrome ORPHA:397596; Primary myelofibrosis ORPHA:824; Gingival fibromatosis-hypertrichosis syndrome ORPHA:2026; Mowat-Wilson syndrome due to a ZEB2 point mutation ORPHA:261552; Mowat-Wilson syndrome due to monosomy 2q22 ORPHA:261537; Budd-Chiari syndrome ORPHA:131; Thyroid hypoplasia ORPHA:95720; Achromatopsia ORPHA:49382",0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7150309491065155; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Variola virus semaphorin-like protein (gene: A44R),0.8999095837312036,,,,
MAFB,"leukemia; Leukemia, Myelocytic, Acute; Lymphoma; Triangular face; Liver carcinoma; Leukemia, Plasma Cell; Duane Retraction Syndrome; Multiple Myeloma; Cleft palate, isolated; Oculomotor Nerve Paralysis; Increase in blood pressure; Nasopharyngeal carcinoma; Cleft Palate; Abnormal vertebral segmentation and fusion; Anteverted nostril; Ulnar deviation of hand; Cleft upper lip; Prominent eyes; Protruding eyes; Prominent globes; Exophthalmos; Generalized osteopenia; Sunken eyes; Enophthalmos; Gait abnormality; Limitation of joint mobility; Short palpebral fissure; Kidney Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Cardiac Lymphoma; Electromyogram abnormal; Arthralgia; Diabetes Mellitus, Non-Insulin-Dependent; Slender long bone; Osteopenia; Retrusion of upper jaw bones; Decreased projection of maxilla; Deficiency of upper jaw bones; Hypoplasia of the maxilla; Hypotrophic maxilla; Maxillary retrognathia; Milroy Disease; Strabismus; Osteogenesis Imperfecta; Cachexia; Kidney damage; Hypertensive disease; Flexion contracture of proximal interphalangeal joint; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Proteinuria; Low posterior hairline; Blepharophimosis; Renal failure in adulthood; Renal Insufficiency; Intellectual Disability; Sensorineural Hearing Loss (disorder); Uranostaphyloschisis; Congenital pes cavus; Kidney Failure",0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8578473133580928; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8769418330148872; 0.8851456306720444; 0.9189398569397552; 0.929814249105729; 0.946564927793026; 0.9478210444156088; 0.9520060723130308; 0.9534337109847604; 0.957487573707278; 0.9894341523578486,Congenital Hypoplasia Of Radius; Plagiocephaly; Hypoplasia Of The Maxilla; Nystagmus; Hypertension; Aniridia; Developmental Delay; Microcornea; Duane Retraction Syndrome; Fundus Coloboma; Osteopenia; Retinal Coloboma; Oculomotor Nerve Palsy; Proptosis; Hearing Loss; Congenital Camptodactyly; Stenosis Of External Auditory Canal; Kidney Disease; Blepharospasm; Hypoplasia Of Optic Disc; Neck Webbing; Ectopic Kidney; Microcephaly; Strabismus; Spina Bifida Occulta; Congenital Coloboma Of Iris; Micrognathism; Blepharophimosis; Polydactyly; Renal Insufficiency; Ptosis; Congenital Clubfoot; Brachydactyly,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.8210988731657684; 0.829560580336605; 0.8337953215113012; 0.861756360478846; 0.8903630091389316; 0.8908485337686392; 0.9166047043368432; 0.9318760199717074; 0.9398381935810408; 0.9543024119762946; 0.9578111936867284; 0.9726837163662044; 0.9832345076528324; 0.9832345076528324; 0.9887104428514284,Congenital brain dysgenesis due to glutamine synthetase deficiency ORPHA:71278; Thrombomodulin-related bleeding disorder ORPHA:436169; ACys amyloidosis ORPHA:100008; Charcot-Marie-Tooth disease type 4D ORPHA:99950; Duane retraction syndrome with congenital deafness ORPHA:529574; Multicentric carpo-tarsal osteolysis with or without nephropathy ORPHA:2774; Atypical Gaucher disease due to saposin C deficiency ORPHA:309252; Ayme-Gripp syndrome ORPHA:1272; Beckwith-Wiedemann syndrome due to CDKN1C mutation ORPHA:231120; Charcot-Marie-Tooth disease type 4H ORPHA:99954; Encephalopathy due to prosaposin deficiency ORPHA:139406; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome ORPHA:436144; Tangier disease ORPHA:31150; Acute myeloid leukemia with CEBPA somatic mutations ORPHA:319480; Cerebrotendinous xanthomatosis ORPHA:909; Duane retraction syndrome ORPHA:233; C1 inhibitor deficiency ORPHA:459353; Hereditary angioedema type 1 ORPHA:100050; Hereditary angioedema type 2 ORPHA:100051; NON RARE IN EUROPE: Berger disease ORPHA:34145; Sanfilippo syndrome type C ORPHA:79271; Inherited acute myeloid leukemia ORPHA:319465; Semantic dementia ORPHA:100069,0.1040670578681756; 0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Japanese encephalitis virus hypothetical protein; Salivirus NG-J1 3D; Human enteric coronavirus 4408 spike protein (gene: S); Human enteric coronavirus strain 4408 spike protein; Rotavirus A NSP4; Human parainfluenza virus 1 strain Washington/1964 phosphoprotein (gene: P); Human respirovirus 1 phosphoprotein (gene: P); Sagiyama virus full_polyprotein 1..1253 (gene: C-E3-E2-6K-E1); Variola virus hypothetical protein (gene: A28L); Japanese encephalitis virus anchored core protein C; Japanese encephalitis virus prodexcised_polyprotein 1..794; West Nile virus lineage 1 capsid protein C (gene: flavivirus polyprotein),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,In vitro,0.71,Homo sapiens,Homo sapiens
MAP3K14,"Malignant neoplasm of breast; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; B-Cell Lymphomas; Lymphoma; Glioma; Myotonic Dystrophy; Liver carcinoma; Lymphopenia; Glioblastoma; Primary immune deficiency disorder; Prostatic Neoplasms; Biliary cirrhosis; melanoma; Peutz-Jeghers Syndrome; Ovarian Mucinous Adenocarcinoma; vascular ischemia; Neoplastic Syndromes, Hereditary; Classical Hodgkin's Lymphoma; Sjogren's Syndrome; Anaplastic thyroid carcinoma; Neurofibromatosis, Type 3, mixed central and peripheral; Virus Diseases; Pick Disease of the Brain; Embryonal Carcinoma; Schizophrenia; Herpes Simplex Infections; Diabetes Mellitus, Insulin-Dependent; Primary biliary cirrhosis; Tuberculosis; Down Syndrome; Medullary carcinoma of thyroid; Heart failure; Congestive heart failure; Frontotemporal dementia; Sicca Syndrome",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8212681436603975; 0.8368219249856942; 0.8420665668584452; 0.8757755363384367; 0.8867509400747969; 0.8976039441125321; 0.9024758035783405; 0.9039108388826153,Ovarian Adenocarcinoma,0.7765582368651238,Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; NIK deficiency ORPHA:447731; Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.1991445465001551; 0.1991445465001551; 0.7929682744768703; 0.7929682744768703,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Yaba-like disease virus 142R protein (gene: 142R); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9237501457186692,,,,
MAPKAPK2,Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Carcinogenesis; Malignant neoplasm of pancreas; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Invasive carcinoma of breast; Malignant Head and Neck Neoplasm; Liver and Intrahepatic Biliary Tract Carcinoma; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of liver; Van der Woude syndrome; Multiple Myeloma; Nasopharyngeal carcinoma; Alzheimer's Disease; Pemphigus Vulgaris; Psoriasis; Epstein-Barr Virus Infections; Clostridium; difficile (disorder); Inflammatory disorder; Heart failure; Pulmonary Fibrosis; Congestive heart failure,0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8232134984476662; 0.8554819098734854; 0.882453254162044; 0.8867509400747969; 0.8911256045597441; 0.8976039441125321,Oral Ulcer,0.7765582368651238,"Atrial septal defect, sinus venosus type ORPHA:99105; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; Early-onset posterior subcapsular cataract ORPHA:441447; Desbuquois syndrome ORPHA:1425; Chronic myelomonocytic leukemia ORPHA:98823; Schneckenbecken dysplasia ORPHA:3144; Dejerine-Sottas syndrome ORPHA:64748",0.0155394890951578; 0.1991445465001551; 0.220389120533256; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Variola virus hypothetical protein (gene: B1R); Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Cowpox virus CPXV206 protein (gene: CPXV206 CDS); Vaccinia virus ser/thr kinase (gene: B1R); Vaccinia virus Ankara Serine/threonine-protein kinase; Horsepox virus HSPV179 (Serine/Threonine protein kinase, Vaccinia Related Kinase); Yaba monkey tumor virus 142R",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
MAPRE2,Adenomatous Polyposis Coli; Carcinogenesis; leukemia; Malignant neoplasm of pancreas; Pancreatic carcinoma; Rotting teeth; Liver carcinoma; Dental caries; Colorectal Cancer; Body fluid retention; Diffusely thickened skin; Thick skin; Hypoplasia of corpus callosum; Broad neck; Decreased corneal diameter; Microcornea; Squamous cell carcinoma; Edema; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Short palpebral fissure; Posteriorly rotated ear; Delayed speech and language development; Precursor B-cell lymphoblastic leukemia; Upward slant of palpebral fissure; Downward slant of palpebral fissure; No development of motor milestones; Hypoplasia of scrotum; Motor delay; Abnormally small eyeball; Decreased size of eyeball; Irregular hyperpigmentation; Speech impairment; Cryptorchidism; Language Delay; Generalized hypotonia; Speech Delay; Microstomia; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Low set ears; Flat face; Congenital Epicanthus; Congenital small ears; Microphthalmos; Penile hypospadias; Intellectual Disability; Seizures; Hypospadias; Uranostaphyloschisis; Short neck; Epilepsy,0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8026798872257774; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8554819098734854; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8700543109506378; 0.882453254162044; 0.8867509400747969; 0.8959157818691486; 0.9154499654632742; 0.9393256300017014; 0.9478210444156088; 0.9478210444156088; 0.94939825643792; 0.9534337109847604; 0.954882372756482; 0.963331724428282,Developmental Delay; Microcornea; Hypoplasia Of Corpus Callosum; Retinal Diseases; Motor Delay; Mental Retardation; Cryptorchidism; Posteriorly Rotated Ear; Microcephaly; Microtia; Micrognathism; Microphthalmos; Dwarfism; Congestive Heart Failure; Neuroblastoma; Microstomia; Hypospadias; Congenital Epicanthus; Congenital Exomphalos,0.7765582368651238; 0.7765582368651238; 0.7949861636679444; 0.8115918568696846; 0.8210988731657684; 0.8337953215113012; 0.861756360478846; 0.8903301324869451; 0.8903630091389316; 0.8974842552599366; 0.9398381935810408; 0.941216656523771; 0.9510372690456612; 0.9543024119762946; 0.9543024119762946; 0.9543024119762946; 0.974502015052702; 0.974502015052702; 0.980894832851993,Intellectual disability-developmental delay-contractures syndrome ORPHA:3454; Multiple benign circumferential skin creases on limbs ORPHA:2505; Fried syndrome ORPHA:85335; X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome ORPHA:1568; X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome ORPHA:85329; Prader-Willi syndrome due to translocation ORPHA:177907,0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
MARVELD3,Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Malignant neoplasm of lung; Primary malignant neoplasm of lung; Carcinoma of lung; Calcification of coronary artery,0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.9377696084218796,,,"Apparent mineralocorticoid excess ORPHA:320; Autosomal dominant popliteal pterygium syndrome ORPHA:1300; Autosomal recessive cerebral atrophy ORPHA:363969; Congenital intrauterine infection-like syndrome ORPHA:1229; Congenital tufting enteropathy ORPHA:92050; EEM syndrome ORPHA:1897; Hypotrichosis with juvenile macular degeneration ORPHA:1573; Isolated neonatal sclerosing cholangitis ORPHA:480556; Lethal congenital contracture syndrome type 2 ORPHA:137776; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome ORPHA:423454; Generalized pseudohypoaldosteronism type 1 ORPHA:171876; Liddle syndrome ORPHA:526; Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome ORPHA:476119; Congenital hereditary endothelial dystrophy type I ORPHA:98975; Familial hyperprolactinemia ORPHA:397685; RFVT3-related riboflavin transporter deficiency ORPHA:572550; Syndromic congenital sodium diarrhea ORPHA:563708; Blepharo-cheilo-odontic syndrome ORPHA:1997; Cholangiocarcinoma ORPHA:70567; Idiopathic bronchiectasis ORPHA:60033; Low isolated anorectal malformation ORPHA:171215; Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome ORPHA:397744; Congenital bilateral absence of vas deferens ORPHA:48; Microvillus inclusion disease ORPHA:2290; Progressive familial intrahepatic cholestasis type 1 ORPHA:79306; NON RARE IN EUROPE: Recurrent acute pancreatitis ORPHA:64740; Familial thyroid dyshormonogenesis ORPHA:95716; Epidermolysis bullosa simplex due to exophilin 5 deficiency ORPHA:412189; Xanthinuria type I ORPHA:93601; Neonatal severe primary hyperparathyroidism ORPHA:417; Carnitine palmitoyl transferase II deficiency, myopathic form ORPHA:228302; Carnitine palmitoyl transferase II deficiency, neonatal form ORPHA:228308; Carnitine palmitoyl transferase II deficiency, severe infantile form ORPHA:228305",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
MBNL2,"Myotonic Dystrophy; MYOTONIC DYSTROPHY 1; Infant, Premature; HUNTINGTON DISEASE-LIKE 2; Diabetes Mellitus; Alcoholic Intoxication, Chronic; Tetralogy of Fallot; Myopathy",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8769418330148872; 0.9557184806547836,,,GNE myopathy ORPHA:602; Sialuria ORPHA:3166; 1p31p32 microdeletion syndrome ORPHA:401986; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Familial Alzheimer-like prion disease ORPHA:280397; Fatal familial insomnia ORPHA:466; Gerstmann-Straussler-Scheinker syndrome ORPHA:356; Huntington disease-like 1 ORPHA:157941; Inherited Creutzfeldt-Jakob disease ORPHA:282166; Kuru ORPHA:454745; Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome ORPHA:444138; PrP systemic amyloidosis ORPHA:397606; Sporadic fatal insomnia ORPHA:586130; PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation ORPHA:438216; Recessive X-linked ichthyosis ORPHA:461; Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion ORPHA:314655; Syndromic recessive X-linked ichthyosis ORPHA:281090; Acrodysostosis ORPHA:950; Acrodysostosis with multiple hormone resistance ORPHA:280651; HELLP syndrome ORPHA:244242; X-linked myotubular myopathy-abnormal genitalia syndrome ORPHA:456328; Obesity due to leptin receptor gene deficiency ORPHA:179494; Autosomal dominant Emery-Dreifuss muscular dystrophy ORPHA:98853,0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
MDC1,Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Esophageal carcinoma; Cervix carcinoma; Esophageal Neoplasms; Malignant tumor of cervix; Malignant neoplasm of lung; Malignant neoplasm of prostate; Malignant neoplasm of esophagus; Prostate carcinoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Carcinoma of lung; Malignant neoplasm of nasopharynx; Malignant neoplasm of stomach; Cancer of Nasopharynx; Nasopharyngeal carcinoma; Tumor Progression; Stomach Carcinoma; Rheumatoid Arthritis; Aortic Valve Insufficiency; Body mass index; Finding of body mass index,0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8867509400747969; 0.8867509400747969,Rheumatoid Arthritis,0.9251646147729308,"X-linked intellectual disability, Siderius type ORPHA:85287; Precursor T-cell acute lymphoblastic leukemia ORPHA:99861; Oculofaciocardiodental syndrome ORPHA:2712; 15q24 microdeletion syndrome ORPHA:94065; Autosomal dominant Charcot-Marie-Tooth disease type 2Z ORPHA:466768; Floating-Harbor syndrome ORPHA:2044; Methylmalonic acidemia with homocystinuria, type cblX ORPHA:369962; SIN3A-related intellectual disability syndrome due to a point mutation ORPHA:500166; Juvenile amyotrophic lateral sclerosis ORPHA:300605; Coffin-Siris syndrome ORPHA:1465; NUT midline carcinoma ORPHA:443167; Familial infantile bilateral striatal necrosis ORPHA:225154; Familial isolated hyperparathyroidism ORPHA:99879; Osteopathia striata-cranial sclerosis syndrome ORPHA:2780; SMARCA4-deficient sarcoma of thorax ORPHA:466962; Small cell carcinoma of the ovary ORPHA:370396; Lujan-Fryns syndrome ORPHA:776; Clear cell sarcoma of kidney ORPHA:457246; Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome ORPHA:457485",0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6467006456772204; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.44,Homo sapiens,chemical synthesis
MED26,,,Schizophrenia,0.7860378120955526,Hermansky-Pudlak syndrome type 8 ORPHA:231537; Congenital cataracts-facial dysmorphism-neuropathy syndrome ORPHA:48431,0.3832844616405875; 0.5867963421058087,,,,,,
MEF2B,"Diffuse Large B-Cell Lymphoma; Carcinogenesis; Leukemogenesis; Lymphoma, Non-Hodgkin; Serum total cholesterol measurement; Hodgkin Disease; Lymphoma, Follicular; Multiple Sclerosis; Ataxia; Low density lipoprotein cholesterol measurement; Cerebellar Ataxia",0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8402911822757345; 0.8648405521677974; 0.906476206143938,,,Polydactyly of a biphalangeal thumb ORPHA:93339,0.3832844616405875,Human parechovirus 5 full_polyprotein 1..2185,0.9057542447893764,,,,
MERTK,"Malignant neoplasm of breast; Breast Carcinoma; leukemia; Leukemia, Myelocytic, Acute; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Lymphoma; Progressive visual loss; Leukemogenesis; Non-Small Cell Lung Carcinoma; Decreased visual acuity, progressive; Glioma; Middle East Respiratory Syndrome; Malignant neoplasm of lung; Malignant neoplasm of prostate; IMMUNE SUPPRESSION; Pulmonary Thromboembolisms; Thromboembolism; Rhabdomyosarcoma; Lymphopenia; Multiple malignancy; Glioblastoma; Prostate carcinoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Malignant Neoplasms; melanoma; Retinal Diseases; Difficulties with night vision; Night Blindness; Pallor of optic disc; Brain Neoplasms; Conductive hearing loss; Tumor Progression; Lupus Erythematosus, Systemic; Hematological Disease; Photophobia; Photoreceptor degeneration; Arteriosclerosis; Atherosclerosis; Acute lymphocytic leukemia; Nystagmus; Pulmonary Embolism; Anteverted nostril; Autoimmune Diseases; Hepatitis C; Glaucoma; Thrombus; Abnormality of the retinal vasculature; Demyelinating Diseases; Carcinoma; Conventional (Clear Cell) Renal Cell Carcinoma; Photodysphoria; Virus Diseases; Optic Atrophy; Atrophoderma maculatum; Electroretinogram abnormal; Primary malignant neoplasm; Carcinoma, Spindle-Cell; Undifferentiated carcinoma; IGA Glomerulonephritis; Hyperinsulinism; Allergic disposition; Benign neoplasm of aortic body and other paraganglia; Malignant Adrenal Medulla Neoplasm; Malignant neoplasm of aortic body and other paraganglia; Multiple Sclerosis; Leukopenia; Myocardial Infarction; Benign neoplasm of adrenal gland; Blindness, Legal; Lupus Erythematosus; Blindness; Lupus Erythematosus, Discoid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Liver diseases; Congenital anomaly of testis; Progressive night blindness; Precursor Cell Lymphoblastic Leukemia Lymphoma; Carcinomatosis; Peritonitis; Retinal Dystrophies; Broad flat nasal bridge; Liver Cirrhosis; Nasal bridge wide; Congenital hypoplasia of penis; Severe Acute Respiratory Syndrome; Fibrosis, Liver; Atypical scarring of skin; Glioblastoma Multiforme; Retinitis Pigmentosa; Anaplastic carcinoma; Mental deficiency; Thrombosis; Hypogonadism; Carotid Atherosclerosis; Amaurosis congenita of Leber, type 1; Autosomal recessive retinitis pigmentosa; Keratoconus; Childhood Leukemia; Dull intelligence; Low intelligence; Cataract; Encephalitis, St. Louis; Poor school performance; Age related macular degeneration; Obesity; Ophthalmoplegia; Lymphoid leukemia; Lens Opacities; Paraganglioma; Mental Retardation; Intellectual Disability; Sensorineural Hearing Loss (disorder); Genetic Diseases, Inborn",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7950434752274518; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8140222479282434; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8213459222602666; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.8342163953428735; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8497448945325101; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8610447277138289; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8769418330148872; 0.8913141512402477; 0.8980854850210683; 0.8989612563669234; 0.900167961295542; 0.9083161862856644; 0.9117936912777788; 0.9119978323790848; 0.922229272318747; 0.9478210444156088; 0.9520060723130308; 0.9926099929361648,Carcinoma Of The Head And Neck; Retinal Dystrophy; Liver Cirrhosis; Nystagmus; Nyctalopia; Pulmonary Thromboembolism; Leukemia; Disorder Of Eye; Optic Atrophy; Hereditary Paraganglioma-Pheochromocytoma Syndromes; Hearing Loss; Anetoderma; Anaplastic Carcinoma; Mental Retardation; Leber Congenital Amaurosis; Retinitis Pigmentosa; Hyperinsulinism; Renal Carcinoma; Keratoconus; Rod-cone Dystrophy; Glaucoma; Glomerulonephritis; Carcinoma; Diabetes Mellitus; Hypogonadism; Cataract; Multiple Sclerosis; Congenital Hypoplasia Of Penis; Obesity,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.8727045307126416; 0.8879896755141929; 0.8903301324869451; 0.8903630091389316; 0.9005327950701606; 0.9069867032339078; 0.919442421650838; 0.9259420053407031; 0.974502015052702; 0.980894832851993; 0.9832345076528324; 0.9832345076528324,Retinitis pigmentosa ORPHA:791,0.8922466888454011,"Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Variola virus hypothetical protein (gene: B20R); Ectromelia virus ERPV IFN alpha/beta receptor; Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Human immunodeficiency virus 1 Envelope surface glycoprotein gp160, precursor (gene: env); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Cowpox virus CPXV209 protein (gene: CPXV209 CDS); Human herpesvirus 4 type 2 BARF1; Human adenovirus 56 CR1 beta protein (gene: E3); Vaccinia virus IL-beta-binding protein (gene: VACWR-B15R); Vaccinia virus Ankara soluble and cell surface interferon-alpha/beta receptor; Monkeypox virus IFN-alpha/beta-receptor-like secreted glycoprotein; Monkeypox virus Zaire-96-I-16 B16R (gene: B16R); Vaccinia virus IFN-alpha/beta-receptor-like secreted glycoprotein (gene: B19R); Horsepox virus HSPV195 (immunoglobulin like protein); Cowpox virus CPXV212 protein (gene: CPXV212 CDS); Vaccinia virus Ankara Interleukin-1 beta receptor; Horsepox virus HSPV192 (IL-beta-binding protein; Provisional); Human adenovirus 64 E3 48.9 kDa protein; Human adenovirus 23 CR1 b protein (gene: E3); Human adenovirus 65 E3 CR1-b; Human adenovirus 19 CR1-beta (gene: E3)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9237501457186692; 0.9397923093369096,,,,
METTL18,Ischemic stroke,0.9896536639644284,,,"Lipoyl transferase 2 deficiency ORPHA:447795; Lipoyl transferase 1 deficiency ORPHA:401862; Aspartylglucosaminuria ORPHA:93; Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency ORPHA:308425; PRUNE1-related neurological syndrome ORPHA:544469; Pontocerebellar hypoplasia type 10 ORPHA:411493; Pontocerebellar hypoplasia type 2 ORPHA:2524; ALG6-CDG ORPHA:79320; Cernunnos-XLF deficiency ORPHA:169079; Primary dystonia, DYT6 type ORPHA:98806; Catel-Manzke syndrome ORPHA:1388; Combined oxidative phosphorylation defect type 30 ORPHA:478042; SLC35A1-CDG ORPHA:238459; Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome ORPHA:488627; LIG4 syndrome ORPHA:99812; Microcephalic primordial dwarfism-insulin resistance syndrome ORPHA:436182",0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
MICA,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Thromboangiitis Obliterans; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Malignant tumor of colon; Leukemogenesis; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Hypercholesterolemia; Carcinoma breast stage IV; Thyroid Neoplasm; Malignant tumor of cervix; Platelet distribution width measurement; Platelet distribution width result; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; stage, non-small cell lung cancer; Liver carcinoma; Pyothorax-Associated Lymphoma; Malignant Head and Neck Neoplasm; Osteosarcoma; Thyroid carcinoma; Triploidy syndrome; Cholelithiasis; Colorectal Cancer; Epithelial ovarian cancer; Spondylarthritis; Liver and Intrahepatic Biliary Tract Carcinoma; Osteosarcoma of bone; Prostate carcinoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Epithelioma; Carcinoma of lung; Malignant neoplasm of thyroid; Squamous cell carcinoma of the head and neck; Malignant neoplasm of liver; Neuroblastoma; Central neuroblastoma; Serum total cholesterol measurement; Immunologic Deficiency Syndromes; Hematologic Neoplasms; melanoma; Multiple Myeloma; Neoplasms; Malignant neoplasm of stomach; Burkitt Lymphoma; Vesicular Stomatitis; Skin Carcinogenesis; Viral hepatitis; Congenital contractural arachnodactyly; Hodgkin Disease; Melanoma recurrent; Nasopharyngeal carcinoma; Hepatitis B Virus-Related Hepatocellular Carcinoma; Tumor Progression; Lupus Erythematosus, Systemic; Renal Cell Carcinoma; Takayasu Arteritis; Arteriosclerosis; Atherosclerosis; Hypersensitive syndrome; Stomach Carcinoma; Ocular Toxoplasmosis; Hepatitis C; Squamous cell carcinoma; Rheumatoid Arthritis; Diabetes; Gastrointestinal symptom; Maxillary Sinus Squamous Cell Carcinoma; Diabetes Mellitus; Ankylosing spondylitis; Ductal Carcinoma In Situ with Microinvasion; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Autoimmune Primary Adrenal Insufficiency; Crohn Disease; Vasculitis; Cytomegalovirus Infections; Virus Diseases; Myeloid Leukemia, Chronic; Leprosy, Paucibacillary; Thymus Hyperplasia; Malignant Glioma; Experimental Organism Basal Cell Carcinoma; Chronic Chagas' disease; Leukemia, Large Granular Lymphocytic; Multiple Sclerosis; Psoriasis; Myocardial Infarction; Kidney Failure, Chronic; Addison Disease; Diabetes, Autoimmune; Liver neoplasms; T-Cell Large Granular Lymphocyte Leukemia; Adenocarcinoma of lung (disorder); Acute GVH disease; Addison's disease due to autoimmunity; Liver diseases; Diabetes Mellitus, Insulin-Dependent; Coronary Aneurysm; Ulcerative Colitis; Acute colitis; Latent autoimmune diabetes mellitus in adult; Diabetes Mellitus, Non-Insulin-Dependent; Intestinal Diseases; Primary sclerosing cholangitis; Hypersensitivity; Psoriasis vulgaris; Glioblastoma Multiforme; Lymphatic Metastasis; Malignant Squamous Cell Neoplasm; Thymoma; Acute anterior uveitis; Oral Submucous Fibrosis; Celiac Disease; Toxoplasmosis; Hepatitis B; Chronic graft-versus-host disease; Rous Sarcoma; Bronchiectasis; Respiratory Syncytial Virus Infections; Familial Mediterranean Fever; Azoospermia; Giant Cell Arteritis; Hepatitis B, Chronic; Familial M??ni??re disease; Inflammatory Bowel Diseases; Arthritis, Psoriatic; Heart Diseases; Leprosy; Secondary malignant neoplasm of lymph node; HIV-1 infection; Skin carcinoma; Hamman-Rich syndrome; Malignant neoplasm of skin; Body Height; Idiopathic Pulmonary Fibrosis; Hepatitis; Pleural effusion disorder; Hepatitis C, Chronic; Behcet Syndrome; Hepatitis A; Merkel cell carcinoma; Muscle Weakness; Chronic kidney disease stage 5",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8101097852323003; 0.8138488881521341; 0.8140222479282434; 0.8145035474981049; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8272008757995397; 0.8342163953428735; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8523465762428218; 0.8610447277138289; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8745234584149799; 0.8769418330148872; 0.8815127642200768; 0.8946938397586319; 0.8989612563669234; 0.9001392794088324; 0.900167961295542; 0.9119978323790848; 0.9214835359141188; 0.9262273158806068; 0.93413028051677; 0.9390727893210336; 0.9393256300017014; 0.939985154445373; 0.9431511078237256; 0.9432051631882106; 0.9446671211493156; 0.9459312971127588; 0.9459312971127588; 0.9512505437112568; 0.9694882155560866,Liver Carcinoma; Coronary Aneurysm; Oral Submucous Fibrosis; Behcet Syndrome; Psoriatic Arthritis; Ankylosing Spondylitis; Diabetes Mellitus; Rheumatoid Arthritis,0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8611702959552964; 0.8706864397989688; 0.8903301324869451; 0.919442421650838; 0.9251646147729308,NON RARE IN EUROPE: Hemochromatosis type 1 ORPHA:139498; Sporadic porphyria cutanea tarda ORPHA:443057; Symptomatic form of hemochromatosis type 1 ORPHA:465508,0.7929682744768703; 0.7929682744768703; 0.7929682744768703,"Yaba-like disease virus 2L protein (gene: 2L); Human betaherpesvirus 6B glycoprotein (gene: U85); Yaba monkey tumor virus MHC-like TNF binding protein; Human mastadenovirus D membrane glycoprotein E3 gp19K (gene: E3); Human adenovirus 56 19K protein (gene: E3); Macacine alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Human herpesvirus 4 type 2 BARF1; Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Human betaherpesvirus 5 membrane glycoprotein UL16 (gene: UL16); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Human adenovirus 65 E3 gp19K; Human adenovirus 67 E3 gp19K; Human mastadenovirus D E3 gp19K; Human adenovirus 19 gp19K (gene: E3); Cowpox virus CPXV203 protein (gene: CPXV203 CDS); Human adenovirus 46 156R; Human adenovirus 54 17.6 kDa protein; Human adenovirus 23 gp 19K protein (gene: E3); Human alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Human adenovirus 1 E3 gp19K; Human adenovirus 5 E3 gp19K; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Human mastadenovirus C membrane glycoprotein E3 gp19K (gene: E3A); Human adenovirus 2 E3 gp19K; Human adenovirus 6 E3gp19k (gene: E3); Human adenovirus 58 18.4 kDa protein (gene: E3); Human adenovirus 28 E3 gp19K-like protein (gene: E3); Human adenovirus 36 E3 18.4K; Human adenovirus 43 gp19K-like protein (gene: E3); Human adenovirus 71 E3 immune modulating protein (gene: E3); Human adenovirus 64 E3 18.6 kDa protein; Human adenovirus D37 18.6 kDa (gene: E3); Horsepox virus HSPV177 (Immunoglobulin like); Human adenovirus D10 19KDa protein (gene: E3); Human adenovirus 61 E3 CR1 beta; Molluscum contagiosum virus subtype 1 MC033L (gene: MC033L); Vaccinia virus hemagglutinin (gene: A56R); Yaba-like disease virus 123R protein (gene: 123R); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Vaccinia virus Ankara Haemagglutinin; Yaba monkey tumor virus IEV and EEV membrane glycoprotein; Human betaherpesvirus 5 membrane glycoprotein UL18 (gene: UL18)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9103786566415374; 0.9237501457186692; 0.9287050575620676; 0.9397923093369096; 0.9687349764960514,,,,
MICAL2,Prostatic Intraepithelial Neoplasias; Malignant neoplasm of prostate; Prostate carcinoma; Neoplasm Metastasis; Prostatic Neoplasms; Malignant neoplasm of stomach; Tumor Progression; Narcolepsy; RESTING HEART RATE; Cerebrovascular accident,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8610447277138289; 0.8648405521677974,Stroke; Narcolepsy; Alzheimer Disease,0.7765582368651238; 0.8260230451542778; 0.8457525389282121,"Charcot-Marie-Tooth disease type 4D ORPHA:99950; Charcot-Marie-Tooth disease type 4C ORPHA:99949; Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease ORPHA:439854; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; NON RARE IN EUROPE: Wolff-Parkinson-White syndrome ORPHA:907; Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome ORPHA:444138; Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome ORPHA:85167",0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,,,,
MIDN,,,,,"Atrial septal defect, sinus venosus type ORPHA:99105; Early-onset posterior subcapsular cataract ORPHA:441447; Desbuquois syndrome ORPHA:1425; Acute megakaryoblastic leukemia without Down syndrome ORPHA:329469; Fibrolamellar hepatocellular carcinoma ORPHA:401920; NUT midline carcinoma ORPHA:443167; RERE-related neurodevelopmental syndrome ORPHA:494344; Leber plus disease ORPHA:99718",0.0155394890951578; 0.220389120533256; 0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 6 U31, large tegument protein (gene: U31); Human betaherpesvirus 6A large tegument protein (gene: U31); Human betaherpesvirus 6B large tegument protein (gene: U31); Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Dugbe virus L protein; Human betaherpesvirus 7 large tegument protein (gene: U31); Rotavirus A NSP4; Monkeypox virus Zaire-96-I-16 B1R (gene: B1R); Variola virus hypothetical protein (gene: B24R)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
MLLT11,"Malignant neoplasm of breast; Breast Carcinoma; Malignant neoplasm of ovary; Ovarian Carcinoma; Colorectal Carcinoma; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Leukemogenesis; Mammary Neoplasms; Colorectal Cancer; Epithelial ovarian cancer; Adult Myelodysplastic Syndrome; Neoplasm Metastasis; Acute myelomonocytic leukemia; Malignant Neoplasms; Hematologic Neoplasms; Juvenile Myelomonocytic Leukemia; Metastatic malignant neoplasm to brain; Malignant neoplasm of large intestine; Tumor Progression; Acute leukemia; Infant, Premature; Congenital chromosomal disease; Solid Neoplasm; Adult Solid Neoplasm; Secondary malignant neoplasm of liver; Childhood Acute Myeloid Leukemia; Childhood Solid Neoplasm; Secondary malignant neoplasm of lung; MIXED LINEAGE LEUKEMIA; Adult Acute Myeloblastic Leukemia; Hyperactive behavior",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8232134984476662; 0.8232134984476662; 0.841396342333011; 0.8878860377518915,,,Early-onset parkinsonism-intellectual disability syndrome ORPHA:2379; Progressive myoclonic epilepsy type 3 ORPHA:263516; Intellectual disability-developmental delay-contractures syndrome ORPHA:3454; Multiple benign circumferential skin creases on limbs ORPHA:2505; Lissencephaly due to TUBA1A mutation ORPHA:171680,0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011,,,,,,
MMP24,"Glioblastoma; Neoplasm Metastasis; Brain Neoplasms; Tumor Progression; Alzheimer's Disease; Diabetes; Diabetes Mellitus; Multiple Sclerosis; Kidney Failure, Chronic; Impaired cognition; Protein C antigen measurement; Protein C measurement; Amyloidosis; Pain; Diabetic Nephropathy; Body Height; Hyperalgesia, Thermal; Hyperalgesia; Chronic kidney disease stage 5; Kidney Failure",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8648405521677974; 0.8648405521677974; 0.8672189956534445; 0.887595340546704; 0.9390727893210336; 0.9390727893210336; 0.9441119274323576; 0.9514640836642632; 0.9694882155560866; 0.9894341523578486,,,,,,,,,,
MRAP2,"Adrenocortical carcinoma; Aplasia Cutis Congenita; Obesity; Obesity, Morbid; Agenesis of corpus callosum",0.8232134984476662; 0.8911256045597441; 0.8989612563669234; 0.946564927793026; 0.9701053690483854,Prader-Willi Syndrome; Obesity,0.7860378120955526; 0.9832345076528324,,,,,,,,
MRPL19,"Malignant neoplasm of breast; Breast Carcinoma; Endometrial Carcinoma; Mammary Neoplasms; Dyslexia; Mammary Neoplasms, Human",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8815127642200768,Leukemia; Mammary Neoplasms; Marfan Syndrome; Breast Cancer; Breast Carcinoma,0.7765582368651238; 0.8165359516083085; 0.8477374749042494; 0.8903630091389316; 0.9398381935810408,"Hereditary coproporphyria ORPHA:79273; Combined oxidative phosphorylation defect type 24 ORPHA:444458; Congenital bile acid synthesis defect type 4 ORPHA:79095; Exercise-induced hyperinsulinism ORPHA:165991; Ketoacidosis due to monocarboxylate transporter-1 deficiency ORPHA:438075; Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome ORPHA:478049; Metabolic myopathy due to lactate transporter defect ORPHA:171690; Peters plus syndrome ORPHA:709; Spinocerebellar ataxia type 10 ORPHA:98761; 2p21 microdeletion syndrome without cystinuria ORPHA:369881; 3-methylcrotonyl-CoA carboxylase deficiency ORPHA:6; Autosomal erythropoietic protoporphyria ORPHA:79278; BRESEK syndrome ORPHA:85284; Beta-ketothiolase deficiency ORPHA:134; Brain calcification, Rajab type ORPHA:178506; Combined oxidative phosphorylation defect type 11 ORPHA:324535; Combined oxidative phosphorylation defect type 9 ORPHA:319509; Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome ORPHA:521432; EVEN-plus syndrome ORPHA:496751; Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome ORPHA:505237; FASTKD2-related infantile mitochondrial encephalomyopathy ORPHA:166105; Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 ORPHA:137681; Ichthyosis follicularis-alopecia-photophobia syndrome ORPHA:2273; Lathosterolosis ORPHA:46059; Medium chain acyl-CoA dehydrogenase deficiency ORPHA:42; Methylcobalamin deficiency type cblE ORPHA:2169; Microcephaly-capillary malformation syndrome ORPHA:294016; Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome ORPHA:280679; Progressive encephalopathy with leukodystrophy due to DECR deficiency ORPHA:431361; Pyridoxal phosphate-responsive seizures ORPHA:79096; Thiamine-responsive megaloblastic anemia syndrome ORPHA:49827; WARS2-related combined oxidative phosphorylation defect ORPHA:572798; Classic maple syrup urine disease ORPHA:268145; Intermittent maple syrup urine disease ORPHA:268173; Thiamine-responsive maple syrup urine disease ORPHA:268184; Infantile Refsum disease ORPHA:772; Neonatal adrenoleukodystrophy ORPHA:44; Zellweger syndrome ORPHA:912; Propionic acidemia ORPHA:35; Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome ORPHA:436174; Combined oxidative phosphorylation defect type 26 ORPHA:477684; Combined oxidative phosphorylation defect type 39 ORPHA:565624; Congenital lactic acidosis, Saguenay-Lac-Saint-Jean type ORPHA:70472; Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome ORPHA:313772; Endosteal sclerosis-cerebellar hypoplasia syndrome ORPHA:85186; Fumaric aciduria ORPHA:24; Glycogen storage disease due to glycogen debranching enzyme deficiency ORPHA:366; Hereditary leiomyomatosis and renal cell cancer ORPHA:523; Hyperinsulinism-hyperammonemia syndrome ORPHA:35878; Hypermethioninemia encephalopathy due to adenosine kinase deficiency ORPHA:289290; Hypotonia with lactic acidemia and hyperammonemia ORPHA:137908; Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome ORPHA:314051; Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria ORPHA:1933; Pyruvate dehydrogenase E2 deficiency ORPHA:79244; Pyruvate dehydrogenase E3 deficiency ORPHA:2394; Pyruvate dehydrogenase E3-binding protein deficiency ORPHA:255182; Spinocerebellar ataxia type 28 ORPHA:101109; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B ORPHA:308393; TRIM32-related  limb-girdle muscular dystrophy R8 ORPHA:1878; Vitamin B12-unresponsive methylmalonic acidemia type mut- ORPHA:79312; Vitamin B12-unresponsive methylmalonic acidemia type mut0 ORPHA:289916; Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy ORPHA:329336; Shwachman-Diamond syndrome ORPHA:811",0.1991445465001551; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
MRPL54,,,,,"Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; Marinesco-Sjogren syndrome ORPHA:559; CCDC115-CDG ORPHA:468684; 3C syndrome ORPHA:7; Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect ORPHA:521411; Carnitine-acylcarnitine translocase deficiency ORPHA:159; Familial hypocalciuric hypercalcemia type 3 ORPHA:101050; Hyperbiliverdinemia ORPHA:276405; Ethylmalonic encephalopathy ORPHA:51188; Glutaryl-CoA dehydrogenase deficiency ORPHA:25; MPDU1-CDG ORPHA:79323; Prolidase deficiency ORPHA:742; Spondylometaphyseal dysplasia, Sedaghatian type ORPHA:93317; Acromegaly ORPHA:963; 3-methylglutaconic aciduria type 8 ORPHA:505208; Adenine phosphoribosyltransferase deficiency ORPHA:976; Autosomal recessive spastic paraplegia type 77 ORPHA:466722; Combined oxidative phosphorylation defect type 14 ORPHA:319519; HSD10 disease, atypical type ORPHA:85295; HSD10 disease, infantile type ORPHA:391428; HSD10 disease, neonatal type ORPHA:391457; Hepatoerythropoietic porphyria ORPHA:95159; ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement ORPHA:457375; Autosomal recessive severe congenital neutropenia due to JAGN1 deficiency ORPHA:423384; Combined oxidative phosphorylation defect type 29 ORPHA:478029; DPM3-CDG ORPHA:263494; Hamel cerebro-palato-cardiac syndrome ORPHA:93946; Kostmann syndrome ORPHA:99749; Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome ORPHA:2570; Pentosuria ORPHA:2843; Primary immunodeficiency syndrome due to LAMTOR2 deficiency ORPHA:90023; SSR4-CDG ORPHA:370927; SURF1-related Charcot-Marie-Tooth disease type 4 ORPHA:391351; X-linked intellectual disability, Golabi-Ito-Hall type ORPHA:93947; X-linked intellectual disability, Porteous type ORPHA:93945; X-linked intellectual disability, Sutherland-Haan type ORPHA:93950; Isolated succinate-CoQ reductase deficiency ORPHA:3208; Leigh syndrome with cardiomyopathy ORPHA:70474",0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
MTHFS,"Neuroblastoma; Central neuroblastoma; Cleft palate, isolated; Cleft Palate; Cleft upper lip",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,Dysautonomia; Salaam Seizures; Developmental Delay; Cerebellar Atrophy; Hypotonic Seizures; Epilepsy; Seizure; Dyscognitive Seizures; Microcephaly; Esotropia; Dwarfism,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8337953215113012; 0.8601151608808731; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.8903630091389316; 0.9510372690456612,Autosomal dominant dopa-responsive dystonia ORPHA:98808; GTP cyclohydrolase I deficiency ORPHA:2102; Carnitine-acylcarnitine translocase deficiency ORPHA:159; Cystic leukoencephalopathy without megalencephaly ORPHA:85136; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency ORPHA:404493; Tyrosinemia type 1 ORPHA:882; Early-onset generalized limb-onset dystonia ORPHA:256; Multiple mitochondrial dysfunctions syndrome type 4 ORPHA:457406,0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
MTMR1,Myotonic Dystrophy; Congenital Myotonic Dystrophy; Dystrophia myotonica 2; Intellectual Disability; Arthrogryposis,0.7880542567584415; 0.7880542567584415; 0.8769418330148872; 0.9478210444156088; 0.9896536639644284,,,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy ORPHA:363454; Cardiofaciocutaneous syndrome ORPHA:1340,0.5867963421058087; 0.795266832401002,,,,,,
MYZAP,"High density lipoprotein measurement; Juvenile psoriatic arthritis; Juvenile-Onset Still Disease; Juvenile arthritis; Cardiomyopathy, Dilated",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.9564633032157428,"Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Seronegative Polyarthritis; Still Disease; Atrial Fibrillation; Coronary Heart Disease; Arthritis; Cardiomyopathy",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.861756360478846; 0.9046917974656596; 0.9145387439550552,Hemochromatosis type 5 ORPHA:447792,0.3832844616405875,,,,,,
N4BP1,drug response; Rheumatoid Arthritis,0.7880542567584415; 0.7880542567584415,Rheumatoid Arthritis,0.9251646147729308,Dyschromatosis symmetrica hereditaria ORPHA:41; Desbuquois syndrome ORPHA:1425; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome ORPHA:529977; Autosomal recessive spastic paraplegia type 45 ORPHA:320396; Polyvalvular heart disease syndrome ORPHA:228410,0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011,,,,,,
NAE1,Oropharyngeal disorders; Alzheimer's Disease; Down Syndrome; Amyloidosis,0.7880542567584415; 0.7880542567584415; 0.8420665668584452; 0.8672189956534445,,,"Vocal cord and pharyngeal distal myopathy ORPHA:600; Charcot-Marie-Tooth disease type 4B1 ORPHA:99955; DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect ORPHA:330050; Autosomal recessive spastic paraplegia type 61 ORPHA:401780; Brachydactyly-short stature-retinitis pigmentosa syndrome ORPHA:166035; Combined oxidative phosphorylation defect type 24 ORPHA:444458; Hypomyelination with brain stem and spinal cord involvement and leg spasticity ORPHA:363412; Spinocerebellar ataxia type 10 ORPHA:98761; Succinyl-CoA:3-oxoacid CoA transferase deficiency ORPHA:832; 2p21 microdeletion syndrome without cystinuria ORPHA:369881; Autosomal thrombocytopenia with normal platelets ORPHA:168629; Autosomal dominant optic atrophy, classic form ORPHA:98673; Acute infantile liver failure-multisystemic involvement syndrome ORPHA:370088; Combined oxidative phosphorylation defect type 13 ORPHA:319514; Combined oxidative phosphorylation defect type 9 ORPHA:319509; Glycogen storage disease due to lactate dehydrogenase H-subunit deficiency ORPHA:284435; Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome ORPHA:280679; Multiple mitochondrial dysfunctions syndrome type 6 ORPHA:569290; Parkinson-dementia complex of Guam ORPHA:90020; Dystonia 16 ORPHA:210571; Glomuvenous malformation ORPHA:83454; MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect ORPHA:485421; Pontocerebellar hypoplasia type 6 ORPHA:166073; Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome ORPHA:436245; Rhizomelic chondrodysplasia punctata type 2 ORPHA:309796; X-linked myopathy with excessive autophagy ORPHA:25980; Pontocerebellar hypoplasia type 1 ORPHA:2254",0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
NDC80,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Colon Carcinoma; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Endometrial Carcinoma; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Liver carcinoma; Osteosarcoma; Epithelial ovarian cancer; Osteosarcoma of bone; Primary malignant neoplasm of lung; cervical cancer; Malignant neoplasm of testis; Carcinoma of lung; Malignant neoplasm of liver; Primary Malignant Liver Neoplasm; Neoplasms; Mucinous Adenocarcinoma; MYELOPROLIFERATIVE SYNDROME, TRANSIENT; Well Differentiated Oligodendroglioma; oligodendroglioma; Hemangioma; Cervical Adenocarcinoma; Childhood Osteosarcoma; Benign neoplasm of breast; Endometrial adenocarcinoma; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Adenocarcinoma, Endometrioid; Malignant Pleural Mesothelioma; Overweight",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8190761496232595; 0.8769418330148872; 0.8771562273432176; 0.8774809019744603; 0.8935933996254593; 0.929814249105729,Liver Carcinoma,0.7765582368651238,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; Stromme syndrome ORPHA:506307; Ear-patella-short stature syndrome ORPHA:2554; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Combined immunodeficiency due to GINS1 deficiency ORPHA:505227; Denys-Drash syndrome ORPHA:220; Frasier syndrome ORPHA:347; Meacham syndrome ORPHA:3097; Familial prostate cancer ORPHA:1331; Li-Fraumeni syndrome ORPHA:524; Nephroblastoma ORPHA:654; Primary peritoneal carcinoma ORPHA:168829; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Muir-Torre syndrome ORPHA:587; Osteosarcoma ORPHA:668; Familial pancreatic carcinoma ORPHA:1333; Fanconi anemia ORPHA:84; Bloom syndrome ORPHA:125; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; Spinocerebellar ataxia with axonal neuropathy type 1 ORPHA:94124; VACTERL with hydrocephalus ORPHA:3412; Combined immunodeficiency with faciooculoskeletal anomalies ORPHA:221139; ICF syndrome ORPHA:2268; Seckel syndrome ORPHA:808; Hereditary breast cancer ORPHA:227535; Autosomal recessive primary microcephaly ORPHA:2512; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome ORPHA:314404; Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary sensory neuropathy-deafness-dementia syndrome ORPHA:456318; Microcephaly-complex motor and sensory axonal neuropathy syndrome ORPHA:423894; Roberts syndrome ORPHA:3103; Xeroderma pigmentosum variant ORPHA:90342; Weaver syndrome ORPHA:3447; Facioscapulohumeral dystrophy ORPHA:269; Hereditary breast and ovarian cancer syndrome ORPHA:145; Pleomorphic salivary gland adenoma ORPHA:454821,0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2844858212863536; 0.3891940933600213; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7593059616185558; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8211968342881582; 0.8329982337461243; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
NDRG1,"Malignant neoplasm of breast; Bladder Neoplasm; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Endometrial Neoplasms; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Prostatic Intraepithelial Neoplasias; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Endometrial Carcinoma; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Osteosarcoma; Acute Promyelocytic Leukemia; Colorectal Cancer; Multiple malignancy; Hepatocarcinogenesis; Glioblastoma; Osteosarcoma of bone; Hemangioblastoma; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Neuroepithelioma; Prostatic Neoplasms; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Malignant neoplasm of liver; Neuroblastoma; Decreased nerve conduction velocity; Central neuroblastoma; Malignant Neoplasms; melanoma; Multiple Myeloma; Metastatic Prostate Carcinoma; Neoplasms; Abnormal visual evoked potential; Secondary malignant neoplasm of prostate; Malignant neoplasm of stomach; Brain Neoplasms; Nasopharyngeal carcinoma; Tumor Progression; Abnormal auditory evoked potential; Oropharyngeal Neoplasms; Renal Cell Carcinoma; Neuroectodermal Tumor, Primitive; Segmental peripheral demyelination/remyelination; Axonal loss; Stomach Carcinoma; Squamous cell carcinoma; Solid Neoplasm; Demyelinating Diseases; Carcinoma, Pancreatic Ductal; Peripheral demyelinating neuropathy; Papillary Renal Cell Carcinoma; Aortic Valve Insufficiency; Adenoma of large intestine; Small cell carcinoma of lung; Conventional (Clear Cell) Renal Cell Carcinoma; Dejerine-Sottas Disease (disorder); Metastatic Neoplasm; Hereditary motor and sensory neuropathy, types I-IV; Hypertrophic neuropathy of infancy; Peroneal muscular atrophy (axonal type) (hypertrophic type); Secondary malignant neoplasm of liver; Malignant neoplasm of colon stage IV; Metastasis from malignant tumor of prostate; Primary malignant neoplasm; Smooth Muscle Tumor; Liver Cirrhosis, Experimental; Oropharyngeal Carcinoma; Chromophobe Renal Cell Carcinoma; Gait abnormality; Congenital deafness; Roussy-Levy Syndrome (disorder); Multiple Sclerosis; Childhood Osteosarcoma; Liver neoplasms; Onion bulb formation; Adenocarcinoma of lung (disorder); Hearing Loss, Partial; Childhood Cerebral Astrocytoma; Intracranial Astrocytoma; Hereditary hemochromatosis; Cerebral Astrocytoma; Protoplasmic astrocytoma; Deafness; Lip and Oral Cavity Carcinoma; Sarcomatoid Renal Cell Carcinoma; Grade I Astrocytoma; Colonic Neoplasms; Fibrillary Astrocytoma; Hereditary Motor and Sensory Neuropathies; Mixed oligoastrocytoma; Mouth Neoplasms; Collecting Duct Carcinoma of the Kidney; Juvenile Pilocytic Astrocytoma; hearing impairment; Glioblastoma Multiforme; Subependymal Giant Cell Astrocytoma; Decreased tendon reflex; Malignant neoplasm of stomach stage IV; CATARACT, ANTERIOR POLAR; Gemistocytic astrocytoma; Peripheral Neuropathy; Inherited neuropathies; Hand deformities; Squamous cell carcinoma of esophagus; Paresis; Renal carcinoma; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Kidney Neoplasm; Mammary Neoplasms, Human; Diffuse Astrocytoma; Malignant neoplasm of kidney; Absent tendon reflex; Reflex, Deep Tendon, Absent; Absent reflex; Malignant neoplasm of mouth; Secondary malignant neoplasm of lymph node; Distal amyotrophy; Giant Cell Glioblastoma; Distal sensory impairment; Sensory neuropathy; Distal muscle weakness; Neuropathy; Distal limb muscle weakness due to peripheral neuropathy; Anoxia; Anaplastic astrocytoma; Secondary Neoplasm; Intellectual Disability; Muscle Weakness; Pilocytic Astrocytoma; Charcot-Marie-Tooth Disease; Tumor Angiogenesis; Substance Use Disorders; Drug abuse; Malignant neoplasm of brain",0.4084380369379369; 0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8138488881521341; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8342163953428735; 0.8368219249856942; 0.8391186563955684; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8610447277138289; 0.8642802827048847; 0.8648405521677974; 0.8769418330148872; 0.8771562273432176; 0.8774809019744603; 0.8815127642200768; 0.8815127642200768; 0.8818220091065441; 0.8867509400747969; 0.8911256045597441; 0.8911256045597441; 0.8946938397586319; 0.900167961295542; 0.9024758035783405; 0.9039108388826153; 0.906476206143938; 0.9098977259629772; 0.9146732238562176; 0.914995991166204; 0.9154499654632742; 0.9184153253162451; 0.9262273158806068; 0.9432051631882106; 0.9478210444156088; 0.9512505437112568; 0.9540608878641196; 0.963331724428282; 0.9656926709728724; 0.9658628445524134; 0.9658628445524134; 0.9769594699984444,Carcinoma Of The Head And Neck; Oropharyngeal Carcinoma; Prostate Cancer; Melanoma; Hemangioblastoma; Prostatic Neoplasms; Pancreatic Ductal Carcinoma; Intracranial Astrocytoma; Grade I Astrocytoma; Oligoastrocytoma; Fibrillary Astrocytoma; Protoplasmic Astrocytoma; Gemistocytic Astrocytoma; Lung Carcinoma; Mammary Neoplasms; Anaplastic Astrocytoma; Chromophobe Carcinoma; Papillary Renal Carcinoma; Marfan Syndrome; Astrocytoma; Kidney Cancer; Renal Carcinoma; Kidney Neoplasm; Mouth Neoplasms; Breast Cancer; Charcot-Marie-Tooth Disease; Liver Cancer; Breast Carcinoma; Giant Cell Glioblastoma; Liver Neoplasms; Distal Amyotrophy; Glioblastoma,0.4532988396145482; 0.6734982286750932; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8139950454942313; 0.8165359516083085; 0.8201196687803188; 0.8356859041719433; 0.8476516371290275; 0.8477374749042494; 0.861756360478846; 0.861756360478846; 0.8727045307126416; 0.8759421888249375; 0.8903301324869451; 0.8903630091389316; 0.9087218501169084; 0.924275664330454; 0.9398381935810408; 0.9398381935810408; 0.9543024119762946; 0.963385108667098; 0.9832345076528324,"Charcot-Marie-Tooth disease type 4D ORPHA:99950; Mitochondrial DNA depletion syndrome, myopathic form ORPHA:254875; Familial Alzheimer-like prion disease ORPHA:280397; Fatal familial insomnia ORPHA:466; Gerstmann-Straussler-Scheinker syndrome ORPHA:356; Huntington disease-like 1 ORPHA:157941; Inherited Creutzfeldt-Jakob disease ORPHA:282166; Kuru ORPHA:454745; PrP systemic amyloidosis ORPHA:397606; Sporadic fatal insomnia ORPHA:586130; Keratolytic winter erythema ORPHA:50943; Autosomal dominant secondary polycythemia ORPHA:247511",0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Vaccinia virus Ankara putative monoglyceride lipase f2,0.9057542447893764,,,,
NES,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Atrial Premature Complexes; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Carcinoma breast stage IV; Pancreatic intraepithelial neoplasia; Adenoma; Thyroid Neoplasm; Endometrial Carcinoma; Malignant tumor of cervix; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Osteosarcoma; Ataxia Telangiectasia; Rhabdomyosarcoma; Leukemia, Plasma Cell; Glioblastoma; Osteosarcoma of bone; Hemangioblastoma; Astrocytoma; Nephroblastoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Prostatic Neoplasms; Monoclonal Gammopathy of Undetermined Significance; Carcinoma of lung; Cockayne Syndrome, Type I; Triple Negative Breast Neoplasms; Neuroblastoma; Central neuroblastoma; Immunologic Deficiency Syndromes; Malignant Neoplasms; melanoma; Increased drug resistance; Multiple Myeloma; Lung Neoplasms; Retinal Diseases; Metastatic malignant neoplasm to brain; Neoplasms; Membranous glomerulonephritis; Well Differentiated Oligodendroglioma; Brain Neoplasms; Nasopharyngeal carcinoma; oligodendroglioma; Large cell neuroendocrine carcinoma; Dementia; Tumor Progression; Pericytic Neoplasm; Sarcoma; Childhood Glioblastoma; Acquired Immunodeficiency Syndrome; Photophobia; Adult Glioblastoma; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Alzheimer's Disease; Epilepsy, Tonic-Clonic, Familial; Epilepsy, Tonic-Clonic, Symptomatic; Cryptogenic Tonic-Clonic Epilepsy; Secondary pulmonary hypertension; Acute myocardial infarction; Squamous cell carcinoma; Infiltrating Cervical Carcinoma; Solid Neoplasm; Nervous System Neoplasms; Uterine Corpus Carcinosarcoma; Nephrosis; Hyperglycemia; Small cell carcinoma of lung; Intrahepatic Cholangiocarcinoma; Metastatic Neoplasm; Tonic-Clonic Epilepsy; Myeloid Leukemia, Chronic; Malignant Glioma; Secondary malignant neoplasm of liver; Primary malignant neoplasm; Chronic myeloproliferative disorder; Nerve Sheath Tumors; Cortical Dysplasia; Myocardial Infarction; Focal glomerulosclerosis; Fibrosarcoma; Carotid artery occlusion; neurofibroma; Kidney Diseases; Uterine Carcinosarcoma; Indian childhood cirrhosis; Schizophrenia; Neurofibromatoses; Herpes Simplex Infections; Vascular anomaly; Mixed Oligodendroglioma-Astrocytoma; Congenital Hyperinsulinism; Diabetes Mellitus, Insulin-Dependent; Secondary malignant neoplasm of lung; Microcephaly; Malignant Peripheral Nerve Sheath Tumor; Abscess; Pituitary Adenoma; Glioblastoma Multiforme; Motor neuron atrophy; Recurrent tumor; Pituitary Neoplasms; Gastroesophageal reflux disease; Amyotrophic Lateral Sclerosis; Cervical Intraepithelial Neoplasia; Sleep Apnea, Central; Medulloblastoma; Exanthema; Anaplasia; Cerebrovascular accident; Migraine Disorders; Neurologic Symptoms; Brain Infarction; Uterine Cancer; tumor vasculature; Dentatorubral-Pallidoluysian Atrophy; Hydrocephalus; Heart failure; Neurilemmoma; Coronary Artery Disease; Congestive heart failure; Barrett Esophagus; Brain Ischemia; Central Nervous System Neoplasms; Secondary malignant neoplasm of lymph node; Encephalitis; Glioblastoma, IDH-Wildtype; synovial sarcoma; Coronary heart disease; Creutzfeldt-Jakob disease; Kidney Failure, Acute; Fibroid Tumor; Seizures; Uterine Fibroids; Interstitial lung fibrosis; Epilepsy; Tumor Angiogenesis; Tuberous Sclerosis",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7945683314244791; 0.7967714690735718; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8145035474981049; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8342163953428735; 0.8363138748299018; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8548862007194026; 0.8619324281003841; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8690346447728063; 0.876210765330195; 0.8774809019744603; 0.8806784681730055; 0.8815127642200768; 0.8851456306720444; 0.8867509400747969; 0.887595340546704; 0.887595340546704; 0.8976039441125321; 0.8980854850210683; 0.8980854850210683; 0.8989612563669234; 0.900167961295542; 0.900167961295542; 0.906476206143938; 0.9119978323790848; 0.9119978323790848; 0.9193385822373632; 0.9373358316580888; 0.9373358316580888; 0.9478210444156088; 0.9557184806547836; 0.9564633032157428; 0.963331724428282; 0.9656926709728724; 0.9884235744717738,Cryptogenic Tonic-Clonic Epilepsy; Tonic-Clonic Epilepsy; Nephrosis; Epilepsy,0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8611702959552964,"Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; Monosomy 22q13.3 ORPHA:48652; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Frank-Ter Haar syndrome ORPHA:137834; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; Dermatofibrosarcoma protuberans ORPHA:31112; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Persistent hyperplastic primary vitreous ORPHA:91495; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Classic Bartter syndrome ORPHA:93605; Lateral meningocele syndrome ORPHA:2789; Pierson syndrome ORPHA:2670; 3M syndrome ORPHA:2616; Autosomal dominant otospondylomegaepiphyseal dysplasia ORPHA:166100; Autosomal recessive Robinow syndrome ORPHA:1507; Carpenter syndrome ORPHA:65759; Hyperostosis corticalis generalisata ORPHA:3416; 46,XX ovotesticular disorder of sex development ORPHA:2138; Acrocallosal syndrome ORPHA:36; Congenital fibrosis of extraocular muscles ORPHA:45358; Ollier disease ORPHA:296; Silver-Russell syndrome due to a point mutation ORPHA:397590; Familial exudative vitreoretinopathy ORPHA:891; Colobomatous microphthalmia ORPHA:98938; Tetralogy of Fallot ORPHA:3303; Early-onset nuclear cataract ORPHA:98991; 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome ORPHA:168563; Brachydactyly type B1 ORPHA:572385; Congenital muscular dystrophy with integrin alpha-7 deficiency ORPHA:34520; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome ORPHA:69735; Keipert syndrome ORPHA:2662; Kuskokwim syndrome ORPHA:1149; Legius syndrome ORPHA:137605; Muscle filaminopathy ORPHA:171445; Polymicrogyria due to TUBB2B mutation ORPHA:300573; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A ORPHA:308386; Familial avascular necrosis of femoral head ORPHA:86820; Hypoplastic left heart syndrome ORPHA:2248; Roussy-Levy syndrome ORPHA:3115; Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Butterfly-shaped pigment dystrophy ORPHA:99001; Duane retraction syndrome ORPHA:233; Isolated hemihyperplasia ORPHA:2128; Retinopathy of prematurity ORPHA:90050; Familial bicuspid aortic valve ORPHA:402075; Familial progressive cardiac conduction defect ORPHA:871; Familial isolated restrictive cardiomyopathy ORPHA:75249; Skeletal Ewing sarcoma ORPHA:319; Atrial septal defect, ostium secundum type ORPHA:99103; Bilateral striopallidodentate calcinosis ORPHA:1980; Familial porencephaly ORPHA:99810; Simpson-Golabi-Behmel syndrome ORPHA:373; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome ORPHA:352654; Familial schizencephaly ORPHA:481986; Glycogen storage disease due to muscle phosphofructokinase deficiency ORPHA:371; HANAC syndrome ORPHA:73229; Oculodentodigital dysplasia ORPHA:2710; Optic atrophy-intellectual disability syndrome ORPHA:401777; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Retinal arterial tortuosity ORPHA:75326; Stuve-Wiedemann syndrome ORPHA:3206; Steel syndrome ORPHA:438117; Syndactyly type 3 ORPHA:93404; Tubulinopathy-associated dysgyria ORPHA:467166; Cerebrofacioarticular syndrome ORPHA:314679; Congenital ptosis ORPHA:91411; Fibrochondrogenesis ORPHA:2021; Non-seminomatous germ cell tumor of testis ORPHA:363494; Pfeiffer syndrome type 1 ORPHA:93258; Postaxial polydactyly type B ORPHA:93335; Sclerosteosis ORPHA:3152; Silver-Russell syndrome due to 11p15 microduplication ORPHA:231144; Silver-Russell syndrome due to an imprinting defect of 11p15 ORPHA:231140; Spondylometaphyseal dysplasia, 'corner fracture' type ORPHA:93315; NON RARE IN EUROPE: Infantile capillary hemangioma ORPHA:464293; Isolated brachycephaly ORPHA:35099; Isolated plagiocephaly ORPHA:35098; 46,XX testicular disorder of sex development ORPHA:393; Hirschsprung disease ORPHA:388; Osteogenesis imperfecta type 4 ORPHA:216820; Lobar holoprosencephaly ORPHA:93924; Midline interhemispheric variant of holoprosencephaly ORPHA:93926; Septopreoptic holoprosencephaly ORPHA:280195; Microform holoprosencephaly ORPHA:280200; Kallmann syndrome ORPHA:478; Familial isolated dilated cardiomyopathy ORPHA:154; Achondrogenesis type 2 ORPHA:93296; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ORPHA:440354; Autosomal dominant rhegmatogenous retinal detachment ORPHA:209867; Autosomal recessive omodysplasia ORPHA:93329; BNAR syndrome ORPHA:217266; Blomstrand lethal chondrodysplasia ORPHA:50945; Brachydactyly-arterial hypertension syndrome ORPHA:1276; Butyrylcholinesterase deficiency ORPHA:132; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Congenital alveolar capillary dysplasia ORPHA:210122; Congenital factor X deficiency ORPHA:328; Craniodiaphyseal dysplasia ORPHA:1513; Curry-Jones syndrome ORPHA:1553; Dysbetalipoproteinemia ORPHA:412; Dysspondyloenchondromatosis ORPHA:85198; Eiken syndrome ORPHA:79106; Familial sick sinus syndrome ORPHA:166282; Gamma-sarcoglycan-related  limb-girdle muscular dystrophy R5 ORPHA:353; Hartsfield syndrome ORPHA:2117; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hypochondrogenesis ORPHA:93297; Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation ORPHA:254534; Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion ORPHA:254528; Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14 ORPHA:96334; Kniest dysplasia ORPHA:485; Legg-Calve-Perthes disease ORPHA:2380; Lipoprotein glomerulopathy ORPHA:329481; Marshall syndrome ORPHA:560; Metaphyseal chondrodysplasia, Jansen type ORPHA:33067; Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis ORPHA:93279; Multiple epiphyseal dysplasia, Beighton type ORPHA:166011; Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement ORPHA:168953; Oculotrichoanal syndrome ORPHA:2717; Osteoglosphonic dysplasia ORPHA:2645; Platyspondylic dysplasia, Torrance type ORPHA:85166; Primary failure of tooth eruption ORPHA:412206; Sea-blue histiocytosis ORPHA:158029; Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome ORPHA:466688; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Spondyloepimetaphyseal dysplasia congenita, Strudwick type ORPHA:93346; Spondyloepiphyseal dysplasia congenita ORPHA:94068; Spondyloepiphyseal dysplasia with metatarsal shortening ORPHA:137678; Spondyloepiphyseal dysplasia, Stanescu type ORPHA:459051; Spondylometaphyseal dysplasia, Schmidt type ORPHA:93316; Spondyloperipheral dysplasia-short ulna syndrome ORPHA:1856; Stickler syndrome type 1 ORPHA:90653; Stickler syndrome type 2 ORPHA:90654; Temple syndrome due to maternal uniparental disomy of chromosome 14 ORPHA:96184; Temple syndrome due to paternal 14q32.2 hypomethylation ORPHA:254531; Temple syndrome due to paternal 14q32.2 microdeletion ORPHA:254525; Agnathia-holoprosencephaly-situs inversus syndrome ORPHA:990; Congenital communicating hydrocephalus ORPHA:269505; Infantile myofibromatosis ORPHA:2591; Isolated trigonocephaly ORPHA:3366; Townes-Brocks syndrome ORPHA:857; Waardenburg syndrome type 2 ORPHA:895; Left ventricular noncompaction ORPHA:54260; Alobar holoprosencephaly ORPHA:93925; Semilobar holoprosencephaly ORPHA:220386",0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6196505963261838; 0.6467006456772204; 0.7007232363756918; 0.7895126437786436; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.795266832401002; 0.8029813443753846; 0.8029813443753846; 0.8105918570729571; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.896422440954666; 0.9016687655325558; 0.9025296114347576,,,,,,
NEURL3,,,Leukemia,0.7765582368651238,Familial expansile osteolysis ORPHA:85195; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Autosomal dominant primary hypomagnesemia with hypocalciuria ORPHA:34528; Familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement ORPHA:31043,0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.8922466888454011,,,,,,
NME6,Colon Carcinoma; Malignant tumor of colon; Stomach Carcinoma; Crohn Disease,0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415,,,TMEM199-CDG ORPHA:466703; Combined oxidative phosphorylation defect type 15 ORPHA:319524; Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders ORPHA:505248,0.3832844616405875; 0.7929682744768703; 0.8922466888454011,Human adenovirus 21 DNA polymerase (gene: E2B); Human adenovirus 21a DNA polymerase (gene: E2B); Human adenovirus 16 DNA polymerase (gene: E2B); Human adenovirus 68 DNA polymerase (gene: E2B); Human adenovirus 7d2 DNA polymerase (gene: E2B); Human adenovirus 50 DNA polymerase (gene: E2B); Human adenovirus 66 DNA polymerase (gene: E2B); Human mastadenovirus B DNA polymerase (gene: E2B); Human adenovirus B3 E2B DNA polymerase (gene: E2B); Human adenovirus 3+7 DNA polymerase (gene: E2B); Human mastadenovirus E DNA polymerase (gene: E2B); Human adenovirus E4 DNA polymerase,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
NMI,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Mammary Neoplasms; Glioma; Glioblastoma; Neoplasm Metastasis; Malignant Neoplasms; melanoma; Neoplasms; Malignant neoplasm of stomach; Stomach Carcinoma; Metastatic Neoplasm; Primary malignant neoplasm; malignant neoplasm of breast staging; Liver Cirrhosis, Experimental",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8014900279306119,,,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Aicardi-Goutieres syndrome ORPHA:51; Autosomal dominant dopa-responsive dystonia ORPHA:98808; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; GTP cyclohydrolase I deficiency ORPHA:2102; Waldenstrom macroglobulinemia ORPHA:33226; Dehydrated hereditary stomatocytosis ORPHA:3202; Takayasu arteritis ORPHA:3287; Cleidocranial dysplasia ORPHA:1452; Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504; Variant ABeta2M amyloidosis ORPHA:314652; Autosomal dominant severe congenital neutropenia ORPHA:486; Herpes simplex virus encephalitis ORPHA:1930; Exfoliative ichthyosis ORPHA:289586; Immunodeficiency by defective expression of MHC class I ORPHA:34592; Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome ORPHA:391487; Autoimmune lymphoproliferative syndrome with recurrent viral infections ORPHA:275517; Autosomal dominant Kenny-Caffey syndrome ORPHA:93325; B4GALT1-CDG ORPHA:79332; Congenital isolated ACTH deficiency ORPHA:199296; Familial normophosphatemic tumoral calcinosis ORPHA:306658; Galactose mutarotase deficiency ORPHA:570422; Generalized glucocorticoid resistance syndrome ORPHA:786; Haim-Munk syndrome ORPHA:2342; Hereditary pediatric Behcet-like disease ORPHA:476102; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome ORPHA:529977; Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency ORPHA:70592; Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia ORPHA:572428; MIRAGE syndrome ORPHA:494433; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency ORPHA:319595; Neutral lipid storage disease with ichthyosis ORPHA:98907; Neutrophil immunodeficiency syndrome ORPHA:183707; Orofaciodigital syndrome type 5 ORPHA:2919; Osteocraniostenosis ORPHA:2763; Papillon-Lefevre ORPHA:678; Proteasome-associated autoinflammatory syndrome ORPHA:324977; Susceptibility to viral and mycobacterial infections due to STAT1 deficiency ORPHA:391311; USP18 deficiency ORPHA:481665; Familial Chilblain lupus ORPHA:481662; Familial cerebral cavernous malformation ORPHA:221061; Familial platelet disorder with associated myeloid malignancy ORPHA:71290; Singleton-Merten dysplasia ORPHA:85191; Acatalasemia ORPHA:926; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency ORPHA:404493; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency ORPHA:574957; Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome ORPHA:486815; Griscelli syndrome type 2 ORPHA:79477; NON RARE IN EUROPE: Hemochromatosis type 1 ORPHA:139498; Overgrowth-macrocephaly-facial dysmorphism syndrome ORPHA:137634; STING-associated vasculopathy with onset in infancy ORPHA:425120; Sporadic porphyria cutanea tarda ORPHA:443057; Symptomatic form of hemochromatosis type 1 ORPHA:465508; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia ORPHA:632; Ataxia-pancytopenia syndrome ORPHA:2585; Hemolytic anemia due to pyrimidine 5' nucleotidase deficiency ORPHA:35120; SLC39A8-CDG ORPHA:468699; Acral peeling skin syndrome ORPHA:263534; Vogt-Koyanagi-Harada disease ORPHA:3437; Congenital generalized hypercontractile muscle stiffness syndrome ORPHA:476406; Hepatic veno-occlusive disease-immunodeficiency syndrome ORPHA:79124,0.1040670578681756; 0.1294848460749822; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human adenovirus 21a 100 kDa hexon-assembly associated protein (gene: L4); Human adenovirus 68 100 kDa hexon assembly-associated protein (gene: L4); Human adenovirus 66 100 kDa hexon assembly-associated protein (gene: L4); Human adenovirus 7 100K; Human adenovirus 16 100 kDa hexon assembly-associated protein (gene: L4); Human adenovirus 7d2 100 kDa hexon assembly-associated protein (gene: L4); Cercopithecine betaherpesvirus 5 tegument protein UL37 (gene: UL47),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
NOL3,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Mitochondrial Respiratory Chain Deficiencies; Colorectal Carcinoma; Pancreatic carcinoma; Leukemia, Myelocytic, Acute; Lymphoma; Mammary Neoplasms; Liver carcinoma; Colorectal Cancer; T-Cell Lymphoma; Neuroblastoma; Central neuroblastoma; Ductal Carcinoma; Spasmodic movement; Involuntary jerking movements; High density lipoprotein measurement; Hodgkin Disease; Renal Cell Carcinoma; Myoclonus; AIDS related complex; Electron Transport Chain Deficiencies, Mitochondrial; Stomach Carcinoma; Oxidative Phosphorylation Deficiencies; Falls; Wiskott-Aldrich Syndrome; Lip and Oral Cavity Carcinoma; Colonic Neoplasms; Pain; Mitochondrial Diseases; Cerebellar Ataxia; Chagas Disease; Hypertrophic Cardiomyopathy; Cardiomyopathy, Dilated; Asthma",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8190761496232595; 0.8212681436603975; 0.887595340546704; 0.8989612563669234; 0.906476206143938; 0.9193385822373632; 0.9459312971127588; 0.9564633032157428; 0.9672478180546946,Mitochondrial Electron Transport Chain Deficiencies; Mitochondrial Respiratory Chain Deficiencies; Oxidative Phosphorylation Deficiency; Mitochondrial Diseases,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.924275664330454,"Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Familial cortical myoclonus ORPHA:319189; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Dyschromatosis universalis hereditaria ORPHA:241; Familial pseudohyperkalemia ORPHA:90044; Muscular dystrophy, Selcen type ORPHA:199340; Congenital bile acid synthesis defect type 1 ORPHA:79301; Dopa-responsive dystonia due to sepiapterin reductase deficiency ORPHA:70594; Hemolytic anemia due to adenylate kinase deficiency ORPHA:86817; Adenylosuccinate synthetase-like 1-related distal myopathy ORPHA:482601; Glycogen storage disease due to muscle phosphorylase kinase deficiency ORPHA:715",0.0414176838632111; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
NOS1AP,"Malignant neoplasm of breast; Breast Carcinoma; Chronic heart failure; Serum total cholesterol measurement; Monocyte count procedure; Monocyte count result; High density lipoprotein measurement; Mental disorders; Abnormal behavior; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Electrocardiogram; Diabetes; Vascular occlusion; Diabetes Mellitus; Brugada Syndrome (disorder); Diabetic peripheral neuropathy; Severe depression; Skin Erosion; Schizophrenia; Long QT Syndrome; Romano-Ward Syndrome; Congenital long QT syndrome; Diabetes Mellitus, Non-Insulin-Dependent; Triglycerides measurement; Cardiac Arrest; cardiac event; Sudden Cardiac Death; Low density lipoprotein cholesterol measurement; Ventricular arrhythmia; Mental Depression; Heart failure; Coronary Artery Disease; Congestive heart failure; Bipolar Disorder; Depressive disorder; Coronary heart disease; Sciatic Neuropathy; Post-Traumatic Stress Disorder; Hypertrophic Cardiomyopathy",0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8138488881521341; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8402911822757345; 0.8523465762428218; 0.8554819098734854; 0.8648405521677974; 0.8745234584149799; 0.8769418330148872; 0.8867509400747969; 0.887595340546704; 0.8976039441125321; 0.900167961295542; 0.9103315000053974; 0.9119978323790848; 0.929235785949896; 0.9446671211493156; 0.9459312971127588,Dysautonomia; Schizophrenia; Romano-Ward Syndrome; Torsades De Pointes,0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846,"Spectrin-associated autosomal recessive cerebellar ataxia ORPHA:352403; Spinocerebellar ataxia type 5 ORPHA:98766; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; Persistent hyperplastic primary vitreous ORPHA:91495; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; Achondroplasia ORPHA:15; Autosomal dominant adult-onset proximal spinal muscular atrophy ORPHA:209335; Autosomal dominant spastic paraplegia type 31 ORPHA:101011; Camptodactyly-tall stature-scoliosis-hearing loss syndrome ORPHA:85164; Crouzon syndrome-acanthosis nigricans syndrome ORPHA:93262; Hypochondroplasia ORPHA:429; Muenke syndrome ORPHA:53271; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome ORPHA:85165; Thanatophoric dysplasia type 1 ORPHA:1860; Thanatophoric dysplasia type 2 ORPHA:93274; Wilson disease ORPHA:905; Atypical juvenile parkinsonism ORPHA:391411; NON RARE IN EUROPE: Aldosterone-producing adenoma ORPHA:85142; Pontocerebellar hypoplasia type 3 ORPHA:97249; Hypoplastic tibiae-postaxial polydactyly syndrome ORPHA:3332; Polydactyly of a triphalangeal thumb ORPHA:93336; Radial hemimelia ORPHA:93321; Syndactyly type 4 ORPHA:93405; Triphalangeal thumb-polysyndactyly syndrome ORPHA:2950; Usher syndrome type 2 ORPHA:231178; 2q32q33 microdeletion syndrome ORPHA:251019; SATB2-associated syndrome due to a chromosomal rearrangement ORPHA:251028; SATB2-associated syndrome due to a pathogenic variant ORPHA:576283; CHARGE syndrome ORPHA:138; Renal hypoplasia, bilateral ORPHA:97362; Romano-Ward syndrome ORPHA:101016",0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.8029813443753846; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9091525520868836,,,,,,
NOXA1,Adenocarcinoma; Colon Carcinoma; Malignant tumor of colon; Vascular Diseases; Arteriosclerosis; Atherosclerosis,0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415,,,"Familial lipase maturation factor 1 deficiency ORPHA:535453; D-2-hydroxyglutaric aciduria ORPHA:79315; CLN10 disease ORPHA:228337; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; Scheie syndrome ORPHA:93474; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; 5-oxoprolinase deficiency ORPHA:33572; Glycogen storage disease due to acid maltase deficiency, infantile onset ORPHA:308552; Glycogen storage disease due to acid maltase deficiency, late-onset ORPHA:420429; Congenital sodium diarrhea ORPHA:103908",0.0155394890951578; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2386105733903937; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,Human immunodeficiency virus nef protein (gene: nef); Human immunodeficiency virus 1 Nef (gene: nef); Variola virus hypothetical protein (gene: J7R); Human immunodeficiency virus 2 nef protein; Human gammaherpesvirus 4 EBNA-2 nuclear protein (gene: BYRF1); Human herpesvirus 4 type 2 EBNA-2,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764,,,,
NSA2,"Biliary cirrhosis; Biliary Cirrhosis, Secondary; Diabetes; Diabetes Mellitus; Hyperglycemia; Kidney Diseases; Diabetes Mellitus, Non-Insulin-Dependent; Primary biliary cirrhosis; Diabetic Nephropathy",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8190761496232595; 0.8212681436603975; 0.9390727893210336,Biliary Cholangitis; Biliary Cirrhosis,0.7765582368651238; 0.7765582368651238,Alazami syndrome ORPHA:319671; Brachydactyly-short stature-retinitis pigmentosa syndrome ORPHA:166035; Hypomyelination with brain stem and spinal cord involvement and leg spasticity ORPHA:363412; Autosomal dominant aplasia and myelodysplasia ORPHA:314399; Multiple mitochondrial dysfunctions syndrome type 6 ORPHA:569290; Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome ORPHA:52055; Pelizaeus-Merzbacher-like disease due to AIMP1 mutation ORPHA:280293; Blackfan-Diamond anemia ORPHA:124,0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
NUAK1,Malignant neoplasm of breast; Breast Carcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Non-Small Cell Lung Carcinoma; Liver carcinoma; Malignant Head and Neck Neoplasm; Colorectal Cancer; T-Cell Lymphoma; Neoplasm Metastasis; Squamous cell carcinoma of the head and neck; Malignant Neoplasms; melanoma; Multiple Myeloma; Malignant neoplasm of stomach; Burkitt Lymphoma; Tumor Progression; Stomach Carcinoma; Metastatic Neoplasm; Primary malignant neoplasm; Metastatic melanoma; Secondary malignant neoplasm of lung; Neoplasm Invasiveness; Plasmacytoma; Secondary malignant neoplasm of lymph node; Diabetic Nephropathy,0.4084380369379369; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7940665326856218; 0.8232134984476662; 0.8232134984476662; 0.8608860081595284; 0.900167961295542; 0.9390727893210336,Multiple Myeloma; Attention Deficit Hyperactivity Disorder,0.963385108667098; 0.980894832851993,"NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; Monosomy 22q13.3 ORPHA:48652; Frank-Ter Haar syndrome ORPHA:137834; Benign hereditary chorea ORPHA:1429; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Non-immune hydrops fetalis ORPHA:363999; Dermatofibrosarcoma protuberans ORPHA:31112; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Persistent hyperplastic primary vitreous ORPHA:91495; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; Isolated biliary atresia ORPHA:30391; Microphthalmia with limb anomalies ORPHA:1106; Multiple epiphyseal dysplasia type 5 ORPHA:93311; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; Wolfram-like syndrome ORPHA:411590; Autosomal recessive Robinow syndrome ORPHA:1507; Spondyloepimetaphyseal dysplasia with joint laxity ORPHA:93359; Silver-Russell syndrome due to a point mutation ORPHA:397590; Colobomatous microphthalmia ORPHA:98938; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; Tetralogy of Fallot ORPHA:3303; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; 20p12.3 microdeletion syndrome ORPHA:261295; ABeta amyloidosis, Arctic type ORPHA:324723; ABeta amyloidosis, Dutch type ORPHA:100006; ABeta amyloidosis, Iowa type ORPHA:324708; ABeta amyloidosis, Italian type ORPHA:324713; ABetaA21G amyloidosis ORPHA:324718; ABetaL34V amyloidosis ORPHA:324703; Atrial septal defect, ostium primum type ORPHA:99106; Campomelic dysplasia ORPHA:140; Craniosynostosis, Boston type ORPHA:1541; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Isolated Pierre Robin syndrome ORPHA:718; Kuskokwim syndrome ORPHA:1149; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Lymphedema-posterior choanal atresia syndrome ORPHA:99141; Muscle filaminopathy ORPHA:171445; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Nance-Horan syndrome ORPHA:627; Parietal foramina with clavicular hypoplasia ORPHA:251290; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Scalp-ear-nipple syndrome ORPHA:2036; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A ORPHA:308386; Craniometaphyseal dysplasia ORPHA:1522; Hypoplastic left heart syndrome ORPHA:2248; Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 ORPHA:231117; Butterfly-shaped pigment dystrophy ORPHA:99001; Duane retraction syndrome ORPHA:233; Isolated hemihyperplasia ORPHA:2128; Saethre-Chotzen syndrome ORPHA:794; Distal hereditary motor neuropathy type 2 ORPHA:139525; Familial progressive cardiac conduction defect ORPHA:871; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Bilateral striopallidodentate calcinosis ORPHA:1980; Renal agenesis, unilateral ORPHA:93100; Walker-Warburg syndrome ORPHA:899; Familial porencephaly ORPHA:99810; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; 15q14 microdeletion syndrome ORPHA:261190; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal dominant palmoplantar keratoderma and congenital alopecia ORPHA:1010; Autosomal dominant slowed nerve conduction velocity ORPHA:140481; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354; Dicarboxylic aminoaciduria ORPHA:2195; Familial generalized lentiginosis ORPHA:231040; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Familial schizencephaly ORPHA:481986; Growth delay due to insulin-like growth factor I resistance ORPHA:73273; HANAC syndrome ORPHA:73229; HTRA1-related autosomal dominant cerebral small vessel disease ORPHA:482077; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; Hot water reflex epilepsy ORPHA:166412; Microphthalmia with brain and digit anomalies ORPHA:139471; Oculodentodigital dysplasia ORPHA:2710; Optic atrophy-intellectual disability syndrome ORPHA:401777; Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome ORPHA:447961; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome ORPHA:228012; Retinal arterial tortuosity ORPHA:75326; SIX2-related frontonasal dysplasia ORPHA:488437; Short rib-polydactyly syndrome, Saldino-Noonan type ORPHA:93270; Stuve-Wiedemann syndrome ORPHA:3206; Steel syndrome ORPHA:438117; Syndactyly type 3 ORPHA:93404; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; X-linked Alport syndrome ORPHA:88917; X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome ORPHA:500188; Cerebrofacioarticular syndrome ORPHA:314679; Congenital diaphragmatic hernia ORPHA:2140; Malignant peripheral nerve sheath tumor ORPHA:3148; Non-seminomatous germ cell tumor of testis ORPHA:363494; Pfeiffer syndrome type 1 ORPHA:93258; Phakomatosis cesioflammea ORPHA:79483; Sclerosteosis ORPHA:3152; Silver-Russell syndrome due to 11p15 microduplication ORPHA:231144; Silver-Russell syndrome due to an imprinting defect of 11p15 ORPHA:231140; Tetraamelia-multiple malformations syndrome ORPHA:3301; X-linked hypohidrotic ectodermal dysplasia ORPHA:181; Brachydactyly type A2 ORPHA:93396; Isolated aniridia ORPHA:250923; NON RARE IN EUROPE: Infantile capillary hemangioma ORPHA:464293; Epithelioid hemangioendothelioma ORPHA:157791; Hirschsprung disease ORPHA:388; Lobar holoprosencephaly ORPHA:93924; Midline interhemispheric variant of holoprosencephaly ORPHA:93926; Septopreoptic holoprosencephaly ORPHA:280195; Microform holoprosencephaly ORPHA:280200; Allan-Herndon-Dudley syndrome ORPHA:59; Beta-sarcoglycan-related  limb-girdle muscular dystrophy R4 ORPHA:119; CHST3-related skeletal dysplasia ORPHA:263463; Charcot-Marie-Tooth disease type 2R ORPHA:397968; Childhood-onset benign chorea with striatal involvement ORPHA:494541; Diaphanospondylodysostosis ORPHA:66637; Epidermolysis bullosa simplex due to BP230 deficiency ORPHA:412181; Female restricted epilepsy with intellectual disability ORPHA:101039; GAPO syndrome ORPHA:2067; Goldberg-Shprintzen megacolon syndrome ORPHA:66629; Greig cephalopolysyndactyly syndrome ORPHA:380; Hereditary sensory and autonomic neuropathy type 6 ORPHA:314381; Infantile-onset generalized dyskinesia with orofacial involvement ORPHA:494526; Ischiovertebral syndrome ORPHA:85200; Malignant epithelial tumor of salivary glands ORPHA:276145; Metopic ridging-ptosis-facial dysmorphism syndrome ORPHA:502430; Oculocutaneous albinism type 3 ORPHA:79433; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; X-linked intellectual disability, Najm type ORPHA:163937; X-linked osteoporosis with fractures ORPHA:391330; Congenital cataract microcornea with corneal opacity ORPHA:289499; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Renal agenesis, bilateral ORPHA:1848",0.0429491792829903; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6467006456772204; 0.6873535151929783; 0.6873535151929783; 0.7007232363756918; 0.7007232363756918; 0.7895126437786436; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.795266832401002; 0.8029813443753846; 0.8105918570729571; 0.8105918570729571; 0.8211968342881582; 0.8778481542696168; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Yaba monkey tumor virus ankyrin repeat protein; Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Yaba-like disease virus 11L protein (gene: 11L); Cowpox virus CPXV196 protein (gene: CPXV196 CDS); Yaba monkey tumor virus 142R; Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Monkeypox virus ankyrin-like protein; Horsepox virus HSPV033c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Yaba-like disease virus 147R protein (gene: 147R); Yaba monkey tumor virus ankyrin-like protein; Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Variola virus hypothetical protein (gene: B19R); Cowpox virus CPXV039 (gene: CPXV039 CDS); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Vaccinia virus ankyrin-like protein (gene: B18R); Orf virus ORF126 ankyrin repeat protein; Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Horsepox virus HSPV005c (Ankyrin repeats); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Horsepox virus HSPV014c (ankyrin repeats); Vaccinia virus ankyin-like protein (gene: M1L); Cowpox virus CPXV211 protein (gene: CPXV211 CDS); Orf virus ORF129 ankyrin repeat protein; Variola virus ankyin-like protein (gene: O1L); Horsepox virus HSPV012 (ankyrin-like protein; Provisional); Cowpox virus CPXV220 protein (gene: CPXV220 CDS); Yaba-like disease virus 148R protein (gene: 148R),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.915880438522078; 0.915880438522078; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9383505321091749; 0.9386073090182748; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096,In vitro,0.44,chemical synthesis,Homo sapiens
NUMBL,Glioma; Neoplasm Metastasis; Carcinoma of lung; Neuroblastoma; Central neuroblastoma; Schizophrenia; Progressive cGVHD,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8610447277138289,Prostate Cancer; Schizophrenia; Lung Carcinoma,0.7765582368651238; 0.7860378120955526; 0.8139950454942313,"Otospondylomegaepiphyseal dysplasia ORPHA:1427; Spinocerebellar ataxia type 21 ORPHA:98773; Paroxysmal exertion-induced dyskinesia ORPHA:98811; Oculocutaneous albinism type 2 ORPHA:79432; Steinert myotonic dystrophy ORPHA:273; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome ORPHA:412069; Van den Ende-Gupta syndrome ORPHA:2460; Dentatorubral pallidoluysian atrophy ORPHA:101; POMT2-related  limb-girdle muscular dystrophy R14 ORPHA:206559; Isolated scaphocephaly ORPHA:35093; 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome ORPHA:168563",0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703,,,,,,
NUP50,,,Leukemia,0.7765582368651238,Precursor T-cell acute lymphoblastic leukemia ORPHA:99861; Pancreatic agenesis-holoprosencephaly syndrome ORPHA:556955; Acute myeloid leukemia with t(6;9)(p23;q34) ORPHA:402014; Spinocerebellar ataxia with axonal neuropathy type 1 ORPHA:94124; Extraskeletal Ewing sarcoma ORPHA:370334; Atypical pantothenate kinase-associated neurodegeneration ORPHA:216873; CTCF-related neurodevelopmental disorder ORPHA:363611; Classic pantothenate kinase-associated neurodegeneration ORPHA:216866; Greenberg dysplasia ORPHA:1426; Hereditary neuroendocrine tumor of small intestine ORPHA:456333; Infantile-onset periodic fever-panniculitis-dermatosis syndrome ORPHA:500062; Regressive spondylometaphyseal dysplasia ORPHA:448267; Reynolds syndrome ORPHA:779; Melanoma of soft tissue ORPHA:97338; Facioscapulohumeral dystrophy ORPHA:269,0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
NXF1,"Esophageal carcinoma; Lymphoma; Cervix carcinoma; Malignant tumor of cervix; Malignant neoplasm of lung; Skin lesion; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Bloom Syndrome; Primary immune deficiency disorder; Carcinoma of lung; Hermanski-Pudlak Syndrome; Squamous cell carcinoma of the head and neck; Mesothelioma; melanoma; Eclampsia; Lung Neoplasms; Cowpox; Hodgkin Disease; Bare Lymphocyte Syndrome, Type I; Renal Cell Carcinoma; Infant, Premature; Granulomatosis with polyangiitis; Alzheimer's Disease; Marek Disease; Autoimmune Diseases; Hepatitis C; Rheumatoid Arthritis; Ankylosing spondylitis; Reiter Syndrome; Sjogren's Syndrome; Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis; Idiopathic bronchiectasis; Vasculitis; Cholestasis; Virus Diseases; Bacterial Infections; Juvenile arthritis; Autoimmune liver disease; Multiple Sclerosis; Psoriasis; Lung diseases; Bare lymphocyte syndrome 2; Herpes Simplex Infections; Diabetes Mellitus, Insulin-Dependent; Erythema Nodosum; Ulcerative Colitis; Dengue Fever; Cervical high grade squamous intraepithelial lesion; Juvenile rheumatoid arthritis; Tuberculosis; Hepatitis B; Varicella zoster; Bronchiectasis; Dermatitis, Atopic; Secondary malignant neoplasm of lymph node; Eczema; Malnutrition; Sarcoidosis; Behcet Syndrome",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8368219249856942; 0.841396342333011; 0.8554819098734854; 0.8610447277138289; 0.8867509400747969; 0.900167961295542; 0.909484944705772; 0.9184153253162451; 0.929235785949896; 0.9446671211493156,,,"VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Megaconial congenital muscular dystrophy ORPHA:280671; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Autosomal dominant spastic ataxia type 1 ORPHA:251282; Early-onset epilepsy-intellectual disability-brain anomalies syndrome ORPHA:488635; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; CAMOS syndrome ORPHA:83472; Classic galactosemia ORPHA:79239; Craniosynostosis-dental anomalies ORPHA:284149; Grange syndrome ORPHA:79094; QRICH1-related intellectual disability-chondrodysplasia syndrome ORPHA:580940; Glycogen storage disease due to liver phosphorylase kinase deficiency ORPHA:264580; Chronic myelomonocytic leukemia ORPHA:98823; Primary intraosseous venous malformation ORPHA:140436; Ramon syndrome ORPHA:3019; Autosomal dominant multiple pterygium syndrome ORPHA:65743; CLN2 disease ORPHA:228349; Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia ORPHA:284324; Myxoid/round cell liposarcoma ORPHA:99967",0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,Parvovirus NIH-CQV putative capsid protein (gene: cap),0.8999095837312036,In vitro,0.62,Homo sapiens,hhv11
NXPH4,Uric acid measurement (procedure); Autosomal dominant compelling helio ophthalmic outburst syndrome,0.7765852775619541; 0.8009048756462318,Gout; Gouty Arthritis; Achoo Syndrome,0.7765582368651238; 0.7765582368651238; 0.8115918568696846,Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Isolated split hand-split foot malformation ORPHA:2440; Anterior segment developmental anomaly ORPHA:88632; Congenital primary aphakia ORPHA:83461; Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome ORPHA:231720; Idiopathic juvenile osteoporosis ORPHA:85193; Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ORPHA:397623,0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0473879273649914; 0.1991445465001551; 0.1991445465001551; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
OASL,"C-reactive protein measurement; Serum gamma-glutamyl transferase measurement; Lupus Erythematosus, Systemic; Hepatitis C; Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site; Tick-Borne Encephalitis; Aspartate aminotransferase measurement; Diabetes Mellitus, Non-Insulin-Dependent; Inflammation; Systemic Scleroderma; Influenza",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8145035474981049; 0.8190761496232595; 0.8212681436603975; 0.8402911822757345; 0.9193385822373632,Diabetes Mellitus,0.919442421650838,Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Aicardi-Goutieres syndrome ORPHA:51; Autosomal dominant dopa-responsive dystonia ORPHA:98808; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; GTP cyclohydrolase I deficiency ORPHA:2102; Waldenstrom macroglobulinemia ORPHA:33226; Takayasu arteritis ORPHA:3287; Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Metaphyseal anadysplasia ORPHA:1040; Herpes simplex virus encephalitis ORPHA:1930; Exfoliative ichthyosis ORPHA:289586; Immunodeficiency by defective expression of MHC class I ORPHA:34592; Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome ORPHA:391487; Autoimmune lymphoproliferative syndrome with recurrent viral infections ORPHA:275517; Charcot-Marie-Tooth disease type 1C ORPHA:101083; Familial normophosphatemic tumoral calcinosis ORPHA:306658; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome ORPHA:529977; Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia ORPHA:572428; MIRAGE syndrome ORPHA:494433; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency ORPHA:319595; Susceptibility to viral and mycobacterial infections due to STAT1 deficiency ORPHA:391311; USP18 deficiency ORPHA:481665; Singleton-Merten dysplasia ORPHA:85191; Birdshot chorioretinopathy ORPHA:179; Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome ORPHA:486815; Nasopharyngeal carcinoma ORPHA:150; Autosomal recessive hypohidrotic ectodermal dysplasia ORPHA:248,0.0155394890951578; 0.0155394890951578; 0.1040670578681756; 0.1054066549396977; 0.1294848460749822; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 6 U31, large tegument protein (gene: U31); Human betaherpesvirus 6A large tegument protein (gene: U31); Human betaherpesvirus 6B large tegument protein (gene: U31); Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Dugbe virus L protein; Human betaherpesvirus 7 large tegument protein (gene: U31); Human betaherpesvirus 5 large tegument protein (gene: UL48); Vaccinia virus Ankara viral core cysteine proteinase; Variola virus hypothetical protein (gene: K7L); Monkeypox virus viral core cysteine proteinase; Monkeypox virus Zaire-96-I-16 I7L (gene: I7L); Yaba monkey tumor virus 48L; Vaccinia virus viral core cysteine proteinase (gene: I7L); Horsepox virus HSPV077 (Vaccinia virus I7 processing peptidase); Cercopithecine betaherpesvirus 5 large tegument protein (gene: UL48); SARS coronavirus Tor2 replicase 1AB; SARS coronavirus P2 full_polyprotein 1..7073; SARS coronavirus nsp3-pp1a/pp1ab (gene: orf1ab); SARS coronavirus excised_polyprotein 1..4369 (gene: orf1ab); SARS coronavirus P2 full_polyprotein 1..4382",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764,,,,
OIP5,Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Esophageal carcinoma; Esophageal Neoplasms; Malignant neoplasm of lung; Liver carcinoma; Malignant neoplasm of esophagus; Glioblastoma; Malignant Neoplasms; Malignant neoplasm of stomach; Stomach Carcinoma; Squamous cell carcinoma; Primary malignant neoplasm; Obesity,0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8989612563669234,,,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; X-linked intellectual disability, Snyder type ORPHA:3063; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Hereditary coproporphyria ORPHA:79273; Lipoyl transferase 2 deficiency ORPHA:447795; Acute intermittent porphyria ORPHA:79276; Hemolytic anemia due to glutathione reductase deficiency ORPHA:90030; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; ALG8-CDG ORPHA:79325; Amish nemaline myopathy ORPHA:98902; Combined oxidative phosphorylation defect type 24 ORPHA:444458; Spondyloepimetaphyseal dysplasia with multiple dislocations ORPHA:93360; Autosomal recessive Kenny-Caffey syndrome ORPHA:93324; Brody myopathy ORPHA:53347; Cutis marmorata telangiectatica congenita ORPHA:1556; Deafness-encephaloneuropathy-obesity-valvulopathy syndrome ORPHA:254898; Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome ORPHA:496756; Reticular dysgenesis ORPHA:33355; Sanjad-Sakati syndrome ORPHA:2323; Anaplastic oligodendroglioma ORPHA:251630; Oligodendroglioma ORPHA:251627; Adenylosuccinate lyase deficiency ORPHA:46; Combined oxidative phosphorylation defect type 2 ORPHA:254920; Mohr-Tranebjaerg syndrome ORPHA:52368; Multiple system atrophy, cerebellar type ORPHA:227510; Multiple system atrophy, parkinsonian type ORPHA:98933",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
OMA1,Carcinoma of bladder; Malignant neoplasm of urinary bladder; Colorectal Cancer; Duane Retraction Syndrome; Autistic Disorder; Impaired cognition; Cognition Disorders; Familial multiple trichoepitheliomata,0.4084380369379369; 0.5071083164302358; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8190761496232595; 0.8270909867833504; 0.8523465762428218,Colorectal Cancer,0.9832345076528324,Alacrimia-choreoathetosis-liver dysfunction syndrome ORPHA:404454; Lipoyl transferase 1 deficiency ORPHA:401862; Orofaciodigital syndrome type 5 ORPHA:2919; 6q terminal deletion syndrome ORPHA:75857; 3-methylglutaconic aciduria type 1 ORPHA:67046; ALG6-CDG ORPHA:79320; COG2-CDG ORPHA:435934; Intermediate maple syrup urine disease ORPHA:268162; Cowden syndrome ORPHA:201,0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8953775799945711,,,,,,
OSBPL7,,,Diabetes Mellitus,0.919442421650838,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533,0.0414176838632111,,,,,,
P4HA2,Malignant neoplasm of breast; Breast Carcinoma; Mammary Neoplasms; Liver carcinoma; Neoplasm Metastasis; Triple Negative Breast Neoplasms; Eosinophil count procedure; Eosinophil count result; Squamous cell carcinoma of mouth; Temporal Arteritis; Crohn Disease; Degenerative polyarthritis; Liver neoplasms; Blood basophil count (lab test); Secondary malignant neoplasm of lung; Hepatitis B; Severe myopia,0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8232134984476662; 0.841396342333011; 0.9432051631882106,Temporal Arteritis; Hypertension; Crohn Disease; Myopia,0.7765582368651238; 0.7765582368651238; 0.8903630091389316; 0.9832345076528324,"Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Familial cortical myoclonus ORPHA:319189; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; Atypical Werner syndrome ORPHA:79474; Autosomal recessive Emery-Dreifuss muscular dystrophy ORPHA:98855; Autosomal semi-dominant severe lipodystrophic laminopathy ORPHA:280365; Charcot-Marie-Tooth disease type 2B1 ORPHA:98856; Congenital muscular dystrophy due to LMNA mutation ORPHA:157973; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome ORPHA:2229; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation ORPHA:300751; Familial partial lipodystrophy, Dunnigan type ORPHA:2348; Familial partial lipodystrophy, Kobberling type ORPHA:79084; Heart-hand syndrome, Slovenian type ORPHA:168796; LMNA-related cardiocutaneous progeria syndrome ORPHA:363618; Mandibuloacral dysplasia with type A lipodystrophy ORPHA:90153; Thyroid ectopia ORPHA:95712; Multiple osteochondromas ORPHA:321; Adult-onset autosomal recessive cerebellar ataxia ORPHA:284289; Colobomatous macrophthalmia-microcornea syndrome ORPHA:468672; Multiple epiphyseal dysplasia type 5 ORPHA:93311; Multiple myeloma ORPHA:29073; Pseudohypoaldosteronism type 2B ORPHA:88939; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; Xanthinuria type II ORPHA:93602; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Bruck syndrome ORPHA:2771; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Arnold-Chiari malformation type I ORPHA:268882; Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency ORPHA:91135; Chondrosarcoma ORPHA:55880; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome ORPHA:412022; Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency ORPHA:300179; Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa ORPHA:436274; Familial primary localized cutaneous amyloidosis ORPHA:353220; Papillary renal cell carcinoma ORPHA:319298; Distal hereditary motor neuropathy type 2 ORPHA:139525; Aromatase deficiency ORPHA:91; Aromatase excess syndrome ORPHA:178345; Fibronectin glomerulopathy ORPHA:84090; Hereditary papillary renal cell carcinoma ORPHA:47044; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Isolated hyperchlorhidrosis ORPHA:542657; Lipoid proteinosis ORPHA:530; Multiple paragangliomas associated with polycythemia ORPHA:324299; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Ulnar-mammary syndrome ORPHA:3138; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; Juvenile Paget disease ORPHA:2801; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Auriculocondylar syndrome ORPHA:137888; Brachydactyly type A2 ORPHA:93396; Complete atrioventricular septal defect with ventricular hypoplasia ORPHA:99067; Partial atrioventricular septal defect ORPHA:1330; Giant cell arteritis ORPHA:397; Adenocarcinoma of ovary ORPHA:213504; Autosomal recessive brachyolmia ORPHA:448242; Hypodontia-dysplasia of nails syndrome ORPHA:2228; Lethal hydranencephaly-diaphragmatic hernia syndrome ORPHA:480528; PPARG-related familial partial lipodystrophy ORPHA:79083; Primary CD59 deficiency ORPHA:169464; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Trehalase deficiency ORPHA:103909; Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) ORPHA:402020; Brachydactyly type A1 ORPHA:93388; Mutilating palmoplantar keratoderma with periorificial keratotic plaques ORPHA:659",0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
PACSIN2,leukemia; Platelet distribution width measurement; Platelet distribution width result; Platelet Count measurement; Platelet mean volume determination (procedure); Juvenile psoriatic arthritis; Juvenile-Onset Still Disease; Juvenile arthritis; Diabetic Nephropathy,0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.9390727893210336,"Juvenile Arthritis; Polyarthritis, Rheumatoid Factor Positive; Seronegative Polyarthritis; Still Disease; Arthritis",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.9046917974656596,MYH9-related disease ORPHA:182050,0.1991445465001551,"Cowpox virus Ati or CPXV158 protein (gene: ati); Macacine alphaherpesvirus 1 large tegument protein (gene: UL36); Papiine alphaherpesvirus 2 large tegument protein (gene: UL36); Marburg marburgvirus glycoprotein (gene: GP); Marburg virus - Musoke, Kenya, 1980 glycoprotein (gene: GP)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,In vitro,0.85,Homo sapiens,Homo sapiens
PAN2,"Adenocarcinoma; Colorectal Carcinoma; Colorectal Cancer; Cholestasis; Drug-Induced Liver Disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced",0.750391252594775; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8523465762428218; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8578473133580928,Cholestasis; Colorectal Cancer,0.8115918568696846; 0.9832345076528324,"Adult-onset dystonia-parkinsonism ORPHA:199351; Infantile neuroaxonal dystrophy ORPHA:35069; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955; Succinic semialdehyde dehydrogenase deficiency ORPHA:22; X-linked intellectual disability, Siderius type ORPHA:85287; Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons ORPHA:401964; Deafness-enamel hypoplasia-nail defects syndrome ORPHA:3220; Isobutyryl-CoA dehydrogenase deficiency ORPHA:79159; NEK9-related lethal skeletal dysplasia ORPHA:464366; Nevus comedonicus syndrome ORPHA:64754; 6q terminal deletion syndrome ORPHA:75857; COG7-CDG ORPHA:79333",0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703,"Human betaherpesvirus 6B glycoprotein (gene: U85); Yaba-like disease virus 141R protein (gene: 141R); Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Ectromelia virus ERPV hemagglutinin; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Yaba monkey tumor virus DNA polymerase; Ectromelia virus ERPV DNA polymerase; Variola virus hypothetical protein (gene: J9R); Vaccinia virus DNA polymerase (gene: E9L); Horsepox virus HSPV066 (DNA polymerase; Provisional); Vaccinia virus Ankara DNA polymerase; Variola virus DNA polymerase (gene: E9L); Cowpox virus CPXV075 protein (gene: CPXV075 CDS); Horsepox virus HSPV177 (Immunoglobulin like); Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Vaccinia virus Ankara Haemagglutinin",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9197295331382644; 0.9237501457186692; 0.9287050575620676,,,,
PDLIM7,"Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; B-Cell Lymphomas; Superinfection; leukemia; Adenocarcinoma; Reticulosarcoma; Epidermodysplasia Verruciformis; Asymptomatic human immunodeficiency virus infection; Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Leukemogenesis; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Hemophagocytic Syndrome; Malignant tumor of cervix; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Skin lesion; Lymphoma, Non-Hodgkin; Liver carcinoma; Pyothorax-Associated Lymphoma; Malignant Head and Neck Neoplasm; Osteosarcoma; Thyroid carcinoma; Ataxia Telangiectasia; Rhabdomyosarcoma; T-Cell Lymphoma; Osteosarcoma of bone; Prostate carcinoma; cervical cancer; Neoplasm Metastasis; Epithelioma; Immunologic Deficiency Syndromes; Malignant Neoplasms; Hematologic Neoplasms; Malignant neoplasm of nasopharynx; Increased drug resistance; Lymphoid hyperplasia; Nasal and nasal-type NK/T-cell lymphoma; Malignant neoplasm of stomach; Burkitt Lymphoma; African Burkitt's lymphoma; Mental disorders; Cancer of Nasopharynx; Oropharyngeal disorders; Malignant mesothelioma; Hodgkin Disease; Lymphocytosis; Severe Combined Immunodeficiency; Nasopharyngeal carcinoma; Tumor Progression; Persistent Polyclonal B-Cell Lymphocytosis; Lupus Erythematosus, Systemic; Acquired Immunodeficiency Syndrome; Chemical Carcinogenesis; Primary Effusion Lymphoma; Familial dilated cardiomyopathy; Congenital chromosomal disease; AIDS related complex; Adenolymphoma; Stomach Carcinoma; Lymphoepithelial carcinoma; Autoimmune Diseases; Hepatitis C; Primary Cutaneous Follicle Center Lymphoma; Squamous cell carcinoma; Classical Hodgkin's Lymphoma; Rheumatoid Arthritis; Skin callus; AIDS-Related Non-Hodgkin Lymphoma; Gastritis, Atrophic; Coinfection; Ankylosing spondylitis; Lyme Disease; Nevi and Melanomas; Lymphohistiocytosis, Hemophagocytic; Central nervous system lymphoma; Intrahepatic Cholangiocarcinoma; Hyperkeratosis lenticularis perstans; Post-transplant lymphoproliferative disorder; Rheumatism; Virus Diseases; Gingivitis; Primary central nervous system lymphoma; Pulpitis; Melanoma, Amelanotic; Nasal Type Extranodal NK/T-Cell Lymphoma; Undifferentiated carcinoma; Otitis Media with Effusion; Adult Hodgkin Lymphoma; Multiple Sclerosis; Chronic Lymphocytic Leukemia; Degenerative polyarthritis; Liver neoplasms; Lymphomatoid Papulosis; Precancerous Conditions; Pharyngeal Carcinoma; Herpes Simplex Infections; Lymphoma, AIDS-Related; HIV Infections; Diabetes Mellitus, Insulin-Dependent; Collagen Diseases; Opportunistic Infections; Epstein-Barr Virus Infections; MIXED LINEAGE LEUKEMIA; Aggressive Non-Hodgkin Lymphoma; Immunoblastic Large-Cell Lymphoma; Infectious Mononucleosis; Recurrent tumor; Papilloma; Nodular Sclerosis Classical Hodgkin Lymphoma; Intervertebral Disc Degeneration; Lymphoproliferative Disorders; Angioimmunoblastic Lymphadenopathy; Squamous cell carcinoma of esophagus; Hantavirus Infections; Peripheral T-Cell Lymphoma; Dermatitis, Atopic; Hyperactive behavior; Arthritis, Psoriatic; Secondary malignant neoplasm of lymph node; Niemann-Pick Disease, Type C; Eczema; Intraepithelial Neoplasia; Myasthenia Gravis; Graves Disease; Tumor Angiogenesis",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8026504676141903; 0.8067197998685076; 0.8098851543361193; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8145035474981049; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8508164886128737; 0.8578473133580928; 0.8610447277138289; 0.8648405521677974; 0.876210765330195; 0.8867509400747969; 0.8878860377518915; 0.8946938397586319; 0.900167961295542; 0.9024758035783405; 0.909484944705772; 0.9262273158806068; 0.9390727893210336; 0.94939825643792; 0.9656926709728724,Breast Cancer,0.8903630091389316,"Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Crisponi syndrome ORPHA:1545; CLN11 disease ORPHA:314629; Adrenomyeloneuropathy ORPHA:139399; Classic Hodgkin lymphoma, nodular sclerosis type ORPHA:98843; Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; X-linked cerebral adrenoleukodystrophy ORPHA:139396; Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Hemochromatosis type 5 ORPHA:447792; Cap myopathy ORPHA:171881; Congenital short bowel syndrome ORPHA:2301; Autosomal dominant omodysplasia ORPHA:93328; Proximal symphalangism ORPHA:3250; Truncus arteriosus ORPHA:3384; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Amish nemaline myopathy ORPHA:98902; Becker nevus syndrome ORPHA:64755; Developmental malformations-deafness-dystonia syndrome ORPHA:79107; FLNA-related X-linked myxomatous valvular dysplasia ORPHA:555877; Melnick-Needles syndrome ORPHA:2484; Neuronal intestinal pseudoobstruction ORPHA:99811; Otopalatodigital syndrome type 1 ORPHA:90650; Otopalatodigital syndrome type 2 ORPHA:90652; Terminal osseous dysplasia-pigmentary defects syndrome ORPHA:88630; X-linked Ehlers-Danlos syndrome ORPHA:75497; X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome ORPHA:482606; X-linked Emery-Dreifuss muscular dystrophy ORPHA:98863; Deafness-lymphedema-leukemia syndrome ORPHA:3226; Glycogen storage disease due to muscle and heart glycogen synthase deficiency ORPHA:137625; Monocytopenia with susceptibility to infections ORPHA:228423; SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:157965; Hereditary sensory and autonomic neuropathy type 5 ORPHA:64752",0.0144185025972157; 0.0155394890951578; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human papillomavirus type 6 E5B (gene: E5B); Yaba monkey tumor virus 66R; Yaba-like disease virus 66R protein (gene: 66R); Yaba-like disease virus 147R protein (gene: 147R); Molluscum contagiosum virus subtype 1 MC034L (gene: MC034L); Cowpox virus CPXV039 (gene: CPXV039 CDS); Ectromelia virus ERPV ankyrin; Horsepox virus HSPV005c (Ankyrin repeats),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.915880438522078,,,,
PDZK1IP1,"Malignant neoplasm of breast; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Carcinogenesis; Ovarian Carcinoma; Adenoma; Mammary Neoplasms; Malignant neoplasm of prostate; Thyroid carcinoma; Dental caries; Prostatic Neoplasms; Malignant neoplasm of thyroid; Mesothelioma; Malignant Neoplasms; Hematologic Neoplasms; melanoma; Multiple Myeloma; Noninfiltrating Intraductal Carcinoma; Tumor Progression; Uterine Cervical Neoplasm; Solid Neoplasm; Primary malignant neoplasm; Adenomatous polyp of colon; Precancerous Conditions; Ulcerative Colitis; Caries (morphologic abnormality); Dermatitis, Atopic; Eczema; Dermatologic disorders",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8026504676141903; 0.8190761496232595; 0.8648405521677974; 0.8867509400747969; 0.909484944705772; 0.9912501168001682,Prostate Cancer; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238,"Bilateral frontoparietal polymicrogyria ORPHA:101070; Alkaptonuria ORPHA:56; 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency ORPHA:752; Hemochromatosis type 4 ORPHA:139491; Autosomal recessive extra-oral halitosis ORPHA:562538; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency ORPHA:477857; Cranio-osteoarthropathy ORPHA:1525; Isolated congenital digital clubbing ORPHA:217059; Dominant hypophosphatemia with nephrolithiasis or osteoporosis ORPHA:244305; McLeod neuroacanthocytosis syndrome ORPHA:59306",0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,In vitro,0.36,Homo sapiens;chemical synthesis,Homo sapiens;chemical synthesis
PGS1,Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Serum total cholesterol measurement; High density lipoprotein measurement,0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415,Leukemia,0.7765582368651238,Idiopathic CD4 lymphocytopenia ORPHA:228000; Megaconial congenital muscular dystrophy ORPHA:280671; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Autosomal dominant spastic ataxia type 1 ORPHA:251282; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Pontocerebellar hypoplasia type 9 ORPHA:369920; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Polydactyly of a biphalangeal thumb ORPHA:93339; Primary intraosseous venous malformation ORPHA:140436; Ramon syndrome ORPHA:3019,0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087,,,,,,
PHF14,Carcinogenesis; Cerebrovascular accident,0.7333611688795861; 0.8648405521677974,Stroke; Alzheimer Disease; Asthma,0.7765582368651238; 0.8457525389282121; 0.9832345076528324,Vocal cord and pharyngeal distal myopathy ORPHA:600; X-linked intellectual disability-short stature-overweight syndrome ORPHA:457240; Nijmegen breakage syndrome-like disorder ORPHA:240760,0.3832844616405875; 0.5867963421058087; 0.8922466888454011,Human papillomavirus 122 transforming protein E7 (gene: E7); Human papillomavirus 111 E7 protein (gene: E7),0.8999095837312036; 0.8999095837312036,,,,
PIGB,,,Developmental Delay; Mental Retardation,0.7765582368651238; 0.8337953215113012,Alacrimia-choreoathetosis-liver dysfunction syndrome ORPHA:404454; TOR1AIP1-related limb-girdle muscular dystrophy ORPHA:424261; Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; Autoimmune lymphoproliferative syndrome with recurrent viral infections ORPHA:275517; Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency ORPHA:70592; Lipoyl transferase 1 deficiency ORPHA:401862; Orofaciodigital syndrome type 5 ORPHA:2919; Familial cerebral cavernous malformation ORPHA:221061; Combined oxidative phosphorylation defect type 15 ORPHA:319524; Obesity due to CEP19 deficiency ORPHA:397615; Severe combined immunodeficiency due to DCLRE1C deficiency ORPHA:275; Prenatal-onset spinal muscular atrophy with congenital bone fractures ORPHA:486811; Severe intellectual disability and progressive spastic paraplegia ORPHA:280763,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
PITPNM1,Malignant neoplasm of breast; Breast Carcinoma; Neoplasm Metastasis; Retinal Degeneration; Schizophrenia; Secondary malignant neoplasm of lung,0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8232134984476662,Schizophrenia,0.7860378120955526,Idiopathic CD4 lymphocytopenia ORPHA:228000; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; Kufor-Rakeb syndrome ORPHA:306674; Pontocerebellar hypoplasia type 9 ORPHA:369920; CLN4B disease ORPHA:228343; Leukonychia totalis ORPHA:2387; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; Ataxia-hypogonadism-choroidal dystrophy syndrome ORPHA:1180; Autosomal recessive spastic paraplegia type 39 ORPHA:139480; Laurence-Moon syndrome ORPHA:2377; Neuralgic amyotrophy ORPHA:2901; Trichomegaly-retina pigmentary degeneration-dwarfism syndrome ORPHA:3363; Autosomal dominant Charcot-Marie-Tooth disease type 2M ORPHA:228179; Autosomal dominant intermediate Charcot-Marie-Tooth disease type B ORPHA:100044; Fetal akinesia-cerebral and retinal hemorrhage syndrome ORPHA:363409; Intellectual disability-craniofacial dysmorphism-cryptorchidism syndrome ORPHA:329224,0.0155394890951578; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2386105733903937; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
PLA2G10,"Malignant neoplasm of breast; Adenomatous Polyposis Coli; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Allergic bronchitis; Colorectal Carcinoma; Colon Carcinoma; androgen independent prostate cancer; Malignant tumor of colon; Non-Small Cell Lung Carcinoma; Adenoma; Cholangitis; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Invasive carcinoma of breast; Cholelithiasis; Colorectal Cancer; Lymphopenia; Intestinal Polyposis; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; Prostatic Neoplasms; Carcinoma of lung; Lung Neoplasms; Adenovirus Infections; Adenocarcinoma of colon; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Coprophilia (disorder); Cholecystolithiasis; Cardiovascular Diseases; Rheumatoid Arthritis; Crohn Disease; Childhood Astrocytoma; Myeloid Leukemia; Pleurisy; Psoriasis; Kidney Failure, Chronic; Liver neoplasms; Tangier Disease; Diabetes Mellitus, Non-Insulin-Dependent; polyps; Retinitis Pigmentosa; Endothelial dysfunction; Craniosynostosis; Chronic Obstructive Airway Disease; Coronary Artery Disease; nervous system disorder; Bipolar Disorder; Depressive disorder; Coronary heart disease; Arthritis; Aortic Aneurysm, Abdominal; Nasal Polyps; Asthma; Chronic kidney disease stage 5; Colitis",0.4084380369379369; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8486035047899471; 0.8648405521677974; 0.887595340546704; 0.8959157818691486; 0.900167961295542; 0.9103315000053974; 0.9119978323790848; 0.9431511078237256; 0.9578035687879456; 0.9614320311453906; 0.9672478180546946; 0.9694882155560866; 0.9738491767258852,,,,,,,,,,
PLEKHM1,Ovarian Carcinoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Osteopetrosis; Epithelial ovarian cancer; Erlenmeyer flask deformity of the femurs; Generalized osteopenia; Ovarian Serous Adenocarcinoma; Osteosclerosis,0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8402911822757345; 0.8402911822757345,Osteopetrosis; Ovarian Neoplasm; Ovarian Serous Adenocarcinoma; Osteomyelitis; Osteopenia; Anodontia; Mental Depression; Alopecia; Anemia,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.829560580336605; 0.8903630091389316; 0.9367173114041438; 0.9369188149054885,"Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Intermediate osteopetrosis ORPHA:210110; Birt-Hogg-Dube syndrome ORPHA:122; Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome ORPHA:500144; Familial spontaneous pneumothorax ORPHA:2903; Mucolipidosis type IV ORPHA:578; NIK deficiency ORPHA:447731; CLN3 disease ORPHA:228346; Clear cell renal carcinoma ORPHA:319276; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; Mucopolysaccharidosis type 4A ORPHA:309297; Multiple intestinal atresia ORPHA:2300; Palmoplantar keratoderma-esophageal carcinoma syndrome ORPHA:2198; Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome ORPHA:480864; Desbuquois syndrome ORPHA:1425; Hermansky-Pudlak syndrome with pulmonary fibrosis ORPHA:231500; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; Combined immunodeficiency due to STIM1 deficiency ORPHA:317430; Early-onset Lafora body disease ORPHA:324290; Autosomal recessive progressive external ophthalmoplegia ORPHA:254886; Nodular fasciitis ORPHA:477742; Chronic mucocutaneous candidiasis ORPHA:1334; Autosomal recessive spastic paraplegia type 15 ORPHA:100996; Oculocerebrofacial syndrome, Kaufman type ORPHA:2707",0.0081550609410495; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.8922466888454011,,,In vitro,0.59,Homo sapiens,chemical synthesis
PLIN3,"Cervix carcinoma; Liver carcinoma; Carcinoma of lung; Hepatitis C; Liver Cirrhosis, Experimental; Liver neoplasms; Obesity",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8019075543217649; 0.8989612563669234,Lung Carcinoma,0.8139950454942313,"Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; CLN11 disease ORPHA:314629; Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Quebec platelet disorder ORPHA:220436; Cap myopathy ORPHA:171881; Rare isolated myopia ORPHA:98619; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972; Proximal symphalangism ORPHA:3250; Ethylmalonic encephalopathy ORPHA:51188; Martinique crinkled retinal pigment epitheliopathy ORPHA:466718; Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome ORPHA:85167; Familial porphyria cutanea tarda ORPHA:443062",0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
PLK4,"Malignant neoplasm of breast; Breast Carcinoma; leukemia; Colorectal Carcinoma; Colon Carcinoma; Cortical gyral simplification; MYELODYSPLASTIC SYNDROME; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Malignant tumor of colon; Lymphoma; Malignant neoplasm of prostate; Liver carcinoma; Rhabdoid Tumor; Colorectal Cancer; Hepatocarcinogenesis; Prostate carcinoma; Embryonal Neoplasm; Neoplasm Metastasis; Biparietal narrowing; Decreased width of the skull; Muscle Hypertonia; Sloping forehead; Malignant Neoplasms; Hematologic Neoplasms; Abnormality of the eyelashes; Sparse scalp hair; Microlissencephaly; Eye Diseases, Hereditary; Aplasia/Hypoplasia of the cerebellum; Low Vision; Supratentorial atrophy; Seckel syndrome; Tumor Progression; Decreased corneal diameter; Microcornea; Acute lymphocytic leukemia; Nystagmus; Protruding ear; Anteverted nostril; Prominent ear; Cognitive delay; Glaucoma; Absent earlobe; Visual Impairment; Malformations of Cortical Development, Group II; Degenerative brain disorder; Congenital absence of germinal epithelium of testes; Pointed chin; Global developmental delay; Optic Atrophy; Mental and motor retardation; Primary malignant neoplasm; PITUITARY DWARFISM I; Mild global developmental delay; Psychomotor retardation, mild; Cerebral atrophy; Curvature of little finger; Clinodactyly of the 5th finger; Prematurely aged appearance; Primary microcephaly; Abnormality of the skull; Costello syndrome (disorder); Downward slant of palpebral fissure; Precursor Cell Lymphoblastic Leukemia Lymphoma; Reduced number of teeth; Impaired cognition; Severe Congenital Microcephaly; Broad flat nasal bridge; Nasal bridge wide; Microcephaly; Sandal gap; Tooth agenesis; Cone-shaped epiphysis; Abnormally small eyeball; Decreased size of eyeball; Strabismus; Curvature of spine; Defective tooth enamel; Dystrophic tooth enamel; Mental deficiency; Cachexia; Acquired scoliosis; Abnormality of dental enamel; Craniosynostosis; Convex nasal ridge; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Azoospermia; Aplasia/Hypoplasia of the mandible; Micrognathism; Dull intelligence; Low intelligence; Mental impairment; Cataract; Delayed bone age; Thin face; Narrow face; Cerebellar atrophy; Short stature; Cerebellar degeneration; Poor school performance; Infant, Small for Gestational Age; Dwarfism; Intrauterine retardation; Lens Opacities; Hip Dislocation, Congenital; Microphthalmos; Mental Retardation; Infratentorial atrophy; Fetal Growth Retardation; Joint hyperflexibility; Intellectual Disability; Seizures; Epilepsy; Small head",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8213459222602666; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8486035047899471; 0.8578473133580928; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8757755363384367; 0.8757755363384367; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8815127642200768; 0.8815127642200768; 0.8838621755797691; 0.8913141512402477; 0.9083161862856644; 0.9098977259629772; 0.9111864999692114; 0.9117936912777788; 0.914995991166204; 0.9154499654632742; 0.922229272318747; 0.9265708351135048; 0.9307095582633488; 0.9473064300361868; 0.9478210444156088; 0.9478210444156088; 0.963331724428282; 0.9822381479823692,Microcephaly With Chorioretinopathy; Microlissencephaly; Eye Diseases; Nystagmus; Developmental Delay; Microcornea; Optic Atrophy; Congenital Microcephaly; Malformation Of Cortical Development; Seckel Syndrome; Craniosynostosis; Cerebellar Atrophy; Mental Retardation; Cerebral Atrophy; Cerebral Cortical Atrophy; Microcephaly; Glaucoma; Strabismus; Impaired Cognition; Scoliosis; Micrognathism; Microphthalmos; Camptodactyly Of Fingers; Dwarfism; Cataract,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.8337953215113012; 0.8339308890552987; 0.861756360478846; 0.8903630091389316; 0.8903630091389316; 0.8908485337686392; 0.9231137872214272; 0.924275664330454; 0.9398381935810408; 0.941216656523771; 0.943322675973118; 0.9510372690456612; 0.974502015052702,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971; 46,XX gonadal dysgenesis ORPHA:243; 46,XY complete gonadal dysgenesis ORPHA:242; Combined immunodeficiency due to partial RAG1 deficiency ORPHA:231154; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Jawad syndrome ORPHA:313795; Linear nevus sebaceus syndrome ORPHA:2612; Familial prostate cancer ORPHA:1331; Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome ORPHA:477993; Inclusion body myopathy with Paget disease of bone and frontotemporal dementia ORPHA:52430; Nephroblastoma ORPHA:654; 1q44 microdeletion syndrome ORPHA:238769; Acute myeloid leukemia with NPM1 somatic mutations ORPHA:402026; Chudley-McCullough syndrome ORPHA:314597; Primary peritoneal carcinoma ORPHA:168829; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Autosomal recessive chorioretinopathy-microcephaly syndrome ORPHA:2518; Muir-Torre syndrome ORPHA:587; Osteosarcoma ORPHA:668; Familial pancreatic carcinoma ORPHA:1333; Fanconi anemia ORPHA:84; Combined immunodeficiency with granulomatosis ORPHA:157949; Severe combined immunodeficiency due to complete RAG1/2 deficiency ORPHA:331206; Bloom syndrome ORPHA:125; DNA2-related mitochondrial DNA deletion syndrome ORPHA:352470; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations ORPHA:319462; Spinocerebellar ataxia with axonal neuropathy type 1 ORPHA:94124; VACTERL with hydrocephalus ORPHA:3412; RAS-associated autoimmune leukoproliferative disease ORPHA:268114; ICF syndrome ORPHA:2268; Seckel syndrome ORPHA:808; Hereditary breast cancer ORPHA:227535; Autosomal recessive primary microcephaly ORPHA:2512; Hereditary site-specific ovarian cancer syndrome ORPHA:213524; Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome ORPHA:314404; Hereditary sensory neuropathy-deafness-dementia syndrome ORPHA:456318; Microcephaly-complex motor and sensory axonal neuropathy syndrome ORPHA:423894; Acute myeloblastic leukemia without maturation ORPHA:98833; Constitutional mismatch repair deficiency syndrome ORPHA:252202; Weaver syndrome ORPHA:3447; Hypothyroidism due to deficient transcription factors involved in pituitary development or function ORPHA:226307; Hereditary breast and ovarian cancer syndrome ORPHA:145; Borjeson-Forssman-Lehmann syndrome ORPHA:127; X-linked intellectual disability, Van Esch type ORPHA:163976; X-linked reticulate pigmentary disorder ORPHA:85453; Xeroderma pigmentosum-Cockayne syndrome complex ORPHA:220295",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1068643725150898; 0.1419890644363008; 0.1479888965090844; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7593059616185558; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8211968342881582; 0.8329982337461243; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Yaba monkey tumor virus ankyrin repeat protein; Variola virus Ser/Thr kinase (gene: C14L); Yaba-like disease virus 11L protein (gene: 11L); Horsepox virus HSPV011a; Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Monkeypox virus ankyrin-like protein; Horsepox virus HSPV033c (ankyrin repeats); Horsepox virus HSPV011c (ankyrin repeats); Horsepox virus HSPV201a (ankyrin repeats); Vaccinia virus Ankara 54.4k ankyrin repeat protein f1",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9058994261255549,Escherichia coli,0.83,Homo sapiens,Homo sapiens
PNMA1,Encephalomyelitis; CNS disorder,0.8019075543217649; 0.8168901801930506,,,Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Mazabraud syndrome ORPHA:57782; McCune-Albright syndrome ORPHA:562; Monostotic fibrous dysplasia ORPHA:93277; Polyostotic fibrous dysplasia ORPHA:93276; Progressive osseous heteroplasia ORPHA:2762; Pseudohypoparathyroidism type 1A ORPHA:79443; Pseudohypoparathyroidism type 1C ORPHA:79444; Pseudopseudohypoparathyroidism ORPHA:79445; Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome ORPHA:488613; Lissencephaly due to TUBA1A mutation ORPHA:171680; FRAXF syndrome ORPHA:100974,0.0144185025972157; 0.0144185025972157; 0.1040670578681756; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
PNPT1,"Malignant neoplasm of pancreas; Mitochondrial Respiratory Chain Deficiencies; Pancreatic carcinoma; Liver carcinoma; Choreoathetoid movements; Nonverbal; Dyskinetic syndrome; Absent speech; Neuroblastoma; Decreased nerve conduction velocity; Central neuroblastoma; Choreoathetosis; melanoma; Myxoid cyst; Adenocarcinoma of colon; Adenocarcinoma of prostate; Congenital deafness; Hearing Loss, Partial; Deafness; hearing impairment; Nonsyndromic Deafness; Decreased tendon reflex; Dystonia; Dystonic disease; Leigh Disease; Growth retardation; Poor growth; Growth delay; Severe muscular hypotonia; Very poor growth; Chronic Obstructive Airway Disease; Mitochondrial Diseases; Growth failure; Muscle degeneration; Intellectual Disability; Skeletal muscle atrophy; Neurogenic muscle atrophy, especially in the lower limbs; Neurogenic Muscular Atrophy",0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8098851543361193; 0.8190761496232595; 0.834094492023826; 0.8368219249856942; 0.8391186563955684; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8610447277138289; 0.8610447277138289; 0.8610447277138289; 0.8642802827048847; 0.8648405521677974; 0.8648405521677974; 0.8989612563669234; 0.9066109052713736; 0.9450328871666054; 0.9478210444156088; 0.9902977519938704; 0.9902977519938704; 0.992026975660552,Orofacial Dyskinesia; Dyskinetic Syndrome; Liver Carcinoma; Nystagmus; Combined Oxidative Phosphorylation Deficiency; Developmental Delay; Choreoathetosis; Non-Syndromic Sensorineural Deafness; Leukodystrophy; Hearing Loss; Encephalopathy; Mental Retardation; Hip Contracture; Deafness; Sensory Neuropathy; Hypothyroidism; Cataract,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.8337953215113012; 0.8457525389282121; 0.8457525389282121; 0.8879896755141929; 0.8879896755141929; 0.974502015052702,Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome ORPHA:254343; Combined oxidative phosphorylation defect type 13 ORPHA:319514; Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 ORPHA:137681; QRSL1-related combined oxidative phosphorylation defect ORPHA:570491,0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro;ecoli,0.56,Homo sapiens,Homo sapiens
PPFIA3,,,,,Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Otospondylomegaepiphyseal dysplasia ORPHA:1427; PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Paroxysmal exertion-induced dyskinesia ORPHA:98811; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Oculocutaneous albinism type 2 ORPHA:79432; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Distal hereditary motor neuropathy type 5 ORPHA:139536; Bilateral generalized polymicrogyria ORPHA:208447; Hereditary hypophosphatemic rickets with hypercalciuria ORPHA:157215; Hereditary sensory and autonomic neuropathy type 8 ORPHA:478664; Familial infantile myoclonic epilepsy ORPHA:352582; Spastic paraplegia-optic atrophy-neuropathy syndrome ORPHA:320406; Familial congenital mirror movements ORPHA:238722; Dyschromatosis universalis hereditaria ORPHA:241; Familial pseudohyperkalemia ORPHA:90044; Interstitial lung disease due to ABCA3 deficiency ORPHA:440402; Spectrin-associated autosomal recessive cerebellar ataxia ORPHA:352403; Spinocerebellar ataxia type 5 ORPHA:98766; Coloboma of choroid and retina ORPHA:98942; Coloboma of iris ORPHA:98944; Autosomal dominant hyperinsulinism due to Kir6.2 deficiency ORPHA:276580; Autosomal recessive dopa-responsive dystonia ORPHA:101150; Autosomal recessive hyperinsulinism due to Kir6.2 deficiency ORPHA:79644; Autosomal recessive spastic paraplegia type 26 ORPHA:101006; Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency ORPHA:276603; Familial gastric type 1 neuroendocrine tumor ORPHA:464756; Intermediate DEND syndrome ORPHA:99989; Leukoencephalopathy with mild cerebellar ataxia and white matter edema ORPHA:363540; Autosomal dominant otospondylomegaepiphyseal dysplasia ORPHA:166100; Isolated split hand-split foot malformation ORPHA:2440; Hemolytic anemia due to glucophosphate isomerase deficiency ORPHA:712,0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.8922466888454011,Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3),0.8999095837312036,,,,
PPIF,"Malignant neoplasm of breast; Breast Carcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Mammary Neoplasms; Glioma; Liver and Intrahepatic Biliary Tract Carcinoma; Malignant neoplasm of liver; Familial dilated cardiomyopathy; Alzheimer's Disease; Cardiovascular Diseases; Mitochondrial Myopathies; Diabetes; Diabetes Mellitus; Hyperglycemia; Childhood Acute Lymphoblastic Leukemia; Ulcer; Impaired cognition; Intestinal Diseases; Neurodegenerative Disorders; Tuberculosis; Amyotrophic Lateral Sclerosis; Glaucoma, Primary Open Angle; Adrenoleukodystrophy; Amyloidosis; Parkinson Disease; Muscular Dystrophy, Duchenne; Muscle degeneration; Muscular Dystrophy; Myopathy",0.4084380369379369; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8190761496232595; 0.8190761496232595; 0.8272008757995397; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8672189956534445; 0.8772392350816924; 0.8815127642200768; 0.9450328871666054; 0.9540608878641196; 0.9557184806547836,Intestinal Diseases,0.7765582368651238,Purine nucleoside phosphorylase deficiency ORPHA:760; Tyrosinemia type 1 ORPHA:882; Fabry disease ORPHA:324,0.7929682744768703; 0.7929682744768703; 0.8922466888454011,Human immunodeficiency virus 1 capsid (gene: gag); Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Human immunodeficiency virus 1 Gag-Pol (gene: gag-pol); Human immunodeficiency virus 1 Pr55(Gag) (gene: gag); Human immunodeficiency virus gag protein (gene: gag); Human immunodeficiency virus 2 full_polyprotein 1..521 (gene: gag-pol),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
PPP1R13L,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Leukemogenesis; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Adenoma; Thyroid Neoplasm; Malignant tumor of cervix; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Thyroid carcinoma; Glioblastoma; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Malignant neoplasm of testis; Carcinoma of lung; Malignant neoplasm of thyroid; Malignant Neoplasms; melanoma; Multiple Myeloma; Neoplasms; Melanocytic nevus; Epithelial tumor of ovary; Malignant Testicular Germ Cell Tumor; Tumor Progression; Aneurysm, Ruptured; Acute leukemia; Acute lymphocytic leukemia; Virus Diseases; Primary malignant neoplasm; Experimental Organism Basal Cell Carcinoma; Hairy Cell Leukemia; Melanocytic nevus of skin; Chronic Lymphocytic Leukemia; Hereditary hemochromatosis; Liver Cirrhosis; Glioblastoma Multiforme; Arrhythmogenic Right Ventricular Dysplasia; Hepatitis B; Cirrhosis; Rectal Carcinoma; Childhood Leukemia; Cerebral Aneurysm; Medullary carcinoma of thyroid; Papillary thyroid carcinoma; Adenocarcinoma, Clear Cell; Cardiomyopathies",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8138488881521341; 0.8232134984476662; 0.8342163953428735; 0.8402911822757345; 0.841396342333011; 0.8554819098734854; 0.8584283190330553; 0.8610447277138289; 0.8642802827048847; 0.8757755363384367; 0.8757755363384367; 0.946564927793026; 0.9557184806547836,Leukemia; LEOPARD Syndrome; Cardiomyopathy,0.7765582368651238; 0.8115918568696846; 0.9145387439550552,Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Cleft lip/palate ORPHA:199306; Cleft lip and alveolus ORPHA:141291; Isolated cleft lip ORPHA:199302; Localized junctional epidermolysis bullosa ORPHA:251393; Aneurysm-osteoarthritis syndrome ORPHA:284984; Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism ORPHA:100034; Sebocystomatosis ORPHA:841; Tricho-dento-osseous syndrome ORPHA:3352; Self-improving collodion baby ORPHA:281122; Acral self-healing collodion baby ORPHA:281127; Bathing suit ichthyosis ORPHA:100976; MUC1-related autosomal dominant tubulointerstitial kidney disease ORPHA:88949; Monilethrix ORPHA:573; Progressive symmetric erythrokeratodermia ORPHA:316,0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.1991445465001551; 0.2567797333165013; 0.3891940933600213; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus nef protein (gene: nef); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Banna virus strain JKT-6423 vp12; Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Human adenovirus 1 fiber; Human adenovirus 5 fiber; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Cowpox virus CPXV213 protein (gene: CPXV213 CDS); Cowpox virus CPXV027 protein (gene: CPXV027 CDS); Titi monkey adenovirus ECC-2011 fiber; Vaccinia virus hypothetical protein; Vaccinia virus Ankara 72.4k ankyrin repeat protein f1; Cowpox virus CPXV011 protein (gene: CPXV011 CDS); Horsepox virus HSPV022 (ankyrin-like protein; Provisional); Monkeypox virus ankyrin-like protein; Monkeypox virus Zaire-96-I-16 J3L (gene: J3L); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Variola virus hypothetical protein (gene: D6L); Vaccinia virus ankyrin-like protein (gene: B4R); Vaccinia virus ankyrin-like protein (gene: C9L); Horsepox virus HSPV201a (ankyrin repeats); Yaba-like disease virus 147R protein (gene: 147R); Horsepox virus HSPV004 (ankyrin repeats); Yaba monkey tumor virus ankyrin-like protein; Horsepox virus HSPV196 (ankyrin-like protein; Provisional); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Variola virus hypothetical protein (gene: B19R); Vaccinia virus Ankara CP77 Host range protein f1; Cowpox virus CPXV039 (gene: CPXV039 CDS); Variola virus hypothetical protein (gene: B21R); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Cowpox virus VHR1 or CPXV025 protein (gene: VHR1); Vaccinia virus ankyrin-like protein (gene: B18R); Horsepox virus HSPV033b (Ankyrin repeats); Orf virus ORF126 ankyrin repeat protein; Monkeypox virus Zaire-96-I-16 B17R (gene: B17R); Vaccinia virus Ankara CP77 host range protein f3; Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D9L); Cowpox virus CPXV019 protein (gene: CPXV019 CDS); Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Cowpox virus CPXV016 protein (gene: CPXV016 CDS); Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Vaccinia virus Ankara 67.9k ankyrin repeat protein; Cowpox virus CPXV008 protein (gene: CPXV008 CDS); Vaccinia virus ankyin-like protein (gene: M1L); Variola virus hypothetical protein (gene: B6R); Vaccinia virus ankyrin-like protein; Orf virus ORF129 ankyrin repeat protein; Cowpox virus CPXV220 protein (gene: CPXV220 CDS),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9071659214187592; 0.915880438522078; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9364561700418303; 0.9366403811337995; 0.9383505321091749; 0.9397923093369096,In vitro,0.68,Homo sapiens,Homo sapiens
PREPL,"Nephrolithiasis; Frontal bossing; Myasthenic Syndrome; Increased appetite (finding); Hyperphagia; Tented mouth; Tented upper lip; Tented upper lip vermilion; Cognitive delay; Cystinuria; Lambert-Eaton Myasthenic Syndrome; Global developmental delay; Mental and motor retardation; Mitochondrial respiratory chain defects; Myasthenic Syndromes, Congenital, Slow Channel; Moderate mental retardation (I.Q. 35-49); Congenital Myasthenic Syndromes, Presynaptic; Congenital Myasthenic Syndromes, Postsynaptic; Myasthenias; Isolated somatotropin deficiency; No development of motor milestones; Reduced fetal movement; Motor delay; Somatotropin deficiency; Feeding difficulties; Turridolichocephaly; Narrow cranium shape; Narrow head shape; Narrow skull shape; Long narrow head; Hypogonadism; Generalized hypotonia; Myasthenic Syndromes, Congenital; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Hypocalcemia; Growth retardation; Poor growth; Growth delay; Very poor growth; Long eyelashes; Hypernasal voice; Nasal voice; Short stature; Congenital Epicanthus; Failure to Thrive; Fatigue; Growth failure; Muscle hypotonia; Acidosis, Lactic; Intellectual Disability; Seizures; Retrognathia; Epilepsy; Lactic acidemia; Low-set, posteriorly rotated ears; Blepharoptosis; Undergrowth; Failure to gain weight; Pediatric failure to thrive",0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8101097852323003; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8486035047899471; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8584283190330553; 0.8610447277138289; 0.8610447277138289; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.876210765330195; 0.876210765330195; 0.8815127642200768; 0.8867509400747969; 0.8959157818691486; 0.9029289778792944; 0.9066109052713736; 0.9124568647908072; 0.942246125102556; 0.9478210444156088; 0.9478210444156088; 0.9514640836642632; 0.963331724428282; 0.9692578766570316; 0.9692578766570316; 0.9770263358372888; 0.9884235744717738; 0.9896536639644284; 0.9896536639644284,Nephrolithiasis; Cystinuria; Hypoglycemia; Somatotropin Deficiency; Developmental Delay; Isolated Somatotropin Deficiency; Frontal Bossing; Motor Delay; Mental Retardation; Myasthenic Syndrome; Premature Menopause; Hypogonadism; Dolichocephaly; Dwarfism; Congenital Epicanthus; Ptosis,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8210988731657684; 0.8337953215113012; 0.8476516371290275; 0.8903630091389316; 0.9259420053407031; 0.9398381935810408; 0.9510372690456612; 0.974502015052702; 0.9832345076528324,"Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Distal hereditary motor neuropathy type 5 ORPHA:139536; Succinic semialdehyde dehydrogenase deficiency ORPHA:22; Primary pigmented nodular adrenocortical disease ORPHA:189439; Autosomal dominant Charcot-Marie-Tooth disease type 2A1 ORPHA:99946; Autosomal dominant adult-onset proximal spinal muscular atrophy ORPHA:209335; Autosomal dominant spastic paraplegia type 31 ORPHA:101011; Autosomal recessive spastic paraplegia type 67 ORPHA:401820; DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect ORPHA:330050; DOORS syndrome ORPHA:79500; Focal epilepsy-intellectual disability-cerebro-cerebellar malformation ORPHA:352587; Progressive myoclonic epilepsy with dystonia ORPHA:352596; Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome ORPHA:163727; Atypical juvenile parkinsonism ORPHA:391411; Autosomal dominant non-syndromic intellectual disability ORPHA:178469; APC-related attenuated familial adenomatous polyposis ORPHA:247806; Autosomal dominant Charcot-Marie-Tooth disease type 2K ORPHA:99944; Autosomal dominant keratitis ORPHA:2334; Autosomal dominant striatal neurodegeneration ORPHA:228169; Autosomal recessive Charcot-Marie-Tooth disease with hoarseness ORPHA:101097; Autosomal recessive intermediate Charcot-Marie-Tooth disease type A ORPHA:217055; Autosomal recessive spastic paraplegia type 54 ORPHA:320380; COG6-CGD ORPHA:464443; Charcot-Marie-Tooth disease type 2H ORPHA:101102; Charcot-Marie-Tooth disease type 4A ORPHA:99948; Christianson syndrome ORPHA:85278; Familial adenomatous polyposis due to 5q22.2 microdeletion ORPHA:261584; Foveal hypoplasia-presenile cataract syndrome ORPHA:2253; Gardner syndrome ORPHA:79665; Gastric adenocarcinoma and proximal polyposis of the stomach ORPHA:314022; Hyperphenylalaninemia due to DNAJC12 deficiency ORPHA:508523; Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome ORPHA:363523; Infantile-onset ascending hereditary spastic paralysis ORPHA:293168; Isolated optic nerve hypoplasia/aplasia ORPHA:137902; Lissencephaly due to LIS1 mutation ORPHA:95232; Morning glory disc anomaly ORPHA:35737; Mulibrey nanism ORPHA:2576; Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome ORPHA:521390; Succinyl-CoA:3-oxoacid CoA transferase deficiency ORPHA:832; Turcot syndrome with polyposis ORPHA:99818; 2p21 microdeletion syndrome without cystinuria ORPHA:369881; Aniridia-cerebellar ataxia-intellectual disability syndrome ORPHA:1065; Cenani-Lenz syndrome ORPHA:3258; Congenital neutropenia-myelofibrosis-nephromegaly syndrome ORPHA:369852; Short rib-polydactyly syndrome, Majewski type ORPHA:93269; Inherited congenital spastic tetraplegia ORPHA:210141; Male infertility due to globozoospermia ORPHA:171709; NON RARE IN EUROPE: Aldosterone-producing adenoma ORPHA:85142; Jeune syndrome ORPHA:474; Young-onset Parkinson disease ORPHA:2828; 17q11 microdeletion syndrome ORPHA:97685; 17q11.2 microduplication syndrome ORPHA:139474; Anterior maxillary protrusion-strabismus-intellectual disability syndrome ORPHA:562559; Carney complex ORPHA:1359; Familial atrial myxoma ORPHA:615; Glycogen storage disease due to muscle phosphofructokinase deficiency ORPHA:371; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion ORPHA:363700; PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation ORPHA:438216; Progressive encephalopathy with leukodystrophy due to DECR deficiency ORPHA:431361; Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome ORPHA:505242; Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion ORPHA:314655; Sudden infant death-dysgenesis of the testes syndrome ORPHA:168593; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C ORPHA:308400; X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome ORPHA:500188; 17p13.3 microduplication syndrome ORPHA:217385; Desmoid tumor ORPHA:873; Short rib-polydactyly syndrome, Beemer-Langer type ORPHA:93268; Atypical hypotonia-cystinuria syndrome ORPHA:238523; Isolated aniridia ORPHA:250923; 2p21 microdeletion syndrome ORPHA:163693; Hereditary sensory and autonomic neuropathy type 2 ORPHA:970; Short rib-polydactyly syndrome, Verma-Naumoff type ORPHA:93271; Hereditary hyperekplexia ORPHA:3197; Bardet-Biedl syndrome ORPHA:110; Epileptic encephalopathy with global cerebral demyelination ORPHA:353217; Familial encephalopathy with neuroserpin inclusion bodies ORPHA:85110; Metachondromatosis ORPHA:2499; Short rib-polydactyly syndrome type 5 ORPHA:498497; Angelman syndrome due to maternal 15q11q13 deletion ORPHA:98794; Hypomyelination with atrophy of basal ganglia and cerebellum ORPHA:139441; Hypotonia-cystinuria syndrome ORPHA:163690; Subcortical band heterotopia ORPHA:99796; Catecholaminergic polymorphic ventricular tachycardia ORPHA:3286; Pilomyxoid astrocytoma ORPHA:251615; X-linked non-syndromic intellectual disability ORPHA:777; Non-specific early-onset epileptic encephalopathy ORPHA:442835",0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8029813443753846; 0.8105918570729571; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9308133040426916; 0.9381787052130178,,,,,,
PRRT2,"Malignant neoplasm of breast; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Thromboangiitis Obliterans; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Gastrointestinal Stromal Tumors; Colon Carcinoma; Leukemia, Myelocytic, Acute; Paresthesia; androgen independent prostate cancer; Malignant tumor of colon; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Segmental dystonia; Myelomonocytic leukemia; Carcinoma breast stage IV; Laryngeal dystonia; Rhabdoid Tumor of the Kidney; Vascular Diseases; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Myotonic Dystrophy; Hyperparathyroidism, Secondary; Lymphoma, Non-Hodgkin; Liver carcinoma; Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement; Thyroid carcinoma; Acute Promyelocytic Leukemia; Colorectal Cancer; Choreoathetoid movements; Glioblastoma; Prostate carcinoma; Astrocytoma; Sudden infant death syndrome; Dyskinetic syndrome; Pulmonary Edema; Primary malignant neoplasm of lung; CATARACT, MARNER TYPE; cervical cancer; Neoplasm Metastasis; Abnormality of vision; Bloom Syndrome; Carcinoma of lung; Malignant neoplasm of thyroid; Mesothelioma; Neuroblastoma; Muscle Hypertonia; Central neuroblastoma; Choreoathetosis; Interstitial Cystitis; Malignant Neoplasms; melanoma; Ewings sarcoma; Intestinal Neoplasms; Multiple Myeloma; Spasmodic movement; Involuntary jerking movements; Afebrile seizure; Benign neonatal epilepsy; Burning sensation; Involuntary dystonic or choreiform movements; Malignant neoplasm of stomach; Burkitt Lymphoma; Invasive Ductal Breast Carcinoma; AL-RAQAD SYNDROME; Hemiplegic migraine; Lupus Erythematosus, Systemic; Renal Cell Carcinoma; MYOTONIC DYSTROPHY 1; Myoclonus; Alzheimer's Disease; Acute lymphocytic leukemia; Nystagmus; Stomach Carcinoma; Dyskinesias, Paroxysmal; Generalized Epilepsy with Febrile Seizures Plus; Autoimmune Diseases; Axenfeld-Rieger syndrome; Hyperactive deep tendon reflexes; Infrequent generalized seizures; Squamous cell carcinoma; Rheumatoid Arthritis; Peripheral demyelinating neuropathy; Disorder of face; Abnormality of the face; Adenocarcinoma of prostate; Hyperglycemia; Familial benign neonatal epilepsy; Familial Hemiplegic Migraine; Lingual-Facial-Buccal Dyskinesia; Malignant melanoma of choroid; Tumor Immunity; Hemiplegia/hemiparesis; Dysesthesia; Cholestasis; Mental Retardation, Psychosocial; Human immunodeficiency virus II infection; Immunosuppression; Primary malignant neoplasm; Myoclonic dystonia; Metastatic melanoma; Large cell carcinoma of lung; Cavernous Hemangioma of Brain; Sunken eyes; Enophthalmos; Profound Mental Retardation; Dystonia, Paroxysmal; Disturbance of consciousness; Dystonia Musculorum Deformans; Multiple Sclerosis; Febrile Convulsions; Episodic Ataxia; Paroxysmal nonkinesigenic dyskinesia; Chronic Lymphocytic Leukemia; Glomerulosclerosis (disorder); West Syndrome; Dystonia, Primary; MOHR-TRANEBJAERG SYNDROME; Convulsions; HIV Infections; Torticollis; Absence Seizures; Generalized seizures; Lip and Oral Cavity Carcinoma; Diabetes Mellitus, Non-Insulin-Dependent; Epilepsy, Rolandic; Seizures, Focal; Scleroderma; Colonic Neoplasms; Hepatic Fibrosis, Congenital; Infantile Severe Myoclonic Epilepsy; Pemphigus; Secondary malignant neoplasm of lung; Dystonia Disorders; Severe Acute Respiratory Syndrome; Diabetic Retinopathy; airway disease; Dystonia; Systemic Scleroderma; Intermittent migraine headaches; Peripheral Neuropathy; Mental deficiency; ATRICHIA WITH PAPULAR LESIONS; NONAKA MYOPATHY; Follicular thyroid carcinoma; Squamous cell carcinoma of esophagus; Migraine Disorders; Amyloidosis; Familial Alzheimer Disease (FAD); Inflammatory Bowel Diseases; Hypertrophic disorder of skin, unspecified; Migraine with Aura; Heart failure; Hyperactive behavior; Pulmonary Fibrosis; Malignant neoplasm of mouth; nervous system disorder; Chorea; Congestive heart failure; Inflammatory pain; Cerebellar Ataxia; Paroxysmal kinesigenic choreoathetosis; Muscle hypotonia; Leishmaniasis, Visceral; Epileptic encephalopathy; Polycystic Kidney, Autosomal Dominant; Mental Retardation; Encephalopathies; Ataxias, Hereditary; Uveal melanoma; Movement Disorders; Developmental Disabilities; Arthritis; Intellectual Disability; Seizures; Congenital anomaly of face; Endometriosis; Epilepsy; Autism Spectrum Disorders; Asthma; Cystic Fibrosis",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7940665326856218; 0.7967714690735718; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8578473133580928; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8672189956534445; 0.8786853464107758; 0.8815127642200768; 0.8815127642200768; 0.8851456306720444; 0.8867509400747969; 0.8878860377518915; 0.8911256045597441; 0.8946938397586319; 0.8959157818691486; 0.8959157818691486; 0.8976039441125321; 0.900167961295542; 0.906476206143938; 0.9083161862856644; 0.9124568647908072; 0.9154499654632742; 0.917543617287358; 0.9193385822373632; 0.922229272318747; 0.9265708351135048; 0.9265708351135048; 0.929235785949896; 0.929235785949896; 0.929814249105729; 0.9431511078237256; 0.9478210444156088; 0.9478210444156088; 0.9561991866282916; 0.960644037248553; 0.963331724428282; 0.9639249377588224; 0.9672478180546946; 0.9874278479946328,Paroxysmal Nonkinesigenic Dyskinesia; Stereotyped Behavior; Dyskinesia; Orofacial Dyskinesia; Focal Seizures; Dyskinetic Syndrome; Benign Epilepsy; Nystagmus; Choreoathetosis; Trismus; Writer`s Cramp; Hearing Loss; Dystonia; Hemiplegia/hemiparesis; Movement Disorders; Hallucinations; Mental Retardation; Anxiety Disorder; Epilepsy; Seizure; Retinitis Pigmentosa; Dysphasia; Speech Disorders; Migraine; Specific Learning Disorder,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8082616889285628; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.829560580336605; 0.8337953215113012; 0.8337953215113012; 0.8507213163251659; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.9069867032339078; 0.9658957825498884; 0.9832345076528324,Paroxysmal exertion-induced dyskinesia ORPHA:98811; Interstitial lung disease due to ABCA3 deficiency ORPHA:440402; Infant acute respiratory distress syndrome ORPHA:70587; Paroxysmal non-kinesigenic dyskinesia ORPHA:98810; Early infantile epileptic encephalopathy ORPHA:1934; Distal hereditary motor neuropathy type 7 ORPHA:139589; Horizontal gaze palsy with progressive scoliosis ORPHA:2744; Infantile convulsions and choreoathetosis ORPHA:31709; Myoclonic-astatic epilepsy ORPHA:1942; Presynaptic congenital myasthenic syndromes ORPHA:98914; Autosomal dominant spastic paraplegia type 73 ORPHA:444099; Paroxysmal kinesigenic dyskinesia ORPHA:98809; Familial or sporadic hemiplegic migraine ORPHA:569; Benign familial infantile epilepsy ORPHA:306,0.0155394890951578; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7593059616185558; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
PRSS16,"Carcinogenesis; Infantile Colic; Autoimmune Diseases; Schizophrenia; Diabetes Mellitus, Insulin-Dependent; Colitis",0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8145035474981049; 0.9738491767258852,Schizophrenia,0.7860378120955526,Currarino syndrome ORPHA:1552,0.0155394890951578,,,,,,
PSIP1,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Malignant neoplasm of pancreas; Osteopetrosis; Pancreatic carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; MYELODYSPLASTIC SYNDROME; Leukemogenesis; Non-Small Cell Lung Carcinoma; Mammary Neoplasms; Glioma; Chronic Fatigue Syndrome; Malignant neoplasm of prostate; Ki-1+ Anaplastic Large Cell Lymphoma; Epithelial ovarian cancer; T-Cell Lymphoma; Prostate carcinoma; Neoplasm Metastasis; Acute Myeloid Leukemia, M1; Neuroblastoma; Central neuroblastoma; Immunologic Deficiency Syndromes; melanoma; Malignant neoplasm of stomach; Congenital contractural arachnodactyly; Malignant mesothelioma; Hodgkin Disease; Pancreatitis, Chronic; Photoreceptor degeneration; Acute leukemia; Retinoblastoma; Primary Effusion Lymphoma; Neuroectodermal Tumor, Primitive; Alzheimer's Disease; TNF receptor-associated periodic fever syndrome (TRAPS); Stomach Carcinoma; Autoimmune Diseases; Acute Myeloid Leukemia (AML-M2); Hyperlipidemia, Familial Combined; Squamous cell carcinoma; Diabetes; Diabetes Mellitus; Abnormality of the skeletal system; Ankylosing spondylitis; Huntington Disease; Hormone refractory prostate cancer; Cytomegalovirus Infections; Myeloid Leukemia, Chronic; Myeloid Leukemia; Adenosquamous carcinoma; Childhood Acute Myeloid Leukemia; Leukemia, Large Granular Lymphocytic; Alveolitis; Fibrosarcoma; Chronic Lymphocytic Leukemia; Blepharitis; Eating Disorders; Myeloproliferative disease; Liver diseases; HIV Infections; Primary infection NOS; MIXED LINEAGE LEUKEMIA; Infection; Psoriasis vulgaris; Amyotrophic Lateral Sclerosis; Epiretinal Membrane; Rhinitis; Alopecia; Medulloblastoma; Neoplasm, Residual; Squamous cell carcinoma of esophagus; Progressive sensorineural hearing impairment; Amyloidosis; Alopecia Areata; Dermatitis, Atopic; Neurilemmoma; Eczema; Allergic rhinitis (disorder); Limb ischemia; Carcinoma of larynx; Unipolar Depression; Malaria; Major Depressive Disorder; Asthma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8101097852323003; 0.8138488881521341; 0.8140222479282434; 0.8145035474981049; 0.8168901801930506; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8523465762428218; 0.8548862007194026; 0.8578473133580928; 0.8610447277138289; 0.8648405521677974; 0.8672189956534445; 0.8690346447728063; 0.8867509400747969; 0.887595340546704; 0.909484944705772; 0.922577745415874; 0.929235785949896; 0.9377696084218796; 0.9455834988784428; 0.9512505437112568; 0.9658628445524134; 0.9672478180546946,Leukemia; Myeloid Leukemia,0.7765582368651238; 0.8356859041719433,Early-onset parkinsonism-intellectual disability syndrome ORPHA:2379; Neuroendocrine tumor of stomach ORPHA:100075; Acute myeloblastic leukemia with maturation ORPHA:98834; B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome ORPHA:567502; Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome ORPHA:504476; Monosomy 9q22.3 ORPHA:77301; Schilbach-Rott syndrome ORPHA:2353; Succinyl-CoA:3-oxoacid CoA transferase deficiency ORPHA:832; NON RARE IN EUROPE: Primary ovarian failure ORPHA:619; Glycogen storage disease due to lactate dehydrogenase H-subunit deficiency ORPHA:284435,0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus 1 capsid (gene: gag); Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Human immunodeficiency virus 1 Gag-Pol (gene: gag-pol); Human immunodeficiency virus 1 p66 subunit (gene: gag-pol); Human immunodeficiency virus 1 reverse transcriptase p51 subunit (gene: gag-pol); Human T-lymphotropic virus 2 Gag-Pro-Pol; Human immunodeficiency virus pol protein (gene: pol); Human immunodeficiency virus 1 integrase (gene: gag-pol); Human immunodeficiency virus 1 Pol (gene: gag-pol); Human immunodeficiency virus 1 aspartic peptidase (gene: gag-pol); Human T-lymphotropic virus 2 full_polyprotein 1..982; African green monkey simian foamy virus Pol precursor (gene: pol); Human T-cell leukemia virus type I p15NC-p14PR-p95RT/IN (gene: gag-pro-pol); Human T-cell leukemia virus type I Pr gag-pro-pol (gene: gag-pro-pol); Human T-lymphotropic virus 4 polymerase (gene: pol); Human T-lymphotropic virus 3 polymerase (gene: pol),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9056300531913352; 0.9057542447893764; 0.9224369592826992; 0.9224878266317492; 0.9237501457186692; 0.9397923093369096,,,,
PSTK,Hypertensive disease,0.8474481237156937,Hypertension,0.7765582368651238,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect ORPHA:466784; Lipoic acid synthetase deficiency ORPHA:401859; POGLUT1-related  limb-girdle muscular dystrophy R21 ORPHA:480682,0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
PTGES3,Malignant neoplasm of breast; Reticulocyte count (procedure); Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Non-Small Cell Lung Carcinoma; Mammary Neoplasms; Malignant neoplasm of prostate; Prostate carcinoma; Neoplasm Metastasis; Isodicentric Chromosome 15 Syndrome; Malignant neoplasm of stomach; Retinoblastoma; Invasive Carcinoma; Alzheimer's Disease; Periodontitis; Stomach Carcinoma; Lyme Disease; Developmental reading disorder; Fibrosarcoma; Schizophrenia; Tremor; Amyloidosis; Pervasive Development Disorder; Autism Spectrum Disorders,0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8672189956534445; 0.8806784681730055; 0.9639249377588224,,,Linear nevus sebaceus syndrome ORPHA:2612; Autosomal recessive spastic paraplegia type 61 ORPHA:401780; Spinocerebellar ataxia type 10 ORPHA:98761; Distal 17p13.3 microdeletion syndrome ORPHA:261257; Microcephaly-capillary malformation syndrome ORPHA:294016; Mitochondrial non-syndromic sensorineural deafness ORPHA:90641; Hypoxanthine guanine phosphoribosyltransferase partial deficiency ORPHA:79233; Lesch-Nyhan syndrome ORPHA:510; Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion ORPHA:352665; Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation ORPHA:453504; Proximal myotonic myopathy ORPHA:606; Spinocerebellar ataxia type 38 ORPHA:423296; Thrombocytopenia-absent radius syndrome ORPHA:3320; Frontotemporal dementia with motor neuron disease ORPHA:275872; Amyotrophic lateral sclerosis ORPHA:803,0.2047219337649946; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.937224824246693,Dengue virus 2 envelope protein E (gene: flavivirus polyprotein); Cercopithecine betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Human gammaherpesvirus 8 K4.1 (gene: K4.1); Macacine alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Human betaherpesvirus 5 chemokine vCXCL1 (gene: UL146); Human betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Molluscum contagiosum virus subtype 1 MC148R (gene: MC148R); Cercopithecine betaherpesvirus 5 chemokine vCXCL10 (gene: UL146G),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9237501457186692,,,,
PTPRU,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Leukemia, Myelocytic, Acute; Colorectal Neoplasms; Carcinoma breast stage IV; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Osteosarcoma; Colorectal Cancer; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Carcinoma of lung; Turner Syndrome, Male; Malignant Neoplasms; melanoma; Adenocarcinoma of pancreas; Lung Neoplasms; Neoplasms; Membranous glomerulonephritis; Renal Cell Carcinoma; Congenital chromosomal disease; Fanconi Anemia; Diabetes in children; Polycythemia Vera; Diabetes; Diabetes Mellitus; Nephrosis; Hyperglycemia; Primary malignant neoplasm; Noonan Syndrome; Multiple Sclerosis; Focal glomerulosclerosis; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Adenocarcinoma of lung (disorder); Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Non-Insulin-Dependent; Neuroectodermal Tumors; Stage IV Skin Melanoma; Glioblastoma Multiforme; Hypertensive disease; Renal carcinoma; Kidney Neoplasm; Inflammatory Bowel Diseases; Malignant neoplasm of kidney; Obesity; Clear-cell metastatic renal cell carcinoma; Pheochromocytoma",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8145035474981049; 0.8190761496232595; 0.8232134984476662; 0.8270909867833504; 0.8342163953428735; 0.8474481237156937; 0.8648405521677974; 0.8774809019744603; 0.8815127642200768; 0.8818220091065441; 0.8989612563669234; 0.8989612563669234; 0.9557184806547836,Colorectal Cancer,0.9832345076528324,"Antley-Bixler syndrome ORPHA:83; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Monosomy 22q13.3 ORPHA:48652; Saldino-Mainzer syndrome ORPHA:140969; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Familial cortical myoclonus ORPHA:319189; Frank-Ter Haar syndrome ORPHA:137834; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Benign hereditary chorea ORPHA:1429; Progressive myoclonic epilepsy type 5 ORPHA:402082; Familial hypercholanemia ORPHA:238475; Early-onset posterior polar cataract ORPHA:98993; Cleft lip/palate ORPHA:199306; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Congenital insensitivity to pain with severe intellectual disability ORPHA:453510; Dyschromatosis universalis hereditaria ORPHA:241; Familial pseudohyperkalemia ORPHA:90044; Hereditary folate malabsorption ORPHA:90045; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Spectrin-associated autosomal recessive cerebellar ataxia ORPHA:352403; Spinocerebellar ataxia type 5 ORPHA:98766; Crouzon disease ORPHA:207; Alopecia-intellectual disability syndrome ORPHA:2850; Coloboma of choroid and retina ORPHA:98942; Coloboma of iris ORPHA:98944; NON RARE IN EUROPE: Hypodontia ORPHA:2227; Lethal acantholytic erosive disorder ORPHA:158687; Achondroplasia ORPHA:15; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Camptodactyly-tall stature-scoliosis-hearing loss syndrome ORPHA:85164; Carvajal syndrome ORPHA:65282; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Classic Bartter syndrome ORPHA:93605; Congenital hereditary endothelial dystrophy type II ORPHA:293603; Corneal dystrophy-perceptive deafness syndrome ORPHA:1490; Crouzon syndrome-acanthosis nigricans syndrome ORPHA:93262; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Hyperprolinemia type 2 ORPHA:79101; Hypochondroplasia ORPHA:429; Hypomaturation-hypoplastic amelogenesis imperfecta with taurodontism ORPHA:100034; Isolated biliary atresia ORPHA:30391; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Lateral meningocele syndrome ORPHA:2789; Muenke syndrome ORPHA:53271; POMT2-related  limb-girdle muscular dystrophy R14 ORPHA:206559; Pierson syndrome ORPHA:2670; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome ORPHA:85165; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Thanatophoric dysplasia type 1 ORPHA:1860; Thanatophoric dysplasia type 2 ORPHA:93274; Tricho-dento-osseous syndrome ORPHA:3352; Wilson disease ORPHA:905; Wolfram-like syndrome ORPHA:411590; X-linked creatine transporter deficiency ORPHA:52503; 3M syndrome ORPHA:2616; Autosomal recessive Robinow syndrome ORPHA:1507; Carpenter syndrome ORPHA:65759; Hyperostosis corticalis generalisata ORPHA:3416; 46,XX ovotesticular disorder of sex development ORPHA:2138; Acrocallosal syndrome ORPHA:36; Aplasia cutis congenita ORPHA:1114; Familial exudative vitreoretinopathy ORPHA:891; Juvenile nephronophthisis ORPHA:93592; Colobomatous microphthalmia ORPHA:98938; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; Tetralogy of Fallot ORPHA:3303; Early-onset nuclear cataract ORPHA:98991; Acrokeratosis verruciformis of Hopf ORPHA:79151; Alpha-dystroglycan-related  limb-girdle muscular dystrophy R16 ORPHA:280333; Autosomal dominant Charcot-Marie-Tooth disease type 2C ORPHA:99937; Autosomal dominant brachyolmia ORPHA:93304; Autosomal dominant congenital benign spinal muscular atrophy ORPHA:1216; Autosomal dominant osteopetrosis type 1 ORPHA:2783; Autosomal spastic paraplegia type 58 ORPHA:397946; Brachydactyly type B1 ORPHA:572385; Campomelic dysplasia ORPHA:140; Craniosynostosis, Boston type ORPHA:1541; Darier disease ORPHA:218; Dent disease type 2 ORPHA:93623; Endosteal hyperostosis, Worth type ORPHA:2790; Familial congenital nasolacrimal duct obstruction ORPHA:451612; Familial digital arthropathy-brachydactyly ORPHA:85169; Familial hypocalciuric hypercalcemia type 2 ORPHA:101049; Isolated Pierre Robin syndrome ORPHA:718; Keipert syndrome ORPHA:2662; LAMA5-related multisystemic syndrome ORPHA:521450; LRP5-related primary osteoporosis ORPHA:498481; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Metatropic dysplasia ORPHA:2635; Muscle-eye-brain disease with bilateral multicystic leucodystrophy ORPHA:370997; Neurodegenerative syndrome due to cerebral folate transport deficiency ORPHA:217382; Oculocerebrorenal syndrome of Lowe ORPHA:534; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; Parastremmatic dwarfism ORPHA:2646; Parietal foramina with clavicular hypoplasia ORPHA:251290; Phakomatosis cesiomarmorata ORPHA:79484; Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome ORPHA:477673; Scalp-ear-nipple syndrome ORPHA:2036; Scapuloperoneal spinal muscular atrophy ORPHA:431255; Spondyloepiphyseal dysplasia, Maroteaux type ORPHA:263482; Spondylometaphyseal dysplasia, Kozlowski type ORPHA:93314; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A ORPHA:308386; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Familial avascular necrosis of femoral head ORPHA:86820; Butterfly-shaped pigment dystrophy ORPHA:99001; Retinopathy of prematurity ORPHA:90050; Saethre-Chotzen syndrome ORPHA:794; Atypical glycine encephalopathy ORPHA:289863; Familial progressive cardiac conduction defect ORPHA:871; Infantile glycine encephalopathy ORPHA:289860; Peters anomaly ORPHA:708; Renal agenesis, unilateral ORPHA:93100; Oligodontia ORPHA:99798; Walker-Warburg syndrome ORPHA:899; Total early-onset cataract ORPHA:98994; Simpson-Golabi-Behmel syndrome ORPHA:373; X-linked Alport syndrome-diffuse leiomyomatosis ORPHA:1018; 22q11.2 duplication syndrome ORPHA:1727; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Craniofacial dysplasia-osteopenia syndrome ORPHA:314555; Desmosterolosis ORPHA:35107; Fraser syndrome ORPHA:2052; Frontonasal dysplasia-alopecia-genital anomalies syndrome ORPHA:228390; Helicoid peripapillary chorioretinal degeneration ORPHA:86813; SIX2-related frontonasal dysplasia ORPHA:488437; Ulnar-mammary syndrome ORPHA:3138; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; X-linked Alport syndrome ORPHA:88917; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Lacrimoauriculodentodigital syndrome ORPHA:2363; Rieger anomaly ORPHA:91483; X-linked hypohidrotic ectodermal dysplasia ORPHA:181; BOR syndrome ORPHA:107; Complete atrioventricular septal defect with ventricular hypoplasia ORPHA:99067; Complete atrioventricular septal defect-tetralogy of Fallot ORPHA:99068; Partial atrioventricular septal defect ORPHA:1330; Coloboma of eye lens ORPHA:98943; Coloboma of eyelid ORPHA:98946; Coloboma of macula ORPHA:98945; Coloboma of optic disc ORPHA:98947; Split hand-split foot-deafness syndrome ORPHA:71271; Branchiootic syndrome ORPHA:52429; Enlarged parietal foramina ORPHA:60015; Matthew-Wood syndrome ORPHA:2470; X-linked non-syndromic sensorineural deafness type DFN ORPHA:90625",0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2475924359068358; 0.2567797333165013; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.3977968344535308; 0.4621817429362311; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6196505963261838; 0.6335420546867965; 0.6467006456772204; 0.6873535151929783; 0.6873535151929783; 0.7007232363756918; 0.7007232363756918; 0.7895126437786436; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.795266832401002; 0.795266832401002; 0.8029813443753846; 0.8211968342881582; 0.8778481542696168; 0.8778481542696168; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Human herpesvirus 4 type 2 BARF1; Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Monkeypox virus soluble interferon-gamma receptor-like protein; Monkeypox virus Zaire-96-I-16 B9R (gene: B9R); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Horsepox virus HSPV185 (Interferon gamma receptor IFNGR1); Ectromelia virus ERPV interferon gamma receptor; Human adenovirus 41 E3 31.6K; Human adenovirus 18 CR1-beta protein (gene: E3),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.915880438522078; 0.9197295331382644,In vitro,0.51,Homo sapiens,Homo sapiens
RAB11FIP3,Malignant neoplasm of breast; Breast Carcinoma; Cervix carcinoma; Platelet distribution width measurement; Platelet distribution width result; Neoplasm Metastasis; Platelet Count measurement; Chondrosarcoma; Neural Tube Defects; Coinfection; Acrania,0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8190761496232595,,,Otospondylomegaepiphyseal dysplasia ORPHA:1427; Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Spinocerebellar ataxia type 21 ORPHA:98773; 1p36 deletion syndrome ORPHA:1606; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; Cerebellar-facial-dental syndrome ORPHA:444072; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Steinert myotonic dystrophy ORPHA:273; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Saldino-Mainzer syndrome ORPHA:140969; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome ORPHA:412069; Brachyolmia-amelogenesis imperfecta syndrome ORPHA:2899; Charcot-Marie-Tooth disease type 4F ORPHA:99952; Hereditary hypophosphatemic rickets with hypercalciuria ORPHA:157215; Knobloch syndrome ORPHA:1571; Lethal congenital contracture syndrome type 3 ORPHA:137783; Progressive myoclonic epilepsy type 5 ORPHA:402082; Synaptic congenital myasthenic syndromes ORPHA:98915; Autosomal dominant intermediate Charcot-Marie-Tooth disease type E ORPHA:93114; Interstitial lung disease due to ABCA3 deficiency ORPHA:440402; Perry syndrome ORPHA:178509; Congenital muscular dystrophy with intellectual disability ORPHA:370968; Dentatorubral pallidoluysian atrophy ORPHA:101; Mazabraud syndrome ORPHA:57782; McCune-Albright syndrome ORPHA:562; Monostotic fibrous dysplasia ORPHA:93277; Polyostotic fibrous dysplasia ORPHA:93276; Progressive osseous heteroplasia ORPHA:2762; Pseudohypoparathyroidism type 1A ORPHA:79443; Pseudohypoparathyroidism type 1C ORPHA:79444; Pseudopseudohypoparathyroidism ORPHA:79445; Acute megakaryoblastic leukemia without Down syndrome ORPHA:329469; Neurofibromatosis-Noonan syndrome ORPHA:638; Pseudohypoparathyroidism type 1B ORPHA:94089,0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,Escherichia coli,0.44,Homo sapiens,Homo sapiens
RAB36,,,Leukemia,0.7765582368651238,Orofaciodigital syndrome type 3 ORPHA:2752,0.8922466888454011,Langat virus envelope membrane-associated glycoprotein; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Louping ill virus envelope protein,0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
RAB42,,,,,"Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223",0.1991445465001551; 0.1991445465001551,,,,,,
RAB9A,Hypercholesterolemia; Mycoplasma Infections; Lipoidosis; Streptococcal Infections; Pneumonia,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8098851543361193; 0.834094492023826,,,"Hemolytic anemia due to diphosphoglycerate mutase deficiency ORPHA:714; Hyperbiliverdinemia ORPHA:276405; Aspartylglucosaminuria ORPHA:93; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency ORPHA:404493; X-linked intellectual disability, Nascimento type ORPHA:163956",0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,Human betaherpesvirus 5 regulatory protein IE2 (gene: UL122); Hendra henipavirus phosphoprotein P (gene: P/V/C),0.8999095837312036; 0.8999095837312036,In vitro,0.44;0.59,Homo sapiens,Homo sapiens;chemical synthesis
RALGPS1,Bladder Neoplasm; Malignant neoplasm of urinary bladder,0.4084380369379369; 0.5071083164302358,Schizophrenia; Bladder Neoplasm; Urinary Bladder Cancer,0.7860378120955526; 0.8115918568696846; 0.8115918568696846,"Succinic semialdehyde dehydrogenase deficiency ORPHA:22; Usher syndrome type 1 ORPHA:231169; Gamma-aminobutyric acid transaminase deficiency ORPHA:2066; Monosomy 9q22.3 ORPHA:77301; Schilbach-Rott syndrome ORPHA:2353; AXIN2-related attenuated familial adenomatous polyposis ORPHA:401911; Autosomal dominant focal dystonia, DYT25 type ORPHA:329466; Hyperprolinemia type 1 ORPHA:419; Oligodontia-cancer predisposition syndrome ORPHA:300576; Isolated anencephaly ORPHA:563609; Isolated exencephaly ORPHA:563612; ANK3-related intellectual disability-sleep disturbance syndrome ORPHA:356996; Autism spectrum disorder due to AUTS2 deficiency ORPHA:352490",0.1991445465001551; 0.2661730864557679; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RASA4,Juvenile Myelomonocytic Leukemia; Monosomy; Colorectal cancer metastatic,0.7880542567584415; 0.7880542567584415; 0.8402911822757345,,,Autosomal dominant centronuclear myopathy ORPHA:169189; Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome ORPHA:352662; Craniosynostosis-dental anomalies ORPHA:284149; Glycogen storage disease due to muscle glycogen phosphorylase deficiency ORPHA:368; XYLT1-CDG ORPHA:370930; Autosomal recessive centronuclear myopathy ORPHA:169186; Primary sclerosing cholangitis ORPHA:171; NON RARE IN EUROPE: Berger disease ORPHA:34145; Benign Samaritan congenital myopathy ORPHA:324581; Central core disease ORPHA:597; Congenital multicore myopathy with external ophthalmoplegia ORPHA:98905; Congenital myopathy with myasthenic-like onset ORPHA:424107; Exercise-induced malignant hyperthermia ORPHA:466650; King-Denborough syndrome ORPHA:99741; Moderate multiminicore disease with hand involvement ORPHA:178145,0.0036432528126817; 0.0081550609410495; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RASGRP2,"Prolonged bleeding time; Leukocyte Adhesion Deficiency, Type III; Epistaxis; Frequent nosebleeds; Leukocyte adhesion deficiency type 1; Thrombocytopenia; Blood Platelet Disorders",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8272008757995397,Bleeding Disorder; Platelet-type Bleeding Disorder,0.7765582368651238; 0.8115918568696846,Autosomal dominant centronuclear myopathy ORPHA:169189; Familial isolated pituitary adenoma ORPHA:314777; Autosomal dominant spastic ataxia type 1 ORPHA:251282; LIPE-related familial partial lipodystrophy ORPHA:435660; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; 8p11.2 deletion syndrome ORPHA:251066; Bleeding disorder due to CalDAG-GEFI deficiency ORPHA:420566; Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome ORPHA:352662; Glycogen storage disease due to muscle glycogen phosphorylase deficiency ORPHA:368; Nephrogenic syndrome of inappropriate antidiuresis ORPHA:93606; Osteogenesis imperfecta type 5 ORPHA:216828; Polydactyly of a biphalangeal thumb ORPHA:93339; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; Severe combined immunodeficiency due to CARMIL2 deficiency ORPHA:542301; Severe combined immunodeficiency due to CORO1A deficiency ORPHA:228003; Hereditary sensory and autonomic neuropathy type 4 ORPHA:642; Laron syndrome with immunodeficiency ORPHA:220465; Obesity due to pro-opiomelanocortin deficiency ORPHA:71526; XYLT1-CDG ORPHA:370930; NON RARE IN EUROPE: Vitiligo ORPHA:3435; Aland Islands eye disease ORPHA:178333; T-B+ severe combined immunodeficiency due to JAK3 deficiency ORPHA:35078; Familial medullary thyroid carcinoma ORPHA:99361; Complete hydatidiform mole ORPHA:254688; Hereditary central diabetes insipidus ORPHA:30925; Short stature due to growth hormone qualitative anomaly ORPHA:629; TSH-secreting pituitary adenoma ORPHA:91347; Isolated growth hormone deficiency type II ORPHA:231679; Partial hydatidiform mole ORPHA:254693; Hereditary elliptocytosis ORPHA:288; Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16 ORPHA:98791; Hb Bart's hydrops fetalis ORPHA:163596; Hemoglobin H disease ORPHA:93616; Acute myeloid leukemia with minimal differentiation ORPHA:98832; Isolated growth hormone deficiency type IA ORPHA:231662; Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) ORPHA:98829,0.0036432528126817; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RASL10A,"Glioma; Glioblastoma; Platelet mean volume determination (procedure); Neuroepithelial, Perineurial, and Schwann Cell Neoplasm; Malignant Glioma",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,,,Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Vaccinia virus cowpox A-type inclusion protein,0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
RBM7,Non-Small Cell Lung Carcinoma,0.7765852775619541,Lung Carcinoma,0.8139950454942313,Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; DNAJB6-related  limb-girdle muscular dystrophy D1 ORPHA:34516; Prenatal-onset spinal muscular atrophy with congenital bone fractures ORPHA:486811; Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly ORPHA:402364,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Human adenovirus 21a 100 kDa hexon-assembly associated protein (gene: L4); Human adenovirus 68 100 kDa hexon assembly-associated protein (gene: L4); Human mastadenovirus B hexon assembly protein 100K (gene: L4); Human adenovirus B3 L4 100-kDa protein (gene: L4); Human adenovirus 66 100 kDa hexon assembly-associated protein (gene: L4); Cercopithecine betaherpesvirus 5 tegument protein UL37 (gene: UL47); Human papillomavirus type 43 E2 protein (gene: E2),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
RBX1,"Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Esophageal carcinoma; Vascular Diseases; Esophageal Neoplasms; Liver carcinoma; Malignant neoplasm of esophagus; Malignant Head and Neck Neoplasm; Liver and Intrahepatic Biliary Tract Carcinoma; Neoplasm Metastasis; Squamous cell carcinoma of the head and neck; Malignant neoplasm of liver; Neoplasms; Malignant neoplasm of stomach; Transitional cell carcinoma of bladder; GLOMUVENOUS MALFORMATIONS; Tumor Progression; Renal Cell Carcinoma; Stomach Carcinoma; Crohn Disease; Conventional (Clear Cell) Renal Cell Carcinoma; Toxic Epidermal Necrolysis; Stomach Neoplasms; Drug-Induced Stevens Johnson Syndrome; Mycoplasma-Induced Stevens-Johnson Syndrome; Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum; Carcinoma, Transitional Cell; Stevens-Johnson Syndrome; Von Hippel-Lindau Syndrome; Clear-cell metastatic renal cell carcinoma; Polycythemia",0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8044379824544406; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8368219249856942; 0.8610447277138289; 0.8648405521677974; 0.8989612563669234; 0.8989612563669234,Anxiety Disorder; Stevens-Johnson Syndrome,0.8507213163251659; 0.8611702959552964,DNAJB6-related  limb-girdle muscular dystrophy D1 ORPHA:34516; C11ORF73-related autosomal recessive hypomyelinating leukodystrophy ORPHA:495844; Multiple mitochondrial dysfunctions syndrome type 4 ORPHA:457406,0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61); Parainfluenza virus 5 V protein (gene: V/P); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Orf virus ORF008 ankyrin repeat protein; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Monkeypox virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: B4R); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Yaba-like disease virus 34L protein (gene: 34L); Orf virus ORF126 ankyrin repeat protein; Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Variola virus hypothetical protein (gene: B6R),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9237501457186692; 0.9364561700418303,,,,
RCCD1,Non-Small Cell Lung Carcinoma,0.7765852775619541,Mammary Neoplasms; Marfan Syndrome; Breast Cancer; Breast Carcinoma,0.8165359516083085; 0.8477374749042494; 0.8903630091389316; 0.9398381935810408,Combined oxidative phosphorylation defect type 23 ORPHA:444013,0.5867963421058087,,,,,,
RDH13,"Liver Cirrhosis, Experimental; Drug-Induced Liver Disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced; Necrosis",0.8014900279306119; 0.8523465762428218; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8578473133580928; 0.8648405521677974,,,Pityriasis rubra pilaris ORPHA:2897; Autosomal dominant optic atrophy and cataract ORPHA:67036; 3-methylglutaconic aciduria type 3 ORPHA:67047,0.5867963421058087; 0.8922466888454011; 0.8922466888454011,Ectromelia virus ERPV hydroxysteroid dehydrogenase; Cowpox virus CPXV182 protein (gene: CPXV182 CDS); Vaccinia virus hydroxysteroid dehydrogenase (gene: A44L); Horsepox virus HSPV166 (Rossmann-fold NAD(P)(+)-binding proteins); Vaccinia virus Ankara 3 beta-hydroxysteroid dehydrogenase; Molluscum contagiosum virus subtype 1 MC152R (gene: MC152R); Yaba-like disease virus 133L protein (gene: 133L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
REC8,Malignant neoplasm of prostate; Thyroid carcinoma; Prostatic Neoplasms; Malignant neoplasm of thyroid; melanoma; Congenital absence of germinal epithelium of testes; Gastrointestinal Stromal Sarcoma; Dysmorphic features; Mental Retardation; Intellectual Disability,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8648405521677974; 0.922229272318747; 0.9478210444156088,Prostate Cancer; Melanoma; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238; 0.7765582368651238,"Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955",0.0414176838632111; 0.1991445465001551,,,,,,
REEP6,"Colon Carcinoma; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Malignant tumor of colon; Difficulties with night vision; Night Blindness; Conductive hearing loss; Photophobia; Nystagmus; Anteverted nostril; Glaucoma; Abnormality of the retinal vasculature; Crohn Disease; Photodysphoria; Optic Atrophy; Electroretinogram abnormal; Hyperinsulinism; Reduced visual acuity; Posterior subcapsular cataract; Blindness, Legal; Blindness; Congenital anomaly of testis; Progressive night blindness; Ulcerative Colitis; Broad flat nasal bridge; Nasal bridge wide; Congenital hypoplasia of penis; Atypical scarring of skin; Retinitis Pigmentosa; Mental deficiency; Hypogonadism; Keratoconus; Dull intelligence; Low intelligence; Cataract; Inflammatory Bowel Diseases; Poor school performance; Obesity; Ophthalmoplegia; Lens Opacities; Mental Retardation; Intellectual Disability; Sensorineural Hearing Loss (disorder)",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8213459222602666; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8584283190330553; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8815127642200768; 0.8913141512402477; 0.8989612563669234; 0.900167961295542; 0.9117936912777788; 0.922229272318747; 0.9478210444156088; 0.9520060723130308,Nystagmus; Nyctalopia; Capsular Cataract; Optic Atrophy; Hearing Loss; Mental Retardation; Retinitis Pigmentosa; Hyperinsulinism; Keratoconus; Rod-cone Dystrophy; Glaucoma; Diabetes Mellitus; Hypogonadism; Cataract; Congenital Hypoplasia Of Penis; Obesity,0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.861756360478846; 0.861756360478846; 0.8879896755141929; 0.8903301324869451; 0.8903630091389316; 0.919442421650838; 0.9259420053407031; 0.974502015052702; 0.9832345076528324; 0.9832345076528324,"Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Congenital factor XII deficiency ORPHA:330; F12-related hereditary angioedema with normal C1Inh ORPHA:100054; Hyperammonemia due to N-acetylglutamate synthase deficiency ORPHA:927; Hyperprolinemia type 2 ORPHA:79101; Ollier disease ORPHA:296; Congenital bile acid synthesis defect type 4 ORPHA:79095; Essential fructosuria ORPHA:2056; Hyperimmunoglobulinemia D with periodic fever ORPHA:343; Mevalonic aciduria ORPHA:29; Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib ORPHA:79259; Guanidinoacetate methyltransferase deficiency ORPHA:382; Isolated sedoheptulokinase deficiency ORPHA:440713; Neurological conditions associated with aminoacylase 1 deficiency ORPHA:137754; Maffucci syndrome ORPHA:163634; Retinitis pigmentosa ORPHA:791; Autosomal dominant mitochondrial myopathy with exercise intolerance ORPHA:457050; Lower motor neuron syndrome with late-adult onset ORPHA:276435; Pterin-4 alpha-carbinolamine dehydratase deficiency ORPHA:1578; Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome ORPHA:1369",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RGS11,Ankylosing spondylitis,0.7880542567584415,,,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Lethal congenital contracture syndrome type 3 ORPHA:137783; Interstitial lung disease due to ABCA3 deficiency ORPHA:440402; Hypomyelination neuropathy-arthrogryposis syndrome ORPHA:2680; Paroxysmal non-kinesigenic dyskinesia ORPHA:98810; Permanent neonatal diabetes mellitus ORPHA:99885; CLN13 disease ORPHA:352709; Familial dyskinesia and facial myokymia ORPHA:324588; Familial benign flecked retina ORPHA:363989; Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome ORPHA:251279; Transient neonatal diabetes mellitus ORPHA:99886,0.0155394890951578; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5959529547720634; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RHEBL1,"Leukemia, Myelocytic, Acute; Conventional (Clear Cell) Renal Cell Carcinoma; Childhood Acute Myeloid Leukemia",0.7765852775619541; 0.7880542567584415; 0.8009048756462318,,,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Amish lethal microcephaly ORPHA:99742; Progressive polyneuropathy with bilateral striatal necrosis ORPHA:217396; Combined immunodeficiency with faciooculoskeletal anomalies ORPHA:221139,0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,Langat virus envelope membrane-associated glycoprotein; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R),0.8999095837312036; 0.8999095837312036,,,,
RHPN1,Sclerocystic Ovaries; Polycystic Ovary Syndrome,0.7880542567584415; 0.9174808175273056,Sclerocystic Ovaries; Polycystic Ovary Syndrome,0.7765582368651238; 0.7765582368651238,Congenital myopathy with internal nuclei and atypical cores ORPHA:319160; Autosomal dominant spondylocostal dysostosis ORPHA:1797,0.1991445465001551; 0.8922466888454011,,,,,,
RHPN2,Colorectal Carcinoma; Colorectal Neoplasms; Glioma; Colorectal Cancer; Glioblastoma; Nasopharyngeal Neoplasms; Malignant Glioma; Adenocarcinoma of large intestine,0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649,Nasopharyngeal Carcinoma; Colorectal Adenoma; Colonic Neoplasms; Colorectal Neoplasms; Colorectal Cancer,0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.9510372690456612; 0.9832345076528324,Currarino syndrome ORPHA:1552; Apparent mineralocorticoid excess ORPHA:320; Congenital intrauterine infection-like syndrome ORPHA:1229; Congenital tufting enteropathy ORPHA:92050; Isolated neonatal sclerosing cholangitis ORPHA:480556; Lethal congenital contracture syndrome type 2 ORPHA:137776; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Hereditary folate malabsorption ORPHA:90045; Bartsocas-Papas syndrome ORPHA:1234; CHAND syndrome ORPHA:1401; Leukoencephalopathy with mild cerebellar ataxia and white matter edema ORPHA:363540; Wilson disease ORPHA:905; Xanthinuria type II ORPHA:93602; Microvillus inclusion disease ORPHA:2290; Familial steroid-resistant nephrotic syndrome with adrenal insufficiency ORPHA:506334; Neurodegenerative syndrome due to cerebral folate transport deficiency ORPHA:217382; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; 17q12 microdeletion syndrome ORPHA:261265; Oligodontia ORPHA:99798; Hereditary hypercarotenemia and vitamin A deficiency ORPHA:199285; Hypoplastic tibiae-postaxial polydactyly syndrome ORPHA:3332; Polydactyly of a triphalangeal thumb ORPHA:93336; Radial hemimelia ORPHA:93321; Syndactyly type 4 ORPHA:93405; Triphalangeal thumb-polysyndactyly syndrome ORPHA:2950; Senior-Boichis syndrome ORPHA:84081,0.0155394890951578; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8778481542696168; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Molluscum contagiosum virus subtype 1 MC034L (gene: MC034L),0.8999095837312036,,,,
RIMS3,Rat Adrenal Gland Pheochromocytoma; Autistic Disorder; Schizophrenia,0.7880542567584415; 0.8019075543217649; 0.8067197998685076,Schizophrenia,0.7860378120955526,"Distal 22q11.2 microdeletion syndrome ORPHA:261330; Primary dystonia, DYT4 type ORPHA:98805; Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome ORPHA:1171; Rapid-onset dystonia-parkinsonism ORPHA:71517; Ventriculomegaly-cystic kidney disease ORPHA:443988",0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
RIOK3,Reticulocyte count (procedure); Pancreatic Neoplasm; Neoplasm Metastasis; Adenocarcinoma of pancreas; Virus Diseases; Secondary malignant neoplasm of lung; Measles,0.5071083164302358; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8232134984476662; 0.8938510789776706,,,Hemolytic anemia due to diphosphoglycerate mutase deficiency ORPHA:714; Neutral lipid storage disease with ichthyosis ORPHA:98907; Spinocerebellar ataxia type 18 ORPHA:98771; X-linked centronuclear myopathy ORPHA:596; Noonan syndrome-like disorder with loose anagen hair ORPHA:2701; Autosomal recessive spastic paraplegia type 45 ORPHA:320396; Hemolytic anemia due to pyrimidine 5' nucleotidase deficiency ORPHA:35120,0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Human betaherpesvirus 6B Phosphotransferase (gene: U69)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
RNF24,HIV Infections; Drug-Induced Liver Disease,0.8145035474981049; 0.8523465762428218,,,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Obesity due to CEP19 deficiency ORPHA:397615; Atypical pantothenate kinase-associated neurodegeneration ORPHA:216873; Classic pantothenate kinase-associated neurodegeneration ORPHA:216866; Autosomal dominant macrothrombocytopenia ORPHA:140957,0.0155394890951578; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RNF41,Malignant neoplasm of breast; Breast Carcinoma; Colorectal Carcinoma; Mammary Neoplasms; Glioma; Malignant neoplasm of prostate; Colorectal Cancer; Glioblastoma; Prostate carcinoma; Neoplasm Metastasis; Mental disorders; Vesicular Stomatitis; Malignant neoplasm of large intestine; Tumor Progression; Childhood Glioblastoma; Adult Glioblastoma; Tumor Initiation; Chronic Lymphocytic Leukemia; Mammary Tumorigenesis; Parkinson Disease; Bipolar Disorder; Unipolar Depression; Anxiety Disorders; Seizures; Major Depressive Disorder; Anxiety,0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8190761496232595; 0.8772392350816924; 0.900167961295542; 0.9455834988784428; 0.946564927793026; 0.9478210444156088; 0.9658628445524134; 0.9708740267329932,Mental Depression; Bipolar Disorder,0.8903630091389316; 0.943322675973118,,,Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61),0.8999095837312036; 0.8999095837312036,,,,
RPUSD1,,,,,"Crisponi syndrome ORPHA:1545; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Incontinentia pigmenti ORPHA:464; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Multiple endocrine neoplasia type 1 ORPHA:652; Focal dermal hypoplasia ORPHA:2092; Adrenomyeloneuropathy ORPHA:139399; X-linked cerebral adrenoleukodystrophy ORPHA:139396; CADDS ORPHA:369942; Early myoclonic encephalopathy ORPHA:1935; Galactokinase deficiency ORPHA:79237; Ichthyosis-prematurity syndrome ORPHA:88621; Intellectual disability-strabismus syndrome ORPHA:363528; Lipoyl transferase 2 deficiency ORPHA:447795; MOGS-CDG ORPHA:79330; Spondylo-ocular syndrome ORPHA:85194; TELO2-related intellectual disability-neurodevelopmental disorder ORPHA:488642; Testicular regression syndrome ORPHA:983; 3C syndrome ORPHA:7; Rare isolated myopia ORPHA:98619; Autosomal recessive ataxia due to PEX10 deficiency ORPHA:247815; Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect ORPHA:521411; Autosomal recessive cerebellar ataxia due to STUB1 deficiency ORPHA:412057; Class I glucose-6-phosphate dehydrogenase deficiency ORPHA:466026; Combined oxidative phosphorylation defect type 23 ORPHA:444013; Congenital factor XII deficiency ORPHA:330; F12-related hereditary angioedema with normal C1Inh ORPHA:100054; Familial atypical multiple mole melanoma syndrome ORPHA:404560; Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome ORPHA:363694; Lethal brain and heart developmental defects ORPHA:580933; Lethal neonatal spasticity-epileptic encephalopathy syndrome ORPHA:435845; Melanoma and neural system tumor syndrome ORPHA:252206; NON RARE IN EUROPE: Glucose-6-phosphate-dehydrogenase deficiency ORPHA:362; Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome ORPHA:529665; Ocular anomalies-axonal neuropathy-developmental delay syndrome ORPHA:496790; RFVT2-related riboflavin transporter deficiency ORPHA:572543; THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome ORPHA:363444; Transketolase deficiency ORPHA:488618; Familial melanoma ORPHA:618; 8q24.3 microdeletion syndrome ORPHA:508488; Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome ORPHA:466794; Auditory neuropathy-optic atrophy syndrome ORPHA:542585; Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency ORPHA:308410; B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:75496; Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome ORPHA:330054; DDX41-related hematologic malignancy predisposition syndrome ORPHA:488647; Disseminated superficial actinic porokeratosis ORPHA:79152; GMPPB-related  limb-girdle muscular dystrophy R19 ORPHA:363623; Glycogen storage disease due to aldolase A deficiency ORPHA:57; Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome ORPHA:508498; Larsen-like syndrome, B3GAT3 type ORPHA:284139; Leukocyte adhesion deficiency type II ORPHA:99843; Macrocephaly-developmental delay syndrome ORPHA:397612; Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome ORPHA:363649; Methylmalonic aciduria due to transcobalamin receptor defect ORPHA:280183; NTHL1-related attenuated familial adenomatous polyposis ORPHA:454840; Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome ORPHA:543470; PYCR2-related microcephaly-progressive leukoencephalopathy ORPHA:481152; Pontocerebellar hypoplasia type 8 ORPHA:324569; Spinocerebellar ataxia type 4 ORPHA:98765; Insulinoma ORPHA:97279; MEDNIK syndrome ORPHA:171851; Microlissencephaly ORPHA:1083; Hereditary isolated aplastic anemia ORPHA:397692; Schwannomatosis ORPHA:93921; ALG12-CDG ORPHA:79324; Adenine phosphoribosyltransferase deficiency ORPHA:976; Autosomal recessive spondylometaphyseal dysplasia, Megarbane type ORPHA:401979; B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:536467; Congenital muscular dystrophy with intellectual disability and severe epilepsy ORPHA:329178; Costello syndrome ORPHA:3071; Phakomatosis pigmentokeratotica ORPHA:2874; TARP syndrome ORPHA:2886; Woolly hair nevus ORPHA:79414; Null pituitary adenoma ORPHA:314790; Pituitary gigantism ORPHA:99725; Silent pituitary adenoma ORPHA:314786; Baraitser-Winter cerebrofrontofacial syndrome ORPHA:2995; Acrofacial dysostosis, Rodriguez type ORPHA:1788; COASY protein-associated neurodegeneration ORPHA:397725; D,L-2-hydroxyglutaric aciduria ORPHA:356978; FADD-related immunodeficiency ORPHA:306550; Nager syndrome ORPHA:245; Ogden syndrome ORPHA:276432; Pontocerebellar hypoplasia type 4 ORPHA:166063; Oculootodental syndrome ORPHA:99806",0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6873535151929783; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RRP9,Malignant neoplasm of breast; Disease Exacerbation; Malignant neoplasm of stomach; Hereditary Diffuse Gastric Cancer; Stomach Neoplasms,0.4084380369379369; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8044379824544406,Stomach Neoplasms; Gastric Cancer; Breast Cancer,0.7765582368651238; 0.861756360478846; 0.8903630091389316,"Focal dermal hypoplasia ORPHA:2092; Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Lipoyl transferase 2 deficiency ORPHA:447795; Testicular regression syndrome ORPHA:983; Acute intermittent porphyria ORPHA:79276; Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome ORPHA:363694; Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome ORPHA:502423; Ocular anomalies-axonal neuropathy-developmental delay syndrome ORPHA:496790; RFVT2-related riboflavin transporter deficiency ORPHA:572543; Schnyder corneal dystrophy ORPHA:98967; THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome ORPHA:363444; Transketolase deficiency ORPHA:488618; Familial melanoma ORPHA:618; 8q24.3 microdeletion syndrome ORPHA:508488; Auditory neuropathy-optic atrophy syndrome ORPHA:542585; B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:75496; Bjornstad syndrome ORPHA:123; Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome ORPHA:330054; DDX41-related hematologic malignancy predisposition syndrome ORPHA:488647; Disseminated superficial actinic porokeratosis ORPHA:79152; GRACILE syndrome ORPHA:53693; Glutaryl-CoA dehydrogenase deficiency ORPHA:25; Hyperimmunoglobulinemia D with periodic fever ORPHA:343; Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome ORPHA:508498; Leydig cell hypoplasia due to LHB deficiency ORPHA:325448; MPDU1-CDG ORPHA:79323; Macrocephaly-developmental delay syndrome ORPHA:397612; Methylmalonic aciduria due to transcobalamin receptor defect ORPHA:280183; Mevalonic aciduria ORPHA:29; NTHL1-related attenuated familial adenomatous polyposis ORPHA:454840; Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome ORPHA:543470; Renal tubulopathy-encephalopathy-liver failure syndrome ORPHA:254902; Richieri Costa-Pereira syndrome ORPHA:3102; S-adenosylhomocysteine hydrolase deficiency ORPHA:88618; Spinocerebellar ataxia type 4 ORPHA:98765; Lymphomatoid papulosis ORPHA:98842; Primary cutaneous anaplastic large cell lymphoma ORPHA:300865; Dyskeratosis congenita ORPHA:1775; 3-methylglutaconic aciduria type 8 ORPHA:505208; ALG1-CDG ORPHA:79327; Autosomal recessive cerebelloparenchymal disorder type 3 ORPHA:1170; Autosomal recessive spondylometaphyseal dysplasia, Megarbane type ORPHA:401979; Cerebrocostomandibular syndrome ORPHA:1393; Combined oxidative phosphorylation defect type 17 ORPHA:369913; DK1-CDG ORPHA:91131; Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome ORPHA:404437; HSD10 disease, atypical type ORPHA:85295; HSD10 disease, infantile type ORPHA:391428; HSD10 disease, neonatal type ORPHA:391457; ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement ORPHA:457375; Lenz-Majewski hyperostotic dwarfism ORPHA:2658; MUTYH-related attenuated familial adenomatous polyposis ORPHA:247798; Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome ORPHA:423306; Pontocerebellar hypoplasia type 7 ORPHA:284339; Spinal muscular atrophy with respiratory distress type 2 ORPHA:404521; Spinocerebellar ataxia type 36 ORPHA:276198; Mitochondrial myopathy and sideroblastic anemia ORPHA:2598; Triple A syndrome ORPHA:869; Hyperphosphatasia-intellectual disability syndrome ORPHA:247262; Hoyeraal-Hreidarsson syndrome ORPHA:3322; Perrault syndrome ORPHA:2855; ALG3-CDG ORPHA:79321; Acyl-CoA dehydrogenase 9 deficiency ORPHA:99901; Atypical teratoid rhabdoid tumor ORPHA:99966; Autosomal dominant Charcot-Marie-Tooth disease type 2U ORPHA:397735; Autosomal recessive spastic ataxia with leukoencephalopathy ORPHA:314603; Autosomal recessive spastic paraplegia type 70 ORPHA:401835; Burkitt lymphoma ORPHA:543; CHILD syndrome ORPHA:139; CK syndrome ORPHA:251383; Combined oxidative phosphorylation defect type 25 ORPHA:447954; Combined oxidative phosphorylation defect type 4 ORPHA:254925; DDOST-CDG ORPHA:300536; DPAGT1-CDG ORPHA:86309; Distal hereditary motor neuropathy, Jerash type ORPHA:139552; Glutathione synthetase deficiency with 5-oxoprolinuria ORPHA:289846; Glutathione synthetase deficiency without 5-oxoprolinuria ORPHA:289849; Lethal ataxia with deafness and optic atrophy ORPHA:1187; MEND syndrome ORPHA:401973; MEPAN syndrome ORPHA:508093; NAD(P)HX epimerase deficiency ORPHA:555407; Severe early-onset pulmonary alveolar proteinosis due to MARS deficiency ORPHA:440427; Severe phosphoribosylpyrophosphate synthetase superactivity ORPHA:411543; X-linked Charcot-Marie-Tooth disease type 5 ORPHA:99014; X-linked dominant chondrodysplasia punctata ORPHA:35173; X-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome ORPHA:423479; Autosomal recessive sideroblastic anemia ORPHA:260305; Pyruvate dehydrogenase E1-alpha deficiency ORPHA:79243; Autosomal recessive isolated optic atrophy ORPHA:98676; Congenital or early infantile CACH syndrome ORPHA:157713; Cree leukoencephalopathy ORPHA:99854; Juvenile or adult CACH syndrome ORPHA:157719; Late infantile CACH syndrome ORPHA:157716; Ovarioleukodystrophy ORPHA:99853",0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6873535151929783; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
RWDD2B,,,,,Familial steroid-resistant nephrotic syndrome with sensorineural deafness ORPHA:280406; Pyridoxal phosphate-responsive seizures ORPHA:79096,0.7929682744768703; 0.8922466888454011,,,,,,
S1PR2,"Malignant neoplasm of breast; Reticulocyte count (procedure); Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Vascular Diseases; Glioma; Lymphoma, Non-Hodgkin; Nephroblastoma; Pulmonary Edema; Neoplasm Metastasis; Congenital contractural arachnodactyly; Coronary Arteriosclerosis; Autoimmune Diseases; Limb Deformities, Congenital; Rheumatoid Arthritis; Vascular inflammations; Multiple Sclerosis; Chronic Lymphocytic Leukemia; Neoplasm Invasiveness; DEAFNESS, AUTOSOMAL RECESSIVE (disorder); Fibrosis, Liver; Congenital Abnormality; Cholangiocarcinoma; Diabetes Mellitus, Experimental; Streptozotocin Diabetes; Alloxan Diabetes; Myocardial Ischemia; Chronic Obstructive Airway Disease; Sensorineural hearing loss, bilateral; Heart Diseases; Hematopoietic Neoplasms; Sensorineural Hearing Loss (disorder); Endometriosis",0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8642802827048847; 0.8642802827048847; 0.8642802827048847; 0.8648405521677974; 0.8648405521677974; 0.8942113186235617; 0.8989612563669234; 0.946564927793026; 0.9520060723130308; 0.960644037248553,Non-Syndromic Sensorineural Deafness; Hearing Loss; Deafness; Heart Diseases; Cardiovascular Diseases,0.8115918568696846; 0.8115918568696846; 0.8457525389282121; 0.861756360478846; 0.924275664330454,Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636,0.5867963421058087,,,,,,
SAT2,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Thromboangiitis Obliterans; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Prostatic Intraepithelial Neoplasias; Colorectal Neoplasms; Adenoma; Mammary Neoplasms; Liver carcinoma; Colorectal Cancer; Hepatocarcinogenesis; Nephroblastoma; Epithelioma; melanoma; Intestinal Neoplasms; Malignant neoplasm of stomach; Infection caused by Helicobacter pylori; Stomach Carcinoma; Gastritis, Atrophic; Adenocarcinoma of prostate; Precancerous Conditions; Infection; Atypical Lipoma; Glioblastoma Multiforme; Fibroadenoma",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8026504676141903; 0.8272008757995397; 0.8272008757995397; 0.8342163953428735; 0.8769418330148872,,,Prolidase deficiency ORPHA:742,0.7929682744768703,,,,,,
SBF1P1,,,Leukemia,0.7765582368651238,,,,,,,,
SCAF11,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Malignant neoplasm of ovary; Ovarian Carcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Colon Carcinoma; Malignant tumor of colon; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Liver carcinoma; Hepatocarcinogenesis; cervical cancer; Neoplasm Metastasis; Squamous cell carcinoma of the head and neck; Malignant neoplasm of stomach; Malignant mesothelioma; Mowat-Wilson syndrome; Tumor Progression; Renal Cell Carcinoma; Stomach Carcinoma; Squamous cell carcinoma; Carcinoma, Spindle-Cell; Phyllodes Tumor; Pneumonitis; Liver neoplasms; Adrenocortical carcinoma; Hirschsprung Disease; Pneumonia; Spinal Muscular Atrophy; Congenital Abnormality; Carcinomatosis of peritoneal cavity; Coronary Artery Disease; Squamous cell carcinoma of tongue; Severe mental retardation (I.Q. 20-34); Motor Neuron Disease",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7950434752274518; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8232134984476662; 0.8232134984476662; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8584283190330553; 0.887595340546704; 0.9119978323790848; 0.917543617287358; 0.9614320311453906,Coronary Artery Disease,0.861756360478846,"Alacrimia-choreoathetosis-liver dysfunction syndrome ORPHA:404454; TOR1AIP1-related limb-girdle muscular dystrophy ORPHA:424261; X-linked intellectual disability-short stature-overweight syndrome ORPHA:457240; Familial cerebral cavernous malformation ORPHA:221061; Familial platelet disorder with associated myeloid malignancy ORPHA:71290; Acute promyelocytic leukemia ORPHA:520; Joubert syndrome with Jeune asphyxiating thoracic dystrophy ORPHA:397715; 12q15q21.1 microdeletion syndrome ORPHA:289513; Coffin-Lowry syndrome ORPHA:192; Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome ORPHA:508542; Microcephalic primordial dwarfism, Dauber type ORPHA:319675; Severe combined immunodeficiency due to DCLRE1C deficiency ORPHA:275; Symptomatic form of Coffin-Lowry syndrome in female carriers ORPHA:276630; Xq25 microduplication syndrome ORPHA:521258; Extraskeletal Ewing sarcoma ORPHA:370334; 5p13 microduplication syndrome ORPHA:329802; ALG13-CDG ORPHA:324422; Amyotrophic lateral sclerosis type 4 ORPHA:357043; Autism spectrum disorder-epilepsy-arthrogryposis syndrome ORPHA:370943; Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome ORPHA:444463; Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome ORPHA:457193; Autosomal recessive Charcot-Marie-Tooth disease type 2X ORPHA:466775; Autosomal recessive spastic paraplegia type 11 ORPHA:2822; Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome ORPHA:500150; Cohen syndrome ORPHA:193; Combined immunodeficiency due to MALT1 deficiency ORPHA:397964; Developmental delay-facial dysmorphism syndrome due to MED13L deficiency ORPHA:369891; Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion ORPHA:284169; Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation ORPHA:466950; Fleck corneal dystrophy ORPHA:98970; Fragile X syndrome ORPHA:908; Fragile X-associated tremor/ataxia syndrome ORPHA:93256; Germinoma of the central nervous system ORPHA:91352; Hermansky-Pudlak syndrome with neutropenia ORPHA:183678; Hyperparathyroidism-jaw tumor syndrome ORPHA:99880; Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome ORPHA:2250; Infantile-onset periodic fever-panniculitis-dermatosis syndrome ORPHA:500062; Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome ORPHA:529965; Intellectual disability-hyperkinetic movement-truncal ataxia syndrome ORPHA:369847; Isolated generalized anhidrosis with normal sweat glands ORPHA:468666; Mucolipidosis type II ORPHA:576; Mucolipidosis type III alpha/beta ORPHA:423461; Parathyroid carcinoma ORPHA:143; Primary ciliary dyskinesia-retinitis pigmentosa syndrome ORPHA:247522; Reticulate acropigmentation of Kitamura ORPHA:178307; STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome ORPHA:502434; Spinocerebellar ataxia type 7 ORPHA:94147; Symptomatic form of fragile X syndrome in female carrier ORPHA:449291; TRAPPC11-related  limb-girdle muscular dystrophy R18 ORPHA:369840; X-linked dystonia-parkinsonism ORPHA:53351; X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome ORPHA:480907; Xq27.3q28 duplication syndrome ORPHA:261483; Acquired idiopathic sideroblastic anemia ORPHA:75564; Progressive cerebello-cerebral atrophy ORPHA:247198; Renal-hepatic-pancreatic dysplasia ORPHA:294415; 46,XX ovarian dysgenesis-short stature syndrome ORPHA:444048; Achondrogenesis type 1A ORPHA:93299; Autosomal dominant spastic paraplegia type 42 ORPHA:171863; Autosomal recessive spastic paraplegia type 59 ORPHA:401795; COG5-CDG ORPHA:263487; Congenital cataract-hearing loss-severe developmental delay syndrome ORPHA:300313; Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome ORPHA:397709; Menkes disease ORPHA:565; Mitochondrial DNA depletion syndrome, encephalomyopathic form with variable craniofacial anomalies ORPHA:369897; NPHP3-related Meckel-like syndrome ORPHA:3032; Occipital horn syndrome ORPHA:198; Odontochondrodysplasia ORPHA:166272; Orofaciodigital syndrome type 1 ORPHA:2750; Wrinkly skin syndrome ORPHA:2834; X-linked distal spinal muscular atrophy type 3 ORPHA:139557; Dentin dysplasia type I ORPHA:99789; Hereditary gingival fibromatosis ORPHA:2024",0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7150309491065155; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SEC16A,Malignant neoplasm of breast; Spondylarthritis; Eosinophil count procedure; Eosinophil count result; Parkinson Disease; Squamous cell carcinoma of skin,0.4084380369379369; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8772392350816924; 0.8989612563669234,Skin Carcinoma; Carcinoma,0.861756360478846; 0.9069867032339078,"Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; Lymphangioleiomyomatosis ORPHA:538; Tuberous sclerosis complex ORPHA:805; Early-onset epilepsy-intellectual disability-brain anomalies syndrome ORPHA:488635; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; MYH9-related disease ORPHA:182050; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361; X-linked intellectual disability, Siderius type ORPHA:85287; CAMOS syndrome ORPHA:83472; 17p11.2 microduplication syndrome ORPHA:1713; Dyschromatosis symmetrica hereditaria ORPHA:41; PMP22-RAI1 contiguous gene duplication syndrome ORPHA:477817; Isolated focal cortical dysplasia type IIb ORPHA:269008; Adult hepatocellular carcinoma ORPHA:210159; Idiopathic pulmonary fibrosis ORPHA:2032; Autosomal dominant Charcot-Marie-Tooth disease type 2Z ORPHA:466768; Floating-Harbor syndrome ORPHA:2044; Juvenile Huntington disease ORPHA:248111; Methylmalonic acidemia with homocystinuria, type cblX ORPHA:369962; Isolated focal cortical dysplasia type IIa ORPHA:269001; Schneckenbecken dysplasia ORPHA:3144; Spondylocarpotarsal synostosis ORPHA:3275; 22q11.2 deletion syndrome ORPHA:567; COG7-CDG ORPHA:79333; Infantile-onset X-linked spinal muscular atrophy ORPHA:1145; Kleefstra syndrome due to 9q34 microdeletion ORPHA:96147; Opsismodysplasia ORPHA:2746; Syndromic X-linked intellectual disability due to JARID1C mutation ORPHA:85279; Chronic myeloid leukemia ORPHA:521; Familial advanced sleep-phase syndrome ORPHA:164736; Familial infantile bilateral striatal necrosis ORPHA:225154; Autosomal dominant Charcot-Marie-Tooth disease type 2DD ORPHA:521414; Blepharophimosis-intellectual disability syndrome, MKB type ORPHA:293707; DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome ORPHA:494444; FG syndrome type 1 ORPHA:93932; Jalili syndrome ORPHA:1873; Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome ORPHA:477814; 16q24.3 microdeletion syndrome ORPHA:261250; KBG syndrome ORPHA:2332; Progressive autosomal recessive ataxia-deafness syndrome ORPHA:448251",0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.4491081214880772; 0.5047266821728011; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Papiine alphaherpesvirus 2 helicase-primase helicase subunit (gene: UL5),0.8999095837312036,,,,
SEC23A,"Reduced tensile strength of hair; Fractured hair; Fragile hair; Brittle hair; Rotting teeth; Dental caries; Early tooth exfoliation; Premature tooth loss; Prostate carcinoma; Frontal bossing; Joint laxity; Hyperplasia of supraorbital margins; Hyperplasia of supraorbital ridge; Hypertrophy of supraorbital margins; Hypertrophy of supraorbital ridge; Prominent supraorbital ridges; Large, late-closing fontanelle; Wide bregma sutures; Large bregma sutures; Large fontanelle; Vitamin D measurement; Narrow iliac wings; Narrow thorax; Anteverted nostril; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Strawberry nevus of skin; Rough hair texture; Coarse hair; Hypoplasia of teeth; Increased head circumference; Decreased calcification of skull; Defect of skull ossification; Delayed closure of the soft spot on the skull; Late closure of anterior fontanel; Acquired flat foot; Flatfoot; Degenerative polyarthritis; Thin lips; Big calvaria; Increased size of skull; Decreased width of tooth; Microdontia (disorder); Broad flat nasal bridge; Decreased size of teeth; Nasal bridge wide; Retrusion of upper jaw bones; Decreased projection of maxilla; Deficiency of upper jaw bones; Hypoplasia of the maxilla; Hypotrophic maxilla; Late tooth eruption; Maxillary retrognathia; Convex nasal bridge; Prominent nasal bridge; Osteoarthrosis Deformans; Curvature of spine; Sparse hair; Thin, sparse hair; Cryptorchidism; Acquired scoliosis; Melanoderma (disorder); Hypotrophic malar bone; Malar flattening; Hyperpigmentation; Wide anterior fontanel; Cataract; Smooth philtrum; Short stature; Wide nose; Orbital separation excessive; Abnormal skeletal development; Osteochondrodysplasias; Macrostomia; Long philtrum; Bilateral cataracts (disorder); Thin upper lip vermilion",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7495999465637118; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8168901801930506; 0.8190761496232595; 0.8213459222602666; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8490659121857849; 0.8490659121857849; 0.8578473133580928; 0.8648405521677974; 0.8769418330148872; 0.8774809019744603; 0.8815127642200768; 0.882453254162044; 0.8851456306720444; 0.9039108388826153; 0.9117936912777788; 0.9393256300017014; 0.9459312971127588; 0.9459312971127588; 0.9557184806547836,Hypoplasia Of The Maxilla; Macrocephaly; Hypoplasia Of Teeth; Frontal Bossing; Defect Of Skull Ossification; Strawberry Nevus Of Skin; Skeletal Dysplasia; Osteochondrodysplasia; Osteoarthrosis Deformans; Cryptorchidism; Microdontia; Arthritis; Scoliosis; Dwarfism; High Palate; Macrostomia,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8182883735985873; 0.8210988731657684; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.9046917974656596; 0.924275664330454; 0.9510372690456612; 0.9578111936867284; 0.9832345076528324,"Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223; X-linked intellectual disability, Cabezas type ORPHA:85293; Adult polyglucosan body disease ORPHA:206583; COG6-CGD ORPHA:464443; Craniolenticulosutural dysplasia ORPHA:50814; Glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form ORPHA:308712; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form ORPHA:308684; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form ORPHA:308698; Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form ORPHA:308670; Glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form ORPHA:308655; Glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form ORPHA:308638; Glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form ORPHA:308621; Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome ORPHA:363523; Hypomyelination-congenital cataract syndrome ORPHA:85163; Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency ORPHA:300179; Peters plus syndrome ORPHA:709; Pulmonary venoocclusive disease ORPHA:31837; BRESEK syndrome ORPHA:85284; Chondrodysplasia with joint dislocations, gPAPP type ORPHA:280586; Choroideremia ORPHA:180; Hypopigmentation-punctate palmoplantar keratoderma syndrome ORPHA:324561; Ichthyosis follicularis-alopecia-photophobia syndrome ORPHA:2273; Scott syndrome ORPHA:806; Combined deficiency of factor V and factor VIII ORPHA:35909; PGM1-CDG ORPHA:319646; PGM3-CDG ORPHA:443811; Pulmonary capillary hemangiomatosis ORPHA:199241",0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Cercopithecine betaherpesvirus 5 chemokine vCXCL2 (gene: UL147); Human T-lymphotropic virus 2 Gag-Pro-Pol; Human immunodeficiency virus pol protein (gene: pol); Human immunodeficiency virus 1 integrase (gene: gag-pol); Human immunodeficiency virus 1 Pol (gene: gag-pol); Monkeypox virus ankyrin-like protein; Macaque simian foamy virus Pol (gene: pol),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
SEMA6C,,,,,"Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Otospondylomegaepiphyseal dysplasia ORPHA:1427; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; Spinocerebellar ataxia type 21 ORPHA:98773; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Lymphangioleiomyomatosis ORPHA:538; Tuberous sclerosis complex ORPHA:805; NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Steinert myotonic dystrophy ORPHA:273; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome ORPHA:412069; Charcot-Marie-Tooth disease type 4F ORPHA:99952; Knobloch syndrome ORPHA:1571; Lethal congenital contracture syndrome type 3 ORPHA:137783; Synaptic congenital myasthenic syndromes ORPHA:98915; Congenital insensitivity to pain with severe intellectual disability ORPHA:453510; Telethonin-related  limb-girdle muscular dystrophy R7 ORPHA:34514; Autosomal dominant otospondylomegaepiphyseal dysplasia ORPHA:166100; Gorlin syndrome ORPHA:377; Acetazolamide-responsive myotonia ORPHA:99736; Congenital muscular dystrophy with integrin alpha-7 deficiency ORPHA:34520; Hyperkalemic periodic paralysis ORPHA:682; Myotonia fluctuans ORPHA:99734; Myotonia permanens ORPHA:99735; Paramyotonia congenita of Von Eulenburg ORPHA:684; IMAGe syndrome ORPHA:85173; Autosomal recessive centronuclear myopathy ORPHA:169186; AXIN2-related attenuated familial adenomatous polyposis ORPHA:401911; Glycogen storage disease due to phosphoglycerate mutase deficiency ORPHA:97234; Oligodontia-cancer predisposition syndrome ORPHA:300576; Atrial standstill ORPHA:1344; Fibrochondrogenesis ORPHA:2021; Isolated anencephaly ORPHA:563609; Isolated exencephaly ORPHA:563612; Postsynaptic congenital myasthenic syndromes ORPHA:98913; Acromesomelic dysplasia, Maroteaux type ORPHA:40; Familial mitral valve prolapse ORPHA:741; Tall stature-scoliosis-macrodactyly of the great toes syndrome ORPHA:329191",0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Vaccinia virus Ankara Semaphorin-like protein f1; Cowpox virus CPXV176 protein (gene: CPXV176 CDS); Horsepox virus HSPV161 (semaphorin-like protein; Provisional),0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
SERPINA6,"Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Hepatoblastoma; Endometrial Carcinoma; Chronic Fatigue Syndrome; Lymphoma, Non-Hodgkin; Adrenocorticotropic hormone (ACTH) deficiency (disorder); Liver carcinoma; Increase in blood pressure; Hematological Disease; Granulomatosis with polyangiitis; dowling-degos disease; Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis; Widespread Chronic Pain; Liver Cirrhosis, Experimental; Hyperinsulinism; Liver neoplasms; Liver Cirrhosis; Fibrosis, Liver; Hypotension; Steatohepatitis; Chronic pain; Hypertensive disease; Drug-Induced Liver Disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced; Metabolic Syndrome X; Fatty Liver; Anaplasia; Mental Depression; Pain; Obesity; Fatigue; Lymphoid leukemia; Depressive disorder; Abnormality of metabolism/homeostasis; Hyperthyroidism",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8402911822757345; 0.843190898187174; 0.8474481237156937; 0.8523465762428218; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8578473133580928; 0.8610447277138289; 0.8628363180844141; 0.8648405521677974; 0.8769418330148872; 0.887595340546704; 0.8989612563669234; 0.9029289778792944; 0.9083161862856644; 0.9103315000053974; 0.914995991166204; 0.9557184806547836,Liver Cirrhosis; Hypertension; Fatty Liver; Liver Fibrosis; Mental Depression,0.7765582368651238; 0.7765582368651238; 0.8321692755697452; 0.8903301324869451; 0.8903630091389316,"Alkaptonuria ORPHA:56; Isolated neonatal sclerosing cholangitis ORPHA:480556; Familial hypercholanemia ORPHA:238475; HNF1B-related autosomal dominant tubulointerstitial kidney disease ORPHA:93111; Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome ORPHA:476119; Chromophobe renal cell carcinoma ORPHA:319303; Familial hyperprolactinemia ORPHA:397685; Hyperinsulinism due to HNF1A deficiency ORPHA:324575; Hyperinsulinism due to HNF4A deficiency ORPHA:263455; Alopecia-intellectual disability syndrome ORPHA:2850; Autosomal dominant primary hypomagnesemia with hypocalciuria ORPHA:34528; Bilateral multicystic dysplastic kidney ORPHA:97364; Medullary sponge kidney ORPHA:1309; Renal dysplasia, bilateral ORPHA:93173; Renal dysplasia, unilateral ORPHA:93172; Unilateral multicystic dysplastic kidney ORPHA:97363; Rotor syndrome ORPHA:3111; Aromatic L-amino acid decarboxylase deficiency ORPHA:35708; Dubin-Johnson syndrome ORPHA:234; Progressive familial intrahepatic cholestasis type 5 ORPHA:480476; X-linked Charcot-Marie-Tooth disease type 1 ORPHA:101075; X-linked progressive cerebellar ataxia ORPHA:1175; Phosphoenolpyruvate carboxykinase deficiency ORPHA:2880; Early-onset anterior polar cataract ORPHA:98988; NON RARE IN EUROPE: Heterozygous familial hypercholesterolemia ORPHA:406; Atypical hemolytic uremic syndrome with anti-factor H antibodies ORPHA:93581; C3 glomerulopathy ORPHA:329918; Familial afibrinogenemia ORPHA:98880; Familial dysfibrinogenemia ORPHA:98881; Familial hypodysfibrinogenemia ORPHA:248408; Familial hypofibrinogenemia ORPHA:101041; 3-hydroxy-3-methylglutaryl-CoA synthase deficiency ORPHA:35701; 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency ORPHA:753; AApoAII amyloidosis ORPHA:238269; AFib amyloidosis ORPHA:93562; Brachytelephalangic chondrodysplasia punctata ORPHA:79345; Brain demyelination due to methionine adenosyltransferase deficiency ORPHA:168598; Caroli disease ORPHA:53035; Congenital analbuminemia ORPHA:86816; Congenital bile acid synthesis defect type 2 ORPHA:79303; Congenital factor II deficiency ORPHA:325; Congenital factor XI deficiency ORPHA:329; Congenital high-molecular-weight kininogen deficiency ORPHA:483; Corticosteroid-binding globulin deficiency ORPHA:199247; Dihydropyrimidinuria ORPHA:38874; Familial apolipoprotein A5 deficiency ORPHA:530849; Fanconi-Bickel syndrome ORPHA:2088; Hawkinsinuria ORPHA:2118; Hemolytic anemia due to red cell pyruvate kinase deficiency ORPHA:766; Hereditary thrombophilia due to congenital antithrombin deficiency ORPHA:82; Hyaluronidase deficiency ORPHA:67041; Hypertryptophanemia ORPHA:2224; IRIDA syndrome ORPHA:209981; NON RARE IN EUROPE: Congenital isolated thyroxine-binding globulin deficiency ORPHA:209893; NON RARE IN EUROPE: Familial dysalbuminemic hyperthyroxinemia ORPHA:276271; Severe hereditary thrombophilia due to congenital protein C deficiency ORPHA:745; Thrombocythemia with distal limb defects ORPHA:329319; Tyrosinemia type 2 ORPHA:28378; Tyrosinemia type 3 ORPHA:69723; Urocanic aciduria ORPHA:210128; 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency ORPHA:443087; Cerebral sinovenous thrombosis ORPHA:329217; Cholesterol-ester transfer protein deficiency ORPHA:79506; NON RARE IN EUROPE: Hyperlipoproteinemia type 4 ORPHA:413; Immunodeficiency due to a late component of complement deficiency ORPHA:169150; Homozygous familial hypercholesterolemia ORPHA:391665; Intrahepatic cholestasis of pregnancy ORPHA:69665; Primary Fanconi renotubular syndrome ORPHA:3337; NON RARE IN EUROPE: Non rare thrombophilia ORPHA:64738; 8p23.1 microdeletion syndrome ORPHA:251071; AApoAI amyloidosis ORPHA:93560; ATTRV122I amyloidosis ORPHA:85451; ATTRV30M amyloidosis ORPHA:85447; Abetalipoproteinemia ORPHA:14; Aceruloplasminemia ORPHA:48818; Classic phenylketonuria ORPHA:79254; Congenital alpha2-antiplasmin deficiency ORPHA:79; Congenital deficiency in alpha-fetoprotein ORPHA:168612; Congenital factor VII deficiency ORPHA:327; Formiminoglutamic aciduria ORPHA:51208; GCGR-related hyperglucagonemia ORPHA:438274; Hereditary persistence of alpha-fetoprotein ORPHA:168615; Maternal phenylketonuria ORPHA:2209; Mild hyperphenylalaninemia ORPHA:79651; Mild phenylketonuria ORPHA:79253; Progressive retinal dystrophy due to retinol transport defect ORPHA:352718; Short stature due to primary acid-labile subunit deficiency ORPHA:140941; Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria ORPHA:293284; Generalized arterial calcification of infancy ORPHA:51608; NON RARE IN EUROPE: Non-alcoholic fatty liver disease ORPHA:33271; Pseudoxanthoma elasticum ORPHA:758; Familial papillary or follicular thyroid carcinoma ORPHA:319487; NON RARE IN EUROPE: Familial hypobetalipoproteinemia ORPHA:426",0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SERPINH1,"Malignant neoplasm of breast; Breast Carcinoma; Relative macrocephaly; Laryngeal Squamous Cell Carcinoma; Nephrolithiasis; Adult T-Cell Lymphoma/Leukemia; Triangular face; Nonspecific interstitial pneumonia; Glioma; Skin lesion; Dental caries; Leukemia, T-Cell; Mycosis fungoides/Sezary syndrome NOS; Neuroblastoma; Central neuroblastoma; Neoplasms; Chronic lung disease; Malignant neoplasm of stomach; Joint laxity; Conjunctival scar; Hypercalcemia; Bulging forehead; Prominent forehead; Tumor Progression; Collagen-vascular disease; Coronary artery atheroma; Ocular Cicatricial Pemphigoid; Coronary Arteriosclerosis; Narrow thorax; Stomach Carcinoma; Small midface; Decreased projection of midface; Hypotrophic midface; Midface retrusion; Autoimmune Diseases; Cardiovascular Diseases; Pemphigoid, Benign Mucous Membrane; Generalized joint laxity; Osteogenesis imperfecta type III (disorder); Rheumatoid Arthritis; Broad ribs; Shallow orbits; Endocarditis; Epidermolysis Bullosa Acquisita; Plaque, Amyloid; Generalized osteopenia; Liver Cirrhosis, Experimental; Collapse of vertebra; Compression fracture of vertebral column; Cervical Squamous Cell Carcinoma; Physical Activity Measurement; Dentinogenesis Imperfecta; Senile Plaques; Diabetic foot ulcer; Thin rib; Knee joint valgus deformity; Platyspondyly; High pitched voice; Ulcerative Colitis; Dengue Fever; Scleroderma; Osteopenia; Liver Cirrhosis; Infective endocarditis; Right Middle Cerebral Artery Infarction; Embolic Infarction, Middle Cerebral Artery; Thrombotic Infarction, Middle Cerebral Artery; Left Middle Cerebral Artery Infarction; Middle Cerebral Artery Embolus; Middle Cerebral Artery Syndrome; Middle Cerebral Artery Thrombosis; Fibrosis, Liver; Bacterial Endocarditis; Hip circumference; Micromelia; Tropical Spastic Paraparesis; Systemic Scleroderma; Curvature of spine; Osteogenesis Imperfecta; Cervical Intraepithelial Neoplasia; Blue sclera; Acquired scoliosis; Pyloric Stenosis; Generalized hypotonia; Diabetic Foot; Hypotrophic malar bone; Malar flattening; Squamous cell carcinoma of esophagus; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Hepatitis B, Chronic; Hernia, Inguinal; Narrow forehead; Respiratory Distress Syndrome, Adult; Short stature; Body mass index; Finding of body mass index; High forehead; Middle Cerebral Artery Occlusion; Coronary Artery Disease; Hereditary gingival fibromatosis; Influenza; Complete atrioventricular block; Fibroid Tumor; Body Height; Ischemia; Kaposi Sarcoma; Infarction, Middle Cerebral Artery; Uterine Fibroids; Pheochromocytoma; Hamartoma Syndrome, Multiple",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.8272008757995397; 0.8363138748299018; 0.8363138748299018; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.843190898187174; 0.8490659121857849; 0.8490659121857849; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8745234584149799; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8815127642200768; 0.8867509400747969; 0.8867509400747969; 0.8867509400747969; 0.887595340546704; 0.887595340546704; 0.8980854850210683; 0.9193385822373632; 0.929814249105729; 0.9373358316580888; 0.9390727893210336; 0.9393256300017014; 0.9435654233359168; 0.9514640836642632; 0.9557184806547836; 0.9557184806547836; 0.963331724428282,Nephrolithiasis; Dentinogenesis Imperfecta; Liver Cirrhosis; Macrocephaly; Osteopenia; Osteogenesis Imperfecta; Cerebral Infraction; Cerebral Thrombosis; Coronary Artery Disease; Micromelia; Liver Fibrosis; Respiratory Distress Syndrome; Lung Diseases; Scoliosis; Micrognathism; Dwarfism,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8457525389282121; 0.8566038214826551; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.8903630091389316; 0.8903630091389316; 0.924275664330454; 0.9398381935810408; 0.9510372690456612,"Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Cold-induced sweating syndrome ORPHA:157820; Knobloch syndrome ORPHA:1571; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Early-onset posterior polar cataract ORPHA:98993; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Atypical Werner syndrome ORPHA:79474; Autosomal recessive Emery-Dreifuss muscular dystrophy ORPHA:98855; Autosomal semi-dominant severe lipodystrophic laminopathy ORPHA:280365; Charcot-Marie-Tooth disease type 2B1 ORPHA:98856; Congenital muscular dystrophy due to LMNA mutation ORPHA:157973; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome ORPHA:2229; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation ORPHA:300751; Familial partial lipodystrophy, Dunnigan type ORPHA:2348; Familial partial lipodystrophy, Kobberling type ORPHA:79084; Heart-hand syndrome, Slovenian type ORPHA:168796; LMNA-related cardiocutaneous progeria syndrome ORPHA:363618; Mandibuloacral dysplasia with type A lipodystrophy ORPHA:90153; Muscular dystrophy, Selcen type ORPHA:199340; Quebec platelet disorder ORPHA:220436; Van den Ende-Gupta syndrome ORPHA:2460; Congenital short bowel syndrome ORPHA:2301; Dermatofibrosarcoma protuberans ORPHA:31112; Thyroid ectopia ORPHA:95712; Multiple osteochondromas ORPHA:321; Aarskog-Scott syndrome ORPHA:915; Adult-onset autosomal recessive cerebellar ataxia ORPHA:284289; Autosomal dominant omodysplasia ORPHA:93328; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Multiple epiphyseal dysplasia type 5 ORPHA:93311; Multiple myeloma ORPHA:29073; Pseudohypoaldosteronism type 2B ORPHA:88939; Seizures-scoliosis-macrocephaly syndrome ORPHA:466926; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; 3M syndrome ORPHA:2616; Autosomal recessive Robinow syndrome ORPHA:1507; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Hereditary combined deficiency of vitamin K-dependent clotting factors ORPHA:98434; Hyperostosis corticalis generalisata ORPHA:3416; Truncus arteriosus ORPHA:3384; Acrocallosal syndrome ORPHA:36; Isolated scaphocephaly ORPHA:35093; Myxofibrosarcoma ORPHA:79105; Silver-Russell syndrome due to a point mutation ORPHA:397590; Familial exudative vitreoretinopathy ORPHA:891; Tetralogy of Fallot ORPHA:3303; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; 20p12.3 microdeletion syndrome ORPHA:261295; 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome ORPHA:168563; Arnold-Chiari malformation type I ORPHA:268882; Autosomal dominant Charcot-Marie-Tooth disease type 2C ORPHA:99937; Autosomal dominant brachyolmia ORPHA:93304; Autosomal dominant congenital benign spinal muscular atrophy ORPHA:1216; Autosomal dominant osteopetrosis type 1 ORPHA:2783; Blepharophimosis-ptosis-epicanthus inversus syndrome plus ORPHA:572333; Blepharophimosis-ptosis-epicanthus inversus syndrome type 1 ORPHA:572354; Blepharophimosis-ptosis-epicanthus inversus syndrome type 2 ORPHA:572361; Brachydactyly type B1 ORPHA:572385; Chondrosarcoma ORPHA:55880; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Craniofrontonasal dysplasia ORPHA:1520; Craniosynostosis, Boston type ORPHA:1541; Distal myopathy with posterior leg and anterior hand involvement ORPHA:63273; Endosteal hyperostosis, Worth type ORPHA:2790; Familial digital arthropathy-brachydactyly ORPHA:85169; Kuskokwim syndrome ORPHA:1149; LRP5-related primary osteoporosis ORPHA:498481; Metatropic dysplasia ORPHA:2635; Multiple epiphyseal dysplasia, Al-Gazali type ORPHA:166024; Muscle filaminopathy ORPHA:171445; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; Parastremmatic dwarfism ORPHA:2646; Parietal foramina with clavicular hypoplasia ORPHA:251290; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Scapuloperoneal spinal muscular atrophy ORPHA:431255; Spondyloepiphyseal dysplasia, Maroteaux type ORPHA:263482; Spondylometaphyseal dysplasia, Kozlowski type ORPHA:93314; Familial avascular necrosis of femoral head ORPHA:86820; Hypoplastic left heart syndrome ORPHA:2248; Familial bicuspid aortic valve ORPHA:402075; Familial isolated restrictive cardiomyopathy ORPHA:75249; Osteogenesis imperfecta type 2 ORPHA:216804; Peters anomaly ORPHA:708; Skeletal Ewing sarcoma ORPHA:319; Atrial septal defect, ostium secundum type ORPHA:99103; Autosomal dominant polycystic kidney disease ORPHA:730; Osteogenesis imperfecta type 3 ORPHA:216812; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; Caffey disease ORPHA:1310; Congenital contractural arachnodactyly ORPHA:115; Dyssegmental dysplasia, Silverman-Handmaker type ORPHA:1865; Dystonia-parkinsonism-hypermanganesemia syndrome ORPHA:521406; Fibronectin glomerulopathy ORPHA:84090; Glutaric acidemia type 3 ORPHA:35706; Microphthalmia with brain and digit anomalies ORPHA:139471; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Schwartz-Jampel syndrome ORPHA:800; Vein of Galen aneurysmal malformation ORPHA:1053; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Cole-Carpenter syndrome ORPHA:2050; Hereditary sensory and autonomic neuropathy type 5 ORPHA:64752; Postaxial polydactyly type B ORPHA:93335; Rieger anomaly ORPHA:91483; Spondylometaphyseal dysplasia, 'corner fracture' type ORPHA:93315; BOR syndrome ORPHA:107; Milroy disease ORPHA:79452; Autosomal dominant Robinow syndrome ORPHA:3107; Osteogenesis imperfecta type 4 ORPHA:216820; Classical Ehlers-Danlos syndrome ORPHA:287; Multicentric osteolysis-nodulosis-arthropathy spectrum ORPHA:371428; Ablepharon macrostomia syndrome ORPHA:920; Arterial tortuosity syndrome ORPHA:3342; Barber-Say syndrome ORPHA:1231; Focal facial dermal dysplasia type III ORPHA:1807; High bone mass osteogenesis imperfecta ORPHA:314029; Lymphedema-distichiasis syndrome ORPHA:33001; Ring dermoid of cornea ORPHA:91481; NON RARE IN EUROPE: Ventricular septal defect ORPHA:1480",0.0414176838632111; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2475924359068358; 0.2844858212863536; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6196505963261838; 0.7007232363756918; 0.7895126437786436; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8029813443753846; 0.8029813443753846; 0.8029813443753846; 0.8029813443753846; 0.8105918570729571; 0.8105918570729571; 0.8211968342881582; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Cowpox virus SPI3 or CPXV042 protein (gene: SPI3),0.8999095837312036,,,,
SERTAD2,Carcinogenesis; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Colorectal Carcinoma; Liver carcinoma; Mean Corpuscular Volume (result),0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415,,,Aggressive systemic mastocytosis ORPHA:98850,0.8029813443753846,,,,,,
SGSM2,"Insulin measurement; Diabetes Mellitus, Non-Insulin-Dependent; Obesity",0.7880542567584415; 0.8190761496232595; 0.8989612563669234,,,"Otospondylomegaepiphyseal dysplasia ORPHA:1427; Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Familial lipase maturation factor 1 deficiency ORPHA:535453; 1p36 deletion syndrome ORPHA:1606; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Adult-onset dystonia-parkinsonism ORPHA:199351; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Infantile neuroaxonal dystrophy ORPHA:35069; Lymphangioleiomyomatosis ORPHA:538; Oculocutaneous albinism type 2 ORPHA:79432; Tuberous sclerosis complex ORPHA:805; Cerebellar-facial-dental syndrome ORPHA:444072; DNAJB2-related Charcot-Marie-Tooth disease type 2 ORPHA:443950; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; Young adult-onset distal hereditary motor neuropathy ORPHA:314485; Bilateral perisylvian polymicrogyria ORPHA:98889; Saldino-Mainzer syndrome ORPHA:140969; Birt-Hogg-Dube syndrome ORPHA:122; Brachyolmia-amelogenesis imperfecta syndrome ORPHA:2899; Early-onset epilepsy-intellectual disability-brain anomalies syndrome ORPHA:488635; Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome ORPHA:500144; Familial spontaneous pneumothorax ORPHA:2903; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955; POMT1-related  limb-girdle muscular dystrophy R11 ORPHA:86812; Scheie syndrome ORPHA:93474; TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome ORPHA:562569; Progressive myoclonic epilepsy type 5 ORPHA:402082; Synaptic congenital myasthenic syndromes ORPHA:98915; 17p11.2 microduplication syndrome ORPHA:1713; Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons ORPHA:401964; Distal 16p11.2 microdeletion syndrome ORPHA:261222; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression ORPHA:391316; PMP22-RAI1 contiguous gene duplication syndrome ORPHA:477817; Proximal 16p11.2 microdeletion syndrome ORPHA:261197; Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency ORPHA:329249; Deafness-enamel hypoplasia-nail defects syndrome ORPHA:3220; Isolated focal cortical dysplasia type IIb ORPHA:269008; Congenital muscular dystrophy with intellectual disability ORPHA:370968; Uveal melanoma ORPHA:39044; Adult hepatocellular carcinoma ORPHA:210159; COG1-CDG ORPHA:263508; Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome ORPHA:459061; Isolated focal cortical dysplasia type IIa ORPHA:269001; Primary lateral sclerosis ORPHA:35689; SYNGAP1-related developmental and epileptic encephalopathy ORPHA:544254; Spastic paraplegia type 7 ORPHA:99013; Familial advanced sleep-phase syndrome ORPHA:164736; Pseudohypoparathyroidism type 1B ORPHA:94089",0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.3977968344535308; 0.4491081214880772; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
SH2B2,"Malignant neoplasm of prostate; Prostate carcinoma; Hyperhomocysteinemia; Lupus Erythematosus, Systemic; Chondrosarcoma; Autoimmune Diseases; Antiphospholipid Syndrome; Autoimmune Primary Adrenal Insufficiency; Cryopyrin-Associated Periodic Syndromes; Systemic Inflammatory Response Syndrome; Addison Disease; Thrombophilia; Respiratory Distress Syndrome, Adult; Pain; Blood Coagulation Disorders",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8232134984476662; 0.8769418330148872; 0.887595340546704; 0.9307095582633488,,,Autosomal dominant centronuclear myopathy ORPHA:169189; Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Idiopathic CD4 lymphocytopenia ORPHA:228000; Polydactyly of a biphalangeal thumb ORPHA:93339; Native American myopathy ORPHA:168572,0.0036432528126817; 0.0144185025972157; 0.0155394890951578; 0.3832844616405875; 0.8922466888454011,Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Vaccinia virus Ser/Thr kinase (gene: F10L); Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Hendra henipavirus phosphoprotein P (gene: P/V/C); Nipah henipavirus P phosphoprotein; Monkeypox virus ankyrin-like protein; Enterovirus B genome polyportein; Enterovirus B73 full_polyprotein 1..2188; Enterovirus B106 full_polyprotein 1..2192; Echovirus E5 full_polyprotein 1..2196; Echovirus E9 full_polyprotein 1..2203; Echovirus E30 full_polyprotein 1..2194; Coxsackievirus B6 full_polyprotein 1..2184; Vaccinia virus Ankara serine proteinase inhibitor / SPI-2 f2,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.903486026792944; 0.9057542447893764; 0.9359472799230178; 0.9364561700418303; 0.9366403811337995,,,,
SH2B3,"Malignant neoplasm of breast; Reticulocyte count (procedure); Breast Carcinoma; Malignant neoplasm of ovary; leukemia; Ovarian Carcinoma; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Colorectal Carcinoma; Acrocyanosis; Leukemia, Myelocytic, Acute; Paresthesia; MYELODYSPLASTIC SYNDROME; Arterial thrombosis; Leukemogenesis; Endometrial Neoplasms; Uric acid measurement (procedure); Endometrial Carcinoma; Malignant neoplasm of lung; Colorectal Cancer; Primary malignant neoplasm of lung; Carcinoma of lung; Red Blood Cell Count measurement; Platelet Count measurement; Serum total cholesterol measurement; Biliary cirrhosis; Monocyte count procedure; Monocyte count result; Hematologic Neoplasms; Juvenile Myelomonocytic Leukemia; Eosinophil count procedure; Eosinophil count result; Libman-Sacks Disease; Beta-2-microglobulin measurement; Hematocrit increased; Processing speed; MYELOPROLIFERATIVE SYNDROME, TRANSIENT; Hemoglobin increased; Increased megakaryocyte count; Increase in blood pressure; Mean corpuscular hemoglobin concentration determination; Prolonged bleeding time; Lupus Erythematosus, Systemic; Hematological Disease; Thrombocytosis, Autosomal Dominant; Coronary Arteriosclerosis; Alzheimer's Disease; Platelet hematocrit measurement; Acute lymphocytic leukemia; Abnormal platelet morphology; Amaurosis Fugax; Impaired platelet aggregation; Autoimmune Diseases; Cardiovascular Diseases; Polycythemia Vera; Solid Neoplasm; Rheumatoid Arthritis; Antiphospholipid Syndrome; Diabetes; Diabetes Mellitus; Fibrinogen assay; Abnormality of the skeletal system; Ankylosing spondylitis; Acute Cerebrovascular Accidents; Increased number of platelets; Crohn Disease; Global developmental delay; Thrombocytosis; Myeloid Leukemia, Chronic; Hemoglobin measurement; Bacterial Infections; Vascular inflammations; Chronic myeloproliferative disorder; Juvenile arthritis; Thrombocythemia, Essential; Vitiligo; Psoriasis; Myocardial Infarction; Neutrophil count (procedure); Diabetes, Autoimmune; Familial erythrocytosis; Systolic Pressure; Blast Phase; Myeloproliferative disease; Diabetes Mellitus, Insulin-Dependent; Brain hemorrhage; Ulcerative Colitis; Precursor Cell Lymphoblastic Leukemia Lymphoma; Blood basophil count (lab test); Primary sclerosing cholangitis; Granulocyte count; Inflammation; Headache; Cholangitis, Sclerosing; Venous Thrombosis; Splenomegaly; Amyotrophic Lateral Sclerosis; Immune System Diseases; Transient Cerebral Ischemia; Celiac Disease; Hematocrit procedure; Hypertensive disease; Dyspnea on exertion; Dizziness; Low density lipoprotein cholesterol measurement; Cerebrovascular accident; Vertigo; Primary Myelofibrosis; Tetralogy of Fallot; Malignant neoplasm of endometrium; Eosinophilia; Uterine Corpus Cancer; Inflammatory Bowel Diseases; Cerebral Hemorrhage; Coronary Artery Disease; nervous system disorder; Systemic arterial pressure; Blood Pressure; Blood pressure finding; Chest Pain; Fatigue; Coronary heart disease; Eosinophilic disorder; Myelofibrosis; White Blood Cell Count procedure; Lymphocyte Count measurement; Graves Disease; Diastolic blood pressure; Hepatitis, Autoimmune; Thyroid Diseases; Hypothyroidism; Developmental delay (disorder)",0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.7945683314244791; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8114747041691183; 0.8138488881521341; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8212681436603975; 0.8270909867833504; 0.8337767145465158; 0.8363138748299018; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8554819098734854; 0.8642802827048847; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.8769418330148872; 0.8771562273432176; 0.8815127642200768; 0.882453254162044; 0.887595340546704; 0.8959157818691486; 0.900167961295542; 0.900167961295542; 0.900167961295542; 0.900167961295542; 0.9029289778792944; 0.9119978323790848; 0.9193385822373632; 0.9325666311629114; 0.9431511078237256; 0.9473064300361868; 0.94939825643792; 0.9505280654948344; 0.9571401094099016; 0.9639249377588224; 0.9816840072553962; 0.9874278479946328,Gout; Gouty Arthritis; Stroke; Hematologic Neoplasms; Ovarian Neoplasm; Ovarian Endometrioid Carcinoma; Sclerosing Cholangitis; Prostate Cancer; Ovarian Serous Adenocarcinoma; Nonbacterial Verrucal Endocardiosis; Myelomonocytic Leukemia; Lymphocytic Leukemia; Polycythemia Vera; Vascular Diseases; Myelodysplastic Syndrome; Vitiligo; Ischemic Stroke; Hypertension; Thrombocythemia; Myelofibrosis; Leukemia; Erythrocytosis; Lymphoblastic Leukemia; Coronary Arteriosclerosis; Endometrial Neoplasms; Autoimmune Hepatitis; Myelodysplasia; Endometrial Carcinoma; Lung Carcinoma; Colonic Neoplasms; Thrombocytosis; Myeloproliferative Disorder; Myocardial Infarction; Inflammatory Bowel Disease; Blood Coagulation Disorders; Brittle Diabetes Mellitus; Coronary Artery Disease; Ulcerative Colitis; Coronary Heart Disease; Autoimmune Diabetes; Hypothyroidism; Cholangitis; Transient Ischemic Attack; Ankylosing Spondylitis; Immune System Diseases; Crohn Disease; Lupus Erythematosus; Diabetes Mellitus; Cardiovascular Diseases; Celiac Disease; Lung Adenocarcinoma; Breast Carcinoma; Colorectal Neoplasms; Psoriasis; Tetralogy Of Fallot; Autoimmune Diseases; Colorectal Cancer,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8139950454942313; 0.8210988731657684; 0.8457525389282121; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8879896755141929; 0.8885757656973042; 0.8903301324869451; 0.8903301324869451; 0.8903301324869451; 0.8903630091389316; 0.9145387439550552; 0.919442421650838; 0.924275664330454; 0.9246807042779188; 0.9350723667380212; 0.9398381935810408; 0.9510372690456612; 0.974502015052702; 0.9832345076528324; 0.9832345076528324; 0.9832345076528324,"Camurati-Engelmann disease ORPHA:1328; Infantile inflammatory bowel disease with neurological involvement ORPHA:565788; Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223; Growth retardation-mild developmental delay-chronic hepatitis syndrome ORPHA:391366; Nodular fasciitis ORPHA:477742; Fetal and neonatal alloimmune thrombocytopenia ORPHA:853; Autosomal dominant Charcot-Marie-Tooth disease type 2I ORPHA:99942; Autosomal dominant Charcot-Marie-Tooth disease type 2J ORPHA:99943; Autosomal dominant intermediate Charcot-Marie-Tooth disease type D ORPHA:100046; Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain ORPHA:324585; Charcot-Marie-Tooth disease type 1B ORPHA:101082; Essential thrombocythemia ORPHA:3318; Bleeding diathesis due to thromboxane synthesis deficiency ORPHA:220443; Combined immunodeficiency due to Moesin deficiency ORPHA:504530; Infantile systemic hyalinosis ORPHA:2176; Juvenile hyaline fibromatosis ORPHA:2028; Autosomal dominant macrothrombocytopenia ORPHA:140957",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SH2D3C,Malignant neoplasm of breast; Breast Carcinoma; Mammary Neoplasms; Neuroblastoma; Central neuroblastoma; Diarrhea; Rotavirus Infections,0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8642802827048847,,,Autosomal dominant centronuclear myopathy ORPHA:169189; Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Familial isolated pituitary adenoma ORPHA:314777; LIPE-related familial partial lipodystrophy ORPHA:435660; Acute encephalopathy with biphasic seizures and late reduced diffusion ORPHA:363549; Bleeding disorder due to CalDAG-GEFI deficiency ORPHA:420566; Congenital non-communicating hydrocephalus ORPHA:269510; Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome ORPHA:352662; Glycogen storage disease due to muscle glycogen phosphorylase deficiency ORPHA:368; Nephrogenic syndrome of inappropriate antidiuresis ORPHA:93606; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; Severe combined immunodeficiency due to CARMIL2 deficiency ORPHA:542301; Severe combined immunodeficiency due to CORO1A deficiency ORPHA:228003; Spinocerebellar ataxia type 40 ORPHA:423275; Diencephalic-mesencephalic junction dysplasia ORPHA:319192; Hereditary sensory and autonomic neuropathy type 4 ORPHA:642; Laron syndrome with immunodeficiency ORPHA:220465; Obesity due to pro-opiomelanocortin deficiency ORPHA:71526; WHIM syndrome ORPHA:51636; XYLT1-CDG ORPHA:370930; NON RARE IN EUROPE: Vitiligo ORPHA:3435; Autosomal dominant Charcot-Marie-Tooth disease type 2I ORPHA:99942; Autosomal dominant Charcot-Marie-Tooth disease type 2J ORPHA:99943; Autosomal dominant intermediate Charcot-Marie-Tooth disease type D ORPHA:100046; Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain ORPHA:324585; Charcot-Marie-Tooth disease type 1B ORPHA:101082; Antenatal Bartter syndrome ORPHA:93604; Familial medullary thyroid carcinoma ORPHA:99361; Autosomal agammaglobulinemia ORPHA:33110; TSH-secreting pituitary adenoma ORPHA:91347; Hereditary elliptocytosis ORPHA:288; Precursor B-cell acute lymphoblastic leukemia ORPHA:99860,0.0036432528126817; 0.0081550609410495; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SH3PXD2A,"Cervix carcinoma; Malignant tumor of cervix; cervical cancer; Neoplasm Metastasis; Eclampsia; Congenital chromosomal disease; Adenocarcinoma of prostate; Acute Cerebrovascular Accidents; Neurofibrosarcoma; Schizophrenia; Adenocarcinoma of lung (disorder); familial atrial fibrillation; Persistent atrial fibrillation; Malignant Peripheral Nerve Sheath Tumor; Alzheimer Disease, Late Onset; Cerebrovascular accident; Atrial Fibrillation; Paroxysmal atrial fibrillation",0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8067197998685076; 0.8098851543361193; 0.8168901801930506; 0.8168901801930506; 0.8272008757995397; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8815127642200768,Stroke; Neurofibrosarcoma; Schizophrenia; Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Rheumatoid Arthritis; Asthma,0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.8115918568696846; 0.8115918568696846; 0.9251646147729308; 0.9832345076528324,"GNE myopathy ORPHA:602; Sialuria ORPHA:3166; Shprintzen-Goldberg syndrome ORPHA:2462; Atrophoderma vermiculata ORPHA:79100; Craniometaphyseal dysplasia ORPHA:1522; Duchenne muscular dystrophy ORPHA:98896; Familial calcium pyrophosphate deposition ORPHA:1416; Malignant peripheral nerve sheath tumor ORPHA:3148; Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome ORPHA:83473; Acrofacial dysostosis, Weyers type ORPHA:952",0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus nef protein (gene: nef); Human immunodeficiency virus 1 Nef (gene: nef); Human immunodeficiency virus 2 nef protein; Human T-cell leukemia virus type I p15NC-p14PR-p95RT/IN (gene: gag-pro-pol); Human T-cell leukemia virus type I Pr gag-pro-pol (gene: gag-pro-pol),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9224369592826992; 0.9224878266317492,,,,
SHF,Neoplasm Metastasis; Neuroblastoma; Central neuroblastoma,0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,,,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Monkeypox virus ser/thr kinase; Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Cowpox virus CPXV168 protein (gene: CPXV168 CDS); Hendra henipavirus phosphoprotein P (gene: P/V/C); Nipah henipavirus P phosphoprotein; Monkeypox virus bifunctional EEV membrane phosphoglycoprotein/associates with A36R; Monkeypox virus Zaire-96-I-16 A35R (gene: A35R); Monkeypox virus ankyrin-like protein; Lake Victoria marburgvirus - Leiden glycoprotein (gene: GP)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
SIRPB1,Reticulosarcoma; Schizophrenia; Impulsive character (finding),0.7765852775619541; 0.8067197998685076; 0.8402911822757345,Schizophrenia,0.7860378120955526,Cleidocranial dysplasia ORPHA:1452; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504; Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome ORPHA:480864; Growth retardation-mild developmental delay-chronic hepatitis syndrome ORPHA:391366; 1p21.3 microdeletion syndrome ORPHA:293948; Cherubism ORPHA:184; Dihydropyrimidine dehydrogenase deficiency ORPHA:1675; Essential thrombocythemia ORPHA:3318; Attenuated Chediak-Higashi syndrome ORPHA:352723; Autosomal dominant deafness-onychodystrophy syndrome ORPHA:79499; Autosomal dominant vitreoretinochoroidopathy ORPHA:3086; Autosomal recessive bestrophinopathy ORPHA:139455; Best vitelliform macular dystrophy ORPHA:1243; Chediak-Higashi syndrome ORPHA:167; Corpus callosum agenesis-neuronopathy syndrome ORPHA:1496; Diaphragmatic hernia-short bowel-asplenia syndrome ORPHA:527468; Histidinemia ORPHA:2157; MRCS syndrome ORPHA:263347; Polycythemia vera ORPHA:729; Susceptibility to localized juvenile periodontitis ORPHA:447740; Intermittent hydrarthrosis ORPHA:329967; Jervell and Lange-Nielsen syndrome ORPHA:90647; Primary myelofibrosis ORPHA:824; Hereditary clear cell renal cell carcinoma ORPHA:422526; Atypical chronic myeloid leukemia ORPHA:98824; Autosomal recessive severe congenital neutropenia due to CSF3R deficiency ORPHA:420702; Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency ORPHA:420699; Beta-mannosidosis ORPHA:118; CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome ORPHA:566067; CINCA syndrome ORPHA:1451; Childhood encephalopathy due to thiamine pyrophosphokinase deficiency ORPHA:293955; Chronic neutrophilic leukemia ORPHA:86829; Cyclic neutropenia ORPHA:2686; Familial Mediterranean fever ORPHA:342; Familial cold urticaria ORPHA:47045; Ghosal hematodiaphyseal dysplasia ORPHA:1802; Hereditary neutrophilia ORPHA:279943; Muckle-Wells syndrome ORPHA:575; Myeloperoxidase deficiency ORPHA:2587; NLRC4-related familial cold autoinflammatory syndrome ORPHA:576349; NLRP12-associated hereditary periodic fever syndrome ORPHA:247868; Periodic fever-infantile enterocolitis-autoinflammatory syndrome ORPHA:436166; Properdin deficiency ORPHA:2966; Sweet syndrome ORPHA:3243; Tuberculosis ORPHA:3389; Vibratory urticaria ORPHA:493342; Microcephaly-polymicrogyria-corpus callosum agenesis syndrome ORPHA:171703,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Molluscum contagiosum virus subtype 1 MC069R (gene: MC069R); Ntaya virus full_polyprotein 1..3427; Ilheus virus full_polyprotein 1..3424; Adeno-associated virus 3B capsid protein VP1; Vaccinia virus IMV membrane protein (gene: L1R); Vaccinia virus Ankara myristylated IMV virion protein; Variola virus hypothetical protein (gene: M1R); Cowpox virus CPXV099 protein (gene: CPXV099 CDS); Monkeypox virus myristylprotein; Monkeypox virus Zaire-96-I-16 M1R (gene: M1R); Ectromelia virus ERPV IMV myristylated membrane protein; Horsepox virus HSPV089 (Lipid membrane protein); Yaba monkey tumor virus 60R; Yaba-like disease virus 60R protein (gene: 60R); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) hemagglutinin (gene: HA); Yaba-like disease virus 2L protein (gene: 2L); Human orthopneumovirus fusion protein (gene: F); Human betaherpesvirus 6B glycoprotein (gene: U85); Hepatitis B virus pre-capsid protein (gene: C); Influenza A virus (A/Northern Territory/60/1968(H3N2)) HA2 (gene: HA); HBV genotype D HBeAg (gene: PreC/C); Yaba monkey tumor virus MHC-like TNF binding protein; Influenza A virus (A/Korea/426/1968(H2N2)) HA1 (gene: HA); Influenza A virus (A/New York/392/2004(H3N2)) HA1 (gene: HA); HBV genotype H PC/C protein (gene: PC/C); HBV genotype B preC/C protein (gene: preC/C); HBV genotype C core protein (gene: C); HBV genotype C HBeAg (gene: PreC/C); HBV recombinant C/G HBeAg (gene: preC/C); Hepatitis B virus capsid protein (gene: C); HBV recombinant B/C HBc protein (gene: C); HBV genotype C preC/C protein (gene: preC/C); Macacine alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Influenza A virus (A/New York/599/1996(H3N2)) HA1 (gene: HA); HBV genotype C HBc protein (gene: C); Human gammaherpesvirus 4 BARF1 protein (gene: BARF1); Influenza A virus (A/Korea/426/1968(H2N2)) hemagglutinin (gene: HA); Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Adeno-associated virus - 2 major coat protein VP3; Adeno-associated virus - 2 major coat protein VP2; HBV genotype B C protein (gene: C); Influenza A virus (A/Northern Territory/60/1968(H3N2)) HA1 (gene: HA); West Nile virus SA93/01 envelope protein; West Nile virus SPU116/89 envelope protein; Human alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Influenza A virus (A/New York/599/1996(H3N2)) hemagglutinin (gene: HA); West Nile virus lineage 1 envelope protein E (gene: flavivirus polyprotein); HBV genotype C C protein (gene: C); Adeno-associated virus - 2 major coat protein VP1; Adeno-associated virus - 3 capsid protein; Influenza A virus (A/New York/392/2004(H3N2)) hemagglutinin (gene: HA); West Nile virus SA381/00 envelope protein; Human herpesvirus 4 type 2 BARF1; Influenza A virus (A/New York/602/1996(H3N2)) hemagglutinin (gene: HA); Murray Valley encephalitis virus envelope protein E; West Nile virus H442 envelope protein; Influenza A virus (A/Puerto Rico/8/1934(H1N1)) haemagglutinin (gene: HA); Human betaherpesvirus 7 membrane glycoprotein UL119 (gene: U85); Influenza A virus (A/Northern Territory/60/1968(H3N2)) hemagglutinin (gene: HA); Influenza A virus (A/Shanghai/02/2013(H7N9)) neuraminidase (gene: NA); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Adeno-associated virus - 6 capsid protein VP1; Orf virus ORF047 putative myristylated IMV envelope protein; Rotavirus C outer capsid protein (gene: VP7); Macacine alphaherpesvirus 1 envelope glycoprotein D (gene: US6); Dengue virus full_polyprotein 1..3387; Rotavirus A VP7 (gene: VP7); West Nile virus lineage 1 excised_polyprotein 1..787 (gene: flavivirus polyprotein); Papiine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Hendra henipavirus phosphoprotein P (gene: P/V/C); Dengue virus 4 envelope protein E (gene: flavivirus polyprotein); Cercopithecine alphaherpesvirus 2 envelope glycoprotein D (gene: US6); Influenza A virus (A/New York/602/1996(H3N2)) HA1 (gene: HA); Human betaherpesvirus 5 membrane protein UL6 (gene: UL6); Influenza A virus (A/Hong Kong/1073/99(H9N2)) neuraminidase (gene: na); Monkeypox virus Zaire-96-I-16 E8L (gene: E8L); Influenza A virus (A/Northern Territory/60/1968(H3N2)) neuraminidase (gene: NA); Monkeypox virus IMV membrane protein; Ectromelia virus ERPV hemagglutinin; Vaccinia virus IMV membrane protein (gene: D8L); Influenza A virus (A/New York/392/2004(H3N2)) neuraminidase (gene: NA); Influenza A virus (A/New York/599/1996(H3N2)) neuraminidase (gene: NA); Influenza A virus (A/New York/602/1996(H3N2)) neuraminidase (gene: NA); Murray Valley encephalitis virus prodexcised_polyprotein 1..793; Human betaherpesvirus 5 envelope glycoprotein UL4 (gene: UL4); Human alphaherpesvirus 1 envelope glycoprotein C (gene: UL44); Influenza A virus (A/Korea/426/1968(H2N2)) neuraminidase (gene: NA); Horsepox virus HSPV114 (Eukaryotic-type carbonic anhydrase); Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Cowpox virus CPXV194 protein (gene: CPXV194 CDS); Human betaherpesvirus 6 U85, OX-2 homologue (gene: U85); Human betaherpesvirus 6A membrane glycoprotein UL119 (gene: U85); Cowpox virus CPXV125 protein (gene: CPV125 CDS); Ectromelia virus ERPV carbonic anhydrase; Vaccinia virus Ankara IMV chondroitin-binding membrane protein; Variola virus hypothetical protein (gene: J9R); Human mastadenovirus A E3 CR1-beta1; Variola virus hypothetical protein (gene: F8L); Horsepox virus HSPV177 (Immunoglobulin like); Human adenovirus 61 E3 CR1 beta; Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 41 E3 31.6K; Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Molluscum contagiosum virus subtype 1 MC080R (gene: MC080R); Vaccinia virus Ankara Haemagglutinin",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.915880438522078; 0.9197295331382644; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676,,,,
SLC16A3,Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Pancreatic carcinoma; Cervix carcinoma; Carcinoma breast stage IV; Glioma; Malignant neoplasm of prostate; Liver carcinoma; Rhabdomyosarcoma; Glioblastoma; Prostate carcinoma; Astrocytoma; Neoplasm Metastasis; Van der Woude syndrome; Multiple Myeloma; Neoplasms; Tumor Progression; Adenocarcinoma of colon; Renal Cell Carcinoma; Tumor Initiation; Arteriosclerosis; Atherosclerosis; Squamous cell carcinoma; Rheumatoid Arthritis; Small cell carcinoma of lung; Conventional (Clear Cell) Renal Cell Carcinoma; Luminal A Breast Carcinoma; Degenerative polyarthritis; West Nile viral infection; Patent ductus arteriosus; Renal carcinoma; Malignant neoplasm of kidney; Disseminated Malignant Neoplasm; Malignant Pleural Mesothelioma; Addictive Behavior; Arthritis,0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8101097852323003; 0.8402911822757345; 0.8648405521677974; 0.8818220091065441; 0.8867509400747969; 0.8935933996254593; 0.9015731019095328; 0.9431511078237256,Stomach Neoplasms; Mammary Neoplasms; Marfan Syndrome; Gastric Cancer; Breast Cancer; Breast Carcinoma,0.7765582368651238; 0.8165359516083085; 0.8477374749042494; 0.861756360478846; 0.8903630091389316; 0.9398381935810408,"Crisponi syndrome ORPHA:1545; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; Mucopolysaccharidosis type 4A ORPHA:309297; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; B4GALT1-CDG ORPHA:79332; Niemann-Pick disease type C, adult neurologic onset ORPHA:216986; Niemann-Pick disease type C, juvenile neurologic onset ORPHA:216981; Niemann-Pick disease type C, late infantile neurologic onset ORPHA:216978; Niemann-Pick disease type C, severe early infantile neurologic onset ORPHA:216975; Niemann-Pick disease type C, severe perinatal form ORPHA:216972; Epithelial basement membrane dystrophy ORPHA:98956; Granular corneal dystrophy type I ORPHA:98962; Granular corneal dystrophy type II ORPHA:98963; Lattice corneal dystrophy type I ORPHA:98964; NON RARE IN EUROPE: Hemochromatosis type 1 ORPHA:139498; Reis-Bucklers corneal dystrophy ORPHA:98961; Sporadic porphyria cutanea tarda ORPHA:443057; Symptomatic form of hemochromatosis type 1 ORPHA:465508; Thiel-Behnke corneal dystrophy ORPHA:98960",0.0155394890951578; 0.0414176838632111; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,,,,,,
SLC19A2,"Malignant neoplasm of breast; Breast Carcinoma; Paresthesia; Sideroblastic anemia; Anemia, Megaloblastic; Hoarseness; Cone-Rod Dystrophies; Pallor; Diarrhea; Wernicke-Korsakoff Syndrome; Thiamine Deficiency; Nystagmus; Abnormal vision; Anorexia; Neural Tube Defects; Diabetes; Diabetes Mellitus; Cone dystrophy; Retinal Degeneration; Myeloid Leukemia, Chronic; Optic Atrophy; Vitamin B 12 Deficiency; Liver Cirrhosis, Experimental; Decreased platelet count; Thrombocytopenia; Kidney Failure, Chronic; Activated Protein C Resistance; Diabetes Mellitus, Non-Insulin-Dependent; Headache; Neonatal diabetes mellitus; Retinitis Pigmentosa; Abnormal urinary amino-acid findings; Aminoaciduria; Skin Abnormalities; Short stature; Mitochondrial Diseases; Cytopenia; Congenital anemia; Abnormal heart beat; ECG abnormality; Cardiac conduction abnormality; Electrocardiogram abnormal; Electrocardiographic changes; Lethargy; Sensorineural Hearing Loss (disorder); Cardiac Arrhythmia; Atrial Septal Defects; Dermatologic disorders; Ventricular Septal Defects",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8190761496232595; 0.8270909867833504; 0.8368219249856942; 0.8402911822757345; 0.8486035047899471; 0.8584283190330553; 0.8690346447728063; 0.8815127642200768; 0.8989612563669234; 0.9001392794088324; 0.9015731019095328; 0.9366917377729386; 0.9366917377729386; 0.9387505562433404; 0.9390727893210336; 0.9393256300017014; 0.9446671211493156; 0.9520060723130308; 0.9586815140144712; 0.9768262648503316; 0.9912501168001682; 0.9920086799398428,Sideroblastic Anemia; Stroke; Retinal Dystrophy; Nystagmus; Anorexia; Cone-rod Dystrophy; Optic Atrophy; Hearing Loss; Diabetes Mellitus; Anemia; Dwarfism; Congestive Heart Failure; Atrial Septal Defect; Ventricular Septal Defect,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8091514409416879; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.919442421650838; 0.9369188149054885; 0.9510372690456612; 0.9543024119762946; 0.9832345076528324; 0.998271416892984,Citrullinemia type II ORPHA:247585; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Dent disease type 1 ORPHA:93622; Thiamine-responsive megaloblastic anemia syndrome ORPHA:49827,0.0414176838632111; 0.0414176838632111; 0.5867963421058087; 0.8922466888454011,,,,,,
SLC23A2,"Malignant neoplasm of breast; Breast Carcinoma; Lymphoma; Adenoma; Lymphoma, Non-Hodgkin; Malignant Head and Neck Neoplasm; Neuroblastoma; Central neuroblastoma; Malignant neoplasm of stomach; Stomach Carcinoma; Cardiovascular Diseases; Cholestasis; Hyperinsulinism; Chronic Periodontitis; Autistic Disorder; Chronic Lymphocytic Leukemia; Acute Coronary Syndrome; Liver diseases; Spinal Muscular Atrophy; Cholangiocarcinoma; Adult Cholangiocarcinoma; Premature Birth; SVEINSSON CHORIORETINAL ATROPHY; Choriocarcinoma; Obesity; Cystic Fibrosis",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8037546774788534; 0.8140222479282434; 0.8402911822757345; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8690346447728063; 0.8769418330148872; 0.8989612563669234; 0.9874278479946328,Cholestasis; Autism,0.8115918568696846; 0.911896615143974,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997,0.5867963421058087,,,,,,
SLC25A25,,,,,NAD(P)HX dehydratase deficiency ORPHA:555402,0.1991445465001551,,,,,,
SLC25A27,"Neuroblastoma; Central neuroblastoma; Alzheimer's Disease; Multiple Sclerosis; Degenerative polyarthritis; Schizophrenia; Alzheimer Disease, Late Onset; Nicotinamide adenine dinucleotide coenzyme Q reductase deficiency",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8402911822757345; 0.8402911822757345,Schizophrenia; Hashimoto Disease; Autoimmune Thyroiditis; Graves Disease,0.7860378120955526; 0.8115918568696846; 0.8662301945830305; 0.8903630091389316,Benign hereditary chorea ORPHA:1429; Synaptic congenital myasthenic syndromes ORPHA:98915; Primary pigmented nodular adrenocortical disease ORPHA:189439; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; 1p31p32 microdeletion syndrome ORPHA:401986; Microphthalmia with limb anomalies ORPHA:1106; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Autosomal dominant striatal neurodegeneration ORPHA:228169; Inherited congenital spastic tetraplegia ORPHA:210141; Episodic ataxia type 6 ORPHA:209967; PLIN1-related familial partial lipodystrophy ORPHA:280356; Oculocutaneous albinism type 4 ORPHA:79435; Sjogren-Larsson syndrome ORPHA:816,0.1991445465001551; 0.1991445465001551; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SLC25A44,Carcinoma testes; Testicular Germ Cell Tumor,0.8272008757995397; 0.8648405521677974,Leukemia; Testicular Neoplasms; Testicular Germ Cell Tumor,0.7765582368651238; 0.8201196687803188; 0.8903301324869451,Hermansky-Pudlak syndrome type 8 ORPHA:231537; Autosomal dominant optic atrophy and cataract ORPHA:67036; 3-methylglutaconic aciduria type 3 ORPHA:67047,0.3832844616405875; 0.8922466888454011; 0.8922466888454011,,,,,,
SLC46A1,"leukemia; Colorectal Carcinoma; Non-Small Cell Lung Carcinoma; Malignant neoplasm of lung; Colorectal Cancer; Epithelial ovarian cancer; Basal ganglia calcification; Dyskinetic syndrome; Primary malignant neoplasm of lung; Carcinoma of lung; Anemia, Megaloblastic; Mesothelioma; Hyperhomocysteinemia; Pallor; Diarrhea; Abnormal behavior; Folic Acid Deficiency; Severe Combined Immunodeficiency; Hemifacial microsomia; Recurrent infections; Red and sore lips; Feeding difficulties in infancy; Infant, Premature; Pancytopenia; Anorexia; Cheilitis; Cognitive delay; Solid Neoplasm; Global developmental delay; Behavioral Symptoms; Mental and motor retardation; Liver Cirrhosis, Experimental; Alcoholic Intoxication, Chronic; Decreased platelet count; Leukopenia; Thrombocytopenia; Athetosis; Kidney Failure, Chronic; Neutrophil count decreased; Inborn Errors of Metabolism; Oral Ulcer; Hemochromatosis; Hypogammaglobulinemia; Irritation - emotion; Gastroesophageal reflux disease; Malabsorption Syndrome; Peripheral Neuropathy; Mental deficiency; Generalized hypotonia; Anemia; Decreased antibody level in blood; Dull intelligence; Low intelligence; Iron deficiency; HEMOCHROMATOSIS, TYPE 1; Poor school performance; Acid reflux; Cerebellar Ataxia; Neuropathy; Heartburn; Mental Retardation; Movement Disorders; Malabsorption; Intellectual Disability; Seizures; Nausea and vomiting; Epilepsy; Cystic Fibrosis; Undergrowth; Failure to gain weight; Pediatric failure to thrive",0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8014900279306119; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8101097852323003; 0.8138488881521341; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8584283190330553; 0.8584283190330553; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8806784681730055; 0.8913141512402477; 0.8962930275917275; 0.906476206143938; 0.914995991166204; 0.9214835359141188; 0.922229272318747; 0.929235785949896; 0.9432051631882106; 0.9478210444156088; 0.9478210444156088; 0.9586815140144712; 0.963331724428282; 0.9874278479946328; 0.9884235744717738; 0.9896536639644284; 0.9896536639644284,Hyperhomocysteinemia; Oral Ulcer; Dyskinetic Syndrome; Glossitis; Immunologic Deficiency Syndromes; Eosinophilia; Cheilitis; Developmental Delay; Leukopenia; Anorexia; Mental Retardation; Neutropenia; Pancytopenia; Anemia; Nervous System Diseases; Malabsorption Syndrome; Gastroesophageal Reflux Disease,0.7311975666200533; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8091514409416879; 0.8091514409416879; 0.8337953215113012; 0.8476516371290275; 0.861756360478846; 0.9369188149054885; 0.9492120794677584; 0.9850811241696034; 0.9870402800551054,Hereditary folate malabsorption ORPHA:90045; Systemic primary carnitine deficiency ORPHA:158; Isolated sulfite oxidase deficiency ORPHA:99731,0.3832844616405875; 0.5867963421058087; 0.8922466888454011,,,In vitro,0.44,Homo sapiens,Homo sapiens
SMYD5,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; leukemia; Leukemia, Myelocytic, Acute; Non-Small Cell Lung Carcinoma; Monocytic leukemia; Liver carcinoma; Acute Promyelocytic Leukemia; Neuroblastoma; Central neuroblastoma; M5b Acute differentiated monocytic leukemia",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,Focal dermal hypoplasia ORPHA:2092; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome ORPHA:363694; Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome ORPHA:502423; Bjornstad syndrome ORPHA:123; GRACILE syndrome ORPHA:53693; POMGNT1-related  limb-girdle muscular dystrophy R15 ORPHA:206564; Renal tubulopathy-encephalopathy-liver failure syndrome ORPHA:254902; Schwannomatosis ORPHA:93921; Spinal muscular atrophy with respiratory distress type 2 ORPHA:404521; Triple A syndrome ORPHA:869; Perrault syndrome ORPHA:2855; Infantile Refsum disease ORPHA:772; Neonatal adrenoleukodystrophy ORPHA:44; Zellweger syndrome ORPHA:912; Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome ORPHA:457279,0.1040670578681756; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SNAPC5,,,Melanoma,0.7765582368651238,,,,,,,,
SNPH,Malignant Neoplasms; Primary malignant neoplasm,0.7880542567584415; 0.7908231553833205,,,"Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; LIPE-related familial partial lipodystrophy ORPHA:435660; 8p11.2 deletion syndrome ORPHA:251066; Brachydactyly type B2 ORPHA:140908; Progressive myoclonic epilepsy type 3 ORPHA:263516; Stapes ankylosis with broad thumbs and toes ORPHA:140917; Tarsal-carpal coalition syndrome ORPHA:1412; Fuhrmann syndrome ORPHA:2854; Phocomelia, Schinzel type ORPHA:2879; NON RARE IN EUROPE: Vitiligo ORPHA:3435; Autosomal recessive centronuclear myopathy ORPHA:169186; Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome ORPHA:83473; Multiple synostoses syndrome ORPHA:3237",0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
SNRNP35,Cholera,0.9459312971127588,,,Hermansky-Pudlak syndrome type 8 ORPHA:231537; TMEM199-CDG ORPHA:466703; CEDNIK syndrome ORPHA:66631; Familial steroid-resistant nephrotic syndrome with sensorineural deafness ORPHA:280406,0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703,,,,,,
SNUPN,Mycoses,0.7880542567584415,,,Combined oxidative phosphorylation defect type 15 ORPHA:319524; Navajo neurohepatopathy ORPHA:255229,0.7929682744768703; 0.7929682744768703,,,,,,
SNX18,"Drug-Induced Liver Disease; Hepatitis, Toxic; Chemical and Drug Induced Liver Injury; Chemically-Induced Liver Toxicity; Drug-Induced Acute Liver Injury; Hepatitis, Drug-Induced",0.8523465762428218; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8548862007194026; 0.8578473133580928,,,Acromelic frontonasal dysplasia ORPHA:1827; BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy ORPHA:363454; Autosomal dominant intermediate Charcot-Marie-Tooth disease type F ORPHA:352670; Loeys-Dietz syndrome ORPHA:60030; Charcot-Marie-Tooth disease type 2T ORPHA:495274; Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization ORPHA:69063; MME-related autosomal dominant Charcot Marie Tooth disease type 2 ORPHA:497757; Spinocerebellar ataxia type 43 ORPHA:497764; Alagille syndrome due to a NOTCH2 point mutation ORPHA:261629; Hajdu-Cheney syndrome ORPHA:955,0.1040670578681756; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus nef protein (gene: nef); Human immunodeficiency virus 1 Nef (gene: nef),0.8999095837312036; 0.8999095837312036,,,,
SNX29,Fatty acid measurement; Narcolepsy; Schizophrenia; Body mass index; Finding of body mass index; Intelligence; Smoking Behaviors,0.7765852775619541; 0.8067197998685076; 0.8067197998685076; 0.8867509400747969; 0.8867509400747969; 0.9093740881835894; 0.9564633032157428,Schizophrenia; Narcolepsy; Mental Depression,0.7860378120955526; 0.8260230451542778; 0.8903630091389316,"Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Autosomal recessive ataxia, Beauce type ORPHA:88644; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency ORPHA:404499; Autosomal recessive myogenic arthrogryposis multiplex congenita ORPHA:319332; External auditory canal aplasia/hypoplasia ORPHA:141074; XYLT1-CDG ORPHA:370930; Autosomal recessive spastic paraplegia type 15 ORPHA:100996; GM3 synthase deficiency ORPHA:370933; Griscelli syndrome type 1 ORPHA:79476; Neuroectodermal melanolysosomal disease ORPHA:33445; Nicolaides-Baraitser syndrome ORPHA:3051; Estrogen resistance syndrome ORPHA:785; Oculocerebrofacial syndrome, Kaufman type ORPHA:2707; Moyamoya disease ORPHA:2573",0.0081550609410495; 0.0155394890951578; 0.0155394890951578; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SPAG7,Platelet mean volume determination (procedure),0.7880542567584415,,,,,,,,,,
SPAG9,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; leukemia; Ovarian Carcinoma; Colorectal Carcinoma; Colon Carcinoma; TARSAL-CARPAL COALITION SYNDROME; Malignant tumor of colon; Lymphoma; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Thyroid Neoplasm; Malignant tumor of cervix; Mammary Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Liver carcinoma; Thyroid carcinoma; Colorectal Cancer; Epithelial ovarian cancer; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Malignant neoplasm of testis; Carcinoma of lung; Malignant neoplasm of thyroid; Triple Negative Breast Neoplasms; Malignant Neoplasms; Neoplasms; Burkitt Lymphoma; Cleft palate, isolated; Transitional cell carcinoma of bladder; African Burkitt's lymphoma; Tumor Progression; Renal Cell Carcinoma; Acquired Immunodeficiency Syndrome; Alzheimer's Disease; Acute lymphocytic leukemia; Squamous cell carcinoma; Uterine Cervical Neoplasm; Malignant hyperpyrexia due to anesthesia; Childhood Acute Lymphoblastic Leukemia; Follicular adenoma; Myeloid Leukemia, Chronic; Thyroid Gland Follicular Adenoma; Systemic Scleroderma; Renal carcinoma; Malignant neoplasm of kidney; Cerebral Palsy",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8232134984476662; 0.8402911822757345; 0.8648405521677974; 0.8818220091065441; 0.9193385822373632,,,Acromelic frontonasal dysplasia ORPHA:1827; GNE myopathy ORPHA:602; Sialuria ORPHA:3166; Non-specific syndromic intellectual disability ORPHA:528084; Autosomal dominant Charcot-Marie-Tooth disease type 2A1 ORPHA:99946; Autosomal recessive spastic paraplegia type 67 ORPHA:401820; Dent disease type 1 ORPHA:93622; Polyendocrine-polyneuropathy syndrome ORPHA:453533; Atypical juvenile parkinsonism ORPHA:391411; APC-related attenuated familial adenomatous polyposis ORPHA:247806; Familial adenomatous polyposis due to 5q22.2 microdeletion ORPHA:261584; Gardner syndrome ORPHA:79665; Gastric adenocarcinoma and proximal polyposis of the stomach ORPHA:314022; Griscelli syndrome type 1 ORPHA:79476; Infantile-onset ascending hereditary spastic paralysis ORPHA:293168; Lissencephaly due to LIS1 mutation ORPHA:95232; Neuroectodermal melanolysosomal disease ORPHA:33445; Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome ORPHA:521390; Turcot syndrome with polyposis ORPHA:99818; Cenani-Lenz syndrome ORPHA:3258; Congenital neutropenia-myelofibrosis-nephromegaly syndrome ORPHA:369852; Congenitally uncorrected transposition of the great arteries ORPHA:860; 17q11 microdeletion syndrome ORPHA:97685; 17q11.2 microduplication syndrome ORPHA:139474; Autosomal dominant Charcot-Marie-Tooth disease type 2O ORPHA:284232; Charcot-Marie-Tooth disease type 4B2 ORPHA:99956; DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy ORPHA:209341; Distal monosomy 12p ORPHA:280325; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion ORPHA:363700; Autosomal recessive spastic paraplegia type 23 ORPHA:101003; Desmoid tumor ORPHA:873; Moebius syndrome ORPHA:570; Tessier number 7 facial cleft ORPHA:141276; Hereditary sensory and autonomic neuropathy type 2 ORPHA:970; Hereditary late-onset Parkinson disease ORPHA:411602; Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome ORPHA:444077; PEHO-like syndrome ORPHA:99807; Craniopharyngioma ORPHA:54595; Freeman-Sheldon syndrome ORPHA:2053,0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.44,Homo sapiens,Homo sapiens
SPIN1,"Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Triple Negative Breast Neoplasms; Seasonal Affective Disorder; Squamous cell carcinoma; Herpes Simplex Infections; Lipomatosis, Multiple; Lipoma; Hepatitis B; liposarcoma",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8098851543361193; 0.8190761496232595; 0.8272008757995397; 0.841396342333011; 0.8806784681730055,,,"Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Non-specific syndromic intellectual disability ORPHA:528084; Autosomal recessive spastic paraplegia type 67 ORPHA:401820; Charcot-Marie-Tooth disease type 4B1 ORPHA:99955; Spondyloepimetaphyseal dysplasia with joint laxity ORPHA:93359; Juvenile myelomonocytic leukemia ORPHA:86834; Differentiated thyroid carcinoma ORPHA:146; Autosomal recessive spastic paraplegia type 61 ORPHA:401780; Lissencephaly due to LIS1 mutation ORPHA:95232; Mulibrey nanism ORPHA:2576; Peters plus syndrome ORPHA:709; Congenital neutropenia-myelofibrosis-nephromegaly syndrome ORPHA:369852; Male infertility due to globozoospermia ORPHA:171709; Chondrodysplasia with joint dislocations, gPAPP type ORPHA:280586; Lathosterolosis ORPHA:46059; Microcystic stromal tumor ORPHA:569248; Pilomatrixoma ORPHA:91414; Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome ORPHA:505242; Reticular dystrophy of the retinal pigment epithelium ORPHA:99002; Severe intellectual disability-progressive spastic diplegia syndrome ORPHA:404473; Sudden infant death-dysgenesis of the testes syndrome ORPHA:168593; 17p13.3 microduplication syndrome ORPHA:217385; Miller-Dieker syndrome ORPHA:531; Joubert syndrome with oculorenal defect ORPHA:2318; Periventricular nodular heterotopia ORPHA:98892; Congenital muscular dystrophy, Fukuyama type ORPHA:272; Familial benign chronic pemphigus ORPHA:2841; Fukutin-related  limb-girdle muscular dystrophy R13 ORPHA:206554; Encephalocraniocutaneous lipomatosis ORPHA:2396",0.1040670578681756; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6196505963261838; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,In vitro,0.65,Homo sapiens,chemical synthesis
SPOCK2,Glioma; Ankylosing spondylitis; Bronchopulmonary Dysplasia,0.7880542567584415; 0.7880542567584415; 0.9446671211493156,Bronchopulmonary Dysplasia,0.7765582368651238,"Autosomal dominant spastic ataxia type 1 ORPHA:251282; Distal monosomy 1q ORPHA:36367; 2q37 microdeletion syndrome ORPHA:1001; Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085; Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome ORPHA:352662; Early-onset parkinsonism-intellectual disability syndrome ORPHA:2379; Glycogen storage disease due to muscle glycogen phosphorylase deficiency ORPHA:368; Severe combined immunodeficiency due to CARMIL2 deficiency ORPHA:542301; Fuhrmann syndrome ORPHA:2854; Phocomelia, Schinzel type ORPHA:2879; Pseudohypoaldosteronism type 2D ORPHA:300525; Multiple endocrine neoplasia type 4 ORPHA:276152; Dopamine beta-hydroxylase deficiency ORPHA:230; PDE4D haploinsufficiency syndrome ORPHA:439822; Imerslund-Grasbeck syndrome ORPHA:35858; Isolated congenital anosmia ORPHA:88620",0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SPON2,"Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Malignant neoplasm of prostate; Liver carcinoma; Colorectal Cancer; Prostatic Neoplasms; Malignant neoplasm of large intestine; Tumor Progression; Diabetes Mellitus, Non-Insulin-Dependent; Metabolic Diseases",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8190761496232595; 0.9564633032157428,Prostate Cancer; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238,Charcot-Marie-Tooth disease type 2T ORPHA:495274; Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization ORPHA:69063; MME-related autosomal dominant Charcot Marie Tooth disease type 2 ORPHA:497757; Renin-angiotensin-aldosterone system-blocker-induced angioedema ORPHA:100057; Spinocerebellar ataxia type 43 ORPHA:497764,0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SPRY2,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; B-Cell Lymphomas; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Non-Small Cell Lung Carcinoma; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Lymphoma, Non-Hodgkin; Liver carcinoma; Osteosarcoma; Thyroid carcinoma; Epithelial ovarian cancer; Liver and Intrahepatic Biliary Tract Carcinoma; Hepatocarcinogenesis; Osteosarcoma of bone; Prostate carcinoma; Primary malignant neoplasm of lung; Prostatic Neoplasms; Carcinoma of lung; Malignant neoplasm of thyroid; Malignant neoplasm of liver; Neuroblastoma; melanoma; Adenocarcinoma of pancreas; Lung Neoplasms; Cartilage-hair hypoplasia; Cleft palate, isolated; Benign Prostatic Hyperplasia; Seminoma; Cleft Palate; Cardiovascular Diseases; Rheumatoid Arthritis; Cleft upper lip; Lymphoma, Diffuse; Secondary malignant neoplasm of liver; IGA Glomerulonephritis; Esophageal Achalasia; Lung diseases; Fibrosarcoma; Degenerative polyarthritis; Diabetes Mellitus, Non-Insulin-Dependent; Liver Cirrhosis; Fibrosis, Liver; Glioblastoma Multiforme; Yolk Sac Tumor; Cirrhosis; Papillary thyroid carcinoma; Arthritis; Hematopoietic Neoplasms; Craniofacial Abnormalities",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8232134984476662; 0.8272008757995397; 0.8342163953428735; 0.8402911822757345; 0.8554819098734854; 0.8757755363384367; 0.9431511078237256; 0.946564927793026; 0.9856761890270216,Lung Cancer; Lung Neoplasms; Lung Diseases; Glomerulonephritis,0.8706864397989688; 0.8903301324869451; 0.8903630091389316; 0.9005327950701606,20p12.3 microdeletion syndrome ORPHA:261295; Legius syndrome ORPHA:137605; Roussy-Levy syndrome ORPHA:3115; Skeletal Ewing sarcoma ORPHA:319,0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846,,,,,,
SPSB3,,,,,"Autosomal dominant centronuclear myopathy ORPHA:169189; Familial lipase maturation factor 1 deficiency ORPHA:535453; Idiopathic CD4 lymphocytopenia ORPHA:228000; Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Barth syndrome ORPHA:111; Incontinentia pigmenti ORPHA:464; Megaconial congenital muscular dystrophy ORPHA:280671; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Familial isolated pituitary adenoma ORPHA:314777; LIPE-related familial partial lipodystrophy ORPHA:435660; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; D-2-hydroxyglutaric aciduria ORPHA:79315; Marinesco-Sjogren syndrome ORPHA:559; Beta-propeller protein-associated neurodegeneration ORPHA:329284; CCDC115-CDG ORPHA:468684; Leukonychia totalis ORPHA:2387; Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Metachromatic leukodystrophy, adult form ORPHA:309271; Metachromatic leukodystrophy, juvenile form ORPHA:309263; Metachromatic leukodystrophy, late infantile form ORPHA:309256; Classic galactosemia ORPHA:79239; D-glyceric aciduria ORPHA:941; Mucolipidosis type III gamma ORPHA:423470; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; Prolactinoma ORPHA:2965; Arnold-Chiari malformation type II ORPHA:1136; Polyglucosan body myopathy type 1 ORPHA:397937; Acromegaly ORPHA:963; Tubular aggregate myopathy ORPHA:2593",0.0036432528126817; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1054066549396977; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703,,,,,,
SRSF8,,,,,Hereditary myopathy with lactic acidosis due to ISCU deficiency ORPHA:43115,0.5867963421058087,Cercopithecine betaherpesvirus 5 tegument protein UL37 (gene: UL47),0.8999095837312036,,,,
ST3GAL5,"Thromboangiitis Obliterans; Malignant neoplasm of ovary; Ovarian Carcinoma; Lower limb hyperreflexia; Leukemia, Myelocytic, Acute; Liver carcinoma; Epithelial ovarian cancer; Choreoathetoid movements; Nonverbal; Absent speech; Choreoathetosis; Spasmodic movement; Involuntary jerking movements; Feeding difficulties in infancy; Myoclonus; Abnormal vision; Cognitive delay; Rheumatoid Arthritis; Global developmental delay; Optic Atrophy; Mental and motor retardation; Global brain atrophy; Pick Disease of the Brain; Degenerative polyarthritis; Vomiting; Irritation - emotion; Cortical visual impairment; Generalized hypotonia; Blindness, Cortical; Hypermelanotic macule; Central visual impairment; Tonic - clonic seizures; Status Epilepticus; Epileptic encephalopathy; Thyroid associated opthalmopathies; Arthritis; Intellectual Disability; Congenital Disorders of Glycosylation; Epilepsy; Psychomotor regression, progressive; Loss of developmental milestones; Mental deterioration in childhood; Neurodevelopmental regression; Psychomotor regression; Psychomotor regression beginning in infancy; Psychomotor regression in infants; Developmental regression; Undergrowth; Failure to gain weight; Pediatric failure to thrive",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8270909867833504; 0.8270909867833504; 0.8402911822757345; 0.843190898187174; 0.843190898187174; 0.8523465762428218; 0.8584283190330553; 0.8648405521677974; 0.914995991166204; 0.917543617287358; 0.9258401930327972; 0.9431511078237256; 0.9478210444156088; 0.9540608878641196; 0.963331724428282; 0.9692578766570316; 0.9692578766570316; 0.9692578766570316; 0.9692578766570316; 0.9692578766570316; 0.9692578766570316; 0.9707275133033936; 0.9707275133033936; 0.9884235744717738; 0.9896536639644284; 0.9896536639644284,Paroxysmal Nonkinesigenic Dyskinesia; Stereotyped Behavior; Dyskinetic Syndrome; Nystagmus; Developmental Delay; Choreoathetosis; Optic Atrophy; Hearing Loss; Central Visual Impairment; Mental Retardation; Cerebral Cortical Atrophy; Seizure; Cerebral Palsy; Microcephaly; Status Epilepticus; Developmental Regression,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8337953215113012; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.8903630091389316; 0.9543024119762946; 0.9658957825498884,"Mucopolysaccharidosis type 2, attenuated form ORPHA:217093; Mucopolysaccharidosis type 2, severe form ORPHA:217085; Progressive myoclonic epilepsy type 3 ORPHA:263516; Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome ORPHA:447997; GM3 synthase deficiency ORPHA:370933",0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703,,,,,,
STARD3,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Mammary Neoplasms; Malignant neoplasm of prostate; Prostate carcinoma; Prostatic Neoplasms; Malignant neoplasm of stomach; High density lipoprotein measurement; Noninfiltrating Intraductal Carcinoma; Stomach Carcinoma; cocaine use; Asthma,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.9672478180546946,Prostate Cancer; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238,"Autosomal dominant centronuclear myopathy ORPHA:169189; Idiopathic CD4 lymphocytopenia ORPHA:228000; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Barth syndrome ORPHA:111; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Incontinentia pigmenti ORPHA:464; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Intermediate osteopetrosis ORPHA:210110; Albers Schonberg osteopetrosis ORPHA:53; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Pontocerebellar hypoplasia type 9 ORPHA:369920; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; Leukonychia totalis ORPHA:2387; Mucolipidosis type IV ORPHA:578; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Charcot-Marie-Tooth disease type 2B2 ORPHA:101101; Metachromatic leukodystrophy, adult form ORPHA:309271; Metachromatic leukodystrophy, juvenile form ORPHA:309263; Metachromatic leukodystrophy, late infantile form ORPHA:309256; Ataxia-oculomotor apraxia type 4 ORPHA:459033; D-glyceric aciduria ORPHA:941; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; 3C syndrome ORPHA:7; Prolactinoma ORPHA:2965; Ataxia-hypogonadism-choroidal dystrophy syndrome ORPHA:1180; Autosomal recessive spastic paraplegia type 39 ORPHA:139480; Laurence-Moon syndrome ORPHA:2377; Polyglucosan body myopathy type 1 ORPHA:397937; Trichomegaly-retina pigmentary degeneration-dwarfism syndrome ORPHA:3363; Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis ORPHA:329173; Yunis-Varon syndrome ORPHA:3472; Infantile nephropathic cystinosis ORPHA:411629; Juvenile nephropathic cystinosis ORPHA:411634; Ocular cystinosis ORPHA:411641; Sanfilippo syndrome type A ORPHA:79269; Alveolar soft tissue sarcoma ORPHA:163699; H syndrome ORPHA:168569",0.0036432528126817; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
STK11IP,Adenocarcinoma; Peutz-Jeghers Syndrome,0.750391252594775; 0.7880542567584415,,,Idiopathic CD4 lymphocytopenia ORPHA:228000; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Barth syndrome ORPHA:111; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Albers Schonberg osteopetrosis ORPHA:53; Congenital myopathy with internal nuclei and atypical cores ORPHA:319160; Early-onset epilepsy-intellectual disability-brain anomalies syndrome ORPHA:488635; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Early-onset autosomal dominant Alzheimer disease ORPHA:1020; Charcot-Marie-Tooth disease type 2B2 ORPHA:101101; Ataxia-oculomotor apraxia type 4 ORPHA:459033; MOGS-CDG ORPHA:79330; Mucopolysaccharidosis type 4A ORPHA:309297; 3C syndrome ORPHA:7; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Prolactinoma ORPHA:2965; Alpers-Huttenlocher syndrome ORPHA:726; Ataxia-hypogonadism-choroidal dystrophy syndrome ORPHA:1180; Autosomal recessive spastic paraplegia type 39 ORPHA:139480; Autosomal recessive spastic paraplegia type 48 ORPHA:306511; Laurence-Moon syndrome ORPHA:2377; Lethal neonatal spasticity-epileptic encephalopathy syndrome ORPHA:435845; MAN1B1-CDG ORPHA:397941; Recessive mitochondrial ataxia syndrome ORPHA:94125; Spinocerebellar ataxia with epilepsy ORPHA:254881; Trichomegaly-retina pigmentary degeneration-dwarfism syndrome ORPHA:3363; Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis ORPHA:329173; Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome ORPHA:70595; Yunis-Varon syndrome ORPHA:3472; COG7-CDG ORPHA:79333; Charcot-Marie-Tooth disease type 2S ORPHA:443073; Porphyria variegata ORPHA:79473; Spinal muscular atrophy with respiratory distress type 1 ORPHA:98920,0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2386105733903937; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703,,,,,,
STK17B,"Malignant neoplasm of breast; Breast Carcinoma; Colorectal Carcinoma; Mammary Neoplasms; IMMUNE SUPPRESSION; Thyroid carcinoma; Colorectal Cancer; Autoimmune Diseases; Multiple Sclerosis; Lymphoma, T-Cell, Cutaneous; Diabetes Mellitus, Insulin-Dependent; Papillary thyroid carcinoma; Idiopathic Pulmonary Fibrosis",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8098851543361193; 0.8145035474981049; 0.8757755363384367; 0.9393256300017014,,,Alacrimia-choreoathetosis-liver dysfunction syndrome ORPHA:404454; Cleidocranial dysplasia ORPHA:1452; Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome ORPHA:566175; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504; TOR1AIP1-related limb-girdle muscular dystrophy ORPHA:424261; Variant ABeta2M amyloidosis ORPHA:314652; Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; Autoimmune lymphoproliferative syndrome with recurrent viral infections ORPHA:275517; Autosomal dominant Kenny-Caffey syndrome ORPHA:93325; Familial normophosphatemic tumoral calcinosis ORPHA:306658; Generalized glucocorticoid resistance syndrome ORPHA:786; Hereditary pediatric Behcet-like disease ORPHA:476102; Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency ORPHA:70592; MIRAGE syndrome ORPHA:494433; Orofaciodigital syndrome type 5 ORPHA:2919; Osteocraniostenosis ORPHA:2763; Familial cerebral cavernous malformation ORPHA:221061; Familial platelet disorder with associated myeloid malignancy ORPHA:71290; Acute promyelocytic leukemia ORPHA:520; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency ORPHA:574957; Coffin-Lowry syndrome ORPHA:192; Griscelli syndrome type 2 ORPHA:79477; Severe combined immunodeficiency due to DCLRE1C deficiency ORPHA:275; Symptomatic form of Coffin-Lowry syndrome in female carriers ORPHA:276630; X-linked centronuclear myopathy ORPHA:596; Loeys-Dietz syndrome ORPHA:60030; Squamous cell carcinoma of the esophagus ORPHA:99977; Aggressive systemic mastocytosis ORPHA:98850; Essential thrombocythemia ORPHA:3318; Omenn syndrome ORPHA:39041; Bannayan-Riley-Ruvalcaba syndrome ORPHA:109; Combined immunodeficiency due to MALT1 deficiency ORPHA:397964; Familial cylindromatosis ORPHA:211; Familial multiple trichoepithelioma ORPHA:867; Hydranencephaly ORPHA:2177; Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome ORPHA:2250; Infantile systemic hyalinosis ORPHA:2176; Juvenile hyaline fibromatosis ORPHA:2028; Lhermitte-Duclos disease ORPHA:65285; NDE1-related microhydranencephaly ORPHA:443162; Proteus-like syndrome ORPHA:2969; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome ORPHA:137608; X-linked Charcot-Marie-Tooth disease type 6 ORPHA:352675; Vogt-Koyanagi-Harada disease ORPHA:3437; Activated PI3K-delta syndrome ORPHA:397596; High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement ORPHA:480541; Combined immunodeficiency due to STK4 deficiency ORPHA:314689; Distal monosomy 15q ORPHA:1596; Intellectual disability-severe speech delay-mild dysmorphism syndrome ORPHA:391372; Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptodactyly syndrome ORPHA:487796; T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency ORPHA:169154; MALT lymphoma ORPHA:52417,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7150309491065155; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8029813443753846; 0.8105918570729571; 0.8447648476081987; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Human orthopneumovirus fusion protein (gene: F); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Monkeypox virus ankyrin-like protein; Vaccinia virus ankyrin-like protein (gene: B4R); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Human Respiratory syncytial virus 9320 F; Respiratory syncytial virus Fusion protein (F) (gene: F); Respiratory syncytial virus type A fusion protein (gene: F); Orf virus ORF126 ankyrin repeat protein,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549,,,,
SUGT1,Heart failure; Congestive heart failure,0.8867509400747969; 0.8976039441125321,,,MEGDEL syndrome ORPHA:352328; ALG9-CDG ORPHA:79328; Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome ORPHA:254343; Diaphyseal medullary stenosis-bone malignancy syndrome ORPHA:85182; Atypical hypotonia-cystinuria syndrome ORPHA:238523; 2p21 microdeletion syndrome ORPHA:163693; Giant axonal neuropathy ORPHA:643; Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency ORPHA:88639; NON RARE IN EUROPE: Barrett esophagus ORPHA:1232; Preeclampsia ORPHA:275555,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Vaccinia virus cowpox A-type inclusion protein,0.8999095837312036,,,,
SYNCRIP,leukemia; Colon Carcinoma; Malignant tumor of colon; Myeloid Leukemia; Spinal Muscular Atrophy; Septicemia; Sepsis; Intellectual Disability,0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.8402911822757345; 0.917543617287358; 0.9189398569397552; 0.9478210444156088,Leukemia,0.7765582368651238,Linear nevus sebaceus syndrome ORPHA:2612; Familial multinodular goiter ORPHA:276399; Inclusion body myopathy with Paget disease of bone and frontotemporal dementia ORPHA:52430; 1q44 microdeletion syndrome ORPHA:238769; Charcot-Marie-Tooth disease type 4B1 ORPHA:99955; Acute myeloblastic leukemia with maturation ORPHA:98834; Juvenile myelomonocytic leukemia ORPHA:86834; Familial pancreatic carcinoma ORPHA:1333; Differentiated thyroid carcinoma ORPHA:146; Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome ORPHA:504476; RAS-associated autoimmune leukoproliferative disease ORPHA:268114; Autosomal dominant aplasia and myelodysplasia ORPHA:314399; EVEN-plus syndrome ORPHA:496751; Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome ORPHA:505237; Gabriele-de Vries syndrome ORPHA:506358; Pseudohypoaldosteronism type 2E ORPHA:300530; Acute myeloblastic leukemia without maturation ORPHA:98833; Dubowitz syndrome ORPHA:235,0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6196505963261838; 0.6599133692748571; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human immunodeficiency virus 1 capsid (gene: gag); Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Influenza B virus (B/Memphis/12/97) HA protein; Human papillomavirus 94 E2 protein (gene: E2); Human immunodeficiency virus 1 Gag-Pol (gene: gag-pol); Human immunodeficiency virus 1 Pr55(Gag) (gene: gag); Human adenovirus 21a 100 kDa hexon-assembly associated protein (gene: L4); Human immunodeficiency virus gag protein (gene: gag); Human papillomavirus type 27 early protein (gene: E2); Human adenovirus 68 100 kDa hexon assembly-associated protein (gene: L4); Human papillomavirus type XS2 E2 (gene: E2); Human mastadenovirus B hexon assembly protein 100K (gene: L4); Human adenovirus B3 L4 100-kDa protein (gene: L4); Molluscum contagiosum virus subtype 1 MC161R (gene: MC161R); Human immunodeficiency virus 1 Envelope surface glycoprotein gp160, precursor (gene: env); Human immunodeficiency virus 2 full_polyprotein 1..521 (gene: gag-pol); Human adenovirus 66 100 kDa hexon assembly-associated protein (gene: L4); Human papillomavirus type 72b E2 protein (gene: E2); Human papillomavirus type 78 regulatory protein E2 (gene: E2); Human papillomavirus 3 envelope protein (gene: E2); Human adenovirus 7 100K; BK polyomavirus large T antigen; Human herpesvirus 4 type 2 EBNA-1; Human papillomavirus type 62 putative regulatory protein E2 (gene: E2); Human papillomavirus type 68a E2 protein; Human papillomavirus type 34 early protein (gene: E2); Human adenovirus 16 100 kDa hexon assembly-associated protein (gene: L4); Human adenovirus 7d2 100 kDa hexon assembly-associated protein (gene: L4); Human papillomavirus 179 E2 protein (gene: E2); Human papillomavirus E2 (gene: E2); Human papillomavirus type 53 early protein (gene: E2); Human papillomavirus type 68b E2 protein (gene: E2); Variola virus sulfhydryl oxidase (gene: E10R); Cercopithecine betaherpesvirus 5 tegument protein UL37 (gene: UL47); Human papillomavirus type 13 E2 (gene: E2); Human papillomavirus type 43 E2 protein (gene: E2); Human papillomavirus 173 E2; Human papillomavirus type 102 E2 protein; Human papillomavirus type 30 early protein (gene: E2); Human papillomavirus type 68 E2 (gene: E2); Human papillomavirus type 90 putative regulatory protein E2 (gene: E2); Human papillomavirus type 10 envelope protein (gene: E2); Human papillomavirus type 114 E2 protein (gene: E2); Human papillomavirus type 119 regulatory protein E2 (gene: E2); Human papillomavirus type 67 E2; Human papillomavirus 125 putative E2 protein (gene: E2); Titi monkey adenovirus ECC-2011 100K; Trichodysplasia spinulosa-associated polyomavirus large T antigen (gene: T); Human papillomavirus type 112 E2 protein (gene: E2); Human papillomavirus type 128 E2 (gene: E2); Human papillomavirus type 83 transactivator (gene: E2); Human papillomavirus type 57 E2; Human papillomavirus type 52 early protein (gene: E2); Human papillomavirus type 27b E2 protein (gene: E2); Human papillomavirus type 106 E2 protein; Influenza A virus (A/California/04/2009(H1N1)) HA2 (gene: HA); Influenza A virus (A/California/07/2009(H1N1)) HA2 (gene: HA); Alphapapillomavirus 3 regulatory protein E2 (gene: E2); Human papillomavirus type 40 early protein (gene: E2); Human papillomavirus type 81 E2 protein (gene: E2); Human papillomavirus type 7 early protein (gene: E2); Alphapapillomavirus 4 early protein E2 (gene: E2); Human papillomavirus type 2 E2 protein (gene: E2); Human papillomavirus type 32 early protein (gene: E2)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9018002218631122; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9103786566415374; 0.915880438522078; 0.9176018655958595; 0.9176018655958595; 0.9224878266317492; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9287050575620676; 0.9287050575620676; 0.9318782091866168; 0.9318782091866168; 0.9325850920715436; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9397923093369096; 0.9446489750009684,,,,
SYNGR3,,,,,"PRKAR1B-related neurodegenerative dementia with intermediate filaments ORPHA:412066; Paroxysmal exertion-induced dyskinesia ORPHA:98811; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome ORPHA:391376; Familial gastric type 1 neuroendocrine tumor ORPHA:464756; Primary dystonia, DYT4 type ORPHA:98805; Idiopathic central precocious puberty ORPHA:169615",0.0155394890951578; 0.0155394890951578; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,,,,,,
SYNPO,"Malignant neoplasm of breast; Breast Carcinoma; Epidermodysplasia Verruciformis; Malignant neoplasm of prostate; Nephroblastoma; Focal Segmental Glomerulosclerosis, Not Otherwise Specified; Renal glomerular disease; Membranous glomerulonephritis; Primary Focal Segmental Glomerulosclerosis; hypertensive nephropathy; IGA Glomerulonephritis; Nephrosclerosis; Pre-Eclampsia; Focal glomerulosclerosis; Kidney Diseases; Schizophrenia; AIDS-Associated Nephropathy; Nephrotic Syndrome",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8232134984476662,Glomerulosclerosis; Focal Segmental Glomerulosclerosis,0.7765582368651238; 0.7765582368651238,NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; Bilateral perisylvian polymicrogyria ORPHA:98889; Brachyolmia-amelogenesis imperfecta syndrome ORPHA:2899; 19p13.3 microduplication syndrome ORPHA:447980; Malan overgrowth syndrome ORPHA:420179; Marshall-Smith syndrome ORPHA:561; Non-immune hydrops fetalis ORPHA:363999; Aneurysm-osteoarthritis syndrome ORPHA:284984; NON RARE IN EUROPE: Benign familial hematuria ORPHA:97562; Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome ORPHA:69735; RIN2 syndrome ORPHA:217335; Craniometaphyseal dysplasia ORPHA:1522; Distal hereditary motor neuropathy type 2 ORPHA:139525; Alpha-B crystallin-related late-onset myopathy ORPHA:399058; Fatal infantile hypertonic myofibrillar myopathy ORPHA:280553; Multiple paragangliomas associated with polycythemia ORPHA:324299; Recessive X-linked ichthyosis ORPHA:461; Syndromic recessive X-linked ichthyosis ORPHA:281090; Acromicric dysplasia ORPHA:969; Duchenne muscular dystrophy ORPHA:98896; Familial calcium pyrophosphate deposition ORPHA:1416; Autosomal dominant secondary polycythemia ORPHA:247511; Autosomal dominant Alport syndrome ORPHA:88918; Autosomal recessive Alport syndrome ORPHA:88919; De novo thrombotic microangiopathy after kidney transplantation ORPHA:244275; Complement component 3 deficiency ORPHA:280133; Familial GPIHBP1 deficiency ORPHA:535458; Familial drusen ORPHA:75376; Familial retinal arterial macroaneurysm ORPHA:284247; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Immunodeficiency with factor I anomaly ORPHA:200418; LIMS2-related limb-girdle muscular dystrophy ORPHA:466801; Geleophysic dysplasia ORPHA:2623; Familial cerebral saccular aneurysm ORPHA:231160; NON RARE IN EUROPE: Age-related macular degeneration ORPHA:279,0.0429491792829903; 0.1068643725150898; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SYT7,Glioblastoma; Childhood Glioblastoma; Adult Glioblastoma; Intelligence,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.9093740881835894,,,"Antley-Bixler syndrome ORPHA:83; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Monosomy 22q13.3 ORPHA:48652; Distal hereditary motor neuropathy type 5 ORPHA:139536; Apparent mineralocorticoid excess ORPHA:320; Bilateral generalized polymicrogyria ORPHA:208447; Lethal congenital contracture syndrome type 2 ORPHA:137776; MYO5B-related progressive familial intrahepatic cholestasis ORPHA:480491; Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; Benign hereditary chorea ORPHA:1429; Familial infantile myoclonic epilepsy ORPHA:352582; Familial hypercholanemia ORPHA:238475; Usher syndrome type 1 ORPHA:231169; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Hereditary folate malabsorption ORPHA:90045; Spectrin-associated autosomal recessive cerebellar ataxia ORPHA:352403; Spinocerebellar ataxia type 5 ORPHA:98766; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; Alopecia-intellectual disability syndrome ORPHA:2850; Persistent hyperplastic primary vitreous ORPHA:91495; NON RARE IN EUROPE: Hypodontia ORPHA:2227; Autosomal recessive non-syndromic sensorineural deafness type DFNB ORPHA:90636; Achondroplasia ORPHA:15; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Autosomal dominant adult-onset proximal spinal muscular atrophy ORPHA:209335; Autosomal dominant hyperinsulinism due to Kir6.2 deficiency ORPHA:276580; Autosomal dominant spastic paraplegia type 31 ORPHA:101011; Autosomal recessive dopa-responsive dystonia ORPHA:101150; Autosomal recessive hyperinsulinism due to Kir6.2 deficiency ORPHA:79644; Camptodactyly-tall stature-scoliosis-hearing loss syndrome ORPHA:85164; Carvajal syndrome ORPHA:65282; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Cholangiocarcinoma ORPHA:70567; Crouzon syndrome-acanthosis nigricans syndrome ORPHA:93262; Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency ORPHA:276603; Erythrokeratodermia-cardiomyopathy syndrome ORPHA:476096; Hypochondroplasia ORPHA:429; Intermediate DEND syndrome ORPHA:99989; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Lateral meningocele syndrome ORPHA:2789; Low isolated anorectal malformation ORPHA:171215; Microphthalmia with limb anomalies ORPHA:1106; Muenke syndrome ORPHA:53271; Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome ORPHA:397744; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome ORPHA:85165; Skin fragility-woolly hair-palmoplantar keratoderma syndrome ORPHA:293165; Thanatophoric dysplasia type 1 ORPHA:1860; Thanatophoric dysplasia type 2 ORPHA:93274; Wilson disease ORPHA:905; X-linked recessive ocular albinism ORPHA:54; 46,XX ovotesticular disorder of sex development ORPHA:2138; Ollier disease ORPHA:296; Permanent neonatal diabetes mellitus ORPHA:99885; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form ORPHA:293899; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form ORPHA:293888; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form ORPHA:293910; DEND syndrome ORPHA:79134; Apert syndrome ORPHA:87; Campomelic dysplasia ORPHA:140; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome ORPHA:1555; FGFR2-related bent bone dysplasia ORPHA:313855; Familial congenital nasolacrimal duct obstruction ORPHA:451612; Familial scaphocephaly syndrome, McGillivray type ORPHA:168624; Hyperphenylalaninemia due to DNAJC12 deficiency ORPHA:508523; Isolated Pierre Robin syndrome ORPHA:718; Jackson-Weiss syndrome ORPHA:1540; Pfeiffer syndrome type 2 ORPHA:93259; Pfeiffer syndrome type 3 ORPHA:93260; Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome ORPHA:477673; Autosomal dominant hypocalcemia ORPHA:428; Saethre-Chotzen syndrome ORPHA:794; Atypical glycine encephalopathy ORPHA:289863; Early-onset anterior polar cataract ORPHA:98988; Infantile glycine encephalopathy ORPHA:289860; NON RARE IN EUROPE: Aldosterone-producing adenoma ORPHA:85142; Renal agenesis, unilateral ORPHA:93100; Dicarboxylic aminoaciduria ORPHA:2195; Familial dyskinesia and facial myokymia ORPHA:324588; Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome ORPHA:397618; Hot water reflex epilepsy ORPHA:166412; Monoamine oxidase A deficiency ORPHA:3057; OBSOLETE: Alpha-1-antichymotrypsin deficiency ORPHA:93594; Pontocerebellar hypoplasia type 3 ORPHA:97249; Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome ORPHA:228012; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C ORPHA:308400; Thrombocythemia with distal limb defects ORPHA:329319; Lacrimoauriculodentodigital syndrome ORPHA:2363; Complete atrioventricular septal defect-tetralogy of Fallot ORPHA:99068; Multiple endocrine neoplasia type 2A ORPHA:247698; Multiple endocrine neoplasia type 2B ORPHA:247709",0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2661730864557679; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.4621817429362311; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6873535151929783; 0.6873535151929783; 0.7007232363756918; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.795266832401002; 0.795266832401002; 0.8029813443753846; 0.8211968342881582; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
SYTL3,Chediak-Higashi Syndrome; Lipoprotein (a) measurement; airway disease,0.7880542567584415; 0.7880542567584415; 0.8402911822757345,Vascular Diseases,0.7765582368651238,Cleidocranial dysplasia ORPHA:1452; Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ORPHA:2504,0.3832844616405875; 0.3832844616405875,,,,,,
TADA1,"Infant, Premature; Rheumatoid Arthritis; Post MI; Degenerative polyarthritis; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Non-Insulin-Dependent",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8145035474981049; 0.8190761496232595,,,PRUNE1-related neurological syndrome ORPHA:544469; COG2-CDG ORPHA:435934; Methylcobalamin deficiency type cblE ORPHA:2169; Anaplastic oligodendroglioma ORPHA:251630; Oligodendroglioma ORPHA:251627,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TAOK2,"Adenocarcinoma; Leukemia, Myelocytic, Acute; Liver carcinoma; Malignant neoplasm of stomach; Dementia; Acute leukemia; Presenile dementia; Alzheimer's Disease; Stomach Carcinoma; Small cell carcinoma of lung; Senile Plaques; Schizophrenia; Carcinoma, Small Cell; Adenocarcinoma of lung (disorder); Klinefelter Syndrome; Klinefelter's syndrome - male with more than two X chromosomes; Pervasive Development Disorder; Autism Spectrum Disorders",0.750391252594775; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8190761496232595; 0.8368219249856942; 0.8806784681730055; 0.9639249377588224,Psychosis; Schizophrenia,0.7765582368651238; 0.7860378120955526,Otospondylomegaepiphyseal dysplasia ORPHA:1427; Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Charcot-Marie-Tooth disease type 2P ORPHA:300319; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Lymphangioleiomyomatosis ORPHA:538; Oculocutaneous albinism type 2 ORPHA:79432; Tuberous sclerosis complex ORPHA:805; NON RARE IN EUROPE: Metabolic syndrome ORPHA:411969; ATP13A2-related juvenile neuronal ceroid lipofuscinosis ORPHA:314632; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; Autosomal recessive spastic paraplegia type 78 ORPHA:513436; Cerebellar-facial-dental syndrome ORPHA:444072; Kufor-Rakeb syndrome ORPHA:306674; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; Steinert myotonic dystrophy ORPHA:273; Smith-Magenis syndrome ORPHA:819; Saldino-Mainzer syndrome ORPHA:140969; Brachyolmia-amelogenesis imperfecta syndrome ORPHA:2899; CLN4B disease ORPHA:228343; Charcot-Marie-Tooth disease type 4F ORPHA:99952; Congenital myopathy with internal nuclei and atypical cores ORPHA:319160; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; Hereditary hypophosphatemic rickets with hypercalciuria ORPHA:157215; Knobloch syndrome ORPHA:1571; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; POMT1-related  limb-girdle muscular dystrophy R11 ORPHA:86812; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome ORPHA:562569; Progressive myoclonic epilepsy type 5 ORPHA:402082; 17p11.2 microduplication syndrome ORPHA:1713; Autosomal dominant intermediate Charcot-Marie-Tooth disease type E ORPHA:93114; Distal 16p11.2 microdeletion syndrome ORPHA:261222; Distal 22q11.2 microdeletion syndrome ORPHA:261330; PMP22-RAI1 contiguous gene duplication syndrome ORPHA:477817; Perry syndrome ORPHA:178509; Proximal 16p11.2 microdeletion syndrome ORPHA:261197; Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency ORPHA:329249; Crouzon disease ORPHA:207; Familial multinodular goiter ORPHA:276399; Isolated focal cortical dysplasia type IIb ORPHA:269008; Congenital muscular dystrophy with intellectual disability ORPHA:370968; Wolf-Hirschhorn syndrome ORPHA:280; Adult hepatocellular carcinoma ORPHA:210159; Idiopathic pulmonary fibrosis ORPHA:2032; Familial lambdoid synostosis ORPHA:3267; Frontorhiny ORPHA:391474; Isolated cloverleaf skull syndrome ORPHA:2343; Juvenile Huntington disease ORPHA:248111; MAN1B1-CDG ORPHA:397941; Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract ORPHA:500545; Autosomal recessive progressive external ophthalmoplegia ORPHA:254886; Isolated focal cortical dysplasia type IIa ORPHA:269001; Schneckenbecken dysplasia ORPHA:3144; 22q11.2 deletion syndrome ORPHA:567; Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder ORPHA:500180; Opsismodysplasia ORPHA:2746; Syndromic X-linked intellectual disability due to JARID1C mutation ORPHA:85279; Acute megakaryoblastic leukemia without Down syndrome ORPHA:329469; Neurofibromatosis-Noonan syndrome ORPHA:638; Chronic myeloid leukemia ORPHA:521; Congenital muscular dystrophy without intellectual disability ORPHA:370980; Autosomal dominant Charcot-Marie-Tooth disease type 2A2 ORPHA:99947; Hereditary motor and sensory neuropathy type 5 ORPHA:64751; Jalili syndrome ORPHA:1873; Multiple symmetric lipomatosis ORPHA:2398; Ocular albinism ORPHA:284804; Severe early-onset axonal neuropathy due to MFN2 deficiency ORPHA:90118; Oxoglutaric aciduria ORPHA:31; Proteus syndrome ORPHA:744,0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1117946631214258; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.4100904865085126; 0.4491081214880772; 0.5047266821728011; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Cowpox virus CPXV057 protein (gene: CPXV057 CDS); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Human betaherpesvirus 6B Phosphotransferase (gene: U69)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
TBC1D8,Malignant neoplasm of ovary; Ovarian Carcinoma; Eosinophil count procedure; Eosinophil count result; Brain Neoplasms; Renal Cell Carcinoma; Alzheimer's Disease; Conventional (Clear Cell) Renal Cell Carcinoma; Neutrophil count (procedure); Ovarian adenocarcinoma; Granulocyte count; Hyperlipoproteinemia Type IIa; Osteoporosis,0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8212681436603975; 0.8402911822757345; 0.9639249377588224,Osteoporosis; Impaired Cognition,0.8903301324869451; 0.9231137872214272,Charcot-Marie-Tooth disease type 4H ORPHA:99954,0.5867963421058087,,,,,,
TBPL1,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Carcinogenesis; leukemia; Beckwith-Wiedemann Syndrome; Colorectal Carcinoma; Colon Carcinoma; Malignant tumor of colon; Lymphoma; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Mammary Neoplasms; Malignant neoplasm of prostate; Promyelocytic leukemia; Liver carcinoma; Colorectal Cancer; Chronic heart failure; Leukemia, T-Cell; Hepatocarcinogenesis; Glioblastoma; Prostate carcinoma; CATARACT, MARNER TYPE; Neoplasm Metastasis; Isodicentric Chromosome 15 Syndrome; Prostatic Neoplasms; Monoclonal Gammopathy of Undetermined Significance; Focal Segmental Glomerulosclerosis, Not Otherwise Specified; Neuroblastoma; Central neuroblastoma; Interstitial Cystitis; Immunologic Deficiency Syndromes; Multiple Myeloma; Pelizaeus-Merzbacher Disease; Renal glomerular disease; Malignant neoplasm of stomach; Noninfiltrating Intraductal Carcinoma; Familial Nonmedullary Thyroid Gland Carcinoma; Lubs X-linked mental retardation syndrome; Renal Cell Carcinoma; Acute leukemia; Invasive Carcinoma; Stomach Carcinoma; Fanconi Anemia; Cardiovascular Diseases; Squamous cell carcinoma; Mitochondrial Myopathies; Mucolipidosis Type IV; Crohn Disease; Channelopathies; Nijmegen Breakage Syndrome; Cockayne Syndrome, Type II; Focal glomerulosclerosis; FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder); Skin Erosion; Kidney Diseases; Tooth Attrition; Schizophrenia; Liver diseases; Pancreatitis; Polycystic Kidney Diseases; Ulcerative Colitis; Chronic interstitial cystitis; Desmoplastic; precancerous lesions; Iron Overload; Glioblastoma Multiforme; Degenerative disorder; Premature aging syndrome; Ataxia; Inflammatory dermatosis; Common Migraine; Migraine Disorders; Inflammatory Bowel Diseases; Dermatitis; Heart failure; Pain; Congestive heart failure; Cerebellar Ataxia; Hypertriglyceridemia; Polycystic Kidney, Autosomal Dominant; Coughing; Malignant neoplasm of skin; Skin Neoplasms; Ataxia, Spinocerebellar; Nicotine Dependence; Asthma",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8140222479282434; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8272008757995397; 0.8342163953428735; 0.8363138748299018; 0.8402911822757345; 0.8402911822757345; 0.8554819098734854; 0.8648405521677974; 0.8648405521677974; 0.8815127642200768; 0.8815127642200768; 0.8867509400747969; 0.887595340546704; 0.8976039441125321; 0.906476206143938; 0.9154499654632742; 0.9193385822373632; 0.9262273158806068; 0.93413028051677; 0.9434459508692176; 0.94939825643792; 0.9557184806547836; 0.9672478180546946,,,Hemolytic anemia due to diphosphoglycerate mutase deficiency ORPHA:714; DNAJB6-related  limb-girdle muscular dystrophy D1 ORPHA:34516; Spinocerebellar ataxia type 18 ORPHA:98771; Multiple mitochondrial dysfunctions syndrome type 5 ORPHA:569274,0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,Human gammaherpesvirus 8 ORF36 (gene: ORF36),0.8999095837312036,,,,
TBX19,"Neonatal hypoglycemia; Small adrenal gland; Adrenal hypoplasia; Adrenocorticotropic hormone (ACTH) deficiency (disorder); Prolonged neonatal jaundice; Adrenocorticotropin deficient adrenal insufficiency; Neonatal Jaundice; X-linked Adrenal Hypoplasia; Hypoglycemic seizures; Decreased circulating cortisol level; Hypocortisolemia; Alcoholic Intoxication, Chronic; Alcohol abuse; Fasting Hypoglycemia; Alcohol Use Disorder; Hypotension; Hyponatremia; Common Variable Immunodeficiency; Endocrine System Diseases; Pituitary-dependent Cushing's disease; Mental Depression; Fatigue; Depressive disorder",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8168901801930506; 0.8272008757995397; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8584283190330553; 0.8648405521677974; 0.8769418330148872; 0.9029289778792944; 0.9103315000053974,Adrenocorticotropin Deficient Adrenal Insufficiency; Adrenocorticotropic Hormone Deficiency; Hypoglycemia; Hypoglycemic Seizures; Mental Depression,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8903630091389316,Congenital isolated ACTH deficiency ORPHA:199296,0.5867963421058087,,,,,,
TCAP,"Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Increased connective tissue; Familial dilated cardiomyopathy; Areflexia of lower limbs; Distal lower limb muscle weakness; Lower limb atrophy; Lower limb muscle hypotrophy; Proximal muscle weakness in lower limbs; Foot-drop; Foot dorsiflexor weakness; Distal lower limb amyotrophy; Autosomal recessive, childhood type, muscular dystrophy resembling Duchenne or Becker muscular dystrophy; Benign scapuloperoneal muscular dystrophy with early contractures [Emery-Dreifuss]; Congenital muscular dystrophy with specific morphological abnormalities of the muscle fiber; Severe [Duchenne] muscular dystrophy; Ocular muscular dystrophy; Rimmed vacuoles on biopsy; Difficulty running; Calf muscle hypertrophy; Difficulty walking up stairs; Muscular Dystrophy, Facioscapulohumeral; Congenital muscular dystrophy (disorder); X-Linked Emery-Dreifuss Muscular Dystrophy; Increased variability in muscle fiber diameter; Muscular Dystrophy, Oculopharyngeal; Becker Muscular Dystrophy; Distal Muscular Dystrophies; Lower limb muscle weakness; Difficulty walking; Muscle biopsy shows dystrophic changes; Cardiomyopathy, Hypertrophic, Familial; Conduction disorder of the heart; Muscular Dystrophies, Limb-Girdle; Neuromuscular Diseases; Hypertrophic Cardiomyopathy; Muscular Dystrophy; Myopathy; Cardiomyopathies; Cardiomyopathy, Dilated; Charcot-Marie-Tooth Disease; Elevated creatine kinase; Creatine phosphokinase serum increased; Arthrogryposis",0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8168901801930506; 0.8168901801930506; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.843190898187174; 0.8769418330148872; 0.8774809019744603; 0.8959157818691486; 0.906476206143938; 0.9262273158806068; 0.9377481698983606; 0.9459312971127588; 0.9540608878641196; 0.9557184806547836; 0.9557184806547836; 0.9564633032157428; 0.963331724428282; 0.97164261098259; 0.9736199434973628; 0.9896536639644284,Lipoatrophy; Lipodystrophy; Hearing Loss; Distal Lower Limb Amyotrophy; Dilated Cardiomyopathy; Cardiomyopathy; Muscular Dystrophy; Hypertrophic Cardiomyopathy; Palmoplantar Keratoderma; Myopathy,0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.861756360478846; 0.9145387439550552; 0.9318760199717074; 0.9726837163662044; 0.9832345076528324; 0.986561188259959,"Autosomal dominant centronuclear myopathy ORPHA:169189; Glycogen storage disease due to muscle glycogen phosphorylase deficiency ORPHA:368; Telethonin-related  limb-girdle muscular dystrophy R7 ORPHA:34514; Acetazolamide-responsive myotonia ORPHA:99736; Hyperkalemic periodic paralysis ORPHA:682; Myotonia fluctuans ORPHA:99734; Myotonia permanens ORPHA:99735; Paramyotonia congenita of Von Eulenburg ORPHA:684; Brody myopathy ORPHA:53347; Glycogen storage disease due to muscle beta-enolase deficiency ORPHA:99849; Glycogen storage disease due to phosphoglycerate mutase deficiency ORPHA:97234; Atrial standstill ORPHA:1344; Lafora disease ORPHA:501; Fetal akinesia deformation sequence ORPHA:994; Familial isolated dilated cardiomyopathy ORPHA:154; Congenital myopathy with excess of thin filaments ORPHA:98904; Distal myopathy, Tateyama type ORPHA:488650; Ebstein malformation of the tricuspid valve ORPHA:1880; Hyaline body myopathy ORPHA:53698; Isolated asymptomatic elevation of creatine phosphokinase ORPHA:206599; Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome ORPHA:447974; Laing early-onset distal myopathy ORPHA:59135; MYH7-related late-onset scapuloperoneal muscular dystrophy ORPHA:437572; Progressive scapulohumeroperoneal distal myopathy ORPHA:447977; Rippling muscle disease ORPHA:97238; Thomsen and Becker disease ORPHA:614; Vacuolar myopathy with sarcoplasmic reticulum protein aggregates ORPHA:88635; Zebra body myopathy ORPHA:97240; Rigid spine syndrome ORPHA:97244; Childhood-onset nemaline myopathy ORPHA:171439; Intermediate nemaline myopathy ORPHA:171433; Sheldon-Hall syndrome ORPHA:1147; Congenital fiber-type disproportion myopathy ORPHA:2020; Distal arthrogryposis type 1 ORPHA:1146; NON RARE IN EUROPE: Familial isolated hypertrophic cardiomyopathy ORPHA:155",0.0036432528126817; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.9075572232275184,Cowpox virus CPXV209 protein (gene: CPXV209 CDS); Vaccinia virus Ankara Interleukin-1 beta receptor; Variola virus hypothetical protein (gene: J9R); Horsepox virus HSPV177 (Immunoglobulin like); Vaccinia virus hemagglutinin (gene: A56R),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9058994261255549,,,,
TCERG1,Huntington Disease; Narcolepsy; Neurodegenerative Disorders,0.7880542567584415; 0.8067197998685076; 0.8272008757995397,Narcolepsy,0.8260230451542778,Precursor T-cell acute lymphoblastic leukemia ORPHA:99861; Oculofaciocardiodental syndrome ORPHA:2712; Vocal cord and pharyngeal distal myopathy ORPHA:600; Non-specific syndromic intellectual disability ORPHA:528084; 1q44 microdeletion syndrome ORPHA:238769; DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect ORPHA:330050; X-linked intellectual disability-short stature-overweight syndrome ORPHA:457240; Acute myeloid leukemia with t(6;9)(p23;q34) ORPHA:402014; Neuroendocrine tumor of stomach ORPHA:100075; Acute myeloblastic leukemia with maturation ORPHA:98834; Autosomal recessive chorioretinopathy-microcephaly syndrome ORPHA:2518; Joubert syndrome with ocular defect ORPHA:220493; Coffin-Siris syndrome ORPHA:1465; Differentiated thyroid carcinoma ORPHA:146; 16p13.2 microdeletion syndrome ORPHA:500055; Autosomal recessive spastic paraplegia type 71 ORPHA:401840; Microcephalic osteodysplastic primordial dwarfism type II ORPHA:2637; Desmoplastic small round cell tumor ORPHA:83469; Familial isolated hyperparathyroidism ORPHA:99879; Autosomal thrombocytopenia with normal platelets ORPHA:168629; NON RARE IN EUROPE: Primary ovarian failure ORPHA:619; ANE syndrome ORPHA:157954; Absence of fingerprints-congenital milia syndrome ORPHA:1658; Acute infantile liver failure-multisystemic involvement syndrome ORPHA:370088; HNRNPDL-related  limb-girdle muscular dystrophy D3 ORPHA:55596; Huriez syndrome ORPHA:384; Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency ORPHA:404440; Isolated congenital adermatoglyphia ORPHA:289465; Werner syndrome ORPHA:902; Woodhouse-Sakati syndrome ORPHA:3464; 17q24.2 microdeletion syndrome ORPHA:529962; Nijmegen breakage syndrome-like disorder ORPHA:240760; Proximal spinal muscular atrophy type 1 ORPHA:83330; Proximal spinal muscular atrophy type 2 ORPHA:83418; Proximal spinal muscular atrophy type 3 ORPHA:83419; Cornelia de Lange syndrome ORPHA:199; Extraskeletal myxoid chondrosarcoma ORPHA:209916; Infantile nephronophthisis ORPHA:93591; Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome ORPHA:137639; Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome ORPHA:447893; Odontoleukodystrophy ORPHA:77295; Rothmund-Thomson syndrome type 1 ORPHA:221008; Tremor-ataxia-central hypomyelination syndrome ORPHA:447896; Wiedemann-Rautenstrauch syndrome ORPHA:3455; Bohring-Opitz syndrome ORPHA:97297; NON RARE IN EUROPE: FG syndrome phenotypic spectrum ORPHA:323,0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.6467006456772204; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Human immunodeficiency virus 2 full_polyprotein 1..1550 (gene: gag-pol); Rio Bravo virus anchored core protein C; Human adenovirus 41 E2A DBP; Rio Bravo virus core protein C; Modoc virus capsid protein; Tai Forest ebolavirus spike glycoprotein (gene: GP); Ectromelia virus ERPV hydroxysteroid dehydrogenase; Reston ebolavirus spike glycoprotein (gene: GP); Bundibugyo ebolavirus spike glycoprotein (gene: GP); Human adenovirus Chiba_E086/2012 DNA binding protein (gene: E2A); Variola virus hypothetical protein (gene: I1L); Cercopithecine alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Human adenovirus 5 DBP; Human adenovirus 66 DNA binding protein (gene: E2A); Human adenovirus 7 DBP; Sagiyama virus full_polyprotein 1..1253 (gene: C-E3-E2-6K-E1); Human mastadenovirus C single-stranded DNA-binding protein (gene: E2A); Human mastadenovirus E single-stranded DNA-binding protein (gene: E2A); Human adenovirus 2 DBP; Human adenovirus 6 DBP 59 kDa protein (gene: E2A); Human adenovirus 7d2 DNA binding protein (gene: E2A); Human adenovirus E4 E2A DNA binding protein; Human immunodeficiency virus 1 Envelope surface glycoprotein gp160, precursor (gene: env); Human papillomavirus type 72b E1 protein (gene: E1); Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; Human papillomavirus type 150 putative E1 product (gene: E1); Human adenovirus 16 DNA binding protein (gene: E2A); Human adenovirus 23 DNA binding protein (gene: E2A); Human adenovirus 3+7 DNA binding protein (gene: E2A); Human adenovirus 46 DBP; Human adenovirus B3 E2A DNA binding protein DBP (gene: E2A); Cowpox virus CPXV110 protein (gene: CPXV110 CDS); Human adenovirus 58 DNA binding protein (gene: E2A); Rhinovirus C 3D; Macacine alphaherpesvirus 1 tegument protein VP22 (gene: UL49); Papiine alphaherpesvirus 2 large tegument protein (gene: UL36); Human adenovirus 21 DNA-binding protein (gene: E2A); Human adenovirus 22 DNA binding protein (gene: E2A); Human adenovirus 43 DNA binding protein (gene: E2A); Human adenovirus 50 DNA binding protein (gene: E2A); Human adenovirus 54 DNA binding protein; Human adenovirus 71 ssDNA-binding protein (gene: E2A); Human adenovirus D8 DNA binding protein (gene: E2A); Human papillomavirus type 103 E1; Human adenovirus 1 DBP; Human adenovirus 49 DNA Binding Protein; Human adenovirus 21a DNA-binding protein (gene: E2A); Human adenovirus 36 DBP; Human adenovirus 19 DNA binding (gene: E2A); Human adenovirus 56 DNA-binding protein (gene: E2A); Human adenovirus 65 E2A DNA binding protein; Human adenovirus D10 DNA binding protein (gene: E2A); Human adenovirus 63 DNA-binding protein (gene: E2A); Human adenovirus 64 E2A DNA binding protein; Human adenovirus 68 DNA binding protein (gene: E2A); Human adenovirus D37 DNA-binding protein (gene: E2A); Human mastadenovirus B single-stranded DNA-binding protein (gene: E2A); Human adenovirus 67 E2A DNA binding protein; Human mastadenovirus D single-stranded DNA-binding protein (gene: E2A); Human adenovirus 28 single-stranded DNA binding protein (gene: E2A); Sudan ebolavirus spike glycoprotein (gene: GP); Sudan ebolavirus - Nakisamata structural glycoprotein (gene: GP); Monkeypox virus cowpox A-type inclusion protein; Human enterovirus 79 3D; Human herpesvirus 3 strain Dumas Tegument protein VP22 (gene: ORF9); Human alphaherpesvirus 3 tegument protein VP22 (gene: ORF9); Echovirus E29 3D; Echovirus E16 3D; Coxsackievirus B5 polyprotein region 11 (gene: 1A); Influenza A virus (A/Hong Kong/1073/99(H9N2)) matrix protein 1 (gene: M1); Influenza A virus (A/goose/Guangdong/1/1996(H5N1)) matrix protein 1 (gene: M1); Influenza A virus (A/California/07/2009(H1N1)) matrix protein 1 (gene: M1); Influenza A virus (A/California/04/2009(H1N1)) matrix protein 1 (gene: M1); Human alphaherpesvirus 2 tegument protein VP22 (gene: UL49); Echovirus E32 3D; Human alphaherpesvirus 1 tegument protein VP22 (gene: UL49); Echovirus 9 strain Barty polymerase; Echovirus E6 3D; Echovirus E21 3D",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9028576823827708,In vitro,0.64,Homo sapiens,Homo sapiens
TCFL5,"Colon Carcinoma; Adenoma; Liver carcinoma; Multiple malignancy; Glioblastoma; Seminoma; Acute lymphocytic leukemia; Myocardial Infarction; Peritonitis; Cerebrovascular accident; Premature Menopause; Ovarian Failure, Premature; Cystic Fibrosis",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8190761496232595; 0.8648405521677974; 0.9707275133033936; 0.9816840072553962; 0.9874278479946328,,,,,,,,,,
TCIRG1,"Osteopetrosis; Compression of optic nerve; Rotting teeth; Mycoses; Dental caries; Frontal bossing; Pathological fracture; Pallor; Lymphadenopathy; Abnormal visual evoked potential; Opsoclonus; Abnormality of hair consistency; Abnormality of hair curl pattern; Abnormality of hair texture; Abnormality of hair volume; Low Vision; Osteoporosis with pseudoglioma; Varying degree of multiple fractures; Frequent fractures; Increased fracture rate; Fractures, Multiple; Facial paralysis; Bowing of the long bones; Nystagmus; Pancytopenia; Narrow thorax; Reduced bone mineral density; Abnormality of temperature regulation; Alkaline phosphatase raised; Congenital neutropenia; Infantile malignant osteopetrosis; Visual Impairment; Severe congenital neutropenia; Increased head circumference; Body Temperature Changes; Chronic rhinitis; Optic Atrophy; Bone pain; Precocious exfoliation of primary tooth; Ophthalmoparesis; Congenital deafness; Tetany; Blindness, Legal; Blindness; Abnormality of the skull; Hearing Loss, Partial; Big calvaria; Increased size of skull; Flared metaphysis; Infection of bone; Deafness; Tremor; Diabetes Mellitus, Non-Insulin-Dependent; Late tooth eruption; Hip joint varus deformity - observation; hearing impairment; Splenomegaly; Infection by Cryptococcus neoformans; Idiopathic pulmonary hypertension; Otitis Media; Craniosynostosis; Bone Diseases; Abnormality of the ribs; Anemia; Growth retardation; Poor growth; Growth delay; Very poor growth; Abnormality of epiphysis morphology; Hemoglobin low; Osteomyelitis; Skin blisters; Abnormal blistering of the skin; Hydrocephalus; Skin bullae; Hepatomegaly; Encephalitis; Growth failure; Recurrent respiratory infections; Abnormality of the metaphysis; Sepsis; Facial muscle weakness of muscles innervated by CN VII; Bell Palsy; Facial Paresis; Idiopathic pulmonary arterial hypertension; Seizures; Congenital clubfoot; Epilepsy; Undergrowth; Failure to gain weight; Pediatric failure to thrive",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8270909867833504; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8486035047899471; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8610447277138289; 0.8610447277138289; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8769418330148872; 0.882453254162044; 0.882453254162044; 0.8851456306720444; 0.8851456306720444; 0.887595340546704; 0.900167961295542; 0.9066109052713736; 0.9083161862856644; 0.9083161862856644; 0.9189398569397552; 0.9189398569397552; 0.9258401930327972; 0.9258401930327972; 0.9262273158806068; 0.9478210444156088; 0.951016614400691; 0.963331724428282; 0.9884235744717738; 0.9896536639644284; 0.9896536639644284,Osteopetrosis; Oral Ulcer; Gingivitis; Opsoclonus; Pharyngitis; Myelodysplastic Syndrome; Monocytosis; Pyoderma Gangrenosum; Osteomyelitis; Eosinophilia; Nystagmus; Lymphopenia; Cranial Nerve Paralysis; Macrocephaly; Leukemia; Lymphoblastic Leukemia; Periodontitis; Congenital Neutropenia; Osteopenia; Otitis Media; Frontal Bossing; Optic Atrophy; Aplastic Anemia; Myelodysplasia; Craniosynostosis; Neutropenia; Aphthous Ulcer; Pancytopenia; Pulmonary Arterial Hypertension; Rhinitis; Hemangioma; Anemia; Hydrocephalus; Facial Paralysis,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8082616889285628; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8476516371290275; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.9046917974656596; 0.9251646147729308; 0.9369188149054885; 0.9574431947800732; 0.9832345076528324,"Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Incontinentia pigmenti ORPHA:464; Megaconial congenital muscular dystrophy ORPHA:280671; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Tumor necrosis factor receptor 1 associated periodic syndrome ORPHA:32960; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; Intermediate osteopetrosis ORPHA:210110; CLN11 disease ORPHA:314629; Heme oxygenase-1 deficiency ORPHA:562509; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Congenital chronic diarrhea with protein-losing enteropathy ORPHA:329242; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Marinesco-Sjogren syndrome ORPHA:559; Adrenomyeloneuropathy ORPHA:139399; Alpha-mannosidosis, adult form ORPHA:309288; Alpha-mannosidosis, infantile form ORPHA:309282; Bacterial susceptibility due to TLR signaling pathway deficiency ORPHA:183713; Beta-propeller protein-associated neurodegeneration ORPHA:329284; Camurati-Engelmann disease ORPHA:1328; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Deficiency in anterior pituitary function-variable immunodeficiency syndrome ORPHA:293978; Gamma-glutamyl transpeptidase deficiency ORPHA:33573; Infantile inflammatory bowel disease with neurological involvement ORPHA:565788; MYH9-related disease ORPHA:182050; Mucolipidosis type IV ORPHA:578; NIK deficiency ORPHA:447731; Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; Waldenstrom macroglobulinemia ORPHA:33226; X-linked cerebral adrenoleukodystrophy ORPHA:139396; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204; Dehydrated hereditary stomatocytosis ORPHA:3202; Takayasu arteritis ORPHA:3287; Autosomal recessive malignant osteopetrosis ORPHA:667; Metachromatic leukodystrophy, adult form ORPHA:309271; Metachromatic leukodystrophy, juvenile form ORPHA:309263; Metachromatic leukodystrophy, late infantile form ORPHA:309256; CLN3 disease ORPHA:228346; Clear cell renal carcinoma ORPHA:319276; Combined immunodeficiency-enteropathy spectrum ORPHA:436252; D-glyceric aciduria ORPHA:941; Gray platelet syndrome ORPHA:721; Mucolipidosis type III gamma ORPHA:423470; Mucopolysaccharidosis type 4A ORPHA:309297; Multiple intestinal atresia ORPHA:2300; NON RARE IN EUROPE: Pseudoarylsulfatase A deficiency ORPHA:751; Palmoplantar keratoderma-esophageal carcinoma syndrome ORPHA:2198; Ependymoma ORPHA:251636; RELA fusion-positive ependymoma ORPHA:530792; Solitary fibrous tumor/hemangiopericytoma ORPHA:2126; Dysosteosclerosis ORPHA:1782; Pediatric systemic lupus erythematosus ORPHA:93552; Autosomal dominant severe congenital neutropenia ORPHA:486; Epidermodysplasia verruciformis ORPHA:302; Systemic-onset juvenile idiopathic arthritis ORPHA:85414; Herpes simplex virus encephalitis ORPHA:1930; Immunodeficiency by defective expression of MHC class I ORPHA:34592; Autosomal dominant Kenny-Caffey syndrome ORPHA:93325; Autosomal recessive spastic paraplegia type 48 ORPHA:306511; B4GALT1-CDG ORPHA:79332; Cathepsin A-related arteriopathy-strokes-leukoencephalopathy ORPHA:575553; Combined immunodeficiency due to ORAI1 deficiency ORPHA:317428; Congenital isolated ACTH deficiency ORPHA:199296; Galactosialidosis ORPHA:351; Genetic hyperferritinemia without iron overload ORPHA:254704; Growth retardation-mild developmental delay-chronic hepatitis syndrome ORPHA:391366; Hereditary hyperferritinemia-cataract syndrome ORPHA:163; Hereditary pediatric Behcet-like disease ORPHA:476102; Hypocalcemic vitamin D-resistant rickets ORPHA:93160; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome ORPHA:529977; L-ferritin deficiency ORPHA:440731; Mucopolysaccharidosis type 7 ORPHA:584; Neuroferritinopathy ORPHA:157846; Osteocraniostenosis ORPHA:2763; Polyglucosan body myopathy type 1 ORPHA:397937; Proteasome-associated autoinflammatory syndrome ORPHA:324977; Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis ORPHA:329173; Familial Chilblain lupus ORPHA:481662; Mitochondrial neurogastrointestinal encephalomyopathy ORPHA:298; Chronic mucocutaneous candidiasis ORPHA:1334; Birdshot chorioretinopathy ORPHA:179; CLN2 disease ORPHA:228349; Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia ORPHA:284324; Embryonal rhabdomyosarcoma ORPHA:99757; Fowler vasculopaty ORPHA:221126; Overgrowth-macrocephaly-facial dysmorphism syndrome ORPHA:137634; STING-associated vasculopathy with onset in infancy ORPHA:425120; Sanfilippo syndrome type A ORPHA:79269; Transaldolase deficiency ORPHA:101028; Recurrent infection due to specific granule deficiency ORPHA:169142; Alpha-N-acetylgalactosaminidase deficiency type 1 ORPHA:79279; Alpha-N-acetylgalactosaminidase deficiency type 2 ORPHA:79280; Alpha-N-acetylgalactosaminidase deficiency type 3 ORPHA:79281; Carnitine palmitoyl transferase 1A deficiency ORPHA:156; H syndrome ORPHA:168569; Marfan syndrome type 2 ORPHA:284973; Martinique crinkled retinal pigment epitheliopathy ORPHA:466718; Predisposition to invasive fungal disease due to CARD9 deficiency ORPHA:457088",0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1054066549396977; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.2047219337649946; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.3891940933600213; 0.3891940933600213; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Monkeypox virus ankyrin-like protein,0.8999095837312036,,,,
TESK2,"Reticulocyte count (procedure); Platelet distribution width measurement; Platelet distribution width result; Infiltrating duct carcinoma of female breast; Platelet Count measurement; Platelet mean volume determination (procedure); Platelet hematocrit measurement; Alcoholic Intoxication, Chronic",0.5071083164302358; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649,Infiltrating Duct Carcinoma Of Female Breast; Chronic Obstructive Pulmonary Disease,0.7765582368651238; 0.966063509695942,,,"Human betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Vaccinia virus Ankara Serine/threonine-protein kinase 2; Horsepox virus HSPV050 (Ser/Thr kinase; Provisional); Human alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 serine/threonine protein kinase US3 (gene: US3); Human gammaherpesvirus 8 ORF72; Human alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Macacine alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 3 tegument serine/threonine protein kinase (gene: ORF47); Human betaherpesvirus 6 U69, ganciclovir kinase, phosphotransferase (gene: U69); Human betaherpesvirus 6A tegument serine/threonine protein kinase (gene: U69); Human betaherpesvirus 7 tegument serine/threonine protein kinase (gene: U69); Human alphaherpesvirus 3 serine/threonine protein kinase US3 (gene: ORF66); Monkeypox virus Zaire-96-I-16 Ser/Thr kinase (gene: C16L); Human herpesvirus 3 strain Dumas serine-threonine protein kinase; Ectromelia virus ERPV serine/threonine kinase; Papiine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Cercopithecine alphaherpesvirus 2 serine/threonine protein kinase US3 (gene: US3); Papiine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Monkeypox virus Zaire-96-I-16 B3R (gene: B3R); Human alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Cercopithecine alphaherpesvirus 2 tegument serine/threonine protein kinase (gene: UL13); Human alphaherpesvirus 1 tegument serine/threonine protein kinase (gene: UL13); Human gammaherpesvirus 8 ORF36 (gene: ORF36); Vaccinia virus Ser/Thr kinase (gene: F10L); Human betaherpesvirus 6B Phosphotransferase (gene: U69); Yaba monkey tumor virus ankyrin repeat protein; Monkeypox virus ser/thr kinase; Variola virus Ser/Thr kinase (gene: C14L); Cercopithecine betaherpesvirus 5 tegument serine/threonine protein kinase (gene: UL97); Human gammaherpesvirus 4 BGLF4 protein (gene: BGLF4); Human herpesvirus 4 type 2 BGLF4; Yaba-like disease virus 11L protein (gene: 11L); Molluscum contagiosum virus subtype 1 MC017L (gene: MC017L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV011a; Melaka orthoreovirus sigma C",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
TLCD1,,,,,Currarino syndrome ORPHA:1552; Citrullinemia type II ORPHA:247585; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Autosomal recessive cutis laxa type 2B ORPHA:357064; PYCR1-related De Barsy syndrome ORPHA:293633; Congenital hereditary endothelial dystrophy type II ORPHA:293603; Corneal dystrophy-perceptive deafness syndrome ORPHA:1490; Dopa-responsive dystonia due to sepiapterin reductase deficiency ORPHA:70594; Familial atypical multiple mole melanoma syndrome ORPHA:404560; Melanoma and neural system tumor syndrome ORPHA:252206; Xanthinuria type II ORPHA:93602; Familial clubfoot due to 5q31 microdeletion ORPHA:293144; Familial clubfoot due to PITX1 point mutation ORPHA:293150; Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome ORPHA:478049; Leydig cell hypoplasia due to LHB deficiency ORPHA:325448; Mirror-image polydactyly ORPHA:498494; Brachydactyly-elbow wrist dysplasia syndrome ORPHA:1275; 3-methylcrotonyl-CoA carboxylase deficiency ORPHA:6; Branchio-oculo-facial syndrome ORPHA:1297; Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome ORPHA:521432; DK1-CDG ORPHA:91131; Erythrocyte galactose epimerase deficiency ORPHA:308473; Generalized galactose epimerase deficiency ORPHA:308487; Neurological conditions associated with aminoacylase 1 deficiency ORPHA:137754; PMM2-CDG ORPHA:79318; SRD5A3-CDG ORPHA:324737; Vitamin B12-responsive methylmalonic acidemia type cblB ORPHA:79311; Congenital myasthenic syndromes with glycosylation defect ORPHA:353327,0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TMCC2,Reticulocyte count (procedure); Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Platelet distribution width measurement; Platelet distribution width result; Platelet Count measurement; Mean corpuscular hemoglobin concentration determination; Platelet mean volume determination (procedure); Mean Corpuscular Volume (result),0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,Autosomal dominant spastic paraplegia type 12 ORPHA:100993; Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; 8p11.2 deletion syndrome ORPHA:251066; Distal 22q11.2 microdeletion syndrome ORPHA:261330; Polymicrogyria with optic nerve hypoplasia ORPHA:250972; CLCN4-related X-linked intellectual disability syndrome ORPHA:485350; NON RARE IN EUROPE: Vitiligo ORPHA:3435; Young-onset Parkinson disease ORPHA:2828,0.0144185025972157; 0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.8668760866668862,,,,,,
TMED1,"Malignant neoplasm of breast; Malignant neoplasm of lung; Mycoses; Primary malignant neoplasm of lung; Carcinoma of lung; Adenocarcinoma of pancreas; Pancreatitis, Chronic; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Autoimmune Diseases; Cardiovascular Diseases; Crohn Disease; HIV Infections; Osteopenia; Coronary Artery Disease; Coronary heart disease; Carcinoma, Lewis Lung; Asthma",0.4084380369379369; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8145035474981049; 0.8212681436603975; 0.887595340546704; 0.9119978323790848; 0.9432051631882106; 0.9672478180546946,Breast Cancer,0.8903630091389316,"Multiple endocrine neoplasia type 1 ORPHA:652; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; CADDS ORPHA:369942; Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency ORPHA:95699; Galactokinase deficiency ORPHA:79237; Rare isolated myopia ORPHA:98619; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; Familial hypocalciuric hypercalcemia type 3 ORPHA:101050; Hyperammonemia due to N-acetylglutamate synthase deficiency ORPHA:927; Hyperbiliverdinemia ORPHA:276405; Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome ORPHA:529665; Sanfilippo syndrome type B ORPHA:79270; THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome ORPHA:363444; Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency ORPHA:308410; Biotinidase deficiency ORPHA:79241; Glycogen storage disease due to aldolase A deficiency ORPHA:57; Infantile nephropathic cystinosis ORPHA:411629; Juvenile nephropathic cystinosis ORPHA:411634; MPDU1-CDG ORPHA:79323; Ocular cystinosis ORPHA:411641; Pontocerebellar hypoplasia type 8 ORPHA:324569; Prolidase deficiency ORPHA:742; Spondylometaphyseal dysplasia, Sedaghatian type ORPHA:93317; Hepatoerythropoietic porphyria ORPHA:95159; Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome ORPHA:369837; Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome ORPHA:369939",0.0473879273649914; 0.1040670578681756; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TMEM129,Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder,0.4084380369379369; 0.4084380369379369; 0.5071083164302358,,,"Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Short chain acyl-CoA dehydrogenase deficiency ORPHA:26792; D-2-hydroxyglutaric aciduria ORPHA:79315; Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome ORPHA:95433; Classic Hodgkin lymphoma, nodular sclerosis type ORPHA:98843; NAD(P)HX dehydratase deficiency ORPHA:555402; Very long chain acyl-CoA dehydrogenase deficiency ORPHA:26793; Spondylo-ocular syndrome ORPHA:85194; Autosomal dominant Charcot-Marie-Tooth disease type 2V ORPHA:447964; Autosomal recessive ataxia due to PEX10 deficiency ORPHA:247815; Autosomal recessive cerebellar ataxia due to STUB1 deficiency ORPHA:412057; Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome ORPHA:529665; Sanfilippo syndrome type B ORPHA:79270; Isovaleric acidemia ORPHA:33",0.0155394890951578; 0.0155394890951578; 0.1040670578681756; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.8922466888454011,,,,,,
TMEM169,,,,,Early-onset parkinsonism-intellectual disability syndrome ORPHA:2379; Progressive myoclonic epilepsy type 3 ORPHA:263516; Idiopathic central precocious puberty ORPHA:169615,0.3832844616405875; 0.3832844616405875; 0.5867963421058087,,,,,,
TMEM170B,,,,,Distal monosomy 1q ORPHA:36367; Polyendocrine-polyneuropathy syndrome ORPHA:453533; Angiocentric glioma ORPHA:251671; Complex lethal osteochondrodysplasia ORPHA:457378; Fried syndrome ORPHA:85335; X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome ORPHA:1568; X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome ORPHA:85329; Bilateral parasagittal parieto-occipital polymicrogyria ORPHA:208441; Charcot-Marie-Tooth disease type 4J ORPHA:139515,0.1040670578681756; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TMEM45B,Carcinogenesis; Malignant neoplasm of lung; Osteosarcoma; Osteosarcoma of bone; Primary malignant neoplasm of lung; Carcinoma of lung; Neoplasms; Childhood Osteosarcoma,0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649,,,"Alkaptonuria ORPHA:56; Autosomal recessive cerebral atrophy ORPHA:363969; Familial expansile osteolysis ORPHA:85195; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Familial hyperprolactinemia ORPHA:397685; Fructose-1,6-bisphosphatase deficiency ORPHA:348; NON RARE IN EUROPE: Recurrent acute pancreatitis ORPHA:64740; Familial thyroid dyshormonogenesis ORPHA:95716; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency ORPHA:477857; Chronic infantile diarrhea due to guanylate cyclase 2C overactivity ORPHA:314373; Cranio-osteoarthropathy ORPHA:1525; Glucose-galactose malabsorption ORPHA:35710; Ichthyosis-hypotrichosis syndrome ORPHA:91132; Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency ORPHA:314376; Isolated congenital digital clubbing ORPHA:217059; Serrated polyposis syndrome ORPHA:157798; Peroxisomal acyl-CoA oxidase deficiency ORPHA:2971; Familial hyperphosphatemic tumoral calcinosis/Hyperphosphatemic hyperostosis syndrome ORPHA:306661; Autosomal dominant hypohidrotic ectodermal dysplasia ORPHA:1810",0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TNFRSF10B,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Adenomatous Polyposis Coli; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; leukemia; Ovarian Carcinoma; Adenocarcinoma; Malignant neoplasm of pancreas; Colorectal Carcinoma; Pancreatic carcinoma; Laryngeal Squamous Cell Carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Esophageal carcinoma; Lymphoma; Cervix carcinoma; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Pancreatic Ductal Adenocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasm; Cholestatic liver disease; Esophageal Neoplasms; Malignant tumor of cervix; Mammary Neoplasms; Glioma; Malignant neoplasm of lung; Malignant neoplasm of prostate; Lymphoma, Non-Hodgkin; Liver carcinoma; Malignant neoplasm of esophagus; Malignant Head and Neck Neoplasm; Osteosarcoma; Colorectal Cancer; Epithelial ovarian cancer; Rhabdomyosarcoma; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Primary malignant neoplasm of lung; cervical cancer; Neoplasm Metastasis; Epithelioma; Malignant neoplasm of testis; Carcinoma of lung; Squamous cell carcinoma of the head and neck; Triple Negative Breast Neoplasms; Mesothelioma; Hematologic Neoplasms; melanoma; Ewings sarcoma; Multiple Myeloma; Lung Neoplasms; Adenovirus Infections; Neoplasms; Squamous cell carcinoma of mouth; Malignant neoplasm of stomach; Transitional cell carcinoma of bladder; Brain Neoplasms; Squamous cell carcinoma of lip; Pancreatitis, Chronic; Malignant Testicular Germ Cell Tumor; Sarcoma; Lupus Erythematosus, Systemic; Renal Cell Carcinoma; Primary Effusion Lymphoma; Stomach Carcinoma; Squamous cell carcinoma; Solid Neoplasm; Rheumatoid Arthritis; Adenoma of large intestine; Small cell carcinoma of lung; Virus Diseases; Secondary malignant neoplasm of liver; Multiple Sclerosis; Psoriasis; Chronic Lymphocytic Leukemia; Embryonal Carcinoma; Liver neoplasms; Nonalcoholic Steatohepatitis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Early-Stage Breast Carcinoma; Dengue Fever; Squamous cell carcinoma of the hypopharynx; Colonic Neoplasms; Infection; Glioblastoma Multiforme; Amyotrophic Lateral Sclerosis; Patent ductus arteriosus; Malignant Squamous Cell Neoplasm; Sezary Syndrome; Colorectal cancer metastatic; Liver Neoplasms, Experimental; Experimental Hepatoma; Hepatoma, Novikoff; Hepatoma, Morris; Hepatitis, Chronic; tumor vasculature; Squamous cell carcinoma of oropharynx; Secondary malignant neoplasm of lymph node; Anoxia",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.5196624042573144; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8138488881521341; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8272008757995397; 0.8342163953428735; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8711129600224142; 0.8769418330148872; 0.8806784681730055; 0.887595340546704; 0.900167961295542; 0.9184153253162451,Carcinoma Of The Head And Neck; Oropharyngeal Carcinoma; Oral Cavity Carcinoma; Pancreatic Neoplasm; Pancreatic Cancer; Carcinoma,0.4532988396145482; 0.6734982286750932; 0.7765582368651238; 0.861756360478846; 0.8903301324869451; 0.9069867032339078,Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Squamous cell carcinoma of salivary glands ORPHA:500481; Squamous cell carcinoma of the hypopharynx ORPHA:494547; Squamous cell carcinoma of the larynx ORPHA:494550; Squamous cell carcinoma of the lip ORPHA:502366; Squamous cell carcinoma of the nasal cavity and paranasal sinuses ORPHA:500464; Squamous cell carcinoma of the oral cavity ORPHA:502363; Squamous cell carcinoma of the oropharynx ORPHA:500478; Bilateral microtia-deafness-cleft palate syndrome ORPHA:140963; Microtia ORPHA:83463,0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.8922466888454011; 0.8922466888454011,Human betaherpesvirus 6B glycoprotein (gene: U85); Human adenovirus 52 E3 CR1-beta1 (gene: E3); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Human betaherpesvirus 5 membrane glycoprotein UL141 (gene: UL141); Cercopithecine betaherpesvirus 5 membrane glycoprotein UL141 (gene: UL141); Monkeypox virus bifunctional hemagglutinin/type-I membrane glycoprotein; Monkeypox virus Zaire-96-I-16 B2R (gene: B2R); Variola virus hypothetical protein (gene: J9R); Human mastadenovirus A E3 CR1-beta1; Horsepox virus HSPV177 (Immunoglobulin like); Human adenovirus 61 E3 CR1 beta; Human mastadenovirus F membrane glycoprotein E3 CR1-beta (gene: E3A); Vaccinia virus hemagglutinin (gene: A56R); Human adenovirus 41 E3 31.6K; Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta); Vaccinia virus Ankara Haemagglutinin,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.915880438522078; 0.9197295331382644; 0.9237501457186692; 0.9287050575620676,In vitro,0.44,Homo sapiens;In vitro,Homo sapiens;In vitro
TNFRSF11A,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; leukemia; Osteopetrosis; Compression of optic nerve; Leukemia, Myelocytic, Acute; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Esophageal carcinoma; Progressive visual loss; Non-Small Cell Lung Carcinoma; Adult T-Cell Lymphoma/Leukemia; Decreased visual acuity, progressive; Tooth problem; Endometrial Carcinoma; Esophageal Neoplasms; Mammary Neoplasms; Glioma; Abnormality of the dentition; Malignant neoplasm of lung; Malignant neoplasm of prostate; Refractory anemias; Liver carcinoma; Invasive carcinoma of breast; Malignant neoplasm of esophagus; Osteosarcoma; Spondylarthritis; Early tooth exfoliation; Premature tooth loss; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; Primary malignant neoplasm of lung; Neoplasm Metastasis; Prostatic Neoplasms; Carcinoma of lung; melanoma; Pathological fracture; Multiple Myeloma; Metastatic Prostate Carcinoma; Renal glomerular disease; Hyperphosphatasemia with bone disease; Abnormal trabecular bone morphology; Neoplasm of skeletal system; Increase in blood pressure; Giant Cell Tumor of Bone; Conductive hearing loss; Tumor Progression; Thick skull bones; Cranial hyperostosis; Enlargement of skull bones; Excessive growth of skull bones; Hypertrophy of cranial bones; Sarcoma; Paget Disease; Varying degree of multiple fractures; Frequent fractures; Increased fracture rate; Fractures, Multiple; Recurrent pulmonary infections; Multiple pulmonary infections; Hydroxyprolinuria; Coronary Arteriosclerosis; Arteriosclerosis; Atherosclerosis; Periodontitis; Recurrent pneumonia; Bowing of the long bones; Hemophilia B; Secondary Sj??gren's syndrome; Hereditary Autoinflammatory Diseases; Nystagmus; Chondrosarcoma; Osteitis Deformans; Cognitive delay; Autoimmune Diseases; Alkaline phosphatase raised; Acute myocardial infarction; Cardiovascular Diseases; Thin bony cortex; Squamous cell carcinoma; Solid Neoplasm; Rheumatoid Arthritis; Increased head circumference; PACHYONYCHIA CONGENITA 3; Global developmental delay; Optic Atrophy; Mental and motor retardation; Osteoporosis, Postmenopausal; Bone pain; Rough bone trabeculation; Juvenile arthritis; Chronic multifocal osteomyelitis; Congenital deafness; Vitiligo; Chronic Lymphocytic Leukemia; Infectious disease of lung; Degenerative polyarthritis; Temporomandibular Joint Disorders; Abnormality of the clavicle; Acute Coronary Syndrome; Angina, Unstable; Hearing Loss, Partial; Big calvaria; Increased size of skull; Breast adenocarcinoma; Agammaglobulinemia; Diabetes Mellitus, Insulin-Dependent; Autoinflammatory disorder; Stable angina; Congenital pectus carinatum; Congenital malformation syndrome; aggressive cancer; Ulcerative Colitis; Myocarditis; Deafness; Gastrointestinal Carcinoid Tumor; Mammary Tumorigenesis; Arthralgia; Osteopenia; Juvenile rheumatoid arthritis; Secondary malignant neoplasm of lung; bone destruction; Hypersensitivity; Hypogammaglobulinemia; Pneumonia; hearing impairment; Lytic lesion; Left Ventricular Hypertrophy; Non-small cell lung cancer metastatic; Osteogenesis Imperfecta; Hypertensive disease; Bone Diseases; Anemia; Squamous cell carcinoma of esophagus; Bone Diseases, Developmental; Early Rheumatoid Arthritis; Atrial Fibrillation; Hemoglobin low; Malignant neoplasm of endometrium; Uterine Corpus Cancer; Short stature; Inflammatory disorder; Coronary Artery Disease; Cooley's anemia; Hyperactive behavior; Hyperuricemia; Bone neoplasms; Obesity; Congenital Heart Defects; Coronary heart disease; Influenza; Hemophilia A; Myasthenia Gravis; Arthritis; Secondary malignant neoplasm of bone; Malaria; Osteoporosis",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8037546774788534; 0.8067197998685076; 0.8098851543361193; 0.8098851543361193; 0.8098851543361193; 0.8138488881521341; 0.8138488881521341; 0.8145035474981049; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.8232134984476662; 0.834094492023826; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8578473133580928; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8769418330148872; 0.8771562273432176; 0.8815127642200768; 0.882453254162044; 0.887595340546704; 0.887595340546704; 0.8878860377518915; 0.8942113186235617; 0.8959157818691486; 0.8989612563669234; 0.9098977259629772; 0.9119978323790848; 0.9193385822373632; 0.9193385822373632; 0.9390727893210336; 0.9431511078237256; 0.946564927793026; 0.9512505437112568; 0.9639249377588224,Osteopetrosis; Melanocytic Nevus; Lymphocytic Leukemia; Brain Stem Compression; Hypocalcemic Seizures; Vitiligo; Nystagmus; Hypertension; Cranial Nerve Paralysis; Developmental Delay; Macrocephaly; Paget Disease; Optic Atrophy; Proptosis; Hearing Loss; Motor Delay; Hyperuricemia; Osteoporosis; Osteosarcoma; Congenital Pectus Carinatum; Myasthenia Gravis; Anemia; Dwarfism; Hydrocephalus; Eczema; Asthma,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.8897718769742773; 0.8903301324869451; 0.8903301324869451; 0.9024492468099392; 0.924275664330454; 0.9369188149054885; 0.9510372690456612; 0.9574431947800732; 0.9658957825498884; 0.9832345076528324,Familial expansile osteolysis ORPHA:85195; Osteopetrosis-hypogammaglobulinemia syndrome ORPHA:178389; Dysosteosclerosis ORPHA:1782; NON RARE IN EUROPE: Paget disease of bone ORPHA:280110; Juvenile Paget disease ORPHA:2801; Adult-onset myasthenia gravis ORPHA:391490,0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Vaccinia virus Ankara soluble TNF receptor II precursor f1; Monkeypox virus Zaire-96-I-16 Tumor necrosis Factor-receptor like protein (gene: K1R); Cowpox virus CrmC or CPXV191 protein (gene: CrmC); Vaccinia virus secreted TNF-receptor-like protein (gene: A53R); Horsepox virus HSPV175 (Tumor necrosis factor receptor superfamily (TNFRSF)); Cercopithecine betaherpesvirus 5 membrane glycoprotein UL144 (gene: UL144); Vaccinia virus Ankara TNF receptor domain/CrmC; Variola virus hypothetical protein (gene: G4R); Horsepox virus HSPV003 (Tumor necrosis factor receptor superfamily members); Human betaherpesvirus 5 membrane glycoprotein UL144 (gene: UL144); Monkeypox virus Zaire-96-I-16 J2L (gene: J2L); Cowpox virus CrmB or CPXV005 protein (gene: crmB); Monkeypox virus TNF-alpha-receptor-like protein,0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9056300531913352; 0.9057542447893764; 0.9057542447893764,,,,
TNFSF9,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; B-Cell Lymphomas; Ovarian Carcinoma; Adenocarcinoma; Colorectal Carcinoma; Colon Carcinoma; Leukemia, Myelocytic, Acute; Malignant tumor of colon; Lymphoma; Cervix carcinoma; Colorectal Neoplasms; Malignant tumor of cervix; Malignant neoplasm of prostate; IMMUNE SUPPRESSION; Liver carcinoma; Colorectal Cancer; Epithelial ovarian cancer; Prostate carcinoma; cervical cancer; Neuroblastoma; Lymphocytic infiltration; Central neuroblastoma; Malignant Neoplasms; Malignant neoplasm of stomach; Burkitt Lymphoma; Mycobacterium avium infection; Stromal Neoplasm; Takayasu Arteritis; Arteriosclerosis; Atherosclerosis; Autoimmune Diseases; Single tumor; Rheumatoid Arthritis; Crohn Disease; Tumor Immunity; Mycobacterium avium-intracellulare Infection; Primary malignant neoplasm; Multiple Sclerosis; Chronic Lymphocytic Leukemia; Hereditary Diffuse Gastric Cancer; Stomach Neoplasms; HIV Infections; Primary biliary cirrhosis; Contact hypersensitivity; Contact Dermatitis; Influenza",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8044379824544406; 0.8145035474981049; 0.8212681436603975; 0.8942113186235617; 0.917543617287358; 0.9193385822373632,Stomach Neoplasms; Gastric Cancer; Dermatitis,0.7765582368651238; 0.861756360478846; 0.861756360478846,Crisponi syndrome ORPHA:1545; Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Bosley-Salih-Alorainy syndrome ORPHA:69737; Familial atypical multiple mole melanoma syndrome ORPHA:404560; Melanoma and neural system tumor syndrome ORPHA:252206,0.0155394890951578; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,,,,,,
TNKS1BP1,Malignant Neoplasms; Primary malignant neoplasm,0.7880542567584415; 0.7908231553833205,,,"Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Congenital thrombotic thrombocytopenic purpura ORPHA:93583; Antley-Bixler syndrome ORPHA:83; Cleft lip/palate-ectodermal dysplasia syndrome ORPHA:3253; Monosomy 22q13.3 ORPHA:48652; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Steinert myotonic dystrophy ORPHA:273; Bilateral perisylvian polymicrogyria ORPHA:98889; Saldino-Mainzer syndrome ORPHA:140969; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Epidermolysis bullosa simplex with muscular dystrophy ORPHA:257; Familial cortical myoclonus ORPHA:319189; Frank-Ter Haar syndrome ORPHA:137834; Knobloch syndrome ORPHA:1571; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement ORPHA:79401; Plectin-related  limb-girdle muscular dystrophy R17 ORPHA:254361; Pyruvate carboxylase deficiency, benign type ORPHA:353320; Pyruvate carboxylase deficiency, infantile type ORPHA:353308; Pyruvate carboxylase deficiency, severe neonatal type ORPHA:353314; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Progressive myoclonic epilepsy type 5 ORPHA:402082; Familial hypercholanemia ORPHA:238475; Early-onset posterior subcapsular cataract ORPHA:441447; Early-onset posterior polar cataract ORPHA:98993; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Alopecia universalis ORPHA:701; Atrichia with papular lesions ORPHA:86819; Atypical Werner syndrome ORPHA:79474; Autosomal dominant intermediate Charcot-Marie-Tooth disease type E ORPHA:93114; Autosomal recessive Emery-Dreifuss muscular dystrophy ORPHA:98855; Autosomal recessive intermediate Charcot-Marie-Tooth disease type C ORPHA:369867; Autosomal recessive lower motor neuron disease with childhood onset ORPHA:206580; Autosomal semi-dominant severe lipodystrophic laminopathy ORPHA:280365; Charcot-Marie-Tooth disease type 2B1 ORPHA:98856; Congenital muscular dystrophy due to LMNA mutation ORPHA:157973; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome ORPHA:2229; Dyschromatosis universalis hereditaria ORPHA:241; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation ORPHA:300751; Familial partial lipodystrophy, Dunnigan type ORPHA:2348; Familial partial lipodystrophy, Kobberling type ORPHA:79084; Familial pseudohyperkalemia ORPHA:90044; Heart-hand syndrome, Slovenian type ORPHA:168796; LMNA-related cardiocutaneous progeria syndrome ORPHA:363618; Mandibuloacral dysplasia with type A lipodystrophy ORPHA:90153; Muscular dystrophy, Selcen type ORPHA:199340; Non-immune hydrops fetalis ORPHA:363999; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Spectrin-associated autosomal recessive cerebellar ataxia ORPHA:352403; Spinocerebellar ataxia type 5 ORPHA:98766; Van den Ende-Gupta syndrome ORPHA:2460; Crouzon disease ORPHA:207; Dermatofibrosarcoma protuberans ORPHA:31112; Shprintzen-Goldberg syndrome ORPHA:2462; Alopecia-intellectual disability syndrome ORPHA:2850; Idiopathic pulmonary fibrosis ORPHA:2032; Lethal acantholytic erosive disorder ORPHA:158687; Multiple osteochondromas ORPHA:321; Aarskog-Scott syndrome ORPHA:915; Acute neonatal citrullinemia type I ORPHA:247546; Adult-onset citrullinemia type I ORPHA:247573; Alagille syndrome due to 20p12 microdeletion ORPHA:261600; Alagille syndrome due to a JAG1 point mutation ORPHA:261619; Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Congenital hereditary endothelial dystrophy type II ORPHA:293603; Corneal dystrophy-perceptive deafness syndrome ORPHA:1490; Dentatorubral pallidoluysian atrophy ORPHA:101; Dopa-responsive dystonia due to sepiapterin reductase deficiency ORPHA:70594; Hyperprolinemia type 2 ORPHA:79101; Isolated biliary atresia ORPHA:30391; Isolated congenital breast hypoplasia/aplasia ORPHA:180188; Lateral meningocele syndrome ORPHA:2789; Multiple myeloma ORPHA:29073; POMT2-related  limb-girdle muscular dystrophy R14 ORPHA:206559; Pierson syndrome ORPHA:2670; Seizures-scoliosis-macrocephaly syndrome ORPHA:466926; Severe congenital hypochromic anemia with ringed sideroblasts ORPHA:300298; Wolfram-like syndrome ORPHA:411590; X-linked creatine transporter deficiency ORPHA:52503; 3M syndrome ORPHA:2616; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Carpenter syndrome ORPHA:65759; Hyperostosis corticalis generalisata ORPHA:3416; Spondylocarpotarsal synostosis ORPHA:3275; Spondyloepimetaphyseal dysplasia with joint laxity ORPHA:93359; Acrocallosal syndrome ORPHA:36; Hereditary diffuse gastric cancer ORPHA:26106; Isolated scaphocephaly ORPHA:35093; Myxofibrosarcoma ORPHA:79105; Aplasia cutis congenita ORPHA:1114; Familial exudative vitreoretinopathy ORPHA:891; Juvenile nephronophthisis ORPHA:93592; Acrokeratosis verruciformis of Hopf ORPHA:79151; Alpha-dystroglycan-related  limb-girdle muscular dystrophy R16 ORPHA:280333; Atelosteogenesis type I ORPHA:1190; Atelosteogenesis type III ORPHA:56305; Autosomal dominant osteopetrosis type 1 ORPHA:2783; Autosomal spastic paraplegia type 58 ORPHA:397946; Boomerang dysplasia ORPHA:1263; Craniofrontonasal dysplasia ORPHA:1520; Darier disease ORPHA:218; Dent disease type 2 ORPHA:93623; Endosteal hyperostosis, Worth type ORPHA:2790; Familial congenital nasolacrimal duct obstruction ORPHA:451612; Familial hypocalciuric hypercalcemia type 2 ORPHA:101049; LAMA5-related multisystemic syndrome ORPHA:521450; LRP5-related primary osteoporosis ORPHA:498481; Larsen syndrome ORPHA:503; MUC1-related autosomal dominant tubulointerstitial kidney disease ORPHA:88949; Multiple epiphyseal dysplasia, Al-Gazali type ORPHA:166024; Muscle-eye-brain disease with bilateral multicystic leucodystrophy ORPHA:370997; Naxos disease ORPHA:34217; Oculocerebrorenal syndrome of Lowe ORPHA:534; Osteoporosis-pseudoglioma syndrome ORPHA:2788; Osteosclerosis-developmental delay-craniosynostosis syndrome ORPHA:178377; POMGNT1-related  limb-girdle muscular dystrophy R15 ORPHA:206564; Phakomatosis cesiomarmorata ORPHA:79484; Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome ORPHA:477673; Autosomal dominant non-syndromic sensorineural deafness type DFNA ORPHA:90635; Autosomal dominant hypocalcemia ORPHA:428; Retinopathy of prematurity ORPHA:90050; Familial bicuspid aortic valve ORPHA:402075; Autosomal dominant polycystic kidney disease ORPHA:730; Osteogenesis imperfecta type 3 ORPHA:216812; Walker-Warburg syndrome ORPHA:899; Total early-onset cataract ORPHA:98994; 22q11.2 duplication syndrome ORPHA:1727; Autosomal dominant Charcot-Marie-Tooth disease type 2DD ORPHA:521414; Autosomal dominant neovascular inflammatory vitreoretinopathy ORPHA:329211; Craniofacial dysplasia-osteopenia syndrome ORPHA:314555; Desmosterolosis ORPHA:35107; Dyssegmental dysplasia, Silverman-Handmaker type ORPHA:1865; Dystonia-parkinsonism-hypermanganesemia syndrome ORPHA:521406; Microcystic stromal tumor ORPHA:569248; Pilomatrixoma ORPHA:91414; Schwartz-Jampel syndrome ORPHA:800; Severe intellectual disability-progressive spastic diplegia syndrome ORPHA:404473; Vein of Galen aneurysmal malformation ORPHA:1053; Isolated polycystic liver disease ORPHA:2924; Milroy disease ORPHA:79452; Autosomal dominant Robinow syndrome ORPHA:3107; Familial multiple meningioma ORPHA:263662; Autosomal recessive spastic paraplegia type 18 ORPHA:209951; Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome ORPHA:280384; Cervical spina bifida aperta ORPHA:268392; Cervical spina bifida cystica ORPHA:268762; Cervicothoracic spina bifida aperta ORPHA:268397; Cervicothoracic spina bifida cystica ORPHA:268766; Lumbosacral spina bifida aperta ORPHA:268388; Lumbosacral spina bifida cystica ORPHA:268758; Muscle-eye-brain disease ORPHA:588; Thoracolumbosacral spina bifida aperta ORPHA:268384; Thoracolumbosacral spina bifida cystica ORPHA:268752; Total spina bifida aperta ORPHA:268377; Total spina bifida cystica ORPHA:268748; Upper thoracic spina bifida aperta ORPHA:268740; Upper thoracic spina bifida cystica ORPHA:268770",0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.220389120533256; 0.2475924359068358; 0.2844858212863536; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5047266821728011; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6196505963261838; 0.6335420546867965; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8105918570729571; 0.8211968342881582; 0.8778481542696168; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TOE1,Spasmodic movement; Involuntary jerking movements; Large auricle; Large pinnae; Macrotia; Thick upper lip vermilion; Supratentorial atrophy; Hypoplasia of corpus callosum; Myoclonus; Nystagmus; Cognitive delay; Degenerative brain disorder; Hypoplasia of the pons; Defective or absent horizontal voluntary eye movements; Pontoneocerebellar hypoplasia; Global developmental delay; Progressive microcephaly; Congenital pontocerebellar hypoplasia; Optic Atrophy; Mental and motor retardation; Oculomotor apraxia; Disorders of Sex Development; Cerebral atrophy; Spastic Paraplegia; Apnea; Broad flat nasal bridge; Nasal bridge wide; Congenital hypoplasia of penis; Cerebellar Hypoplasia; Generalized hypotonia; Concave bridge of nose; Depressed nasal root/bridge; Depressed nasal bridge; Retrusion of lower jaw; Decreased projection of lower jaw; Decreased projection of mandible; Hypoplastic mandible condyle; Aplasia/Hypoplasia of the mandible; Micrognathism; Ambiguous Genitalia; Congenital Epicanthus; Intellectual Disability; Seizures; Epilepsy; Hyperreflexia,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8145035474981049; 0.8213459222602666; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.843190898187174; 0.8578473133580928; 0.8578473133580928; 0.8584283190330553; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8867509400747969; 0.9478210444156088; 0.9478210444156088; 0.963331724428282; 0.998046372175909,Oculovestibuloauditory Syndrome; Oculomotor Apraxia; Hereditary Cancer Syndrome; Nystagmus; Developmental Delay; Hypoplasia Of Corpus Callosum; Macrotia; Hypertrophy Of Clitoris; Pontoneocerebellar Hypoplasia; Optic Atrophy; Penis Agenesis; Spastic Paraplegia; Mental Retardation; Cerebral Atrophy; Cerebellar Hypoplasia; Ambiguous Genitalia; Cryptorchidism; Gonadal Dysgenesis; Microcephaly; Micrognathism; High Palate; Congenital Epicanthus,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7949861636679444; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8182883735985873; 0.8337953215113012; 0.8339308890552987; 0.8601151608808731; 0.8611702959552964; 0.861756360478846; 0.861756360478846; 0.8903630091389316; 0.9398381935810408; 0.9578111936867284; 0.974502015052702,Combined immunodeficiency due to CD70 deficiency ORPHA:538958; Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome ORPHA:502423; Schnyder corneal dystrophy ORPHA:98967; Amish lethal microcephaly ORPHA:99742; Pontocerebellar hypoplasia type 10 ORPHA:411493; Progressive polyneuropathy with bilateral striatal necrosis ORPHA:217396; Purine nucleoside phosphorylase deficiency ORPHA:760; Severe combined immunodeficiency due to adenosine deaminase deficiency ORPHA:277; Combined immunodeficiency with faciooculoskeletal anomalies ORPHA:221139; Pontocerebellar hypoplasia type 2 ORPHA:2524; Dyskeratosis congenita ORPHA:1775; Bowen-Conradi syndrome ORPHA:1270; Cernunnos-XLF deficiency ORPHA:169079; Deafness-encephaloneuropathy-obesity-valvulopathy syndrome ORPHA:254898; Early-onset generalized limb-onset dystonia ORPHA:256; Lenz-Majewski hyperostotic dwarfism ORPHA:2658; MUTYH-related attenuated familial adenomatous polyposis ORPHA:247798; Pontocerebellar hypoplasia type 7 ORPHA:284339; RFT1-CDG ORPHA:244310; Ribose-5-P isomerase deficiency ORPHA:440706; Spinocerebellar ataxia type 17 ORPHA:98759; Hypocalcemic vitamin D-dependent rickets ORPHA:289157; Mitochondrial myopathy and sideroblastic anemia ORPHA:2598; Immunodeficiency by defective expression of MHC class II ORPHA:572; Hyperphosphatasia-intellectual disability syndrome ORPHA:247262; Hoyeraal-Hreidarsson syndrome ORPHA:3322; Arthrogryposis-renal dysfunction-cholestasis syndrome ORPHA:2697; Arthrogryposis-anterior horn cell disease syndrome ORPHA:53696; Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency ORPHA:453521; Lethal congenital contracture syndrome type 1 ORPHA:1486; Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome ORPHA:391307; Xeroderma pigmentosum ORPHA:910,0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8668760866668862; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TP53I3,"Malignant neoplasm of breast; Breast Carcinoma; Colorectal Carcinoma; Non-Small Cell Lung Carcinoma; Malignant neoplasm of prostate; Colorectal Cancer; Prostate carcinoma; Squamous cell carcinoma of the head and neck; melanoma; Ewings sarcoma; Coinfection; Carcinoma; Carcinoma, Spindle-Cell; Undifferentiated carcinoma; Adenoma of lung; Carcinomatosis; Mammary Carcinoma, Animal; Animal Mammary Neoplasms; Anaplastic carcinoma",0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7950434752274518; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345,Anaplastic Carcinoma; Breast Cancer; Carcinoma,0.8115918568696846; 0.8903630091389316; 0.9069867032339078,Hereditary thrombocytopenia with early-onset myelofibrosis ORPHA:480851; Quebec platelet disorder ORPHA:220436; Adult-onset autosomal recessive cerebellar ataxia ORPHA:284289; Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria ORPHA:99646,0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.8922466888454011,,,,,,
TPPP,"Bladder Neoplasm; Superinfection; leukemia; Reticulosarcoma; Asymptomatic human immunodeficiency virus infection; Colon Carcinoma; Adult T-Cell Lymphoma/Leukemia; HIV Encephalopathy; HIV encephalitis; Chronic Fatigue Syndrome; Prion Diseases; Hepatitis D Infection; Immunologic Deficiency Syndromes; Lymphadenopathy; Renal Cell Carcinoma; Acquired Immunodeficiency Syndrome; Infant, Premature; Alzheimer's Disease; Ketosis; Sjogren's Syndrome; Huntington Disease; Virus Diseases; Acute HIV infection; Viremia; Primary HIV infection; Leukoencephalopathy, Progressive Multifocal; Lung diseases; Borna Disease; HIV Infections; Primary infection NOS; CNS disorder; Welts; Neurodegenerative Disorders; Common acute lymphoblastic leukemia; Tuberculosis; Amyotrophic Lateral Sclerosis; Cerebellar Diseases; Mycobacterium Infections; Hepatitis B; Memory impairment; Hippocampal sclerosis; Tuberculosis, Pulmonary; Cerebrovascular accident; Amyloidosis; Neurologic Symptoms; Adenocarcinoma Of Esophagus; Parkinson Disease; Parasitemia; Lewy Body Disease; Shy-Drager Syndrome; Mood Disorders; Influenza; Psychotic Disorders; Unipolar Depression; Urticaria; Malaria; Major Depressive Disorder",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8145035474981049; 0.8168901801930506; 0.8168901801930506; 0.8168901801930506; 0.8272008757995397; 0.834094492023826; 0.8368219249856942; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.841396342333011; 0.8474481237156937; 0.8584283190330553; 0.8610447277138289; 0.8648405521677974; 0.8672189956534445; 0.8690346447728063; 0.8769418330148872; 0.8772392350816924; 0.882453254162044; 0.8851456306720444; 0.8989612563669234; 0.9093740881835894; 0.9193385822373632; 0.939985154445373; 0.9455834988784428; 0.9473064300361868; 0.9512505437112568; 0.9658628445524134,Esophageal Cancer; Barrett Esophagus; Mental Depression,0.8165359516083085; 0.8457525389282121; 0.8903630091389316,"Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha ORPHA:566231; 1p36 deletion syndrome ORPHA:1606; Succinic semialdehyde dehydrogenase deficiency ORPHA:22; Infant acute respiratory distress syndrome ORPHA:70587; Early infantile epileptic encephalopathy ORPHA:1934; Autosomal dominant focal dystonia, DYT25 type ORPHA:329466; Chronic respiratory distress with surfactant metabolism deficiency ORPHA:217566; Hyperprolinemia type 1 ORPHA:419; Interstitial lung disease due to SP-C deficiency ORPHA:440392; Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease ORPHA:163746",0.0155394890951578; 0.0184072076199886; 0.1991445465001551; 0.5867963421058087; 0.7593059616185558; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TRAM2,,,Vascular Diseases,0.7765582368651238,"Atrial septal defect, sinus venosus type ORPHA:99105; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; MYH9-related disease ORPHA:182050; Mucopolysaccharidosis type 6, rapidly progressing ORPHA:276212; Mucopolysaccharidosis type 6, slowly progressing ORPHA:276223; Musculocontractural Ehlers-Danlos syndrome ORPHA:2953; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; Cap myopathy ORPHA:171881; Congenital short bowel syndrome ORPHA:2301; Chronic myelomonocytic leukemia ORPHA:98823; Multiple osteochondromas ORPHA:321; Aneurysm-osteoarthritis syndrome ORPHA:284984; Pseudohypoaldosteronism type 2B ORPHA:88939; Seizures-scoliosis-macrocephaly syndrome ORPHA:466926; Hereditary combined deficiency of vitamin K-dependent clotting factors ORPHA:98434; Proximal symphalangism ORPHA:3250; Schneckenbecken dysplasia ORPHA:3144; Spondylocarpotarsal synostosis ORPHA:3275; Myxofibrosarcoma ORPHA:79105; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Adult polyglucosan body disease ORPHA:206583; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form ORPHA:308712; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form ORPHA:308684; Glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form ORPHA:308698; Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form ORPHA:308670; Glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form ORPHA:308655; Glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form ORPHA:308638; Glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form ORPHA:308621; Osteogenesis imperfecta type 2 ORPHA:216804; Autosomal dominant polycystic kidney disease ORPHA:730; Scott syndrome ORPHA:806; Cole-Carpenter syndrome ORPHA:2050; Neurogenic arthrogryposis multiplex congenita ORPHA:1143; Frontometaphyseal dysplasia ORPHA:1826",0.0155394890951578; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2844858212863536; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3891940933600213; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TREX1,"Lower limb hyperreflexia; Acrocyanosis; Progressive visual loss; Decreased visual acuity, progressive; Glioma; Mycoses; Ataxia Telangiectasia; Basal ganglia calcification; Neoplasm Metastasis; Prolonged neonatal jaundice; melanoma; Retinal Diseases; Libman-Sacks Disease; Chilblain lupus 1; Focal white matter lesions; Abnormal behavior; Retinal Hemorrhage; Aicardi-Goutieres Syndrome 2; Pain in limb; Progressive brain disease; Low Vision; Neonatal Jaundice; Supratentorial atrophy; Dementia; Polyposis, Gastric; Progressive encephalopathy; Pseudo-TORCH syndrome; Lupus Erythematosus, Systemic; Feeding difficulties in infancy; Nystagmus; Raynaud Disease; Cognitive delay; Autoimmune Diseases; Macular retinal edema; Visual Impairment; Rheumatoid Arthritis; Abnormality of the retinal vasculature; Degenerative brain disorder; Vasculitis of the skin; Chronic inflammatory disorder; Global developmental delay; Behavioral Symptoms; Progressive microcephaly; Hemiplegia/hemiparesis; AICARDI-GOUTIERES SYNDROME; Morphological abnormality of the pyramidal tract; Pyramidal tract disease; Virus Diseases; Mental and motor retardation; Malignant Glioma; Lupus Erythematosus, Cutaneous; Abnormality of the periventricular white matter; AICARDI-GOUTIERES SYNDROME 1; Porencephalic cyst; Arhinencephaly; Coloboma of eyelid; Raynaud Phenomenon; Profound Mental Retardation; Decreased platelet count; Cerebral atrophy; Extrapyramidal sign; Thrombocytopenia; Spider Veins; Petechiae; Degenerative polyarthritis; Kidney Diseases; Congenital infectious disease; ESR raised; Poor head control; Lupus Erythematosus; Respiratory Tract Infections; Lupus Erythematosus, Discoid; HIV Infections; Fever; Arthralgia; Inflammation; Lupus Vulgaris; Skin Ulcer; Muscular hypotonia of the trunk; Retroviridae Infections; Dermatomyositis, Childhood Type; Strabismus; Immune System Diseases; Dystonia; Systemic Scleroderma; Intermittent migraine headaches; Dystonic disease; High urine occult blood; Apraxias; Liver Dysfunction; Telangiectasis; Hematuria; Mental deterioration; Cerebrovascular accident; Subclinical abnormal liver function tests; Transaminases increased; Elevated liver enzymes; Increased liver function tests; Liver enzymes abnormal; Liver function tests abnormal finding; Migraine Disorders; Elevated hepatic transaminases; Chlamydia Infections; Extrapyramidal Disorders; Hepatosplenomegaly; Hemiparesis; Profound intellectual disabilities; Proteinuria; Inclusion Body Myopathy, Sporadic; Inflammatory disorder; Leukoencephalopathies; Epileptic encephalopathy; Influenza; Encephalopathies; Intellectual Disability; Seizures; Leukodystrophy; Muscle Spasticity; Epilepsy; Brain Diseases; Dysarthria",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.7908231553833205; 0.8009048756462318; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8098851543361193; 0.8145035474981049; 0.8168901801930506; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8578473133580928; 0.8610447277138289; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.8648405521677974; 0.876210765330195; 0.876210765330195; 0.8769418330148872; 0.8769418330148872; 0.882453254162044; 0.9154499654632742; 0.917543617287358; 0.9193385822373632; 0.9265708351135048; 0.9478210444156088; 0.9478210444156088; 0.954882372756482; 0.9564633032157428; 0.963331724428282; 0.9740616963450036; 0.9972800266537104,"Stroke; Spastic Quadriplegia; Nonbacterial Verrucal Endocardiosis; Macular Edema; Gastric Polyposis; Lymphocytic Leukemia; Chilblain Lesions; Pseudo-TORCH Syndrome; Degeneration Of The Striatum; Enchondroma; Aicardi Goutieres Syndrome; Plagiocephaly; Lipoatrophy; Nystagmus; Psychosis; Developmental Delay; Alloimmune Thrombocytopenia; Renal Glomerular Disease; Hypoplasia Of Corpus Callosum; Leukopenia; Retinal Diseases; Micronodular Cirrhosis; Panniculitis; Vasculitis; Lipodystrophy; Leukodystrophy; Raynaud Phenomenon; Hemiplegia/hemiparesis; Penis Agenesis; Acquired Porencephaly; Porencephalic Cyst; Kidney Disease; Cutis Marmorata; Pleuritis; Mental Retardation; Cerebral Atrophy; Systemic Lupus Erythematosus; Pericarditis; Apraxia; Arrhinencephaly; Autoinflammatory Disease; Cerebellar Hypoplasia; Demyelinating Neuropathy; Glaucoma, Congenital; Dementia; Hypothyroidism; Microcephaly; Myositis; Glaucoma; Strabismus; Brain Atrophy; Arthritis; Lupus Erythematosus; Diabetes Mellitus; Scoliosis; Anemia; Dwarfism; Leukoencephalopathy; Aortic Aneurysm; Nephritis; Developmental Regression; Migraine; Hypertrophic Cardiomyopathy; Ptosis; Dysarthria; Epileptic Encephalopathy",0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7949861636679444; 0.8091514409416879; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8210988731657684; 0.831108575640545; 0.8337953215113012; 0.8337953215113012; 0.8339308890552987; 0.8356859041719433; 0.8457525389282121; 0.8457525389282121; 0.8476516371290275; 0.8476516371290275; 0.8601151608808731; 0.861756360478846; 0.861756360478846; 0.861756360478846; 0.8879896755141929; 0.8903630091389316; 0.8903630091389316; 0.8903630091389316; 0.8908485337686392; 0.9024492468099392; 0.9046917974656596; 0.9145387439550552; 0.919442421650838; 0.924275664330454; 0.9369188149054885; 0.9510372690456612; 0.9540785594585928; 0.9543024119762946; 0.957165873648102; 0.9658957825498884; 0.9658957825498884; 0.9726837163662044; 0.9832345076528324; 0.988987376043163; 0.9969015583346668,Predisposition to severe viral infection due to IRF7 deficiency ORPHA:574918; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations ORPHA:247691; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency ORPHA:319563; Hypohidrotic ectodermal dysplasia with immunodeficiency ORPHA:98813; Marinesco-Sjogren syndrome ORPHA:559; Aicardi-Goutieres syndrome ORPHA:51; Stormorken-Sjaastad-Langslet syndrome ORPHA:3204; Revesz syndrome ORPHA:3088; Herpes simplex virus encephalitis ORPHA:1930; Proteasome-associated autoinflammatory syndrome ORPHA:324977; Familial Chilblain lupus ORPHA:481662; Systemic lupus erythematosus ORPHA:536,0.0155394890951578; 0.0155394890951578; 0.1040670578681756; 0.1054066549396977; 0.1054066549396977; 0.1294848460749822; 0.1991445465001551; 0.3832844616405875; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.8922466888454011,,,,,,
TRIM13,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; B-Cell Lymphomas; leukemia; Ovarian Carcinoma; Colorectal Carcinoma; Leukemia, Myelocytic, Acute; Lymphoma; Cholestatic liver disease; Adenoma; Glioma; Malignant neoplasm of prostate; Lymphoma, Non-Hodgkin; Liver carcinoma; Osteosarcoma; Ataxia Telangiectasia; Colorectal Cancer; Tumor Promotion; Glioblastoma; Osteosarcoma of bone; Prostate carcinoma; Astrocytoma; Parathyroid Adenoma; Immunologic Deficiency Syndromes; Malignant Neoplasms; Hematologic Neoplasms; melanoma; Multiple Myeloma; Adenoviral infections; Brain Neoplasms; Sarcoma; Tumor Initiation; Alzheimer's Disease; Acute lymphocytic leukemia; Solid Neoplasm; X-linked agammaglobulinemia with growth hormone deficiency; Hypoparathyroidism - autosomal dominant; Adult Lymphoma; Acute Cerebrovascular Accidents; Autosomal dominant hypocalcemia; Childhood Lymphoma; Cholestasis; Virus Diseases; Carney Complex, Type 1; Primary malignant neoplasm; Leukopenia; Chronic Lymphocytic Leukemia; Liver neoplasms; Precursor B-cell lymphoblastic leukemia; Precursor Cell Lymphoblastic Leukemia Lymphoma; Secondary malignant neoplasm of lung; Genitourinary Cancer; Icterus; MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA; Hypoparathyroidism; Restenosis; Childhood Leukemia; Obesity; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Neutropenia; Cardiomyopathy, Dilated; Hypothyroidism",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8168901801930506; 0.8190761496232595; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8508164886128737; 0.8610447277138289; 0.8989612563669234; 0.8989612563669234; 0.9387505562433404; 0.9564633032157428; 0.9816840072553962,,,MEGDEL syndrome ORPHA:352328; Dyggve-Melchior-Clausen disease ORPHA:239; Smith-McCort dysplasia ORPHA:178355; Macrocephaly-intellectual disability-autism syndrome ORPHA:210548,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61),0.8999095837312036; 0.8999095837312036,,,,
TRIM15,Colon Carcinoma; Malignant tumor of colon; Rheumatoid Arthritis; Vitiligo; Psoriasis,0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649,Vitiligo; Ulcerative Colitis; Rheumatoid Arthritis,0.7765582368651238; 0.861756360478846; 0.9251646147729308,"Alkaptonuria ORPHA:56; HNF1B-related autosomal dominant tubulointerstitial kidney disease ORPHA:93111; Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome ORPHA:476119; Chromophobe renal cell carcinoma ORPHA:319303; Hyperinsulinism due to HNF1A deficiency ORPHA:324575; Hyperinsulinism due to HNF4A deficiency ORPHA:263455; Bilateral multicystic dysplastic kidney ORPHA:97364; Medullary sponge kidney ORPHA:1309; Renal dysplasia, bilateral ORPHA:93173; Renal dysplasia, unilateral ORPHA:93172; Unilateral multicystic dysplastic kidney ORPHA:97363; Acrocapitofemoral dysplasia ORPHA:63446; Aromatic L-amino acid decarboxylase deficiency ORPHA:35708; CIDEC-related familial partial lipodystrophy ORPHA:435651; Progressive familial intrahepatic cholestasis type 5 ORPHA:480476; X-linked Charcot-Marie-Tooth disease type 1 ORPHA:101075; X-linked progressive cerebellar ataxia ORPHA:1175; Phosphoenolpyruvate carboxykinase deficiency ORPHA:2880; Early-onset anterior polar cataract ORPHA:98988; NON RARE IN EUROPE: Heterozygous familial hypercholesterolemia ORPHA:406; Congenital chloride diarrhea ORPHA:53689; Congenital sucrase-isomaltase deficiency ORPHA:35122; Hemolytic anemia due to red cell pyruvate kinase deficiency ORPHA:766; Marie Unna hereditary hypotrichosis ORPHA:444; Homozygous familial hypercholesterolemia ORPHA:391665; Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome ORPHA:309854; Hartnup disease ORPHA:2116",0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8105918570729571; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61); Human alphaherpesvirus 2 envelope glycoprotein C (gene: UL44); Papiine alphaherpesvirus 2 envelope glycoprotein C (gene: UL44),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
TRIM47,Carcinogenesis; Non-Small Cell Lung Carcinoma,0.7333611688795861; 0.7765852775619541,,,"Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Familial cortical myoclonus ORPHA:319189; Epidermolysis bullosa simplex with pyloric atresia ORPHA:158684; Muscular dystrophy, Selcen type ORPHA:199340; Congenital bile acid synthesis defect type 1 ORPHA:79301; Hyperammonemia due to N-acetylglutamate synthase deficiency ORPHA:927",0.0414176838632111; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087,,,,,,
TRIP10,Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Ovarian Carcinoma; Cervix carcinoma; Adenoma; Malignant tumor of cervix; Mammary Neoplasms; Malignant neoplasm of prostate; Liver and Intrahepatic Biliary Tract Carcinoma; Prostate carcinoma; cervical cancer; Neoplasm Metastasis; Triple Negative Breast Neoplasms; Malignant neoplasm of liver; Bile duct carcinoma; Brain Neoplasms; Huntington Disease; Chronic Lymphocytic Leukemia; Secondary malignant neoplasm of lung; Streptococcal pneumonia; Cholangiocarcinoma; Lobar Pneumonia; Mucocutaneous Lymph Node Syndrome,0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7768809924982332; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8232134984476662; 0.8368219249856942; 0.8402911822757345; 0.9098977259629772; 0.914995991166204,,,"Autosomal dominant Charcot-Marie-Tooth disease type 2F ORPHA:99940; Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Early-onset posterior subcapsular cataract ORPHA:441447; Early-onset posterior polar cataract ORPHA:98993; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Atypical Werner syndrome ORPHA:79474; Autosomal recessive Emery-Dreifuss muscular dystrophy ORPHA:98855; Autosomal semi-dominant severe lipodystrophic laminopathy ORPHA:280365; Charcot-Marie-Tooth disease type 2B1 ORPHA:98856; Congenital muscular dystrophy due to LMNA mutation ORPHA:157973; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome ORPHA:2229; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation ORPHA:300751; Familial partial lipodystrophy, Dunnigan type ORPHA:2348; Familial partial lipodystrophy, Kobberling type ORPHA:79084; Heart-hand syndrome, Slovenian type ORPHA:168796; LMNA-related cardiocutaneous progeria syndrome ORPHA:363618; Mandibuloacral dysplasia with type A lipodystrophy ORPHA:90153; Muscular dystrophy, Selcen type ORPHA:199340; Progressive familial intrahepatic cholestasis type 4 ORPHA:480483; Quebec platelet disorder ORPHA:220436; Cap myopathy ORPHA:171881; Thyroid ectopia ORPHA:95712; Congenital hereditary endothelial dystrophy type II ORPHA:293603; Corneal dystrophy-perceptive deafness syndrome ORPHA:1490; Dopa-responsive dystonia due to sepiapterin reductase deficiency ORPHA:70594; Severe congenital hypochromic anemia with ringed sideroblasts ORPHA:300298; Craniofrontonasal dysplasia ORPHA:1520; Male infertility due to large-headed multiflagellar polyploid spermatozoa ORPHA:137893; Lipoid proteinosis ORPHA:530; NON RARE IN EUROPE: Primary adult open-angle glaucoma ORPHA:353225",0.0414176838632111; 0.1040670578681756; 0.220389120533256; 0.2475924359068358; 0.2844858212863536; 0.2844858212863536; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,Human immunodeficiency virus nef protein (gene: nef); Variola virus hypothetical protein (gene: B20R); Ectromelia virus ERPV IFN alpha/beta receptor; Vaccinia virus Ankara 150k A-type inclusion protein (ATI) f1; Pichinde mammarenavirus N protein; Hendra henipavirus phosphoprotein P (gene: P/V/C); Nipah henipavirus P phosphoprotein; Human gammaherpesvirus 4 EBNA-2 nuclear protein (gene: BYRF1); Human herpesvirus 4 type 2 EBNA-2; Cercopithecine betaherpesvirus 5 membrane glycoprotein US2 (gene: US2); Mumps virus phoshoprotein (gene: V/P); Mumps virus genotype G phosphoprotein (gene: P),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9287050575620676; 0.9597398910543528; 0.9626366082099888,In vitro,0.74,Homo sapiens,Homo sapiens
TSC22D2,,,Moyamoya Disease,0.8611702959552964,Acromelic frontonasal dysplasia ORPHA:1827; Spinocerebellar ataxia type 2 ORPHA:98756,0.1040670578681756; 0.8922466888454011,,,,,,
TSPAN5,drug response,0.7880542567584415,Rheumatoid Arthritis,0.9251646147729308,Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Intellectual disability-developmental delay-contractures syndrome ORPHA:3454; Proximal symphalangism ORPHA:3250; Multiple synostoses syndrome ORPHA:3237; Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome ORPHA:352333; Spinocerebellar ataxia type 34 ORPHA:1955,0.0144185025972157; 0.0144185025972157; 0.5867963421058087; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TUBB3,"Malignant neoplasm of breast; Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Breast Carcinoma; Malignant neoplasm of ovary; Ovarian Carcinoma; Adenocarcinoma; Colorectal Carcinoma; Non-Small Cell Lung Carcinoma; Segmental dystonia; Amblyopia; Carcinoma breast stage IV; Laryngeal dystonia; Mammary Neoplasms; Malignant neoplasm of prostate; Colorectal Cancer; Glioblastoma; Prostate carcinoma; Agyria; Neoplasm Metastasis; Prostatic Neoplasms; Neuroblastoma; Hoarseness; Central neuroblastoma; Malignant Neoplasms; Lung Neoplasms; Extraskeletal Myxoid Chondrosarcoma; Metastatic malignant neoplasm to brain; Lissencephaly; Malformations of Cortical Development; Well Differentiated Oligodendroglioma; oligodendroglioma; Tumor Progression; Congenital Fibrosis of the Extraocular Muscles; Hypoplasia of corpus callosum; Nystagmus; Chondrosarcoma; Cognitive delay; Mixed sensory-motor polyneuropathy; Squamous cell carcinoma; Solid Neoplasm; Malformations of Cortical Development, Group II; Global developmental delay; Vocal Cord Paralysis; Mental and motor retardation; Mobius Syndrome; Moderate mental retardation (I.Q. 35-49); Oropharyngeal Carcinoma; Cortical Dysplasia; Kallmann Syndrome; ovarian neoplasm; Malignant transformation; Klinefelter Syndrome; Exotropia; Dysphonia; Desmoplastic; Hypoglycemia; Dystonia Disorders; Vomiting; Muscular hypotonia of the trunk; Malignant neoplasm of oropharynx; Hypoplasia of the brainstem; Glioblastoma Multiforme; Cerebellar Hypoplasia; Congenital Abnormality; Strabismus; Dystonia; Ptosis; Macular dystrophy, corneal type 1; Malonic aciduria; Medulloblastoma; Polymicrogyria; Hypogonadotropic hypogonadism; Mammary Neoplasms, Human; Secondary malignant neoplasm of lymph node; Epileptic encephalopathy; Rash and Dermatitis Adverse Event Associated with Chemoradiation; Refractory cancer; Cerebrovascular Disorders; Intellectual Disability; Muscle Spasticity; Charcot-Marie-Tooth Disease; Agenesis of corpus callosum; Blepharoptosis; Small head",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8067197998685076; 0.8067197998685076; 0.8168901801930506; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8270909867833504; 0.8270909867833504; 0.8272008757995397; 0.834094492023826; 0.8342163953428735; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8548862007194026; 0.8584283190330553; 0.8769418330148872; 0.8815127642200768; 0.900167961295542; 0.917543617287358; 0.9366917377729386; 0.9377696084218796; 0.9387505562433404; 0.9478210444156088; 0.9564633032157428; 0.963331724428282; 0.9701053690483854; 0.9770263358372888; 0.9822381479823692,Stereotyped Behavior; Spastic Quadriplegia; Oculovestibuloauditory Syndrome; Ovarian Neoplasm; Focal Seizures; Oculomotor Apraxia; Hypoplasia Of The Olfactory Bulb; Dysgenesis Of The Hippocampus; Dysautonomia; Lissencephaly; Cubitus Valgus; Partial Agenesis Of Corpus Callosum; Cortical Dysplasia With Other Brain Malformations; Plagiocephaly; Nystagmus; Cortical Dysplasia; Developmental Delay; Macrocephaly; Polymicrogyria; Spastic Ataxia; Ovarian Cancer; Hypoplasia Of Corpus Callosum; Cobblestone Lissencephaly; Congenital Microcephaly; Malformation Of Cortical Development; Social Communication Disorder; Mammary Neoplasms; Exotropia; Spastic Diplegia; Mental Retardation; Marfan Syndrome; Cerebellar Hypoplasia; Hypoplasia Of The Optic Nerve; Microcephaly; Esotropia; Breast Cancer; Strabismus; Mood Swings; Acquired Kyphoscoliosis; Congenital Kyphoscoliosis; Micrognathism; Breast Carcinoma; Sensorineural Hearing Loss; Hydrocephalus; High Palate; Multiple Congenital Anomalies; Congenital Epicanthus; Agenesis Of Corpus Callosum; Ptosis; Dysarthria,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7797212851906329; 0.7949861636679444; 0.8082616889285628; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.8165359516083085; 0.8201196687803188; 0.8337953215113012; 0.8337953215113012; 0.8477374749042494; 0.8601151608808731; 0.8903301324869451; 0.8903630091389316; 0.8903630091389316; 0.8903630091389316; 0.8908485337686392; 0.9069867032339078; 0.9145387439550552; 0.9147194468246628; 0.9398381935810408; 0.9398381935810408; 0.9543024119762946; 0.9574431947800732; 0.9578111936867284; 0.963385108667098; 0.974502015052702; 0.980894832851993; 0.9832345076528324; 0.988987376043163,"Classic glucose transporter type 1 deficiency syndrome ORPHA:71277; Hereditary cryohydrocytosis with reduced stomatin ORPHA:168577; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity ORPHA:53583; Spinocerebellar ataxia type 21 ORPHA:98773; Paroxysmal exertion-induced dyskinesia ORPHA:98811; Autosomal recessive spondylocostal dysostosis ORPHA:2311; Hydrocephalus with stenosis of the aqueduct of Sylvius ORPHA:2182; MASA syndrome ORPHA:2466; X-linked complicated corpus callosum dysgenesis ORPHA:1497; X-linked complicated spastic paraplegia type 1 ORPHA:306617; Cold-induced sweating syndrome ORPHA:157820; Distal hereditary motor neuropathy type 5 ORPHA:139536; Familial congenital mirror movements ORPHA:238722; Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation ORPHA:300570; 9q33.3q34.11 microdeletion syndrome ORPHA:495818; Coloboma of choroid and retina ORPHA:98942; Coloboma of iris ORPHA:98944; Aarskog-Scott syndrome ORPHA:915; Autosomal recessive dopa-responsive dystonia ORPHA:101150; Autosomal recessive spastic paraplegia type 26 ORPHA:101006; Multiple epiphyseal dysplasia type 5 ORPHA:93311; POMT2-related  limb-girdle muscular dystrophy R14 ORPHA:206559; Progressive myoclonic epilepsy type 8 ORPHA:424027; Spondyloepimetaphyseal dysplasia, matrilin-3 type ORPHA:156728; 46,XX ovotesticular disorder of sex development ORPHA:2138; Congenital fibrosis of extraocular muscles ORPHA:45358; Myoclonus-dystonia syndrome ORPHA:36899; Colobomatous microphthalmia ORPHA:98938; Arnold-Chiari malformation type I ORPHA:268882; Blepharophimosis-ptosis-epicanthus inversus syndrome plus ORPHA:572333; Blepharophimosis-ptosis-epicanthus inversus syndrome type 1 ORPHA:572354; Blepharophimosis-ptosis-epicanthus inversus syndrome type 2 ORPHA:572361; Multiple epiphyseal dysplasia, Al-Gazali type ORPHA:166024; Polymicrogyria due to TUBB2B mutation ORPHA:300573; Autosomal spastic paraplegia type 72 ORPHA:401849; Classic homocystinuria ORPHA:394; Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome ORPHA:352654; Neurofibromatosis type 2 ORPHA:637; Tubulinopathy-associated dysgyria ORPHA:467166; Tetraamelia-multiple malformations syndrome ORPHA:3301; 46,XX testicular disorder of sex development ORPHA:393; Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome ORPHA:522077; X-linked adrenal hypoplasia congenita ORPHA:95702",0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1068643725150898; 0.1068643725150898; 0.2120485863056726; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.606625035400596; 0.6467006456772204; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Yaba monkey tumor virus ankyrin repeat protein; Yaba-like disease virus 11L protein (gene: 11L); Monkeypox virus Zaire-96-I-16 B5R (gene: B5R); Horsepox virus HSPV020e (ankyrin repeats); Orf virus ORF008 ankyrin repeat protein; Horsepox virus HSPV181 (ankyrin repeats); Orf virus ORF123 ankyrin repeat protein; Vaccinia virus hypothetical protein; Vaccinia virus Ankara 72.4k ankyrin repeat protein f2; Monkeypox virus ankyrin-like protein; Horsepox virus HSPV033c (ankyrin repeats); Horsepox virus HSPV011c (ankyrin repeats); Vaccinia virus Ankara 78.7k Ankyrin repeat protein f1; Vaccinia virus ankyrin-like protein (gene: B4R); Vaccinia virus ankyrin-like protein (gene: C9L); Horsepox virus HSPV201a (ankyrin repeats); Cowpox virus CPXV198 protein (gene: CPXV198 CDS); Ectromelia virus ERPV ankyrin; Orf virus ORF128 ankyrin repeat protein; Horsepox virus HSPV033b (Ankyrin repeats); Orf virus ORF126 ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f1; Horsepox virus HSPV005b (ankyrin repeats); Monkeypox virus Zaire-96-I-16 ankyin-like protein (gene: O1L); Yaba-like disease virus 8L protein (gene: 8L); Vaccinia virus Ankara 65.4k Ankyrin repeat protein; Vaccinia virus Ankara 54.4k ankyrin repeat protein f2; Variola virus hypothetical protein (gene: B6R); Monkeypox virus Zaire-96-I-16 ankyrin-like protein (gene: D7L),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9058994261255549; 0.9058994261255549; 0.915880438522078; 0.915880438522078; 0.9224878266317492; 0.9237501457186692; 0.9237501457186692; 0.9364561700418303; 0.9563208507960556,,,,
TUBGCP3,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse; Carcinogenesis; Glioblastoma; Astrocytoma; Mucinous Adenocarcinoma; Liver neoplasms; Primary microcephaly",0.7333611688795861; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076,Microcephaly,0.8903630091389316,,,,,,,,
TUBGCP5,Autistic Disorder; Speech Disorders; Obsessive compulsive behavior; Prader-Willi Syndrome,0.8019075543217649; 0.8402911822757345; 0.8648405521677974; 0.8648405521677974,,,Joubert syndrome ORPHA:475; ALG9-CDG ORPHA:79328; Holocarboxylase synthetase deficiency ORPHA:79242,0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
TUBGCP6,"Cortical gyral simplification; Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Biparietal narrowing; Decreased width of the skull; Muscle Hypertonia; Sloping forehead; Abnormality of the eyelashes; Retinal Diseases; Pallor of optic disc; Aplasia/Hypoplasia of the cerebellum; Low Vision; Abnormal pigmentation; Supratentorial atrophy; Seckel syndrome; Nystagmus; Protruding ear; Anteverted nostril; Prominent ear; Cognitive delay; Visual Impairment; Malformations of Cortical Development, Group II; Degenerative brain disorder; Pointed chin; Global developmental delay; Optic Atrophy; Mental and motor retardation; Chorioretinal dysplasia; Cerebral atrophy; Primary microcephaly; Retinal Dystrophies; Broad flat nasal bridge; Nasal bridge wide; Microcephaly; Cerebellar Hypoplasia; Congenital Abnormality; Abnormally small eyeball; Decreased size of eyeball; Strabismus; Curvature of spine; Pachygyria; Mental deficiency; Acquired scoliosis; Dull intelligence; Low intelligence; Cataract; Short stature; Poor school performance; Infant, Small for Gestational Age; Intrauterine retardation; Lens Opacities; Microphthalmos; Mental Retardation; Retinal Detachment; Fetal Growth Retardation; Intellectual Disability; Seizures; Epilepsy; Small head",0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8067197998685076; 0.8190761496232595; 0.8213459222602666; 0.8232134984476662; 0.8232134984476662; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8757755363384367; 0.8757755363384367; 0.8769418330148872; 0.8815127642200768; 0.8913141512402477; 0.9083161862856644; 0.9111864999692114; 0.9117936912777788; 0.9154499654632742; 0.922229272318747; 0.929814249105729; 0.9307095582633488; 0.9478210444156088; 0.9478210444156088; 0.963331724428282; 0.9822381479823692,Microcephaly With Chorioretinopathy; Retinal Dystrophy; Nystagmus; Retinal Detachment; Developmental Delay; Leukemia; Optic Atrophy; Malformation Of Cortical Development; Pachygyria; Mental Retardation; Cerebral Atrophy; Cerebellar Hypoplasia; Cerebral Cortical Atrophy; Microcephaly; Strabismus; Scoliosis; Microphthalmos; Dwarfism; Cataract,0.4532988396145482; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8210988731657684; 0.8337953215113012; 0.8339308890552987; 0.8601151608808731; 0.861756360478846; 0.8903630091389316; 0.8908485337686392; 0.924275664330454; 0.941216656523771; 0.9510372690456612; 0.974502015052702,"Autosomal dominant centronuclear myopathy ORPHA:169189; Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Familial lipase maturation factor 1 deficiency ORPHA:535453; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis ORPHA:88924; Adult-onset dystonia-parkinsonism ORPHA:199351; Barth syndrome ORPHA:111; Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Infantile neuroaxonal dystrophy ORPHA:35069; Megaconial congenital muscular dystrophy ORPHA:280671; Proximal myopathy with focal depletion of mitochondria ORPHA:521305; Lymphangioleiomyomatosis ORPHA:538; Tuberous sclerosis complex ORPHA:805; Albers Schonberg osteopetrosis ORPHA:53; Autosomal dominant spastic ataxia type 1 ORPHA:251282; Cerebellar-facial-dental syndrome ORPHA:444072; LIPE-related familial partial lipodystrophy ORPHA:435660; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; D-2-hydroxyglutaric aciduria ORPHA:79315; Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome ORPHA:95433; Birt-Hogg-Dube syndrome ORPHA:122; Combined oxidative phosphorylation defect type 27 ORPHA:477774; Early-onset epilepsy-intellectual disability-brain anomalies syndrome ORPHA:488635; Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome ORPHA:500144; Familial spontaneous pneumothorax ORPHA:2903; Hurler syndrome ORPHA:93473; Hurler-Scheie syndrome ORPHA:93476; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; POMT1-related  limb-girdle muscular dystrophy R11 ORPHA:86812; Scheie syndrome ORPHA:93474; TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome ORPHA:562569; CAMOS syndrome ORPHA:83472; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Coats plus syndrome ORPHA:313838; Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons ORPHA:401964; Classic galactosemia ORPHA:79239; Craniosynostosis-dental anomalies ORPHA:284149; Distal 16p11.2 microdeletion syndrome ORPHA:261222; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression ORPHA:391316; Proximal 16p11.2 microdeletion syndrome ORPHA:261197; Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency ORPHA:329249; Deafness-enamel hypoplasia-nail defects syndrome ORPHA:3220; Glycogen storage disease due to liver phosphorylase kinase deficiency ORPHA:264580; Hermansky-Pudlak syndrome with pulmonary fibrosis ORPHA:231500; Isolated focal cortical dysplasia type IIb ORPHA:269008; Uveal melanoma ORPHA:39044; Alpers-Huttenlocher syndrome ORPHA:726; COG1-CDG ORPHA:263508; Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome ORPHA:459061; Isobutyryl-CoA dehydrogenase deficiency ORPHA:79159; NEK9-related lethal skeletal dysplasia ORPHA:464366; Nevus comedonicus syndrome ORPHA:64754; Recessive mitochondrial ataxia syndrome ORPHA:94125; Spinocerebellar ataxia with epilepsy ORPHA:254881; Autosomal recessive progressive external ophthalmoplegia ORPHA:254886; Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome ORPHA:70595; Autosomal recessive chorioretinopathy-microcephaly syndrome ORPHA:2518; Autosomal dominant Charcot-Marie-Tooth disease type 2M ORPHA:228179; Autosomal dominant intermediate Charcot-Marie-Tooth disease type B ORPHA:100044; Autosomal dominant multiple pterygium syndrome ORPHA:65743; Charcot-Marie-Tooth disease type 2S ORPHA:443073; Familial LCAT deficiency ORPHA:79293; Fetal akinesia-cerebral and retinal hemorrhage syndrome ORPHA:363409; Fish-eye disease ORPHA:79292; Kleefstra syndrome due to 9q34 microdeletion ORPHA:96147; Perlman syndrome ORPHA:2849; Primary lateral sclerosis ORPHA:35689; Short stature-brachydactyly-obesity-global developmental delay syndrome ORPHA:464288; Spastic paraplegia type 7 ORPHA:99013; Spinal muscular atrophy with respiratory distress type 1 ORPHA:98920; Congenital dyserythropoietic anemia type I ORPHA:98869; Primary sclerosing cholangitis ORPHA:171; Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia ORPHA:313808; Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins ORPHA:217371; Mitochondrial myopathy with reversible cytochrome C oxidase deficiency ORPHA:254864",0.0036432528126817; 0.0081550609410495; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Orf virus ORF057 putative protein-tyrosine phosphatase,0.8999095837312036,,,,
TXNIP,"Malignant neoplasm of breast; Carcinoma of bladder; Bladder Neoplasm; Malignant neoplasm of urinary bladder; Breast Carcinoma; Diffuse Large B-Cell Lymphoma; Carcinogenesis; leukemia; Malignant neoplasm of pancreas; Pancreatic carcinoma; Leukemia, Myelocytic, Acute; Malignant neoplasm of body of stomach; Malignant tumor of greater curve of stomach; Malignant tumor of lesser curve of stomach; Adult T-Cell Lymphoma/Leukemia; Pancreatic Neoplasm; Carcinoma breast stage IV; Thyroid Neoplasm; Vascular Diseases; Malignant neoplasm of lung; Malignant neoplasm of prostate; Promyelocytic leukemia; Liver carcinoma; Thyroid carcinoma; Acute Promyelocytic Leukemia; Ataxia Telangiectasia; Leukemia, T-Cell; Hepatocarcinogenesis; Prostate carcinoma; Disease Exacerbation; Primary malignant neoplasm of lung; Neoplasm Metastasis; Prostatic Neoplasms; Carcinoma of lung; Cockayne Syndrome, Type I; Malignant neoplasm of thyroid; Squamous cell carcinoma of the head and neck; Triple Negative Breast Neoplasms; Nodular glomerulosclerosis; Malignant Neoplasms; melanoma; Multiple Myeloma; Retinal Diseases; Pregnancy in Diabetics; Neoplasms; Lymphoid hyperplasia; Malignant neoplasm of stomach; Myxoid cyst; Adult Hepatocellular Carcinoma; Malignant mesothelioma; Benign Prostatic Hyperplasia; Brain Neoplasms; ACTH-Secreting Pituitary Adenoma; Renal Cell Carcinoma; Insulin resistance in diabetes; Coronary Arteriosclerosis; Stomach Carcinoma; Hyperlipidemia, Familial Combined; Glaucoma; obsolete Combined hyperlipidemia; Rheumatoid Arthritis; Diabetes; Diabetes Mellitus; Hyperglycemia; Wolfram Syndrome; Primary malignant neoplasm; Hyperinsulinism; Stomach Neoplasms; Schizophrenia; Dyslipidemias; Diabetes Mellitus, Insulin-Dependent; Ulcerative Colitis; Diabetes Mellitus, Non-Insulin-Dependent; Inflammation; Hypoglycemia; Neurodegenerative Disorders; Diabetic Retinopathy; Steatohepatitis; Endothelial dysfunction; Hypertensive disease; Adrenal Cushing's syndrome; Fatty Liver; Diabetic Cardiomyopathies; Myocardial Ischemia; Cushing Syndrome; Gestational Diabetes; Cytopenia; Congenital anemia; Hypertriglyceridemia; Anoxia; Diabetic Nephropathy; Hepatitis; Acidosis, Lactic; Endometriosis; Differentiated Thyroid Gland Carcinoma; Tumor Angiogenesis; Asthma; Hyperlipidemia; Impaired glucose tolerance; Endometrioma; Non-alcoholic Fatty Liver Disease",0.4084380369379369; 0.4084380369379369; 0.4084380369379369; 0.5071083164302358; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7688485284765829; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7908231553833205; 0.8019075543217649; 0.8044379824544406; 0.8067197998685076; 0.8138488881521341; 0.8145035474981049; 0.8190761496232595; 0.8190761496232595; 0.8212681436603975; 0.8232134984476662; 0.8272008757995397; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8474481237156937; 0.8578473133580928; 0.8628363180844141; 0.8642802827048847; 0.8648405521677974; 0.882453254162044; 0.882453254162044; 0.9001392794088324; 0.9015731019095328; 0.9154499654632742; 0.9184153253162451; 0.9390727893210336; 0.939985154445373; 0.942246125102556; 0.960644037248553; 0.9639249377588224; 0.9656926709728724; 0.9672478180546946; 0.9676817033456722; 0.9734506818882446; 0.992026975660552; 0.9924277189223056,Diabetic Nephropathy; Glomerulosclerosis; Diffuse Lymphoma; Rheumatoid Arthritis; Endometriosis; Endometrioma,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.9251646147729308; 0.9726139569926774; 0.9832345076528324,Multiple endocrine neoplasia type 4 ORPHA:276152,0.7929682744768703,,,,,,
UBAP2L,Colorectal Carcinoma; Liver carcinoma; Colorectal Cancer; Neoplasm Metastasis; Malignant Neoplasms; Neoplasms; Metastatic Neoplasm,0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,"X-linked intellectual disability, Siderius type ORPHA:85287; Precursor T-cell acute lymphoblastic leukemia ORPHA:99861; Oculofaciocardiodental syndrome ORPHA:2712; QRICH1-related intellectual disability-chondrodysplasia syndrome ORPHA:580940; Autosomal dominant Charcot-Marie-Tooth disease type 2Z ORPHA:466768; Floating-Harbor syndrome ORPHA:2044; Methylmalonic acidemia with homocystinuria, type cblX ORPHA:369962; Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome ORPHA:502423; Pancreatic agenesis-holoprosencephaly syndrome ORPHA:556955; Myxofibrosarcoma ORPHA:79105; Juvenile amyotrophic lateral sclerosis ORPHA:300605; Coffin-Siris syndrome ORPHA:1465; Adult-onset cervical dystonia, DYT23 type ORPHA:420492; Infantile-onset X-linked spinal muscular atrophy ORPHA:1145; Macrocephaly-intellectual disability-left ventricular non compaction syndrome ORPHA:466791; Desmoplastic small round cell tumor ORPHA:83469; Familial infantile bilateral striatal necrosis ORPHA:225154; Familial isolated hyperparathyroidism ORPHA:99879; Autosomal recessive non-syndromic intellectual disability ORPHA:88616; ADNP syndrome ORPHA:404448; Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency ORPHA:404440; SMARCA4-deficient sarcoma of thorax ORPHA:466962; Small cell carcinoma of the ovary ORPHA:370396; Isolated polycystic liver disease ORPHA:2924; Lujan-Fryns syndrome ORPHA:776; Endometrial stromal sarcoma ORPHA:213711; Extraskeletal myxoid chondrosarcoma ORPHA:209916; Clear cell sarcoma of kidney ORPHA:457246; MiT family translocation renal cell carcinoma ORPHA:319308; Mitochondrial non-syndromic sensorineural deafness ORPHA:90641; Autoimmune interstitial lung disease-arthritis syndrome ORPHA:444092; Schimke immuno-osseous dysplasia ORPHA:1830",0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.6467006456772204; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
UBE2Q2,"Carcinogenesis; Erythrocyte Mean Corpuscular Hemoglobin Test; Finding of Mean Corpuscular Hemoglobin; Uric acid measurement (procedure); Squamous cell carcinoma of the head and neck; Hypopharyngeal Carcinoma; Head and Neck Carcinoma; Glomerular filtration rate finding; Creatinine measurement, serum (procedure); Chronic Kidney Diseases",0.7333611688795861; 0.7333611688795861; 0.7333611688795861; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.8648405521677974; 0.8806784681730055; 0.8867509400747969; 0.9393256300017014,Gout; Gouty Arthritis; Diabetes; Kidney Disease; Diabetes Mellitus; Kidney Failure,0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8210988731657684; 0.919442421650838; 0.9658957825498884,Noonan syndrome-like disorder with loose anagen hair ORPHA:2701; Oral-facial-digital syndrome with short stature and brachymesophalangy ORPHA:508501,0.8922466888454011; 0.8922466888454011,Human herpesvirus 3 strain Dumas ring-finger protein; Human alphaherpesvirus 3 ubiquitin E3 ligase ICP0 (gene: ORF61),0.8999095837312036; 0.8999095837312036,,,,
UBXN11,"Malignant neoplasm of ovary; Colon Carcinoma; Malignant tumor of colon; Colorectal Neoplasms; melanoma; Diabetes Mellitus, Insulin-Dependent",0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.8145035474981049,Alzheimer Disease,0.8457525389282121,Beta-propeller protein-associated neurodegeneration ORPHA:329284; Hermansky-Pudlak syndrome with pulmonary fibrosis ORPHA:231500,0.1991445465001551; 0.3832844616405875,Crimean-Congo hemorrhagic fever virus full_polyprotein 1..3945 (gene: RdRp); Dugbe virus L protein; Rotavirus A NSP4,0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
UNC119,"Retinal pigment epithelial abnormality; Abnormality of retinal pigmentation; Lymphopenia; Cone-Rod Dystrophies; Immunologic Deficiency Syndromes; Retinal Diseases; Difficulties with night vision; Night Blindness; Bronchiolitis Obliterans Organizing Pneumonia; Photophobia; LATE-ONSET RETINAL DEGENERATION (disorder); Photoreceptor degeneration; IMMUNODEFICIENCY 13; Photodysphoria; Lung diseases; Recurrent otitis media; Recurrent sinus disease; Recurrent sinusitis; Amyotrophic Lateral Sclerosis; Color vision defect, severe; Abnormal color vision; Loss in color vision; Retinitis Pigmentosa; Color vision defect; Frontotemporal Lobar Degeneration",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8168901801930506; 0.8212681436603975; 0.8212681436603975; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8523465762428218; 0.9325666311629114,Immunologic Deficiency Syndromes; Severe Combined Immunodeficiency Disease; Lymphopenia; Nyctalopia; Disorder Of Eye; Otitis Media; Cone-rod Dystrophy; Immunodeficiency; Retinitis Pigmentosa; Sinusitis,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.8115918568696846; 0.8115918568696846; 0.8115918568696846; 0.861756360478846; 0.8897718769742773,Idiopathic CD4 lymphocytopenia ORPHA:228000; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Pontocerebellar hypoplasia type 9 ORPHA:369920; Cone rod dystrophy ORPHA:1872,0.0155394890951578; 0.1040670578681756; 0.1040670578681756; 0.9157590847454716,,,,,,
UNK,Eosinophil count procedure; Eosinophil count result; Blood basophil count (lab test),0.7880542567584415; 0.7880542567584415; 0.8190761496232595,,,,,,,,,,
USP16,Fanconi Anemia; Down Syndrome,0.7880542567584415; 0.8420665668584452,,,Alacrimia-choreoathetosis-liver dysfunction syndrome ORPHA:404454; Alazami syndrome ORPHA:319671; 12q15q21.1 microdeletion syndrome ORPHA:289513; 6q terminal deletion syndrome ORPHA:75857; Ferro-cerebro-cutaneous syndrome ORPHA:397922; Multiple congenital anomalies-hypotonia-seizures syndrome type 2 ORPHA:300496; Paroxysmal nocturnal hemoglobinuria ORPHA:447; Primary ciliary dyskinesia-retinitis pigmentosa syndrome ORPHA:247522,0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011,,,,,,
USP20,,,,,"Homocystinuria due to methylene tetrahydrofolate reductase deficiency ORPHA:395; Charcot-Marie-Tooth disease type 4G ORPHA:99953; Non-spherocytic hemolytic anemia due to hexokinase deficiency ORPHA:90031; Familial lipase maturation factor 1 deficiency ORPHA:535453; Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome ORPHA:352530; Susceptibility to infection due to TYK2 deficiency ORPHA:331226; VPS11-related autosomal recessive hypomyelinating leukodystrophy ORPHA:466934; Adult-onset dystonia-parkinsonism ORPHA:199351; Barth syndrome ORPHA:111; Infantile neuroaxonal dystrophy ORPHA:35069; Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome ORPHA:500533; Familial isolated pituitary adenoma ORPHA:314777; Autosomal recessive spastic paraplegia type 63 ORPHA:401805; Pontocerebellar hypoplasia type 9 ORPHA:369920; X-linked dominant chondrodysplasia, Chassaing-Lacombe type ORPHA:163966; Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome ORPHA:95433; Leukonychia totalis ORPHA:2387; Microcephalic primordial dwarfism due to ZNF335 deficiency ORPHA:329228; Cerebellar ataxia-hypogonadism syndrome ORPHA:1173; Craniosynostosis-dental anomalies ORPHA:284149; Distal 22q11.2 microdeletion syndrome ORPHA:261330; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression ORPHA:391316; Severe combined immunodeficiency due to CARMIL2 deficiency ORPHA:542301; Familial focal epilepsy with variable foci ORPHA:98820; Prolactinoma ORPHA:2965; Arnold-Chiari malformation type II ORPHA:1136; Combined immunodeficiency due to STIM1 deficiency ORPHA:317430; Hereditary sensory and autonomic neuropathy type 4 ORPHA:642; Isobutyryl-CoA dehydrogenase deficiency ORPHA:79159; Primary intraosseous venous malformation ORPHA:140436; Ramon syndrome ORPHA:3019; Congenital erythropoietic porphyria ORPHA:79277; Tubular aggregate myopathy ORPHA:2593",0.0081550609410495; 0.0144185025972157; 0.0144185025972157; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703,,,,,,
VASN,Liver carcinoma; Liver and Intrahepatic Biliary Tract Carcinoma; Malignant neoplasm of liver; Hepatitis; Hepatitis A,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.939985154445373; 0.9459312971127588,Liver Carcinoma,0.7765582368651238,"Atrial septal defect, sinus venosus type ORPHA:99105; Crisponi syndrome ORPHA:1545; Cold-induced sweating syndrome ORPHA:157820; Autosomal dominant generalized dystrophic epidermolysis bullosa ORPHA:231568; Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form ORPHA:89842; Brachyolmia-amelogenesis imperfecta syndrome ORPHA:2899; Dystrophic epidermolysis bullosa pruriginosa ORPHA:89843; Knobloch syndrome ORPHA:1571; Localized dystrophic epidermolysis bullosa, acral form ORPHA:158673; Localized dystrophic epidermolysis bullosa, nails only ORPHA:158676; Localized dystrophic epidermolysis bullosa, pretibial form ORPHA:79410; Recessive dystrophic epidermolysis bullosa inversa ORPHA:79409; Self-improving dystrophic epidermolysis bullosa ORPHA:79411; Van den Ende-Gupta syndrome ORPHA:2460; Congenital short bowel syndrome ORPHA:2301; Shprintzen-Goldberg syndrome ORPHA:2462; Truncus arteriosus ORPHA:3384; Isolated scaphocephaly ORPHA:35093; Acromesomelic dysplasia, Hunter-Thompson type ORPHA:968; Angel-shaped phalango-epiphyseal dysplasia ORPHA:63442; Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency ORPHA:91135; Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa ORPHA:436274; Osteogenesis imperfecta type 2 ORPHA:216804; Osteogenesis imperfecta type 3 ORPHA:216812; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; Caffey disease ORPHA:1310; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Acromicric dysplasia ORPHA:969; Lethal arteriopathy syndrome due to fibulin-4 deficiency ORPHA:314718",0.0155394890951578; 0.0155394890951578; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8029813443753846; 0.8211968342881582; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
VAT1,"Malignant neoplasm of breast; Breast Carcinoma; Glioma; Glioblastoma; Benign Prostatic Hyperplasia; Carcinoma, Ehrlich Tumor; Coronary Artery Disease",0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8232134984476662; 0.887595340546704,Coronary Artery Disease,0.861756360478846,"Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome ORPHA:300333; Cold-induced sweating syndrome ORPHA:157820; Classic Hodgkin lymphoma, nodular sclerosis type ORPHA:98843; Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency ORPHA:1900; Giant cell glioblastoma ORPHA:251579; Gliosarcoma ORPHA:251576; Connective tissue disorder due to lysyl hydroxylase-3 deficiency ORPHA:300284; Adult-onset autosomal recessive cerebellar ataxia ORPHA:284289; Autosomal dominant omodysplasia ORPHA:93328; Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome ORPHA:508476; Seizures-scoliosis-macrocephaly syndrome ORPHA:466926; Hereditary combined deficiency of vitamin K-dependent clotting factors ORPHA:98434; Truncus arteriosus ORPHA:3384; Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome ORPHA:171848; Roussy-Levy syndrome ORPHA:3115; Dejerine-Sottas syndrome ORPHA:64748; Familial multiple meningioma ORPHA:263662; Gaucher disease type 1 ORPHA:77259",0.1040670578681756; 0.1068643725150898; 0.1991445465001551; 0.1991445465001551; 0.2844858212863536; 0.2844858212863536; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
VNN1,"Colorectal Carcinoma; Acute asthma; Colorectal Cancer; Malignant neoplasm of large intestine; Tumor Progression; Cardiovascular Diseases; Dyslipoproteinemias; Psoriasis; Dyslipidemias; Ulcerative Colitis; Immune thrombocytopenic purpura; Eczema, Infantile; Steatohepatitis; Hypertensive disease; Inflammatory Bowel Diseases; Pustulosis of Palms and Soles; Dermatitis, Atopic; Malaria; Asthma; Colitis",0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8138488881521341; 0.8190761496232595; 0.8232134984476662; 0.834094492023826; 0.8402911822757345; 0.8474481237156937; 0.8815127642200768; 0.882453254162044; 0.8867509400747969; 0.9512505437112568; 0.9672478180546946; 0.9738491767258852,Dyslipidemias; Dermatitis; Inflammatory Bowel Disease; Palmoplantar Pustules; Celiac Disease; Eczema; Psoriasis,0.8115918568696846; 0.861756360478846; 0.861756360478846; 0.8903301324869451; 0.9246807042779188; 0.9658957825498884; 0.974502015052702,"Alkaptonuria ORPHA:56; Hemochromatosis type 4 ORPHA:139491; Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319581; Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency ORPHA:319569; Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease ORPHA:439854; Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency ORPHA:99898; NON RARE IN EUROPE: Wolff-Parkinson-White syndrome ORPHA:907; Alpha-1-antitrypsin deficiency ORPHA:60; Chronic infantile diarrhea due to guanylate cyclase 2C overactivity ORPHA:314373; Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation ORPHA:178396; Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency ORPHA:314376; Congenital factor XIII deficiency ORPHA:331; Congenital factor V deficiency ORPHA:326; East Texas bleeding disorder ORPHA:391320; Hyperlipidemia due to hepatic triacylglycerol lipase deficiency ORPHA:140905; Peroxisomal acyl-CoA oxidase deficiency ORPHA:2971; Hereditary renal hypouricemia ORPHA:94088; Congenital vertebral-cardiac-renal anomalies syndrome ORPHA:521438; Argininemia ORPHA:90; Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation ORPHA:487814; Glycerol kinase deficiency, adult form ORPHA:284414; Glycerol kinase deficiency, juvenile form ORPHA:284411",0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
VWA5B2,,,,,"Autosomal dominant spastic paraplegia type 6 ORPHA:100988; Bilateral generalized polymicrogyria ORPHA:208447; Familial infantile myoclonic epilepsy ORPHA:352582; Autosomal dominant hyperinsulinism due to Kir6.2 deficiency ORPHA:276580; Autosomal recessive hyperinsulinism due to Kir6.2 deficiency ORPHA:79644; Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency ORPHA:276603; Familial gastric type 1 neuroendocrine tumor ORPHA:464756; Intermediate DEND syndrome ORPHA:99989; Leukoencephalopathy with mild cerebellar ataxia and white matter edema ORPHA:363540; Permanent neonatal diabetes mellitus ORPHA:99885; DEND syndrome ORPHA:79134; Autosomal dominant keratitis ORPHA:2334; Foveal hypoplasia-presenile cataract syndrome ORPHA:2253; Isolated optic nerve hypoplasia/aplasia ORPHA:137902; Morning glory disc anomaly ORPHA:35737; Spinocerebellar ataxia type 14 ORPHA:98763; Partial pancreatic agenesis ORPHA:2805; Autosomal dominant hyperinsulinism due to SUR1 deficiency ORPHA:276575; Autosomal recessive hyperinsulinism due to SUR1 deficiency ORPHA:79643; Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency ORPHA:276598; Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome ORPHA:397618; Renal coloboma syndrome ORPHA:1475; MODY ORPHA:552; Corpus callosum agenesis-abnormal genitalia syndrome ORPHA:2508; Infantile epileptic-dyskinetic encephalopathy ORPHA:364063; Intellectual disability, Birk-Barel type ORPHA:166108; Partington syndrome ORPHA:94083; X-linked lissencephaly with abnormal genitalia ORPHA:452; X-linked spasticity-intellectual disability-epilepsy syndrome ORPHA:3175",0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5959529547720634; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,Horsepox virus HSPV177 (Immunoglobulin like); Vaccinia virus hemagglutinin (gene: A56R),0.9057542447893764; 0.9058994261255549,,,,
WARS2,Malignant neoplasm of pancreas; Pancreatic carcinoma; Neoplasm Metastasis; Triple Negative Breast Neoplasms; Neuroblastoma; Central neuroblastoma; Alzheimer's Disease; Rheumatoid Arthritis; Mitochondrial encephalopathy; Myocardial Infarction; Physical Activity Measurement; Lip and Oral Cavity Carcinoma; Malignant neoplasm of mouth; Mitochondrial Diseases; Intellectual Disability; Graves Disease; Metabolic Diseases,0.7688485284765829; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8019075543217649; 0.8190761496232595; 0.8946938397586319; 0.8989612563669234; 0.9478210444156088; 0.94939825643792; 0.9564633032157428,Stereotyped Behavior; Spastic Quadriplegia; Dyskinetic Syndrome; Salaam Seizures; Hypoglycemia; Nystagmus; Cortical Dysplasia; Combined Oxidative Phosphorylation Deficiency; Developmental Delay; Polymicrogyria; Hypoplasia Of Corpus Callosum; Optic Atrophy; Central Visual Impairment; Dyssomnia; Exotropia; Motor Delay; Cerebellar Atrophy; Mental Retardation; Cerebral Atrophy; Absence Of Septum Pellucidum; Sleep Disorders; Seizure; Microcephaly; Mental Depression; Autism; Alopecia; Liver Failure,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7949861636679444; 0.8115918568696846; 0.8115918568696846; 0.8201196687803188; 0.8201196687803188; 0.8210988731657684; 0.8337953215113012; 0.8337953215113012; 0.8339308890552987; 0.8476516371290275; 0.8601151608808731; 0.861756360478846; 0.8903630091389316; 0.8903630091389316; 0.911896615143974; 0.9367173114041438; 0.9543024119762946,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome ORPHA:478049; Combined oxidative phosphorylation defect type 11 ORPHA:324535; FASTKD2-related infantile mitochondrial encephalomyopathy ORPHA:166105; WARS2-related combined oxidative phosphorylation defect ORPHA:572798; ALG2-CDG ORPHA:79326; Progressive myoclonic epilepsy type 6 ORPHA:280620; X-linked sideroblastic anemia and spinocerebellar ataxia ORPHA:2802; Leigh syndrome with nephrotic syndrome ORPHA:255249,0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
WDR45,"Nonverbal; Absent speech; Supratentorial atrophy; Dementia; Hypoplasia of corpus callosum; Alzheimer's Disease; Cognitive delay; Degenerative brain disorder; Global developmental delay; Mental and motor retardation; Nerve Degeneration; Neurodegeneration with brain iron accumulation (NBIA); Neuro-degenerative disease; Cerebral atrophy; Abnormal ocular motility; West Syndrome; Difficulty speaking; Problems speaking; Delayed speech and language development; Poor speech; Tremor; Dysautonomia; Dystonia Disorders; Neurodegenerative Disorders; Gross motor development delay; Dystonia; Dystonic disease; Mental deficiency; Autonomic nervous system disorders; Parkinsonian Disorders; Infantile Spasm; Muscle Rigidity; Paraparesis, Spastic; Dull intelligence; Low intelligence; Bradykinesia; Parkinson Disease; Cerebellar atrophy; Cerebellar degeneration; Poor school performance; Neurodevelopmental Disorders; Epileptic encephalopathy; Mental Retardation; Encephalopathies; Infratentorial atrophy; Intellectual Disability; Seizures; Muscle Spasticity; Brain Diseases; Genetic Diseases, Inborn",0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8009048756462318; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8019075543217649; 0.8138488881521341; 0.8138488881521341; 0.8168901801930506; 0.8168901801930506; 0.8190761496232595; 0.8232134984476662; 0.8232134984476662; 0.8272008757995397; 0.834094492023826; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8402911822757345; 0.8486035047899471; 0.8486035047899471; 0.8648405521677974; 0.8690346447728063; 0.8757755363384367; 0.8757755363384367; 0.876210765330195; 0.8772392350816924; 0.8815127642200768; 0.8838621755797691; 0.8913141512402477; 0.9015731019095328; 0.917543617287358; 0.922229272318747; 0.9265708351135048; 0.9265708351135048; 0.9478210444156088; 0.9478210444156088; 0.9564633032157428; 0.9740616963450036; 0.9926099929361648,Dysautonomia; Nephropathy With Pretibial Epidermolysis Bullosa And Deafness; Neurodevelopmental Disorders; Developmental Delay; Spasms Syndrome; Hypoplasia Of Corpus Callosum; Optic Atrophy; Infantile Spasms; Parkinson Disease; Dyssomnia; Movement Disorders; Cerebellar Atrophy; Mental Retardation; Cerebral Atrophy; Sleep Disorders; Epilepsy; Dementia; West Syndrome; Heart Failure; Multiple Congenital Anomalies; Dysmorphic Features,0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7765582368651238; 0.7860378120955526; 0.7949861636679444; 0.8115918568696846; 0.8115918568696846; 0.8182883735985873; 0.8201196687803188; 0.829560580336605; 0.8337953215113012; 0.8337953215113012; 0.8339308890552987; 0.8601151608808731; 0.8611702959552964; 0.861756360478846; 0.8903301324869451; 0.9024492468099392; 0.963385108667098; 0.9726139569926774,Marinesco-Sjogren syndrome ORPHA:559; Beta-propeller protein-associated neurodegeneration ORPHA:329284; Mucolipidosis type IV ORPHA:578; Classic galactosemia ORPHA:79239; Mucolipidosis type III gamma ORPHA:423470; Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome ORPHA:480864; Hereditary myopathy with lactic acidosis due to ISCU deficiency ORPHA:43115; Infantile spasms syndrome ORPHA:3451,0.1054066549396977; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.9039465713743752,,,,,,
WDR6,,,,,"Autosomal recessive cerebellar ataxia with late-onset spasticity ORPHA:352641; Autosomal recessive spastic paraplegia type 46 ORPHA:320391; Early-onset epilepsy-intellectual disability-brain anomalies syndrome ORPHA:488635; Methylmalonic acidemia with homocystinuria, type cblJ ORPHA:369955; NAD(P)HX dehydratase deficiency ORPHA:555402; POMT1-related  limb-girdle muscular dystrophy R11 ORPHA:86812; Rhizomelic chondrodysplasia punctata type 5 ORPHA:468717; TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome ORPHA:562569; Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons ORPHA:401964; MOGS-CDG ORPHA:79330; QRICH1-related intellectual disability-chondrodysplasia syndrome ORPHA:580940; Congenital muscular dystrophy with intellectual disability ORPHA:370968; Wolf-Hirschhorn syndrome ORPHA:280; Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome ORPHA:459061; Frontorhiny ORPHA:391474; MAN1B1-CDG ORPHA:397941; Infantile-onset X-linked spinal muscular atrophy ORPHA:1145; Porphyria variegata ORPHA:79473; Short stature-brachydactyly-obesity-global developmental delay syndrome ORPHA:464288; Congenital dyserythropoietic anemia type I ORPHA:98869; Congenital muscular dystrophy without intellectual disability ORPHA:370980; Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome ORPHA:404437; Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib ORPHA:79259; Isovaleric acidemia ORPHA:33; Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome ORPHA:457284; Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome ORPHA:423306; Congenital muscular dystrophy with cerebellar involvement ORPHA:370959; COG4-CDG ORPHA:263501; Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome ORPHA:496641; Microcephalic osteodysplastic dysplasia, Saul-Wilson type ORPHA:85172",0.0155394890951578; 0.0155394890951578; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3977968344535308; 0.4100904865085126; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.795266832401002; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
WFIKKN1,,,,,Hereditary hypophosphatemic rickets with hypercalciuria ORPHA:157215; IMAGe syndrome ORPHA:85173; Persistent Mullerian duct syndrome ORPHA:2856,0.1991445465001551; 0.7929682744768703; 0.8922466888454011,Japanese encephalitis virus hypothetical protein; Ntaya virus full_polyprotein 1..3427; Ilheus virus full_polyprotein 1..3424; Dengue virus 3 nonstructural protein NS3 (gene: flavivirus polyprotein); Human betaherpesvirus 6B glycoprotein (gene: U85); Wesselsbron virus full_polyprotein 1..3405; Murray Valley encephalitis virus NS3; Karshi virus (Royal Farm virus) full_polyprotein 1..3416; Omsk hemorrhagic fever virus full_polyprotein 1..3414; Saint Louis encephalitis virus full_polyprotein 1..3430; Japanese encephalitis virus non-structural protein NS3; West Nile virus H442 non-structural protein 3; West Nile virus SA381/00 non-structural protein 3; West Nile virus SA93/01 non-structural protein 3; West Nile virus SPU116/89 non-structural protein 3; West Nile virus lineage 1 nonstructural protein NS3 (gene: flavivirus polyprotein); Powassan virus non-structural protein NS3; West Nile virus lineage 2 nonstructural protein NS3 (gene: flavivirus polyprotein); Yellow fever virus non-structural protein NS3; Langat virus nonstructural protein NS3; Alkhumra hemorrhagic fever virus non-structural protein NS3; Rio Bravo virus non-structural protein NS3; West Nile virus lineage 2 excised_polyprotein 1..2273 (gene: flavivirus polyprotein); Orf virus ORF132 vascular endothelial growth factor-like protein; Kyasanur Forest disease virus NS3; Louping ill virus nonstructural protein NS3; Modoc virus non-structural protein 3; Human adenovirus 18 CR1-beta protein (gene: E3); Human adenovirus 31 cr1 beta protein (gene: E3 cr1 beta),0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9056300531913352; 0.9056300531913352; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9057542447893764; 0.9197295331382644; 0.9237501457186692,,,,
YIF1B,,,,,"Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome ORPHA:69088; Incontinentia pigmenti ORPHA:464; X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency ORPHA:319612; CADDS ORPHA:369942; Galactokinase deficiency ORPHA:79237; Familial hypocalciuric hypercalcemia type 3 ORPHA:101050; Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency ORPHA:308410; Glycogen storage disease due to aldolase A deficiency ORPHA:57; Larsen-like syndrome, B3GAT3 type ORPHA:284139; Navajo neurohepatopathy ORPHA:255229; PYCR2-related microcephaly-progressive leukoencephalopathy ORPHA:481152; Tyrosinemia type 1 ORPHA:882; Congenital erythropoietic porphyria ORPHA:79277; Hereditary isolated aplastic anemia ORPHA:397692; Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency ORPHA:331176; Congenital muscular dystrophy with intellectual disability and severe epilepsy ORPHA:329178; Primary familial polycythemia ORPHA:90042",0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.1991445465001551; 0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ZBED1,"Malignant neoplasm of breast; Breast Carcinoma; Carcinogenesis; Adenocarcinoma; Prostatic Intraepithelial Neoplasias; Malignant neoplasm of prostate; Prostate carcinoma; Sudden infant death syndrome; Neoplasm Metastasis; Prostatic Neoplasms; Familial lichen amyloidosis; Vesicular Stomatitis; Adenocarcinoma of prostate; Global developmental delay; Febrile Convulsions; Carcinoma, Neuroendocrine; Obesity; Status Epilepticus",0.4084380369379369; 0.7333611688795861; 0.7333611688795861; 0.750391252594775; 0.7765852775619541; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8019075543217649; 0.8232134984476662; 0.8989612563669234; 0.914995991166204,Prostate Cancer; Prostatic Neoplasms,0.7765582368651238; 0.7765582368651238,,,,,,,,
ZBTB33,Adenocarcinoma; Colorectal Neoplasms; Invasive Lobular Breast Carcinoma; Colonic Neoplasms,0.750391252594775; 0.7765852775619541; 0.7880542567584415; 0.8212681436603975,,,"Familial multinodular goiter ORPHA:276399; X-linked intellectual disability, Cabezas type ORPHA:85293; Christianson syndrome ORPHA:85278; Ferro-cerebro-cutaneous syndrome ORPHA:397922; Multiple congenital anomalies-hypotonia-seizures syndrome type 2 ORPHA:300496; Paroxysmal nocturnal hemoglobinuria ORPHA:447; Severe myopia-generalized joint laxity-short stature syndrome ORPHA:527450; Xq25 microduplication syndrome ORPHA:521258; RAS-associated autoimmune leukoproliferative disease ORPHA:268114; Autosomal dominant spastic paraplegia type 4 ORPHA:100985; Autosomal recessive spastic paraplegia type 60 ORPHA:401800; Buschke-Ollendorff syndrome ORPHA:1306; Hereditary neuroendocrine tumor of small intestine ORPHA:456333; Isolated osteopoikilosis ORPHA:166119; Melorheostosis with osteopoikilosis ORPHA:1879; Reticular dystrophy of the retinal pigment epithelium ORPHA:99002; Toriello-Carey syndrome ORPHA:3338; Toriello-Lacassie-Droste syndrome ORPHA:3339; X-linked intellectual disability-hypotonia-movement disorder syndrome ORPHA:457260; NON RARE IN EUROPE: Melanoma ORPHA:411533; Monosomy 13q14 ORPHA:1587; Multiple self-healing squamous epithelioma ORPHA:65748; Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome ORPHA:391408",0.3832844616405875; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,"Horsepox virus HSPV197 (Hypothetical protein); Yaba-like disease virus 140R protein (gene: 140R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV008; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Yaba-like disease virus 19L protein (gene: 19L); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Ectromelia virus ERPV kelch-like protein; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Vaccinia virus kelch-like protein (gene: A55R); Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Yaba monkey tumor virus kelch-like protein; Horsepox virus HSPV043 (Kelch-like protein; Provisional); Horsepox virus HSPV029 (kelch-like protein; Provisional); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus kelch-like protein (gene: C2L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Monkeypox virus kelch-like protein; Monkeypox virus Zaire-96-I-16 B18R (gene: B18R); Vaccinia virus hypothetical protein (gene: C5L)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.9057542447893764,,,,
ZBTB5,Thyroid carcinoma; Malignant neoplasm of thyroid; Malignant neoplasm of muscle; Retinoblastoma,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,"X-linked intellectual disability, Siderius type ORPHA:85287; Severe myopia-generalized joint laxity-short stature syndrome ORPHA:527450; Osteopathia striata-cranial sclerosis syndrome ORPHA:2780; Wolcott-Rallison syndrome ORPHA:1667",0.1991445465001551; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,"Horsepox virus HSPV197 (Hypothetical protein); Yaba-like disease virus 140R protein (gene: 140R); Cowpox virus CPXV215 Protein (gene: CPXV215 CDS); Vaccinia virus Ankara Kelch-like protein, modulator of inflammation; Cowpox virus CPXV050 (gene: CPXV050 CDS); Horsepox virus HSPV008; Cowpox virus CPXV013 protein (gene: CPXV013 CDS); Yaba-like disease virus 19L protein (gene: 19L); Cowpox virus CPXV193 protein (gene: CPXV193 CDS); Ectromelia virus ERPV kelch-like protein; Vaccinia virus Kelch-like protein (gene: F3L); Vaccinia virus Ankara Kelch-like protein; Vaccinia virus kelch-like protein (gene: A55R); Monkeypox virus Zaire-96-I-16 Kelch-like protein (gene: C9L); Yaba monkey tumor virus kelch-like protein; Horsepox virus HSPV043 (Kelch-like protein; Provisional); Horsepox virus HSPV029 (kelch-like protein; Provisional); Variola virus hypothetical protein (gene: B22R); Cowpox virus CPXV035 protein (gene: CPXV035 CDS); Vaccinia virus Ankara 64.7k Kelch-like protein f1; Vaccinia virus kelch-like protein (gene: C2L); Horsepox virus HSPV176 (kelch-like protein; Provisional); Monkeypox virus kelch-like protein; Monkeypox virus Zaire-96-I-16 B18R (gene: B18R)",0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036; 0.8999095837312036,,,,
ZFAND2A,,,Cardiovascular Diseases,0.924275664330454,Spinocerebellar ataxia type 18 ORPHA:98771,0.7929682744768703,,,,,,
ZNF277,Malignant neoplasm of breast; Carcinogenesis; Colon Carcinoma; Malignant tumor of colon; Specific language impairment; Autistic Disorder,0.4084380369379369; 0.7333611688795861; 0.7765852775619541; 0.7765852775619541; 0.7880542567584415; 0.8019075543217649,Breast Cancer,0.8903630091389316,Vitamin B12-responsive methylmalonic acidemia type cblA ORPHA:79310; Smith-McCort dysplasia ORPHA:178355,0.8922466888454011; 0.8922466888454011,,,,,,
ZNF516,Colorectal Carcinoma; Colorectal Cancer,0.7765852775619541; 0.7880542567584415,,,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation ORPHA:320385; Acromelic frontonasal dysplasia ORPHA:1827; Wagner disease ORPHA:898,0.0155394890951578; 0.1040670578681756; 0.8922466888454011,,,,,,
ZNF598,,,,,"Charcot-Marie-Tooth disease type 4B3 ORPHA:363981; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Multiple endocrine neoplasia type 1 ORPHA:652; Albers Schonberg osteopetrosis ORPHA:53; BAP1-related tumor predisposition syndrome ORPHA:289539; Smith-Magenis syndrome ORPHA:819; Congenital myopathy with internal nuclei and atypical cores ORPHA:319160; Early myoclonic encephalopathy ORPHA:1935; Early-onset posterior subcapsular cataract ORPHA:441447; Ichthyosis-prematurity syndrome ORPHA:88621; Intellectual disability-strabismus syndrome ORPHA:363528; MOGS-CDG ORPHA:79330; Spondylo-ocular syndrome ORPHA:85194; TELO2-related intellectual disability-neurodevelopmental disorder ORPHA:488642; Testicular regression syndrome ORPHA:983; Wolf-Hirschhorn syndrome ORPHA:280; Alpers-Huttenlocher syndrome ORPHA:726; Autosomal recessive ataxia due to PEX10 deficiency ORPHA:247815; Baller-Gerold syndrome ORPHA:1225; Class I glucose-6-phosphate dehydrogenase deficiency ORPHA:466026; Combined oxidative phosphorylation defect type 23 ORPHA:444013; Congenital cataracts-facial dysmorphism-neuropathy syndrome ORPHA:48431; Congenital factor XII deficiency ORPHA:330; F12-related hereditary angioedema with normal C1Inh ORPHA:100054; Familial lambdoid synostosis ORPHA:3267; Frontorhiny ORPHA:391474; Isolated cloverleaf skull syndrome ORPHA:2343; Lethal brain and heart developmental defects ORPHA:580933; Lethal neonatal spasticity-epileptic encephalopathy syndrome ORPHA:435845; Methylmalonic acidemia with homocystinuria, type cblX ORPHA:369962; NON RARE IN EUROPE: Glucose-6-phosphate-dehydrogenase deficiency ORPHA:362; Neuralgic amyotrophy ORPHA:2901; Ocular anomalies-axonal neuropathy-developmental delay syndrome ORPHA:496790; Peutz-Jeghers syndrome ORPHA:2869; RAPADILINO syndrome ORPHA:3021; RFVT2-related riboflavin transporter deficiency ORPHA:572543; Recessive mitochondrial ataxia syndrome ORPHA:94125; Rothmund-Thomson syndrome type 2 ORPHA:221016; Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract ORPHA:500545; Spinocerebellar ataxia with epilepsy ORPHA:254881; Transketolase deficiency ORPHA:488618; Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome ORPHA:70595; 22q11.2 deletion syndrome ORPHA:567; AKT2-related familial partial lipodystrophy ORPHA:79085; Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome ORPHA:466794; Adult-onset cervical dystonia, DYT23 type ORPHA:420492; Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder ORPHA:500180; Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome ORPHA:330054; FLNA-related X-linked myxomatous valvular dysplasia ORPHA:555877; Hypoinsulinemic hypoglycemia and body hemihypertrophy ORPHA:293964; Leydig cell hypoplasia due to LHB deficiency ORPHA:325448; Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome ORPHA:363649; Melnick-Needles syndrome ORPHA:2484; Neuronal intestinal pseudoobstruction ORPHA:99811; Opsismodysplasia ORPHA:2746; Otopalatodigital syndrome type 1 ORPHA:90650; Otopalatodigital syndrome type 2 ORPHA:90652; Spinocerebellar ataxia type 4 ORPHA:98765; Syndromic X-linked intellectual disability due to JARID1C mutation ORPHA:85279; Terminal osseous dysplasia-pigmentary defects syndrome ORPHA:88630; X-linked Ehlers-Danlos syndrome ORPHA:75497; X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome ORPHA:482606; Congenital dyserythropoietic anemia type I ORPHA:98869; Insulinoma ORPHA:97279; Lymphomatoid papulosis ORPHA:98842; MEDNIK syndrome ORPHA:171851; Microlissencephaly ORPHA:1083; Primary cutaneous anaplastic large cell lymphoma ORPHA:300865; Chronic myeloid leukemia ORPHA:521; NON RARE IN EUROPE: Paget disease of bone ORPHA:280110; B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome ORPHA:536467; CODAS syndrome ORPHA:1458; Costello syndrome ORPHA:3071; MORM syndrome ORPHA:75858; Ocular albinism ORPHA:284804; Oculopharyngeal muscular dystrophy ORPHA:270; Phakomatosis pigmentokeratotica ORPHA:2874; TARP syndrome ORPHA:2886; Woolly hair nevus ORPHA:79414; MiT family translocation renal cell carcinoma ORPHA:319308; Williams syndrome ORPHA:904; Familial rhabdoid tumor ORPHA:231108; Spinocerebellar ataxia type 26 ORPHA:101112; Microphthalmia, Lenz type ORPHA:568; Meningioma ORPHA:2495",0.0414176838632111; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1117946631214258; 0.1991445465001551; 0.1991445465001551; 0.220389120533256; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.4100904865085126; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.896422440954666,,,,,,
ZNF628,Alzheimer's Disease,0.7880542567584415,,,"Atrial septal defect, sinus venosus type ORPHA:99105; Crisponi syndrome ORPHA:1545; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Multiple endocrine neoplasia type 1 ORPHA:652; BAP1-related tumor predisposition syndrome ORPHA:289539; Focal dermal hypoplasia ORPHA:2092; Smith-Magenis syndrome ORPHA:819; Adrenomyeloneuropathy ORPHA:139399; Charcot-Marie-Tooth disease type 4F ORPHA:99952; Neutral lipid storage myopathy ORPHA:98908; Triglyceride deposit cardiomyovasculopathy ORPHA:565612; X-linked cerebral adrenoleukodystrophy ORPHA:139396; Early myoclonic encephalopathy ORPHA:1935; Charcot-Marie-Tooth disease type 2B2 ORPHA:101101; Ataxia-oculomotor apraxia type 4 ORPHA:459033; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; Intellectual disability-strabismus syndrome ORPHA:363528; TELO2-related intellectual disability-neurodevelopmental disorder ORPHA:488642; Testicular regression syndrome ORPHA:983; Ependymoma ORPHA:251636; RELA fusion-positive ependymoma ORPHA:530792; Class I glucose-6-phosphate dehydrogenase deficiency ORPHA:466026; Congenital cataracts-facial dysmorphism-neuropathy syndrome ORPHA:48431; Familial lambdoid synostosis ORPHA:3267; Isolated cloverleaf skull syndrome ORPHA:2343; Lethal brain and heart developmental defects ORPHA:580933; NON RARE IN EUROPE: Glucose-6-phosphate-dehydrogenase deficiency ORPHA:362; Neuralgic amyotrophy ORPHA:2901; Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract ORPHA:500545; 22q11.2 deletion syndrome ORPHA:567; AKT2-related familial partial lipodystrophy ORPHA:79085; Adult-onset cervical dystonia, DYT23 type ORPHA:420492; Charcot-Marie-Tooth disease type 2S ORPHA:443073; Hypoinsulinemic hypoglycemia and body hemihypertrophy ORPHA:293964; Spinal muscular atrophy with respiratory distress type 1 ORPHA:98920; Alveolar soft tissue sarcoma ORPHA:163699; Fibrolamellar hepatocellular carcinoma ORPHA:401920; Insulinoma ORPHA:97279; Childhood-onset basal ganglia degeneration syndrome ORPHA:497906; FKRP-related  limb-girdle muscular dystrophy R9 ORPHA:34515",0.0155394890951578; 0.0155394890951578; 0.0414176838632111; 0.0473879273649914; 0.1040670578681756; 0.1040670578681756; 0.1117946631214258; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.6599133692748571; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011,,,,,,
ZNF653,,,,,Charcot-Marie-Tooth disease type 2P ORPHA:300319; Cushing syndrome due to macronodular adrenal hyperplasia ORPHA:189427; Autosomal recessive spastic paraplegia type 44 ORPHA:320401; BAP1-related tumor predisposition syndrome ORPHA:289539; Pelizaeus-Merzbacher-like disease due to GJC2 mutation ORPHA:280282; CLN4B disease ORPHA:228343; Charcot-Marie-Tooth disease type 4F ORPHA:99952; Congenital myopathy with internal nuclei and atypical cores ORPHA:319160; Basel-Vanagaite-Smirin-Yosef syndrome ORPHA:464738; Intellectual disability-strabismus syndrome ORPHA:363528; Congenital cataracts-facial dysmorphism-neuropathy syndrome ORPHA:48431; Familial lambdoid synostosis ORPHA:3267; Frontorhiny ORPHA:391474; Isolated cloverleaf skull syndrome ORPHA:2343; Peutz-Jeghers syndrome ORPHA:2869; Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract ORPHA:500545,0.0414176838632111; 0.0414176838632111; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087,Human papillomavirus type 6 E5B (gene: E5B),0.8999095837312036,,,,
ZNF689,Liver carcinoma; Liver and Intrahepatic Biliary Tract Carcinoma; Hepatocarcinogenesis; Malignant neoplasm of liver,0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415,,,Lipoyl transferase 2 deficiency ORPHA:447795; Schnyder corneal dystrophy ORPHA:98967; Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders ORPHA:505248,0.3832844616405875; 0.5867963421058087; 0.8922466888454011,Human papillomavirus type 6 E5B (gene: E5B),0.8999095837312036,,,,
ZNF697,,,,,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome ORPHA:508533; Congenital insensitivity to pain with severe intellectual disability ORPHA:453510; Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome ORPHA:476126; Dent disease type 1 ORPHA:93622; Congenital contractural arachnodactyly ORPHA:115,0.1040670578681756; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.8922466888454011,Human papillomavirus type 6 E5B (gene: E5B),0.8999095837312036,,,,
ZNF830,,,,,"TMEM199-CDG ORPHA:466703; Lipoyl transferase 1 deficiency ORPHA:401862; Primary dystonia, DYT6 type ORPHA:98806; Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome ORPHA:467176; Spinocerebellar ataxia type 17 ORPHA:98759",0.3832844616405875; 0.5867963421058087; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
ZWINT,"Malignant neoplasm of breast; Breast Carcinoma; Malignant neoplasm of prostate; Prostate carcinoma; Sarcoma; Scoliosis, unspecified",0.4084380369379369; 0.7333611688795861; 0.7880542567584415; 0.7880542567584415; 0.7880542567584415; 0.8648405521677974,Liver Carcinoma,0.7765582368651238,"Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Mosaic variegated aneuploidy syndrome ORPHA:1052; 21q22.11q22.12 microdeletion syndrome ORPHA:261323; Adult-onset autosomal dominant leukodystrophy ORPHA:99027; Congenital dyserythropoietic anemia type III ORPHA:98870; Constitutional megaloblastic anemia with severe neurologic disease ORPHA:319651; Currarino syndrome ORPHA:1552; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Microcephaly-lymphedema-chorioretinopathy syndrome ORPHA:2526; PCNA-related progressive neurodegenerative photosensitivity syndrome ORPHA:438134; Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome ORPHA:314394; Stromme syndrome ORPHA:506307; Intrauterine growth restriction-congenital multiple cafe-au-lait macules-increased sister chromatid exchange syndrome ORPHA:508512; Ear-patella-short stature syndrome ORPHA:2554; Citrullinemia type II ORPHA:247585; Microcephaly-micromelia syndrome ORPHA:572768; Microcephaly-short stature-limb abnormalities syndrome ORPHA:572773; Mutilating hereditary sensory neuropathy with spastic paraplegia ORPHA:139578; Neonatal intrahepatic cholestasis due to citrin deficiency ORPHA:247598; Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency ORPHA:75391; X-linked intellectual disability, Snyder type ORPHA:3063; Large congenital melanocytic nevus ORPHA:626; Small cell lung cancer ORPHA:70573; Hyper-IgM syndrome type 5 ORPHA:101092; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome ORPHA:415; Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome ORPHA:137898; Progressive external ophthalmoplegia-myopathy-emaciation syndrome ORPHA:352447; Severe combined immunodeficiency due to CTPS1 deficiency ORPHA:420573; Hydrolethalus ORPHA:2189; 46,XX gonadal dysgenesis ORPHA:243; 3-phosphoserine phosphatase deficiency, infantile/juvenile form ORPHA:79350; Autosomal recessive cutis laxa type 2B ORPHA:357064; Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome ORPHA:544488; Hereditary coproporphyria ORPHA:79273; PYCR1-related De Barsy syndrome ORPHA:293633; Spondylo-megaepiphyseal-metaphyseal dysplasia ORPHA:228387; Linear nevus sebaceus syndrome ORPHA:2612; Autosomal recessive spastic paraplegia type 62 ORPHA:401785; Inclusion body myopathy with Paget disease of bone and frontotemporal dementia ORPHA:52430; Acquired partial lipodystrophy ORPHA:79087; Acute intermittent porphyria ORPHA:79276; Acute myeloid leukemia with NPM1 somatic mutations ORPHA:402026; Athabaskan brainstem dysgenesis syndrome ORPHA:69739; Autosomal dominant spastic paraplegia type 13 ORPHA:100994; Baller-Gerold syndrome ORPHA:1225; Bosley-Salih-Alorainy syndrome ORPHA:69737; Hemolytic anemia due to glutathione reductase deficiency ORPHA:90030; Pelizaeus-Merzbacher-like disease due to HSPD1 mutation ORPHA:280288; Progressive myoclonic epilepsy type 9 ORPHA:457265; RAPADILINO syndrome ORPHA:3021; Rothmund-Thomson syndrome type 2 ORPHA:221016; ALDH18A1-related De Barsy syndrome ORPHA:35664; ALG8-CDG ORPHA:79325; Adrenocortical carcinoma ORPHA:1501; Autosomal dominant spastic paraplegia type 9A ORPHA:447753; Autosomal dominant spastic paraplegia type 9B ORPHA:447757; Autosomal recessive spastic paraplegia type 9B ORPHA:447760; Choroid plexus carcinoma ORPHA:251899; Macrocephaly-intellectual disability-left ventricular non compaction syndrome ORPHA:466791; Papilloma of choroid plexus ORPHA:2807; Richieri Costa-Pereira syndrome ORPHA:3102; S-adenosylhomocysteine hydrolase deficiency ORPHA:88618; STT3A-CDG ORPHA:370921; Spondyloepimetaphyseal dysplasia with multiple dislocations ORPHA:93360; Desmoplastic small round cell tumor ORPHA:83469; Familial isolated congenital asplenia ORPHA:101351; Geroderma osteodysplastica ORPHA:2078; Lymphomatoid papulosis ORPHA:98842; Primary cutaneous anaplastic large cell lymphoma ORPHA:300865; AICA-ribosiduria ORPHA:250977; Combined immunodeficiency due to TFRC deficiency ORPHA:476113; Mandibulofacial dysostosis-microcephaly syndrome ORPHA:79113; Reticular dysgenesis ORPHA:33355; SPONASTRIME dysplasia ORPHA:93357; Spinocerebellar ataxia type 36 ORPHA:276198; Caudal regression sequence ORPHA:3027; Hypocalcemic vitamin D-dependent rickets ORPHA:289157; Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome ORPHA:83629; Severe X-linked mitochondrial encephalomyopathy ORPHA:238329; Warsaw breakage syndrome ORPHA:280558; X-linked Charcot-Marie-Tooth disease type 4 ORPHA:101078; X-linked hereditary sensory and autonomic neuropathy with deafness ORPHA:139583; Polymerase proofreading-related adenomatous polyposis ORPHA:447877",0.0144185025972157; 0.0149557947723539; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0155394890951578; 0.0184072076199886; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0414176838632111; 0.0429491792829903; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1040670578681756; 0.1054066549396977; 0.1419890644363008; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.1991445465001551; 0.2047219337649946; 0.3832844616405875; 0.3832844616405875; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.5867963421058087; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.7929682744768703; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011; 0.8922466888454011,,,,,,
